2021-01-18 15:02:01 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_comma/checkpoint_last.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out_fp32/nl_comma_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_comma', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_comma/checkpoint_last.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out_fp32/nl_comma_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-18 15:02:02 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-18 15:02:02 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-18 15:02:02 | INFO | fairseq_cli.generate | loading model(s) from /global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_comma/checkpoint_last.pt
2021-01-18 15:07:01 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.src
2021-01-18 15:07:01 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.label
2021-01-18 15:07:01 | INFO | fairseq.tasks.translation | ./postprocessed/en_comma test src-label 2024 examples
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise ; cardiovascular
H-1900	-1.3765711784362793	▁exercise ▁; ▁cardiovascular ▁system
D-1900	-1.3765711784362793	exercise ; cardiovascular system
P-1900	-6.3752 -0.7686 -0.5119 -0.1523 -0.3331 -0.1184
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse events
H-1988	-0.34035301208496094	
D-1988	-0.34035301208496094	
P-1988	-0.5621 -0.1186
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox proportional hazards models
H-712	-0.3861270248889923	▁co x ▁proportion al ▁hazard s
D-712	-0.3861270248889923	cox proportional hazards
P-712	-0.3277 -0.3611 -0.0827 -0.0615 -0.2024 -1.4325 -0.5088 -0.1123
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.532628059387207	
D-1451	-0.532628059387207	
P-1451	-0.9064 -0.1589
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.5702710747718811	▁EH
D-1528	-0.5702710747718811	EH
P-1528	-1.1607 -0.3725 -0.1776
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.5343521237373352	
D-664	-0.5343521237373352	
P-664	-0.9275 -0.1412
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.258791446685791	
D-133	-0.258791446685791	
P-133	-0.4333 -0.0842
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.1061736345291138	
D-1685	-1.1061736345291138	
P-1685	-2.0001 -0.2122
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.2719491422176361	
D-228	-0.2719491422176361	
P-228	-0.4512 -0.0927
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient ; hf
H-364	-0.7469484210014343	▁ HF
D-364	-0.7469484210014343	HF
P-364	-2.2891 -0.2878 -0.2584 -0.1525
S-949	No major complications occurred during follow-up.<unk>
T-949	complications ; follow-up
H-949	-0.27627721428871155	▁follow - up
D-949	-0.27627721428871155	follow-up
P-949	-0.4484 -0.5736 -0.0615 -0.1871 -0.1108
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting ; cell ; anand
H-1037	-0.2828996181488037	▁Cell ▁; ▁Anand
D-1037	-0.2828996181488037	Cell ; Anand
P-1037	-0.1503 -0.2459 -0.0004 -0.9720 -0.0458
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin ; injected
H-957	-0.19342106580734253	▁do xor ubi cin
D-957	-0.19342106580734253	doxorubicin
P-957	-0.2998 -0.0204 -0.0144 -0.1739 -0.4879 -0.1641
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors ; blood transfusions
H-1684	-1.0234335660934448	▁blood ▁trans fusion s
D-1684	-1.0234335660934448	blood transfusions
P-1684	-4.3481 -0.0450 -0.0375 -0.8567 -0.6092 -0.2442
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.24031010270118713	▁FM
D-18	-0.24031010270118713	FM
P-18	-0.3161 -0.3112 -0.0936
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse events
H-1916	-0.6003825664520264	
D-1916	-0.6003825664520264	
P-1916	-0.9594 -0.2414
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart failure
H-1066	-0.7984616756439209	▁devices ▁; ▁heart ▁failure
D-1066	-0.7984616756439209	devices ; heart failure
P-1066	-1.6609 -1.3193 -1.1897 -0.1667 -0.2873 -0.1669
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.7615059018135071	▁d XA
D-1496	-0.7615059018135071	dXA
P-1496	-0.3610 -0.6492 -1.8921 -0.1437
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver disease
H-233	-0.4290018081665039	▁Live r ▁disease
D-233	-0.4290018081665039	Liver disease
P-233	-1.1042 -0.0999 -0.1671 -0.6620 -0.1118
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.5391035676002502	
D-307	-0.5391035676002502	
P-307	-0.9619 -0.1163
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf ; pna
H-1699	-0.818013608455658	▁ HF ▁; ▁p NA
D-1699	-0.818013608455658	HF ; pNA
P-1699	-2.2756 -0.7143 -0.3426 -0.4107 -1.6650 -0.2518 -0.0662
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise ; cardiovascular ; health
H-1897	-1.7913026809692383	
D-1897	-1.7913026809692383	
P-1897	-3.3986 -0.1840
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal artery stenosis
H-1592	-0.13213442265987396	▁Ren al ▁arter y ▁sten osis
D-1592	-0.13213442265987396	Renal artery stenosis
P-1592	-0.1024 -0.0993 -0.0132 -0.3707 -0.0092 -0.0215 -0.3081 -0.1326
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective cohort study
H-1712	-0.5553423762321472	
D-1712	-0.5553423762321472	
P-1712	-0.9794 -0.1313
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute care surgery ; heart transplant
H-1279	-1.4886770248413086	▁heart ▁transplant ▁recipient s
D-1279	-1.4886770248413086	heart transplant recipients
P-1279	-6.8268 -0.1488 -0.3319 -0.9424 -0.4922 -0.1900
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary end point ; inhospital ; mortality
H-190	-0.7343036532402039	▁in hospital ▁mortal iteit
D-190	-0.7343036532402039	inhospital mortaliteit
P-190	-1.4481 -0.0231 -0.1438 -2.3608 -0.2589 -0.1711
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.2093072086572647	▁molecular ▁mechanism
D-1607	-0.2093072086572647	molecular mechanism
P-1607	-0.4258 -0.0334 -0.2665 -0.1116
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.5103521347045898	▁tertia ry ▁refer ral ▁centre
D-1497	-0.5103521347045898	tertiary referral centre
P-1497	-0.8959 -1.5344 -0.0820 -0.1633 -0.4707 -0.2663 -0.1598
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.5511347651481628	▁ec
D-256	-0.5511347651481628	ec
P-256	-0.7126 -0.8699 -0.0709
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.561089813709259	▁ HF
D-346	-0.561089813709259	HF
P-346	-1.4179 -0.4234 -0.2900 -0.1131
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate models
H-241	-0.3949161469936371	
D-241	-0.3949161469936371	
P-241	-0.6143 -0.1755
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.23056560754776	
D-1944	-0.23056560754776	
P-1944	-0.3668 -0.0943
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.39760372042655945	
D-1982	-0.39760372042655945	
P-1982	-0.6648 -0.1304
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.588860809803009	
D-589	-0.588860809803009	
P-589	-1.0403 -0.1374
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic breathing ; heart beat
H-1345	-0.6629906892776489	▁breath ing ▁; ▁heart ▁beat
D-1345	-0.6629906892776489	breathing ; heart beat
P-1345	-1.2873 -0.2334 -0.6122 -2.0285 -0.0556 -0.3160 -0.1080
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.5132238864898682	
D-796	-0.5132238864898682	
P-796	-0.8143 -0.2122
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective cohort
H-211	-0.6712642908096313	▁Retro spec tive ▁co hor t
D-211	-0.6712642908096313	Retrospective cohort
P-211	-2.7363 -0.0347 -1.1099 -0.0397 -0.7329 -0.2521 -0.3050 -0.1595
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart failure ; latin america
H-1788	-0.6213883757591248	▁heart ▁failure ▁; ▁Latin ▁America
D-1788	-0.6213883757591248	heart failure ; Latin America
P-1788	-2.1393 -0.3654 -0.6533 -0.3697 -0.3497 -0.3485 -0.1239
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational cohort study
H-811	-0.44134628772735596	
D-811	-0.44134628772735596	
P-811	-0.7633 -0.1194
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.3824863135814667	
D-44	-0.3824863135814667	
P-44	-0.6007 -0.1643
S-422	Heart rate was minimally altered.<unk>
T-422	heart rate
H-422	-0.42451921105384827	▁Heart ▁rate
D-422	-0.42451921105384827	Heart rate
P-422	-0.4259 -0.5694 -0.5225 -0.1802
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.7037453651428223	
D-1846	-0.7037453651428223	
P-1846	-1.2330 -0.1745
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.6088113188743591	▁doctor s
D-1686	-0.6088113188743591	doctors
P-1686	-1.5739 -0.4980 -0.2905 -0.0728
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart failure
H-1356	-0.5960939526557922	▁nutrition ▁; ▁heart ▁failure
D-1356	-0.5960939526557922	nutrition ; heart failure
P-1356	-2.0170 -0.6107 -0.4494 -0.2107 -0.1875 -0.1012
S-1620	SETTING: Northwest United States.<unk>
T-1620	united states
H-1620	-0.7709209322929382	▁North west ▁United ▁States
D-1620	-0.7709209322929382	Northwest United States
P-1620	-3.1685 -0.0148 -0.8807 -0.2167 -0.2542 -0.0905
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.4139835238456726	
D-795	-0.4139835238456726	
P-795	-0.6697 -0.1583
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.23154518008232117	▁unilateral
D-1595	-0.23154518008232117	unilateral
P-1595	-0.2750 -0.2541 -0.1655
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.3679848611354828	
D-363	-0.3679848611354828	
P-363	-0.6066 -0.1294
S-1683	She is going into heart failure.<unk>
T-1683	heart failure
H-1683	-0.718432605266571	▁heart ▁failure
D-1683	-0.718432605266571	heart failure
P-1683	-1.8165 -0.6018 -0.3001 -0.1553
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.8884056806564331	▁INTER ven TIONS
D-798	-0.8884056806564331	INTERvenTIONS
P-798	-1.3765 -0.3568 -2.2575 -0.3625 -0.0886
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.3799951374530792	
D-1249	-0.3799951374530792	
P-1249	-0.5060 -0.2540
S-979	Heart failure in the young.<unk>
T-979	heart failure
H-979	-0.5241804718971252	▁Heart ▁failure
D-979	-0.5241804718971252	Heart failure
P-979	-0.2823 -0.9078 -0.7613 -0.1452
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.3942400813102722	
D-1687	-0.3942400813102722	
P-1687	-0.6586 -0.1299
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.3669387698173523	▁c lin
D-1246	-0.3669387698173523	clin
P-1246	-0.3572 -0.3624 -0.6546 -0.0935
S-1248	Sci.<unk>
T-1248	
H-1248	-1.0120688676834106	▁Sci
D-1248	-1.0120688676834106	Sci
P-1248	-0.2258 -2.6864 -0.1240
S-1247	Trans.<unk>
T-1247	
H-1247	-1.1685205698013306	▁trans
D-1247	-1.1685205698013306	trans
P-1247	-0.3721 -3.0146 -0.1189
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.3796476423740387	
D-1963	-0.3796476423740387	
P-1963	-0.5652 -0.1941
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.6342959403991699	▁CHF ▁treatment s
D-222	-0.6342959403991699	CHF treatments
P-222	-0.0682 -2.2690 -0.2603 -0.4843 -0.0897
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic balance
H-1375	-0.3250667452812195	▁autonomi c ▁balance
D-1375	-0.3250667452812195	autonomic balance
P-1375	-0.4757 -0.3177 -0.3554 -0.3423 -0.1341
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral growth
H-511	-1.2104777097702026	▁competitive
D-511	-1.2104777097702026	competitive
P-511	-2.5938 -0.8868 -0.1508
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.32819926738739014	▁inter media te ▁fra il ty
D-1005	-0.32819926738739014	intermediate frailty
P-1005	-1.3317 -0.2413 -0.1115 -0.0179 -0.3398 -0.2859 -0.2060 -0.0913
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.6290901303291321	▁ HF p EF
D-1078	-0.6290901303291321	HFpEF
P-1078	-2.2086 -0.4472 -0.0211 -0.5127 -0.5026 -0.0824
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 ; functional capacity
H-702	-0.7611203789710999	▁ST 2
D-702	-0.7611203789710999	ST2
P-702	-1.6129 -0.2078 -1.0641 -0.1598
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end point
H-1763	-0.2970537543296814	
D-1763	-0.2970537543296814	
P-1763	-0.4789 -0.1153
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.23612043261528015	▁do d son
D-205	-0.23612043261528015	dodson
P-205	-0.3458 -0.0494 -0.0088 -0.7162 -0.0604
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.5341415405273438	
D-392	-0.5341415405273438	
P-392	-0.9119 -0.1564
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv fibrosis
H-280	-0.5796422362327576	▁LV ▁fibro sis ▁; ANS ▁mi ce
D-280	-0.5796422362327576	LV fibrosis ;ANS mice
P-280	-0.0816 -0.0954 -0.2528 -0.9330 -2.4714 -0.8116 -0.2078 -0.2774 -0.0858
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.5305719971656799	
D-126	-0.5305719971656799	
P-126	-0.8884 -0.1728
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness ; anemia
H-1679	-1.429215669631958	▁Jehovah s ▁Wit ness ▁; ▁an emia
D-1679	-1.429215669631958	Jehovahs Witness ; anemia
P-1679	-0.0844 -6.1954 -0.3438 -1.6702 -1.1624 -1.5753 -1.3219 -0.3498 -0.1596
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient ; medical ; conditions
H-1688	-0.6419830918312073	▁in patient ▁medical ▁conditions
D-1688	-0.6419830918312073	inpatient medical conditions
P-1688	-1.1789 -0.0147 -0.6739 -1.4961 -0.2950 -0.1932
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient ; hospital ; heart failure
H-1960	-1.4608460664749146	▁heart ▁failure
D-1960	-1.4608460664749146	heart failure
P-1960	-5.1133 -0.2988 -0.2975 -0.1337
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended criteria cardiac transplantation
H-707	-0.4292280077934265	▁cardiac ▁transplant ation
D-707	-0.4292280077934265	cardiac transplantation
P-707	-0.3194 -0.1289 -1.1505 -0.3920 -0.1553
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated ; mixed linear models
H-325	-0.6346516609191895	▁co ▁; ▁mix ed ▁linear ▁models
D-325	-0.6346516609191895	co ; mixed linear models
P-325	-0.7331 -2.6303 -0.6430 -0.0465 -0.0587 -0.3533 -0.4881 -0.1243
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty ; hf
H-624	-0.5663503408432007	▁fra il ty ▁; ▁ HF
D-624	-0.5663503408432007	frailty ; HF
P-624	-0.4584 -0.4075 -0.2577 -0.7104 -1.4741 -0.4101 -0.6673 -0.1454
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary outcomes ; quality of life
H-1654	-0.5880672931671143	▁cognitive ▁function
D-1654	-0.5880672931671143	cognitive function
P-1654	-0.6450 -0.3232 -1.1874 -0.1967
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart failure ; mortality
H-204	-0.48454749584198	▁Heart ▁failure ▁; ▁cognitive ▁im pair ment
D-204	-0.48454749584198	Heart failure ; cognitive impairment
P-204	-0.3113 -0.1585 -0.2815 -0.0846 -0.5201 -0.0388 -0.7616 -2.0974 -0.1071
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf ; hf
H-1309	-1.0160338878631592	▁con current ▁ HF ▁; ▁ HF
D-1309	-1.0160338878631592	concurrent HF ; HF
P-1309	-3.9417 -0.0351 -0.7804 -0.2722 -0.5983 -2.0007 -0.4850 -0.9163 -0.1145
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up duration
H-495	-0.25208574533462524	▁follow - up
D-495	-0.25208574533462524	follow-up
P-495	-0.1615 -0.6077 -0.1297 -0.2550 -0.1065
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology ; hospital
H-812	-0.8585060834884644	▁card i ology ▁; ▁hospital
D-812	-0.8585060834884644	cardiology ; hospital
P-812	-1.5714 -1.1388 -0.3062 -1.4699 -1.2160 -0.2069 -0.1004
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.566951334476471	
D-575	-0.566951334476471	
P-575	-1.0294 -0.1045
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart rate variability ; risk stratification ; cardiac ; patients
H-1584	-0.8722708225250244	▁Heart ▁rate ▁variabil ity ▁; ▁cardiac ▁patients
D-1584	-0.8722708225250244	Heart rate variability ; cardiac patients
P-1584	-0.5322 -0.7139 -1.6211 -2.5538 -0.5218 -0.6383 -0.6195 -0.4121 -0.2379
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote ischemic conditioning ; patients ; heart failure
H-53	-0.8063406348228455	▁Remote ▁ ische mic ▁condition ing ▁; ▁patients ▁; ▁heart ▁failure
D-53	-0.8063406348228455	Remote ischemic conditioning ; patients ; heart failure
P-53	-1.6241 -0.5313 -0.0794 -0.8901 -0.0100 -0.2547 -0.6648 -2.1530 -2.5102 -1.0457 -0.2815 -0.3216 -0.1161
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air ; heart failure
H-1805	-0.2613172233104706	▁air ▁pollution ▁; ▁heart ▁failure
D-1805	-0.2613172233104706	air pollution ; heart failure
P-1805	-0.2094 -0.2850 -0.2451 -0.4924 -0.1949 -0.2663 -0.1362
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.5417917370796204	
D-1399	-0.5417917370796204	
P-1399	-0.9041 -0.1795
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.5116937160491943	▁Sham - opera ted ▁animals
D-1339	-0.5116937160491943	Sham-operated animals
P-1339	-0.1880 -0.2895 -0.0866 -0.7134 -1.5594 -0.5450 -0.1999
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.5328349471092224	
D-885	-0.5328349471092224	
P-885	-0.9158 -0.1499
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.2761196494102478	
D-311	-0.2761196494102478	
P-311	-0.4316 -0.1207
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-1.3176065683364868	▁policy
D-312	-1.3176065683364868	policy
P-312	-2.2143 -1.6611 -0.0774
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-1.4036452770233154	▁Comp liance ▁; ▁treatment
D-749	-1.4036452770233154	Compliance ; treatment
P-749	-5.1443 -0.3083 -2.4747 -0.2707 -0.1478 -0.0762
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.43428561091423035	
D-1754	-0.43428561091423035	
P-1754	-0.7279 -0.1406
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-0.9337000846862793	▁tax ono my
D-1125	-0.9337000846862793	taxonomy
P-1125	-2.7211 -0.1128 -1.3448 -0.3760 -0.1137
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.2533685863018036	▁CHF
D-673	-0.2533685863018036	CHF
P-673	-0.1416 -0.4946 -0.1240
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart failure
H-1886	-0.8737918138504028	▁Heart ▁failure ▁; ▁uk
D-1886	-0.8737918138504028	Heart failure ; uk
P-1886	-1.6320 -0.7626 -0.6834 -1.4384 -0.5346 -0.1917
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients ; followed up
H-825	-0.3019104599952698	
D-825	-0.3019104599952698	
P-825	-0.4851 -0.1187
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients ; cardiovascular disease
H-247	-0.7616640329360962	▁cardiovascular ▁disease
D-247	-0.7616640329360962	cardiovascular disease
P-247	-2.1382 -0.4112 -0.3373 -0.1599
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf ; mi
H-1101	-0.9590765237808228	▁ HF ▁; ▁MI
D-1101	-0.9590765237808228	HF ; MI
P-1101	-2.7446 -0.5143 -0.6575 -0.2744 -1.4386 -0.1249
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal support
H-1296	-0.3485957086086273	
D-1296	-0.3485957086086273	
P-1296	-0.6372 -0.0600
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart failure ; disease ; therapeutics
H-1073	-0.5834476351737976	▁Heart ▁failure ▁; ▁disease
D-1073	-0.5834476351737976	Heart failure ; disease
P-1073	-0.4135 -0.2829 -1.6575 -0.6132 -0.4034 -0.1302
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary outcomes ; hemostasis
H-1116	-0.4796082675457001	▁hemos tas is
D-1116	-0.4796082675457001	hemostasis
P-1116	-1.3928 -0.2006 -0.3628 -0.2956 -0.1463
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective matched cohort study
H-1619	-0.4802878201007843	
D-1619	-0.4802878201007843	
P-1619	-0.8238 -0.1367
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 ; gene expression ; heart failure
H-169	-0.43713268637657166	▁Cas pas e -3 ▁gene ▁expression ▁; ▁heart ▁failure
D-169	-0.43713268637657166	Caspase-3 gene expression ; heart failure
P-169	-0.0381 -0.0060 -0.3203 -0.2117 -1.6984 -0.2660 -0.4053 -0.6995 -0.5697 -0.4050 -0.1885
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic ; heart failure ; outcomes
H-1198	-0.7650807499885559	▁di ure tic ▁use ▁; ▁heart ▁failure
D-1198	-0.7650807499885559	diuretic use ; heart failure
P-1198	-1.1323 -1.0114 -0.7122 -2.2759 -0.3608 -0.4401 -0.6062 -0.2392 -0.1076
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute right heart failure ; pulmonary hypertension
H-1090	-0.310833603143692	▁right ▁heart ▁failure ▁; ▁pulmonar y ▁hyper tension
D-1090	-0.310833603143692	right heart failure ; pulmonary hypertension
P-1090	-1.6681 -0.4585 -0.2018 -0.2247 -0.0020 -0.0782 -0.1066 -0.0369 -0.2296 -0.1018
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart failure ; patients ; bisphosphonates
H-1534	-0.29712218046188354	▁Heart ▁failure ▁; ▁bis phos phon ates
D-1534	-0.29712218046188354	Heart failure ; bisphosphonates
P-1534	-0.2961 -0.1104 -0.4415 -0.2782 -0.0363 -0.3247 -0.5033 -0.5329 -0.1507
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients ; functional capacity ; symptoms
H-550	-1.0517654418945312	
D-550	-1.0517654418945312	
P-550	-1.9173 -0.1862
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology ; diagnosed
H-352	-0.19779060781002045	▁MR ▁; ▁MS
D-352	-0.19779060781002045	MR ; MS
P-352	-0.1921 -0.3499 -0.0731 -0.2995 -0.0744
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients ; hypertension
H-1889	-1.1780091524124146	▁hyper tension
D-1889	-1.1780091524124146	hypertension
P-1889	-4.2060 -0.0967 -0.2369 -0.1725
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american ; hf
H-1843	-1.0112367868423462	▁American ▁; ▁Canadian ▁; ▁ HF
D-1843	-1.0112367868423462	American ; Canadian ; HF
P-1843	-2.8401 -0.6100 -0.1259 -0.4053 -2.1645 -1.3072 -0.5624 -0.0745
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart rate ; arterial pressure
H-424	-0.4386688470840454	▁Heart ▁rate ▁; ▁arterial ▁pressure
D-424	-0.4386688470840454	Heart rate ; arterial pressure
P-424	-0.5069 -0.4491 -0.7055 -0.1764 -0.7858 -0.3521 -0.0949
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up ; patients
H-1009	-0.4350173771381378	
D-1009	-0.4350173771381378	
P-1009	-0.7453 -0.1247
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic hf ; death
H-1796	-0.2127968668937683	▁Chro nic ▁ HF
D-1796	-0.2127968668937683	Chronic HF
P-1796	-0.0856 -0.0754 -0.1754 -0.1019 -0.7217 -0.1167
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac amyloidosis
H-997	-0.2473990023136139	▁Card iac ▁a my lo idos is
D-997	-0.2473990023136139	Cardiac amyloidosis
P-997	-0.3084 -0.0147 -0.1242 -0.2537 -0.0774 -0.3665 -0.6992 -0.3022 -0.0804
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training ; heart failure ; patients
H-1911	-0.8021031618118286	▁Robot - assist ed ▁training ▁; ▁heart ▁failure ▁patients
D-1911	-0.8021031618118286	Robot-assisted training ; heart failure patients
P-1911	-1.5687 -0.6670 -0.0134 -0.2104 -1.6987 -1.1194 -1.2988 -0.3862 -1.2226 -0.4394 -0.1986
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.718651533126831	
D-1616	-0.718651533126831	
P-1616	-1.3208 -0.1165
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.5008005499839783	▁Interna l ▁reli ability ▁; ▁Cro n bach
D-786	-0.5008005499839783	Internal reliability ; Cronbach
P-786	-0.8682 -0.5394 -0.4945 -0.2656 -0.4045 -0.3767 -0.0422 -0.0188 -1.9000 -0.0981
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients ; hfpef
H-787	-0.5191190242767334	▁ HF p EF
D-787	-0.5191190242767334	HFpEF
P-787	-1.3245 -0.6102 -0.0530 -0.5435 -0.4171 -0.1664
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection fraction ; bnp
H-194	-0.36854854226112366	▁e je ction ▁ fraction ▁; ▁sex ▁; ▁b NP
D-194	-0.36854854226112366	ejection fraction ; sex ; bNP
P-194	-0.8735 -0.1949 -0.0154 -0.2412 -0.0184 -0.2845 -0.5855 -0.3995 -0.8073 -0.6274 -0.2698 -0.1053
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic ; medication ; death
H-507	-0.3380614221096039	▁Pig s ▁; ▁anti ar rhythm ic ▁medication
D-507	-0.3380614221096039	Pigs ; antiarrhythmic medication
P-507	-0.5807 -0.1933 -0.8785 -0.0492 -0.1376 -0.0898 -0.1354 -0.1518 -1.0322 -0.1322
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients ; therapy ; beta blockade
H-1736	-0.8756603002548218	▁ therapy ▁; ▁beta ▁block ade
D-1736	-0.8756603002548218	therapy ; beta blockade
P-1736	-4.4955 -0.1097 -1.6039 -0.1419 -0.1938 -0.0703 -0.2626 -0.1275
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf ; patients ; intubated
H-219	-0.5111011862754822	▁CHF ▁patients ▁; ▁in tuba ted
D-219	-0.5111011862754822	CHF patients ; intubated
P-219	-0.0233 -1.9712 -0.8706 -0.0537 -0.1329 -0.6678 -0.2785 -0.0907
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical ; hypothermic circulatory arrest
H-598	-0.3510553240776062	▁circula tory ▁arrest
D-598	-0.3510553240776062	circulatory arrest
P-598	-1.1590 -0.1996 -0.0771 -0.2154 -0.1042
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary outcomes ; functional capacity ; quality of life
H-616	-0.8671971559524536	▁functional ▁capacity
D-616	-0.8671971559524536	functional capacity
P-616	-0.6549 -1.7110 -0.9421 -0.1608
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end point
H-266	-0.3662193715572357	
D-266	-0.3662193715572357	
P-266	-0.6483 -0.0841
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected ; patients ; systolic dysfunction
H-1069	-0.2736946940422058	▁sy sto lic ▁dys function
D-1069	-0.2736946940422058	systolic dysfunction
P-1069	-0.5356 -0.2804 -0.2304 -0.0692 -0.2073 -0.4832 -0.1098
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.3260469436645508	
D-32	-0.3260469436645508	
P-32	-0.5276 -0.1245
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.36449718475341797	
D-804	-0.36449718475341797	
P-804	-0.6081 -0.1208
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise ; quality of life ; heart failure
H-612	-1.5822337865829468	▁exercise ▁; ▁heart ▁failure
D-612	-1.5822337865829468	exercise ; heart failure
P-612	-3.3055 -0.9113 -4.3152 -0.3993 -0.4122 -0.1499
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.29449278116226196	▁implant ed ▁monitoring ▁devices
D-156	-0.29449278116226196	implanted monitoring devices
P-156	-0.3878 -0.3754 -0.0094 -0.6412 -0.2506 -0.1025
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.7938046455383301	
D-1469	-0.7938046455383301	
P-1469	-1.4750 -0.1126
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient ; conditions
H-0	-0.9465431571006775	▁patient ▁safety
D-0	-0.9465431571006775	patient safety
P-0	-1.5613 -1.6887 -0.3207 -0.2155
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea ; afterload
H-518	-1.0951662063598633	▁HR ▁; ▁Ea
D-518	-1.0951662063598633	HR ; Ea
P-518	-2.7479 -0.1952 -0.3724 -2.0373 -0.1229
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths ; strokes
H-778	-1.044467806816101	
D-778	-1.044467806816101	
P-778	-2.0110 -0.0779
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.4192066192626953	
D-677	-0.4192066192626953	
P-677	-0.6923 -0.1461
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras ; atherosclerosis
H-1594	-0.8745697736740112	RAS ▁; ▁at hero sc ler osis
D-1594	-0.8745697736740112	RAS ; atherosclerosis
P-1594	-0.3354 -0.5754 -2.0442 -0.3997 -0.0441 -3.9298 -0.1221 -0.3009 -0.1196
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty ; heart failure
H-1000	-0.5080117583274841	▁fra il ty ▁; ▁heart ▁failure
D-1000	-0.5080117583274841	frailty ; heart failure
P-1000	-0.1884 -0.3227 -0.2276 -1.0570 -1.5071 -0.2171 -0.3851 -0.1591
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas ; heart failure ; disease
H-1479	-0.3082861602306366	▁micro RNA s ▁; ▁heart ▁failure ▁; ▁disease ▁management
D-1479	-0.3082861602306366	microRNAs ; heart failure ; disease management
P-1479	-0.1276 -0.0532 -0.1847 -0.5314 -0.7053 -0.3085 -0.7832 -0.2283 -0.1157 -0.2696 -0.0837
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard ratios ; cox regression analysis
H-1770	-0.5390737056732178	▁co x ▁re gression ▁analysis
D-1770	-0.5390737056732178	cox regression analysis
P-1770	-2.5129 -0.2770 -0.1123 -0.0643 -0.2845 -0.3589 -0.1636
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss ; exercise ; training ; outcomes
H-1932	-1.0778651237487793	▁PS SS
D-1932	-1.0778651237487793	PSSS
P-1932	-1.6118 -1.1858 -1.4100 -0.1038
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart failure with preserved ejection fraction
H-1885	-0.45529404282569885	▁management ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1885	-0.45529404282569885	management ; heart failure ; ejection fraction
P-1885	-1.2872 -0.8650 -0.4397 -0.0522 -0.3279 -1.5716 -0.1356 -0.0558 -0.3948 -0.0075 -0.2307 -0.0956
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology ; bromodomain ; halts ; heart failure
H-1033	-0.4922475218772888	▁Card i ology ▁; ▁bro modo main ▁inhibi tion ▁; ▁heart ▁failure
D-1033	-0.4922475218772888	Cardiology ; bromodomain inhibition ; heart failure
P-1033	-0.4875 -0.8295 -0.1637 -0.3320 -0.6346 -0.0069 -0.3117 -0.0754 -0.3586 -0.3905 -2.6043 -0.2999 -0.3080 -0.0888
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.39965206384658813	▁AT
D-1759	-0.39965206384658813	AT
P-1759	-0.6979 -0.3385 -0.1626
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin ; congestive heart failure
H-633	-0.45640721917152405	▁vaso press in ▁; ▁con ges tive ▁heart ▁failure
D-633	-0.45640721917152405	vasopressin ; congestive heart failure
P-633	-0.0813 -0.1663 -0.6954 -0.2778 -0.0509 -0.3740 -2.1782 -0.6017 -0.2367 -0.2686 -0.0896
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral stenosis ; medical treatment ; heart failure
H-332	-0.6748340725898743	▁mit ral ▁sten osis ▁; ▁medical ▁treatment ▁; ▁heart ▁failure
D-332	-0.6748340725898743	mitral stenosis ; medical treatment ; heart failure
P-332	-1.4701 -0.0686 -0.0679 -0.0332 -0.6551 -2.3269 -1.4085 -0.7693 -0.2932 -0.3465 -0.4921 -0.1666
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart failure ; hospitalization ; cardiovascular death
H-410	-0.7770092487335205	▁heart ▁failure ▁hospital ization ▁; ▁cardiovascular ▁death
D-410	-0.7770092487335205	heart failure hospitalization ; cardiovascular death
P-410	-1.7733 -0.3308 -2.4018 -0.8472 -0.5844 -0.0576 -0.6295 -0.2478 -0.1207
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity ; patients ; breast cancer
H-669	-0.6150733232498169	▁Tras tuz um ab - related ▁cardio toxic iteit ▁; ▁breast ▁cancer
D-669	-0.6150733232498169	Trastuzumab-related cardiotoxiciteit ; breast cancer
P-669	-0.4133 -0.1957 -0.1693 -0.7011 -0.3153 -0.6673 -0.1258 -0.9149 -2.2394 -0.7751 -1.3106 -0.1657 -0.4476 -0.1699
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart failure ; hf ; therapy
H-1067	-0.9972635507583618	▁Device s ▁; ▁heart ▁failure ▁; HF
D-1067	-0.9972635507583618	Devices ; heart failure ;HF
P-1067	-1.7893 -0.0897 -0.8718 -3.1636 -0.1498 -0.3080 -0.1503 -2.3362 -0.1166
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality ; sts
H-159	-1.2898471355438232	▁mortal iteit ▁; ▁s ts ▁ HM
D-159	-1.2898471355438232	mortaliteit ; sts HM
P-159	-3.8768 -2.2756 -0.8251 -0.8885 -1.7250 -1.1093 -0.3957 -0.3938 -0.1188
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 ; hf
H-1211	-0.5113478899002075	▁p de 2 ▁; ▁ HF
D-1211	-0.5113478899002075	pde2 ; HF
P-1211	-1.1608 -0.7173 -0.0270 -0.1896 -0.8561 -0.8608 -0.1962 -0.0830
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital ; coprimary outcome
H-1651	-0.967705249786377	▁Night s ▁spent ▁in ▁hospital
D-1651	-0.967705249786377	Nights spent in hospital
P-1651	-2.6985 -0.1613 -1.5436 -1.7456 -0.2212 -0.2878 -0.1160
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart failure ; public ; health
H-1606	-1.5166690349578857	▁Heart ▁failure
D-1606	-1.5166690349578857	Heart failure
P-1606	-1.7179 -0.9997 -3.0961 -0.2530
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative ; albumin
H-539	-0.6063752770423889	▁album in ▁level
D-539	-0.6063752770423889	albumin level
P-539	-1.7676 -0.4656 -0.1280 -0.5726 -0.0981
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet ; aortic pressure
H-581	-0.6616408824920654	▁l VET ▁; ▁a or tic ▁pressure ▁cur ve
D-581	-0.6616408824920654	lVET ; aortic pressure curve
P-581	-2.5105 -0.1752 -0.4615 -0.2861 -0.3102 -1.1121 -1.3585 -0.4924 -0.1736 -0.2908 -0.1070
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician ; outcomes ; discharge
H-1414	-0.5638365745544434	▁physician ▁continu ity ▁; ▁dis charge
D-1414	-0.5638365745544434	physician continuity ; discharge
P-1414	-0.8004 -0.1482 -1.3527 -0.8274 -0.9992 -0.0873 -0.1758 -0.1198
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication ; sst2
H-403	-0.808617889881134	▁Medica tion ▁regime n ▁; ▁s st 2
D-403	-0.808617889881134	Medication regimen ; sst2
P-403	-0.9329 -0.6921 -0.8731 -0.3026 -1.0482 -0.0026 -2.5722 -0.1552 -1.3759 -0.1314
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-0.8225802779197693	
D-150	-0.8225802779197693	
P-150	-1.5292 -0.1159
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac ; symptoms ; congenital ; lesions
H-983	-0.5473446846008301	▁Card iac ▁symptoms ▁; ▁children
D-983	-0.5473446846008301	Cardiac symptoms ; children
P-983	-0.4563 -0.0485 -0.5059 -0.7955 -1.3437 -0.5736 -0.1079
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone ; systolic heart failure
H-437	-0.155248761177063	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-437	-0.155248761177063	spironolactone ; systolic heart failure
P-437	-0.0679 -0.0394 -0.0489 -0.0472 -0.3025 -0.0248 -0.1176 -0.0724 -0.5157 -0.2118 -0.2905 -0.1244
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular scaffolds ; heart ; pathology
H-989	-0.7373697757720947	▁e RK 1/2 ▁molecular ▁sc af fold s ▁; ▁heart ▁path ology
D-989	-0.7373697757720947	eRK1/2 molecular scaffolds ; heart pathology
P-989	-1.4671 -0.0632 -0.5108 -0.3478 -1.4727 -2.7353 -0.8019 -0.2344 -0.4196 -0.5470 -0.4451 -0.7224 -0.3855 -0.1704
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional ms ; reported ; patients ; degenerative mr
H-339	-0.19138289988040924	▁Fun ction al ▁MS ▁; ▁de genera tive ▁MR
D-339	-0.19138289988040924	Functional MS ; degenerative MR
P-339	-0.2418 -0.0178 -0.0099 -0.0536 -0.5566 -0.3013 -0.0220 -0.3714 -0.0664 -0.3556 -0.1087
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology ; chronic heart failure ; bisoprolol
H-645	-0.6069236993789673	▁chronic ▁heart ▁failure ▁; ▁bis o pro lol
D-645	-0.6069236993789673	chronic heart failure ; bisoprolol
P-645	-3.1811 -1.0389 -0.2012 -0.1219 -0.1198 -0.6734 -0.0806 -0.0798 -0.4422 -0.1302
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart failure ; hf ; leading ; mortality ; society
H-1034	-0.531175434589386	▁Heart ▁failure ▁; HF
D-1034	-0.531175434589386	Heart failure ;HF
P-1034	-0.4441 -0.0639 -0.1986 -0.1434 -2.2166 -0.1204
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate adjustment ; cox proportional hazards models
H-785	-0.66054767370224	▁co x ▁proportion al ▁hazard s
D-785	-0.66054767370224	cox proportional hazards
P-785	-0.1160 -2.4102 -0.0818 -0.0433 -0.0902 -1.3759 -1.0181 -0.1489
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician ; hospital ; physician
H-1726	-1.4390859603881836	▁physician ▁volume
D-1726	-1.4390859603881836	physician volume
P-1726	-2.0277 -1.9489 -1.5980 -0.1819
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan ; vasopressin type 2 receptor antagonist
H-1195	-0.37641721963882446	▁Tol va p tan ▁; ▁vaso press in ▁; ▁receptor
D-1195	-0.37641721963882446	Tolvaptan ; vasopressin ; receptor
P-1195	-0.0400 -0.0347 -0.1336 -0.0396 -0.3723 -0.1155 -0.0774 -0.8264 -1.1421 -0.0104 -1.5921 -0.1329
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs ; expenditures
H-1238	-0.9169473052024841	▁ar rhythm ia - related ▁costs
D-1238	-0.9169473052024841	arrhythmia-related costs
P-1238	-1.4583 -0.2983 -1.2689 -0.2083 -0.2040 -2.7541 -1.0201 -0.1236
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.7423312664031982	▁ metric ▁; ▁read mission ▁metri cs
D-134	-0.7423312664031982	metric ; readmission metrics
P-134	-0.4986 -0.1108 -0.9845 -0.9151 -2.4206 -0.1969 -1.0986 -0.3355 -0.1203
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.9090361595153809	▁read mission ▁ metric
D-145	-0.9090361595153809	readmission metric
P-145	-0.5874 -2.3748 -1.3898 -0.0387 -0.9488 -0.1146
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.5890747308731079	
D-1998	-0.5890747308731079	
P-1998	-1.0206 -0.1576
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.5521340370178223	▁media n ▁follow - up
D-1758	-0.5521340370178223	median follow-up
P-1758	-2.7218 -0.1719 -0.0723 -0.5575 -0.0570 -0.1942 -0.0902
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.578599214553833	
D-1261	-0.578599214553833	
P-1261	-0.9660 -0.1912
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-0.8411703109741211	
D-958	-0.8411703109741211	
P-958	-1.5516 -0.1307
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-0.5910981893539429	▁black ▁patients
D-1634	-0.5910981893539429	black patients
P-1634	-0.4473 -1.3830 -0.3551 -0.1790
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-0.8027966022491455	▁et ▁; ▁CHF
D-261	-0.8027966022491455	et ; CHF
P-261	-2.2650 -0.8406 -0.3816 -0.4096 -0.1172
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable hf
H-481	-0.6779093146324158	▁ HF
D-481	-0.6779093146324158	HF
P-481	-2.0342 -0.3024 -0.2939 -0.0811
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-1.1425954103469849	▁follow - up
D-1839	-1.1425954103469849	follow-up
P-1839	-5.0996 -0.2493 -0.0767 -0.1970 -0.0904
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality of life
H-1919	-1.0622901916503906	
D-1919	-1.0622901916503906	
P-1919	-2.0061 -0.1185
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.6187286972999573	▁pro pens ity
D-1837	-0.6187286972999573	propensity
P-1837	-0.3775 -0.0573 -2.3338 -0.2249 -0.1000
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb ; correlated ; baseline ; hrqol
H-840	-0.5562549829483032	▁h gb ▁level ▁; ▁HR Qo L
D-840	-0.5562549829483032	hgb level ; HRQoL
P-840	-0.3344 -0.1224 -0.3673 -0.3222 -1.7084 -0.0106 -1.6578 -0.3628 -0.1202
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved ejection fraction ; outcomes
H-1464	-0.31528279185295105	▁e je ction ▁ fraction
D-1464	-0.31528279185295105	ejection fraction
P-1464	-0.1870 -0.1986 -0.0625 -0.8475 -0.0184 -0.7738 -0.1191
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic ; biomarkers ; chronic heart failure
H-1471	-0.2939104735851288	▁bio mark ers ▁; ▁chronic ▁heart ▁failure
D-1471	-0.2939104735851288	biomarkers ; chronic heart failure
P-1471	-0.1044 -0.1882 -0.3483 -0.3639 -0.2939 -0.8173 -0.1593 -0.2633 -0.1067
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated hf ; cardiovascular ; hospitalization
H-1797	-0.4838707745075226	▁ HF ▁; ▁cardiovascular ▁hospital ization
D-1797	-0.4838707745075226	HF ; cardiovascular hospitalization
P-1797	-1.4489 -0.3315 -0.4967 -0.1046 -0.4352 -0.7547 -0.1821 -0.1173
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients ; cardiac ; inflammatory ; biomarkers
H-1914	-0.30498161911964417	▁cardiac ▁; ▁infla mma tory ▁bio mark ers
D-1914	-0.30498161911964417	cardiac ; inflammatory biomarkers
P-1914	-0.0680 -0.8101 -0.0927 -0.7070 -0.1986 -0.0263 -0.1989 -0.4696 -0.3141 -0.1645
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed ; mortality ; random-effects models
H-64	-0.7698368430137634	▁mortal iteit
D-64	-0.7698368430137634	mortaliteit
P-64	-0.1726 -2.2470 -0.4653 -0.1944
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes ; patients ; heart failure ; emergency department
H-461	-1.2520132064819336	▁heart ▁failure
D-461	-1.2520132064819336	heart failure
P-461	-3.4025 -0.5128 -0.9429 -0.1498
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological ; acute heart failure
H-1465	-0.8266194462776184	▁Pharma c ological ▁treatment ▁; ▁a cute ▁heart ▁failure
D-1465	-0.8266194462776184	Pharmacological treatment ; acute heart failure
P-1465	-3.5625 -0.0929 -0.5476 -2.0289 -0.6248 -0.1545 -0.0489 -1.0442 -0.1863 -0.6893 -0.1129
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping ; baseline ; heart failure
H-1059	-1.5854980945587158	▁heart ▁failure
D-1059	-1.5854980945587158	heart failure
P-1059	-3.7121 -0.5291 -1.9355 -0.1653
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal ; heartmate ii
H-772	-0.3317171633243561	▁off - pump ▁; ▁ster nal ▁spar ing ▁approach ▁; ▁Heart Mate ▁II ▁exchange
D-772	-0.3317171633243561	off-pump ; sternal sparing approach ; HeartMate II exchange
P-772	-0.0065 -0.1750 -0.1693 -1.1404 -0.2369 -0.4590 -0.2708 -0.0589 -0.8446 -0.3163 -0.4494 -0.1006 -0.6534 -0.0241 -0.3047 -0.0976
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis ; patients ; implantation
H-913	-0.4901931881904602	▁di al ysis ▁patients ▁; ▁device ▁implant ation
D-913	-0.4901931881904602	dialysis patients ; device implantation
P-913	-0.2243 -0.0670 -0.0341 -1.3802 -0.6802 -0.8683 -0.1095 -0.9629 -0.4476 -0.1279
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary angiography ; lesions
H-349	-0.6453574895858765	▁Corona ry ▁ang i ography
D-349	-0.6453574895858765	Coronary angiography
P-349	-0.0270 -2.2924 -0.2738 -1.2160 -0.2274 -0.3742 -0.1067
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic phenotype ; fontan
H-223	-0.27491554617881775	▁Hem o dynamic ▁ph eno type ▁; ▁Font an
D-223	-0.27491554617881775	Hemodynamic phenotype ; Fontan
P-223	-0.6551 -0.4621 -0.0073 -0.4948 -0.1584 -0.0096 -0.2921 -0.3574 -0.1069 -0.4081 -0.0723
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient ; surgery ; echocardiography
H-358	-0.3149714767932892	▁MS ▁; ▁e cho card i ography
D-358	-0.3149714767932892	MS ; echocardiography
P-358	-0.0774 -0.5192 -0.5817 -0.1010 -0.1906 -0.8889 -0.1478 -0.2653 -0.0628
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise ; life expectancy
H-1902	-0.7228153944015503	
D-1902	-0.7228153944015503	
P-1902	-1.2669 -0.1788
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate analyses
H-826	-0.9804499745368958	
D-826	-0.9804499745368958	
P-826	-1.8384 -0.1225
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart failure ; cox proportional hazard analyses
H-1537	-0.37551599740982056	▁heart ▁failure ▁; ▁co x ▁proportion al ▁hazard ▁analyse s
D-1537	-0.37551599740982056	heart failure ; cox proportional hazard analyses
P-1537	-1.9604 -0.3088 -0.6523 -0.0498 -0.0874 -0.0668 -0.0209 -0.1122 -0.6332 -0.3243 -0.2073 -0.0829
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized ; walking ; patients ; severe heart failure
H-567	-1.3435444831848145	▁Nordic ▁walking ▁; ▁heart ▁failure
D-567	-1.3435444831848145	Nordic walking ; heart failure
P-567	-1.1685 -1.9588 -0.6542 -4.6797 -0.3490 -0.3975 -0.1972
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric ; self-care of heart failure index version 6.2
H-1503	-0.48916083574295044	▁Psycho metric ▁testing ▁; ▁Self - car e ▁of ▁Heart ▁Fail ure ▁index
D-1503	-0.48916083574295044	Psychometric testing ; Self-care of Heart Failure index
P-1503	-1.0393 -0.0194 -0.3276 -0.3780 -0.2371 -0.0534 -1.4311 -0.5196 -0.8686 -0.5345 -0.2704 -0.8253 -0.5028 -0.2347 -0.0956
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient ; postoperatively ; multiorgan failure ; sepsis
H-551	-0.2251998484134674	▁multi organ ▁failure ▁; ▁se psis
D-551	-0.2251998484134674	multiorgan failure ; sepsis
P-551	-0.7722 -0.0367 -0.2850 -0.3108 -0.0733 -0.0074 -0.2049 -0.1112
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients ; acute kidney injury ; postoperatively
H-975	-0.6303313970565796	▁a cute ▁ki dne y ▁injury
D-975	-0.6303313970565796	acute kidney injury
P-975	-2.4745 -0.0533 -0.0665 -1.1372 -0.1192 -0.5898 -0.4512 -0.1509
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max ; significance
H-1255	-0.41148585081100464	▁VO 2 max
D-1255	-0.41148585081100464	VO2max
P-1255	-1.1527 -0.2521 -0.0769 -0.4463 -0.1295
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive statistics ; cox proportional hazards models
H-675	-0.3922758996486664	▁co x ▁proportion al ▁hazard s
D-675	-0.3922758996486664	cox proportional hazards
P-675	-0.1887 -0.1595 -0.0778 -0.0298 -0.1375 -1.2052 -1.1855 -0.1540
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle heart failure model
H-2011	-0.4579404294490814	▁Seattle ▁Heart ▁Fail ure ▁model
D-2011	-0.4579404294490814	Seattle Heart Failure model
P-2011	-0.4393 -0.7903 -0.3559 -0.3342 -0.9251 -0.2621 -0.0987
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-1.7814806699752808	
D-603	-1.7814806699752808	
P-603	-3.3626 -0.2003
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart failure
H-1204	-1.2798280715942383	▁heart ▁failure
D-1204	-1.2798280715942383	heart failure
P-1204	-4.0207 -0.5995 -0.3716 -0.1275
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.33924978971481323	
D-1854	-0.33924978971481323	
P-1854	-0.5323 -0.1462
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.4505974054336548	
D-1923	-0.4505974054336548	
P-1923	-0.7467 -0.1545
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.3978573977947235	
D-800	-0.3978573977947235	
P-800	-0.7255 -0.0703
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.7285082936286926	▁ab normal ▁cardiac ▁t 2
D-746	-0.7285082936286926	abnormal cardiac t2
P-746	-0.8393 -0.0097 -0.0325 -2.5801 -0.0241 -1.5232 -0.0907
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-1.0327996015548706	▁voordelen
D-1028	-1.0327996015548706	voordelen
P-1028	-2.7243 -0.2925 -0.0815
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.486532598733902	
D-1206	-0.486532598733902	
P-1206	-0.8642 -0.1088
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated ; hf
H-608	-0.38760048151016235	▁HR ▁; HF
D-608	-0.38760048151016235	HR ;HF
P-608	-0.1768 -0.3755 -1.0385 -0.2596 -0.0877
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.41928672790527344	
D-591	-0.41928672790527344	
P-591	-0.6618 -0.1768
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug ; japan
H-1197	-0.667540431022644	▁drug ▁; ▁japan
D-1197	-0.667540431022644	drug ; japan
P-1197	-1.1355 -0.7639 -1.0710 -0.2861 -0.0811
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.20790068805217743	▁bio mark ers
D-70	-0.20790068805217743	biomarkers
P-70	-0.1578 -0.1075 -0.2064 -0.4346 -0.1332
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome ; tug test
H-799	-0.8229851126670837	▁m AIN ▁o UTC OME ▁; ▁tu g ▁test
D-799	-0.8229851126670837	mAIN oUTCOME ; tug test
P-799	-3.0657 -0.2144 -0.6106 -0.0236 -0.1153 -1.3367 -0.4862 -2.6514 -0.2748 -0.2195 -0.0548
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients ; esrd
H-394	-1.0303970575332642	▁ES RD
D-394	-1.0303970575332642	ESRD
P-394	-2.6798 -0.8385 -0.3791 -0.2242
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart failure with preserved left ventricular ejection fraction
H-1299	-0.47018495202064514	▁Heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1299	-0.47018495202064514	Heart failure ; left ventricular ejection fraction
P-1299	-0.1460 -0.1194 -0.2730 -1.9714 -0.0638 -1.5973 -0.3521 -0.1808 -0.2838 -0.1431 -0.9849 -0.0123 -0.3588 -0.0959
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome ; all-cause readmissions
H-1580	-0.9045921564102173	▁m AIN ▁o UTC OME ▁; ▁read missions
D-1580	-0.9045921564102173	mAIN oUTCOME ; readmissions
P-1580	-3.9592 -0.3483 -1.1518 -0.0420 -0.4297 -2.2921 -0.3020 -0.1844 -0.2443 -0.0922
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence ; systolic hf
H-1798	-0.22928614914417267	▁sy sto lic ▁ HF
D-1798	-0.22928614914417267	systolic HF
P-1798	-0.1338 -0.2196 -0.0261 -0.6041 -0.2728 -0.2545 -0.0941
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary outcome ; patient ; post
H-617	-0.5531589984893799	
D-617	-0.5531589984893799	
P-617	-0.9425 -0.1638
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients ; lvad ; implantation
H-545	-0.5258715748786926	▁l VAD ▁implant ation
D-545	-0.5258715748786926	lVAD implantation
P-545	-0.9183 -0.0674 -0.7383 -0.8850 -0.4097 -0.1365
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation ; postsystolic function
H-331	-0.5555956363677979	▁posts y sto lic ▁function
D-331	-0.5555956363677979	postsystolic function
P-331	-2.0103 -0.5113 -0.3344 -0.0620 -0.4121 -0.4559 -0.1032
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication ; resting hemodynamics
H-828	-0.3885817527770996	▁medication ▁; ▁rest ing ▁hem o dynamic s
D-828	-0.3885817527770996	medication ; resting hemodynamics
P-828	-0.6103 -0.3259 -0.3374 -0.1190 -0.5603 -1.1127 -0.0159 -0.2595 -0.4488 -0.0961
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis ; pathophysiological
H-1276	-0.8884585499763489	
D-1276	-0.8884585499763489	
P-1276	-1.6658 -0.1111
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac ; cardiac hypertrophy
H-1782	-0.45589834451675415	▁a ac ▁; ▁cardiac ▁hyper trop hy
D-1782	-0.45589834451675415	aac ; cardiac hypertrophy
P-1782	-0.3331 -0.3778 -0.3701 -0.2062 -0.5577 -0.0856 -1.7626 -0.3032 -0.1068
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha ; esc
H-1908	-1.1145257949829102	AHA ▁; ▁ESC
D-1908	-1.1145257949829102	AHA ; ESC
P-1908	-0.6112 -0.5511 -3.3715 -0.8917 -0.1472
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician ; outcomes ; patients ; heart failure
H-1720	-1.8670486211776733	▁heart ▁failure
D-1720	-1.8670486211776733	heart failure
P-1720	-6.2305 -0.4775 -0.4666 -0.2936
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal muscle ; exercise capacity ; fontan circulation
H-1491	-0.6820021867752075	kelet al ▁muscle ▁ab normal ities ▁; ▁exercise ▁capacity ▁; ▁Font an ▁circulation
D-1491	-0.6820021867752075	keletal muscle abnormalities ; exercise capacity ; Fontan circulation
P-1491	-4.7698 -0.1201 -0.2061 -0.2097 -0.0759 -1.6830 -0.3752 -0.3510 -0.6311 -0.3417 -0.9650 -0.0501 -0.0603 -0.2936 -0.0975
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission ; hospital ; heart failure ; discharge
H-147	-0.9682636260986328	▁hospital ▁; ▁heart ▁failure
D-147	-0.9682636260986328	hospital ; heart failure
P-147	-3.0908 -1.0699 -0.9726 -0.1905 -0.3392 -0.1467
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease ; lead ; hypertension ; kidney failure
H-1598	-0.40249890089035034	▁progressive ▁disease ▁; ▁hyper tension ▁; ▁ki dne y ▁failure
D-1598	-0.40249890089035034	progressive disease ; hypertension ; kidney failure
P-1598	-2.4388 -0.4344 -0.2230 -0.6685 -0.0300 -0.1439 -0.1131 -0.3163 -0.0611 -0.0867 -0.2356 -0.0786
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients ; chronic kidney disease ; ckd
H-898	-0.5762943029403687	▁chronic ▁ki dne y ▁disease ▁; CK d
D-898	-0.5762943029403687	chronic kidney disease ;CKd
P-898	-1.3385 -0.2752 -1.1787 -0.4204 -0.2746 -0.4311 -0.7435 -0.6264 -0.3265 -0.1481
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income ; expenditure ; health
H-1792	-0.5813911557197571	▁gross ▁income ▁; ▁ex pendi ture ▁; ▁health ▁per ▁capita
D-1792	-0.5813911557197571	gross income ; expenditure ; health per capita
P-1792	-1.6715 -0.4377 -0.2993 -0.6426 -0.0874 -1.2966 -0.8910 -0.5832 -0.4669 -0.0163 -0.4783 -0.1059
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations ; hospital ; longitudinal ; change
H-143	-0.4693368673324585	▁hospital
D-143	-0.4693368673324585	hospital
P-143	-0.9868 -0.2325 -0.1887
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr variability ; cardiac death
H-1589	-0.6661794781684875	▁ab normal ▁HR ▁variabil ity ▁; ▁cardiac ▁death
D-1589	-0.6661794781684875	abnormal HR variability ; cardiac death
P-1589	-1.5656 -0.0093 -0.6247 -0.3966 -1.5862 -0.3613 -1.1928 -0.6095 -0.1912 -0.1246
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient ; circulation
H-1824	-0.41760900616645813	▁circulation
D-1824	-0.41760900616645813	circulation
P-1824	-0.8890 -0.2319 -0.1320
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic blood pressure
H-1048	-0.7191527485847473	▁ toxic iteit ▁; ▁system ic ▁blood ▁pressure
D-1048	-0.7191527485847473	toxiciteit ; systemic blood pressure
P-1048	-0.4602 -0.7208 -2.2577 -0.4040 -0.8621 -0.3079 -0.9563 -0.7441 -0.3573 -0.1210
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.40452101826667786	
D-1881	-0.40452101826667786	
P-1881	-0.6276 -0.1815
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.3534640073776245	
D-1576	-0.3534640073776245	
P-1576	-0.5460 -0.1609
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.5280316472053528	
D-1965	-0.5280316472053528	
P-1965	-0.9350 -0.1211
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north america
H-75	-0.4896382987499237	▁North ▁America
D-75	-0.4896382987499237	North America
P-75	-1.2130 -0.4657 -0.2051 -0.0747
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.3280462920665741	▁c PG s
D-1848	-0.3280462920665741	cPGs
P-1848	-0.6544 -0.3777 -0.0973 -0.3808 -0.1300
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.3987707495689392	▁MS ▁; ▁surgery
D-372	-0.3987707495689392	MS ; surgery
P-372	-0.1024 -1.5010 -0.0377 -0.2590 -0.0938
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity ; outcomes
H-709	-1.0443476438522339	
D-709	-1.0443476438522339	
P-709	-1.9509 -0.1378
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute heart failure
H-1014	-0.6180605888366699	▁a cute ▁heart ▁failure
D-1014	-0.6180605888366699	acute heart failure
P-1014	-1.0846 -0.0399 -0.4513 -0.1456 -1.8759 -0.1112
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients ; heart failure
H-1821	-1.2807718515396118	▁patients ▁; ▁heart ▁failure
D-1821	-1.2807718515396118	patients ; heart failure
P-1821	-3.2736 -2.8211 -1.0246 -0.2008 -0.2328 -0.1318
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic ; hf
H-1072	-0.7469460964202881	▁stand - a lone ▁diagnostic ▁devices ▁; HF
D-1072	-0.7469460964202881	stand-alone diagnostic devices ;HF
P-1072	-1.3916 -0.1852 -0.3941 -0.0446 -1.4092 -0.2566 -0.5023 -2.9872 -0.1962 -0.1024
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end stage heart failure
H-1669	-1.6834486722946167	▁heart ▁failure
D-1669	-1.6834486722946167	heart failure
P-1669	-6.0994 -0.2884 -0.2665 -0.0795
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician ; hf
H-1732	-0.9258333444595337	▁ HF
D-1732	-0.9258333444595337	HF
P-1732	-2.0417 -0.4331 -1.0818 -0.1467
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial function ; flow-mediated dilatation
H-253	-0.43394359946250916	▁en dot heli al ▁function ▁; ▁di la tation
D-253	-0.43394359946250916	endothelial function ; dilatation
P-253	-1.3344 -0.6892 -0.1571 -0.0188 -0.0657 -0.8727 -0.8102 -0.4943 -0.0438 -0.2120 -0.0752
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone ; severe heart failure
H-1701	-0.3502238094806671	▁Race ▁; ▁spi rono lac tone ▁; ▁heart ▁failure
D-1701	-0.3502238094806671	Race ; spironolactone ; heart failure
P-1701	-0.4949 -0.2749 -0.1459 -0.0405 -0.1227 -0.1012 -0.3710 -1.7836 -0.1286 -0.2433 -0.1459
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients ; heart failure ; cardiac rehabilitation
H-568	-0.859961986541748	▁heart ▁failure ▁; ▁cardiac ▁rehabilita tion
D-568	-0.859961986541748	heart failure ; cardiac rehabilitation
P-568	-3.6575 -0.6792 -0.7778 -0.1012 -0.1248 -0.9512 -0.4309 -0.1572
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control ; outcomes
H-1232	-0.7627469301223755	▁ Rhythm - ▁and ▁rate - control
D-1232	-0.7627469301223755	Rhythm- and rate-control
P-1232	-0.9026 -0.0781 -0.1490 -3.4874 -0.0905 -0.3574 -0.0283 -1.6378 -0.1335
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise ; training ; outcomes
H-1640	-0.9114550948143005	▁race ▁; ▁exercise
D-1640	-0.9114550948143005	race ; exercise
P-1640	-2.1605 -1.0530 -0.0944 -1.1352 -0.1142
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia ; patients ; heart disease
H-39	-1.2196775674819946	▁voordelen ▁; ▁an emia ▁treatment ▁; ▁heart ▁disease
D-39	-1.2196775674819946	voordelen ; anemia treatment ; heart disease
P-39	-3.4510 -0.7345 -0.5868 -0.6146 -2.6874 -0.4278 -2.8233 -0.3782 -0.3597 -0.1334
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians ; patients ; hf
H-1724	-1.211512565612793	▁ HF
D-1724	-1.211512565612793	HF
P-1724	-3.8056 -0.5388 -0.3868 -0.1149
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial infarction
H-1137	-0.3407769501209259	▁My o card ial ▁in far ction ▁; ▁Wi star ▁rat s
D-1137	-0.3407769501209259	Myocardial infarction ; Wistar rats
P-1137	-0.3343 -0.4575 -0.3405 -0.6539 -0.0415 -0.5863 -0.1267 -0.7316 -0.5905 -0.1470 -0.0783 -0.1680 -0.3823 -0.1325
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad ai
H-543	-0.498037189245224	▁algorithm s ▁; ▁post - ▁l VAD ▁AI
D-543	-0.498037189245224	algorithms ; post- lVAD AI
P-543	-1.2576 -0.3851 -0.7876 -0.1052 -0.0256 -1.4897 -0.0416 -0.3580 -0.4225 -0.1074
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients ; surgical
H-547	-0.6000787615776062	▁AI
D-547	-0.6000787615776062	AI
P-547	-0.5046 -1.1585 -0.1372
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus rhythm ; adverse outcomes
H-1644	-0.24039104580879211	▁sinus ▁ rhythm ▁; ▁AF
D-1644	-0.24039104580879211	sinus rhythm ; AF
P-1644	-0.2491 -0.2485 -0.2329 -0.4252 -0.2292 -0.2223 -0.0756
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public reporting ; patients ; hospitals
H-1689	-1.319343090057373	▁public ▁report ing ▁; ▁hospital s
D-1689	-1.319343090057373	public reporting ; hospitals
P-1689	-2.6660 -0.0881 -0.0933 -1.3763 -5.2364 -0.5530 -0.4010 -0.1406
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative ; operative ; outcomes
H-299	-0.2729109823703766	
D-299	-0.2729109823703766	
P-299	-0.4580 -0.0878
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth ; longitudinal ; medicare
H-1617	-0.6550883054733276	▁care ▁management ▁; ▁tele health ▁; ▁medica re
D-1617	-0.6550883054733276	care management ; telehealth ; medicare
P-1617	-3.7168 -0.0920 -0.1919 -0.3041 -0.4024 -0.4081 -0.0131 -0.0532 -1.2185 -0.1507
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal ; diagnostic ; filling pressures
H-490	-0.7084273099899292	▁diagnosti ▁; ▁fill ing ▁pressure s
D-490	-0.7084273099899292	diagnosti ; filling pressures
P-490	-1.5245 -2.3342 -0.3783 -0.1557 -0.3163 -0.4401 -0.4403 -0.0781
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity pathway analysis
H-875	-0.9803601503372192	▁ingen u ity
D-875	-0.9803601503372192	ingenuity
P-875	-0.7888 -0.6730 -1.7691 -1.5120 -0.1588
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf ; chromatin hyperacetylation
H-1036	-0.4494505822658539	▁molecular ▁level ▁; ▁ HF ▁; ▁chr omat in ▁hyper ace ty lation
D-1036	-0.4494505822658539	molecular level ; HF ; chromatin hyperacetylation
P-1036	-1.3579 -0.1087 -0.3047 -1.3897 -0.2303 -0.3417 -0.0928 -0.0297 -1.3946 -0.1426 -0.3270 -0.5785 -0.1060 -0.2684 -0.0690
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing ; nursing
H-1397	-1.0075191259384155	
D-1397	-1.0075191259384155	
P-1397	-1.8383 -0.1768
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute heart failure
H-468	-0.5784076452255249	▁a cute ▁heart ▁failure
D-468	-0.5784076452255249	acute heart failure
P-468	-1.4846 -0.0553 -1.3665 -0.1247 -0.2826 -0.1567
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse events
H-1263	-0.43276140093803406	
D-1263	-0.43276140093803406	
P-1263	-0.7827 -0.0828
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.8712759613990784	▁MS
D-370	-0.8712759613990784	MS
P-370	-1.1178 -1.3794 -0.1166
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-0.3413029909133911	▁g LS ▁; ▁CV ▁events ▁; ▁AF
D-810	-0.3413029909133911	gLS ; CV events ; AF
P-810	-0.1786 -0.6257 -0.3245 -0.3491 -0.4988 -0.5658 -0.1478 -0.3107 -0.0707
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit index
H-1006	-0.27627119421958923	▁deficit ▁index
D-1006	-0.27627119421958923	deficit index
P-1006	-0.4371 -0.0400 -0.5380 -0.0899
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.22272174060344696	
D-1855	-0.22272174060344696	
P-1855	-0.3418 -0.1036
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.3588063418865204	▁follow - up
D-1165	-0.3588063418865204	follow-up
P-1165	-0.9361 -0.4536 -0.0683 -0.2544 -0.0816
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-0.9578960537910461	▁mortal iteit
D-1696	-0.9578960537910461	mortaliteit
P-1696	-0.8916 -2.5258 -0.2673 -0.1469
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients ; hospitals
H-3	-0.8744291067123413	▁hospital s
D-3	-0.8744291067123413	hospitals
P-3	-2.2480 -0.9153 -0.2110 -0.1234
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs duration
H-888	-1.2496470212936401	▁QR s
D-888	-1.2496470212936401	QRs
P-888	-1.0590 -1.5493 -2.2850 -0.1053
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort study
H-1829	-0.3859122097492218	
D-1829	-0.3859122097492218	
P-1829	-0.6763 -0.0955
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf ; unilateral renal dnx ; cardiac ; autonomic balance
H-1372	-0.21803250908851624	▁CHF ▁; ▁unilateral ▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance
D-1372	-0.21803250908851624	CHF ; unilateral renal DNx ; cardiac autonomic balance
P-1372	-0.0027 -0.3719 -0.0042 -0.0123 -0.9009 -0.0664 -0.5063 -0.0337 -0.0235 -0.1809 -0.3177 -0.3411 -0.0727
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral regurgitation ; hf ; symptoms ; surgery
H-362	-0.48363640904426575	▁mit ral ▁re gur gi tation ▁; ▁ HF
D-362	-0.48363640904426575	mitral regurgitation ; HF
P-362	-2.0962 -0.1436 -0.1583 -0.3274 -0.4185 -0.2683 -0.4009 -0.5653 -0.4967 -0.3439 -0.1010
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone system inhibitors ; heart failure
H-1486	-0.22244207561016083	▁re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁; ▁heart ▁failure
D-1486	-0.22244207561016083	renin-angiotensin-aldosterone system inhibitors ; heart failure
P-1486	-0.2103 -0.1542 -0.0643 -0.0005 -0.2049 -0.5105 -0.1180 -0.0198 -0.2192 -0.0535 -0.5402 -0.0761 -0.4100 -0.3308 -0.4230 -0.1883 -0.2799 -0.2875 -0.1353
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic ; anaerobic threshold ; heart failure
H-1752	-0.43883824348449707	▁ana ero bic ▁thre s hold ▁; ▁heart ▁failure
D-1752	-0.43883824348449707	anaerobic threshold ; heart failure
P-1752	-0.8291 -1.2227 -0.7889 -0.1276 -0.2592 -0.1946 -0.3143 -0.4285 -0.2432 -0.3113 -0.1077
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical ; patients ; functional ms
H-373	-0.5908962488174438	▁MS
D-373	-0.5908962488174438	MS
P-373	-1.1697 -0.4780 -0.1249
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients ; patients ; echocardiographic
H-813	-0.7166272401809692	▁AF ▁patients ▁; ▁e cho car dio graphic ▁examina tion
D-813	-0.7166272401809692	AF patients ; echocardiographic examination
P-813	-0.8258 -1.9797 -0.5262 -0.1334 -0.2206 -0.1041 -1.4370 -1.2589 -0.3053 -1.3588 -0.3365 -0.1134
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses ; patients ; disease
H-2020	-1.329147219657898	▁patients ▁; ▁disease
D-2020	-1.329147219657898	patients ; disease
P-2020	-3.0151 -1.8196 -1.4575 -0.2095 -0.1440
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic ; accounting ; cost
H-1582	-0.677402675151825	▁net ▁economic ▁sav ings ▁; ▁cost
D-1582	-0.677402675151825	net economic savings ; cost
P-1582	-0.9012 -0.5869 -0.3765 -0.0861 -0.7685 -2.3569 -0.2642 -0.0789
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf ; pb
H-1349	-0.49343347549438477	▁PV f ▁; ▁recovery ▁; ▁p b
D-1349	-0.49343347549438477	PVf ; recovery ; pb
P-1349	-0.1994 -1.4010 -0.2764 -0.5697 -0.2415 -0.8264 -0.5474 -0.3126 -0.0665
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life ; patients
H-161	-0.6665445566177368	
D-161	-0.6665445566177368	
P-161	-1.1688 -0.1643
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital ; heart ; lesions
H-985	-0.41788455843925476	▁con geni tal ▁heart ▁les ions
D-985	-0.41788455843925476	congenital heart lesions
P-985	-0.5882 -0.0505 -0.1412 -0.8698 -0.8621 -0.4418 -0.3038 -0.0857
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf ; surgical
H-353	-0.4878607392311096	▁MS ▁; HF ▁; ▁MS
D-353	-0.4878607392311096	MS ;HF ; MS
P-353	-0.0286 -0.4018 -0.3185 -0.2769 -2.1206 -0.1931 -0.0756
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu ; mortality
H-582	-1.0516397953033447	▁ ICU
D-582	-1.0516397953033447	ICU
P-582	-0.8763 -0.0759 -3.1017 -0.1528
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray ; genes ; heart failure
H-1605	-0.6789180636405945	▁bio informati c ▁analysis ▁; ▁micro arra y ▁; ▁gene s ▁; ▁heart ▁failure
D-1605	-0.6789180636405945	bioinformatic analysis ; microarray ; genes ; heart failure
P-1605	-0.1726 -0.1496 -0.1184 -0.5924 -0.4705 -0.0277 -0.0380 -0.0957 -1.1230 -4.5052 -0.5182 -0.9487 -1.2640 -0.3678 -0.3593 -0.1117
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up ; cardiovascular events ; deaths
H-974	-0.8329086899757385	▁cardiovascular ▁events
D-974	-0.8329086899757385	cardiovascular events
P-974	-1.5249 -0.4921 -1.2185 -0.0961
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic ; outcomes ; hf
H-1202	-0.756557285785675	▁di ure tic ▁; HF
D-1202	-0.756557285785675	diuretic ;HF
P-1202	-0.6704 -0.6755 -0.9425 -1.1363 -1.5330 -0.2561 -0.0820
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad ; systolic hf ; prognostic
H-1183	-0.18251566588878632	▁CAD ▁; ▁sy sto lic ▁ HF
D-1183	-0.18251566588878632	CAD ; systolic HF
P-1183	-0.0634 -0.3274 -0.0378 -0.0960 -0.0183 -0.4443 -0.1459 -0.4465 -0.0631
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin ; inflammation ; metabolism ; heart disease
H-940	-0.6225820183753967	▁ inflammation ▁; ▁metabolism ▁; ▁heart ▁disease
D-940	-0.6225820183753967	inflammation ; metabolism ; heart disease
P-940	-3.0862 -0.3460 -0.2648 -0.0306 -0.2727 -0.7255 -0.4686 -0.2653 -0.1435
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 ; therapy
H-401	-0.6497259736061096	▁s st 2 ▁concentration s ▁; ▁benefit ▁; ▁BB ▁ therapy
D-401	-0.6497259736061096	sst2 concentrations ; benefit ; BB therapy
P-401	-0.0657 -2.5039 -0.0925 -1.6083 -0.2291 -0.3672 -1.8318 -0.5072 -0.3606 -0.3784 -0.0270 -0.3629 -0.1118
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart block ; pulmonary artery ; bivp
H-322	-0.300449401140213	▁Heart ▁block ▁; ▁pulmonar y ▁arter y ▁snar ed ▁; ▁Bi VP
D-322	-0.300449401140213	Heart block ; pulmonary artery snared ; BiVP
P-322	-0.8592 -0.1141 -0.3181 -0.0306 -0.1093 -0.0074 -0.2928 -1.1941 -0.1865 -0.2331 -0.4766 -0.1087 -0.2151 -0.0608
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance ; attrition
H-1319	-0.5420774221420288	
D-1319	-0.5420774221420288	
P-1319	-1.0023 -0.0819
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt ; patients
H-905	-0.6306322813034058	▁c RT ▁; ▁di al ysis - dependent ▁patients
D-905	-0.6306322813034058	cRT ; dialysis-dependent patients
P-905	-0.3834 -3.7138 -0.8736 -0.3545 -0.0800 -0.0349 -0.3060 -0.0749 -0.5355 -0.4243 -0.1560
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.27075472474098206	▁beta - block ers
D-865	-0.27075472474098206	beta-blockers
P-865	-0.4881 -0.0938 -0.2914 -0.2631 -0.4003 -0.0879
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf ; patients
H-217	-0.4320777356624603	▁CHF
D-217	-0.4320777356624603	CHF
P-217	-0.0970 -1.1029 -0.0964
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-0.4623323976993561	▁RM
D-163	-0.4623323976993561	RM
P-163	-0.9504 -0.2952 -0.1414
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.9532009363174438	▁ HF
D-556	-0.9532009363174438	HF
P-556	-2.9617 -0.3092 -0.4421 -0.0997
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac function ; catheter
H-1143	-0.3744582533836365	▁Card iac ▁function ▁; ▁pressure - volu me ▁conduct ance ▁; ▁cat heter ▁system
D-1143	-0.3744582533836365	Cardiac function ; pressure-volume conductance ; catheter system
P-1143	-0.3242 -0.2130 -0.0990 -0.6789 -1.1322 -0.0756 -0.0091 -0.1912 -0.0339 -0.5035 -1.6501 -0.4632 -0.0158 -0.1817 -0.3419 -0.0779
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence ; idiopathic dilated cardiomyopathy
H-1741	-0.3209545910358429	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1741	-0.3209545910358429	idiopathic dilated cardiomyopathy
P-1741	-1.3712 -0.0258 -0.0120 -0.0899 -0.1910 -0.2015 -0.1104 -0.8207 -0.4781 -0.0140 -0.4450 -0.0918
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded protein response ; cardiac sodium ; systolic ; heart failure
H-1079	-0.2872505486011505	▁un fold ed ▁protein ▁response ▁; ▁cardiac ▁so dium ▁current ▁; ▁sy sto lic ▁human ▁heart ▁failure
D-1079	-0.2872505486011505	unfolded protein response ; cardiac sodium current ; systolic human heart failure
P-1079	-0.8392 -0.0017 -0.0398 -0.3779 -0.2301 -0.6945 -0.3782 -0.0218 -0.0204 -0.0472 -0.2213 -0.0744 -0.0506 -0.0225 -1.5211 -0.2516 -0.2604 -0.2892 -0.1158
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia ; prognostic ; patients ; heart failure
H-529	-0.5712103247642517	▁Hypo album in emia ▁; ▁heart ▁failure
D-529	-0.5712103247642517	Hypoalbuminemia ; heart failure
P-529	-1.4471 -0.0622 -0.2956 -0.0904 -0.5009 -1.9531 -0.3998 -0.2609 -0.1309
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient ; diagnosed ; hypertensive lv dysfunction
H-350	-0.19684790074825287	▁hyper tensi ve ▁LV ▁dys function ▁; ▁MR ▁; ▁MS
D-350	-0.19684790074825287	hypertensive LV dysfunction ; MR ; MS
P-350	-0.9177 -0.1238 -0.0226 -0.0097 -0.0634 -0.0620 -0.2721 -0.0793 -0.1822 -0.3734 -0.1838 -0.0722
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis ; hf ; etiologies
H-1795	-1.3641713857650757	▁c ▁d ▁ HF
D-1795	-1.3641713857650757	c d HF
P-1795	-1.6866 -3.8405 -1.6395 -0.4966 -0.4314 -0.0905
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin receptor neprilysin inhibitor ; heart failure
H-1461	-0.4992814064025879	▁ang io ten sin ▁receptor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁heart ▁failure
D-1461	-0.4992814064025879	angiotensin receptor ; neprilysin inhibitor ; heart failure
P-1461	-1.7203 -1.4846 -0.0855 -1.0584 -0.1357 -0.8705 -0.0292 -0.2865 -0.7439 -0.0657 -0.0474 -0.6546 -0.1326 -0.1919 -0.3578 -0.1239
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western blot ; immunohistochemistry ; electron microscopy
H-1252	-0.339830607175827	▁Western ▁blot ▁analysis ▁; ▁immun oh isto che mist ry ▁; ▁electro n ▁micro s copy
D-1252	-0.339830607175827	Western blot analysis ; immunohistochemistry ; electron microscopy
P-1252	-0.1872 -0.0257 -0.2484 -0.2166 -0.0056 -0.0852 -0.8161 -0.4474 -0.6814 -1.3056 -0.2605 -0.0050 -0.0229 -0.0296 -0.5979 -0.6083 -0.4571 -0.1164
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic dysfunction ; patients ; peripheral artery disease
H-1566	-0.2228819876909256	▁dia sto lic ▁dys function ▁; ▁per i pher al ▁arter y ▁disease
D-1566	-0.2228819876909256	diastolic dysfunction ; peripheral artery disease
P-1566	-0.0141 -0.2115 -0.0867 -0.1179 -0.1376 -0.3490 -0.3360 -0.2689 -0.0388 -0.1597 -0.0444 -0.6648 -0.3254 -0.4561 -0.1324
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic cardiomyopathy ; mortality
H-67	-0.7239097356796265	▁cardio my o pathy ▁; ▁male ▁sex ▁; ▁mortal iteit
D-67	-0.7239097356796265	cardiomyopathy ; male sex ; mortaliteit
P-67	-1.8861 -0.7267 -0.6923 -0.0147 -0.4333 -1.0504 -0.4997 -0.6975 -0.2187 -2.0863 -0.2375 -0.1437
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical ; hfpef
H-943	-0.8601808547973633	▁AF ▁; ▁precipit ating ▁factor ▁; ▁h FP EF
D-943	-0.8601808547973633	AF ; precipitating factor ; hFPEF
P-943	-0.5971 -0.5750 -2.9708 -0.4154 -0.0838 -0.4618 -0.9870 -1.4456 -1.3663 -0.4289 -0.1303
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients ; heart transplant ; ecct
H-714	-0.8463760614395142	▁heart ▁transplant ▁; ▁ec CT
D-714	-0.8463760614395142	heart transplant ; ecCT
P-714	-3.6798 -0.1112 -0.5161 -0.2344 -1.0044 -0.2604 -0.1183
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome ; hdl
H-254	-0.7196125388145447	▁prote ome ▁; ▁HD L ▁parti cles ▁; ▁shot gun ▁; LC - MS
D-254	-0.7196125388145447	proteome ; HDL particles ; shotgun ;LC-MS
P-254	-0.8406 -0.1396 -0.5670 -0.2530 -2.6199 -0.2531 -0.0540 -0.7371 -0.5673 -0.0348 -0.5360 -1.7702 -0.1083 -0.2821 -2.6578 -0.0929
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty ; hf
H-632	-0.829177737236023	▁fra il ty ▁; ▁ HF
D-632	-0.829177737236023	frailty ; HF
P-632	-1.5139 -0.7471 -0.2022 -0.3564 -2.3945 -0.2616 -1.0479 -0.1098
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota ; hf
H-1003	-0.519457221031189	▁south e a stern ▁Minnesota ▁residents ▁; ▁ HF
D-1003	-0.519457221031189	southeastern Minnesota residents ; HF
P-1003	-2.4312 -0.0277 -0.0396 -0.0567 -0.1246 -0.9060 -0.5967 -0.6361 -0.5724 -0.2534 -0.0696
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left bundle branch block
H-1153	-0.7016613483428955	▁bund le ▁bran ch ▁block ▁; ▁electric al ▁activa tion ▁se que nce
D-1153	-0.7016613483428955	bundle branch block ; electrical activation sequence
P-1153	-0.8842 -1.0984 -0.2155 -0.1917 -0.9460 -0.9553 -0.6613 -0.1314 -0.0108 -0.6699 -0.5893 -2.5223 -1.2445 -0.3111 -0.0932
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4 inhibitors ; drugs
H-1834	-0.25586381554603577	▁h HF ▁; ▁d PP -4 ▁inhibi tors ▁; ▁drugs
D-1834	-0.25586381554603577	hHF ; dPP-4 inhibitors ; drugs
P-1834	-0.0205 -0.6125 -0.3748 -0.1517 -0.3640 -0.0695 -0.0644 -0.2420 -0.7697 -0.0603 -0.2465 -0.0945
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins ; tac
H-872	-0.7903837561607361	▁protein s ▁; TAC
D-872	-0.7903837561607361	proteins ;TAC
P-872	-2.0050 -0.3700 -0.8274 -1.2735 -0.1738 -0.0925
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac cachexia
H-9	-0.458118736743927	▁Card iac ▁cache xia ▁; cc
D-9	-0.458118736743927	Cardiac cachexia ;cc
P-9	-1.0851 -0.0226 -0.0315 -0.1202 -0.4711 -0.1306 -1.6979 -0.1060
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling pathways ; cardiac remodelling
H-992	-0.8004229664802551	▁cardiac ▁remodel ling
D-992	-0.8004229664802551	cardiac remodelling
P-992	-3.3010 -0.0921 -0.1884 -0.2902 -0.1305
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications ; dialysis ; patients
H-908	-0.4919499456882477	▁di al ysis ▁patients
D-908	-0.4919499456882477	dialysis patients
P-908	-1.0505 -0.0716 -0.0480 -1.3470 -0.3023 -0.1323
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end point ; neurological ; cardiovascular events
H-1872	-0.7427453398704529	▁neurologi cal ▁; ▁cardiovascular ▁events
D-1872	-0.7427453398704529	neurological ; cardiovascular events
P-1872	-0.5709 -0.9959 -0.9731 -0.0200 -2.2015 -0.2979 -0.1399
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary disease ; leading ; heart failure
H-981	-0.7340722680091858	▁corona ry ▁disease ▁; ▁heart ▁failure
D-981	-0.7340722680091858	coronary disease ; heart failure
P-981	-0.4114 -3.0195 -0.3028 -0.2493 -1.3273 -0.2079 -0.2521 -0.1023
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ; ffm ; stable
H-20	-0.724463164806366	▁f FM ▁; ▁FM ▁; ▁body ▁weight ▁; ▁CC
D-20	-0.724463164806366	fFM ; FM ; body weight ; CC
P-20	-0.4035 -1.4824 -0.5089 -1.9590 -0.4869 -1.8804 -0.1546 -0.4810 -0.2817 -0.2241 -0.1067
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart failure ; nurse
H-84	-0.95490562915802	▁heart ▁failure ▁; ▁nurse ▁leaders
D-84	-0.95490562915802	heart failure ; nurse leaders
P-84	-3.7267 -0.1583 -1.7853 -0.4958 -0.0719 -0.3255 -0.1208
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise ; training ; endothelial function
H-248	-0.6057613492012024	▁ Protect ive ▁effects ▁; ▁exercise ▁training ▁; ET ▁; ▁en dot heli al ▁function
D-248	-0.6057613492012024	Protective effects ; exercise training ;ET ; endothelial function
P-248	-4.1367 -0.5623 -0.2006 -0.3892 -0.7311 -0.1975 -0.5354 -0.3053 -1.5139 -0.4899 -0.0432 -0.5584 -0.1157 -0.0193 -0.0506 -0.3717 -0.0771
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery ; mva
H-361	-0.37451040744781494	▁MS
D-361	-0.37451040744781494	MS
P-361	-0.2137 -0.8079 -0.1019
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise ; exercise
H-1931	-1.934533715248108	▁social ▁support ▁; ▁exercise ▁; ▁exercise
D-1931	-1.934533715248108	social support ; exercise ; exercise
P-1931	-3.5400 -1.5764 -0.5668 -4.3043 -1.9246 -1.2714 -2.1571 -0.1357
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart rate
H-1446	-1.4533069133758545	▁heart ▁rate ▁variation
D-1446	-1.4533069133758545	heart rate variation
P-1446	-3.7169 -0.6458 -2.3792 -0.3575 -0.1671
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.361847460269928	▁c RF
D-1769	-0.361847460269928	cRF
P-1769	-0.5649 -0.5078 -0.2872 -0.0875
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.5137208700180054	▁Mediterrane an ▁; ▁DAS h
D-688	-0.5137208700180054	Mediterranean ; DASh
P-688	-0.7753 -0.0502 -0.5786 -0.0189 -0.1662 -1.8782 -0.1286
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.7726398706436157	▁re hospital ization
D-1711	-0.7726398706436157	rehospitalization
P-1711	-2.6091 -0.0545 -0.7615 -0.2947 -0.1435
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl ; hno ; acute ; heart failure
H-412	-0.7083300352096558	▁ni tro x yl ▁; ▁h no ▁; ▁a cute ▁treatment ▁; ▁heart ▁failure
D-412	-0.7083300352096558	nitroxyl ; hno ; acute treatment ; heart failure
P-412	-0.4569 -0.0339 -0.2533 -0.1026 -0.1535 -1.7265 -1.2403 -0.2844 -3.9448 -0.1589 -1.1354 -0.9766 -0.3246 -0.1651 -0.2634 -0.1131
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization therapy ; heart failure ; narrow qrs complex
H-844	-0.6235726475715637	▁Card iac - re syn chron ization ▁ therapy ▁; ▁heart ▁failure
D-844	-0.6235726475715637	Cardiac-resynchronization therapy ; heart failure
P-844	-0.8495 -0.0523 -0.1068 -0.4966 -0.2299 -0.0170 -1.5187 -2.1392 -0.0497 -0.5510 -0.9711 -0.2859 -1.3638 -0.0985
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate models ; odds ratios ; accounting ; hospital
H-191	-0.5774732828140259	▁odds ▁ratio s ▁; ▁hospital ▁cluster ing
D-191	-0.5774732828140259	odds ratios ; hospital clustering
P-191	-1.1251 -0.0489 -0.2968 -0.5606 -2.6509 -0.0110 -0.0968 -0.2742 -0.1330
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change ; lvet ; admission ; follow-up ; outcome
H-588	-0.7193555235862732	▁l VET ▁; ▁follow - up
D-588	-0.7193555235862732	lVET ; follow-up
P-588	-1.1965 -0.3508 -0.8099 -0.1097 -0.2435 -0.1389 -2.7799 -0.1256
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute walk distance ; peak vo2 ; baseline
H-1636	-0.5915732383728027	▁black s ▁; ▁VO 2
D-1636	-0.5915732383728027	blacks ; VO2
P-1636	-1.0173 -0.1376 -0.8848 -1.4608 -0.0839 -0.3953 -0.1614
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician ; death ; readmission ; discharge ; patients ; heart failure
H-1412	-1.0844820737838745	▁physician ▁continu ity ▁; ▁death ▁; ▁urgent ▁read mission ▁; ▁dis charge ▁; ▁heart ▁failure
D-1412	-1.0844820737838745	physician continuity ; death ; urgent readmission ; discharge ; heart failure
P-1412	-1.2653 -1.2573 -0.9751 -0.6065 -4.8104 -0.2580 -0.5632 -1.8852 -1.0174 -1.2419 -0.6166 -0.1770 -0.8587 -2.2652 -0.1943 -0.3133 -0.1308
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref ; hfpef ; patients ; regression line
H-497	-0.7093745470046997	▁h Fr EF ▁; ▁ HF p EF
D-497	-0.7093745470046997	hFrEF ; HFpEF
P-497	-2.2396 -1.3065 -0.8328 -0.1501 -0.1343 -0.5146 -0.0580 -0.7916 -0.9628 -0.1033
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home ; hospital ; readmission ; congestive heart failure
H-1573	-0.8301645517349243	▁hospital - to - Home ▁; ▁hospital ▁; ▁read mission ▁re duction ▁program ▁; ▁con ges tive ▁heart ▁failure
D-1573	-0.8301645517349243	hospital-to-Home ; hospital ; readmission reduction program ; congestive heart failure
P-1573	-0.5572 -0.2712 -0.0832 -0.1445 -0.3156 -0.9371 -2.3707 -1.2477 -2.0605 -2.4228 -0.1321 -0.0900 -1.9889 -0.6831 -0.0808 -0.4180 -2.1683 -0.6624 -0.2560 -0.4165 -0.1268
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk stratification ; death ; all-cause hospitalization ; heart failure ; clinic ; outpatients
H-377	-1.4274967908859253	▁sterf ▁; ▁heart ▁failure ▁clinic
D-377	-1.4274967908859253	sterf ; heart failure clinic
P-377	-4.5574 -1.4024 -2.0345 -0.1840 -0.2721 -1.3659 -0.1763
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients ; diabetes ; eo-cfus ; functional capacity
H-132	-0.6222467422485352	▁diabetes ▁; ▁e EO - c FU s
D-132	-0.6222467422485352	diabetes ; eEO-cFUs
P-132	-0.1017 -0.6260 -1.0667 -1.4960 -0.0781 -0.9331 -0.2334 -0.5039 -1.0743 -0.1092
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-0.753122091293335	▁patient ▁safety
D-1	-0.753122091293335	patient safety
P-1	-1.9239 -0.7312 -0.2168 -0.1406
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients ; transplants
H-2000	-0.5851839184761047	▁transplant s
D-2000	-0.5851839184761047	transplants
P-2000	-0.8626 -0.3876 -0.9945 -0.0960
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy ; engage ; exercise
H-1903	-1.7063753604888916	▁aero bic ▁exercise
D-1903	-1.7063753604888916	aerobic exercise
P-1903	-6.6339 -0.2552 -1.1482 -0.3323 -0.1622
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals ; outcome
H-1690	-0.6424846053123474	▁hospital s
D-1690	-0.6424846053123474	hospitals
P-1690	-0.9769 -0.9045 -0.5634 -0.1251
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf ; patients
H-671	-0.7020059823989868	▁tras tuz um ab - related ▁CHF
D-671	-0.7020059823989868	trastuzumab-related CHF
P-671	-1.7919 -0.0955 -0.1363 -1.1322 -0.4788 -1.2747 -0.2991 -0.9407 -0.1688
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.49550291895866394	▁hospital s
D-1694	-0.49550291895866394	hospitals
P-1694	-0.9192 -0.7033 -0.2809 -0.0786
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak vo2
H-1498	-0.8019675612449646	▁Peak ▁VO 2
D-1498	-0.8019675612449646	Peak VO2
P-1498	-2.9465 -0.3100 -0.2530 -0.3352 -0.1652
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.6829636693000793	▁ pharma ce ut ically ▁assist ed
D-948	-0.6829636693000793	pharmaceutically assisted
P-948	-0.4667 -0.4801 -1.5519 -0.3720 -0.5159 -1.7726 -0.3197 -0.5812 -0.0866
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.1569066047668457	
D-1955	-1.1569066047668457	
P-1955	-2.1932 -0.1206
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary artery disease ; cad ; systolic heart failure ; hf
H-1182	-0.261433482170105	▁Corona ry ▁arter y ▁disease ▁; CAD ▁; ▁sy sto lic ▁heart ▁failure ▁; HF
D-1182	-0.261433482170105	Coronary artery disease ;CAD ; systolic heart failure ;HF
P-1182	-0.0560 -1.8482 -0.0222 -0.2019 -0.2583 -0.2257 -0.1725 -0.1890 -0.0245 -0.0324 -0.1090 -0.4332 -0.2676 -0.1867 -0.1288 -0.2087 -0.0796
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative ; hypoalbuminemia ; prognosis ; lvad ; surgery
H-538	-0.23402039706707	▁hypo album in emia ▁; ▁l VAD ▁surgery
D-538	-0.23402039706707	hypoalbuminemia ; lVAD surgery
P-538	-0.4960 -0.1908 -0.3006 -0.2308 -0.4543 -0.1371 -0.0113 -0.2353 -0.1638 -0.1200
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis ; atherosclerosis ; cardiovascular events ; rotterdam study
H-1554	-0.6613268852233887	▁psoriasis ▁; ▁at hero sc ler osis ▁; ▁incident ▁cardiovascular ▁events ▁; ▁Rotterdam ▁Study
D-1554	-0.6613268852233887	psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam Study
P-1554	-0.7090 -1.5833 -1.0295 -0.3791 -0.0369 -2.8444 -0.0309 -0.2322 -1.3242 -0.0876 -0.1381 -0.3409 -0.5489 -0.8851 -0.3161 -0.0950
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality ; hf ; hospital ; admissions ; transplant ; ventricular assist device
H-125	-0.5044100880622864	▁mortal iteit ▁; HF ▁hospital ▁ad missions ▁; ▁transplant ▁; ▁vent ri cular ▁assist ▁device
D-125	-0.5044100880622864	mortaliteit ;HF hospital admissions ; transplant ; ventricular assist device
P-125	-0.3677 -1.7152 -0.2940 -1.1865 -0.9022 -0.5146 -0.1280 -0.1400 -0.0168 -0.2697 -0.0458 -1.8055 -0.2638 -0.3550 -0.0957 -0.3863 -0.0881
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart failure ; patients ; rheumatoid arthritis ; tnf antagonist
H-600	-0.42367425560951233	▁Heart ▁failure ▁; ▁rhe um ato id ▁ar thri tis ▁; ▁t NF ▁anta gon ist
D-600	-0.42367425560951233	Heart failure ; rheumatoid arthritis ; tNF antagonist
P-600	-0.3648 -0.4576 -1.0211 -0.6917 -0.0995 -0.3362 -0.2292 -0.0307 -0.2471 -0.5987 -0.8225 -1.0277 -0.0453 -0.7817 -0.0026 -0.1947 -0.5217 -0.1533
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade ; holosystolic murmur ; third heart sound ; apex
H-342	-0.5569249391555786	▁holo sy sto lic ▁mur mur ▁; ▁heart ▁sound
D-342	-0.5569249391555786	holosystolic murmur ; heart sound
P-342	-0.0189 -0.5219 -0.3985 -0.0475 -0.1664 -0.0430 -0.3498 -3.1737 -1.1236 -0.2038 -0.0790
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death ; stroke ; hospitalisation ; heart failure
H-815	-0.5495656728744507	▁CV ▁; ▁death ▁; ▁non - fa tal ▁stroke ▁; ▁hospital isation ▁; ▁heart ▁failure
D-815	-0.5495656728744507	CV ; death ; non-fatal stroke ; hospitalisation ; heart failure
P-815	-0.1788 -0.9165 -4.9085 -0.3624 -0.1171 -0.0648 -0.2514 -0.1041 -0.3926 -0.2172 -0.4807 -0.0420 -0.6154 -0.2192 -0.0860 -0.2664 -0.1196
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling ; hf ; haemodynamic ; neuronal stressors
H-1039	-0.36215004324913025	HF ▁; ▁ha emo dynamic ▁; ▁neuron al ▁stress ors
D-1039	-0.36215004324913025	HF ; haemodynamic ; neuronal stressors
P-1039	-1.9623 -0.8683 -0.0119 -0.1303 -0.0048 -0.1767 -0.0794 -0.0408 -0.1341 -0.5360 -0.3321 -0.0691
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit index ; biological phenotype ; mortality
H-1012	-0.7326565980911255	▁deficit ▁index ▁; ▁bi ological ▁ph eno type ▁; ▁mortal ity
D-1012	-0.7326565980911255	deficit index ; biological phenotype ; mortality
P-1012	-2.1490 -0.0537 -0.2896 -1.2054 -0.2963 -0.7835 -0.7482 -0.0058 -0.6510 -0.2625 -2.7731 -0.1784 -0.1280
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right ventricular function ; prognosis ; heart failure
H-1157	-0.8571977019309998	▁right ▁vent ri cular ▁function ▁; ▁body ▁composition ▁; ▁heart ▁failure
D-1157	-0.8571977019309998	right ventricular function ; body composition ; heart failure
P-1157	-1.0648 -0.1165 -2.2731 -0.4748 -0.3201 -0.3948 -1.4697 -0.1780 -0.1928 -3.9270 -0.3458 -0.2552 -0.1311
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia ; right ventricle ; heart failure
H-1457	-0.4325620234012604	▁Fat ▁; ▁cache xia ▁; ▁right ▁vent ric le ▁; ▁heart ▁failure
D-1457	-0.4325620234012604	Fat ; cachexia ; right ventricle ; heart failure
P-1457	-0.2891 -0.5505 -0.0268 -0.0497 -0.2416 -1.2929 -0.0902 -1.6940 -0.4257 -0.4319 -0.3880 -0.2518 -0.2293 -0.0944
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial fibrillation ; patients ; heart failure
H-1231	-0.5257474184036255	▁At rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure
D-1231	-0.5257474184036255	Atrial fibrillation ;AF ; heart failure
P-1231	-2.7231 -0.0210 -0.6085 -0.0561 -0.1249 -0.4534 -0.6761 -0.4138 -0.5672 -0.1721 -0.3643 -0.1285
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct ; heart failure ; therapy ; patients
H-718	-0.6989868879318237	▁ec CT ▁; ▁advanced ▁heart ▁failure ▁ therapy
D-718	-0.6989868879318237	ecCT ; advanced heart failure therapy
P-718	-0.1912 -2.6819 -0.5311 -1.4058 -0.8657 -0.1993 -0.3574 -0.0377 -0.5527 -0.1671
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart transplantation ; left ventricular assist device
H-306	-1.0061824321746826	▁heart ▁transplant ation ▁; ▁left ▁vent ri cular ▁assist ▁device
D-306	-1.0061824321746826	heart transplantation ; left ventricular assist device
P-306	-2.6353 -0.3467 -1.4068 -0.5284 -0.8881 -0.0812 -3.2522 -0.3126 -1.0044 -0.2634 -1.2454 -0.1099
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise intolerance ; chronic heart failure ; prognosis
H-1273	-0.491270512342453	▁Exerci se ▁in tolerance ▁; ▁chronic ▁heart ▁failure
D-1273	-0.491270512342453	Exercise intolerance ; chronic heart failure
P-1273	-1.2421 -0.1704 -0.0273 -0.0829 -0.3629 -0.9413 -1.2933 -0.3234 -0.3556 -0.1134
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd ; vvd ; free wall rs
H-328	-0.47453737258911133	▁AV d ▁; ▁VVD ▁; ▁co ▁; ▁free ▁wall ▁RS
D-328	-0.47453737258911133	AVd ; VVD ; co ; free wall RS
P-328	-0.1300 -0.6561 -0.1527 -0.3409 -0.3851 -2.2543 -0.5301 -0.0970 -0.2730 -0.5641 -0.2340 -0.0771
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical ; connected ; elevated ; resistin ; heart failure
H-929	-0.72420734167099	▁resist in ▁levels ▁; ▁heart ▁failure
D-929	-0.72420734167099	resistin levels ; heart failure
P-929	-2.5281 -0.8485 -0.9208 -0.3624 -0.6043 -0.2017 -0.2488 -0.0792
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ; ecgs ; electrocardiographers
H-884	-0.3985394239425659	▁e CG s ▁; ▁electro car dio graph ers
D-884	-0.3985394239425659	eCGs ; electrocardiographers
P-884	-0.4464 -0.4609 -0.4280 -0.3087 -0.0482 -0.0386 -1.1364 -0.6396 -0.3631 -0.4199 -0.0942
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left ventricular assist device ; right ventricular support
H-293	-0.5677189230918884	▁left ▁vent ri cular ▁assist ▁device ▁; ▁right ▁vent ri cular ▁support
D-293	-0.5677189230918884	left ventricular assist device ; right ventricular support
P-293	-0.2608 -0.0217 -1.6188 -0.2002 -1.0686 -0.2464 -0.4506 -0.5282 -0.0456 -1.9997 -0.2561 -0.6624 -0.4789 -0.1100
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence ; esrd ; outpatients ; hf
H-388	-0.6787964105606079	▁ES RD ▁; ▁out patient s ▁; HF
D-388	-0.6787964105606079	ESRD ; outpatients ;HF
P-388	-1.7704 -0.4746 -0.2805 -1.7292 -0.0088 -0.0699 -0.4694 -1.6480 -0.2418 -0.0953
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon matched-pairs signed-rank tests
H-923	-0.4599837064743042	▁Wil co xon
D-923	-0.4599837064743042	Wilcoxon
P-923	-0.8779 -0.0180 -0.2834 -0.9880 -0.1327
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical ; atherosclerosis ; linear models
H-1557	-0.7880063652992249	▁sub clin ical ▁at hero sc ler osis ▁; ▁linear ▁models
D-1557	-0.7880063652992249	subclinical atherosclerosis ; linear models
P-1557	-1.1065 -0.3526 -0.8443 -1.1681 -0.5381 -0.0380 -3.7987 -0.0574 -1.2182 -0.0374 -0.6479 -0.3219 -0.1149
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal artery stenosis ; ras ; peripheral arterial disease
H-1593	-0.15671002864837646	▁Ren al ▁arter y ▁sten osis ▁; RAS ▁; ▁per i pher al ▁arterial ▁disease
D-1593	-0.15671002864837646	Renal artery stenosis ;RAS ; peripheral arterial disease
P-1593	-0.3069 -0.0600 -0.0190 -0.3084 -0.0048 -0.0274 -0.2918 -0.0290 -0.3821 -0.0729 -0.2019 -0.0262 -0.0806 -0.0568 -0.4260 -0.2567 -0.1136
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline ; outcomes ; ecct ; cardiac transplant
H-711	-0.47962018847465515	▁ec CT ▁; ▁cardiac ▁transplant ▁recipient s
D-711	-0.47962018847465515	ecCT ; cardiac transplant recipients
P-711	-0.1950 -2.3775 -0.4415 -0.0845 -0.0934 -0.1418 -0.4667 -0.3628 -0.1534
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone ; primary composite endpoint
H-1227	-0.19546733796596527	▁e pler en one
D-1227	-0.19546733796596527	eplerenone
P-1227	-0.2319 -0.0041 -0.0452 -0.3039 -0.4627 -0.1250
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient ; asymptomatic ; follow-up
H-599	-0.6154686212539673	
D-599	-0.6154686212539673	
P-599	-1.1285 -0.1025
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients ; extubated ; blood ; transfusion
H-777	-0.5057216286659241	▁ex tuba ted ▁; ▁blood ▁loss ▁; ▁trans fusion
D-777	-0.5057216286659241	extubated ; blood loss ; transfusion
P-777	-0.7502 -0.0998 -0.6064 -0.7713 -0.9907 -0.2831 -0.3707 -0.0075 -0.0205 -1.5778 -0.0848
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate ii ; lvads ; patients
H-776	-0.5844237208366394	▁techniek ▁; ▁exchange ▁mal function ing ▁Heart Mate ▁II ▁l VAD s
D-776	-0.5844237208366394	techniek ; exchange malfunctioning HeartMate II lVADs
P-776	-0.5635 -0.6249 -2.3979 -0.1937 -0.0677 -0.1129 -1.7465 -0.0513 -0.8990 -0.2796 -0.0210 -0.4981 -0.5844 -0.1415
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart failure ; hf ; cardiovascular ; hospitalization
H-1074	-0.44363582134246826	▁Heart ▁failure ▁; HF ▁; ▁cardiovascular ▁hospital ization
D-1074	-0.44363582134246826	Heart failure ;HF ; cardiovascular hospitalization
P-1074	-0.6196 -0.0685 -0.2438 -0.1221 -0.4157 -0.2022 -0.5827 -0.7202 -1.3387 -0.1228
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf inhibition ; cardiac function ; remodeling
H-458	-0.4179700016975403	▁VE GF ▁inhibi tion ▁; ▁b ▁; ▁cardiac ▁function ▁; ▁remodel ing
D-458	-0.4179700016975403	VEGF inhibition ; b ; cardiac function ; remodeling
P-458	-0.7094 -0.1223 -0.1794 -0.3479 -0.1867 -1.4262 -0.7488 -0.0660 -0.0966 -1.6173 -0.0202 -0.0671 -0.2018 -0.0618
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing ; β-blocker ; sst2
H-400	-0.6042613983154297	▁β - block er ▁; bb ▁; ▁s ST 2
D-400	-0.6042613983154297	β-blocker ;bb ; sST2
P-400	-0.2540 -0.1476 -0.4757 -0.2032 -0.6897 -0.6628 -0.8684 -0.0222 -1.9812 -0.0965 -1.7203 -0.1296
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas ; cardiac ; pathogenesis
H-1484	-0.3060849905014038	▁mi RNA s ▁; ▁cardiac ▁path ogen es is
D-1484	-0.3060849905014038	miRNAs ; cardiac pathogenesis
P-1484	-0.7627 -0.0513 -0.1805 -0.4299 -0.1100 -0.6167 -0.2459 -0.1784 -0.4129 -0.2780 -0.1007
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet ; exercise rehabilitation ; patients ; chf
H-1884	-0.549920380115509	▁c PET ▁gu iding ▁exercise ▁rehabilita tion ▁; ▁CHF
D-1884	-0.549920380115509	cPET guiding exercise rehabilitation ; CHF
P-1884	-0.5073 -2.1485 -1.3032 -0.0387 -0.6224 -0.1745 -0.4214 -0.4010 -0.1074 -0.2242 -0.1005
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient ; heart failure with reduced ejection fraction
H-1203	-0.6103283166885376	▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-1203	-0.6103283166885376	heart failure ; reduced ejection fraction
P-1203	-2.7918 -0.1554 -0.6476 -2.3745 -0.0187 -0.0284 -0.1691 -0.0753 -0.3988 -0.0171 -0.5400 -0.1073
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients ; heart failure ; diagnostic ; medication ; follow-up
H-732	-1.024862289428711	▁heart ▁failure
D-732	-1.024862289428711	heart failure
P-732	-2.6534 -0.4460 -0.8438 -0.1562
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart failure ; hf ; morbidity ; mortality
H-199	-0.45562854409217834	▁Pediatri c ▁heart ▁failure ▁; HF
D-199	-0.45562854409217834	Pediatric heart failure ;HF
P-199	-1.2255 -0.0465 -0.9223 -0.1385 -0.2390 -0.2620 -0.7080 -0.1031
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression ; type i regulatory subunit ; ri ; hf
H-1429	-0.6697192192077637	▁regulator y ▁sub un it ▁; RI ▁; HF
D-1429	-0.6697192192077637	regulatory subunit ;RI ;HF
P-1429	-1.6655 -0.1737 -0.0526 -1.1467 -0.1782 -0.3540 -0.6725 -0.3345 -2.4662 -0.2325 -0.0903
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients ; discharge ; follow-up ; medication
H-730	-0.9974491596221924	▁follow - up ▁medication
D-730	-0.9974491596221924	follow-up medication
P-730	-4.5926 -0.1828 -0.0477 -0.3413 -0.6842 -0.1360
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain proteins
H-1042	-0.2803913652896881	bro modo main ▁protein s
D-1042	-0.2803913652896881	bromodomain proteins
P-1042	-0.8592 -0.1474 -0.0613 -0.2897 -0.1563 -0.3588 -0.0900
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative ; clinical ; mortality
H-532	-1.1481281518936157	▁mortal iteit
D-532	-1.1481281518936157	mortaliteit
P-532	-1.4965 -2.7757 -0.1972 -0.1230
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart failure ; readmission ; outcome
H-1030	-0.8796442151069641	▁heart ▁failure
D-1030	-0.8796442151069641	heart failure
P-1030	-1.1281 -0.1255 -2.1278 -0.1372
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt ; dt ; implantation
H-315	-0.5612726211547852	▁b t ▁; ▁ DT
D-315	-0.5612726211547852	bt ; DT
P-315	-1.0457 -0.8847 -0.3902 -0.5880 -0.4829 -0.4481 -0.0893
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes ; hospitalization
H-566	-0.8378526568412781	
D-566	-0.8378526568412781	
P-566	-1.5405 -0.1352
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse event ; hypotension
H-1970	-0.48159703612327576	▁hypo tension
D-1970	-0.48159703612327576	hypotension
P-1970	-1.1304 -0.1119 -0.5831 -0.1010
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers ; hf
H-1475	-0.5584588050842285	▁bio mark ers ▁; ▁treatment ▁; ▁ HF
D-1475	-0.5584588050842285	biomarkers ; treatment ; HF
P-1475	-0.0176 -0.1379 -0.3102 -0.3980 -1.8848 -0.8635 -1.3226 -0.3101 -0.2341 -0.1058
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up ; hf
H-288	-0.9873936772346497	▁ HF
D-288	-0.9873936772346497	HF
P-288	-2.7481 -0.8017 -0.3001 -0.0997
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 ; patients ; plasma
H-699	-1.0105030536651611	▁ST 2
D-699	-1.0105030536651611	ST2
P-699	-0.6163 -0.1907 -3.1100 -0.1250
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients ; condition ; economic
H-1575	-1.275757908821106	▁economische
D-1575	-1.275757908821106	economische
P-1575	-3.0925 -0.5644 -0.1704
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing ; medications ; heart failure
H-1121	-1.127103567123413	▁medication s ▁; ▁adults ▁; ▁heart ▁failure
D-1121	-1.127103567123413	medications ; adults ; heart failure
P-1121	-3.5132 -0.3189 -0.8951 -2.0968 -1.9237 -0.7347 -0.1093 -0.4076 -0.1447
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient ; mortality ; therapeutic
H-1667	-0.942773699760437	
D-1667	-0.942773699760437	
P-1667	-1.7309 -0.1547
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary heart disease ; stroke ; heart failure
H-1564	-0.5072476863861084	▁corona ry ▁heart ▁disease ▁; ▁stroke ▁; ▁heart ▁failure
D-1564	-0.5072476863861084	coronary heart disease ; stroke ; heart failure
P-1564	-0.1509 -2.2637 -0.4692 -0.6723 -0.2620 -0.2118 -0.2086 -0.7449 -0.2517 -0.2376 -0.1070
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality of life ; mlhf questionnaire
H-1991	-0.8061817288398743	▁ ML HF ▁Question naire
D-1991	-0.8061817288398743	MLHF Questionnaire
P-1991	-2.7164 -0.3232 -1.4326 -0.7948 -0.0097 -0.2183 -0.1483
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions ; septal ; surgical
H-984	-0.5278878211975098	▁sept al ▁defect s
D-984	-0.5278878211975098	septal defects
P-984	-0.3565 -0.0697 -0.0470 -0.2703 -2.3360 -0.0878
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis ; mortality ; patients
H-61	-1.050053596496582	▁i CD - HF ▁patients
D-61	-1.050053596496582	iCD-HF patients
P-61	-3.8048 -0.8264 -0.0967 -0.2630 -1.6974 -0.4180 -0.2440
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral renal denervation ; autonomic balance ; chronic heart failure
H-1369	-0.4372965693473816	▁renal ▁den er va tion ▁; ▁autonomi c ▁balance ▁; ▁rabbi ts ▁; ▁chronic ▁heart ▁failure
D-1369	-0.4372965693473816	renal denervation ; autonomic balance ; rabbits ; chronic heart failure
P-1369	-0.6348 -1.0195 -0.4804 -0.3598 -0.5999 -0.4241 -0.0169 -0.3743 -0.4903 -0.3769 -0.1016 -0.0657 -0.4870 -1.0950 -0.6455 -0.2546 -0.3402 -0.1049
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient ; clinical ; symptoms
H-1468	-1.125980019569397	
D-1468	-1.125980019569397	
P-1468	-2.1040 -0.1480
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients ; trastuzumab
H-676	-0.3336966931819916	▁tras tuz um ab
D-676	-0.3336966931819916	trastuzumab
P-676	-0.8087 -0.1271 -0.0614 -0.5162 -0.3767 -0.1121
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna ; genotyped
H-1454	-0.587381899356842	▁germ line ▁DNA ▁; ▁geno type d
D-1454	-0.587381899356842	germline DNA ; genotyped
P-1454	-2.1572 -0.0981 -0.3046 -2.0077 -0.0113 -0.0052 -0.2820 -0.3344 -0.0859
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart failure ; disease ; medical
H-2008	-0.8545463681221008	▁Heart ▁failure ▁disease ▁management
D-2008	-0.8545463681221008	Heart failure disease management
P-2008	-1.1281 -0.3989 -0.5518 -0.4896 -2.4052 -0.1537
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal dnx ; plasma
H-1381	-0.3504285216331482	▁Ren al ▁DN x ▁; ▁circula ting ▁plasma ▁; ▁CHF - in v ▁rabbi ts
D-1381	-0.3504285216331482	Renal DNx ; circulating plasma ; CHF-inv rabbits
P-1381	-0.2505 -0.0158 -0.2594 -0.0648 -0.3656 -0.0015 -0.3613 -0.0446 -0.3823 -2.4336 -0.1026 -0.6562 -0.4552 -0.0365 -0.1219 -0.3033 -0.1022
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow up ; hf
H-627	-0.8585138916969299	▁ HF
D-627	-0.8585138916969299	HF
P-627	-2.4064 -0.6080 -0.3268 -0.0929
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients ; blood ; medication
H-729	-1.6920884847640991	
D-729	-1.6920884847640991	
P-729	-3.1724 -0.2117
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses ; patients
H-1021	-0.3407798707485199	▁ NP ▁assessment ▁; ▁ED ▁patients
D-1021	-0.3407798707485199	NP assessment ; ED patients
P-1021	-0.9344 -0.0785 -0.1256 -0.3118 -0.0323 -0.9285 -0.2012 -0.1139
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac hypertrophy ; energy metabolism
H-1778	-0.48347043991088867	▁Card iac ▁hyper trop hy ▁; ▁energy ▁metabolism
D-1778	-0.48347043991088867	Cardiac hypertrophy ; energy metabolism
P-1778	-1.4380 -0.0639 -0.1788 -0.0657 -1.4536 -0.3025 -0.7383 -0.0384 -0.4361 -0.1194
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients ; lvad ; implantation
H-531	-0.31948596239089966	▁l VAD ▁implant ation
D-531	-0.31948596239089966	lVAD implantation
P-531	-0.3598 -0.0372 -0.4152 -0.5160 -0.4835 -0.1052
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.5055793523788452	▁HD L - bound ▁malo ndi alde hy de ▁; ▁ec
D-252	-0.5055793523788452	HDL-bound malondialdehyde ; ec
P-252	-2.5284 -0.7788 -0.0376 -0.0875 -0.0762 -0.1712 -0.0301 -0.9148 -0.3031 -0.3734 -0.4709 -0.6989 -0.1017
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal dysfunction ; morbidity
H-719	-0.39788275957107544	▁renal ▁dys function ▁; ▁post - trans plant ▁morbi d iteit
D-719	-0.39788275957107544	renal dysfunction ; post-transplant morbiditeit
P-719	-0.1632 -0.1589 -0.2734 -0.5904 -0.0963 -0.0472 -0.0436 -0.0418 -0.5393 -0.1757 -2.6696 -0.2472 -0.1258
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients ; cad ; cad
H-1189	-0.8576051592826843	▁deriva tion ▁co hor t ▁; ▁CAD
D-1189	-0.8576051592826843	derivation cohort ; CAD
P-1189	-1.9246 -0.3546 -0.0227 -0.6439 -0.0623 -0.4672 -0.1072 -4.0351 -0.1008
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.35110217332839966	
D-154	-0.35110217332839966	
P-154	-0.6093 -0.0929
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients ; randomized
H-1874	-0.6932299137115479	
D-1874	-0.6932299137115479	
P-1874	-1.2444 -0.1421
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital ; discharge
H-302	-1.1572691202163696	▁hospital ▁dis charge
D-302	-1.1572691202163696	hospital discharge
P-302	-4.0734 -1.2121 -0.1928 -0.2036 -0.1044
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.8028375506401062	▁hospital s
D-1713	-0.8028375506401062	hospitals
P-1713	-1.4548 -1.3357 -0.2931 -0.1278
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia ; heart disease
H-40	-0.8997800350189209	▁an emia ▁; ▁adults ▁; ▁heart ▁disease
D-40	-0.8997800350189209	anemia ; adults ; heart disease
P-40	-3.6048 -0.5537 -0.4220 -1.2635 -1.3919 -0.2839 -0.1799 -0.2826 -0.1156
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right atrial myxoma ; pulmonary embolism ; right heart failure
H-592	-0.33308646082878113	▁Right ▁at rial ▁my xo ma ▁; ▁pulmonar y ▁e mbol ism ▁; ▁right ▁heart ▁failure
D-592	-0.33308646082878113	Right atrial myxoma ; pulmonary embolism ; right heart failure
P-592	-0.5465 -0.1786 -0.0622 -1.0911 -0.0381 -0.3173 -0.5845 -0.0286 -0.1042 -0.0929 -0.0367 -1.0650 -0.3272 -0.2444 -0.4237 -0.4648 -0.3101 -0.0796
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
H-638	-0.4224178194999695	▁n fat ▁; ▁mi r -25 ▁; ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁heart ▁failure
D-638	-0.4224178194999695	nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
P-638	-2.7442 -0.0743 -0.1584 -0.1664 -1.1228 -0.0431 -0.3582 -0.1059 -0.0803 -0.1162 -0.8030 -0.1954 -0.0674 -0.8733 -0.1296 -0.1432 -0.2728 -0.1490
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation ; resistin ; correlated ; ejection fraction
H-938	-0.2812408208847046	▁resist in ▁; ▁e je ction ▁ fraction
D-938	-0.2812408208847046	resistin ; ejection fraction
P-938	-0.1459 -0.5844 -0.2980 -0.1025 -0.1166 -0.0764 -0.3173 -0.0110 -1.0371 -0.1231
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic heart transplantation ; oht ; end-stage heart failure
H-1280	-0.7676340341567993	▁Ort ho topic ▁heart ▁transplant ation ▁; ▁o HT ▁; ▁heart ▁failure
D-1280	-0.7676340341567993	Orthotopic heart transplantation ; oHT ; heart failure
P-1280	-0.8799 -0.3384 -0.2477 -1.1906 -0.1477 -0.4012 -0.4875 -0.0403 -2.5155 -0.3704 -3.5286 -0.2518 -0.2489 -0.0984
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas ; right atrium ; embolize ; pulmonary arterial vasculature
H-594	-0.2910502254962921	▁My xo mas ▁; ▁right ▁at rium ▁; ▁pulmonar y ▁arterial ▁vas cula ture
D-594	-0.2910502254962921	Myxomas ; right atrium ; pulmonary arterial vasculature
P-594	-0.3682 -0.0205 -0.4125 -0.5106 -0.1248 -0.5351 -0.0209 -0.5701 -0.0060 -0.1833 -0.0183 -0.1014 -0.2524 -1.1136 -0.2878 -0.1313
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change ; readmissions ; follow-up ; heart failure ; readmission
H-720	-0.7364773154258728	▁read missions ▁; ▁follow - up ▁visit s ▁; ▁heart ▁failure ▁; ▁read mission
D-720	-0.7364773154258728	readmissions ; follow-up visits ; heart failure ; readmission
P-720	-2.3130 -0.1477 -0.3628 -0.0071 -0.2519 -0.0341 -0.6421 -0.1294 -0.4089 -0.6908 -0.1987 -1.1260 -1.7385 -1.2292 -2.3587 -0.1447
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas ; bridge to transplantation ; destination therapy
H-1999	-0.4109537899494171	▁l VAS ▁; ▁ bridge ▁to ▁transplant ation
D-1999	-0.4109537899494171	lVAS ; bridge to transplantation
P-1999	-0.2152 -0.2143 -1.1258 -0.5364 -0.0306 -0.1944 -0.0392 -0.6747 -0.9942 -0.0847
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac overexpression ; mammalian enabled ; mena ; heart failure
H-1809	-0.35974961519241333	▁Card iac ▁over expression ▁; ▁Mamma lian ▁enabled ▁; ▁men a ▁; ▁heart ▁failure
D-1809	-0.35974961519241333	Cardiac overexpression ; Mammalian enabled ; mena ; heart failure
P-1809	-0.3103 -0.0284 -0.3501 -0.0895 -0.3981 -0.1399 -0.0528 -0.8927 -0.2798 -0.9730 -0.0595 -0.2760 -1.2367 -0.1406 -0.4198 -0.1088
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs ; functional capacity ; peak vo2
H-123	-0.637902557849884	▁c PC s ▁; ▁functional ▁capacity ▁; ▁VO 2
D-123	-0.637902557849884	cPCs ; functional capacity ; VO2
P-123	-0.1706 -2.2022 -0.1344 -0.5604 -0.0382 -0.6560 -0.6409 -1.4236 -0.7132 -0.3435 -0.1339
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction ; pump ; driveline ; pump ; curative
H-774	-0.5112578868865967	▁pump ▁failure ▁; ▁drive line ▁injury ▁; ▁isola ted ▁pump ▁replace ment
D-774	-0.5112578868865967	pump failure ; driveline injury ; isolated pump replacement
P-774	-1.4899 -1.2150 -0.1733 -0.1983 -0.0451 -0.0628 -0.3193 -1.3675 -0.0753 -1.2911 -0.2533 -0.3593 -0.2154 -0.0920
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis ; chronic heart failure ; tachycardia
H-164	-0.8489809036254883	▁apo pto sis ▁; ▁chronic ▁heart ▁failure ▁; ▁ta chy car dia
D-164	-0.8489809036254883	apoptosis ; chronic heart failure ; tachycardia
P-164	-6.2677 -0.3807 -0.6295 -0.3363 -1.8234 -0.9903 -0.2469 -0.5155 -0.1657 -0.1161 -0.0270 -0.0197 -0.2773 -0.0897
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil ; orally ; doxorubicin
H-959	-0.4449346661567688	▁Nico rand il ▁; ▁do xor ubi cin ▁treatment
D-959	-0.4449346661567688	Nicorandil ; doxorubicin treatment
P-959	-0.0047 -0.0482 -0.1179 -0.4277 -1.8907 -0.0365 -0.0361 -0.2573 -1.6626 -0.3348 -0.0777
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical ; outcomes ; hfpef
H-1525	-0.6412047743797302	▁EH ▁; ▁ HF p EF
D-1525	-0.6412047743797302	EH ; HFpEF
P-1525	-0.8886 -0.4659 -1.3044 -1.2378 -0.0550 -0.6835 -0.3676 -0.1269
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east ; rhythm control therapy ; cardiovascular ; complications
H-1648	-0.33813759684562683	▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1648	-0.33813759684562683	east ; rhythm control therapy ; cardiovascular complications ; AF
P-1648	-0.6119 -0.4551 -0.3953 -0.2654 -0.4622 -0.2785 -0.4041 -0.0310 -0.5572 -0.2410 -0.0144 -0.2476 -0.9117 -0.1606 -0.2486 -0.1256
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients ; clinical ; radiological ; hf ; hospitalization
H-560	-0.7631721496582031	▁ HF
D-560	-0.7631721496582031	HF
P-560	-2.2758 -0.2572 -0.3673 -0.1525
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics ; symptoms ; patients ; heart failure ; hf
H-1199	-0.509993314743042	▁di ure tics ▁; ▁con ges tive ▁symptoms ▁; ▁heart ▁failure ▁; HF
D-1199	-0.509993314743042	diuretics ; congestive symptoms ; heart failure ;HF
P-1199	-0.5870 -0.6700 -0.2683 -0.6496 -1.3158 -0.3249 -1.3901 -0.3626 -0.3416 -0.6904 -0.0925 -0.3034 -0.2996 -0.2489 -0.1054
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based ; therapies ; patients ; fes
H-1333	-1.3118728399276733	
D-1333	-1.3118728399276733	
P-1333	-2.4919 -0.1319
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 ; prognosis ; heart failure
H-399	-0.9596627354621887	▁solu ble ▁; ▁sp 2 ▁; ▁heart ▁failure
D-399	-0.9596627354621887	soluble ; sp2 ; heart failure
P-399	-2.6810 -0.6089 -0.5199 -3.6369 -0.0550 -0.4755 -1.0034 -0.2865 -0.2292 -0.1002
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham heart study ; hf ; ef
H-1103	-0.514476478099823	▁Fram ing ham ▁Heart ▁Study ▁criteri a ▁; ▁ HF ▁; ▁EF
D-1103	-0.514476478099823	Framingham Heart Study criteria ; HF ; EF
P-1103	-0.1154 -0.0616 -0.0334 -0.4153 -0.1640 -1.0407 -0.0241 -0.3488 -1.4588 -0.4759 -0.1845 -2.5786 -0.2354 -0.0663
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up ; hf ; deaths
H-1771	-0.5889455676078796	▁ HF
D-1771	-0.5889455676078796	HF
P-1771	-1.0562 -0.4832 -0.6871 -0.1293
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations ; acr ; cms
H-140	-0.33296602964401245	▁a cr ▁; ▁CMS
D-140	-0.33296602964401245	acr ; CMS
P-140	-0.2705 -0.3084 -0.3814 -0.1541 -0.7881 -0.0953
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase ; myocardium
H-171	-0.6024255752563477	▁band ▁; ▁activa ted ▁Cas pas e ▁; ▁pace d ▁my o car dium
D-171	-0.6024255752563477	band ; activated Caspase ; paced myocardium
P-171	-3.0542 -2.1985 -0.0119 -0.2673 -0.0909 -0.0313 -0.3443 -0.3457 -1.7872 -0.0244 -0.7409 -0.1137 -0.0098 -0.1241 -0.3983 -0.0964
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty ; heart failure ; health
H-621	-0.5910923480987549	▁fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; ▁older ▁adults ▁; ▁body ▁composition
D-621	-0.5910923480987549	frailty ; risk ; heart failure ; older adults ; body composition
P-621	-1.3633 -0.2630 -0.1752 -0.2850 -0.9949 -0.3502 -1.0695 -0.3260 -0.4153 -0.4066 -0.2427 -0.9739 -1.9859 -0.0812 -0.4457 -0.0791
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin ; sitagliptin
H-1828	-0.40459150075912476	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin
D-1828	-0.40459150075912476	hHF ; saxagliptin ; sitagliptin
P-1828	-0.0095 -1.4835 -0.2168 -0.1875 -0.0105 -0.4516 -1.0606 -0.1858 -0.5609 -0.1488 -0.0801 -0.8081 -0.3782 -0.0825
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart ; heart failure ; arrhythmias
H-747	-0.8287795782089233	▁Heart ▁t 2 ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-747	-0.8287795782089233	Heart t2 ; heart failure ; arrhythmias
P-747	-0.6912 -3.1864 -0.0094 -0.4887 -2.8659 -0.4263 -0.3153 -0.0260 -0.3299 -1.1677 -0.3567 -0.0818
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic ; inflammatory ; abdominal
H-1285	-0.9690579771995544	▁ ische mic ▁; ▁in flam ma tory ▁abdominal ▁problems ▁; ▁MT
D-1285	-0.9690579771995544	ischemic ; inflammatory abdominal problems ; MT
P-1285	-0.5427 -0.1558 -0.5424 -2.5774 -0.9827 -0.1812 -2.8541 -0.4558 -0.9854 -2.5039 -0.7095 -0.2955 -0.6463 -0.1341
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations ; congestive heart failure
H-208	-0.4284416139125824	▁ED ▁; ▁in tuba tions ▁; ▁con ges tive ▁heart ▁failure
D-208	-0.4284416139125824	ED ; intubations ; congestive heart failure
P-208	-0.1746 -1.3585 -0.0074 -0.2092 -0.2094 -0.7151 -0.0616 -0.2752 -1.6375 -0.4636 -0.1514 -0.2095 -0.0969
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline ; embase ; cinahl
H-62	-0.6567495465278625	▁med Line ▁; ▁ EMBA se ▁; ▁c INA HL
D-62	-0.6567495465278625	medLine ; EMBAse ; cINAHL
P-62	-0.3663 -1.4527 -0.2407 -1.3607 -0.1426 -1.0601 -0.1507 -0.8408 -1.1828 -0.6677 -0.3321 -0.0837
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence ; acp ; clinical practice guidelines
H-35	-0.9132146835327148	▁a CP
D-35	-0.9132146835327148	aCP
P-35	-1.3262 -0.7936 -1.4259 -0.1071
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise ; adverse events ; coronary artery disease ; cad
H-1899	-0.5090727210044861	▁corona ry ▁arter y ▁disease ▁; CAD
D-1899	-0.5090727210044861	coronary artery disease ;CAD
P-1899	-1.3830 -1.7033 -0.0190 -0.3578 -0.1906 -0.5330 -0.0710 -0.2035 -0.1205
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.45595067739486694	
D-1852	-0.45595067739486694	
P-1852	-0.8208 -0.0911
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical ; change
H-792	-0.5451967120170593	
D-792	-0.5451967120170593	
P-792	-1.0228 -0.0676
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-0.7192623615264893	▁ED ▁; ▁CHF
D-216	-0.7192623615264893	ED ; CHF
P-216	-1.6410 -1.5979 -0.0640 -0.1851 -0.1083
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-1.1475255489349365	▁benefit
D-892	-1.1475255489349365	benefit
P-892	-2.4191 -0.9434 -0.0800
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare ; policy
H-1716	-0.6551169753074646	▁Medica re ▁; ▁post - a cute ▁care ▁transfer
D-1716	-0.6551169753074646	Medicare ; post-acute care transfer
P-1716	-0.7466 -0.1017 -1.3747 -0.0691 -0.0662 -0.1636 -0.0768 -1.1864 -1.1249 -2.1053 -0.1910
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-0.5997603535652161	▁Diet ▁score ▁; ▁vegetables ▁; ▁nu ts ▁; ▁whole ▁grain ▁in take ▁; ▁mortal ity
D-692	-0.5997603535652161	Diet score ; vegetables ; nuts ; whole grain intake ; mortality
P-692	-4.4630 -0.4885 -0.4736 -0.2618 -0.3721 -0.0356 -0.0502 -0.3866 -0.0232 -0.1333 -0.1231 -0.6222 -0.4921 -0.1413 -1.8405 -0.1845 -0.1042
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.4080858528614044	
D-1508	-0.4080858528614044	
P-1508	-0.6943 -0.1219
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs ; osprey
H-1611	-0.38049158453941345	▁o spre y
D-1611	-0.38049158453941345	osprey
P-1611	-1.6152 -0.0348 -0.0497 -0.1531 -0.0496
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis ; therapy
H-1467	-0.5755594372749329	▁ therapy
D-1467	-0.5755594372749329	therapy
P-1467	-1.8646 -0.1133 -0.1864 -0.1379
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world health organization ; hf
H-1791	-0.9209243655204773	▁electronic ▁database s ▁; ▁world ▁health ▁Organization ▁; ▁ HF ▁; ▁LA
D-1791	-0.9209243655204773	electronic databases ; world health Organization ; HF ; LA
P-1791	-2.9517 -0.0977 -0.0856 -0.1574 -0.7968 -1.3012 -0.7230 -0.5475 -1.8257 -0.8767 -0.5701 -1.7139 -1.1817 -0.0639
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit index
H-1008	-0.6193593144416809	▁deficit ▁index ▁; SD
D-1008	-0.6193593144416809	deficit index ;SD
P-1008	-0.6282 -0.0529 -1.6342 -1.1701 -0.1255 -0.1052
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients ; implantation ; crt
H-848	-0.8885892033576965	▁device ▁implant ation ▁; ▁c RT
D-848	-0.8885892033576965	device implantation ; cRT
P-848	-0.5932 -0.2377 -0.9195 -0.6019 -0.4215 -2.7410 -1.5037 -0.0902
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-0.6733627915382385	▁benefit
D-619	-0.6733627915382385	benefit
P-619	-1.5957 -0.3032 -0.1213
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.4312323331832886	▁ir on
D-49	-0.4312323331832886	iron
P-49	-0.1604 -0.2385 -1.2208 -0.1053
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote monitoring ; hospital ; discharge ; patients ; heart failure ; meta-analysis
H-146	-0.9155745506286621	▁remote ▁monitoring ▁; ▁hospital ▁dis charge ▁; ▁patients ▁met ▁heart ▁failure
D-146	-0.9155745506286621	remote monitoring ; hospital discharge ; patients met heart failure
P-146	-2.6925 -0.1161 -1.1424 -1.5885 -0.4915 -0.1552 -0.8417 -1.0361 -2.0671 -1.0833 -0.2603 -0.3073 -0.1205
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv filling pressure ; stable ; severe systolic hf
H-489	-0.4140927195549011	▁LV ▁; ▁fill ing ▁pressure ▁; ▁severe ▁sy sto lic ▁ HF
D-489	-0.4140927195549011	LV ; filling pressure ; severe systolic HF
P-489	-0.3074 -1.3453 -0.6354 -0.1472 -0.3529 -0.2481 -1.6086 -0.0118 -0.0635 -0.0171 -0.3872 -0.2665 -0.3184 -0.0877
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ; ambulatory ; patients ; heart failure ; functional capacity ; outcomes
H-695	-0.5002898573875427	▁Solu ble ▁ST 2 ▁; ▁ambula tory ▁patients ▁; ▁heart ▁failure
D-695	-0.5002898573875427	Soluble ST2 ; ambulatory patients ; heart failure
P-695	-0.1774 -0.2994 -0.2658 -0.1229 -0.7980 -0.8431 -0.2341 -0.5027 -1.9499 -0.6519 -0.2300 -0.3124 -0.1161
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline ; echocardiograms ; evidence ; reverse remodeling
H-907	-0.4464186429977417	▁e cho card i ogram s
D-907	-0.4464186429977417	echocardiograms
P-907	-0.2457 -0.1318 -0.2900 -0.9770 -0.0120 -1.0399 -0.7910 -0.0839
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin hypophosphorylation ; myocardial dd
H-771	-0.40650686621665955	▁Tit in ▁hypo phos phor y lation ▁; ▁my o card ial ▁ DD
D-771	-0.40650686621665955	Titin hypophosphorylation ; myocardial DD
P-771	-0.0585 -0.4850 -0.2876 -0.0959 -0.6515 -1.2729 -0.0842 -0.2578 -0.6468 -0.1718 -0.2129 -0.5842 -1.2864 -0.0741 -0.2341 -0.1004
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic ; right ventricular contractile reserve ; patients ; pulmonary hypertension
H-821	-0.3264188766479492	▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension
D-821	-0.3264188766479492	right ventricular contractile reserve ; pulmonary hypertension
P-821	-1.2257 -0.0352 -1.7960 -0.2539 -0.0254 -0.1899 -0.0242 -0.3119 -0.0581 -0.1515 -0.1595 -0.0240 -0.2360 -0.0785
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck stent ; chronic myocardial ischemia ; heart failure
H-502	-0.283348023891449	▁bottle ne ck ▁sten t ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure ▁; ▁pig s
D-502	-0.283348023891449	bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
P-502	-0.2257 -0.0809 -0.0132 -0.0226 -0.0639 -0.6545 -0.4216 -0.8440 -0.3432 -0.3228 -0.6590 -0.1551 -0.0669 -0.6396 -0.1819 -0.3696 -0.0957 -0.5607 -0.0187 -0.1052 -0.3102 -0.0786
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt intervals ; sd of all qt intervals ; sdqt
H-1439	-0.820967435836792	▁ QT ▁interval s ▁; ▁SD QT
D-1439	-0.820967435836792	QT intervals ; SDQT
P-1439	-0.3293 -0.1954 -0.0183 -0.1155 -0.3348 -0.1195 -5.4063 -0.7627 -0.1068
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal bleeding ; patients ; ventricular assist devices ; cardiac ; nurse
H-1656	-0.49755552411079407	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse
D-1656	-0.49755552411079407	Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
P-1656	-0.2868 -0.8208 -1.5273 -0.1473 -0.0999 -0.5621 -0.3135 -0.4892 -0.1330 -1.8038 -0.3276 -0.7931 -0.1879 -0.6953 -0.0252 -0.1246 -0.5089 -0.1097
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker ; uptitration ; hfpef
H-183	-0.7601322531700134	▁benefit ▁; ▁ RAS - ▁; ▁β - block er ▁up tit ration ▁; ▁ HF p EF
D-183	-0.7601322531700134	benefit ; RAS- ; β-blocker uptitration ; HFpEF
P-183	-0.3794 -0.2908 -2.2789 -0.0733 -0.0665 -3.0272 -0.0834 -0.0820 -0.3267 -0.1252 -2.9342 -0.9968 -1.1399 -0.3243 -0.9480 -1.0154 -0.0372 -0.7998 -0.2048 -0.0689
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition ; compliance ; exercise ; injections ; patients
H-1321	-0.7643426656723022	▁inject ions
D-1321	-0.7643426656723022	injections
P-1321	-2.3930 -0.3228 -0.2420 -0.0996
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump ; pump ; pump thrombosis ; hemolysis
H-2004	-0.41844823956489563	▁pump ▁exchange s ▁; ▁pump ▁mal function s ▁; ▁pump ▁ thro mbo sis ▁; ▁hem ol ysis ▁events
D-2004	-0.41844823956489563	pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
P-2004	-0.1628 -0.1752 -0.1620 -0.3717 -0.3458 -1.8866 -0.0607 -0.2458 -0.2728 -0.4479 -0.9903 -0.4586 -0.5681 -0.8216 -0.2060 -0.2006 -0.2617 -0.1413 -0.6891 -0.2436 -0.0750
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac resynchronization therapy ; patients ; heart failure
H-903	-0.4287865459918976	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure
D-903	-0.4287865459918976	cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
P-903	-0.2401 -0.0877 -0.3403 -0.0771 -1.5835 -1.6275 -0.0391 -0.4168 -0.4715 -0.0284 -0.0215 -0.2074 -0.0497 -0.6403 -1.1888 -0.3707 -0.1957 -0.3879 -0.1728
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc ; outcomes ; outcome ; admission ; discharge
H-1401	-0.9598194360733032	▁no c ▁; ▁ad mission ▁to ▁dis charge
D-1401	-0.9598194360733032	noc ; admission to discharge
P-1401	-0.5852 -1.4704 -1.1867 -3.0426 -1.0003 -1.4154 -0.4133 -0.0915 -0.2359 -0.1568
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol ; exercise ; training ; baseline ; hgb
H-843	-0.686404824256897	▁HR Qo L ▁; ▁exercise ▁training ▁; ▁h gb
D-843	-0.686404824256897	HRQoL ; exercise training ; hgb
P-843	-1.0653 -0.0179 -1.5995 -0.4258 -0.6041 -1.0085 -0.4520 -1.7647 -0.2393 -0.2748 -0.0985
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient ; patients ; discharged ; hf
H-1400	-0.6550675630569458	▁in patient ▁records ▁; ▁ HF
D-1400	-0.6550675630569458	inpatient records ; HF
P-1400	-0.1477 -0.0988 -0.4088 -0.4577 -3.2309 -0.5402 -0.2445 -0.1120
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal muscle ; correlated ; vo2 max
H-1500	-0.4606408178806305	▁skelet al ▁muscle ▁mass ▁; ▁VO 2
D-1500	-0.4606408178806305	skeletal muscle mass ; VO2
P-1500	-0.9343 -0.0698 -0.5591 -0.1658 -0.7134 -1.2315 -0.1014 -0.2803 -0.0901
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac catheterization ; patient ; extubated ; transferred
H-1297	-0.5495608448982239	▁cardiac ▁cat heter ization ▁; ▁ex tuba ted
D-1297	-0.5495608448982239	cardiac catheterization ; extubated
P-1297	-1.2431 -0.5747 -0.0423 -1.1379 -1.0020 -0.0676 -0.0433 -0.3442 -0.9773 -0.0633
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial ; exercise ; training ; heart failure ; hf ; patients
H-1925	-0.534523606300354	▁psycho social ▁factors ▁; ▁exercise ▁training ▁; ▁heart ▁failure ▁; HF
D-1925	-0.534523606300354	psychosocial factors ; exercise training ; heart failure ;HF
P-1925	-1.0536 -0.4121 -0.5126 -0.6806 -0.4593 -1.1820 -0.6192 -0.3694 -0.0941 -0.2502 -0.2177 -0.9587 -0.1393
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis ; medical ; heart failure ; canadian cardiovascular society
H-198	-0.8115495443344116	▁medical ▁management ▁; ▁heart ▁failure ▁; ▁children ▁; ▁Canadian ▁Card io vas cular ▁Society
D-198	-0.8115495443344116	medical management ; heart failure ; children ; Canadian Cardiovascular Society
P-198	-4.7302 -0.4225 -0.4163 -0.7307 -0.1098 -0.2114 -1.3942 -0.1973 -0.2082 -0.9612 -1.1501 -0.1966 -0.4508 -0.2843 -1.4167 -0.1043
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized ; double-blind ; active ; placebo
H-77	-1.633805274963379	
D-77	-1.633805274963379	
P-77	-3.1292 -0.1385
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report ; aric ; hf
H-290	-0.6891935467720032	▁a RIC ▁ HF
D-290	-0.6891935467720032	aRIC HF
P-290	-0.5603 -1.2755 -0.4397 -1.0923 -0.6591 -0.1081
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients ; atrial fibrillation ; pacemaker
H-883	-0.4281371831893921	▁at rial ▁fi bril lation ▁; ▁pace maker
D-883	-0.4281371831893921	atrial fibrillation ; pacemaker
P-883	-2.5692 -0.0460 -0.3702 -0.0551 -0.1364 -0.3335 -0.1466 -0.0975 -0.4252 -0.1017
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis ; mortality ; patients
H-68	-1.0869359970092773	▁mortal iteit ▁; ▁i CD - HF
D-68	-1.0869359970092773	mortaliteit ; iCD-HF
P-68	-2.4843 -2.5931 -0.9338 -0.3239 -0.9517 -0.0905 -0.3246 -1.8816 -0.1990
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients ; therapy ; hospitalized ; cardiovascular
H-1223	-0.570782482624054	▁cardiovascular ▁reason
D-1223	-0.570782482624054	cardiovascular reason
P-1223	-1.3783 -0.4703 -0.2680 -0.1665
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter ablation ; sinus rhythm
H-945	-0.6413626670837402	▁AF - free ▁probabil ity ▁; ▁cat heter ▁ab lation ▁; ▁sinus ▁ rhythm
D-945	-0.6413626670837402	AF-free probability ; catheter ablation ; sinus rhythm
P-945	-3.0762 -0.0762 -0.1111 -2.3916 -1.4888 -0.7873 -0.4737 -0.0284 -0.0177 -0.0925 -0.2702 -0.4795 -0.1549 -0.4123 -0.3013 -0.1000
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body mass index ; crf ; exercise
H-1768	-0.3499695062637329	▁body ▁mass ▁index ▁; ▁c RF ▁; ▁tre ad m ill ▁exercise ▁testing
D-1768	-0.3499695062637329	body mass index ; cRF ; treadmill exercise testing
P-1768	-0.7117 -0.1535 -0.0143 -0.2477 -0.2115 -0.6137 -0.4700 -0.2954 -0.0226 -0.3852 -0.1830 -1.0486 -0.4531 -0.3237 -0.1155
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial tissue ; pka
H-1426	-0.5642465353012085	▁human ▁my o card ial ▁tissu e ▁; ▁p ka
D-1426	-0.5642465353012085	human myocardial tissue ; pka
P-1426	-1.3801 -0.9988 -0.2882 -0.2712 -0.5105 -0.0338 -0.2098 -0.5252 -0.4211 -1.1827 -0.8664 -0.0831
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease ; accounting ; cardiac transplants
H-982	-0.2880654036998749	▁pa e dia tric ▁cardiac ▁transplant s
D-982	-0.2880654036998749	paediatric cardiac transplants
P-982	-0.2359 -0.2518 -0.0410 -0.1227 -0.0170 -0.0708 -0.3565 -1.3633 -0.1336
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ; ventricular-arterial coupling
H-526	-0.4542611241340637	▁vent ri cular - arte rial ▁coup ling ▁; ▁SV
D-526	-0.4542611241340637	ventricular-arterial coupling ; SV
P-526	-1.3686 -1.9285 -0.1279 -0.1702 -0.0435 -0.0492 -0.2510 -0.5533 -0.6010 -0.0634 -0.1965 -0.0980
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic failure ; cardiomyopathic
H-986	-0.29908061027526855	▁dia sto lic ▁failure ▁; ▁cardio my o pathi c ▁restriction ▁to ▁flow
D-986	-0.29908061027526855	diastolic failure ; cardiomyopathic restriction to flow
P-986	-0.1222 -0.1123 -0.0663 -0.1333 -0.3423 -0.0852 -0.8560 -0.8327 -0.0097 -0.0514 -0.2868 -1.1944 -0.0733 -0.2305 -0.0897
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic nervous system ; activity ; qtv
H-1436	-0.44791194796562195	▁autonomi c ▁ner vous ▁system ▁; ▁Q TV
D-1436	-0.44791194796562195	autonomic nervous system ; QTV
P-1436	-0.0663 -0.2324 -0.5057 -0.6123 -0.0876 -0.9262 -0.6508 -1.1078 -0.2071 -0.0828
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients ; pneumonia ; surgical ; conditions
H-5	-0.5874078273773193	▁pneu monia ▁; ▁sur g ical ▁conditions
D-5	-0.5874078273773193	pneumonia ; surgical conditions
P-5	-0.6740 -0.6112 -0.9723 -0.2771 -0.6229 -0.7870 -0.9955 -0.2334 -0.1134
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1 mapping ; clinically ; myocardial fibrosis
H-1065	-0.8771536350250244	▁t 1 ▁ma pping ▁; ▁my o card ial ▁fibro sis
D-1065	-0.8771536350250244	t1 mapping ; myocardial fibrosis
P-1065	-3.9887 -0.7323 -0.2738 -0.2151 -0.4734 -2.0247 -0.5445 -0.9064 -1.1734 -0.0274 -0.6556 -0.2911 -0.0965
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.7974876761436462	
D-1862	-0.7974876761436462	
P-1862	-1.4497 -0.1453
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients ; prognosis
H-1315	-0.7205107808113098	
D-1315	-0.7205107808113098	
P-1315	-1.3334 -0.1076
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-1.0085915327072144	▁die t ▁ad her ence ▁; SD
D-1983	-1.0085915327072144	diet adherence ;SD
P-1983	-3.4809 -0.1294 -0.5105 -1.6582 -1.1951 -1.3069 -0.4063 -0.2500 -0.1402
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.9504780769348145	▁white
D-626	-0.9504780769348145	white
P-626	-2.4888 -0.1982 -0.1644
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics rounds
H-1681	-0.4926729202270508	▁e thi cs ▁Round s
D-1681	-0.4926729202270508	ethics Rounds
P-1681	-1.9798 -0.2007 -0.5642 -0.1653 -0.1912 -0.2676 -0.0799
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.45710983872413635	
D-2013	-0.45710983872413635	
P-2013	-0.8137 -0.1006
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
H-13	-0.1631447672843933	▁bio mark ers ▁; ▁neuro hormon al ▁stimul ation ▁; ▁ inflammation ▁; ▁en dot heli al ▁dys function
D-13	-0.1631447672843933	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
P-13	-0.3530 -0.1486 -0.1017 -0.3740 -0.0157 -0.0251 -0.0646 -0.0685 -0.5607 -0.2384 -0.1468 -0.1145 -0.1596 -0.0214 -0.5177 -0.1075 -0.0099 -0.0141 -0.1107 -0.2017 -0.0718
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart failure ; pathophysiology ; diagnosis ; medical treatment ; nursing
H-2018	-0.5269214510917664	▁Heart ▁Fail ure ▁; ▁Path o phy si ology ▁; ▁Medical ▁Treatment ▁Guide lines ▁; ▁Nur sing ▁management
D-2018	-0.5269214510917664	Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing management
P-2018	-0.3840 -0.2619 -0.5392 -0.4044 -0.0940 -1.9041 -0.0805 -2.2709 -0.1814 -0.2752 -0.8065 -0.3658 -0.5088 -0.3023 -0.6246 -0.2013 -0.0466 -1.0325 -0.1605 -0.0940
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia ; patients ; heart disease ; clinical practice guideline ; american college of physicians
H-29	-0.988837480545044	▁an emia ▁; ▁heart ▁disease ▁; ▁clinic al ▁practice ▁guide line ▁; ▁American ▁college ▁of ▁Physic ians
D-29	-0.988837480545044	anemia ; heart disease ; clinical practice guideline ; American college of Physicians
P-29	-0.9385 -0.2833 -0.5528 -3.0940 -0.3595 -0.6592 -5.3271 -0.0669 -0.1728 -0.8535 -0.0309 -0.6327 -2.9680 -1.3252 -0.6608 -0.1299 -0.1195 -0.4942 -0.1189
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart rate reduction ; ivabradine ; left ventricle ; heart failure ; patients
H-515	-0.5730229020118713	▁heart ▁rate ▁re duction ▁; ▁i va bra dine ▁un load s ▁; ▁left ▁vent ric le ▁; ▁heart ▁failure ▁patients
D-515	-0.5730229020118713	heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure patients
P-515	-2.4920 -0.4577 -1.9038 -0.1198 -0.6428 -0.0220 -0.0306 -0.2880 -0.1204 -0.3584 -0.0306 -0.3950 -0.8979 -0.1834 -0.0902 -1.2891 -0.5283 -0.3404 -0.4923 -0.1740 -1.7303 -0.4420 -0.1506
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence ; end-stage renal disease ; outpatients ; systolic heart failure
H-386	-0.44317203760147095	▁renal ▁disease ▁; ▁sy sto lic ▁heart ▁failure
D-386	-0.44317203760147095	renal disease ; systolic heart failure
P-386	-0.1797 -0.1992 -0.2199 -2.6139 -0.0812 -0.1555 -0.4426 -0.1440 -0.2774 -0.1182
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo ; bivp ; correlated ; rs synchrony
H-327	-0.550106942653656	▁ rv PO ▁; ▁Bi VP ▁; ▁co ▁; ▁RS ▁synchron y ▁; ▁CS
D-327	-0.550106942653656	rvPO ; BiVP ; co ; RS synchrony ; CS
P-327	-2.4206 -0.6197 -1.2560 -0.3625 -0.4299 -0.2241 -0.2935 -1.2855 -0.6523 -0.3812 -0.0030 -0.2568 -0.2911 -0.0188 -0.2027 -0.1040
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal dnx ; cardiac ; autonomic balance ; chf ; sympathetic tone
H-1382	-0.25625845789909363	▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance ▁; ▁CHF ▁; ▁sympa the tic ▁tone
D-1382	-0.25625845789909363	renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
P-1382	-0.0662 -0.2406 -0.1005 -0.3762 -0.0551 -0.0282 -0.1707 -0.3188 -0.2588 -0.0173 -0.6943 -0.0135 -0.8004 -0.7718 -0.0519 -0.3203 -0.0717
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin ; acute ; anthracycline-induced cardiotoxicity
H-931	-0.5983251333236694	▁resist in ▁; ▁an thra cycli ne - indu ced ▁cardio toxic iteit
D-931	-0.5983251333236694	resistin ; anthracycline-induced cardiotoxiciteit
P-931	-0.4992 -0.5036 -0.3514 -1.5336 -0.1293 -0.2410 -1.3992 -0.5343 -0.0284 -0.1997 -0.0546 -0.7180 -2.2513 -0.3953 -0.1361
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute ; autonomic nervous system ; qtv ; hf ; patients
H-1447	-0.5415763258934021	▁a cute ▁autonomi c ▁ner vous ▁system ▁modul ation ▁; ▁Q TV ▁; ▁ HF
D-1447	-0.5415763258934021	acute autonomic nervous system modulation ; QTV ; HF
P-1447	-1.2170 -0.0185 -0.0752 -0.1950 -0.4346 -0.6445 -0.0788 -0.9923 -0.3469 -0.2614 -0.5500 -1.0279 -0.1846 -1.4265 -0.3719 -1.2967 -0.0850
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart rate ; aortic ; blood flow ; doxorubicin
H-960	-0.312432199716568	▁Heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁do xor ubi cin
D-960	-0.312432199716568	Heart rate ; aortic blood flow ; doxorubicin
P-960	-0.6931 -0.3506 -0.4298 -0.0660 -0.1554 -0.7145 -0.3651 -0.2613 -0.7530 -0.2075 -0.0188 -0.0548 -0.2771 -0.2740 -0.0655
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical ; outcomes ; hospitalisations ; readmissions ; mortality
H-1850	-0.6088943481445312	
D-1850	-0.6088943481445312	
P-1850	-1.0494 -0.1684
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial ; pde2 ; expression ; activity ; hf
H-1213	-0.9166712164878845	▁My o card ial ▁p de 2 ▁expression ▁; ▁ HF
D-1213	-0.9166712164878845	Myocardial pde2 expression ; HF
P-1213	-0.8669 -0.3778 -0.1815 -0.4405 -1.8052 -1.5015 -0.0538 -1.2431 -0.3860 -3.3263 -1.2407 -0.3517 -0.1417
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat ; sympathetic outflow ; parasympathetic activity
H-1869	-0.9537864327430725	▁BAT ▁; ▁sympa the tic ▁out flow ▁; ▁para sy mpa tische ▁activity
D-1869	-0.9537864327430725	BAT ; sympathetic outflow ; parasympatische activity
P-1869	-0.0090 -1.0722 -0.0651 -0.9938 -0.9293 -2.4751 -0.3217 -0.3612 -0.0892 -0.2994 -0.4472 -5.6079 -1.1561 -0.3697 -0.1098
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
H-426	-0.25709268450737	▁e cho car dio graphic ▁; ▁rever se ▁remodel ing ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-426	-0.25709268450737	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
P-426	-0.7791 -0.0407 -0.0436 -0.5033 -0.3521 -0.7332 -0.0615 -0.0415 -0.0472 -0.1094 -0.3238 -0.0322 -0.0418 -0.0570 -0.0133 -0.9048 -0.6654 -0.0185 -0.2902 -0.0830
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular death ; hf ; hospitalization ; exercise ; training ; patients ; btes
H-1933	-0.5821841955184937	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁exercise ▁training ▁; ▁b tes
D-1933	-0.5821841955184937	cardiovascular death ; HF hospitalization ; exercise training ; btes
P-1933	-0.2735 -0.3704 -0.1569 -1.3424 -0.1009 -0.6744 -0.5574 -0.2834 -0.2284 -0.8547 -0.4386 -2.6773 -0.4102 -0.2717 -0.0925
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise ; training ; patients ; chronic heart failure ; high-density lipoprotein
H-245	-1.2623533010482788	▁chronic ▁heart ▁failure ▁; ▁lipo prote in
D-245	-1.2623533010482788	chronic heart failure ; lipoprotein
P-245	-6.3811 -1.1835 -0.3300 -0.6022 -0.8201 -0.0619 -0.7490 -1.1141 -0.1192
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal ; pathophysiology ; congestive heart failure ; chf
H-634	-0.5703306794166565	▁Neuro hormon al ▁ab normal ities ▁; ▁pat ho phy si ology ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-634	-0.5703306794166565	Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
P-634	-0.7161 -0.0269 -0.0214 -0.0220 -0.0491 -1.8997 -0.2042 -0.9584 -0.1167 -0.1341 -1.7654 -0.3060 -0.2328 -0.0331 -0.3499 -2.1862 -0.8783 -0.1228 -0.1980 -1.4071 -1.2236 -0.1944 -0.0714
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic neurotransmission ; acetylcholinesterase inhibition
H-1135	-0.41413095593452454	▁para sy mpa the tic ▁neuro trans mission ▁; ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.41413095593452454	parasympathetic neurotransmission ; acetylcholinesterase inhibition
P-1135	-0.0256 -0.3163 -0.4905 -1.2960 -0.7755 -0.0835 -0.0188 -1.0869 -0.3042 -0.1281 -0.3458 -0.3025 -0.3924 -0.1278 -0.2290 -0.7358 -0.0594 -1.0658 -0.4133 -0.0853
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential effect ; lvef ; mortality
H-118	-0.7157491445541382	▁LV EF ▁; ▁long - term ▁mortal ity
D-118	-0.7157491445541382	LVEF ; long-term mortality
P-118	-0.5413 -0.6851 -1.1213 -1.2361 -0.2081 -0.3263 -0.2709 -2.2491 -0.3680 -0.1513
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash ; mortality ; heart failure ; health
H-684	-0.7754645943641663	▁Mediterrane an ▁; ▁DAS h ▁die t ▁score s ▁; ▁mortal ity ▁; ▁women ▁; ▁heart ▁failure ▁; ▁Women s ▁Health ▁Initiative
D-684	-0.7754645943641663	Mediterranean ; DASh diet scores ; mortality ; women ; heart failure ; Womens Health Initiative
P-684	-0.9723 -0.0371 -0.7229 -0.0087 -0.1875 -2.0364 -0.1108 -0.2805 -0.1033 -0.2611 -0.0913 -1.5473 -0.2650 -2.3600 -2.3715 -0.3002 -0.2290 -0.2949 -1.0454 -2.9341 -1.8107 -0.1992 -0.3032 -0.1389
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness ; sickle cell disease ; anemia
H-1682	-0.7365077137947083	▁Jehovah ' s ▁Wit ness ▁; ▁sick le ▁cell ▁disease ▁; ▁an emia
D-1682	-0.7365077137947083	Jehovah's Witness ; sickle cell disease ; anemia
P-1682	-0.0400 -4.7070 -0.4200 -0.4331 -1.2031 -1.3293 -0.0507 -0.1666 -0.2816 -0.1441 -0.6403 -0.6487 -0.4925 -0.3177 -0.1730
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas ; therapeutic ; heart failure
H-1485	-0.576996386051178	▁mi RNA s ▁; ▁heart ▁failure
D-1485	-0.576996386051178	miRNAs ; heart failure
P-1485	-0.7707 -0.0337 -0.1854 -0.4471 -2.6692 -0.1647 -0.2468 -0.0985
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine ; furosemide ; outcome
H-586	-0.3329118490219116	▁do bu tamine ▁; ▁fur os em ide ▁dose ▁; ▁oxygen ▁flow
D-586	-0.3329118490219116	dobutamine ; furosemide dose ; oxygen flow
P-586	-0.6001 -0.0313 -0.1176 -0.4533 -1.2771 -0.4684 -0.0567 -0.0506 -0.4311 -0.1339 -0.5215 -0.1603 -0.2985 -0.0603
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health buddy program ; hospital ; hospitalized
H-1626	-0.5222437381744385	▁Health ▁Budd y ▁Program ▁; ▁ED
D-1626	-0.5222437381744385	Health Buddy Program ; ED
P-1626	-1.2681 -0.0403 -0.1062 -0.7172 -0.4089 -0.1128 -1.4238 -0.1008
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad variant ; congestive heart failure
H-1670	-0.8077769875526428	▁l - type ▁ca 2 + ▁current s ▁; ▁Rad ▁; ▁con ges tive ▁heart ▁failure
D-1670	-0.8077769875526428	l-type ca2+ currents ; Rad ; congestive heart failure
P-1670	-3.8201 -0.1357 -0.0048 -0.2297 -0.0950 -1.3941 -0.0494 -0.2567 -0.4522 -2.4845 -1.6377 -0.3076 -0.3456 -1.9731 -0.5948 -0.3151 -0.3159 -0.1281
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs ; outcomes ; patients ; diabetes
H-130	-0.7334399819374084	▁c PC s ▁; ▁diabetes
D-130	-0.7334399819374084	cPCs ; diabetes
P-130	-0.7364 -2.8332 -0.2561 -0.4723 -0.4209 -0.2199 -0.1952
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin ; breast cancer ; patients ; cardiotoxicity
H-936	-0.5646839737892151	▁resist in ▁levels ▁; ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁patients ▁; ▁cardio toxic iteit
D-936	-0.5646839737892151	resistin levels ; anthracycline-treated breast cancer patients ; cardiotoxiciteit
P-936	-0.8576 -0.8944 -0.5713 -0.3840 -0.1410 -0.0779 -0.4521 -1.1637 -0.2268 -0.0273 -0.9868 -0.0908 -0.1100 -1.2713 -0.4620 -0.0645 -0.4613 -2.5510 -0.3881 -0.1117
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left pulmonary artery ; right pulmonary artery
H-597	-0.5396098494529724	▁left ▁pulmonar y ▁arter y ▁; ▁pulmonar y ▁arter y
D-597	-0.5396098494529724	left pulmonary artery ; pulmonary artery
P-597	-0.2693 -0.0307 -0.1539 -0.0189 -0.6288 -0.9296 -3.4125 -0.1351 -0.0207 -0.4705 -0.3042 -0.1009
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri scanner ; baseline ; heart failure
H-1057	-0.7572243213653564	▁m RI ▁scanner ▁; ▁heart ▁failure
D-1057	-0.7572243213653564	mRI scanner ; heart failure
P-1057	-1.2660 -1.1482 -0.1534 -0.5100 -2.0219 -0.4720 -0.3277 -0.1585
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical ; therapeutic
H-1368	-0.46025633811950684	
D-1368	-0.46025633811950684	
P-1368	-0.8065 -0.1140
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive heart failure ; chf
H-209	-0.773917019367218	▁con ges tive ▁heart ▁failure ▁; CH f
D-209	-0.773917019367218	congestive heart failure ;CHf
P-209	-1.2773 -0.4175 -1.1910 -0.5802 -0.1239 -0.3828 -1.7349 -1.6739 -0.2547 -0.1030
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome ; heart failure ; fontan
H-1493	-0.24413837492465973	▁muscle - was ting ▁syndrome ▁; ▁acquire d ▁heart ▁failure ▁; ▁Font an
D-1493	-0.24413837492465973	muscle-wasting syndrome ; acquired heart failure ; Fontan
P-1493	-0.8043 -0.1265 -0.0310 -0.0243 -0.0325 -0.3169 -0.2647 -0.0188 -0.8664 -0.1358 -0.6306 -0.1138 -0.0208 -0.2061 -0.0695
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty ; health ; outcomes
H-623	-0.715462327003479	▁fra il ty ▁; ▁el der ly
D-623	-0.715462327003479	frailty ; elderly
P-623	-0.7682 -0.7233 -0.3915 -0.5305 -1.1935 -0.0456 -0.9360 -1.7484 -0.1022
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf ; intubation
H-221	-0.35462185740470886	▁ED ▁visit s ▁; ▁CHF ▁; ▁in tub ation ▁rates
D-221	-0.35462185740470886	ED visits ; CHF ; intubation rates
P-221	-0.6698 -1.2391 -0.0717 -0.3061 -0.0239 -0.3251 -0.0051 -0.0892 -0.4612 -0.6487 -0.3328 -0.0827
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol ; mortality
H-650	-0.6296794414520264	▁bis o pro lol ▁; ▁mortal iteit
D-650	-0.6296794414520264	bisoprolol ; mortaliteit
P-650	-0.1353 -0.4780 -0.0610 -0.5146 -1.0307 -1.1071 -2.0359 -0.2122 -0.0924
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health buddy program ; telehealth
H-1622	-0.5242798328399658	▁Health ▁Budd y ▁Program ▁; ▁tele health ▁system ▁; ▁care ▁management
D-1622	-0.5242798328399658	Health Buddy Program ; telehealth system ; care management
P-1622	-2.0351 -0.0827 -0.0645 -1.2084 -0.5193 -1.2386 -0.1581 -0.1154 -0.7915 -0.1289 -0.0788 -0.2796 -0.1148
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare ; hospitalizations
H-1714	-0.48987123370170593	▁Medica re
D-1714	-0.48987123370170593	Medicare
P-1714	-0.4224 -0.1139 -1.2951 -0.1281
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician ; conditions ; hospital ; discharge
H-1422	-1.051430106163025	▁physician ▁continu ity
D-1422	-1.051430106163025	physician continuity
P-1422	-0.4069 -0.2802 -1.3179 -3.1448 -0.1073
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic ; patients ; heart failure
H-1740	-1.4921221733093262	▁ therapeut ic ▁; ▁heart ▁failure
D-1740	-1.4921221733093262	therapeutic ; heart failure
P-1740	-4.2856 -0.6688 -0.2959 -1.7975 -4.1918 -0.2114 -0.3469 -0.1392
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss ; btes ; exercise
H-1928	-0.8883805274963379	▁ps s ▁; ▁social ▁support ▁; ▁b tes ▁; ▁exercise
D-1928	-0.8883805274963379	pss ; social support ; btes ; exercise
P-1928	-1.2801 -0.6093 -1.3444 -0.8633 -1.0429 -0.6775 -1.4923 -0.3883 -0.8100 -1.8308 -0.2191 -0.1025
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac stress ; β-ar ; drive
H-1219	-0.5783765912055969	▁cardiac ▁stress ▁; ▁β - AR ▁drive
D-1219	-0.5783765912055969	cardiac stress ; β-AR drive
P-1219	-1.9879 -0.5042 -0.4605 -0.6733 -0.0877 -0.8166 -0.1978 -0.3452 -0.1321
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin subproteome ; diseased ; heart
H-99	-0.4142550826072693	▁chr omat in ▁sub prote ome ▁; ▁mouse ▁heart
D-99	-0.4142550826072693	chromatin subproteome ; mouse heart
P-99	-1.3901 -0.0422 -1.5606 -0.1097 -0.0631 -0.0430 -0.1993 -0.6534 -0.2572 -0.1632 -0.0749
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated ; septal ; wall ; avd ; free wall cs ; vvd
H-329	-0.7953808903694153	▁co ▁; ▁sept al ▁wall ▁; ▁CS ▁; ▁AV d ▁; ▁free ▁wall ▁; ▁CS ▁; ▁VVD
D-329	-0.7953808903694153	co ; septal wall ; CS ; AVd ; free wall ; CS ; VVD
P-329	-2.1651 -1.1854 -0.1000 -0.0639 -0.1057 -1.4291 -2.3324 -0.4507 -2.1811 -0.5163 -0.7351 -0.1358 -0.2081 -1.1183 -0.9380 -0.2963 -0.8525 -0.1976 -0.1009
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv strain ; strain ; echocardiography ; baseline ; ablation
H-946	-0.6952916383743286	▁e cho card i ography ▁; ▁ab lation
D-946	-0.6952916383743286	echocardiography ; ablation
P-946	-2.1096 -0.1057 -0.5157 -0.8861 -0.2100 -2.4216 -0.3223 -0.1027 -0.1878 -0.0915
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed up ; adverse events ; death ; transplantation ; circulatory assist device
H-1162	-0.4900118410587311	▁death ▁; ▁transplant ation ▁; ▁circula tory ▁assist ▁device
D-1162	-0.4900118410587311	death ; transplantation ; circulatory assist device
P-1162	-3.5323 -0.3435 -0.0099 -0.2985 -0.3267 -0.0011 -0.1285 -0.1418 -0.1879 -0.3428 -0.0770
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular pacing ; left heart twist ; strain ; right heart failure
H-318	-0.7183827757835388	▁bi ven tri cular ▁pa cing ▁; ▁left ▁heart ▁; ▁twist ▁; ▁strain ▁; ▁por cine ▁model ▁; ▁right ▁heart ▁failure
D-318	-0.7183827757835388	biventricular pacing ; left heart ; twist ; strain ; porcine model ; right heart failure
P-318	-3.5520 -0.0849 -2.6867 -0.4979 -0.0365 -0.1005 -0.7036 -1.1554 -0.9536 -0.6869 -1.4422 -0.3288 -0.1782 -0.2357 -1.8810 -0.0483 -0.1792 -0.8128 -0.0944 -0.2686 -0.2004 -0.2691 -0.1260
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic ; acute rv failure ; left ventricular dysfunction
H-1092	-0.5011394619941711	▁et i ologic ▁causes ▁; ▁a cute ▁ RV ▁failure ▁; ▁left ▁vent ri cular ▁dys function
D-1092	-0.5011394619941711	etiologic causes ; acute RV failure ; left ventricular dysfunction
P-1092	-1.5098 -0.1740 -0.0670 -1.2440 -0.4391 -0.6197 -0.0287 -0.2891 -0.2523 -0.3551 -0.3152 -0.2733 -0.0621 -2.7517 -0.2984 -0.0516 -0.2660 -0.4004 -0.1243
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs ; functional capacity ; outcomes ; heart failure ; hf
H-121	-0.35336440801620483	▁c PC s ▁; ▁functional ▁capacity ▁; ▁heart ▁failure ▁; HF
D-121	-0.35336440801620483	cPCs ; functional capacity ; heart failure ;HF
P-121	-0.3235 -1.8070 -0.1862 -0.2373 -0.1136 -0.5739 -0.1690 -0.2821 -0.0888 -0.1897 -0.3472 -0.1787 -0.0966
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein kinase a ; guanylate cyclase ; contractile response
H-418	-0.5796284079551697	▁protein ▁kina se ▁; ▁solu ble ▁gua ny late ▁cy cla se ▁; ▁contract ile ▁response
D-418	-0.5796284079551697	protein kinase ; soluble guanylate cyclase ; contractile response
P-418	-2.2220 -0.0341 -0.1244 -1.3041 -0.6635 -1.3712 -0.0386 -1.0966 -0.7509 -0.1237 -0.0637 -0.7216 -0.6681 -0.0064 -0.1636 -0.5607 -0.3770 -0.1428
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating progenitor cells ; outcome ; heart failure ; patients ; longitudinal
H-119	-0.4284003973007202	▁circula ting ▁pro gen itor ▁cell s ▁; ▁heart ▁failure ▁patients
D-119	-0.4284003973007202	circulating progenitor cells ; heart failure patients
P-119	-0.0141 -0.3686 -0.1423 -0.2472 -0.3903 -0.9062 -0.2433 -0.5906 -1.1161 -0.1825 -0.9811 -0.2574 -0.1295
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress doppler echocardiography ; prognostic ; pulmonary hypertension ; patients
H-832	-0.5137739181518555	▁Stress ▁do pp ler ▁e cho card i ography ▁; ▁pulmonar y ▁hyper tension
D-832	-0.5137739181518555	Stress doppler echocardiography ; pulmonary hypertension
P-832	-1.1484 -1.8098 -0.0344 -0.7864 -0.0834 -0.3113 -0.3694 -1.1728 -0.3135 -0.4348 -0.0289 -0.1321 -0.1548 -0.0680 -1.2600 -0.1124
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic ; diastolic mitral leaflet motions ; organic ; lesion
H-351	-0.36670616269111633	▁sy sto lic ▁; ▁dia sto lic ▁mit ral ▁le a flet
D-351	-0.36670616269111633	systolic ; diastolic mitral leaflet
P-351	-0.0585 -0.1796 -0.0325 -0.7534 -0.0050 -0.0782 -0.0333 -0.2548 -0.0837 -0.8915 -0.0788 -0.0254 -2.5478 -0.1112
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity ; mortality ; quality of life ; patients ; hf
H-2023	-0.6711620688438416	▁morbi d iteit ▁; ▁mortal ity ▁; HF
D-2023	-0.6711620688438416	morbiditeit ; mortality ;HF
P-2023	-0.3498 -0.1438 -2.0422 -0.3355 -0.0216 -1.6000 -0.2887 -1.5984 -0.2161 -0.1155
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt ; nt-probnp ; hf
H-291	-0.4183694124221802	▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF
D-291	-0.4183694124221802	ctnt ; NT-probNP ; HF
P-291	-0.0217 -0.2234 -0.0311 -0.1959 -0.1489 -0.0635 -0.1061 -0.0305 -1.3721 -0.5149 -0.2976 -0.6566 -0.4770 -1.9954 -0.1409
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student t test ; confidence intervals ; cis ; regression analyses
H-215	-0.6760929226875305	▁student ▁t ▁test ▁; ▁confidence ▁interval s ▁; CI s
D-215	-0.6760929226875305	student t test ; confidence intervals ;CIs
P-215	-3.2607 -0.0898 -0.2862 -0.6112 -1.3406 -0.0207 -0.1286 -0.3155 -0.5046 -0.1094 -1.3478 -0.0980
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical ; radiological ; hf ; quality of life
H-565	-1.210849642753601	▁ HF
D-565	-1.210849642753601	HF
P-565	-3.5593 -0.5963 -0.5546 -0.1332
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital ; mortality ; patients ; bnp ; mortality
H-195	-0.9455694556236267	▁in hospital ▁mortal ity ▁; ▁b NP ▁level
D-195	-0.9455694556236267	inhospital mortality ; bNP level
P-195	-0.9627 -0.0215 -0.1624 -1.8323 -0.6510 -0.8229 -0.9643 -0.8855 -3.0363 -0.1169
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality ; deaths ; acs ; consultation ; operation
H-1287	-0.9629168510437012	▁Mor t ality ▁; ▁a CS
D-1287	-0.9629168510437012	Mortality ; aCS
P-1287	-1.4494 -0.1831 -0.0666 -0.9869 -1.5482 -3.0564 -0.2974 -0.1155
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right ventricle ; rv ; cardiac function ; medical
H-1091	-0.5193715691566467	▁right ▁vent ric le ▁; RV ▁; ▁cardiac ▁function
D-1091	-0.5193715691566467	right ventricle ;RV ; cardiac function
P-1091	-0.3067 -0.0491 -1.1039 -0.5527 -0.4863 -0.8829 -0.6860 -0.1919 -0.2407 -1.1216 -0.0913
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes ; costs ; patients ; heart failure ; hf
H-1721	-1.26082444190979	▁kosten ▁; ▁heart ▁failure ▁; HF
D-1721	-1.26082444190979	kosten ; heart failure ;HF
P-1721	-6.6204 -0.7716 -1.3017 -0.0994 -0.4312 -0.4345 -0.3064 -0.1214
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv dysfunction ; correlated ; lean body mass
H-1164	-0.6919986009597778	▁ RV ▁dys function ▁; ▁weight ▁loss ▁; ▁fat ▁; lean ▁body ▁mass ▁ratio
D-1164	-0.6919986009597778	RV dysfunction ; weight loss ; fat ;lean body mass ratio
P-1164	-2.0648 -0.8860 -0.3670 -0.1344 -0.4074 -0.9513 -0.7350 -0.4649 -0.6528 -2.0352 -0.5880 -1.0596 -0.1593 -0.0891 -0.3404 -0.1369
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr reduction ; beta blockers ; exercise capacity ; hfref
H-1937	-0.37103497982025146	▁HR ▁re duction ▁; ▁beta ▁block ers ▁; ▁exercise ▁capacity ▁; ▁h Fr EF
D-1937	-0.37103497982025146	HR reduction ; beta blockers ; exercise capacity ; hFrEF
P-1937	-0.5459 -0.6277 -0.0286 -0.3583 -0.0489 -0.1503 -0.0524 -0.4399 -0.1111 -0.2806 -0.3343 -1.1236 -0.7748 -0.6608 -0.3285 -0.0707
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary ; exercise ; prognostically ; heart failure
H-1274	-0.940077543258667	▁cardio pul mon ary ▁exercise ▁; ▁heart ▁failure
D-1274	-0.940077543258667	cardiopulmonary exercise ; heart failure
P-1274	-0.7481 -0.9174 -2.4609 -0.6102 -1.8087 -0.2901 -1.8734 -0.2309 -0.3561 -0.1049
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle cohort study ; canada
H-1951	-0.716526448726654	▁Canada
D-1951	-0.716526448726654	Canada
P-1951	-1.8228 -0.2159 -0.1109
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary outcome ; sympathetic activity ; myocardial washout
H-1115	-0.825232744216919	▁sympa the tic ▁activity ▁; ▁i - mi BG ▁; ▁my o card ial ▁was hout
D-1115	-0.825232744216919	sympathetic activity ; i-miBG ; myocardial washout
P-1115	-0.6477 -0.9574 -0.4472 -1.0876 -0.3285 -0.9503 -0.8741 -0.4113 -2.1852 -1.7432 -1.2012 -0.4553 -0.5420 -0.4649 -1.3019 -0.7831 -0.3303 -0.1430
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial diastolic dysfunction ; dd ; collagen deposition ; titin
H-761	-0.3972187042236328	▁my o card ial ▁dia sto lic ▁dys function ▁; DD ▁; ▁collage n ▁de position
D-761	-0.3972187042236328	myocardial diastolic dysfunction ;DD ; collagen deposition
P-761	-0.6077 -0.3502 -0.2161 -0.6430 -0.0267 -0.1175 -0.0806 -0.0219 -0.1310 -0.4245 -0.3729 -1.1368 -0.0381 -0.0658 -0.1001 -0.2995 -2.4337 -0.0839
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome ; death ; hospitalization ; heart failure
H-849	-1.180224061012268	▁sterf ▁; ▁heart ▁failure
D-849	-1.180224061012268	sterf ; heart failure
P-849	-3.3022 -1.1464 -2.1050 -0.2298 -0.1845 -0.1135
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline ; st2 ; interquartile range
H-701	-0.5362303853034973	▁ST 2 ▁level ▁; inter quart ile ▁range
D-701	-0.5362303853034973	ST2 level ;interquartile range
P-701	-2.3525 -0.1211 -0.2310 -1.4046 -0.6554 -0.0832 -0.0249 -0.0327 -0.3240 -0.1329
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up ; outcomes ; mortality
H-1637	-0.4270436763763428	▁black ▁race ▁; ▁mortal ity
D-1637	-0.4270436763763428	black race ; mortality
P-1637	-0.0204 -0.1333 -0.8277 -0.1131 -1.6063 -0.1772 -0.1113
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome ; change ; hospitalized ; heart failure
H-1395	-1.2867252826690674	▁Nur sing - sensitiv e ▁outcome ▁change ▁score s ▁; ▁older ▁adults ▁; ▁heart ▁failure
D-1395	-1.2867252826690674	Nursing-sensitive outcome change scores ; older adults ; heart failure
P-1395	-8.1180 -0.1402 -0.1122 -0.0025 -0.1012 -0.5972 -4.4748 -0.8805 -0.1481 -0.7462 -2.5036 -0.3763 -1.9571 -0.8899 -0.3410 -0.3113 -0.1743
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic ; diagnostic ; fluid overload
H-1071	-0.9087497591972351	▁diagnosti ▁; ▁fluid ▁over load
D-1071	-0.9087497591972351	diagnosti ; fluid overload
P-1071	-1.9905 -3.4809 -0.0172 -0.0368 -0.3777 -0.3273 -0.1309
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin ; heart failure ; breast cancer
H-927	-0.6336067914962769	▁resist in ▁; ▁che mo therapy - indu ced ▁heart ▁failure ▁; ▁human ized ▁male ▁mi ce ▁; ▁breast ▁cancer
D-927	-0.6336067914962769	resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
P-927	-3.5226 -0.4114 -0.8939 -0.1090 -0.2699 -0.0260 -0.4333 -0.0448 -0.1272 -1.0829 -0.1425 -0.3724 -3.7065 -0.1372 -0.2661 -0.1635 -0.0957 -0.3104 -1.1643 -0.1270 -0.3997 -0.1333
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise ; clinical ; outcomes
H-1926	-0.8699910640716553	
D-1926	-0.8699910640716553	
P-1926	-1.6434 -0.0966
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure ulcers ; surgical ; patients
H-6	-0.4142856001853943	▁pressure ▁ul cer s ▁; ▁sur g ical ▁patients
D-6	-0.4142856001853943	pressure ulcers ; surgical patients
P-6	-0.8349 -0.0822 -0.0294 -0.4351 -0.3674 -0.9550 -0.2481 -0.5751 -0.4889 -0.4321 -0.1090
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf ; valve plasty ; mva
H-369	-0.5179877281188965	▁ HF ▁; ▁val ve ▁plast y ▁; ▁MS
D-369	-0.5179877281188965	HF ; valve plasty ; MS
P-369	-1.2388 -0.5728 -0.3366 -0.9815 -0.0349 -0.0361 -0.5602 -0.2923 -0.0649 -1.5092 -0.0704
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd ; congestive heart failure ; chf
H-902	-0.5508401989936829	▁PD ▁; ▁re frac tory ▁; ▁end - s tage ▁con ges tive ▁heart ▁failure ▁; CH f
D-902	-0.5508401989936829	PD ; refractory ; end-stage congestive heart failure ;CHf
P-902	-0.3941 -0.4098 -0.2208 -0.1154 -0.1168 -0.4705 -2.8143 -0.0706 -0.1467 -0.0150 -0.0369 -0.7060 -1.1787 -0.7539 -0.1071 -0.2621 -1.1876 -1.6149 -0.2974 -0.0980
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression models ; comorbidities
H-662	-0.6830260157585144	▁insurance ▁status
D-662	-0.6830260157585144	insurance status
P-662	-1.5434 -0.3439 -0.7141 -0.1307
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta blockers ; mortality ; patients ; heart failure
H-649	-0.7785928249359131	▁beta ▁block ers ▁; ▁heart ▁failure
D-649	-0.7785928249359131	beta blockers ; heart failure
P-649	-0.9598 -0.5080 -0.2182 -0.6836 -3.2134 -0.2987 -0.2508 -0.0963
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter ; invasive ; surgery
H-553	-0.27061963081359863	▁trans cat heter ▁; ▁surgery
D-553	-0.27061963081359863	transcatheter ; surgery
P-553	-0.0420 -0.2676 -0.0434 -0.8303 -0.3326 -0.2580 -0.1204
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-0.35540807247161865	▁fut ility ▁; ▁safety ▁monitoring ▁board
D-850	-0.35540807247161865	futility ; safety monitoring board
P-850	-0.5810 -0.1936 -0.5413 -0.9038 -0.0536 -0.2567 -0.2210 -0.0924
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic ; complication
H-1661	-0.8195466995239258	▁complica tion
D-1661	-0.8195466995239258	complication
P-1661	-1.4927 -1.4896 -0.2007 -0.0953
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation ; heart iron
H-748	-0.5529244542121887	▁che lation ▁regime ns ▁; ▁remove ▁heart ▁ir on
D-748	-0.5529244542121887	chelation regimens ; remove heart iron
P-748	-0.1816 -0.0204 -0.2516 -0.5081 -0.6834 -2.8583 -0.8414 -0.1093 -0.0547 -0.5029 -0.0706
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients ; consultation ; abdominal
H-1284	-0.7787958979606628	▁MT ▁; ▁abdominal ▁problems
D-1284	-0.7787958979606628	MT ; abdominal problems
P-1284	-0.8568 -1.3371 -0.3169 -1.6516 -0.3715 -0.1388
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients ; chronic organ failure
H-793	-0.7809819579124451	▁Time d ▁Up ▁& ▁Go ▁test ▁; ▁chronic ▁organ ▁failure
D-793	-0.7809819579124451	Timed Up & Go test ; chronic organ failure
P-793	-0.5591 -0.6089 -0.9911 -1.9549 -1.0383 -0.1544 -0.6129 -2.6089 -0.0457 -0.3846 -0.2521 -0.1609
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms ; patients ; nyha
H-1893	-0.6786962151527405	▁NY ha ▁functional ▁assessment
D-1893	-0.6786962151527405	NYha functional assessment
P-1893	-2.2282 -0.9759 -0.5397 -0.0352 -0.1923 -0.1008
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.4741405248641968	▁follow - up
D-727	-0.4741405248641968	follow-up
P-727	-0.6783 -0.3928 -0.0926 -1.1182 -0.0888
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.9621127247810364	
D-2001	-0.9621127247810364	
P-2001	-1.8126 -0.1116
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
H-576	-0.3395502269268036	▁vent ri cular ▁e je ction ▁; ▁a cute ▁heart ▁failure ▁; ▁pre cap illa ry ▁pulmonar y ▁hyper tension
D-576	-0.3395502269268036	ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
P-576	-0.0925 -2.0640 -0.1703 -0.0987 -0.1139 -0.0327 -1.6358 -0.4245 -0.0391 -0.5860 -0.1792 -0.3157 -0.6886 -0.1039 -0.0488 -0.1685 -0.0079 -0.0785 -0.1231 -0.0190 -0.3459 -0.1335
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical ; aortic valve insufficiency ; left ventricular assist device ; implantation
H-541	-0.3791263699531555	▁a or tic ▁val ve ▁insu ffi cie ncy ▁; ▁left ▁vent ri cular ▁assist ▁device ▁implant ation
D-541	-0.3791263699531555	aortic valve insufficiency ; left ventricular assist device implantation
P-541	-0.4344 -0.1522 -0.8142 -0.1430 -0.0890 -0.7780 -0.0903 -0.6071 -0.0324 -0.3083 -0.2264 -0.0369 -1.3304 -0.1040 -0.6875 -0.1976 -0.5904 -0.5721 -0.3020 -0.0863
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection fraction ; clinical ; cardiac resynchronization therapy ; mild heart failure
H-750	-0.2655267119407654	▁e je ction ▁ fraction ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁mild ▁heart ▁failure
D-750	-0.2655267119407654	ejection fraction ; cardiac resynchronization therapy ; mild heart failure
P-750	-0.0400 -0.0925 -0.0355 -0.3841 -0.0165 -0.3119 -0.0648 -0.0414 -0.1609 -0.0267 -0.7861 -0.8122 -0.0227 -0.3496 -1.2098 -0.1911 -0.1481 -0.2467 -0.1046
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary outcome ; functional capacity ; 6-minute walk test ; 6mwt
H-571	-1.2070690393447876	▁functional ▁capacity ▁; ▁m t
D-571	-1.2070690393447876	functional capacity ; mt
P-571	-1.1487 -2.1261 -1.0678 -3.2456 -0.2882 -0.4205 -0.1526
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef ; sodium ; ventricular ; vascular stiffness
H-917	-0.6334391236305237	▁h FP EF ▁; ▁so dium ▁restriction ▁; ▁vent ri cular ▁; ▁vas cular ▁sti ff ness
D-917	-0.6334391236305237	hFPEF ; sodium restriction ; ventricular ; vascular stiffness
P-917	-1.4908 -1.4987 -1.2709 -0.3928 -0.3628 -0.0878 -0.3286 -0.1755 -0.0319 -1.5435 -0.1573 -0.4115 -0.1353 -0.2321 -0.4531 -0.5482 -2.1177 -0.7098 -0.0868
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully magnetically levitated left ventricular assist system ; hf
H-1992	-0.47324228286743164	▁magnet ically ▁Lev itate d ▁le ft ▁vent ri cular ▁Assist ▁system ▁; ▁Tre ating ▁Advanced ▁ HF
D-1992	-0.47324228286743164	magnetically Levitated left ventricular Assist system ; Treating Advanced HF
P-1992	-0.1835 -0.1218 -0.1525 -0.6686 -0.0144 -0.4873 -0.0177 -0.8345 -2.6025 -0.2236 -0.0668 -0.5064 -1.0484 -1.4533 -0.0155 -0.4041 -0.0988 -0.2915 -0.2087 -0.0649
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf ; atrial explants ; cells ; explants
H-1341	-0.5078421831130981	▁CHF ▁at rial ▁ex plant s ▁; ▁sham ▁ex plant s
D-1341	-0.5078421831130981	CHF atrial explants ; sham explants
P-1341	-0.0253 -2.6829 -0.0935 -0.0597 -0.0381 -0.4571 -0.3857 -1.6922 -0.2316 -0.0430 -0.4599 -0.3440 -0.0889
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic heart failure ; chf ; sympathetic tone ; autonomic imbalance
H-1370	-0.49709370732307434	▁chronic ▁heart ▁failure ▁; CH f ▁; ▁sympa the tic ▁tone ▁; ▁autonomi c ▁im balance
D-1370	-0.49709370732307434	chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
P-1370	-0.2173 -0.8605 -0.1453 -0.3007 -1.7612 -1.5857 -0.3535 -0.1115 -0.6686 -0.5483 -0.1153 -0.3779 -0.0064 -0.3229 -1.1816 -0.0296 -0.2617 -0.0997
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart failure ; leading ; mortality ; western ; society ; cardiovascular diseases
H-1480	-0.6378150582313538	▁Heart ▁failure ▁; ▁mortal iteit ▁; ▁Western ▁society ▁; ▁cardiovascular ▁disease s
D-1480	-0.6378150582313538	Heart failure ; mortaliteit ; Western society ; cardiovascular diseases
P-1480	-0.8806 -0.2738 -0.3187 -3.4739 -1.3990 -0.2537 -0.8479 -0.1213 -0.3007 -0.1782 -0.3123 -0.2276 -0.2524 -0.0892
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal membrane oxygenation ; refractory right heart failure
H-1290	-0.2670886218547821	▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ bridge ▁to ▁recovery ▁; ▁in far ction - related ▁re frac tory ▁right ▁heart ▁failure
D-1290	-0.2670886218547821	extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
P-1290	-0.3465 -0.0160 -0.3067 -0.0373 -0.0077 -0.0585 -0.6044 -0.2343 -0.4763 -0.8324 -0.0067 -1.1155 -0.0725 -0.7257 -0.2892 -0.1294 -0.0667 -0.1508 -0.0692 -0.0392 -0.0198 -0.1178 -0.6628 -0.2618 -0.2364 -0.2564 -0.0712
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical ; echocardiographic ; invasive ; hemodynamic ; outcome
H-1527	-0.2566545009613037	▁e cho car dio graphic ▁; ▁invasi ve ▁hem o dynamic
D-1527	-0.2566545009613037	echocardiographic ; invasive hemodynamic
P-1527	-0.1426 -0.0803 -0.0595 -0.7320 -0.6544 -0.2704 -0.0169 -0.1088 -0.2501 -0.5296 -0.0076 -0.3958 -0.0883
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac catheterization ; thrombotic obstruction ; right coronary artery
H-1292	-0.6198510527610779	▁cardiac ▁cat heter ization ▁; ▁ thro mbo tic ▁ob struct ion ▁; ▁right ▁corona ry ▁arter y
D-1292	-0.6198510527610779	cardiac catheterization ; thrombotic obstruction ; right coronary artery
P-1292	-1.5636 -0.6310 -0.0410 -1.2133 -0.3628 -0.2829 -0.5214 -1.1082 -2.2434 -0.5551 -0.0467 -0.0459 -0.4670 -0.3067 -0.0922 -1.5954 -0.0092 -0.9096 -0.2968 -0.1048
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california office of statewide health planning and development patient discharge data nonpublic file
H-136	-0.9346714615821838	▁California ▁office ▁of ▁State wide ▁health plan ning ▁and ▁Development ▁Patient ▁Dis charge
D-136	-0.9346714615821838	California office of Statewide healthplanning and Development Patient Discharge
P-136	-2.0498 -1.9628 -0.7731 -2.0717 -0.1819 -0.8312 -0.9548 -0.0183 -1.5265 -1.1188 -0.5915 -1.2514 -0.0309 -0.5658 -0.0915
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan failure ; systolic ventricular function ; liver disease
H-224	-0.30155619978904724	▁Font an ▁failure ▁; ▁sy sto lic ▁vent ri cular ▁function ▁; ▁ liver ▁disease
D-224	-0.30155619978904724	Fontan failure ; systolic ventricular function ; liver disease
P-224	-0.2877 -0.2580 -0.4768 -0.2796 -0.0245 -0.0636 -0.1023 -0.0484 -1.4147 -0.1385 -0.4531 -0.2305 -0.2259 -0.2860 -0.4495 -0.2892 -0.0984
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing ; outcomes ; hospitalized ; hf
H-1402	-1.4841837882995605	▁ HF
D-1402	-1.4841837882995605	HF
P-1402	-4.9314 -0.3983 -0.4749 -0.1322
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis ; pacing-induced dilated cardiomyopathy
H-165	-0.5526506900787354	▁pa cing - indu ced ▁dil ated ▁cardio my o pathy
D-165	-0.5526506900787354	pacing-induced dilated cardiomyopathy
P-165	-2.7121 -1.4356 -0.0876 -0.0196 -0.1181 -0.4758 -0.3052 -0.0637 -0.8788 -0.6203 -0.0258 -0.3000 -0.1418
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical delay ; dyssynchronous heart failure
H-1146	-0.5195753574371338	▁me chan istic ▁insight ▁; ▁electro me chan ical ▁de lay ▁; ▁dys syn chron ous ▁heart ▁failure
D-1146	-0.5195753574371338	mechanistic insight ; electromechanical delay ; dyssynchronous heart failure
P-1146	-3.4356 -0.0366 -0.4309 -0.4827 -0.3824 -0.4439 -0.0741 -0.0694 -0.3456 -0.0626 -0.1168 -0.6308 -0.0681 -0.0401 -0.0142 -1.3437 -1.1785 -0.1831 -0.9397 -0.1126
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients ; trastuzumab ; cardiac ; comorbidities
H-682	-0.5353546142578125	▁tras tuz um ab ▁; ▁cardiac ▁como rbi di ties
D-682	-0.5353546142578125	trastuzumab ; cardiac comorbidities
P-682	-0.7633 -0.0706 -0.0265 -0.6614 -0.6916 -0.0355 -2.2484 -0.0127 -0.8955 -0.2152 -0.6469 -0.1566
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype ; perioperative ; deaths
H-279	-0.37215450406074524	
D-279	-0.37215450406074524	
P-279	-0.6485 -0.0958
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic ; patients ; heart failure ; québec ; canada
H-1233	-0.7114500999450684	▁economic ▁impact ▁; ▁AF ▁; ▁heart ▁failure ▁; ▁Québec ▁; ▁Canada
D-1233	-0.7114500999450684	economic impact ; AF ; heart failure ; Québec ; Canada
P-1233	-1.7400 -1.6043 -0.3537 -1.6229 -0.3954 -0.4737 -0.1269 -0.5186 -0.7327 -0.5402 -0.8298 -0.2408 -0.0699
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac ; mena deletion ; cardiac dysfunction ; hypertrophy
H-1811	-0.44859200716018677	▁cardiac ▁Men a ▁dele tion ▁; ▁cardiac ▁dys function ▁; ▁hyper trop hy
D-1811	-0.44859200716018677	cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
P-1811	-0.1441 -1.2337 -0.0554 -0.0133 -0.2677 -0.3978 -0.0778 -0.1549 -0.0828 -0.4071 -1.0618 -0.0267 -2.5480 -0.1817 -0.0762
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left bundle-branch block ; lbbb
H-886	-0.41742148995399475	▁bund le - bran ch ▁block ▁; LB bb ▁; ▁non - LB bb
D-886	-0.41742148995399475	bundle-branch block ;LBbb ; non-LBbb
P-886	-0.0632 -0.3115 -0.1048 -0.0268 -0.3944 -0.2432 -0.4637 -0.6159 -1.2382 -0.5218 -1.1528 -0.0639 -0.3065 -0.8252 -0.2372 -0.1097
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein ; genes ; western blot ; dna fragmentation ; tunel
H-167	-0.5064650177955627	▁protein ▁levels ▁; ▁Western ▁blot ▁; ▁DNA ▁fragment ation ▁; ▁tu nel ▁; ▁auto psy ▁sample s
D-167	-0.5064650177955627	protein levels ; Western blot ; DNA fragmentation ; tunel ; autopsy samples
P-167	-0.8005 -0.8346 -0.4933 -1.5783 -0.0923 -0.3642 -0.3496 -0.0652 -0.3318 -0.3957 -0.5909 -0.3771 -2.5698 -0.1416 -0.0202 -0.1753 -0.1363 -0.2233 -0.0829
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine ; dilated cardiomyopathy ; patients ; heart failure
H-1257	-0.3675534427165985	▁Chinese ▁herbal ▁medicine ▁; ▁ad ju nc tive ▁treatment ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure
D-1257	-0.3675534427165985	Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
P-1257	-0.7259 -0.0847 -0.1327 -0.3493 -1.5846 -0.0633 -0.0066 -0.1650 -0.3255 -0.5680 -0.0359 -0.1767 -0.0469 -0.8539 -0.8209 -0.0182 -0.2968 -0.7122 -0.2413 -0.3562 -0.1539
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient ; implantable cardioverter-defibrillator
H-1856	-0.25457891821861267	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1856	-0.25457891821861267	implantable cardioverter-defibrillator deactivation
P-1856	-0.8699 -0.1513 -0.2281 -0.0302 -0.3060 -0.0811 -0.1014 -0.1002 -0.3699 -0.1712 -0.0995 -0.2044 -0.1140 -0.6933 -0.4243 -0.1286
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated ; cardiac filling pressures ; adverse outcomes
H-1532	-0.45660117268562317	▁EH ▁; ▁CH ▁; ▁cardiac ▁fill ing ▁pressure s
D-1532	-0.45660117268562317	EH ; CH ; cardiac filling pressures
P-1532	-1.1285 -0.2457 -0.5800 -0.6717 -0.2295 -0.5767 -0.2202 -0.5218 -0.3748 -0.3738 -0.0999
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right atrium ; prolapse ; tricuspid valve ; stenotic physiology
H-596	-0.4394270181655884	▁right ▁at rium ▁mass ▁; ▁pro lapse ▁; ▁tri cus pid ▁val ve ▁; ▁ste no tic
D-596	-0.4394270181655884	right atrium mass ; prolapse ; tricuspid valve ; stenotic
P-596	-0.1797 -0.4462 -0.0199 -0.1598 -0.3402 -0.2198 -0.1620 -0.5425 -0.0592 -0.1700 -0.0362 -0.1437 -0.1455 -0.5326 -0.0173 -0.0598 -0.5412 -4.5154 -0.0582
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp ; sensitivity
H-271	-0.47709178924560547	▁cut off ▁level ▁; ▁NT - pro b NP
D-271	-0.47709178924560547	cutoff level ; NT-probNP
P-271	-0.6792 -0.2947 -0.3018 -0.4118 -0.1933 -0.0776 -0.0510 -0.8019 -0.6772 -1.6450 -0.1146
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart failure ; protein kinase a ; expression
H-1423	-0.7252755165100098	▁heart ▁failure ▁; ▁protein ▁kina se
D-1423	-0.7252755165100098	heart failure ; protein kinase
P-1423	-3.3765 -0.5124 -0.7668 -0.4989 -0.0091 -0.1360 -0.3746 -0.1278
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up ; patients ; hf
H-1106	-0.5893927812576294	▁ HF
D-1106	-0.5893927812576294	HF
P-1106	-1.6023 -0.3186 -0.3158 -0.1209
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality of life ; seattle heart failure model
H-2012	-0.5138753056526184	▁Seattle ▁Heart ▁Fail ure
D-2012	-0.5138753056526184	Seattle Heart Failure
P-2012	-0.6346 -0.5083 -0.4600 -0.2915 -1.0784 -0.1104
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized ; dopamine ; nesiritide
H-76	-0.2825394570827484	▁dop amine ▁; ▁nesi riti de ▁strategy
D-76	-0.2825394570827484	dopamine ; nesiritide strategy
P-76	-0.1635 -0.1104 -0.2424 -0.0373 -0.0245 -0.1045 -1.4400 -0.3052 -0.1150
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical ; nitrite ; vascular
H-414	-1.0320911407470703	▁nit rite
D-414	-1.0320911407470703	nitrite
P-414	-3.0011 -0.4309 -0.5966 -0.0998
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological ; cardiovascular ; bound
H-1875	-0.4248780310153961	▁neurologi cal ▁; ▁cardiovascular
D-1875	-0.4248780310153961	neurological ; cardiovascular
P-1875	-0.1046 -0.5018 -0.7382 -0.0783 -1.0300 -0.0964
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox regression ; cardiovascular events ; psoriasis
H-1558	-0.17341221868991852	▁co x ▁re gression ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1558	-0.17341221868991852	cox regression ; cardiovascular events ; psoriasis
P-1558	-0.0692 -0.2046 -0.0440 -0.0315 -0.3511 -0.1652 -0.3510 -0.3911 -0.0100 -0.1997 -0.0900
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective studies ; cpg ; hf
H-1845	-1.0752984285354614	▁c PG ▁; ▁ HF
D-1845	-1.0752984285354614	cPG ; HF
P-1845	-0.5618 -1.0712 -0.6008 -3.0356 -1.7169 -0.3975 -0.1434
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation ; flow-mediated dilatation
H-259	-0.5615593791007996	▁no ▁production ▁; ▁flow - media ted ▁di la tation ▁; ▁et
D-259	-0.5615593791007996	no production ; flow-mediated dilatation ; et
P-259	-2.8851 -1.0419 -0.2474 -0.4737 -0.0722 -0.1073 -0.4884 -0.1999 -0.4054 -0.0542 -0.5799 -0.6989 -0.5259 -0.0818
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ; ahf ; risk stratification
H-58	-0.9179132580757141	▁a HF
D-58	-0.9179132580757141	aHF
P-58	-1.2228 -1.3266 -0.9707 -0.1516
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients ; systolic function ; therapeutic
H-1070	-0.6755445003509521	▁sy sto lic ▁function
D-1070	-0.6755445003509521	systolic function
P-1070	-2.4902 -0.2561 -0.0929 -0.1486 -0.9653 -0.1002
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets ; tac ; hf
H-1050	-0.5581329464912415	▁ BET s ▁; ▁mouse ▁ TAC ▁model ▁; ▁human ▁ HF
D-1050	-0.5581329464912415	BETs ; mouse TAC model ; human HF
P-1050	-2.3602 -0.4024 -0.4403 -0.2704 -0.5794 -0.8555 -0.0450 -0.4516 -0.2565 -0.5678 -0.6785 -0.6261 -0.1944 -0.0856
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-1.1715784072875977	
D-614	-1.1715784072875977	
P-614	-2.2533 -0.0899
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac ; nurses
H-1662	-0.22245359420776367	▁cardiac ▁nurse s
D-1662	-0.22245359420776367	cardiac nurses
P-1662	-0.1213 -0.1554 -0.1593 -0.5594 -0.1169
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations ; patients ; patients
H-1282	-0.5560499429702759	
D-1282	-0.5560499429702759	
P-1282	-0.9899 -0.1222
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion ; mortality
H-50	-0.7654956579208374	▁trans fusion ▁thre s hold s ▁; ▁mortal ity
D-50	-0.7654956579208374	transfusion thresholds ; mortality
P-50	-0.1372 -0.3410 -0.6743 -0.4685 -0.7254 -0.4733 -1.0142 -0.2829 -2.2634 -1.8664 -0.1740
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech republic
H-1972	-0.46452996134757996	▁Czech ▁Republic
D-1972	-0.46452996134757996	Czech Republic
P-1972	-0.6633 -0.1778 -0.9002 -0.1168
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients ; madit-crt
H-858	-1.0348777770996094	▁MAD it - c RT ▁; ▁device
D-858	-1.0348777770996094	MADit-cRT ; device
P-858	-0.1865 -1.6473 -0.0547 -1.0402 -4.1617 -1.5967 -0.2936 -0.2187 -0.1144
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients ; randomization
H-851	-0.38161706924438477	
D-851	-0.38161706924438477	
P-851	-0.6694 -0.0938
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c statistics
H-383	-1.4562054872512817	▁UM / VA ▁; ▁va - RT
D-383	-1.4562054872512817	UM/VA ; va-RT
P-383	-0.9148 -2.5276 -1.4950 -3.1581 -0.4529 -0.5690 -3.5177 -0.3714 -0.0994
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart failure
H-1539	-0.8137351870536804	▁heart ▁failure
D-1539	-0.8137351870536804	heart failure
P-1539	-2.6091 -0.2786 -0.2788 -0.0885
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hf
H-1431	-0.6079347133636475	▁Western ▁blot s ▁; ▁mono clo nal ▁anti bo dies ▁; ▁Ser 83 ▁ phos phor y lation ▁; HF
D-1431	-0.6079347133636475	Western blots ; monoclonal antibodies ; Ser83 phosphorylation ;HF
P-1431	-0.1394 -0.0101 -0.1423 -0.5117 -0.0030 -0.3588 -2.1183 -0.0182 -0.1478 -1.7512 -0.3671 -0.5365 -0.7164 -0.2528 -0.0402 -1.8222 -1.6225 -0.0827 -0.2877 -2.0868 -0.2612 -0.0973
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative ; serum albumin ; patients ; left ventricular assist device ; implantation
H-528	-0.8019545078277588	▁se rum ▁album in ▁; ▁left ▁vent ri cular ▁assist ▁device ▁implant ation
D-528	-0.8019545078277588	serum albumin ; left ventricular assist device implantation
P-528	-1.9479 -0.4996 -0.7202 -0.2417 -0.7079 -2.9482 -0.0545 -2.6915 -0.1608 -0.6694 -0.1139 -0.3526 -0.5043 -0.3067 -0.1101
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new york heart association classification ; 6-min walk test ; quality-of-life
H-2005	-1.0030391216278076	▁New ▁York ▁Heart ▁association
D-2005	-1.0030391216278076	New York Heart association
P-2005	-0.7979 -0.6994 -1.5200 -0.6444 -2.2561 -0.1004
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional ms ; ring annuloplasty ; ischemic mr ; lv dilatation
H-366	-0.17922110855579376	▁functional ▁MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁MR ▁; ▁LV ▁di la tation
D-366	-0.17922110855579376	functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
P-366	-0.1999 -0.1431 -0.3079 -0.0055 -0.4213 -0.3835 -0.0635 -0.3806 -0.2169 -0.2575 -0.0242 -0.1008 -0.0372 -0.4094 -0.0162 -0.1280 -0.0881 -0.0267 -0.3110 -0.0630
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change ; paco2 ; cerebral ; blood flow ; perfusion ; carotid
H-1350	-0.22151368856430054	▁Paco 2 ▁; ▁cerebral ▁blood ▁flow ▁; ▁per fusion ▁; ▁caro tid ▁bo dies
D-1350	-0.22151368856430054	Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
P-1350	-0.0275 -0.0536 -0.7546 -0.0255 -0.5101 -0.3555 -0.1600 -0.2248 -0.0165 -0.5221 -0.1901 -0.0725 -0.0163 -0.2800 -0.2411 -0.0941
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin receptor antagonist ; tolvaptan ; heart failure ; patients
H-1194	-0.30620965361595154	▁vaso press in ▁receptor ▁anta gon ist ▁; ▁to lv ap tan ▁; ▁Japanese ▁heart ▁failure ▁patients
D-1194	-0.30620965361595154	vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure patients
P-1194	-0.0332 -0.0710 -0.4241 -0.0155 -0.2810 -0.0045 -0.6132 -0.2154 -0.0229 -0.2578 -0.6520 -0.0474 -0.2197 -0.7285 -0.4862 -0.1185 -1.2446 -0.2841 -0.0982
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology ; hf ; diagnosis ; medical ; nursing
H-2021	-1.0340263843536377	▁pat ho phy si ology ▁; ▁ HF
D-2021	-1.0340263843536377	pathophysiology ; HF
P-2021	-1.5251 -0.9104 -0.4515 -2.7901 -0.3474 -0.2589 -1.6481 -0.7786 -1.5405 -0.0897
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients ; physicians ; hospitals ; new jersey ; new york
H-212	-0.6340025663375854	▁ED ▁physician s ▁; ▁New ▁Jersey ▁; ▁New ▁York
D-212	-0.6340025663375854	ED physicians ; New Jersey ; New York
P-212	-1.2779 -0.5525 -0.1583 -0.5424 -2.1416 -0.1101 -0.6005 -1.0259 -0.2267 -0.2656 -0.0727
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis ; patients ; diastolic blood pressure ; body mass index
H-1560	-0.5588054656982422	▁p sori asis ▁patients ▁; ▁smo ked ▁; ▁dia sto lic ▁blood ▁pressure ▁; ▁body ▁mass ▁index
D-1560	-0.5588054656982422	psoriasis patients ; smoked ; diastolic blood pressure ; body mass index
P-1560	-3.5511 -0.0838 -0.1337 -1.4131 -0.5687 -0.8095 -0.4970 -0.6709 -0.0253 -0.0680 -0.0629 -0.3490 -0.8777 -0.2877 -0.1940 -0.1065 -0.0094 -0.7899 -0.1193
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise intolerance ; heart failure ; exercise ; diagnosis ; prognosis ; therapeutic
H-1272	-0.5808819532394409	▁Exerci se ▁in tolerance ▁; ▁heart ▁failure
D-1272	-0.5808819532394409	Exercise intolerance ; heart failure
P-1272	-2.1511 -0.4639 -0.0212 -0.0315 -0.5355 -0.8779 -0.2194 -0.8341 -0.0933
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients ; clinical ; echocardiography ; baseline ; shunt ; implantation
H-1954	-0.3321818709373474	▁e cho card i ography ▁; ▁shu nt ▁implant ation
D-1954	-0.3321818709373474	echocardiography ; shunt implantation
P-1954	-0.1481 -0.0897 -0.3393 -1.0167 -0.2652 -0.6299 -0.3388 -0.0536 -0.0844 -0.6673 -0.2464 -0.1068
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
H-1383	-0.37128448486328125	▁vent ri cular ▁assist ▁device ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁renal ▁function ▁; ▁heart ▁failure
D-1383	-0.37128448486328125	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
P-1383	-0.0272 -1.8346 -0.2249 -0.7611 -0.2521 -0.3418 -0.0297 -0.0381 -0.3894 -0.0464 -0.0288 -0.0486 -0.4772 -0.5085 -0.3472 -0.0283 -0.1815 -0.2748 -1.6347 -0.2930 -0.2777 -0.1225
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations ; cox models ; st2 ; functional capacity ; outcomes
H-700	-0.5244537591934204	▁co x ▁models ▁; ▁ST 2
D-700	-0.5244537591934204	cox models ; ST2
P-700	-0.1893 -0.1308 -1.3991 -0.7299 -0.3753 -0.0628 -1.2077 -0.1008
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause hospitalisations ; sts
H-160	-0.7532431483268738	▁TM ▁intervention s ▁; ▁s TS
D-160	-0.7532431483268738	TM interventions ; sTS
P-160	-0.3179 -1.9551 -0.1898 -0.6293 -0.2542 -1.4202 -1.1341 -0.1253
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol ; linear mixed models ; intention-to-treat
H-838	-1.1207983493804932	▁HR Qo L
D-838	-1.1207983493804932	HRQoL
P-838	-3.5621 -0.0106 -1.3794 -0.5705 -0.0815
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp ; circulation ; hf ; patients
H-1513	-0.39126336574554443	▁NT - pro b NP ▁; ▁circulation ▁; ▁ HF ▁patients
D-1513	-0.39126336574554443	NT-probNP ; circulation ; HF patients
P-1513	-0.2511 -0.0828 -0.0222 -0.8623 -0.4645 -0.3596 -0.4443 -0.5155 -0.6508 -0.3020 -0.6601 -0.3418 -0.1294
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy metabolism ; heart failure ; hypertrophied ; heart
H-1779	-0.37909573316574097	▁energy ▁metabolism ▁; ▁heart ▁failure ▁; ▁hyper trop hi ed ▁heart
D-1779	-0.37909573316574097	energy metabolism ; heart failure ; hypertrophied heart
P-1779	-1.1368 -0.0852 -0.2165 -1.3333 -0.4369 -0.1456 -0.1977 -0.0396 -0.0185 -0.2081 -0.8844 -0.1508 -0.0750
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional ms ; lv dilatation ; functional ms
H-368	-0.50380539894104	▁MS ▁; ▁LV ▁di la tation ▁; ▁functional ▁MS
D-368	-0.50380539894104	MS ; LV dilatation ; functional MS
P-368	-1.3876 -0.5225 -0.5139 -1.1357 -0.3985 -0.0309 -0.4914 -0.4074 -0.2852 -0.2572 -0.1116
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients ; pad ; ankle-brachial index
H-1568	-0.48477861285209656	PAD ▁; ▁an kle - bra chi al ▁index
D-1568	-0.48477861285209656	PAD ; ankle-brachial index
P-1568	-0.9330 -1.5719 -0.6508 -0.4232 -0.3152 -0.3339 -0.5508 -0.0584 -0.0119 -0.3718 -0.1116
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr reduction ; ivabradine ; tac ; ea
H-525	-0.6740801930427551	▁HR ▁; ▁i va bra dine ▁; ▁ TAC ▁; ▁Ea
D-525	-0.6740801930427551	HR ; ivabradine ; TAC ; Ea
P-525	-3.0533 -1.1145 -0.1654 -0.0557 -0.2657 -0.2490 -0.1179 -0.8733 -0.1345 -0.4487 -1.7923 -0.3397 -0.1531
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline ; mechanical cardiac support ; renal function
H-1388	-0.5606179237365723	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function
D-1388	-0.5606179237365723	mechanical cardiac support ; renal function
P-1388	-2.6379 -0.0553 -0.1614 -1.0074 -0.2898 -0.0507 -0.3406 -0.3686 -0.1339
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ; ecmo ; patients ; vad ; ecmo ; vad
H-1390	-1.0631301403045654	▁ec mo ▁; ▁ VAD ▁; ▁ec mo + VAD
D-1390	-1.0631301403045654	ecmo ; VAD ; ecmo+VAD
P-1390	-0.9880 -1.5149 -1.6570 -1.8143 -0.1318 -0.3755 -0.5308 -2.1043 -2.1972 -0.1629 -1.1179 -0.1632
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality ; morbidity ; health-care ; budget
H-1075	-0.7080538272857666	▁mortal ity ▁; ▁morbi d ity ▁; ▁cancer s ▁; ▁budget
D-1075	-0.7080538272857666	mortality ; morbidity ; cancers ; budget
P-1075	-2.3962 -1.8092 -0.3247 -0.0276 -0.0659 -2.5027 -0.3837 -0.2812 -0.2390 -0.3354 -0.4862 -0.2352 -0.1177
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation ; therapy ; heart disease ; rate control
H-1652	-0.6811841726303101	▁antico ag ulation ▁; ▁heart ▁disease ▁; ▁rate ▁control
D-1652	-0.6811841726303101	anticoagulation ; heart disease ; rate control
P-1652	-0.4085 -0.0864 -0.1296 -0.2129 -4.5561 -0.4073 -0.5942 -0.0730 -0.5745 -0.3414 -0.1091
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic effect ; beta blockers ; heart failure
H-648	-0.35662901401519775	▁in o tropi c ▁effect ▁; ▁beta ▁block ers ▁; ▁heart ▁failure
D-648	-0.35662901401519775	inotropic effect ; beta blockers ; heart failure
P-648	-0.1949 -1.1255 -0.0292 -0.0802 -0.1099 -0.3207 -0.2435 -0.4383 -0.1845 -0.4419 -1.2995 -0.1740 -0.2589 -0.0919
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin receptor ; st2 ; beta-blocker ; therapy ; chronic heart failure
H-398	-0.512540340423584	▁inter le u kin ▁receptor ▁family ▁member ▁; ▁ST 2 ▁; ▁beta - block er ▁ therapy ▁; ▁chronic ▁heart ▁failure
D-398	-0.512540340423584	interleukin receptor family member ; ST2 ; beta-blocker therapy ; chronic heart failure
P-398	-0.3978 -0.3976 -0.0994 -4.8951 -0.0143 -0.7550 -0.5685 -1.6371 -0.1690 -0.0650 -0.2678 -0.1851 -0.0672 -0.2033 -0.0432 -0.3841 -0.0133 -0.4362 -0.2087 -0.3931 -0.2453 -0.2434 -0.0991
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients ; heart failure ; systolic heart failure
H-725	-0.7957319617271423	▁heart ▁failure ▁; ▁sy sto lic ▁heart ▁failure
D-725	-0.7957319617271423	heart failure ; systolic heart failure
P-725	-5.0333 -0.3400 -0.3700 -0.0792 -0.0983 -0.1927 -1.2451 -0.1995 -0.2729 -0.1263
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline ; rhythm-control ; rate-control
H-1237	-0.49186140298843384	▁ rhythm - control ▁; ▁rate - control
D-1237	-0.49186140298843384	rhythm-control ; rate-control
P-1237	-0.4851 -1.4282 -0.4737 -0.0423 -0.6061 -0.7630 -0.4127 -0.0428 -0.5120 -0.1526
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin ; health ; outcomes
H-43	-1.1430552005767822	▁hem o glob in ▁levels
D-43	-1.1430552005767822	hemoglobin levels
P-43	-1.6933 -0.7043 -0.2307 -1.5642 -2.0151 -1.6953 -0.0986
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional ms ; medical treatment ; surgical
H-376	-0.6304229497909546	▁Fun ction al ▁MS
D-376	-0.6304229497909546	Functional MS
P-376	-0.4977 -0.0253 -0.0119 -0.0809 -3.0514 -0.1153
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf ; epidemiology ; health ; hf
H-1790	-0.8223501443862915	▁ HF ▁epidemi ology ▁; ▁health ▁service ▁provision ▁; ▁ HF ▁; ▁LA
D-1790	-0.8223501443862915	HF epidemiology ; health service provision ; HF ; LA
P-1790	-1.1948 -0.2313 -2.6375 -0.3999 -0.2353 -0.8577 -0.6401 -1.6803 -0.2948 -0.8906 -0.3245 -0.4704 -1.7225 -0.6476 -0.1079
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart failure ; hf ; chronic ; disease
H-2019	-0.5007398128509521	▁Heart ▁failure ▁; HF
D-2019	-0.5007398128509521	Heart failure ;HF
P-2019	-0.5125 -0.0851 -0.2716 -0.1856 -1.8502 -0.0995
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes ; heart failure ; hf
H-555	-0.9888656735420227	▁heart ▁failure ▁; HF
D-555	-0.9888656735420227	heart failure ;HF
P-555	-4.6429 -0.1542 -0.3326 -0.4443 -0.2246 -0.1345
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up ; lvad ; patients ; heart failure
H-548	-0.5077372789382935	▁CF ▁l VAD ▁; ▁AI ▁; ▁heart ▁failure
D-548	-0.5077372789382935	CF lVAD ; AI ; heart failure
P-548	-0.3382 -0.7028 -0.0525 -0.6942 -1.3174 -0.3708 -0.9657 -0.2404 -0.2689 -0.1265
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade ; evidence ; anemia ; patients ; heart disease
H-38	-0.73419588804245	▁an emia ▁; ▁heart ▁disease
D-38	-0.73419588804245	anemia ; heart disease
P-38	-1.9561 -0.4109 -0.4183 -1.6427 -0.2913 -0.2537 -0.1664
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients ; left ventricular dilatation ; dysfunction
H-1746	-0.9962864518165588	▁left ▁vent ri cular ▁di la tation
D-1746	-0.9962864518165588	left ventricular dilatation
P-1746	-3.5458 -0.0789 -2.4793 -0.5370 -0.5572 -0.7120 -0.1626 -0.7710 -0.1229
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular assist devices ; therapies
H-203	-0.4377197325229645	▁vent ri cular ▁assist ▁devices ▁; ▁device ▁ therapie s
D-203	-0.4377197325229645	ventricular assist devices ; device therapies
P-203	-0.2583 -2.0519 -0.1311 -0.6649 -0.1577 -0.8033 -0.1246 -0.2269 -0.0962 -0.1736 -0.4375 -0.1268
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted ; patients ; adverse events ; follow-up
H-1956	-1.164078950881958	▁device
D-1956	-1.164078950881958	device
P-1956	-2.5145 -0.8792 -0.0985
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal dysfunction ; mechanical cardiac support
H-1394	-0.3192445635795593	▁renal ▁dys function ▁; ▁mechanic al ▁cardiac ▁support
D-1394	-0.3192445635795593	renal dysfunction ; mechanical cardiac support
P-1394	-0.4623 -0.2047 -0.1031 -0.2627 -0.6621 -0.0437 -0.0480 -1.0057 -0.2979 -0.1024
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.6639068126678467	▁ HF ▁co hor t
D-1002	-0.6639068126678467	HF cohort
P-1002	-1.6680 -0.8331 -0.3785 -1.2288 -0.1116 -0.3010 -0.1263
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions ; hospital
H-144	-0.7279806137084961	▁computing ▁read missions ▁; ▁hospital ▁ranking s
D-144	-0.7279806137084961	computing readmissions ; hospital rankings
P-144	-0.6821 -2.0197 -0.2741 -0.4471 -0.7765 -1.0153 -0.1917 -1.0315 -0.1139
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory factor analysis ; cfa
H-1506	-1.1095033884048462	▁c fa
D-1506	-1.1095033884048462	cfa
P-1506	-2.1858 -1.7379 -0.3595 -0.1549
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb ; patients ; hf
H-1351	-0.834067165851593	▁p b ▁; ▁patients ▁; ▁ HF ▁; ▁centrale ▁pattern ▁generator
D-1351	-0.834067165851593	pb ; patients ; HF ; centrale pattern generator
P-1351	-0.4602 -1.4633 -0.2379 -1.1023 -1.2392 -0.8873 -0.3589 -1.0618 -2.6603 -0.8973 -0.0033 -0.3758 -0.0954
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic ; clinicians ; patients
H-1124	-0.891166627407074	▁non tre at ment
D-1124	-0.891166627407074	nontreatment
P-1124	-3.8714 -0.0967 -0.0744 -0.5164 -0.6772 -0.1109
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates ; coagulability
H-1113	-0.7540596127510071	▁se rum ▁factors ▁; ▁marker s ▁voor ▁coa gul ability
D-1113	-0.7540596127510071	serum factors ; markers voor coagulability
P-1113	-0.8353 -0.3422 -0.1364 -0.7557 -1.2697 -0.1527 -2.2982 -0.7139 -0.5688 -1.6365 -0.2285 -0.1108
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd ; patients
H-65	-0.9053617119789124	▁i CD
D-65	-0.9053617119789124	iCD
P-65	-0.2842 -2.1984 -0.9260 -0.2128
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients ; patients
H-267	-0.8200304508209229	
D-267	-0.8200304508209229	
P-267	-1.4804 -0.1596
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp ; nt-probnp ; diagnostic ; prognostic ; biomarkers ; patients ; heart failure
H-1365	-0.4235633313655853	▁b NP ▁; ▁NT - pro b NP ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1365	-0.4235633313655853	bNP ; NT-probNP ; biomarkers ; heart failure
P-1365	-0.4653 -0.7414 -0.2598 -0.1551 -0.1651 -0.0142 -0.4349 -0.8477 -0.5580 -0.7901 -0.2000 -0.2850 -0.4325 -1.2418 -0.2241 -0.2672 -0.1185
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory fitness ; body mass index ; heart failure ; mortality ; cooper center longitudinal study
H-1765	-0.5428899526596069	▁Card i ore spira tory ▁fitness ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁mortal ity ▁; ▁Cooper ▁Center ▁Long itud in al ▁Study
D-1765	-0.5428899526596069	Cardiorespiratory fitness ; body mass index ; heart failure mortality ; Cooper Center Longitudinal Study
P-1765	-1.3269 -0.9891 -1.1296 -0.0585 -0.1068 -1.4391 -0.2747 -0.2068 -0.1467 -0.0094 -0.2997 -1.3175 -0.5480 -0.2566 -0.8874 -0.3454 -0.3042 -1.3403 -1.0291 -0.0458 -0.2829 -0.0234 -0.6989 -0.3944 -0.1113
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse correlation ; pro-adrenomedullin ; mr-proadm ; ffm
H-15	-0.29725170135498047	▁pro - ad re nom edu llin ▁; MR - pro AD m ▁; ▁f FM
D-15	-0.29725170135498047	pro-adrenomedullin ;MR-proADm ; fFM
P-15	-0.0688 -0.0441 -0.0276 -0.1280 -0.2985 -0.5533 -0.5173 -0.3608 -0.0728 -0.0107 -0.0215 -0.9797 -0.1465 -0.2164 -0.2526 -1.3665 -0.2116 -0.0738
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.2593563795089722	▁die t ▁; ▁exercise ▁; ▁attention ▁control
D-1979	-1.2593563795089722	diet ; exercise ; attention control
P-1979	-2.9007 -0.1223 -0.4883 -0.4967 -0.4938 -1.8513 -0.6981 -4.1593 -0.1237
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart failure ; hf ; elevated ; sympathetic activity ; parasympathetic control ; heart
H-1133	-0.6280126571655273	▁Heart ▁failure ▁; HF ▁; ▁sympa the tic ▁activity ▁; ▁para sy mpa the tic ▁control ▁; ▁heart
D-1133	-0.6280126571655273	Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
P-1133	-0.5101 -0.0916 -0.2303 -0.1879 -0.3765 -0.0714 -0.9641 -1.1112 -1.6575 -0.1310 -0.1288 -0.2123 -0.1680 -1.9681 -1.0724 -1.0113 -0.3312 -2.0269 -0.2167 -0.0930
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality ; patients ; implantable cardiac defibrillator ; meta-analysis
H-59	-0.502803385257721	▁implant able ▁cardiac ▁de fi br illa tor
D-59	-0.502803385257721	implantable cardiac defibrillator
P-59	-3.5246 -0.1208 -0.0241 -0.1452 -0.1301 -0.2410 -0.1996 -0.1558 -0.3413 -0.1456
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp ; xo-mediated ros ; mitochondrial respiration ; contractile function
H-471	-0.18967443704605103	▁ATP ▁demand ▁; ▁ XO - media ted ▁ ROS ▁; ▁mito cho ndri al ▁respira tion ▁; ▁contract ile ▁function
D-471	-0.18967443704605103	ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
P-471	-0.1471 -0.1113 -0.1536 -0.5659 -0.0180 -0.0361 -0.0354 -0.0743 -0.1980 -0.2370 -0.5871 -0.0249 -0.4348 -0.3687 -0.0516 -0.1176 -0.3799 -0.3146 -0.0030 -0.0665 -0.0831 -0.2741 -0.0799
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical ; activity ; cardiovascular ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
H-1898	-0.610336422920227	▁physical ▁activity ▁; ▁cardiovascular ▁; ▁diabetes ▁mell itus ▁; ▁hyper tension ▁; ▁hyper li pida emia
D-1898	-0.610336422920227	physical activity ; cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
P-1898	-2.5859 -2.1155 -0.4692 -0.3116 -2.6946 -0.3325 -0.0088 -0.0379 -0.3159 -0.0496 -0.0575 -0.2023 -0.1343 -0.5360 -0.2535 -0.4326 -0.3242 -0.1242
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients ; systolic hf ; etiology ; coronary angiography
H-1184	-0.32582852244377136	▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology ▁; ▁corona ry ▁ang i ography
D-1184	-0.32582852244377136	systolic HF ; unclear etiology ; coronary angiography
P-1184	-0.0963 -0.1347 -0.0167 -0.5293 -0.1263 -0.3642 -0.0584 -0.0374 -0.0119 -0.1649 -0.1134 -0.3014 -0.1498 -1.7548 -0.6894 -1.0705 -0.1352 -0.3409 -0.0951
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
H-1230	-0.6152753829956055	▁At rial ▁fi bril lation ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ rhythm - control ▁; ▁rate - control ▁strategie s
D-1230	-0.6152753829956055	Atrial fibrillation ; congestive heart failure ; rhythm-control ; rate-control strategies
P-1230	-3.2744 -0.0120 -0.3924 -0.0285 -0.0691 -0.2932 -0.0216 -0.4504 -1.3285 -0.5385 -0.2171 -0.8228 -2.3975 -1.7401 -0.1486 -0.0178 -0.6644 -0.1823 -0.2428 -0.0139 -1.1650 -0.1886 -0.4383 -0.1188
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection fraction ; ef ; infarct ; collateral growth ; myocardial perfusion
H-506	-0.343943327665329	▁e je ction ▁ fraction ▁; EF ▁; ▁in far ct ▁; ▁col lateral ▁growth ▁; ▁my o card ial ▁per fusion
D-506	-0.343943327665329	ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
P-506	-0.2803 -0.1328 -0.0166 -0.3009 -0.0099 -0.3836 -0.7645 -0.2279 -0.1326 -0.1988 -0.5179 -1.7924 -0.0546 -0.0005 -0.3533 -0.2117 -0.5934 -0.4258 -0.1935 -0.9900 -0.3102 -0.0377 -0.2096 -0.1162
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure ; patients
H-1510	-0.37147292494773865	▁circula ting ▁fragment s ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti des ▁; ▁plasma ▁; ▁heart ▁failure ▁patients
D-1510	-0.37147292494773865	circulating fragments ; n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure patients
P-1510	-0.0950 -0.0571 -0.2294 -0.2765 -0.4491 -1.8679 -0.0253 -0.0798 -0.0148 -0.0919 -0.0316 -0.8292 -0.0324 -0.0032 -0.0284 -0.3506 -0.4317 -1.8403 -0.4510 -0.2881 -0.2929 -0.4122 -0.0298 -0.5884 -0.2109 -0.0659 -1.2376 -0.3195 -0.1424
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients ; heart failure ; hf ; preserved left ventricular ejection fraction ; hfpef
H-1300	-0.4464474320411682	▁heart ▁failure ▁; HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; HF p EF
D-1300	-0.4464474320411682	heart failure ;HF ; left ventricular ejection fraction ;HFpEF
P-1300	-2.1928 -0.1044 -0.1860 -0.2203 -0.2573 -1.0613 -0.0618 -1.6837 -0.3609 -0.0878 -0.1779 -0.1347 -0.3896 -0.0079 -0.2484 -1.0730 -0.0310 -0.2762 -0.2809 -0.0934
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients ; end-stage heart failure ; implantation ; ventricular assist device
H-1657	-0.9901424646377563	▁heart ▁failure ▁; ▁implant ation ▁; ▁vent ri cular ▁assist ▁device
D-1657	-0.9901424646377563	heart failure ; implantation ; ventricular assist device
P-1657	-4.9137 -0.3837 -0.6091 -1.4635 -0.3137 -0.6186 -0.3775 -2.6060 -0.2941 -0.3984 -0.1948 -0.5475 -0.1512
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf ; symptom ; cardiac murmurs ; blood pressure
H-356	-0.5945018529891968	▁ HF ▁; ▁cardiac ▁mur mur s ▁; ▁blood ▁pressure ▁; ▁h g
D-356	-0.5945018529891968	HF ; cardiac murmurs ; blood pressure ; hg
P-356	-1.1578 -0.2993 -0.7897 -0.7009 -0.1366 -0.0425 -0.4111 -0.4307 -1.0636 -0.6551 -1.8524 -1.0443 -0.0742 -0.1466 -0.1128
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors ; adenylyl cyclase ; g-protein coupling
H-1406	-0.3262406289577484	▁a den yl yl ▁cy cla se ▁; ▁g - prote in ▁coup ling
D-1406	-0.3262406289577484	adenylyl cyclase ; g-protein coupling
P-1406	-1.4154 -0.1597 -0.0699 -0.1344 -0.0420 -0.0241 -0.6437 -0.5986 -0.2970 -0.0907 -0.0469 -0.4300 -0.0781 -0.7195 -0.3472 -0.1225
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients ; hf ; spontaneous vt ; qt intervals
H-1445	-0.3733329176902771	HF ▁; ▁spontane ous ▁ VT ▁; ▁beat - to - beat ▁ QT ▁interval s
D-1445	-0.3733329176902771	HF ; spontaneous VT ; beat-to-beat QT intervals
P-1445	-1.3573 -0.5081 -0.7121 -0.4796 -0.6721 -0.1152 -0.6878 -0.0278 -0.1041 -0.1585 -0.2073 -0.2836 -0.5858 -0.1086 -0.0761 -0.1325 -0.3853 -0.1183
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular dysfunction ; outcome ; patients ; heartmate ii
H-305	-0.8354871273040771	▁bi ven tri cular ▁dys function ▁; ▁isola ted ▁Heart Mate ▁II
D-305	-0.8354871273040771	biventricular dysfunction ; isolated HeartMate II
P-305	-2.1475 -0.1316 -4.0888 -1.7093 -0.1744 -0.3938 -0.3806 -0.2623 -0.1750 -0.8563 -0.1851 -0.6574 -0.3941 -0.1404
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug test ; patients ; copd ; chf ; crf
H-806	-0.6418561339378357	▁tu g ▁test ▁; ▁COP d ▁; ▁CHF ▁; ▁c RF
D-806	-0.6418561339378357	tug test ; COPd ; CHF ; cRF
P-806	-0.7690 -2.8816 -0.2280 -0.2597 -1.5780 -1.1874 -0.1682 -0.0029 -0.1856 -0.3405 -0.4594 -0.1855 -0.0984
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling pathways ; pressure-overload-induced heart failure
H-877	-0.7780846953392029	▁pressure - over load - indu ced ▁heart ▁failure
D-877	-0.7780846953392029	pressure-overload-induced heart failure
P-877	-5.8176 -0.1198 -0.0290 -0.1356 -0.3527 -0.0665 -0.3099 -1.0595 -0.2439 -0.2629 -0.1616
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing ; mandate ; accountable ; outcomes ; nursing
H-1396	-0.8819149732589722	▁Nur sing ▁; ▁social ▁mandat e ▁; ▁nur sing ▁care
D-1396	-0.8819149732589722	Nursing ; social mandate ; nursing care
P-1396	-2.9223 -0.0722 -0.4861 -2.2052 -0.5678 -0.1835 -0.7725 -1.9764 -0.1003 -0.9896 -0.1775 -0.1295
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical ; patient ; hemodynamically ; cpr
H-1294	-0.986972987651825	▁hem o dynamic ally ▁uns table ▁; ▁c PR
D-1294	-0.986972987651825	hemodynamically unstable ; cPR
P-1294	-5.5905 -0.2927 -0.0079 -0.7666 -1.0866 -0.6280 -0.3056 -0.5994 -1.2006 -0.2882 -0.0907
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol ; cxl-1020 ; myocytes ; hearts
H-419	-0.3570270240306854	▁iso prot eren ol ▁; ▁c XL -10 20 ▁; ▁my o cy tes ▁; ▁heart s
D-419	-0.3570270240306854	isoproterenol ; cXL-1020 ; myocytes ; hearts
P-419	-0.0157 -0.0669 -0.1495 -0.6148 -0.5446 -0.3648 -0.6679 -0.1375 -0.0700 -0.7245 -0.5061 -0.2036 -0.0822 -0.0711 -0.4579 -1.0966 -0.3155 -0.5434 -0.1510
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
H-454	-0.5649570822715759	▁b ▁treatment ▁; ▁cardiac ▁ang io gene sis ▁; ▁in ▁vivo ▁corona ry ▁per fusion ▁; ▁cardiac ▁fibro sis
D-454	-0.5649570822715759	b treatment ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
P-454	-1.9719 -3.1598 -0.3526 -0.0962 -1.1069 -1.0930 -0.2528 -0.5680 -0.2989 -0.4313 -0.0033 -0.0898 -1.0370 -0.3257 -0.0223 -0.3112 -0.0685 -0.0286 -0.2486 -0.3196 -0.0782
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization ; patients ; heart failure ; ventricular tachycardia
H-1434	-0.9843347668647766	▁heart ▁failure ▁; ▁vent ri cular ▁ta chy car dia
D-1434	-0.9843347668647766	heart failure ; ventricular tachycardia
P-1434	-7.7344 -0.2410 -0.4759 -0.4311 -1.7362 -0.1559 -0.2025 -0.1531 -0.0379 -0.0305 -0.4695 -0.1441
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine ; myocyte ; collagen ; left ventricle
H-1141	-0.20583197474479675	▁Pyr ido stig mine ▁; ▁my o cy te ▁diameter ▁; ▁collage n ▁den s ity ▁; ▁left ▁vent ric le
D-1141	-0.20583197474479675	Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
P-1141	-0.0352 -0.0154 -0.0034 -0.0972 -0.1788 -0.4353 -0.1366 -0.0411 -0.0612 -0.1453 -0.1073 -0.0204 -0.0546 -0.1157 -0.4800 -0.7381 -0.1879 -0.3480 -0.0228 -0.6091 -0.5421 -0.2732 -0.0855
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise intolerance ; symptom ; chronic hfpef ; quality of life ; qol
H-1975	-0.8289638757705688	▁Exerci se ▁in tolerance ▁; ▁chronic ▁H FP EF ▁; Q OL
D-1975	-0.8289638757705688	Exercise intolerance ; chronic HFPEF ;QOL
P-1975	-0.8689 -0.2268 -0.0239 -0.0429 -0.3835 -1.3047 -2.8458 -1.1018 -0.5123 -0.3222 -3.2686 -0.3596 -0.2351 -0.1093
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy substrate metabolism ; hearts ; aac
H-1781	-0.5741358399391174	▁energy ▁substrat e ▁metabolism ▁; ▁working ▁heart s ▁; ▁a ac
D-1781	-0.5741358399391174	energy substrate metabolism ; working hearts ; aac
P-1781	-1.1725 -0.0108 -0.0973 -0.1590 -0.4476 -3.5464 -0.4602 -0.1943 -0.6066 -0.2366 -0.3626 -0.0950 -0.0749
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence ; schfi v.6.2 ; clinical
H-1509	-1.1660887002944946	▁ SCH fi
D-1509	-1.1660887002944946	SCHfi
P-1509	-0.8990 -1.7029 -2.6200 -0.5329 -0.0756
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule ; patients ; cad ; patients ; cad
H-1191	-0.9294240474700928	▁CAD ▁; ▁severe ▁CAD
D-1191	-0.9294240474700928	CAD ; severe CAD
P-1191	-0.7137 -0.9698 -3.3735 -0.1903 -0.2140 -0.1152
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes mellitus ; cardiovascular disease ; baseline
H-630	-0.21781684458255768	▁diabetes ▁mell itus ▁; ▁cardiovascular ▁disease
D-630	-0.21781684458255768	diabetes mellitus ; cardiovascular disease
P-630	-0.4102 -0.0035 -0.0490 -0.3738 -0.0112 -0.5307 -0.2071 -0.1571
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd ; psoriasis ; hazard ratio ; confidence interval
H-1563	-0.5043092966079712	▁CV d ▁; ▁psoriasis
D-1563	-0.5043092966079712	CVd ; psoriasis
P-1563	-1.4369 -0.6123 -0.2582 -0.0402 -0.5522 -0.1262
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise ; haemodynamic ; pulmonary
H-1277	-0.49733173847198486	▁ha emo dynamic ▁; ▁pulmonar y
D-1277	-0.49733173847198486	haemodynamic ; pulmonary
P-1277	-0.1981 -0.0935 -0.0043 -0.1765 -0.0115 -0.1740 -3.1771 -0.1437
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic ; rule ; prospectively
H-1188	-1.2641565799713135	▁predict ion ▁rule
D-1188	-1.2641565799713135	prediction rule
P-1188	-5.5546 -0.0288 -0.3811 -0.2708 -0.0855
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam study ; psoriasis ; cardiovascular ; outcomes
H-1556	-0.6535643339157104	▁Rotterdam ▁; ▁psoriasis ▁; ▁cardiovascular ▁outcome s
D-1556	-0.6535643339157104	Rotterdam ; psoriasis ; cardiovascular outcomes
P-1556	-1.0614 -3.3057 -0.2150 -0.3184 -0.0153 -0.5754 -0.1076 -0.2223 -0.0610
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf antagonists ; nbdmard
H-607	-0.5737460255622864	▁HR ▁; ▁t NF ▁; ▁n b DM ARD
D-607	-0.5737460255622864	HR ; tNF ; nbDMARD
P-607	-0.1183 -0.1918 -1.5962 -0.5781 -0.7621 -0.2002 -0.0212 -0.9591 -1.3433 -0.4475 -0.0936
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications ; acs ; patients ; patients ; vad
H-1286	-0.8753966689109802	▁a CS ▁procedure s ▁; ▁MT ▁; ▁ VAD
D-1286	-0.8753966689109802	aCS procedures ; MT ; VAD
P-1286	-0.4799 -3.5424 -1.9553 -0.2320 -0.3779 -0.7001 -0.2522 -1.5502 -0.1053 -0.2731 -0.1608
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital ; cardiac ; hospital ; south dakota
H-1577	-0.9392155408859253	▁hospital ▁; ▁cardiac ▁special ty ▁hospital ▁; ▁South ▁da kota
D-1577	-0.9392155408859253	hospital ; cardiac specialty hospital ; South dakota
P-1577	-4.7765 -0.3010 -0.0433 -0.1764 -0.0349 -0.5898 -0.5097 -3.9078 -0.4979 -0.0200 -0.2891 -0.1241
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.5734130144119263	▁medical ▁records
D-1131	-0.5734130144119263	medical records
P-1131	-1.0762 -0.3642 -0.7453 -0.1079
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo ; egfr ; egfr
H-1392	-0.8056553602218628	▁ec mo ▁group ▁; ▁e g FR ▁; ▁e g FR
D-1392	-0.8056553602218628	ecmo group ; egFR ; egFR
P-1392	-0.2944 -2.0013 -1.7502 -0.2892 -0.0529 -1.8101 -0.4973 -0.4256 -0.1105 -2.3146 -0.5048 -0.3384 -0.0842
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration ; chf
H-683	-0.6765273809432983	▁tras tuz um ab - related ▁CHF
D-683	-0.6765273809432983	trastuzumab-related CHF
P-683	-3.6118 -0.0697 -0.0869 -0.7465 -0.5899 -0.2187 -0.2975 -0.3743 -0.0933
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute hf
H-1018	-0.37667539715766907	▁a cute ▁ HF
D-1018	-0.37667539715766907	acute HF
P-1018	-0.8159 -0.0201 -0.2303 -0.2599 -0.8284 -0.1054
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.7166309952735901	▁bio mark er - guide d ▁clinic al
D-1476	-0.7166309952735901	biomarker-guided clinical
P-1476	-0.2808 -0.1007 -0.0647 -0.1942 -0.0039 -0.0331 -0.2713 -0.1617 -5.9163 -0.1396
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.5122891664505005	▁hospital s
D-142	-0.5122891664505005	hospitals
P-142	-0.6893 -0.5831 -0.6403 -0.1364
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.4443736970424652	
D-272	-0.4443736970424652	
P-272	-0.7807 -0.1081
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac death
H-1905	-0.538657009601593	▁cardiac ▁death
D-1905	-0.538657009601593	cardiac death
P-1905	-0.9350 -0.5501 -0.5533 -0.1163
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia ; rv function
H-1159	-0.4369049072265625	▁ HF - related ▁cache xia ▁; ▁ RV ▁function ▁; ▁body ▁composition
D-1159	-0.4369049072265625	HF-related cachexia ; RV function ; body composition
P-1159	-1.2465 -0.3668 -0.1172 -0.5829 -0.3649 -0.2111 -0.4544 -0.5950 -0.3796 -0.2269 -0.8817 -0.4947 -0.0956 -0.4400 -0.0962
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital ; mortality
H-1692	-0.7259088158607483	▁hospital ▁mortal ity
D-1692	-0.7259088158607483	hospital mortality
P-1692	-0.8397 -0.1634 -2.2634 -0.2115 -0.1516
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital ; rehospitalization
H-1719	-0.451200395822525	▁re hospital ization
D-1719	-0.451200395822525	rehospitalization
P-1719	-1.1327 -0.0517 -0.7437 -0.2114 -0.1165
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality ; readmission
H-207	-0.5600533485412598	▁cognitive ▁im pair ment ▁; ▁mortal iteit
D-207	-0.5600533485412598	cognitive impairment ; mortaliteit
P-207	-0.2590 -0.4546 -0.0686 -0.5968 -1.0246 -0.2750 -1.9510 -0.3036 -0.1072
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic ; histological ; gastrointestinal
H-1359	-1.1804355382919312	▁sono graphic ▁; ▁his t ological ▁; ▁functional ▁ab normal ities
D-1359	-1.1804355382919312	sonographic ; histological ; functional abnormalities
P-1359	-5.0989 -1.7668 -0.3884 -0.5721 -0.2959 -0.4747 -0.2378 -0.1409 -0.3833 -0.0609 -1.9081 -3.8929 -0.1248
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic peptide ; biomarkers ; point of care ; poc
H-1023	-0.6233669519424438	▁na tri ure tic ▁pe pti de ▁; ▁bio mark ers
D-1023	-0.6233669519424438	natriuretic peptide ; biomarkers
P-1023	-0.4998 -0.5329 -0.6120 -1.1940 -0.6320 -0.1396 -0.3266 -1.5221 -0.0347 -0.1349 -0.3252 -2.0725 -0.0774
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
H-1352	-0.33885326981544495	▁antico a gul ants ▁; ▁anti plate let ▁drugs ▁; ▁heart ▁failure ▁; ▁at rial ▁fi bril lation
D-1352	-0.33885326981544495	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
P-1352	-0.4908 -0.1613 -0.3248 -0.2278 -0.2083 -0.0070 -0.1715 -0.2116 -0.3550 -0.3570 -2.3247 -0.2003 -0.1919 -0.6150 -0.0694 -0.3322 -0.0338 -0.1557 -0.2583 -0.0807
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone ; hyperkalemia ; acute kidney injury
H-445	-0.2553686797618866	▁Spir ono lac tone ▁; ▁hyper kal emia ▁; ▁ki dne y ▁injury
D-445	-0.2553686797618866	Spironolactone ; hyperkalemia ; kidney injury
P-445	-0.1900 -0.0976 -0.0385 -0.0430 -0.3236 -0.5618 -0.3810 -0.4390 -0.2777 -0.3688 -0.5215 -0.1368 -0.1208 -0.2316 -0.0988
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence ; bnp ; patients ; pad ; bnp ; hf
H-1572	-0.8886516094207764	▁b NP ▁; PAD ▁; ▁b NP ▁; ▁ HF
D-1572	-0.8886516094207764	bNP ;PAD ; bNP ; HF
P-1572	-2.1869 -0.2246 -0.8872 -1.8722 -0.2121 -1.8554 -0.2092 -0.3770 -1.7588 -0.7620 -0.2283 -0.0900
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic ; parasympathetic activity ; hf ; symptoms ; disease
H-1868	-0.7581495642662048	▁sympa the tic ▁; ▁para sy mpa the tic ▁activity ▁; ▁ HF
D-1868	-0.7581495642662048	sympathetic ; parasympathetic activity ; HF
P-1868	-0.1828 -1.2019 -0.7028 -0.1915 -0.1770 -0.5035 -0.3703 -2.3842 -1.2833 -2.1720 -0.1878 -0.6623 -0.4308 -0.8300 -0.0920
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients ; systolic blood pressure ; renal impairment ; hypertension
H-1529	-0.36882853507995605	▁eh ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁renal ▁im pair ment ▁; ▁hyper tension
D-1529	-0.36882853507995605	eh ; systolic blood pressure ; renal impairment ; hypertension
P-1529	-1.2071 -0.3086 -0.5162 -0.1077 -0.1574 -0.4507 -1.1686 -0.2436 -0.0289 -0.2271 -0.0149 -0.4698 -0.4540 -0.5219 -0.0691 -0.2071 -0.1175
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes ; exercise ; training ; patients ; ambulatory ; hf
H-1631	-1.0688362121582031	▁exercise ▁training ▁; ▁ambula tory ▁ HF
D-1631	-1.0688362121582031	exercise training ; ambulatory HF
P-1631	-7.3438 -0.6122 -0.3720 -0.3270 -0.0978 -0.2527 -0.2394 -0.2343 -0.1403
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf ; transition ; compensated lv hypertrophy ; hf ; hhd
H-283	-0.49387237429618835	▁mouse ▁ HF ▁model ▁; ▁compensa ted ▁LV ▁hyper trop hy ▁; ▁ HF ▁; ▁h HD
D-283	-0.49387237429618835	mouse HF model ; compensated LV hypertrophy ; HF ; hHD
P-283	-0.4493 -2.0924 -0.2532 -1.9552 -0.2892 -0.1812 -0.1814 -0.0606 -0.1286 -0.0326 -1.0722 -0.3065 -0.4339 -0.3616 -0.1417 -0.5117 -0.5854 -0.2805 -0.0665
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global left ventricular longitudinal systolic strain ; cardiovascular events ; patients ; atrial fibrillation
H-808	-0.33358120918273926	▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation
D-808	-0.33358120918273926	left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
P-808	-0.3081 -0.0655 -1.6617 -0.1744 -0.0211 -0.2555 -0.0294 -0.0438 -0.1981 -0.0628 -0.3717 -0.4598 -0.0981 -0.8821 -0.3520 -1.1626 -0.0817 -0.4109 -0.0377 -0.2107 -0.3474 -0.1035
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up ; deaths ; heart transplantations ; lv assist device implantations ; heart failure ; admissions
H-434	-0.6645345687866211	▁heart ▁transplant ations ▁; LV ▁assist ▁device ▁implant ations ▁; ▁heart ▁failure ▁ad missions
D-434	-0.6645345687866211	heart transplantations ;LV assist device implantations ; heart failure admissions
P-434	-4.5302 -0.3079 -0.1482 -0.4002 -0.1751 -1.0239 -0.0733 -0.2091 -0.0372 -0.3368 -0.8578 -0.4900 -1.5354 -0.0970 -0.2763 -0.1342
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic myocardial ischemia ; heart failure ; therapeutic
H-503	-0.8637577295303345	▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure
D-503	-0.8637577295303345	chronic myocardial ischemia ; heart failure
P-503	-4.1591 -2.5729 -0.3581 -0.4225 -0.9622 -0.2342 -0.0712 -1.0172 -0.3035 -0.5274 -0.0868 -0.4039 -0.1098
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients ; hfpef ; adverse outcomes
H-237	-0.5671766996383667	▁ HF p EF
D-237	-0.5671766996383667	HFpEF
P-237	-1.7481 -0.3686 -0.0563 -0.2569 -0.8422 -0.1310
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical cardiac support ; renal function ; end-stage heart failure
H-1384	-0.8651663661003113	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function ▁; ▁heart ▁failure
D-1384	-0.8651663661003113	mechanical cardiac support ; renal function ; heart failure
P-1384	-0.7054 -0.0508 -0.1648 -1.3889 -0.8183 -0.0548 -0.1473 -0.4443 -5.6199 -0.4640 -0.3852 -0.1382
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical ; revascularization ; revascularization
H-1603	-1.1959103345870972	▁Sur g ical ▁re vas cular ization
D-1603	-1.1959103345870972	Surgical revascularization
P-1603	-2.5775 -1.4427 -2.5648 -0.1231 -0.5585 -0.5715 -1.0952 -1.7079 -0.1220
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline ; hgb ; exercise ; training ; kccq
H-841	-1.145190954208374	▁base ▁h gb ▁; ▁exercise ▁training ▁; ▁k cc Q
D-841	-1.145190954208374	base hgb ; exercise training ; kccQ
P-841	-1.9323 -2.8158 -0.1086 -0.6860 -1.2743 -1.9876 -0.3874 -1.5055 -0.0865 -2.5301 -0.3088 -0.1194
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based ; nucleolin ; protein expression
H-96	-0.5847495794296265	▁Mor pho lino - based ▁knock down ▁; ▁nucleo lin ▁; ▁protein ▁expression
D-96	-0.5847495794296265	Morpholino-based knockdown ; nucleolin ; protein expression
P-96	-1.7991 -0.1989 -0.2842 -0.1461 -0.0932 -0.1213 -0.4916 -0.9220 -0.3852 -2.4667 -1.1405 -0.1275 -0.1295 -0.3567 -0.1086
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical ; rule ; cad ; systolic hf
H-1185	-0.2724494934082031	▁CAD ▁; ▁sy sto lic ▁ HF
D-1185	-0.2724494934082031	CAD ; systolic HF
P-1185	-0.7091 -0.4075 -0.0178 -0.0792 -0.0296 -0.5959 -0.1729 -0.3411 -0.0988
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo sternotomy ; cardiopulmonary bypass
H-775	-0.8275859355926514	▁techniek ▁; ▁ster no to my ▁; ▁cardio pul mon ary ▁by pass
D-775	-0.8275859355926514	techniek ; sternotomy ; cardiopulmonary bypass
P-775	-3.9315 -0.3976 -1.6155 -0.1294 -0.2691 -1.3057 -0.2810 -0.0521 -0.6003 -1.2154 -0.2522 -1.8191 -0.0214 -0.3888 -0.1348
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical treatment ; hf ; functional ms ; medical treatment
H-354	-0.7398691177368164	▁MS ▁; ▁ HF ▁; ▁functional ▁MS ▁; ▁medical ▁treatment
D-354	-0.7398691177368164	MS ; HF ; functional MS ; medical treatment
P-354	-0.0826 -0.4970 -4.1437 -0.4928 -0.5857 -0.7342 -0.1943 -0.9204 -0.3627 -0.5381 -0.2544 -0.0724
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence ; parasympathetic ; therapeutic ; hf
H-1134	-0.7504289150238037	▁para sy mpa the tic ▁function ▁; ▁ HF ▁e volution
D-1134	-0.7504289150238037	parasympathetic function ; HF evolution
P-1134	-0.3577 -0.6765 -0.5568 -1.6587 -1.2084 -0.2192 -0.2663 -0.4049 -2.3262 -1.7377 -0.0041 -0.2572 -0.0819
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical treatment ; hf ; hf ; symptom ; mva
H-371	-0.7633532285690308	▁aggressiv e ▁medical ▁treatment ▁; HF ▁; ▁ HF ▁; ▁MS
D-371	-0.7633532285690308	aggressive medical treatment ;HF ; HF ; MS
P-371	-2.9295 -0.0508 -0.2830 -0.6161 -0.2746 -1.9944 -0.2862 -0.7279 -0.4620 -0.4674 -0.6917 -1.0548 -0.0854
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular venous pressure ; peripheral oedema ; patient
H-1895	-0.23705309629440308	▁jugu lar ▁ve nous ▁pressure ▁; ▁per i pher al ▁oed ema
D-1895	-0.23705309629440308	jugular venous pressure ; peripheral oedema
P-1895	-0.0023 -0.1049 -0.6343 -0.1687 -0.3640 -0.1850 -0.0588 -0.1112 -0.0126 -0.0665 -0.1193 -0.0635 -1.3483 -0.0794
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart failure ; hf ; condition ; morbidity ; mortality
H-1487	-0.46252936124801636	▁Heart ▁failure ▁; HF
D-1487	-0.46252936124801636	Heart failure ;HF
P-1487	-0.7583 -0.0818 -0.2648 -0.2206 -1.3495 -0.1002
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported ; functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-333	-0.17773588001728058	▁functional ▁mit ral ▁sten osis ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation
D-333	-0.17773588001728058	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
P-333	-0.0826 -0.5119 -0.0858 -0.0109 -0.0204 -0.3839 -0.0187 -0.2766 -0.3160 -0.0753 -0.2931 -0.2964 -0.2928 -0.0246 -0.1424 -0.1499 -0.1702 -0.0125 -0.0840 -0.2136 -0.1301 -0.4173 -0.0789
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients ; fontan circulation ; svr ; cardiac index
H-232	-0.2875981032848358	▁Font an ▁circulation ▁; ▁s VR ▁index ▁; ▁cardiac ▁index
D-232	-0.2875981032848358	Fontan circulation ; sVR index ; cardiac index
P-232	-0.7687 -0.0955 -0.0887 -0.2773 -0.5744 -0.2014 -0.0167 -0.1539 -0.0446 -0.0173 -1.1238 -0.0889
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients ; lvad ; patients ; biventricular support
H-297	-0.8143996596336365	▁isola ted ▁l VAD ▁; ▁patients
D-297	-0.8143996596336365	isolated lVAD ; patients
P-297	-1.0672 -0.2117 -0.2950 -0.0206 -0.4532 -0.6587 -3.6779 -0.1308
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid receptor antagonists
H-1709	-0.4807964265346527	▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁race
D-1709	-0.4807964265346527	mineralocorticoid receptor antagonists ; race
P-1709	-0.5247 -0.4099 -0.9002 -1.1396 -0.2256 -0.0134 -0.2153 -0.0079 -0.4194 -1.9763 -0.1755 -0.1422 -0.1004
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary ; congenital ; heart ; death
H-1906	-0.7176428437232971	▁her edit ary ▁; ▁con geni tal ▁ab normal ities ▁; ▁heart ▁; ▁non trau matic ▁death
D-1906	-0.7176428437232971	hereditary ; congenital abnormalities ; heart ; nontraumatic death
P-1906	-2.3900 -0.0549 -0.3117 -1.3681 -0.0106 -0.0696 -0.1159 -0.0365 -0.1836 -2.8510 -0.6218 -1.5835 -0.7002 -0.2425 -0.0671 -0.7851 -0.5260 -1.5763 -0.1409
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan circulation ; skeletal muscle ; metabolic
H-1494	-0.34226757287979126	▁Font an ▁circulation ▁; ▁skelet al ▁muscle ▁mass ▁; ▁metabol ic ▁ab normal ities
D-1494	-0.34226757287979126	Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
P-1494	-0.4318 -0.1094 -0.0689 -0.4471 -0.1324 -0.1022 -0.4392 -0.1571 -0.6783 -0.0231 -0.1647 -0.0868 -0.0862 -2.2072 -0.2703 -0.0715
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients ; heartmate ii ; lvad
H-303	-0.4883100688457489	▁isola ted ▁Heart Mate ▁II ▁l VAD
D-303	-0.4883100688457489	isolated HeartMate II lVAD
P-303	-1.5557 -0.3229 -0.8488 -0.1436 -0.7347 -0.1895 -0.0463 -0.4000 -0.1533
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based ; patient ; outcomes
H-85	-0.5450761914253235	
D-85	-0.5450761914253235	
P-85	-0.9526 -0.1376
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health ; health ; u.s. ; drug ; administration
H-1830	-0.9510053396224976	▁health ▁insurance ▁; ▁health ▁system ▁; ▁u . s . ▁Food ▁and ▁Drug ▁Administration
D-1830	-0.9510053396224976	health insurance ; health system ; u.s. Food and Drug Administration
P-1830	-1.5709 -0.3291 -0.4273 -0.3751 -0.1049 -1.1043 -4.8528 -0.2934 -0.6990 -0.4337 -1.1825 -1.6818 -0.4526 -0.1169 -1.4153 -0.1765
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp ; patients ; acute heart failure
H-262	-0.5293228030204773	▁cut off ▁value ▁; ▁NT - pro b NP ▁testing ▁; ▁ED ▁patients ▁; ▁a cute ▁heart ▁failure
D-262	-0.5293228030204773	cutoff value ; NT-probNP testing ; ED patients ; acute heart failure
P-262	-1.2392 -0.1410 -1.3846 -0.3022 -0.1128 -0.0806 -0.0253 -0.7389 -0.3685 -1.8699 -0.3464 -0.1731 -1.1591 -1.3225 -0.1047 -0.0592 -0.4914 -0.1879 -0.3321 -0.1469
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension ; diabetes ; ischemic ; etiology
H-1635	-0.21841979026794434	▁black s ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁ ische mic ▁et i ology ▁; ▁socio economic ▁status ▁; ▁white s
D-1635	-0.21841979026794434	blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
P-1635	-0.7220 -0.1877 -0.3089 -0.1133 -0.0403 -0.1613 -0.0363 -0.1915 -0.0919 -0.0290 -0.2346 -0.0052 -0.3028 -0.1754 -0.2326 -0.2621 -0.1851 -0.0836 -0.5524 -0.4409 -0.2306 -0.3304 -0.1058
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin ; lvad ; postoperative
H-536	-0.7094918489456177	▁album in ▁; ▁l VAD ▁; ▁post operativ e ▁survival
D-536	-0.7094918489456177	albumin ; lVAD ; postoperative survival
P-536	-1.0348 -0.7094 -4.4248 -0.1698 -0.0262 -1.4464 -0.0325 -0.0449 -0.1463 -0.1803 -0.1655 -0.1329
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape ; functional enrichment analysis ; david
H-1612	-0.3153002858161926	▁Cy to scape ▁; ▁functional ▁en rich ment ▁analysis ▁; ▁DA VID
D-1612	-0.3153002858161926	Cytoscape ; functional enrichment analysis ; DAVID
P-1612	-0.2463 -0.1975 -0.1470 -0.2835 -0.1837 -0.0589 -0.1473 -0.4482 -0.4033 -0.3753 -0.8140 -0.0123 -1.0087 -0.0883
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular ; conditions ; patients ; hf
H-694	-1.2989847660064697	▁cardiovascular ▁conditions ▁; ▁ HF
D-694	-1.2989847660064697	cardiovascular conditions ; HF
P-694	-3.5028 -2.0497 -0.4063 -2.3847 -0.3441 -0.2716 -0.1337
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-0.7648362517356873	▁patient ▁safety
D-7	-0.7648362517356873	patient safety
P-7	-0.5297 -1.0704 -1.3458 -0.1134
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling ; emd
H-1151	-1.1414159536361694	▁ HF - indu ced ▁remodel ing
D-1151	-1.1414159536361694	HF-induced remodeling
P-1151	-2.0739 -0.4954 -0.1497 -0.0248 -0.1267 -0.0604 -0.0594 -7.2097 -0.0728
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right heart circulation ; right heart failure
H-1459	-0.676201581954956	▁right ▁heart ▁circulation ▁; ▁right ▁heart ▁failure
D-1459	-0.676201581954956	right heart circulation ; right heart failure
P-1459	-2.0424 -0.6968 -0.3543 -0.3198 -1.3710 -0.3382 -0.5944 -0.2586 -0.1103
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling pathway ; remodelling
H-994	-0.466806560754776	▁Raf - MEK 1/2 - er k 1/2
D-994	-0.466806560754776	Raf-MEK1/2-erk1/2
P-994	-0.0134 -0.1737 -0.0102 -0.1514 -0.1106 -0.9425 -0.4710 -0.5532 -2.1307 -0.1113
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi ; mi ; hf
H-1104	-0.9974255561828613	▁MI ▁; ▁ HF
D-1104	-0.9974255561828613	MI ; HF
P-1104	-0.3190 -0.9023 -2.4349 -1.8512 -0.3017 -0.1756
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate ; heart failure
H-1544	-0.8469833135604858	▁bis phos phon ate ▁; ▁heart ▁failure
D-1544	-0.8469833135604858	bisphosphonate ; heart failure
P-1544	-1.0455 -0.0452 -0.2401 -2.3207 -0.6767 -2.4813 -0.4292 -0.2796 -0.1045
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs ; outcomes
H-2009	-0.8939540982246399	▁kosten
D-2009	-0.8939540982246399	kosten
P-2009	-2.0795 -0.5107 -0.0917
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary outcomes
H-620	-0.4191634953022003	▁sustain ability
D-620	-0.4191634953022003	sustainability
P-620	-0.7021 -0.3908 -0.4969 -0.0868
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-1.2737531661987305	
D-1473	-1.2737531661987305	
P-1473	-2.4576 -0.0899
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine oxidase inhibition ; left ventricular ; systolic ; diastolic function ; cardiac volume overload
H-469	-0.4827956259250641	▁Xan thi ne ▁oxid ase ▁inhibi tion ▁; ▁vent ri cular ▁sy sto lic ▁; ▁dia sto lic ▁function ▁; ▁cardiac ▁volume ▁over load
D-469	-0.4827956259250641	Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac volume overload
P-469	-0.0033 -0.7135 -0.8705 -0.0504 -1.9337 -0.2017 -1.2126 -0.4059 -0.3929 -2.4910 -0.4205 -0.0549 -0.3027 -0.0797 -0.3720 -0.0181 -0.1281 -0.0628 -0.3896 -0.4954 -0.0385 -0.2332 -0.7406 -0.1189 -0.6876 -0.1347
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis ; heart failure with preserved ejection fraction ; clinical ; doppler echocardiography
H-21	-0.36227864027023315	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁do pp ler ▁e cho card i ography
D-21	-0.36227864027023315	heart failure ; preserved ejection fraction ; doppler echocardiography
P-21	-2.2380 -0.1346 -0.4199 -0.1270 -0.1023 -0.4821 -0.0425 -0.1669 -0.0438 -0.4225 -0.0097 -0.3340 -0.4484 -0.0070 -0.8748 -0.1222 -0.1957 -0.2443 -1.0472 -0.1549 -0.2689 -0.0835
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients ; heart failure ; hf ; heart failure adherence and retention trial ; hart
H-238	-0.5060348510742188	▁heart ▁failure ▁; HF ▁; ▁Heart ▁Fail ure ▁ad her ence ▁; ▁re tention ▁tri al ▁; HAR t
D-238	-0.5060348510742188	heart failure ;HF ; Heart Failure adherence ; retention trial ;HARt
P-238	-2.8007 -0.1308 -0.2854 -0.2203 -0.2769 -0.6193 -0.2718 -0.9103 -1.7234 -0.6166 -0.3944 -0.7028 -0.2440 -0.0322 -0.1487 -0.0221 -0.2045 -0.2397 -0.4527 -0.2372 -0.0929
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf with preserved ejection fraction ; hfpef ; hypertension
H-1076	-0.4031461179256439	HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁hyper tension
D-1076	-0.4031461179256439	HF ; preserved ejection fraction ;HFpEF ; hypertension
P-1076	-0.3362 -2.0768 -0.2775 -0.1543 -0.9566 -0.0590 -0.1847 -0.0720 -0.4455 -0.0173 -0.3754 -0.6611 -0.1018 -0.5354 -0.2766 -0.8123 -0.0390 -0.1926 -0.0857
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end points ; nyha functional class ; quality-of-life ; 6-minute hall walk
H-1873	-0.4582747220993042	▁NY ha ▁functional ▁class ▁; ▁quality - of - life ▁score
D-1873	-0.4582747220993042	NYha functional class ; quality-of-life score
P-1873	-0.8582 -0.6204 -1.1670 -0.4231 -0.4725 -0.1146 -0.0934 -0.0143 -0.2685 -0.4944 -0.2536 -1.0013 -0.1763
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial infarction ; left anterior descending coronary artery occlusion
H-1338	-0.558505117893219	▁My o card ial ▁in far ction ▁; ▁left ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.558505117893219	Myocardial infarction ; left anterior descending coronary artery occlusion
P-1338	-1.4957 -0.8195 -0.3953 -0.7288 -0.0879 -1.1362 -0.1183 -0.7710 -1.5954 -0.5852 -0.0782 -0.0362 -0.8390 -1.2151 -0.0071 -0.7951 -0.0211 -0.0093 -0.3779 -0.4832 -0.1333
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical ; symptoms ; hfpef ; symptoms ; breathlessness ; fluid retention
H-1891	-0.6318884491920471	▁ HF p EF ▁; ▁breath less ness ▁; ▁fatigue ▁; ▁fluid ▁re tention
D-1891	-0.6318884491920471	HFpEF ; breathlessness ; fatigue ; fluid retention
P-1891	-1.5503 -0.8313 -0.1090 -0.9112 -0.7396 -1.3997 -0.2819 -2.6072 -0.6115 -0.0958 -0.2309 -0.0035 -0.1178 -0.2141 -0.2795 -0.1268
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection ; nt-probnp ; antibodies ; terminal
H-1521	-0.3088114559650421	▁immun o det ection ▁; ▁NT - pro b NP ▁; ▁anti bo dies
D-1521	-0.3088114559650421	immunodetection ; NT-probNP ; antibodies
P-1521	-0.1254 -0.2839 -0.0973 -0.3241 -0.4865 -0.2353 -0.0974 -0.0248 -0.7896 -0.5516 -0.6793 -0.0170 -0.0607 -0.8381 -0.2429 -0.0872
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; heart failure
H-574	-0.887956976890564	▁Nordic ▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-574	-0.887956976890564	Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
P-574	-0.5632 -1.7046 -0.4534 -0.3371 -0.0950 -0.5049 -0.6567 -2.5705 -2.5536 -0.3748 -1.6953 -0.3651 -0.4060 -0.1512
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
H-1132	-0.38972148299217224	▁para sy mpa the tic ▁tone ▁; ▁py rido stig mine ▁; ▁vent ri cular ▁dys function ▁; ▁heart ▁failure
D-1132	-0.38972148299217224	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
P-1132	-0.1323 -0.7810 -0.2256 -1.6088 -0.8377 -0.1363 -0.2307 -0.0106 -0.0214 -0.0090 -0.1081 -0.2517 -0.0531 -2.2210 -0.4761 -0.0830 -0.1110 -0.2704 -0.4023 -0.2277 -0.2814 -0.0947
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade ; cardiac angiogenesis ; heart failure ; vegf signaling pathway
H-459	-0.4955610930919647	▁β - Block ade ▁; ▁cardiac ▁ang io gene sis ▁; ▁heart ▁failure ▁; ▁VE GF ▁signal ing ▁path way
D-459	-0.4955610930919647	β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
P-459	-0.4556 -0.1234 -0.3425 -0.6449 -0.9297 -0.2355 -0.7802 -1.6519 -0.4234 -0.8806 -0.5064 -0.4822 -0.1999 -0.3651 -0.8494 -0.0247 -0.5027 -0.5042 -0.1280 -0.2681 -0.4480 -0.1558
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes ; myocardial ischemic events ; patients ; cardiac resynchronization therapy
H-101	-0.4953928291797638	▁my o card ial ▁ ische mic ▁events ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.4953928291797638	myocardial ischemic events ; cardiac resynchronization therapy
P-101	-2.3214 -0.4857 -0.3462 -0.9321 -0.2273 -0.0516 -0.9910 -0.5170 -0.3565 -0.1104 -0.0493 -0.0549 -0.0143 -1.1147 -0.8762 -0.0203 -0.3085 -0.1396
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report ; patients ; aortic valve ; surgery ; post-lvad ai
H-544	-0.41036176681518555	▁a or tic ▁val ve ▁surgery ▁; ▁post - ▁l VAD ▁AI
D-544	-0.41036176681518555	aortic valve surgery ; post- lVAD AI
P-544	-0.3941 -0.0923 -0.8764 -0.1670 -0.0476 -0.2058 -0.3398 -0.3353 -0.0151 -0.9427 -0.0273 -1.9916 -0.2090 -0.1009
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart ; hr reduction ; patients ; systolic heart failure
H-527	-0.47745659947395325	▁un load ing ▁; ▁heart ▁; ▁isola ted ▁HR ▁re duction ▁; ▁sy sto lic ▁heart ▁failure
D-527	-0.47745659947395325	unloading ; heart ; isolated HR reduction ; systolic heart failure
P-527	-0.0989 -0.1217 -0.0664 -0.9203 -4.6234 -0.3175 -0.2528 -0.0464 -0.5101 -0.4837 -0.0164 -0.2368 -0.0741 -0.0699 -0.1253 -0.6497 -0.1201 -0.2485 -0.0896
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone ; diagnosed ; systolic heart failure ; clinical
H-439	-0.176359623670578	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-439	-0.176359623670578	spironolactone ; systolic heart failure
P-439	-0.0833 -0.0370 -0.0756 -0.0807 -0.3247 -0.2654 -0.0926 -0.1077 -0.5429 -0.1543 -0.2621 -0.0900
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart failure ; clinical ; medicine ; prevalence ; coronary disease
H-980	-0.7792448401451111	▁Heart ▁failure ▁; ▁adult ▁medicine ▁; ▁a ther omat ous ▁corona ry ▁disease
D-980	-0.7792448401451111	Heart failure ; adult medicine ; atheromatous coronary disease
P-980	-1.0445 -0.2382 -0.3410 -3.7928 -0.4076 -0.2136 -0.0760 -0.4271 -0.0546 -1.6855 -0.1821 -2.5667 -0.2644 -0.2830 -0.1117
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart failure ; hf ; latin america ; health ; hf
H-1789	-0.7696349024772644	▁Heart ▁failure ▁; HF ▁; ▁Latin ▁America ▁; LA ▁; ▁ HF
D-1789	-0.7696349024772644	Heart failure ;HF ; Latin America ;LA ; HF
P-1789	-0.9197 -0.0795 -0.2488 -0.2419 -0.4098 -0.6908 -0.3991 -0.3158 -3.3911 -0.4536 -2.6993 -0.5326 -0.3007 -0.0924
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization ; medicare ; discharged ; nursing
H-1710	-0.6490256190299988	▁re hospital ization ▁; ▁medica re ▁; ▁fee - for - service
D-1710	-0.6490256190299988	rehospitalization ; medicare ; fee-for-service
P-1710	-1.5675 -0.0519 -0.4302 -0.5412 -0.0375 -0.0402 -0.5875 -0.7745 -0.0423 -0.0466 -0.0600 -0.0628 -4.7396 -0.1046
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death ; hf ; hospitalization ; crt ; hazard ratio
H-755	-1.0200536251068115	▁ HF ▁; ▁c RT ▁; haz ard ▁ratio
D-755	-1.0200536251068115	HF ; cRT ;hazard ratio
P-755	-1.4933 -0.6556 -1.7563 -0.7213 -3.9935 -2.0533 -0.1107 -0.0079 -0.0301 -0.2637 -0.1350
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative care ; patients ; terminal ; disease ; therapeutic
H-1820	-1.207930326461792	▁palli ative
D-1820	-1.207930326461792	palliative
P-1820	-0.1855 -0.2123 -4.3237 -0.1102
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic ; hfpef ; medical history ; physical examination
H-1892	-0.9528102874755859	▁diagnosti ▁test ▁; ▁ HF p EF
D-1892	-0.9528102874755859	diagnosti test ; HFpEF
P-1892	-1.3897 -2.0708 -0.3059 -1.2157 -0.6698 -0.0663 -0.5537 -2.1986 -0.1047
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative stress ; gtpase ; rac1 ; activity ; hearts
H-281	-0.5567757487297058	▁o xi da tive ▁stress ▁; ▁GT Pas e ▁Rac 1 ▁; ▁heart s ▁; ▁ ANS ▁mi ce
D-281	-0.5567757487297058	oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
P-281	-1.1195 -0.2142 -0.0431 -0.5688 -0.2409 -0.2735 -1.0918 -1.2834 -0.0222 -0.1862 -1.5366 -0.4251 -1.0442 -0.1297 -0.3753 -1.5480 -0.3002 -0.6614 -0.3572 -0.2034 -0.0676
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin ; insulin resistance ; monocytes ; inflammatory
H-928	-0.49102842807769775	▁circula ting ▁media tor ▁; ▁insulin ▁resist ance ▁; ▁mono cy tes ▁; ▁infla mma tory ▁stimul
D-928	-0.49102842807769775	circulating mediator ; insulin resistance ; monocytes ; inflammatory stimul
P-928	-0.2270 -0.1294 -0.0119 -0.1221 -0.6385 -0.0174 -0.0845 -0.0867 -0.2889 -0.0064 -0.0339 -0.0169 -0.3142 -0.1100 -0.2745 -0.1175 -0.0472 -6.6734 -0.1292
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end point ; cardiovascular death ; cardiac transplant ; secondary end point ; death
H-1757	-0.5134005546569824	▁cardiovascular ▁death ▁; ▁urgent ▁cardiac ▁transplant ▁; ▁death
D-1757	-0.5134005546569824	cardiovascular death ; urgent cardiac transplant ; death
P-1757	-0.8315 -0.9055 -0.2104 -0.1089 -0.0371 -0.1162 -0.8684 -1.7927 -0.1386 -0.1247
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications ; outpatients ; heart failure ; ncdr pinnacle
H-658	-1.0509796142578125	▁medication s ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁NC DR ▁PIN NA CLE
D-658	-1.0509796142578125	medications ; outpatients ; heart failure ; NCDR PINNACLE
P-658	-1.6296 -0.2364 -1.2340 -4.8161 -0.0086 -0.1410 -2.5864 -0.5360 -0.1118 -0.5707 -1.1362 -1.0516 -0.3949 -0.7327 -0.9242 -1.6234 -0.1329
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; patients ; heart failure
H-1110	-0.577144980430603	▁non sel ective ▁; ▁select ive ▁beta - block ers ▁; ▁cardiac ▁sympa the tic ▁activity ▁; ▁hemos tas is ▁; ▁heart ▁failure
D-1110	-0.577144980430603	nonselective ; selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
P-1110	-1.7108 -0.1548 -0.0651 -1.1993 -0.6946 -0.0559 -0.5536 -0.1604 -0.3887 -0.3414 -0.7898 -0.0470 -0.0914 -1.0320 -2.3437 -0.7893 -0.3249 -0.2864 -0.0764 -0.6699 -0.4274 -1.6777 -0.1329 -0.2931 -0.1222
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission ; patients
H-1581	-0.6776900887489319	
D-1581	-0.6776900887489319	
P-1581	-1.1509 -0.2045
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.3620213568210602	
D-86	-0.3620213568210602	
P-86	-0.6191 -0.1049
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous ; symptoms ; patients ; heart failure
H-51	-0.5810243487358093	▁Intra ven ous ▁ir on ▁; ▁heart ▁failure ▁; ▁ir on ▁de fici en cy
D-51	-0.5810243487358093	Intravenous iron ; heart failure ; iron deficiency
P-51	-0.2753 -0.0114 -2.8053 -0.2048 -0.3049 -0.9778 -2.9520 -0.2524 -0.3654 -0.1505 -0.2474 -0.4152 -0.0202 -0.4043 -0.0358 -0.3407 -0.1140
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart failure ; emergency department ; patient ; outcomes
H-462	-0.4629490077495575	▁he art ▁failure ▁; ▁Emer gen cy ▁Department ▁; ED ▁; ▁ED
D-462	-0.4629490077495575	heart failure ; Emergency Department ;ED ; ED
P-462	-0.4885 -0.3885 -0.2838 -0.4478 -0.2133 -0.4121 -0.0580 -0.2171 -0.4764 -0.9035 -0.6751 -0.2210 -1.5687 -0.1274
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions ; remodelling ; leading ; heart failure
H-991	-1.4078642129898071	▁stress ▁conditions ▁; ▁significant ▁; ▁remodel ling ▁; ▁heart ▁failure
D-991	-1.4078642129898071	stress conditions ; significant ; remodelling ; heart failure
P-991	-3.5857 -0.9723 -0.6468 -6.0458 -2.4228 -1.0998 -0.2274 -0.4358 -0.8629 -0.2941 -0.2052 -0.0958
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ; ischemic heart failure
H-1613	-0.4983482360839844	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure
D-1613	-0.4983482360839844	non-ischemic ; ischemic heart failure
P-1613	-0.8964 -0.1036 -0.0967 -0.3539 -1.1977 -0.2571 -0.0756 -0.6486 -1.7169 -0.2692 -0.2490 -0.1155
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis ; systemic ; followed up
H-1559	-1.0417050123214722	▁psoriasis ▁; ▁system ic ▁; UV
D-1559	-1.0417050123214722	psoriasis ; systemic ;UV
P-1559	-0.0312 -0.8714 -0.0846 -0.1917 -4.0387 -0.1159 -2.9043 -0.0958
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv dysfunction ; prognosis ; hf
H-1160	-0.603228747844696	RV ▁dys function ▁; ▁weight ▁loss ▁; ▁ab normal ▁body ▁composition ▁; HF
D-1160	-0.603228747844696	RV dysfunction ; weight loss ; abnormal body composition ;HF
P-1160	-1.4759 -0.4759 -0.1313 -0.3263 -0.6580 -0.6981 -0.3843 -1.1443 -0.0222 -0.4985 -0.0414 -0.2223 -2.7055 -0.1393 -0.1250
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-1.2344354391098022	HR
D-609	-1.2344354391098022	HR
P-609	-2.6542 -0.9196 -0.1296
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.2506052553653717	
D-158	-0.2506052553653717	
P-158	-0.4046 -0.0966
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis ; clinical ; prognostic ; diastolic dysfunction ; leading ; hfpef
H-26	-0.3513387143611908	▁dia sto lic ▁dys function ▁; ▁h FP EF
D-26	-0.3513387143611908	diastolic dysfunction ; hFPEF
P-26	-0.2434 -0.1158 -0.1023 -0.0335 -0.0651 -0.2884 -1.2853 -0.7788 -0.5179 -0.3275 -0.1068
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic receptor blockade ; mortality ; all-cause hospitalizations ; patients ; heart failure ; hf
H-1424	-0.5927372574806213	▁β - Ad r energi c ▁receptor ▁block ade ▁; ▁heart ▁failure ▁; HF
D-1424	-0.5927372574806213	β-Adrenergic receptor blockade ; heart failure ;HF
P-1424	-0.0549 -0.0558 -1.1813 -0.7336 -0.5401 -0.0371 -0.0243 -0.6554 -0.2247 -0.6082 -3.9653 -0.3025 -0.4326 -0.3265 -0.2262 -0.1152
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right ventricle ; leads ; stroke volume ; shortens ; left ventricular ejection time ; lvet
H-578	-0.4925388693809509	▁right ▁vent ric le ▁over load ▁; ▁stroke ▁volume ▁; ▁left ▁vent ri cular ▁e je ction ▁time ▁; ▁l VET
D-578	-0.4925388693809509	right ventricle overload ; stroke volume ; left ventricular ejection time ; lVET
P-578	-1.3321 -0.1706 -1.4819 -0.4536 -0.3778 -0.0684 -0.2647 -0.7573 -0.1476 -0.2753 -0.8310 -0.0794 -2.3092 -0.1791 -0.0948 -0.3009 -0.0980 -1.0064 -0.4867 -0.0759 -0.1069 -0.3387 -0.0920
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp ; hf ; patient ; plasma ; immunoprecipitation ; mass spectrometric analysis
H-1515	-0.48892560601234436	▁NT - pro b NP ▁; ▁ HF ▁patient ▁plasma ▁; ▁immun o preci pit ation ▁; ▁mass ▁spec tro metric ▁analysis
D-1515	-0.48892560601234436	NT-probNP ; HF patient plasma ; immunoprecipitation ; mass spectrometric analysis
P-1515	-0.1867 -0.1019 -0.0168 -0.5112 -0.8072 -0.5938 -2.5640 -0.4728 -1.6741 -0.2288 -0.2836 -0.0390 -0.3772 -0.3099 -0.4734 -0.9308 -0.7454 -0.0404 -0.2097 -0.2616 -0.1817 -0.2645 -0.3636 -0.0962
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated proteins ; chromatin structure ; changing ; dna ; gene expression profile
H-90	-0.6720945239067078	▁Chro mat in - as soci ated ▁protein s ▁; ▁chr omat in ▁; ▁DNA ▁; ▁gene ▁expression ▁profile
D-90	-0.6720945239067078	Chromatin-associated proteins ; chromatin ; DNA ; gene expression profile
P-90	-2.0157 -0.1045 -1.8598 -0.1526 -0.0356 -0.0044 -0.4597 -1.0835 -0.3476 -0.5779 -0.0982 -0.0865 -1.4957 -2.3873 -1.3036 -1.2298 -0.1103 -0.2027 -0.1989 -0.2523 -0.1075
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd ; clinical ; hospitalizations ; complications ; therapy ; end-stage hf
H-895	-0.953319787979126	▁PD ▁; ▁ therapy ▁; HF
D-895	-0.953319787979126	PD ; therapy ;HF
P-895	-0.1920 -0.4921 -2.6920 -0.1940 -0.3827 -3.3700 -0.1771 -0.1268
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive ; patients ; pulmonary hypertension ; heart failure
H-577	-0.44305911660194397	▁pulmonar y ▁hyper tension ▁; PH ▁; ▁heart ▁failure
D-577	-0.44305911660194397	pulmonary hypertension ;PH ; heart failure
P-577	-2.6435 -0.1360 -0.0763 -0.0475 -0.2594 -0.0798 -0.2841 -0.7909 -0.1168 -0.2970 -0.1424
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait ; therapy ; lokomat ; heart failure ; patients
H-1912	-0.486804723739624	▁robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁system ▁; ▁heart ▁failure ▁patients
D-1912	-0.486804723739624	robot-assisted gait therapy ; Lokomat® system ; heart failure patients
P-1912	-2.3733 -0.2734 -0.0142 -0.1059 -0.1700 -0.1904 -0.2744 -0.0237 -0.3491 -0.1260 -0.0238 -2.8819 -0.0459 -0.5962 -0.2351 -0.1084 -1.0766 -0.2757 -0.1052
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
H-1647	-0.21493206918239594	▁cat heter ▁ab lation ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁ rhythm ▁control ▁ therapy
D-1647	-0.21493206918239594	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
P-1647	-0.6936 -0.0268 -0.0167 -0.0971 -0.1317 -0.0391 -0.1730 -0.3231 -0.1213 -0.0476 -0.3569 -0.2424 -0.4497 -0.3554 -0.3004 -0.0198 -0.3564 -0.1178
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy ; hdl ; chf-nyha-iiib ; hdl
H-258	-0.713407039642334	▁ET ▁; ▁HD L ▁function ▁; ▁ET ▁; ▁CHF - NY ha - III b ▁; ▁HD L ▁function
D-258	-0.713407039642334	ET ; HDL function ; ET ; CHF-NYha-IIIb ; HDL function
P-258	-1.5034 -0.5092 -1.7767 -2.4309 -0.1119 -0.5206 -1.7699 -0.4375 -0.1259 -0.2305 -0.1906 -0.4386 -0.1526 -0.1454 -0.0315 -0.6850 -0.6308 -2.8398 -0.1446 -0.2128 -0.0932
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac failure ; death ; patients ; type 2 diabetes ; diabetes ; heart failure
H-652	-0.5181863903999329	▁Card iac ▁failure ▁; ▁diabetes ▁; ▁molecular ▁mechanism ▁; ▁diabetes ▁; ▁heart ▁failure
D-652	-0.5181863903999329	Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
P-652	-1.6958 -0.3006 -0.1226 -0.3386 -0.5761 -0.2264 -2.2378 -0.0077 -0.3462 -0.4167 -0.3374 -0.6099 -0.2169 -0.2340 -0.1062
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient ; symptomatic ; therapeutic ; exercise ; hemodynamic
H-1179	-0.7367894053459167	▁ex er tion ▁; ▁ therapeut ic ▁; ▁exercise ▁; ▁hem o dynamic ▁status
D-1179	-0.7367894053459167	exertion ; therapeutic ; exercise ; hemodynamic status
P-1179	-1.5832 -0.1480 -0.4020 -0.5971 -1.4973 -0.0767 -0.3151 -2.2695 -2.1145 -1.2470 -0.4774 -0.4941 -0.0104 -0.0587 -0.3944 -0.1031
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet ; sensitivity ; specificity ; death ; icu
H-584	-0.6555764675140381	▁l VET ▁; ▁death ▁; ICU
D-584	-0.6555764675140381	lVET ; death ;ICU
P-584	-1.0890 -0.5781 -0.6541 -1.9916 -0.4411 -0.2557 -0.1388 -0.0964
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients ; diagnosis ; congestive heart failure
H-1578	-0.6227505803108215	▁con ges tive ▁heart ▁failure
D-1578	-0.6227505803108215	congestive heart failure
P-1578	-0.7636 -0.5333 -1.8902 -0.6218 -0.2140 -0.2324 -0.1040
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient ; implantable cardioverter-defibrillator
H-1859	-0.3068913519382477	▁a IM ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1859	-0.3068913519382477	aIM ; implantable cardioverter-defibrillator deactivation
P-1859	-0.4834 -0.3865 -0.6005 -0.9663 -0.0588 -0.3539 -0.0455 -0.4080 -0.1110 -0.1620 -0.1644 -0.3373 -0.1852 -0.0566 -0.3504 -0.0620 -0.6456 -0.3428 -0.1107
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial structure ; sarcomeric microstructure
H-1250	-0.4614880383014679	▁mito cho ndri al ▁structure ▁; ▁sar come ric ▁micro structure
D-1250	-0.4614880383014679	mitochondrial structure ; sarcomeric microstructure
P-1250	-0.0444 -0.8369 -0.2221 -0.0535 -1.2269 -0.3818 -0.0813 -0.7896 -1.7274 -0.0398 -0.2436 -0.2513 -0.1009
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients ; heart failure and reduced ejection fraction
H-668	-0.5749441981315613	▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-668	-0.5749441981315613	heart failure ; ejection fraction
P-668	-3.4705 -0.1111 -0.3210 -0.5008 -0.2545 -0.0975 -0.4641 -0.0227 -0.3565 -0.1507
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut ; inflammation ; heart failure ; patients ; heart failure
H-1363	-0.8383411765098572	▁gut ▁; ▁ inflammation ▁; ▁dieta ry ▁intervention s ▁; ▁heart ▁failure ▁; ▁heart ▁failure
D-1363	-0.8383411765098572	gut ; inflammation ; dietary interventions ; heart failure ; heart failure
P-1363	-0.5922 -0.3006 -0.6219 -0.2297 -0.2366 -3.4502 -1.6069 -0.8211 -0.2635 -0.4445 -0.4485 -0.1326 -1.1078 -2.6505 -0.2236 -0.9986 -0.1228
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr ; acr ; cms ; correlated
H-141	-0.4728638827800751	▁p PR ▁; ▁a cr ▁; ▁CMS
D-141	-0.4728638827800751	pPR ; acr ; CMS
P-141	-0.4102 -1.5278 -0.2677 -0.1600 -0.1579 -0.2527 -0.1582 -1.2229 -0.0983
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality ; lcx ; lad ; disease
H-513	-0.8002393841743469	▁ LC x ▁; ▁ LAD ▁; ▁two - ves sel ▁disease
D-513	-0.8002393841743469	LCx ; LAD ; two-vessel disease
P-513	-2.5074 -0.3924 -1.2459 -0.3728 -0.3105 -0.1032 -1.2687 -2.2902 -0.1357 -0.5540 -0.0249 -0.1617 -1.7153 -0.1206
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf ; patients ; emergency department ; intubated
H-210	-0.3594556748867035	▁CHF ▁; ▁emergency ▁department ▁; ED ▁; ▁in tuba ted
D-210	-0.3594556748867035	CHF ; emergency department ;ED ; intubated
P-210	-0.0237 -1.2328 -1.1139 -0.0665 -0.2023 -0.4712 -0.3452 -0.0604 -0.1154 -0.3534 -0.2227 -0.1060
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis ; patients ; chf ; therapeutic ; neurohormonal systems
H-635	-0.32977357506752014	▁CHF ▁; ▁activa ted ▁neuro hormon al ▁systems
D-635	-0.32977357506752014	CHF ; activated neurohormonal systems
P-635	-0.2324 -1.3032 -0.7645 -0.2083 -0.0717 -0.1176 -0.0372 -0.1032 -0.3688 -0.0908
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese ; zsf1 ; heart failure with preserved ejection fraction
H-770	-0.5035781264305115	▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-770	-0.5035781264305115	zSF1 rats ; heart failure ; ejection fraction
P-770	-0.4028 -0.6678 -2.1043 -0.5439 -0.0915 -0.9061 -0.9292 -0.1876 -0.4338 -0.7516 -0.1416 -0.0734 -0.3991 -0.0181 -0.2733 -0.1332
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician ; follow-up ; discharge ; death ; readmission ; patients ; heart failure
H-1413	-0.9823331832885742	▁physician ▁follow - up ▁; ▁dis charge ▁; ▁death ▁; ▁read mission ▁; ▁heart ▁failure
D-1413	-0.9823331832885742	physician follow-up ; discharge ; death ; readmission ; heart failure
P-1413	-2.2132 -0.2394 -0.2313 -0.0448 -2.0670 -0.9063 -0.1959 -0.4793 -4.8295 -0.2771 -1.2797 -0.9936 -0.4350 -1.8893 -0.2175 -0.2862 -0.1147
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart magnetic resonance imaging ; chelation ; compliance ; heart disease ; patients ; thalassaemia major
H-744	-0.5586482882499695	▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁heart ▁disease ▁; ▁tha lassa emia
D-744	-0.5586482882499695	heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
P-744	-2.5981 -0.2078 -1.0477 -0.5627 -0.7436 -0.2908 -0.3210 -0.3436 -0.0603 -0.0217 -0.4480 -0.1662 -0.2634 -1.9484 -0.3470 -0.1814 -0.0513 -0.2395 -1.3224 -0.4527 -0.1140
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial tonometry ; lvet ; prognostic ; patients ; precapillary ph ; heart failure
H-579	-0.41750219464302063	▁arterial ▁ton ometr y ▁; ▁l VET ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-579	-0.41750219464302063	arterial tonometry ; lVET ; precapillary PH ; heart failure
P-579	-0.6844 -0.2506 -0.0629 -0.3783 -0.6488 -0.7554 -0.1532 -0.1992 -0.9967 -0.2393 -0.2291 -0.6326 -0.3114 -0.4430 -0.9885 -0.1464 -0.2731 -0.1221
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk ; heart ; adipose tissue ; cachectic heart failure ; patients ; prospective study
H-8	-0.6701633334159851	▁Cross - talk ▁between ▁the ▁heart ▁; ▁adi pose ▁tissu e ▁; ▁cache ctic ▁heart ▁failure ▁; ▁body ▁composition
D-8	-0.6701633334159851	Cross-talk between the heart ; adipose tissue ; cachectic heart failure ; body composition
P-8	-0.7816 -0.1353 -0.0799 -2.0445 -2.0398 -1.2819 -1.1522 -0.0275 -0.1062 -0.0444 -0.0945 -0.5383 -0.0985 -0.4695 -0.8836 -0.1455 -1.5918 -2.0568 -0.1258 -0.2729 -0.1029
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 ; healthy ; heart muscle ; cells ; phenotype ; pathological ; hypertrophy
H-641	-0.49029409885406494	▁line ▁; ▁mu tant ▁mi ce ▁; ▁over express ing ▁hand 2 ▁; ▁heart ▁muscle ▁cell s
D-641	-0.49029409885406494	line ; mutant mice ; overexpressing hand2 ; heart muscle cells
P-641	-0.3438 -0.4658 -0.0974 -0.3564 -0.1398 -0.2591 -1.0348 -0.2836 -0.1939 -0.0378 -0.7140 -0.2617 -0.3598 -2.4060 -0.4034 -0.2001 -0.1729 -1.5017 -0.0836
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal echocardiography ; shunts ; thrombosis
H-1957	-0.35968056321144104	▁trans o es op hage al ▁e cho card i ography ▁; ▁patent ▁; ▁ thro mbo sis ▁; ▁migration
D-1957	-0.35968056321144104	transoesophageal echocardiography ; patent ; thrombosis ; migration
P-1957	-0.0871 -0.9309 -0.3023 -0.0510 -0.4592 -0.0623 -0.0935 -0.0878 -0.2215 -0.7089 -0.2468 -0.3789 -1.0973 -0.2191 -0.1997 -0.5111 -0.1856 -1.2045 -0.5795 -0.0080 -0.2062 -0.0718
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients ; uptitration ; heart rate ; renal function ; spironolactone
H-180	-0.8528332114219666	▁heart ▁rate ▁; ▁renal ▁function ▁; ▁spi rono lac tone
D-180	-0.8528332114219666	heart rate ; renal function ; spironolactone
P-180	-7.9461 -0.5538 -0.1866 -0.0416 -0.1468 -0.5212 -0.2217 -0.0410 -0.0508 -0.0550 -0.2858 -0.1835
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis ; patients ; adverse events ; echocardiographic ; outcomes
H-914	-0.605732262134552	▁di al ysis ▁patients ▁; ▁e cho car dio graphic
D-914	-0.605732262134552	dialysis patients ; echocardiographic
P-914	-0.2172 -0.1245 -0.0574 -1.2976 -0.6853 -0.2194 -0.1911 -0.0567 -0.6489 -1.7152 -1.9076 -0.1479
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence ; micrornas ; mirnas ; pathogenesis ; heart failure
H-1481	-0.24880234897136688	▁micro RNA s ▁; mi RNA s ▁; ▁heart ▁failure
D-1481	-0.24880234897136688	microRNAs ;miRNAs ; heart failure
P-1481	-0.0711 -0.0602 -0.1277 -0.2699 -0.2665 -0.0322 -0.0929 -0.2803 -1.1851 -0.2304 -0.2744 -0.0950
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf ; shift ; chronic heart failure ; chronic heart failure ; cardiology
H-1964	-0.8075099587440491	▁para dig m - HF ▁; ▁paradigm ▁shift ▁; ▁chronic ▁heart ▁failure ▁; ▁Chro nic ▁heart ▁failure ▁; ▁card i ology
D-1964	-0.8075099587440491	paradigm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
P-1964	-2.4462 -1.4815 -0.3117 -0.1284 -0.2915 -0.3234 -2.6483 -0.4976 -0.3690 -1.6245 -0.9998 -0.3064 -0.4598 -4.1341 -0.1699 -0.6901 -0.1190 -0.2894 -0.4165 -0.3277 -0.1693 -0.2618 -0.1067
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory ; hf ; patients ; left ventricular ejection fraction
H-122	-0.5646003484725952	▁consenti ng ▁ambula tory ▁ HF ▁patients ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction
D-122	-0.5646003484725952	consenting ambulatory HF patients ; left ventricular ejection fraction
P-122	-2.0496 -0.0370 -0.5165 -0.1917 -0.3615 -0.1842 -0.7248 -0.3892 -1.5656 -0.0425 -0.0567 -2.3633 -0.2831 -0.1751 -0.2577 -0.2654 -1.1964 -0.0182 -0.4927 -0.1207
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new zealand ; renal dnx ; pacing-induced chf
H-1373	-0.45183998346328735	▁New ▁Zealand ▁White ▁rabbi ts ▁; ▁renal ▁DN x ▁; ▁CHF
D-1373	-0.45183998346328735	New Zealand White rabbits ; renal DNx ; CHF
P-1373	-2.9424 -0.0527 -1.5584 -0.0242 -0.0486 -0.2871 -0.0320 -0.2123 -0.0507 -0.2833 -0.1063 -0.1999 -0.0761
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt variability ; qtv ; repolarization ; qtv ; cardiac death
H-1435	-0.9212763905525208	▁ QT ▁variabil ity ▁; Q t ▁; ▁repo lar ization ▁la bility ▁; ▁Q TV ▁; ▁cardiac ▁death
D-1435	-0.9212763905525208	QT variability ;Qt ; repolarization lability ; QTV ; cardiac death
P-1435	-1.6371 -0.1698 -0.0984 -1.7470 -0.2983 -1.7224 -1.6375 -0.7795 -3.8764 -0.2509 -0.2870 -0.1729 -0.0505 -0.3310 -0.6903 -2.0830 -0.3239 -2.4246 -0.4614 -0.1886 -0.1161
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker ; patients ; resting hr ; bpm ; p value
H-1941	-0.720348596572876	▁Beta - block er ▁dose ▁; ▁rest ing ▁; ▁HR
D-1941	-0.720348596572876	Beta-blocker dose ; resting ; HR
P-1941	-0.3699 -0.1002 -0.1373 -0.1632 -0.4297 -0.9323 -1.0931 -0.1276 -1.5800 -1.3584 -2.2781 -0.0742
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping ; mri ; tidal respiration ; myocardial t1 ; heart failure
H-1054	-0.43642881512641907	▁m RI ▁; ▁tid al ▁respira tion ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁; ▁heart ▁failure
D-1054	-0.43642881512641907	mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
P-1054	-0.9615 -2.2554 -0.7027 -0.3057 -0.0243 -0.1982 -0.1926 -0.3093 -0.3840 -0.2952 -0.2053 -0.1345 -1.2039 -0.4467 -0.2706 -0.0935 -0.0222 -0.1849 -0.9413 -0.4550 -0.0848 -0.2494 -0.1169
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular disease ; baseline
H-1767	-1.0414466857910156	▁cardiovascular ▁disease
D-1767	-1.0414466857910156	cardiovascular disease
P-1767	-3.0162 -0.6416 -0.3287 -0.1792
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage ; poc
H-1029	-0.6267277002334595	▁PO c ▁technology
D-1029	-0.6267277002334595	POc technology
P-1029	-1.6625 -0.7562 -0.3140 -0.2768 -0.1242
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis ; cardiovascular disease ; cvd
H-1555	-0.6061840057373047	▁psoriasis ▁; ▁cardiovascular ▁disease ▁; CV d
D-1555	-0.6061840057373047	psoriasis ; cardiovascular disease ;CVd
P-1555	-0.4521 -2.8367 -0.3137 -0.6880 -0.2424 -0.2311 -0.2492 -0.3143 -0.1283
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital compare ; ami ; mortality
H-1697	-0.954955518245697	▁hospital ▁Compar e ▁; ▁ AMI ▁mortal ity
D-1697	-0.954955518245697	hospital Compare ; AMI mortality
P-1697	-2.2102 -2.0935 -0.0959 -0.5194 -0.4460 -0.2406 -0.3004 -1.3688 -2.0982 -0.1764
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause readmissions
H-726	-0.7681978940963745	▁read missions
D-726	-0.7681978940963745	readmissions
P-726	-1.5230 -0.4606 -0.9970 -0.0922
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins ; subproteome
H-94	-1.213592767715454	▁protein s ▁; ▁acid
D-94	-1.213592767715454	proteins ; acid
P-94	-3.5549 -0.6200 -0.5147 -2.3067 -0.2116 -0.0737
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm control therapy
H-1645	-0.32377392053604126	▁ Rhythm ▁control ▁ therapy
D-1645	-0.32377392053604126	Rhythm control therapy
P-1645	-0.2462 -0.0906 -0.3011 -0.5445 -0.0452 -0.9496 -0.0892
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal ; likelihood ratio
H-487	-1.0008289813995361	▁e - sept al
D-487	-1.0008289813995361	e-septal
P-487	-0.5406 -4.8611 -0.0680 -0.0222 -0.3794 -0.1336
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs ; clinical
H-2015	-1.0245927572250366	
D-2015	-1.0245927572250366	
P-2015	-1.9161 -0.1331
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
H-1546	-0.22604605555534363	▁cardiac ▁dys function ▁; ▁sub cel lular ▁altera tions ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1546	-0.22604605555534363	cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
P-1546	-0.2394 -0.0912 -0.1179 -0.3640 -0.0132 -0.0652 -0.0451 -0.2748 -0.1396 -0.5077 -0.0234 -0.3288 -0.0233 -0.1368 -0.3839 -0.4114 -0.1292 -0.2553 -0.5947 -0.2688 -0.3483 -0.4397 -0.0593 -0.2119 -0.1966 -0.3055 -0.1284
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv diastolic dysfunction ; filling pressures ; non-invasively ; doppler echocardiography
H-28	-0.3131641149520874	▁dia sto lic ▁dys function ▁; ▁fill ing ▁pressure s ▁; ▁do pp ler ▁e cho card i ography
D-28	-0.3131641149520874	diastolic dysfunction ; filling pressures ; doppler echocardiography
P-28	-0.5015 -0.2572 -0.0363 -0.0412 -0.0646 -0.2908 -0.1522 -0.0871 -0.4723 -0.2442 -0.5601 -0.4407 -0.0162 -1.1468 -0.0911 -0.1086 -0.2706 -0.9986 -0.2032 -0.4622 -0.1309
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac magnetic resonance postcontrast t1 time ; outcome ; patients ; heart failure ; preserved ejection fraction
H-733	-0.3366890847682953	▁Card iac ▁magnetic ▁res on ance ▁post contra st ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-733	-0.3366890847682953	Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
P-733	-0.5326 -0.0836 -0.0718 -0.2287 -0.2794 -0.3005 -0.3802 -0.0710 -0.0453 -0.3750 -2.1954 -0.1835 -0.2756 -0.7675 -0.0981 -0.0812 -0.4033 -0.0197 -0.2548 -0.0867
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial collagen ; collagen cross-linking ; titin ; isoforms ; phosphorylation
H-764	-0.29074475169181824	▁My o card ial ▁collage n ▁; ▁collage n ▁cross - link ing ▁; ▁titi n ▁iso form s ▁; ▁ phos phor y lation
D-764	-0.29074475169181824	Myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
P-764	-0.8980 -0.2438 -0.2113 -0.5751 -0.0440 -0.2347 -0.4676 -0.0808 -0.0922 -1.8194 -0.0319 -0.0144 -0.0839 -0.3276 -0.0366 -0.0999 -0.0094 -0.0816 -0.1816 -0.2759 -0.1053 -0.0415 -0.7710 -0.7463 -0.0804 -0.2162 -0.0796
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker ; uptitration ; clinical ; outcome ; patients ; hfref ; hfpef
H-185	-0.6772907376289368	RAS - block er ▁up tit ration ▁; ▁h Fr EF ▁; ▁ HF p EF
D-185	-0.6772907376289368	RAS-blocker uptitration ; hFrEF ; HFpEF
P-185	-0.7587 -0.1091 -0.3297 -0.1827 -3.1676 -0.6859 -0.9176 -0.5664 -1.1079 -0.7635 -0.7899 -0.3614 -0.6316 -0.6625 -0.1367 -0.6207 -0.2948 -0.1047
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin ; exercise ; training ; health ; patients ; chronic heart failure ; hf-action ; randomized
H-833	-0.8759315609931946	▁Hem o glob in ▁; ▁exercise ▁; ▁health ▁status ▁; ▁chronic ▁heart ▁failure ▁; ▁ HF - ac TION
D-833	-0.8759315609931946	Hemoglobin ; exercise ; health status ; chronic heart failure ; HF-acTION
P-833	-0.6351 -0.4745 -0.1079 -1.1617 -0.6335 -1.9897 -1.2223 -3.7335 -0.3006 -0.3888 -1.5072 -0.4771 -0.4071 -0.8345 -0.5086 -0.3711 -0.0999 -1.0406 -1.9971 -0.3531 -0.1507
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
H-88	-0.6700643301010132	▁systems ▁prote o mics ▁; ▁cardiac ▁chr omat in ▁; ▁nucleo lin ▁; ▁cel lular ▁plastic ity ▁; ▁cardio my o cy tes
D-88	-0.6700643301010132	systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
P-88	-2.6603 -0.8243 -1.2462 -0.0044 -0.3153 -0.0622 -0.0947 -0.0407 -1.4265 -0.3471 -0.1786 -2.0393 -0.2966 -4.1838 -0.0330 -0.0878 -1.2482 -0.2230 -0.0336 -0.2866 -0.6081 -0.0448 -0.0799 -0.3003 -0.0861
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma ; collected ; hf ; patients
H-1514	-0.5806960463523865	▁Plas ma ▁sample s ▁; ▁ HF ▁patients
D-1514	-0.5806960463523865	Plasma samples ; HF patients
P-1514	-0.1413 -1.0050 -0.2796 -0.1713 -0.5938 -0.8953 -0.6316 -0.9135 -1.0946 -0.0810
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes ; hypertrophic
H-1217	-0.46470633149147034	▁cardio my o cy tes ▁; ▁no re pine ph rine - indu ced ▁hyper trop hic ▁response s
D-1217	-0.46470633149147034	cardiomyocytes ; norepinephrine-induced hypertrophic responses
P-1217	-3.7164 -0.8890 -0.7702 -0.2116 -0.1324 -0.7526 -0.0155 -0.0861 -0.0300 -0.5633 -0.0570 -0.2846 -0.0295 -0.1459 -0.0634 -0.0080 -0.4942 -0.6521 -0.3066 -0.4303 -0.1199
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported ; heart failure ; clcnka ; snp
H-1804	-0.9795721769332886	▁heart ▁failure ▁; ▁CL cn ka ▁s NP
D-1804	-0.9795721769332886	heart failure ; CLcnka sNP
P-1804	-4.4894 -0.4001 -0.3614 -0.3324 -1.2995 -1.6150 -0.5626 -0.2652 -0.3690 -0.1012
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt ; gdmt ; bat
H-1871	-0.7736867070198059	▁GD MT ▁; control ▁group ▁; ▁GD MT ▁; ▁BAT ▁; tre at ment ▁group
D-1871	-0.7736867070198059	GDMT ;control group ; GDMT ; BAT ;treatment group
P-1871	-0.2958 -1.6021 -1.1037 -1.7939 -0.7123 -0.5314 -0.3782 -2.0652 -0.7521 -0.0596 -1.8212 -0.0497 -0.0449 -0.2341 -1.3622 -0.2557 -0.0907
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline ; patients ; resting hr ; bpm
H-1940	-1.0337257385253906	▁HR
D-1940	-1.0337257385253906	HR
P-1940	-2.4468 -0.5371 -0.1173
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction pathways ; engage ; signalling proteins
H-993	-0.7541370391845703	▁trans duction ▁path ways ▁; ▁protein s
D-993	-0.7541370391845703	transduction pathways ; proteins
P-993	-0.3145 -0.6813 -0.3654 -0.1325 -0.5525 -4.2361 -0.2104 -0.2121 -0.0825
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate ; alendronate ; heart failure
H-1545	-0.44285261631011963	▁ale ndr onate ▁; ▁ale ndr onate ▁; ▁heart ▁failure
D-1545	-0.44285261631011963	alendronate ; alendronate ; heart failure
P-1545	-0.2537 -0.1042 -0.3261 -0.3466 -0.5644 -0.1275 -0.4114 -0.3918 -2.0301 -0.4098 -0.2379 -0.1107
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients ; cardiovascular disease ; drs
H-1838	-0.38366061449050903	▁cardiovascular ▁disease ▁; ▁d RS ▁deci les
D-1838	-0.38366061449050903	cardiovascular disease ; dRS deciles
P-1838	-0.5678 -0.2438 -0.6025 -0.0964 -0.1587 -0.7365 -0.7408 -0.2193 -0.0871
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician ; patient ; admission ; admission
H-1417	-0.6480200886726379	▁index ▁ad mission
D-1417	-0.6480200886726379	index admission
P-1417	-0.2796 -0.1642 -0.9625 -1.6529 -0.1809
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy ; patients ; follow-up
H-861	-0.6425070762634277	
D-861	-0.6425070762634277	
P-861	-1.1415 -0.1435
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients ; beta-blocker ; therapy
H-1939	-0.44780033826828003	▁beta - block er ▁ therapy
D-1939	-0.44780033826828003	beta-blocker therapy
P-1939	-2.1816 -0.0484 -0.2154 -0.0613 -0.5235 -0.0484 -0.3015 -0.2023
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart failure ; patients ; bisphosphonates
H-1535	-0.7404826283454895	▁heart ▁failure ▁; ▁bis phos phon ates
D-1535	-0.7404826283454895	heart failure ; bisphosphonates
P-1535	-4.2769 -0.1857 -0.2963 -0.3447 -0.0689 -0.4166 -0.4993 -0.4306 -0.1452
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty ; heart failure ; hf
H-622	-0.38875991106033325	▁fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; HF
D-622	-0.38875991106033325	frailty ; risk ; heart failure ;HF
P-622	-0.1929 -0.4678 -0.3331 -0.2421 -0.6934 -0.6767 -0.5365 -0.1204 -0.1899 -0.3946 -0.7059 -0.1117
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas ; cardiac remodeling ; heart failure
H-1483	-0.2560539245605469	▁mi RNA s ▁; ▁cardiac ▁remodel ing ▁; ▁heart ▁failure
D-1483	-0.2560539245605469	miRNAs ; cardiac remodeling ; heart failure
P-1483	-0.5028 -0.0193 -0.1612 -0.2941 -0.1504 -0.0604 -0.0741 -0.1618 -0.5498 -0.2957 -0.7153 -0.0877
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis ; medical ; hf
H-200	-0.9733049273490906	▁early ▁medical ▁management ▁; HF
D-200	-0.9733049273490906	early medical management ;HF
P-200	-4.0220 -0.2485 -0.1426 -0.2371 -1.7650 -0.2998 -0.0981
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical ; diastolic dysfunction ; mortality
H-25	-0.42697054147720337	▁dia sto lic ▁dys function
D-25	-0.42697054147720337	diastolic dysfunction
P-25	-0.1138 -0.1217 -0.1734 -0.0771 -0.1076 -2.3074 -0.0879
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa ; immunoassays ; nt-probnp
H-1516	-0.507167637348175	▁sandwich ▁Alpha LIS a ▁; ▁immun o assa ys ▁; ▁NT - pro b NP
D-1516	-0.507167637348175	sandwich AlphaLISa ; immunoassays ; NT-probNP
P-1516	-1.4583 -1.0954 -0.2541 -0.2851 -0.9784 -0.0058 -0.3187 -0.1103 -1.5615 -1.0337 -0.0348 -0.0377 -0.0261 -0.8336 -0.2643 -0.2507 -0.0734
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic adult fontan ; saf ; patients ; catheterization
H-226	-0.6851885318756104	▁symptom a tic ▁adult ▁Font an ▁; SAF
D-226	-0.6851885318756104	symptomatic adult Fontan ;SAF
P-226	-2.3342 -0.1887 -0.5442 -0.5403 -0.2691 -0.1762 -0.9370 -0.1943 -1.5643 -0.1035
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death ; c-statistics ; biological phenotype ; deficit index
H-1011	-0.7720787525177002	▁death ▁; ▁bi ological ▁ph eno type ▁; ▁deficit ▁index
D-1011	-0.7720787525177002	death ; biological phenotype ; deficit index
P-1011	-1.7599 -1.0347 -4.0564 -0.3636 -0.5697 -0.4778 -0.0105 -0.5712 -0.0699 -0.0241 -0.2058 -0.1214
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients ; sinus rhythm ; antiplatelet agents ; anticoagulants
H-1354	-0.22969916462898254	▁sinus ▁ rhythm ▁; ▁anti plate let ▁agents ▁; ▁antico a gul ants
D-1354	-0.22969916462898254	sinus rhythm ; antiplatelet agents ; anticoagulants
P-1354	-0.1138 -0.2258 -0.2676 -0.4951 -0.0233 -0.1549 -0.3333 -0.2095 -0.2727 -0.0512 -0.1886 -0.3524 -0.3023 -0.3583 -0.0967
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported ; patient ; implantable cardioverter-defibrillator
H-1858	-0.2682967782020569	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1858	-0.2682967782020569	implantable cardioverter-defibrillator deactivation
P-1858	-1.5789 -0.0515 -0.2258 -0.0409 -0.2169 -0.0663 -0.1306 -0.0773 -0.2143 -0.1062 -0.0597 -0.2430 -0.0664 -0.8318 -0.2829 -0.1002
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients ; heart failure ; left ventricular ; ejection fraction
H-22	-0.6671553254127502	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-22	-0.6671553254127502	heart failure ; left ventricular ;LV ; ejection fraction
P-22	-5.1895 -0.2696 -0.2824 -1.8346 -0.0840 -1.6614 -0.0991 -0.2267 -0.0857 -0.5844 -0.0181 -0.0832 -0.0410 -0.4227 -0.0101 -0.3015 -0.1480
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity ; doxorubicin ; anti-neoplastic agent
H-955	-0.3152236044406891	▁cardio toxic iteit ▁; ▁do xor ubi cin ▁; ▁anti - neo plast ic ▁agent ▁; ▁cancer s
D-955	-0.3152236044406891	cardiotoxiciteit ; doxorubicin ; anti-neoplastic agent ; cancers
P-955	-0.1618 -0.7056 -1.8459 -0.3369 -0.1425 -0.0156 -0.0540 -0.2893 -0.4409 -0.0395 -0.1488 -0.0383 -0.2824 -0.0852 -0.0622 -0.4716 -0.2553 -0.5108 -0.3171 -0.1009
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs ; patients ; oht ; transplant ; vad
H-1288	-0.6810153722763062	▁a CS ▁; ▁o HT ▁; ▁transplant ▁; ▁MT ▁; ▁ VAD
D-1288	-0.6810153722763062	aCS ; oHT ; transplant ; MT ; VAD
P-1288	-0.3398 -3.9092 -0.6651 -0.1155 -1.2140 -1.0241 -0.3854 -0.5505 -0.2117 -0.3377 -0.4673 -0.0236 -0.2016 -0.0888
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic peptides ; point of care ; ambulatory
H-1019	-0.755513072013855	▁na tri ure tic ▁pe pti des
D-1019	-0.755513072013855	natriuretic peptides
P-1019	-0.0367 -1.0454 -1.3192 -1.8045 -1.0539 -0.1892 -0.2176 -1.0518 -0.0812
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients ; β-blocker ; patients ; uptitration
H-179	-0.7937720417976379	▁ RAS - ▁; ▁β - block er ▁dose
D-179	-0.7937720417976379	RAS- ; β-blocker dose
P-179	-1.3248 -0.0307 -0.0849 -3.0990 -0.0776 -0.0869 -0.4564 -0.1615 -0.8246 -2.4514 -0.1336
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac angiogenesis ; therapy ; cardiac function ; remodeling
H-460	-0.4400809705257416	▁β - Block er - indu ced ▁enhance ment ▁; ▁cardiac ▁ang io gene sis ▁; ▁ therapy ▁; ▁cardiac ▁function
D-460	-0.4400809705257416	β-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
P-460	-0.0715 -0.0457 -0.2425 -0.0240 -0.0979 -0.0314 -0.5286 -0.9895 -0.2342 -1.1237 -0.0265 -0.6962 -0.8532 -0.3623 -0.5579 -0.4038 -1.7772 -0.0705 -0.8452 -0.0171 -0.1219 -0.9238 -0.0770
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf ; patients ; rheumatoid arthritis ; ra
H-602	-0.5514914393424988	▁ HF ▁; ▁rhe um ato id ▁ar thri tis ▁; RA
D-602	-0.5514914393424988	HF ; rheumatoid arthritis ;RA
P-602	-2.5119 -0.5523 -0.5698 -1.9292 -0.0691 -0.2445 -0.2035 -0.0059 -0.1014 -0.2916 -0.4581 -0.3240 -0.3355 -0.1240
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression ; bax ; bcl-2 ; proteins ; pacing
H-170	-0.3284829556941986	▁Bax ▁; ▁b cl -2 ▁protein s
D-170	-0.3284829556941986	Bax ; bcl-2 proteins
P-170	-0.0551 -0.2159 -0.3325 -0.1037 -0.2224 -0.1860 -0.1834 -1.5649 -0.0924
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal ; hospital ; hf ; patients ; cms ; conditions
H-139	-0.6982371807098389	▁hospital ▁rates ▁; ▁ HF ▁patients ▁; ▁CMS
D-139	-0.6982371807098389	hospital rates ; HF patients ; CMS
P-139	-2.0511 -0.7468 -0.4098 -1.2161 -0.1247 -0.5524 -0.2361 -0.0269 -1.5056 -0.1128
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation ; anti-inflammatory ; chf
H-1362	-0.6677572727203369	▁feed ing ▁; ▁nutrition al ▁strategie s ▁; ▁anti - in flam ma tory ▁effects ▁; ▁CHF
D-1362	-0.6677572727203369	feeding ; nutritional strategies ; anti-inflammatory effects ; CHF
P-1362	-2.0830 -0.2107 -0.3160 -0.9441 -0.1253 -2.1859 -0.1443 -0.3296 -0.1517 -0.1461 -0.5593 -0.0328 -3.3192 -0.4326 -1.0389 -0.2524 -0.1037 -0.2288 -0.0829
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs ; hf with reduced ejection fraction ; hfref
H-1077	-0.39504069089889526	▁drugs ▁; HF ▁; ▁e je ction ▁ fraction ▁; HF r EF
D-1077	-0.39504069089889526	drugs ;HF ; ejection fraction ;HFrEF
P-1077	-0.6630 -0.2853 -1.1657 -0.6621 -0.4804 -0.1358 -0.0280 -0.2998 -0.0052 -0.1930 -1.2364 -0.0706 -0.3657 -0.2726 -0.0619
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia ; acute kidney injury ; spironolactone ; clinical
H-444	-0.31184855103492737	▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury ▁; ▁spi rono lac tone
D-444	-0.31184855103492737	hyperkalemia ; acute kidney injury ; spironolactone
P-444	-1.3242 -0.2301 -0.0915 -0.2446 -1.0002 -0.0217 -0.0259 -0.7910 -0.1212 -0.2758 -0.3352 -0.0209 -0.0280 -0.0447 -0.0198 -0.6359 -0.0905
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal denervation ; dnx ; chf ; patients ; symptomatic
H-1371	-0.5480858087539673	▁Ren al ▁den er va tion ▁; ▁d n x ▁; ▁CHF
D-1371	-0.5480858087539673	Renal denervation ; dnx ; CHF
P-1371	-0.7833 -0.1075 -0.3809 -1.0180 -0.2880 -0.6151 -0.5082 -0.4230 -1.4260 -0.8167 -0.2248 -0.0353 -0.9599 -0.0865
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence ; vad ; acs ; consultations ; operations ; mortality ; morbidity
H-1289	-0.6493337154388428	▁MT ▁; ▁ VAD ▁groups ▁; ▁a CS
D-1289	-0.6493337154388428	MT ; VAD groups ; aCS
P-1289	-0.0431 -0.3479 -0.3622 -0.0469 -0.3340 -0.3764 -0.3187 -3.0615 -1.4993 -0.1033
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
H-893	-0.3708581030368805	▁re frac tory ▁con ges tive ▁heart ▁failure ▁; ▁per ito ne al ▁di al ysis
D-893	-0.3708581030368805	refractory congestive heart failure ; peritoneal dialysis
P-893	-0.3040 -0.0700 -0.8662 -0.0411 -0.8754 -1.2259 -0.9084 -0.1104 -0.5365 -0.1062 -0.4191 -0.4715 -0.0228 -0.3168 -0.0328 -0.0308 -0.2219 -0.1156
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ; hf
H-1810	-0.35940948128700256	▁Mamma lian ▁enabled ▁; ▁men a ▁; ▁cy tos kelet al ▁act in ▁dynamic s ▁; ▁heart ▁failure ▁; HF
D-1810	-0.35940948128700256	Mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ;HF
P-1810	-0.3884 -0.0502 -0.0820 -0.3865 -0.8157 -0.0409 -0.3380 -2.1185 -0.8401 -0.3423 -0.0407 -0.0873 -0.7759 -0.1183 -0.0689 -0.1596 -0.3016 -0.2291 -0.1839 -0.2798 -0.1818 -0.0773
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients ; heart failure ; elevated ; left atrial pressure ; symptoms ; hospital ; admission
H-1949	-1.1965264081954956	▁heart ▁failure ▁; ▁eleva ted ▁left ▁at rial ▁pressure
D-1949	-1.1965264081954956	heart failure ; elevated left atrial pressure
P-1949	-2.8110 -0.2555 -0.4675 -5.2526 -0.1780 -0.5095 -1.3454 -0.4442 -0.4046 -1.3875 -0.1059
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart failure with preserved ejection fraction ; hfpef ; cardiovascular reserve
H-916	-0.4314359426498413	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF ▁; ▁cardiovascular ▁reserve
D-916	-0.4314359426498413	Heart failure ; preserved ejection fraction ; hFPEF ; cardiovascular reserve
P-916	-1.3018 -0.2039 -0.7403 -0.1186 -0.1285 -0.5722 -0.0415 -0.2220 -0.0398 -0.4078 -0.0127 -0.3184 -0.6050 -1.5238 -1.3589 -0.2783 -0.4600 -0.0202 -0.1977 -0.0771
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv diastolic dysfunction ; combination ; figure ; hfpef
H-24	-0.6837058067321777	▁dia sto lic ▁dys function ▁; ▁h FP EF
D-24	-0.6837058067321777	diastolic dysfunction ; hFPEF
P-24	-0.8877 -0.1272 -0.0550 -0.0341 -0.0965 -0.4034 -2.2389 -1.9261 -1.2873 -0.3440 -0.1204
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician ; follow-up ; discharge ; physician ; outcomes ; patients ; heart failure
H-1421	-0.6261211037635803	▁physician ▁follow - up ▁; ▁dis charge ▁; ▁physician ▁continu ity ▁; ▁heart ▁failure
D-1421	-0.6261211037635803	physician follow-up ; discharge ; physician continuity ; heart failure
P-1421	-1.6516 -0.1660 -0.2430 -0.0425 -1.9373 -0.9889 -0.1783 -0.4195 -0.0916 -0.2085 -0.7079 -0.5970 -2.1067 -0.2702 -0.2776 -0.1313
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory ; icd ; patients ; mortality ; multivariable regression
H-63	-0.7146363854408264	▁ambula tory ▁i CD ▁patients ▁; ▁mortal ity
D-63	-0.7146363854408264	ambulatory iCD patients ; mortality
P-63	-0.9943 -0.1890 -0.3689 -0.9591 -0.6052 -0.7041 -1.3572 -1.6978 -0.1553 -0.1154
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni inhibitors ; angiotensin-receptor neprilysin inhibitors
H-1966	-0.38849198818206787	▁AR NI ▁inhibi tors ▁; angi oten sin - recept or ▁nepri ly sin ▁inhibi tors
D-1966	-0.38849198818206787	ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
P-1966	-0.9371 -0.6821 -0.1545 -0.2183 -0.4563 -0.0075 -0.3833 -1.5649 -0.3269 -0.0310 -0.0429 -0.4837 -0.3605 -0.3005 -0.1184 -0.3197 -0.4722 -0.1333
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal bleeding ; reported ; patients ; ventricular assist devices
H-1659	-0.5435391068458557	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices
D-1659	-0.5435391068458557	Gastrointestinal bleeding ; ventricular assist devices
P-1659	-0.5016 -1.1294 -1.5462 -0.1231 -0.1791 -0.6984 -0.3475 -0.3981 -0.0902 -1.7829 -0.2207 -0.4546 -0.1753 -0.3981 -0.1078
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil ; cytotoxic ; doxorubicin ; ehrlich carcinoma
H-966	-0.24710817635059357	▁nic oran dil ▁; ▁cy to toxic ▁effect ▁; ▁do xor ubi cin ▁; ▁eh r lich ▁car cino ma
D-966	-0.24710817635059357	nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
P-966	-0.0349 -0.0613 -0.2736 -0.4001 -0.7463 -0.1896 -0.1127 -0.0708 -0.3643 -0.1528 -0.0219 -0.0275 -0.3032 -0.7074 -0.2569 -0.0176 -0.0083 -0.0051 -0.1633 -1.0392 -0.3731 -0.1067
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas ; cardiac ; benign tumors ; left atrium ; right atrium
H-593	-0.4633041322231293	▁My xo mas ▁; ▁cardiac ▁benign ▁tumor s ▁; ▁left ▁at rium
D-593	-0.4633041322231293	Myxomas ; cardiac benign tumors ; left atrium
P-593	-0.9488 -0.0197 -0.2205 -0.4327 -0.2008 -0.0629 -0.0569 -0.2921 -0.8941 -0.1978 -0.6589 -0.0097 -2.3844 -0.1070
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes ; patients ; preserved ejection fraction ; hfpef
H-1328	-0.46625107526779175	▁f es ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1328	-0.46625107526779175	fes ; preserved ejection fraction ;HFpEF
P-1328	-2.3144 -0.9911 -0.3483 -0.3558 -0.1205 -0.6531 -0.0471 -0.1583 -0.0946 -0.2418 -0.0117 -0.3265 -1.4370 -0.0347 -0.4218 -0.2821 -0.0874
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic ; bnp ; nt-probnp ; patients ; coronary artery disease ; cad
H-1366	-0.4228323698043823	▁b NP ▁; ▁NT - pro b NP ▁; ▁corona ry ▁arter y ▁disease ▁; CAD
D-1366	-0.4228323698043823	bNP ; NT-probNP ; coronary artery disease ;CAD
P-1366	-0.6501 -0.9889 -0.2411 -0.0582 -0.1180 -0.0163 -0.5770 -0.6826 -0.2952 -0.1093 -2.4523 -0.0324 -0.6162 -0.2309 -0.2124 -0.0573 -0.1747 -0.0982
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant ; exercise
H-1883	-0.8334984183311462	
D-1883	-0.8334984183311462	
P-1883	-1.5528 -0.1142
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.5012385845184326	▁circula ting ▁form s ▁; ▁NT - pro b NP
D-1512	-0.5012385845184326	circulating forms ; NT-probNP
P-1512	-0.8598 -0.1695 -0.4411 -0.1163 -0.5349 -0.1272 -0.0911 -0.0363 -0.7281 -0.4122 -2.3975 -0.1009
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ; ecct
H-713	-0.7604472637176514	▁ec CT
D-713	-0.7604472637176514	ecCT
P-713	-0.8026 -1.6949 -0.4197 -0.1246
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.3490552604198456	▁aero bic ▁capacity ▁; ▁left - hand ▁grip ▁; ▁body ▁weight ▁; ▁wa ist ▁circum ferenc e ▁; ▁anxiety
D-573	-0.3490552604198456	aerobic capacity ; left-hand grip ; body weight ; waist circumference ; anxiety
P-573	-0.3503 -0.2495 -0.5421 -0.4940 -0.3708 -0.1564 -0.0941 -0.5258 -1.6113 -0.8974 -0.2392 -0.3748 -0.0037 -0.0829 -0.0058 -0.0517 -0.0849 -0.5822 -0.2799 -0.2147 -0.1186
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.5260030627250671	▁Process ▁re design ▁context ual ▁framework
D-1851	-0.5260030627250671	Process redesign contextual framework
P-1851	-0.7505 -2.0897 -0.8499 -0.1589 -0.0538 -0.0026 -0.2006 -0.1020
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial ; irs1 ; irs2 ; heart failure ; p38alpha ; mapk ; insulin resistance
H-651	-0.36253198981285095	▁My o card ial ▁loss ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁failure ▁; ▁p 38 al pha ▁MA PK ▁; ▁insulin ▁resist ance
D-651	-0.36253198981285095	Myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
P-651	-1.0115 -0.3214 -0.3031 -0.4722 -0.1645 -0.3518 -0.7069 -0.2642 -2.4247 -0.3337 -0.4049 -0.3401 -0.1122 -0.3532 -0.8970 -0.1713 -0.2168 -0.2717 -0.2533 -0.0309 -0.0002 -0.2442 -0.0449 -0.3766 -0.0072 -0.0520 -0.0181 -0.2592 -0.1055
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart failure ; hypertensive heart disease ; angiotensin ii ; infusion ; nephrectomy ; salt loading
H-273	-0.34942197799682617	▁heart ▁failure ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁ang io ten sin ▁II ▁in fusion ▁; ▁nep hr ecto my ▁; ▁salt ▁load ing
D-273	-0.34942197799682617	heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
P-273	-1.9186 -0.1075 -0.3796 -0.2518 -0.2347 -0.0670 -1.3963 -0.5195 -0.2347 -0.3976 -0.5234 -0.0801 -0.4679 -0.5933 -0.0073 -0.0077 -0.2137 -0.0336 -0.4220 -0.1486 -0.5321 -0.3879 -0.0045 -0.0330 -0.0495 -0.3221 -0.1005
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-337	-0.2401765137910843	▁Fun ction al ▁mit ral ▁sten osis ▁; MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation ▁; MR
D-337	-0.2401765137910843	Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
P-337	-0.5878 -0.0257 -0.0452 -0.8628 -0.0683 -0.0126 -0.0471 -0.3424 -1.2587 -0.4686 -0.0241 -0.2018 -0.2627 -0.0584 -0.1913 -0.3427 -0.1164 -0.0347 -0.1842 -0.2295 -0.1857 -0.0113 -0.1615 -0.2432 -0.0784 -0.4205 -0.1017 -0.3228 -0.0752
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened ; lvet ; icu ; admission ; prognostic ; patients ; precapillary ph ; heart failure
H-590	-0.6758362054824829	▁l VET ▁; ICU ▁ad mission ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-590	-0.6758362054824829	lVET ;ICU admission ; precapillary PH ; heart failure
P-590	-2.9288 -0.7429 -0.4063 -0.9562 -0.4737 -0.5734 -0.3184 -1.3450 -0.2336 -0.2429 -0.7938 -0.2732 -0.5031 -1.0995 -0.1341 -0.3146 -0.1497
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart ; hospitalization ; death ; patients ; preserved left ventricular ejection fraction
H-235	-0.7344907522201538	▁heart ▁failure - related ▁hospital ization ▁; ▁death ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-235	-0.7344907522201538	heart failure-related hospitalization ; death ; left ventricular ejection fraction
P-235	-4.1351 -0.5425 -0.3350 -0.1846 -0.2890 -0.7354 -0.5076 -1.4803 -0.4119 -0.7906 -0.0940 -2.4173 -0.4507 -0.1610 -0.3506 -0.2301 -0.9164 -0.0369 -0.3962 -0.2248
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart failure with preserved ejection fraction ; hfpef ; cardiovascular morbidity ; mortality
H-236	-0.42773833870887756	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁cardiovascular ▁morbi d ity
D-236	-0.42773833870887756	Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
P-236	-0.5910 -0.0813 -1.1312 -0.1135 -0.1637 -0.9086 -0.0328 -0.2759 -0.0489 -0.4947 -0.0164 -0.3470 -0.9407 -0.0473 -0.9234 -0.4161 -0.0658 -0.1122 -0.0691 -1.7402 -0.8070 -0.0835
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue doppler ; left ventricular filling pressure ; patients ; stable ; severe systolic heart failure
H-479	-0.5323711633682251	▁tissu e ▁; ▁do pp ler ▁imagin g ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁; ▁sy sto lic ▁heart ▁failure
D-479	-0.5323711633682251	tissue ; doppler imaging ; left ventricular filling pressure ; systolic heart failure
P-479	-0.8877 -0.1114 -0.8648 -0.3615 -0.0212 -1.6554 -0.1344 -0.1076 -0.3616 -0.4829 -0.0842 -2.6227 -0.2421 -1.5306 -0.1965 -1.3165 -0.2973 -0.1228 -0.0662 -0.1099 -0.5693 -0.1581 -0.3522 -0.1202
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 ; hypertensive ; obese ; zsf1 ; hypertensive ; diabetic
H-766	-0.6376183032989502	▁lean ▁; ▁z SF 1 ▁group ▁; ▁obes e ▁; ▁z SF 1 ▁groups ▁; ▁hyper tensi ve ▁; ▁diabet ic
D-766	-0.6376183032989502	lean ; zSF1 group ; obese ; zSF1 groups ; hypertensive ; diabetic
P-766	-0.1545 -2.1847 -0.3685 -0.2866 -1.8412 -1.9631 -0.4436 -1.0056 -0.1390 -1.3927 -0.7979 -0.2453 -1.3384 -0.7286 -0.6325 -0.3013 -0.1620 -0.0508 -0.3125 -0.0238 -0.0538 -0.1734 -0.0656
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence ; heart failure with preserved ejection fraction ; hfpef ; prognosis
H-23	-0.4535277783870697	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF
D-23	-0.4535277783870697	heart failure ; preserved ejection fraction ; hFPEF
P-23	-1.1583 -0.0900 -0.6659 -0.0941 -0.1168 -0.7986 -0.0442 -0.1651 -0.0497 -0.3701 -0.0179 -0.2689 -0.7788 -1.7778 -0.8787 -0.3597 -0.0754
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas city cardiomyopathy questionnaire ; patients ; heart failure ; reduced ejection fraction
H-779	-0.3101056218147278	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-779	-0.3101056218147278	Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
P-779	-0.1835 -0.6697 -0.7983 -0.0598 -0.0996 -1.1834 -0.0745 -0.3453 -0.0044 -0.2515 -1.0191 -0.0626 -0.4161 -0.0719 -0.0891 -0.0409 -0.4605 -0.0133 -0.2211 -0.1375
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial ; pde2 ; intracellular ; antiadrenergic ; therapeutic ; hf
H-1220	-0.6366850137710571	▁activa ting ▁my o card ial ▁p de 2 ▁; ▁intra cel lular ▁anti ad r energi c ▁ therapeut ic ▁strategy ▁; HF
D-1220	-0.6366850137710571	activating myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ;HF
P-1220	-1.1480 -0.2163 -1.1095 -0.2892 -0.1516 -0.5567 -2.0799 -1.2131 -0.0545 -0.3570 -1.0568 -0.0761 -0.0388 -0.0280 -0.1480 -0.3148 -0.2225 -0.1247 -1.4145 -0.3991 -0.4435 -0.8908 -0.3441 -3.5085 -0.2414 -0.1267
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone ; clinical ; medications
H-447	-0.5352720618247986	▁spi rono lac tone ▁; ▁medication s
D-447	-0.5352720618247986	spironolactone ; medications
P-447	-2.1028 -0.0547 -0.0741 -0.0898 -0.9739 -0.7643 -0.2981 -0.3391 -0.1205
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up ; hf ; hospitalization
H-690	-1.0740718841552734	▁ HF ▁hospital ization
D-690	-1.0740718841552734	HF hospitalization
P-690	-2.9343 -0.3480 -1.7946 -0.7466 -0.4983 -0.1226
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart failure ; hf ; death ; crt-d
H-105	-0.7212978005409241	▁IE ▁; ▁heart ▁failure ▁; HF ▁; ▁death ▁; ▁c RT - d
D-105	-0.7212978005409241	IE ; heart failure ;HF ; death ; cRT-d
P-105	-3.6609 -0.4499 -0.8264 -0.0615 -0.1858 -0.2351 -0.3880 -0.4731 -1.4415 -0.2378 -1.3468 -0.0605 -0.5388 -0.8079 -0.1054
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic ; clinical ; pharmacologic
H-1470	-0.6399208307266235	▁ pharma c ologic ▁treatment
D-1470	-0.6399208307266235	pharmacologic treatment
P-1470	-0.3298 -0.5083 -0.1255 -0.0715 -1.4721 -1.8721 -0.1002
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients ; narrow qrs complex ; crt ; patients
H-846	-0.4574083089828491	▁Mechanic al ▁dys syn chron y ▁; ▁QR s ▁complex ▁; ▁c RT
D-846	-0.4574083089828491	Mechanical dyssynchrony ; QRs complex ; cRT
P-846	-0.4912 -0.0132 -0.0525 -0.0349 -0.0073 -0.6286 -0.4568 -0.3867 -1.5837 -0.2286 -0.2404 -0.4401 -1.9151 -0.2696 -0.1123
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary occlusion ; collateral growth ; stent
H-510	-0.5645974278450012	▁corona ry ▁oc clusi on ▁; ▁sten t ▁oc clusi on
D-510	-0.5645974278450012	coronary occlusion ; stent occlusion
P-510	-0.2287 -2.1391 -0.0031 -0.0811 -0.3622 -0.4968 -2.9148 -0.1877 -0.0083 -0.0631 -0.5128 -0.2505 -0.0913
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid intima-media thickness ; psoriasis
H-1561	-0.7218526005744934	▁caro tid ▁intim a - media ▁; ▁psoriasis
D-1561	-0.7218526005744934	carotid intima-media ; psoriasis
P-1561	-0.5589 -0.2511 -1.3907 -0.0773 -0.1982 -0.0976 -3.7645 -0.5597 -0.2106 -0.1099
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions ; patients ; heart disease
H-48	-0.46476879715919495	▁trans fusion s ▁; ▁heart ▁disease
D-48	-0.46476879715919495	transfusions ; heart disease
P-48	-0.1607 -0.0770 -0.3017 -0.7317 -1.5961 -0.2909 -0.4392 -0.1208
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination ; exercise ; peak vo2 ; joint
H-1985	-0.7886610627174377	▁exercise ▁; ▁die t ▁; ▁VO 2 ▁; jo int ▁effect
D-1985	-0.7886610627174377	exercise ; diet ; VO2 ;joint effect
P-1985	-2.7986 -0.3660 -0.6922 -0.1080 -0.4654 -2.6786 -0.0590 -1.3371 -1.0077 -0.1285 -0.0072 -0.4936 -0.1106
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf ; pb ; bp
H-1348	-0.7874893546104431	▁PV f ▁; ▁p b ▁; ▁p b ▁; ▁BP
D-1348	-0.7874893546104431	PVf ; pb ; pb ; BP
P-1348	-0.2757 -1.7331 -0.2258 -1.1362 -0.8108 -1.1011 -1.4030 -0.2225 -1.2009 -1.0356 -0.2152 -0.0899
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence ; chronic heart failure ; hungary
H-646	-0.9254169464111328	▁chronic ▁heart ▁failure ▁; ▁Hungary
D-646	-0.9254169464111328	chronic heart failure ; Hungary
P-646	-2.0792 -1.6839 -0.3347 -0.6031 -1.0097 -0.6567 -0.1107
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv dysfunction ; cardiac cachexia
H-1168	-0.342215895652771	RV ▁dys function ▁; ▁cardiac ▁cache xia
D-1168	-0.342215895652771	RV dysfunction ; cardiac cachexia
P-1168	-1.6955 -0.1198 -0.1049 -0.1812 -0.0389 -0.1000 -0.2246 -0.4792 -0.1359
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote monitoring ; rm ; heart failure
H-148	-0.6118675470352173	▁Remote ▁monitoring ▁; RM ▁; ▁heart ▁failure
D-148	-0.6118675470352173	Remote monitoring ;RM ; heart failure
P-148	-0.9597 -0.0065 -0.2245 -0.1280 -0.5017 -1.9978 -0.1312 -1.4685 -0.0888
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg ; crt ; clinical
H-881	-0.9348875880241394	▁e CG ▁parameter s ▁; ▁c RT
D-881	-0.9348875880241394	eCG parameters ; cRT
P-881	-1.0698 -0.6771 -2.2228 -0.1110 -0.2267 -0.6427 -3.0334 -0.3369 -0.0935
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients ; sst2 ; cardiovascular event
H-407	-0.7899653315544128	▁s st 2 ▁; ▁BB ▁; ▁cardiovascular ▁event
D-407	-0.7899653315544128	sst2 ; BB ; cardiovascular event
P-407	-0.0389 -1.7580 -0.1516 -0.6991 -2.1193 -0.8135 -0.0764 -0.8424 -1.3001 -0.1004
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast cancer ; patients ; chf ; reported ; clinical
H-681	-0.3862607181072235	▁breast ▁cancer ▁patients ▁; ▁tras tuz um b - related ▁CHF
D-681	-0.3862607181072235	breast cancer patients ; trastuzumb-related CHF
P-681	-1.4404 -0.1300 -0.8115 -0.4471 -0.6058 -0.0461 -0.0962 -0.2686 -0.4855 -0.1595 -0.1191 -0.3112 -0.1002
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf ; remodeling ; emd ; dyssynchronous failing heart
H-1150	-0.43705227971076965	▁ HF ▁; ▁EM d ▁; ▁dys syn chron ous ▁fail ing ▁heart
D-1150	-0.43705227971076965	HF ; EMd ; dyssynchronous failing heart
P-1150	-0.5264 -0.5070 -0.4284 -1.2692 -0.4457 -0.2251 -0.1370 -0.0334 -0.0174 -1.3690 -0.0686 -0.0704 -1.1085 -0.2517 -0.0979
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute heart failure ; ahf ; symptoms ; heart failure ; hf
H-1466	-0.6758029460906982	▁a cute ▁heart ▁failure ▁; ▁a HF ▁; ▁heart ▁failure ▁; HF
D-1466	-0.6758029460906982	acute heart failure ; aHF ; heart failure ;HF
P-1466	-1.1113 -0.0264 -0.5250 -0.0811 -0.2154 -1.1388 -1.7636 -0.2391 -2.0290 -0.1482 -0.2053 -1.7419 -0.1318 -0.1044
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis ; post-myocardial infarction ; heart ; heart failure
H-449	-0.7957562208175659	▁ang io gene sis ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁; ▁heart ▁failure
D-449	-0.7957562208175659	angiogenesis ; post-myocardial infarction ; heart ; heart failure
P-449	-3.1582 -2.3404 -0.4871 -1.4854 -0.3159 -0.0981 -0.0562 -0.4450 -0.7043 -0.6999 -0.7072 -0.0776 -0.4799 -0.2383 -2.0446 -0.5375 -0.6007 -1.6296 -0.2086 -0.2881 -0.1084
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical ; clinical ; outcomes ; aldosterone antagonist ; heart failure
H-1734	-0.33288347721099854	▁al do ster one ▁anta gon ist ▁; ▁heart ▁failure
D-1734	-0.33288347721099854	aldosterone antagonist ; heart failure
P-1734	-0.3212 -0.1281 -0.0651 -0.3524 -0.1903 -0.0069 -0.5817 -0.5895 -1.0186 -0.2671 -0.3619 -0.1119
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery ; medical treatment ; hf ; hypertension ; vasodilators ; diuretics
H-355	-0.44326162338256836	▁surgery ▁; ▁ HF ▁; ▁hyper tension ▁; ▁vaso dila tors ▁; ▁di ure tics
D-355	-0.44326162338256836	surgery ; HF ; hypertension ; vasodilators ; diuretics
P-355	-0.5100 -0.3530 -3.7419 -0.1910 -0.3408 -0.0927 -0.0191 -0.3551 -0.0074 -0.0033 -0.1201 -0.3971 -0.1961 -0.4296 -0.3287 -0.3714 -0.0781
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic ; congestive heart failure ; haematopoietic cell transplantation
H-1448	-0.5255731344223022	▁Gene tic ▁sus cept i bility ▁; ▁an thra cycli ne - related ▁con ges tive ▁heart ▁failure ▁; ▁ha e mato po ie tic ▁cell ▁transplant ation
D-1448	-0.5255731344223022	Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
P-1448	-1.2743 -0.3577 -0.9835 -0.0076 -0.6102 -0.1793 -0.4392 -0.0804 -0.2088 -1.0625 -1.1256 -0.3096 -0.2383 -0.0793 -0.7612 -2.4386 -1.4033 -0.2599 -0.3235 -0.0089 -0.1782 -0.0357 -0.1284 -0.8882 -1.1300 -0.2273 -0.0321 -0.5059 -0.3660 -0.1236
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration ; patients ; hr reduction ; beta-blocker ; therapy
H-1947	-1.5337035655975342	▁HR ▁; ▁beta - block er
D-1947	-1.5337035655975342	HR ; beta-blocker
P-1947	-4.1778 -2.3055 -0.2841 -0.1059 -0.3841 -0.0988 -4.7439 -0.1695
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 ; hearts ; acute ; β-ar
H-1218	-0.8714204430580139	▁p de 2 ▁; ▁heart s ▁; ▁β - AR ▁stimul ation
D-1218	-0.8714204430580139	pde2 ; hearts ; β-AR stimulation
P-1218	-1.4894 -0.7663 -0.0675 -0.7623 -3.1908 -0.1728 -0.7384 -2.5123 -0.0375 -0.6545 -0.2563 -1.1003 -0.2665 -0.1850
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis ; patients ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
H-1565	-0.8222255706787109	▁psoriasis ▁; ▁disease ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1565	-0.8222255706787109	psoriasis ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
P-1565	-0.3099 -1.8393 -5.7985 -0.3099 -1.2051 -0.0957 -0.0196 -1.5244 -0.0405 -0.2070 -0.0236 -0.8053 -0.4345 -0.1237 -0.2519 -0.1667
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians ; patient ; anemic ; patients ; heart disease
H-34	-0.7924495935440063	▁a ne mic ▁; ▁ir on - d eficient ▁adult ▁patients ▁; ▁heart ▁disease
D-34	-0.7924495935440063	anemic ; iron-deficient adult patients ; heart disease
P-34	-5.8080 -0.4161 -0.1987 -0.6302 -0.2793 -0.0642 -0.1781 -0.0807 -0.3741 -0.9631 -0.7990 -1.0962 -1.0527 -0.2777 -0.2926 -0.1686
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence ; prevalence ; heart failure ; leading ; death ; hospitalisation
H-1664	-0.7218180298805237	▁heart ▁failure ▁; ▁hospital isation
D-1664	-0.7218180298805237	heart failure ; hospitalisation
P-1664	-1.0683 -0.2580 -0.9157 -1.2063 -0.0593 -1.4054 -0.1396
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr ; diuretics ; hypertension ; patients ; esrd
H-397	-0.4031577706336975	▁e g FR ▁; ▁di ure tics ▁; ▁un control led ▁hyper tension ▁; ▁ES RD
D-397	-0.4031577706336975	egFR ; diuretics ; uncontrolled hypertension ; ESRD
P-397	-0.0544 -2.1889 -0.0857 -0.2765 -0.4403 -0.4750 -0.3632 -0.3191 -0.0430 -0.0082 -0.9487 -0.1056 -0.0332 -0.1805 -1.1077 -0.2655 -0.2351 -0.1260
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab ; chf ; nontrastuzumab users
H-678	-0.5348969101905823	▁tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab
D-678	-0.5348969101905823	trastuzumab ; CHF ; nontrastuzumab
P-678	-0.6545 -0.1108 -0.0760 -0.6463 -0.7149 -0.1545 -0.3807 -0.5822 -0.4308 -0.2173 -0.2367 -1.0679 -2.1209 -0.0950
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus ; mortality ; hazard ratio ; confidence interval
H-129	-1.2580150365829468	▁ EO - c FU s ▁; ▁mortal ity
D-129	-1.2580150365829468	EO-cFUs ; mortality
P-129	-3.8975 -0.2943 -0.0951 -1.2005 -1.6798 -0.6800 -0.8771 -1.5477 -1.9546 -1.4938 -0.1178
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care ; outpatient ; acute heart failure
H-1026	-0.5426371693611145	▁Point - of - care ▁systems ▁; ▁ NP ▁; ▁ED ▁; ▁community ▁out patient ▁setting s ▁; ▁a cute ▁heart ▁failure
D-1026	-0.5426371693611145	Point-of-care systems ; NP ; ED ; community outpatient settings ; acute heart failure
P-1026	-1.2344 -0.1085 -0.0072 -0.0887 -0.1753 -0.3486 -0.8513 -2.5920 -0.1639 -1.4978 -0.4217 -0.2960 -1.1157 -1.3733 -0.0169 -0.6772 -0.0591 -0.4765 -0.5207 -0.0478 -0.3790 -0.1150 -0.3272 -0.1297
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart failure ; preserved ejection fraction ; myocardial infarction
H-1098	-0.37993666529655457	▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁my o card ial ▁in far ction
D-1098	-0.37993666529655457	heart failure ; ejection fraction ; myocardial infarction
P-1098	-1.8454 -0.1803 -0.3214 -0.1132 -0.1213 -0.0256 -0.4261 -0.0069 -0.6261 -0.5695 -0.3622 -0.4334 -0.9804 -0.0368 -0.2757 -0.1372 -0.2767 -0.1007
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective ; lvas
H-1995	-0.5211789608001709	▁l VAS
D-1995	-0.5211789608001709	lVAS
P-1995	-1.4308 -0.2969 -0.2533 -0.1038
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf ; hospitalization ; cardiovascular mortality
H-1639	-0.5589385032653809	▁black ▁race ▁; ▁ HF ▁hospital ization ▁; HR ▁; ▁cardiovascular ▁mortal ity
D-1639	-0.5589385032653809	black race ; HF hospitalization ;HR ; cardiovascular mortality
P-1639	-0.0387 -0.1210 -0.4504 -1.3728 -0.1440 -0.9346 -0.5115 -0.2917 -1.5250 -0.6274 -0.0813 -0.0379 -1.9146 -0.2057 -0.1276
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise ; health ; cardiac disease ; heart failure
H-1904	-1.133554458618164	▁exercise ▁; ▁cardiac ▁disease ▁; ▁heart ▁failure
D-1904	-1.133554458618164	exercise ; cardiac disease ; heart failure
P-1904	-4.7742 -0.6245 -2.6837 -0.5128 -0.2984 -0.6452 -0.3113 -0.2460 -0.1060
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients ; hfpef ; prospective
H-736	-1.1488792896270752	▁H FP EF
D-736	-1.1488792896270752	HFPEF
P-736	-3.0976 -1.1659 -0.9517 -0.4353 -0.0939
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician ; hf ; cpgs
H-1853	-0.5416451692581177	▁physician ▁ad her ence ▁; ▁ HF ▁c PG s
D-1853	-0.5416451692581177	physician adherence ; HF cPGs
P-1853	-0.7463 -0.1205 -0.8785 -0.8943 -0.3642 -0.8294 -0.3221 -1.3473 -0.3150 -0.1443 -0.3825 -0.1554
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf ; hf ; mortality
H-1774	-0.6166959404945374	▁ HF ▁risk ▁factors ▁; ▁fit ▁men ▁; ▁ HF ▁mortal ity ▁; ▁un fit ▁men
D-1774	-0.6166959404945374	HF risk factors ; fit men ; HF mortality ; unfit men
P-1774	-1.1180 -0.2467 -3.5151 -0.1254 -0.2540 -0.2728 -0.6886 -0.3228 -0.5640 -0.2886 -0.5452 -1.6705 -0.4762 -0.0578 -0.0336 -0.4188 -0.3821 -0.1202
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl ; chf ; vascular
H-260	-0.7405616044998169	▁HD L ▁function ▁; ▁CHF ▁; ▁et ▁; ▁HD L - media ted ▁vas cular ▁effects
D-260	-0.7405616044998169	HDL function ; CHF ; et ; HDL-mediated vascular effects
P-260	-2.1617 -2.4439 -0.1754 -0.2229 -0.0303 -0.1810 -0.7128 -1.4933 -1.9275 -2.4577 -0.0953 -0.0459 -0.0792 -0.1476 -0.1719 -0.6468 -0.2542 -0.0830
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical ; coronary artery disease ; patients ; systolic heart failure ; etiology
H-1181	-0.45688506960868835	▁corona ry ▁arter y ▁disease ▁; ▁sy sto lic ▁heart ▁failure
D-1181	-0.45688506960868835	coronary artery disease ; systolic heart failure
P-1181	-0.3125 -2.2770 -0.0332 -0.4737 -0.6170 -0.2142 -0.0229 -0.0594 -0.1961 -0.5495 -0.2198 -0.8618 -0.1024
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt ; implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
H-1953	-0.40550220012664795	▁Shu nt ▁implant s ▁; ▁trans sept al ▁cat heter isation ▁; ▁trans o es op hage al ▁e cho car dio graphic
D-1953	-0.40550220012664795	Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic
P-1953	-0.1378 -0.0308 -0.2137 -0.1673 -0.8607 -0.0096 -0.0835 -0.3488 -0.2155 -0.0161 -0.1451 -0.5825 -0.0041 -1.5777 -0.3847 -0.0372 -0.6951 -0.1006 -0.1237 -0.1022 -0.0565 -0.7030 -1.0921 -2.3492 -0.1002
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea ; total arterial compliance ; tac ; end-systolic elastance ; ees ; baseline
H-520	-0.3737894594669342	▁Ea ▁; ▁total ▁arterial ▁compliance ▁; TAC ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es
D-520	-0.3737894594669342	Ea ; total arterial compliance ;TAC ; end-systolic elastance ; ees
P-520	-0.5496 -0.3755 -0.6464 -0.0048 -0.1097 -0.1866 -0.2722 -0.1957 -2.4659 -0.1060 -0.7457 -0.1266 -0.0302 -0.0746 -0.4205 -0.2268 -0.3678 -0.0283 -0.4793 -0.0635
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular support ; heartmate ii ; lvad ; centrimag ; rvad ; mortality ; hospital ; discharge
H-304	-0.9019321203231812	▁Bi ven tri cular ▁support ▁; ▁Heart Mate ▁II ▁l VAD ▁; ▁Centri Mag ▁r VAD
D-304	-0.9019321203231812	Biventricular support ; HeartMate II lVAD ; CentriMag rVAD
P-304	-3.6065 -0.0528 -3.2766 -0.8318 -0.7777 -0.4441 -1.8059 -0.0441 -0.5956 -0.1508 -0.0184 -0.2263 -0.2412 -0.7039 -1.5612 -0.1431 -1.6080 -0.1469
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal dysfunction ; mortality ; myocardial infarction ; coronary artery bypass grafting ; cabg
H-969	-0.5525913834571838	▁Ren al ▁dys function ▁; ▁my o card ial ▁in far ction ▁; ▁corona ry ▁arter y ▁by pass ▁graf ting ▁; CA BG
D-969	-0.5525913834571838	Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting ;CABG
P-969	-0.6796 -0.1318 -0.0635 -0.0965 -0.4724 -2.2100 -0.3394 -0.2646 -0.5384 -0.0283 -0.3666 -0.0972 -0.6710 -0.0439 -1.1282 -0.0107 -0.7917 -1.9193 -0.1195 -0.0977 -0.8773 -0.4685 -1.9120 -0.6240 -0.2965 -0.1188
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpef
H-1890	-0.390315443277359	▁cardiovascular ▁risk ▁factors ▁; ▁diabetes ▁mell itus ▁; ▁at rial ▁fi bril lation ▁; ▁corona ry ▁arter y ▁disease ▁; ▁ HF p EF
D-1890	-0.390315443277359	cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
P-1890	-0.2507 -1.9389 -0.3038 -0.2311 -0.0509 -0.0048 -0.0549 -0.1834 -0.2547 -0.0140 -0.4327 -0.0440 -0.0734 -0.1675 -0.0363 -1.9046 -0.0247 -0.7820 -0.4555 -0.3910 -1.4083 -0.3256 -0.0364 -0.3849 -0.2873 -0.1070
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline ; isoprenaline ; infusion ; sdqt ; hf ; patients
H-1443	-0.5649543404579163	▁iso pren a line ▁in fusion ▁; ▁SD QT ▁; ▁h Nor m ▁; ▁ HF
D-1443	-0.5649543404579163	isoprenaline infusion ; SDQT ; hNorm ; HF
P-1443	-0.1168 -0.3442 -0.3120 -0.0721 -0.0545 -0.0659 -0.3901 -0.1298 -1.0142 -0.2333 -1.0942 -3.6092 -0.0720 -0.2533 -0.9015 -0.6312 -0.7169 -0.1580
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal dysfunction ; all-cause mortality ; cardiovascular events ; postoperative ; cabg
H-978	-0.475445955991745	▁Ren al ▁dys function ▁; ▁cardiovascular ▁events ▁; ▁ca BG
D-978	-0.475445955991745	Renal dysfunction ; cardiovascular events ; caBG
P-978	-0.9262 -0.1006 -0.0675 -0.1344 -0.4775 -0.3306 -0.6671 -0.7995 -0.9899 -0.9007 -0.1955 -0.1157
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
H-1142	-0.36006245017051697	▁Pyr ido stig mine ▁; ▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ▁protein ▁; ▁left ▁vent ric le ▁; ▁my o card ial ▁ang io gene sis
D-1142	-0.36006245017051697	Pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
P-1142	-0.0658 -0.0112 -0.0025 -0.0998 -0.3410 -0.1019 -0.1459 -0.0123 -0.8568 -0.0900 -0.0127 -0.2899 -0.2944 -0.7404 -2.3610 -0.4179 -0.1117 -0.0443 -1.2053 -0.3600 -0.3334 -0.5802 -0.1783 -0.2814 -0.3669 -0.5006 -0.5022 -0.1345 -0.3018 -0.3082 -0.1095
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr ; vad ; ecmo ; vad ; ecmo
H-1393	-0.9948782324790955	▁e g FR ▁; ▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁ec mo ▁group
D-1393	-0.9948782324790955	egFR ; VAD group ; ecmo+VAD group ; ecmo group
P-1393	-0.0560 -1.7034 -0.7728 -0.1889 -1.1850 -0.1249 -1.8545 -0.2151 -0.3649 -2.0662 -3.4003 -0.1455 -1.4889 -0.2561 -0.6191 -1.3190 -2.6358 -0.4076 -0.0986
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients ; chf ; international classification of diseases
H-213	-0.4423671364784241	▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision
D-213	-0.4423671364784241	CHF ; international Classification of Diseases ; Ninth revision
P-213	-0.7387 -1.0862 -0.3889 -0.0262 -0.0903 -0.1961 -0.0290 -0.0491 -1.6166 -0.0297 -0.0228 -1.2548 -0.0913 -0.8648 -0.1510
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv dysfunction ; body mass index ; fat mass ; cachexia
H-1163	-0.47663089632987976	▁ RV ▁dys function ▁; ▁lower ▁body ▁mass ▁index ▁; ▁fat ▁mass ▁index ▁; ▁cache xia
D-1163	-0.47663089632987976	RV dysfunction ; lower body mass index ; fat mass index ; cachexia
P-1163	-1.4039 -0.7885 -0.3549 -0.1787 -0.5478 -1.8478 -0.8540 -0.0760 -0.0111 -0.5250 -0.5847 -0.0728 -0.0091 -0.5277 -0.2338 -0.1274 -0.2905 -0.1455
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline ; crf ; hf ; mortality ; hf
H-1775	-0.606089174747467	▁c RF ▁; ▁ HF ▁mortal ity ▁risk ▁; ▁men ▁; ▁ HF ▁risk ▁factors
D-1775	-0.606089174747467	cRF ; HF mortality risk ; men ; HF risk factors
P-1775	-0.6132 -1.3324 -0.2873 -0.5238 -0.2500 -0.1882 -0.9424 -1.3813 -0.1952 -1.5207 -0.2634 -0.2733 -0.3622 -1.6314 -0.1620 -0.2561 -0.1207
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait ; therapy ; lokomat ; heart failure ; patients
H-1921	-0.4021829664707184	▁Robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁system ▁; ▁heart ▁failure ▁patients
D-1921	-0.4021829664707184	Robot-assisted gait therapy ; Lokomat® system ; heart failure patients
P-1921	-0.6551 -0.3158 -0.0149 -0.1486 -0.1203 -0.1847 -0.2293 -0.0329 -0.4163 -0.1404 -0.0364 -2.2861 -0.4249 -0.4484 -0.4099 -0.1273 -1.2413 -0.3101 -0.0987
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests ; cardiac growth ; disease ; chromatin ; remodeling
H-92	-0.4070902466773987	▁cardiac ▁growth ▁; ▁plastic iteit ▁; ▁disease ▁recap it ulat es ▁; ▁chr omat in ▁remodel ing
D-92	-0.4070902466773987	cardiac growth ; plasticiteit ; disease recapitulates ; chromatin remodeling
P-92	-0.2400 -1.1541 -0.4722 -0.3576 -1.4151 -0.4185 -0.3014 -0.0664 -0.0217 -0.0054 -0.4161 -0.3235 -0.0520 -0.0244 -0.9213 -0.0482 -0.1088 -1.3084 -0.0795
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis ; idiopathic dilated cardiomyopathy
H-1742	-0.369015097618103	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁co hor t
D-1742	-0.369015097618103	idiopathic dilated cardiomyopathy cohort
P-1742	-1.1435 -0.1033 -0.0460 -0.2108 -0.1842 -0.1493 -0.0896 -1.2955 -0.6139 -0.0293 -0.4197 -0.8266 -0.0845 -0.2304 -0.1087
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine ; nesiritide ; placebo
H-78	-0.5044589638710022	▁dop amine ▁; ▁nesi riti de
D-78	-0.5044589638710022	dopamine ; nesiritide
P-78	-0.0040 -0.0460 -0.1438 -0.2964 -0.0386 -0.1808 -3.2506 -0.0755
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline ; embase ; cochrane ; clinical
H-41	-0.36296945810317993	▁med line ▁; ▁ EMBA se ▁; ▁co ch rane ▁database s ▁; ▁clinic al ▁trial ▁registri es
D-41	-0.36296945810317993	medline ; EMBAse ; cochrane databases ; clinical trial registries
P-41	-0.5630 -1.1118 -0.3124 -1.2076 -0.1297 -0.6318 -0.2580 -0.0755 -0.4202 -0.0570 -0.3062 -0.2009 -0.2318 -0.1392 -0.0646 -0.1686 -0.0589 -0.0388 -1.1238 -0.1598
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician ; nonprescribing ; patient
H-1127	-0.9471744894981384	▁chart ▁review
D-1127	-0.9471744894981384	chart review
P-1127	-3.3193 -0.0477 -0.2604 -0.1613
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients ; severe hf ; prognostic ; hf
H-1764	-0.9896908402442932	▁ HF ▁; ▁ HF
D-1764	-0.9896908402442932	HF ; HF
P-1764	-1.3596 -0.4808 -0.6667 -2.1230 -0.4850 -1.6240 -0.1887
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ; ea ; tac ; ees ; patients
H-522	-0.5264978408813477	▁Ea ▁; ▁ TAC ▁; ▁HR ▁; ▁e es
D-522	-0.5264978408813477	Ea ; TAC ; HR ; ees
P-522	-0.2070 -0.6107 -0.9129 -0.2837 -0.3844 -0.3439 -0.5190 -1.4166 -0.1385 -0.8150 -0.1597
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth ; health ; outcomes ; medicare
H-1628	-0.6438061594963074	▁Care ▁management ▁; ▁content - driv en ▁tele health ▁technology ▁; ▁Medica re
D-1628	-0.6438061594963074	Care management ; content-driven telehealth technology ; Medicare
P-1628	-1.8068 -0.1029 -0.2659 -1.6949 -0.0736 -0.0285 -0.0687 -1.3135 -0.1700 -0.3474 -0.4277 -2.4943 -0.0264 -0.7129 -0.1235
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant ; erc ; epicatechin ; muscle
H-1256	-0.47720572352409363	▁ ERC ▁; ▁pure ▁epi cate chin ▁; ▁muscle ▁function
D-1256	-0.47720572352409363	ERC ; pure epicatechin ; muscle function
P-1256	-1.4979 -0.0831 -0.2276 -0.0821 -0.1605 -0.0174 -0.4982 -0.6475 -1.8199 -0.2239 -0.3465 -0.1217
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical ; nonprescribing ; patients
H-1128	-0.29919496178627014	▁bio medic al ▁reasons ▁; ▁non pre scribi ng
D-1128	-0.29919496178627014	biomedical reasons ; nonprescribing
P-1128	-0.0432 -0.0642 -0.0088 -0.4108 -1.1657 -0.4290 -0.1161 -0.1082 -0.2531 -0.5910 -0.1011
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium ; expression ; pka ; downstream signaling
H-1433	-0.5934240818023682	▁my o car dium ▁display s ▁; ▁p ka ▁sub un its ▁; ▁down stream ▁signal ing
D-1433	-0.5934240818023682	myocardium displays ; pka subunits ; downstream signaling
P-1433	-0.4211 -0.1257 -0.0338 -0.1568 -2.7519 -0.2415 -0.2403 -1.2710 -1.4752 -1.9411 -0.3353 -0.0220 -0.5071 -0.5093 -0.0182 -0.3421 -0.5207 -0.2434 -0.1185
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-867	-0.4138968288898468	▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-867	-0.4138968288898468	atrial fibrillation ; carvedilol ; metoprolol
P-867	-2.7806 -0.0831 -0.5469 -0.0875 -0.1603 -0.6035 -0.0275 -0.0650 -0.0578 -0.6716 -0.1450 -0.6293 -0.0292 -0.1413 -0.4568 -0.1368
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect ; heart failure ; patients ; implantable cardioverter-defibrillator
H-1860	-0.5219280123710632	▁heart ▁failure ▁patients ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
D-1860	-0.5219280123710632	heart failure patients ; implantable cardioverter-defibrillator
P-1860	-4.8172 -0.0831 -1.4159 -0.4181 -0.2945 -0.0509 -0.1224 -0.0308 -0.1796 -0.1817 -0.1578 -0.0332 -0.1544 -0.2141 -0.0981 -0.4979 -0.1230
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-367	-0.23212189972400665	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-367	-0.23212189972400665	functional MS ; valve plasty ; degenerative MR ; LV
P-367	-0.3138 -0.1581 -0.2987 -0.6606 -0.0172 -0.0411 -0.3538 -0.2818 -0.0163 -0.0103 -0.1919 -0.1360 -0.3409 -0.0274 -0.7909 -0.0751
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients ; heartmate ii ; biventricular support ; heartmate ii ; implantation
H-300	-0.9581829905509949	▁Heart Mate ▁II ▁ insertion ▁; ▁Heart Mate ▁II ▁implant ation
D-300	-0.9581829905509949	HeartMate II insertion ; HeartMate II implantation
P-300	-1.5250 -0.1305 -0.6369 -1.2432 -0.1007 -0.2594 -4.7832 -0.3066 -1.1155 -0.9038 -0.8867 -0.3931 -0.1719
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end stage heart failure ; heart failure ; public ; health ; patient ; europe ; north america
H-1663	-1.2150205373764038	▁management ▁; ▁end ▁stage ▁heart ▁failure ▁; ▁Heart ▁failure ▁; ▁public ▁health ▁; ▁europa ▁; ▁north ▁America
D-1663	-1.2150205373764038	management ; end stage heart failure ; Heart failure ; public health ; europa ; north America
P-1663	-3.7883 -1.4510 -1.4643 -0.0553 -1.5722 -0.2357 -0.7478 -3.8126 -0.2715 -0.5464 -0.7474 -1.1966 -1.7945 -2.7145 -0.5147 -0.9509 -0.7132 -0.3585 -0.1499
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient ; st-segment-elevation mis ; killip class ; comorbid ; conditions
H-1105	-0.2989614009857178	▁MI s ▁; ▁Kill ip ▁class
D-1105	-0.2989614009857178	MIs ; Killip class
P-1105	-1.1861 -0.0930 -0.2807 -0.3669 -0.1002 -0.0596 -0.1883 -0.1169
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart failure ; cardiology-cardiovascular surgery consensus report ; heart failure ; disease
H-1818	-0.6270192861557007	▁heart ▁failure ▁; ▁mechanic al ▁support ▁devices ▁; ▁Card i ology - car dio vas cular ▁Sur ger y ▁Cons en sus ▁report ▁; ▁Heart ▁failure
D-1818	-0.6270192861557007	heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus report ; Heart failure
P-1818	-3.0929 -0.2000 -0.1681 -0.1818 -0.0157 -0.4687 -0.3259 -0.2908 -2.3675 -0.1572 -0.3812 -0.0543 -0.5673 -1.2908 -0.3083 -0.3102 -1.1586 -0.3740 -0.1116 -0.2633 -0.0236 -0.0827 -1.1517 -1.8317 -1.2477 -0.2410 -0.7856 -0.1042
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 ; n2bus ; s12884 ; pevk
H-769	-0.8059019446372986	▁elastic ▁n 2 ▁bu s ▁segment ▁; ▁PE v k ▁segment
D-769	-0.8059019446372986	elastic n2 bus segment ; PEvk segment
P-769	-1.6969 -2.4342 -0.0555 -1.0549 -0.1742 -0.1682 -0.3479 -0.8323 -1.0750 -1.3689 -0.9809 -0.1949 -0.0928
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care of heart failure index version 6.2 ; schfi v.6.2 ; psychometric
H-1504	-0.8205135464668274	▁Self - car e ▁of ▁Heart ▁Fail ure ▁index ▁; ▁sch fi
D-1504	-0.8205135464668274	Self-care of Heart Failure index ; schfi
P-1504	-0.1362 -0.0626 -1.5465 -0.2614 -0.4341 -0.5031 -0.4893 -0.8270 -0.3620 -0.4648 -1.5788 -2.5953 -2.1543 -0.0719
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics ; chromatin-associated proteins ; disease
H-93	-0.5992571711540222	▁prote o mics ▁; ▁chr omat in - as soci ated ▁protein s ▁; ▁detergent ▁; ▁disease
D-93	-0.5992571711540222	proteomics ; chromatin-associated proteins ; detergent ; disease
P-93	-1.4621 -1.7114 -0.0269 -0.6708 -0.3989 -0.0288 -0.9890 -0.1074 -0.0632 -0.0041 -0.4452 -0.6844 -0.2069 -1.3187 -0.7756 -1.4974 -0.7600 -0.1541 -0.0810
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate ; left ventricular assist system ; lvas ; patients ; heart failure
H-1993	-0.7929953336715698	▁Heart Mate ▁; ▁left ▁vent ri cular ▁assist ▁system ▁; ▁l VAS ▁; ▁advanced ▁heart ▁failure
D-1993	-0.7929953336715698	HeartMate ; left ventricular assist system ; lVAS ; advanced heart failure
P-1993	-0.7186 -0.2928 -0.6897 -0.6352 -0.1450 -2.9081 -0.5717 -1.2378 -0.1103 -0.4903 -0.0468 -0.3981 -0.5140 -4.0746 -0.6096 -0.3496 -0.3627 -0.1190
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil ; mitochondrial dysfunction ; heart failure ; cardioprotection
H-954	-0.35520434379577637	▁Nico rand il ▁; ▁mito cho ndri al ▁dys function ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁mechanism ▁of ▁cardio protec tion
D-954	-0.35520434379577637	Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; mechanism of cardioprotection
P-954	-0.0015 -0.0913 -0.0762 -0.9630 -0.0340 -1.5185 -0.4631 -0.0627 -0.0604 -0.1521 -0.3269 -0.2500 -0.0056 -0.0182 -0.5396 -0.1613 -0.0710 -0.2814 -0.6830 -0.2011 -0.3135 -0.0660 -0.0594 -0.6726 -0.5196 -1.5343 -0.0831 -0.3105 -0.9655 -0.4205 -0.1054
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic ; acute hf ; adverse event ; chronic hf
H-1016	-0.29291507601737976	▁ pharma c ologic ▁management ▁; ▁a cute ▁ HF ▁; ▁chronic ▁ HF
D-1016	-0.29291507601737976	pharmacologic management ; acute HF ; chronic HF
P-1016	-0.6620 -0.4019 -0.0825 -0.0638 -0.1667 -0.2476 -0.0939 -0.0191 -0.1905 -0.1454 -0.3593 -1.0770 -0.4602 -0.2373 -0.3788 -0.1007
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
H-517	-0.5380989909172058	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁pulsa tile ▁after load ▁; ▁heart ▁; ▁pressure ▁volume ▁relation
D-517	-0.5380989909172058	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
P-517	-0.4839 -0.8136 -0.9029 -0.2510 -1.7172 -0.0142 -0.5917 -0.2454 -0.0164 -1.5039 -0.1167 -0.2685 -1.1254 -0.4477 -0.1800 -0.2319 -0.8375 -0.3924 -0.0836
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 ; hno ; cxl-1051 ; t1
H-416	-0.6737352013587952	▁c XL -10 20 ▁; ▁h no ▁; ▁in active ▁c XL -10 51
D-416	-0.6737352013587952	cXL-1020 ; hno ; inactive cXL-1051
P-416	-0.9201 -0.8145 -0.1673 -0.4054 -0.9328 -2.3716 -0.9934 -0.2113 -0.0563 -0.1270 -1.8135 -0.8742 -0.3506 -0.1956 -0.4019 -0.1443
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf antagonists ; hf ; hospital ; admissions ; nbdmards ; ra
H-611	-0.3316306471824646	▁t NF ▁anta gon ists ▁; ▁ HF ▁hospital ▁ad missions ▁; ▁n b DM ARD s ▁; ▁RA
D-611	-0.3316306471824646	tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
P-611	-1.2189 -0.1123 -0.3784 -0.0126 -0.4699 -0.3658 -0.4967 -0.2928 -1.2773 -0.0806 -0.2786 -0.2962 -0.0379 -0.0137 -0.1782 -0.2747 -0.2115 -0.3156 -0.1217 -0.4132 -0.1175
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ; ejection fraction
H-1236	-0.35336628556251526	▁e je ction ▁ fraction
D-1236	-0.35336628556251526	ejection fraction
P-1236	-0.6727 -0.4132 -0.1951 -0.6125 -0.0322 -0.3898 -0.1580
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate analysis ; gls
H-817	-0.7591073513031006	▁g LS ▁; HR ▁; ▁CV
D-817	-0.7591073513031006	gLS ;HR ; CV
P-817	-0.4350 -0.9721 -0.2453 -1.0968 -0.4606 -1.5999 -1.0821 -0.1810
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized ; exercise ; exercise
H-1981	-0.991135835647583	▁exercise ▁; ▁die t
D-1981	-0.991135835647583	exercise ; diet
P-1981	-3.0254 -0.3598 -0.1765 -0.1041 -2.1418 -0.1393
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality ; hospitals
H-1695	-1.1082699298858643	▁mortal ity
D-1695	-1.1082699298858643	mortality
P-1695	-1.4482 -2.1444 -0.7223 -0.1181
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses ; magnet
H-87	-1.3746778964996338	▁nurse s ▁; ▁magnet
D-87	-1.3746778964996338	nurses ; magnet
P-87	-3.0630 -0.0905 -0.5900 -0.4941 -3.9355 -0.0749
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician ; evidence
H-1842	-0.8458195328712463	▁physician ▁ad her ence ▁; ▁class ▁I ▁recommendations
D-1842	-0.8458195328712463	physician adherence ; class I recommendations
P-1842	-2.3061 -0.3384 -1.1464 -1.0446 -1.0600 -0.9418 -0.5016 -0.1152 -0.9021 -0.1021
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed ; patients ; hf ; drug treatment ; paf ; biosynthetic enzymes ; lyso-paf-at
H-1271	-0.5338228940963745	▁ HF ▁; ▁drug ▁treatment ▁; ▁PA F ▁bio syn the tic ▁enzym es ▁; ▁lys o - pa f - AT
D-1271	-0.5338228940963745	HF ; drug treatment ; PAF biosynthetic enzymes ; lyso-paf-AT
P-1271	-2.0147 -0.4048 -0.5283 -1.2033 -0.2920 -0.3342 -0.5094 -1.5542 -0.0482 -0.0260 -1.0400 -0.9676 -0.0666 -0.1269 -0.4874 -0.0400 -0.1096 -0.0337 -0.4443 -1.2501 -0.0839 -0.7094 -0.4190 -0.1184
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology ; myocardial infarction ; mi ; outcomes ; heart failure ; hf
H-1099	-0.5310760736465454	▁my o card ial ▁in far ction ▁; MI ▁; ▁heart ▁failure ▁; HF
D-1099	-0.5310760736465454	myocardial infarction ;MI ; heart failure ;HF
P-1099	-1.6165 -0.2994 -0.3979 -0.7178 -0.0571 -0.4091 -0.1198 -0.2754 -2.7939 -0.2317 -0.5961 -0.1536 -0.1859 -0.2731 -0.2472 -0.1228
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic ; tests ; cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments ; baseline
H-737	-0.3270932137966156	▁cardiac ▁magnetic ▁res on ance ▁imagin g ▁; ▁t 1 ▁ma pping ▁; ▁invasi ve ▁hem o dynamic ▁assessment s
D-737	-0.3270932137966156	cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
P-737	-0.1298 -0.2006 -0.7819 -0.3191 -0.5343 -0.3246 -0.2885 -0.3010 -1.3010 -0.4142 -0.0246 -0.0403 -0.3012 -0.1179 -0.1250 -0.1690 -0.6706 -0.0099 -0.0406 -0.6418 -0.3536 -0.1065
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart rate reduction ; exercise ; heart failure with reduced ejection fraction ; beta-blocker
H-1935	-0.42278817296028137	▁Heart ▁rate ▁re duction ▁; ▁exercise ▁performance ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁beta - block er
D-1935	-0.42278817296028137	Heart rate reduction ; exercise performance ; heart failure ; ejection fraction ; beta-blocker
P-1935	-0.9210 -0.5595 -0.5297 -0.2024 -0.3881 -0.1636 -1.0523 -0.3227 -1.7670 -0.1466 -0.5743 -0.1352 -0.0739 -0.0282 -0.3368 -0.0060 -1.3254 -0.1608 -0.0297 -0.1527 -0.0391 -0.7042 -0.1048
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ; ras ; asymptomatic ; clinically ; hypertension ; nephropathy ; congestive heart failure
H-1597	-0.3325468599796295	RAS ▁; ▁hyper tension ▁; ▁nep hro pathy ▁; ▁con ges tive ▁heart ▁failure
D-1597	-0.3325468599796295	RAS ; hypertension ; nephropathy ; congestive heart failure
P-1597	-0.3258 -0.8623 -0.5821 -0.0409 -0.1862 -0.0237 -0.0101 -0.0541 -0.1340 -0.0474 -0.3286 -1.9071 -0.3871 -0.0900 -0.2257 -0.1158
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic ; admission ; brain natriuretic peptide ; bnp ; creatinine ; natremia
H-585	-0.5513512492179871	▁se rum ▁levels ▁; ▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁creati nine ▁; ▁na trem ia
D-585	-0.5513512492179871	serum levels ; brain natriuretic peptide ; bNP ; creatinine ; natremia
P-585	-2.8012 -0.2990 -0.9480 -0.3975 -0.3363 -0.0918 -0.5202 -0.2366 -1.9436 -0.3888 -0.1731 -0.7514 -0.2782 -0.5182 -1.0610 -0.1838 -0.0065 -0.1476 -0.2554 -0.0425 -0.0407 -1.3889 -0.2969 -0.1252
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-868	-0.4512782096862793	▁m ADI t - c RT ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy ▁; ▁n CT
D-868	-0.4512782096862793	mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy ; nCT
P-868	-1.2593 -0.0683 -0.1219 -0.0182 -0.6200 -2.4341 -0.4218 -0.3967 -0.0215 -0.3203 -0.0179 -0.3509 -0.0467 -0.5335 -0.0493 -0.2142 -0.2563 -1.1248 -0.2744 -0.0445 -0.6971 -0.1209 -0.0101 -0.6671 -0.2453 -0.6432 -1.6445 -0.3426 -0.4840 -0.0892
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated ; baseline ; nt-probnp ; mr-proanp ; mr-proadm
H-17	-0.35245081782341003	▁NT - pro b NP ▁; ▁MR - pro AN p ▁; ▁MR - pro ad m
D-17	-0.35245081782341003	NT-probNP ; MR-proANp ; MR-proadm
P-17	-0.7656 -0.0731 -0.0161 -1.1665 -0.6261 -0.3666 -0.0742 -0.0526 -0.0222 -1.0695 -0.3065 -0.3178 -0.1042 -0.0557 -0.0403 -1.2221 -0.0783 -0.2280 -0.1110
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric focusing ; riα ; ser77 ; ser83 ; in vivo ; phosphorylation
H-1430	-0.568648636341095	▁iso electric ▁focus ing ▁; ▁RI α ▁; ▁ser 77 ▁; ▁ser 83 ▁; ▁vivo ▁ phos phor y lation ▁sites
D-1430	-0.568648636341095	isoelectric focusing ; RIα ; ser77 ; ser83 ; vivo phosphorylation sites
P-1430	-0.7477 -0.6017 -0.1560 -0.1059 -0.3122 -0.3321 -0.4420 -0.4517 -0.8987 -0.6231 -0.3248 -0.6105 -1.4228 -0.5769 -0.7878 -0.2658 -0.0994 -1.3570 -1.5406 -0.1321 -1.0039 -0.2100 -0.0762
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt ; sd of rr intervals ; sdrr ; qtv ; heart rate variability
H-1440	-0.824233889579773	▁SD QT ▁; ▁SD ▁; ▁ RR ▁interval s ▁; SD RR ▁; ▁index ▁; ▁Q TV ▁; ▁heart ▁rate ▁variabil ity
D-1440	-0.824233889579773	SDQT ; SD ; RR intervals ;SDRR ; index ; QTV ; heart rate variability
P-1440	-0.3188 -0.9314 -0.3569 -0.0981 -3.0880 -1.3191 -1.6544 -0.0315 -0.0324 -0.2207 -2.0091 -2.6478 -0.3579 -0.2394 -0.5534 -1.0821 -1.4489 -0.2041 -0.6808 -0.3574 -0.1553 -1.5293 -0.3353 -0.1293
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs ; septal ; qrs ; resynchronization
H-486	-0.9559234380722046	▁e / e sept al ▁; ▁e / eme an ▁; ▁s ' sept al ▁; ▁QR s ▁ width
D-486	-0.9559234380722046	e/eseptal ; e/emean ; s'septal ; QRs width
P-486	-2.1243 -4.9969 -0.2750 -0.0699 -0.0412 -0.2561 -0.6229 -3.5341 -0.0126 -0.0117 -0.5801 -1.3776 -2.8575 -0.0500 -0.0272 -0.3390 -0.0226 -1.3520 -1.1291 -0.1007 -1.1449 -0.1050
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic regression ; primary outcome ; secondary outcome ; death
H-973	-0.7160182595252991	▁Log istic ▁re gression ▁models
D-973	-0.7160182595252991	Logistic regression models
P-973	-0.6443 -0.0759 -0.0657 -0.0134 -0.9300 -3.1772 -0.1058
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc occlusion ; correlated ; rs ; rs synchrony
H-326	-0.3352656066417694	▁IV c ▁oc clusi on ▁; ▁co ▁cor related ▁; ▁twist ▁; ▁ap ical ▁ro tation ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS
D-326	-0.3352656066417694	IVc occlusion ; co correlated ; twist ; apical rotation ; RS ; RS synchrony ; CS
P-326	-0.3967 -0.7732 -0.0068 -0.0195 -0.6410 -0.3948 -1.1668 -0.6317 -0.6991 -1.4730 -0.0789 -0.3604 -0.1089 -0.2529 -0.0134 -0.0298 -0.1993 -0.0203 -0.3419 -0.1719 -0.0036 -0.1716 -0.4295 -0.0570 -0.1847 -0.0903
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission ; hospital ; congestive heart failure ; united states
H-1574	-0.7301893830299377	▁con ges tive ▁heart ▁failure ▁; ▁United ▁States
D-1574	-0.7301893830299377	congestive heart failure ; United States
P-1574	-1.5402 -0.3226 -1.0606 -0.4389 -0.1774 -0.8997 -1.5127 -0.9018 -0.2917 -0.1563
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective ; diuretics ; morbidity ; mortality
H-1200	-0.6459870934486389	▁di ure tics ▁; ▁morbi d iteit ▁; ▁mortal ity
D-1200	-0.6459870934486389	diuretics ; morbiditeit ; mortality
P-1200	-0.2667 -0.4424 -0.3748 -0.6537 -0.8734 -0.0909 -1.8462 -1.3630 -0.0143 -1.5975 -0.1550 -0.0739
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital ; readmission ; patients ; heart failure ; follow-up
H-731	-1.6263692378997803	▁heart ▁failure ▁; ▁follow - up
D-731	-1.6263692378997803	heart failure ; follow-up
P-731	-7.1951 -0.2234 -3.7316 -0.0072 -0.2645 -0.0443 -1.3756 -0.1693
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health care ; clinically ; gastrointestinal bleeding
H-1658	-0.6271615028381348	▁devices ▁; ▁gastro inte stin al ▁ble ed ing
D-1658	-0.6271615028381348	devices ; gastrointestinal bleeding
P-1658	-2.7416 -0.6706 -0.7316 -0.3544 -0.8894 -0.0895 -0.0846 -0.5843 -0.3129 -0.3506 -0.0893
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients ; t1 times ; cardiac events
H-740	-0.30925190448760986	▁cardiac ▁events
D-740	-0.30925190448760986	cardiac events
P-740	-0.4927 -0.4370 -0.2190 -0.0883
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr ; vad ; ecmo ; vad ; renal function
H-1391	-0.80870121717453	▁e g FR ▁; ▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁renal ▁function
D-1391	-0.80870121717453	egFR ; VAD group ; ecmo+VAD group ; renal function
P-1391	-0.0580 -1.4109 -0.6503 -0.2028 -2.0519 -0.0772 -1.7884 -0.3390 -0.2345 -2.6040 -1.8721 -0.0807 -2.0340 -0.4646 -0.0337 -0.2721 -0.2862 -0.0963
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 ; sst2 ; outcomes
H-406	-0.6447246670722961	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB
D-406	-0.6447246670722961	sst2/low-dose BB ; sst2/high-dose BB
P-406	-0.5811 -1.8410 -0.2108 -0.2065 -0.0450 -0.7771 -0.2107 -0.8679 -0.7512 -0.3944 -1.7934 -0.2216 -1.5220 -0.0837 -1.4102 -0.1426 -0.7325 -0.3442 -0.1138
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf ; chf ; patients ; intubated
H-214	-0.6505511403083801	▁CHF ▁; ▁ED ▁visit s ▁; ▁CHF ▁patients ▁in tuba ted
D-214	-0.6505511403083801	CHF ; ED visits ; CHF patients intubated
P-214	-0.1511 -2.0000 -1.1366 -1.7254 -0.2896 -0.3544 -0.3995 -1.4522 -0.4243 -0.0750 -0.1162 -0.2478 -0.0852
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician ; mortality ; hf ; physicians
H-1731	-0.7133483290672302	▁ HF ▁; ▁non car dio logist ▁physician s
D-1731	-0.7133483290672302	HF ; noncardiologist physicians
P-1731	-3.4634 -0.6890 -0.6812 -0.1900 -0.0373 -0.8366 -0.2110 -1.1915 -0.1366 -0.2894 -0.1208
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin ; genomic reprogramming ; disease
H-100	-0.26552361249923706	▁zebra fish ▁; ▁nu cle olin ▁; ▁genom ic ▁re programm ing
D-100	-0.26552361249923706	zebrafish ; nucleolin ; genomic reprogramming
P-100	-0.0755 -0.0574 -0.2789 -0.2298 -0.0031 -0.0394 -0.8692 -0.0677 -0.1876 -0.0362 -0.2494 -0.0367 -1.5218 -0.0647
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv ejection fraction ; pcwp
H-483	-0.4564155638217926	▁LV ▁e je ction ▁ fraction ▁; ▁pc WP
D-483	-0.4564155638217926	LV ejection fraction ; pcWP
P-483	-0.1983 -1.4916 -0.2391 -0.1357 -0.7886 -0.0317 -0.5642 -0.2022 -0.6413 -0.6085 -0.1194
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence ; hf ; ami ; mortality
H-1314	-0.9263519644737244	▁ HF ▁; ▁ AMI ▁; ▁mortal ity
D-1314	-0.9263519644737244	HF ; AMI ; mortality
P-1314	-1.5946 -0.3534 -0.3058 -2.0207 -0.5640 -0.7168 -1.4868 -1.9669 -0.1537 -0.1009
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency department ; acute heart failure ; clinical ; patient ; collins
H-56	-0.5985465049743652	▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁; ▁Collins
D-56	-0.5985465049743652	emergency department ; acute heart failure ; Collins
P-56	-2.0673 -0.0686 -0.3003 -0.1154 -0.0271 -0.7274 -0.1486 -1.3510 -1.3600 -0.3199 -0.0984
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary exercise test ; quality of life ; muscular ; peak quadriceps force
H-1915	-0.8255296945571899	▁cardio pul mon ary ▁exercise ▁; ▁quality ▁of ▁life ▁score ▁; ▁muscular ▁strength ▁; ▁quadri cep s ▁force
D-1915	-0.8255296945571899	cardiopulmonary exercise ; quality of life score ; muscular strength ; quadriceps force
P-1915	-0.1976 -1.0578 -2.1944 -0.7956 -2.1821 -1.4975 -3.7856 -0.2109 -0.3187 -1.0831 -0.2100 -0.3395 -0.7418 -0.2186 -0.3892 -0.2916 -0.1180 -0.3416 -0.4123 -0.1244
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians ; public ; health ; air ; cardiovascular ; health ; lead ; hospitalisation ; death
H-1808	-0.6576756238937378	▁public ▁health ▁; ▁air ▁pollution ▁; ▁industrial ▁areas ▁; ▁cardiovascular ▁health
D-1808	-0.6576756238937378	public health ; air pollution ; industrial areas ; cardiovascular health
P-1808	-1.3541 -1.0132 -0.5986 -0.1556 -0.2711 -0.3802 -0.7366 -1.0448 -0.7033 -0.3022 -0.9446 -0.9212 -0.1243
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg ; congenital ; accessory ; ion channelopathies ; cardiomyopathy
H-1909	-0.3510371148586273	▁e CG ▁; ▁con geni tal ▁accesso ry ▁path ways ▁; ▁ion ▁channel o pathi es ▁; ▁cardio my o pathy
D-1909	-0.3510371148586273	eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
P-1909	-0.7972 -0.7778 -0.5359 -1.4006 -0.0421 -0.1154 -0.0412 -0.9256 -0.2206 -0.0998 -0.3401 -0.0343 -0.1050 -0.8616 -0.0196 -0.1286 -0.2060 -0.1167 -0.5906 -0.3023 -0.0310 -0.2862 -0.0958
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients ; idiopathic dilated cardiomyopathy ; tuscany ; evidence-based
H-1739	-0.3544980585575104	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁tu sca ny
D-1739	-0.3544980585575104	idiopathic dilated cardiomyopathy ; tuscany
P-1739	-1.1002 -0.0562 -0.0362 -0.1491 -0.1651 -0.2827 -0.1343 -1.2864 -0.5482 -0.0213 -0.4289 -0.0527 -0.0133 -0.8747 -0.4110 -0.1116
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf ; pyridostigmine ; basal heart rate ; sympathetic control of heart rate
H-1140	-0.4270178973674774	▁ HF ▁; ▁py rido stig mine ▁; ▁bas al ▁heart ▁rate ▁; ▁va gal ▁; ▁sympa the tic ▁control ▁; ▁heart ▁rate
D-1140	-0.4270178973674774	HF ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
P-1140	-0.9720 -0.9179 -1.6594 -0.0408 -0.0224 -0.0092 -0.3020 -0.2691 -0.6870 -0.0731 -0.7247 -0.3675 -0.4226 -0.0043 -0.0199 -0.5019 -0.0247 -0.8722 -0.5256 -0.5926 -0.4730 -0.5476 -0.2693 -0.2619 -0.1151
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity ; mortality ; hfpef ; patients ; hf ; reduced ef
H-1301	-0.6227121353149414	▁Morbi d iteit ▁; ▁mortal ity ▁; HF p EF ▁; ▁ HF ▁; ▁EF
D-1301	-0.6227121353149414	Morbiditeit ; mortality ;HFpEF ; HF ; EF
P-1301	-0.1687 -0.1351 -1.3904 -0.4371 -0.0130 -1.5791 -0.2893 -1.4697 -0.0706 -0.1812 -0.3732 -1.7912 -0.2731 -0.3704 -1.0472 -0.9235 -0.0732
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf ; heart failure ; t2d ; type 2 diabetes ; skm ; skeletal muscle
H-1244	-0.38628408312797546	HF ▁; heart ▁failure ▁; ▁t 2 d ▁; Type ▁2 ▁diabetes ▁; ▁Sk m ▁; s kelet al ▁muscle
D-1244	-0.38628408312797546	HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;skeletal muscle
P-1244	-0.3223 -0.8518 -0.6867 -0.0442 -0.1973 -1.1576 -0.0134 -0.3317 -0.1788 -1.1410 -0.5635 -0.0228 -0.4127 -0.0312 -0.1612 -0.3553 -1.5086 -0.0259 -0.0430 -0.1128 -0.2484 -0.0878
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart failure ; hf ; risk stratification ; inpatient ; outpatient
H-378	-0.6933020353317261	▁heart ▁failure ▁; HF ▁; ▁in patient ▁; ▁out patient ▁models
D-378	-0.6933020353317261	heart failure ;HF ; inpatient ; outpatient models
P-378	-0.9663 -0.1753 -0.3950 -0.2615 -0.5842 -2.4979 -0.0190 -0.8745 -1.1507 -0.0169 -1.6614 -0.2880 -0.1221
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence ; biomarkers ; pathophysiology ; chronic hf ; therapeutic
H-1474	-0.4646269977092743	▁molecular ▁bio mark ers ▁; ▁pat ho phy si ology ▁; ▁chronic ▁ HF
D-1474	-0.4646269977092743	molecular biomarkers ; pathophysiology ; chronic HF
P-1474	-0.4918 -0.0553 -0.2829 -0.2874 -0.3693 -1.2856 -0.2688 -0.1479 -2.1221 -0.2447 -0.2105 -0.1813 -0.3265 -0.2840 -0.7806 -0.0954
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol ; metoprolol ; therapy ; heart failure ; patients
H-857	-0.4046369791030884	▁car vedi lol ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁patients ▁; ▁devices
D-857	-0.4046369791030884	carvedilol ; metoprolol ; heart failure patients ; devices
P-857	-0.0327 -0.1138 -0.0566 -0.4823 -0.0217 -0.5734 -0.0486 -0.1638 -0.6414 -1.1434 -0.1266 -1.2151 -1.3421 -0.0766 -0.2924 -0.1438
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating agents ; patients ; anemia ; heart disease
H-52	-0.8539626598358154	▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁heart ▁disease
D-52	-0.8539626598358154	erythropoiesis-stimulating agents ; anemia ; heart disease
P-52	-4.2319 -0.8977 -1.1185 -0.6425 -2.6657 -0.1429 -0.3366 -0.0679 -0.9664 -1.0757 -0.6192 -0.9005 -0.2924 -0.2355 -0.4893 -0.2960 -0.2652 -0.1275
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence ; intravenous ; exercise tolerance ; quality of life ; patients ; heart failure
H-46	-0.7747265100479126	▁intra ven ous ▁ir on ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure
D-46	-0.7747265100479126	intravenous iron ; exercise tolerance ; heart failure
P-46	-2.2839 -0.0122 -2.3782 -0.2128 -0.0905 -0.7347 -1.2045 -0.2742 -0.0081 -0.2975 -2.7111 -0.1859 -0.3435 -0.1091
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report ; mitral valve plasty ; degenerative mitral regurgitation
H-335	-0.20994746685028076	▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁mit ral ▁re gur gi tation
D-335	-0.20994746685028076	mitral valve plasty ; degenerative mitral regurgitation
P-335	-0.2241 -0.0881 -0.0622 -0.0504 -0.2290 -0.4830 -0.2662 -0.0505 -0.0071 -0.4513 -0.2371 -0.3550 -0.0316 -0.2726 -0.3604 -0.2386 -0.2916 -0.0801
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs ; québec health insurance board ; costs ; ontario case costing initiative
H-1235	-0.6025584936141968	▁in - t rial ▁resource ▁utiliza tion ▁; ▁unit ▁costs ▁; ▁Québec ▁Health ▁Insurance ▁Board ▁; ▁kosten ▁; ▁Ontario ▁Case ▁cost ing ▁Initiative
D-1235	-0.6025584936141968	in-trial resource utilization ; unit costs ; Québec Health Insurance Board ; kosten ; Ontario Case costing Initiative
P-1235	-3.4062 -0.1222 -0.2410 -0.0426 -0.0394 -0.3018 -0.3946 -0.4534 -0.0144 -0.3771 -0.5402 -0.1852 -1.2825 -0.5637 -0.2870 -0.6737 -2.3786 -0.4685 -0.8822 -0.4438 -1.1875 -0.1488 -0.2818 -0.2810 -0.0667
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet ; bromodomain-containing protein 4 ; brd4 ; cardiac
H-1045	-0.5604321360588074	▁knock down ▁; ▁ BET ▁bro modo main - conta ining ▁protein ▁4 ▁; br d 4) ▁; ▁cardiac ▁tissu es
D-1045	-0.5604321360588074	knockdown ; BET bromodomain-containing protein 4 ;brd4) ; cardiac tissues
P-1045	-1.8157 -0.2258 -0.5704 -1.9429 -0.2808 -0.7713 -0.0338 -0.3015 -0.1153 -0.0560 -0.2520 -0.0951 -1.2859 -0.7058 -0.6526 -0.1041 -1.8418 -1.2700 -0.0179 -0.0453 -0.1858 -0.2252 -0.0949
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras ; neprilysin inhibition ; change ; stable ; chronic heart failure ; systolic dysfunction
H-1971	-0.5295091867446899	▁Dual ▁ RAS ▁; ▁nepri ly sin ▁inhibi tion ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; ▁treatment
D-1971	-0.5295091867446899	Dual RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction ; treatment
P-1971	-1.2972 -0.2468 -0.0121 -0.7214 -0.0976 -0.4584 -0.9573 -0.1521 -0.6396 -0.8247 -1.2372 -0.6671 -0.1758 -0.4907 -0.0148 -0.0641 -0.2197 -0.0323 -0.0534 -1.9081 -1.3267 -0.4528 -0.1289
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change ; readmission ; follow-up ; follow-up
H-724	-0.4727630913257599	▁follow - up ▁visit s
D-724	-0.4727630913257599	follow-up visits
P-724	-1.1625 -0.1903 -0.0524 -0.6770 -0.1910 -0.9416 -0.0945
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage heart failure ; mechanical cardiac support
H-1386	-1.3575122356414795	▁heart ▁failure ▁; ▁pediatr ic ▁mechanic al ▁cardiac
D-1386	-1.3575122356414795	heart failure ; pediatric mechanical cardiac
P-1386	-6.5383 -0.2803 -0.5302 -1.8916 -0.2751 -0.7251 -0.0345 -0.0374 -3.1321 -0.1306
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence ; economic ; lvad ; outcomes
H-317	-0.6894609928131104	▁economic ▁models ▁; ▁l VAD
D-317	-0.6894609928131104	economic models ; lVAD
P-317	-1.0079 -0.5559 -0.2820 -2.5447 -0.0443 -0.2974 -0.0940
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic ; crt
H-428	-0.7342153191566467	▁e cho car dio graphic ▁score ▁; ▁c RT ▁response
D-428	-0.7342153191566467	echocardiographic score ; cRT response
P-428	-0.8143 -0.2802 -0.0628 -0.3859 -0.5508 -0.4637 -0.1842 -0.3527 -3.5430 -1.8484 -0.2140 -0.1106
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection fraction ; patients
H-909	-0.25617706775665283	▁e je ction ▁ fraction
D-909	-0.25617706775665283	ejection fraction
P-909	-0.3091 -0.3202 -0.1476 -0.3944 -0.0257 -0.4968 -0.0994
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized ; af ablation
H-953	-0.4679359495639801	▁AF ▁ab lation
D-953	-0.4679359495639801	AF ablation
P-953	-1.7729 -0.0181 -0.0606 -0.3399 -0.1481
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel inhibition ; hemodynamic ; exercise tolerance ; heart failure with preserved ejection fraction ; randomized
H-1170	-0.3239838480949402	▁If - chan nel ▁inhibi tion ▁; ▁hem o dynamic ▁status ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1170	-0.3239838480949402	If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
P-1170	-2.1879 -0.1196 -0.0311 -0.0360 -0.2018 -1.0710 -0.8409 -0.2330 -0.5361 -0.0086 -0.0537 -0.2830 -0.4424 -0.1517 -0.0073 -0.2517 -0.2287 -0.1010 -0.4123 -0.3638 -0.0757 -0.6927 -0.0328 -0.1332 -0.0770 -0.4288 -0.0119 -0.2793 -0.1028
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping ; tidal respiration ; administration ; gadolinium-chelate contrast agent
H-1058	-0.30513644218444824	▁tid al ▁respira tion ▁; ▁ gado lini um - che late ▁contrast ▁agent
D-1058	-0.30513644218444824	tidal respiration ; gadolinium-chelate contrast agent
P-1058	-1.1199 -0.0708 -0.2452 -0.4132 -0.6260 -0.4014 -0.0290 -0.1510 -0.0883 -0.1605 -0.0245 -0.5991 -0.4605 -0.0202 -0.3556 -0.1171
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
H-1777	-0.334934800863266	▁Card iac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁energy ▁production ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁pressure - over load ▁hyper trop hy
D-1777	-0.334934800863266	Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
P-1777	-1.2504 -0.0322 -0.2696 -0.0560 -0.1787 -1.0570 -0.0089 -0.2005 -0.0164 -1.0324 -0.2118 -0.0319 -0.6709 -1.5321 -0.2110 -0.0212 -0.0353 -0.0912 -0.5489 -0.3706 -0.3822 -0.0445 -0.1006 -0.0353 -0.0435 -0.2087 -0.0049 -1.0662 -0.2583 -0.0770
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare ; inpatient ; hf ; admissions ; acute ; hospitals ; united states
H-1723	-0.5367556810379028	▁Medica re ▁in patient ▁; ▁ HF ▁ad missions ▁; ▁a cute ▁care ▁hospital s ▁; ▁United ▁States
D-1723	-0.5367556810379028	Medicare inpatient ; HF admissions ; acute care hospitals ; United States
P-1723	-0.0431 -0.0425 -0.1122 -0.0307 -1.3942 -0.8759 -0.6098 -0.9268 -0.2783 -0.8488 -0.0674 -0.0482 -0.9047 -0.2833 -0.3024 -0.7801 -1.5495 -1.0530 -0.4432 -0.1410
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes ; catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction
H-941	-0.2857787311077118	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-941	-0.2857787311077118	catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
P-941	-1.2628 -0.0754 -0.0316 -0.0668 -0.7456 -0.3916 -0.1070 -0.4789 -0.0836 -0.0689 -0.2537 -0.7698 -0.0890 -0.3064 -0.3150 -0.0725 -0.6417 -0.0385 -0.1863 -0.0833 -0.3083 -0.0069 -0.3350 -0.1400
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose ; acute heart failure ; randomized
H-71	-0.4202703833580017	▁dop amine ▁; ▁nesi riti de ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁ro se ▁a cute ▁heart ▁failure
D-71	-0.4202703833580017	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose acute heart failure
P-71	-0.0483 -0.0659 -0.1797 -1.0994 -0.0384 -0.2310 -0.5070 -0.1294 -0.0178 -0.5452 -0.1199 -0.6907 -0.0170 -0.0304 -0.0623 -0.3935 -1.6213 -2.4278 -0.3896 -0.0549 -0.7901 -0.1583 -0.3385 -0.1300
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report ; dapc ; dystrophin-associated protein complex ; sarcomeric microstructure ; baseline
H-1253	-0.2740515172481537	▁DAP c ▁; dys trop hin - as soci ated ▁protein ▁complex ▁; ▁sar come ric ▁micro structure
D-1253	-0.2740515172481537	DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
P-1253	-0.0188 -0.7131 -0.4191 -0.1174 -0.1082 -0.6684 -0.1606 -0.0651 -0.0010 -0.5309 -0.1312 -0.0917 -0.4152 -0.1406 -0.4259 -0.9637 -0.0570 -0.1926 -0.1709 -0.0896
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf ; hhd ; salt loading ; uninephrectomy ; ang ii infusion
H-275	-0.4102867543697357	▁mouse ▁; HF ▁model ▁; ▁h HD ▁; ▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion
D-275	-0.4102867543697357	mouse ;HF model ; hHD ; salt loading ; uninephrectomy ; ANG II infusion
P-275	-0.1893 -0.7845 -1.5660 -0.8265 -0.3170 -0.4103 -1.5190 -0.3485 -0.0885 -0.0350 -0.0830 -0.1991 -0.0181 -0.9194 -1.0795 -0.1247 -0.0361 -0.8241 -0.2445 -0.0633 -0.2561 -0.0059 -0.0093 -0.2236 -0.0857
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf with preserved ejection fraction ; pef ; uptitration ; hospitalization
H-176	-0.5442911982536316	▁ HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁p EF ▁; ▁up tit ration
D-176	-0.5442911982536316	HF ; preserved ejection fraction ; pEF ; uptitration
P-176	-2.8943 -0.8505 -0.5220 -0.9395 -0.1294 -0.7044 -0.0683 -0.3073 -0.1024 -0.4436 -0.0218 -0.4477 -0.2993 -0.5526 -0.5839 -0.3989 -0.2117 -0.1925 -1.1156 -0.1000
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial ; titin hypophosphorylation ; heart failure with preserved ejection fraction ; metabolic
H-759	-0.36725717782974243	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁rat ▁metabol ic ▁risk
D-759	-0.36725717782974243	Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
P-759	-1.1647 -0.1624 -0.1167 -0.2637 -0.1520 -0.1045 -0.2386 -0.1138 -1.1390 -1.3804 -0.0644 -0.3746 -0.9357 -0.1302 -0.4209 -0.0786 -0.0553 -0.0381 -0.4236 -0.0119 -0.4980 -0.1967 -0.1117 -0.0325 -0.6972 -0.9024 -0.1085
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic ; cardiac resynchronization therapy ; crt
H-427	-0.4716073274612427	▁e cho car dio graphic ▁; ▁response ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-427	-0.4716073274612427	echocardiographic ; response ; cardiac resynchronization therapy ; cRT
P-427	-0.0528 -0.1112 -0.0734 -0.7164 -0.3519 -0.9070 -0.6717 -0.9777 -0.0450 -0.0486 -0.0957 -0.0181 -1.0296 -0.4378 -0.0193 -0.2315 -0.6143 -2.6671 -0.2643 -0.0988
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients ; baseline ; serum creatinine ; serum potassium
H-441	-0.5556519031524658	▁se rum ▁creati nine ▁level ▁; ▁se rum ▁po tas s ium ▁level
D-441	-0.5556519031524658	serum creatinine level ; serum potassium level
P-441	-1.6756 -0.3851 -0.5493 -0.5313 -0.2130 -0.4081 -1.1282 -0.2684 -0.7962 -0.4305 -0.5990 -0.1943 -0.1415 -0.8923 -0.1220
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin subproteomes ; heart failure ; proteins ; chromatin structure
H-91	-0.48036184906959534	▁chr omat in ▁sub prote om es ▁; ▁heart ▁failure ▁; ▁protein s ▁; ▁chr omat in ▁structure
D-91	-0.48036184906959534	chromatin subproteomes ; heart failure ; proteins ; chromatin structure
P-91	-0.8978 -0.0624 -1.1518 -0.2191 -0.0953 -0.4463 -0.5715 -0.4708 -0.8623 -0.2039 -0.4722 -1.3793 -0.2185 -0.6262 -0.1435 -0.0911 -0.9671 -0.4465 -0.1839 -0.0978
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac mrna ; inflammatory ; cell adhesion genes ; retn
H-934	-0.3955783545970917	▁Hum - re t n ▁mi ce ▁; ▁cardiac ▁m RNA ▁; ▁infla mma tory ▁; ▁cell ▁a dhe sion ▁gene s ▁; ▁Ret n
D-934	-0.3955783545970917	Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes ; Retn
P-934	-0.1178 -0.0926 -2.3622 -0.1559 -0.0215 -0.9909 -0.3455 -0.4606 -0.1086 -0.0120 -0.0791 -0.6759 -0.6289 -0.2203 -0.1141 -0.4457 -0.1676 -0.2005 -0.0540 -0.3689 -1.0795 -0.2822 -0.5029 -0.0247 -0.0284 -1.0335 -0.1069
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia ; patients ; chronic heart failure ; hf ; prevalence ; outcomes
H-834	-0.5742699503898621	▁an emia ▁; ▁chronic ▁heart ▁failure ▁; HF
D-834	-0.5742699503898621	anemia ; chronic heart failure ;HF
P-834	-1.7221 -0.0711 -0.5045 -0.5886 -1.3150 -0.2138 -0.3626 -0.1809 -0.6560 -0.1282
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university of connecticut heart failure center ; heart failure ; nurse practitioner
H-728	-0.3288976848125458	▁University ▁of ▁Connect i cut ▁Heart ▁Fail ure ▁Center ▁; ▁cardio logist ▁; ▁heart ▁failure
D-728	-0.3288976848125458	University of Connecticut Heart Failure Center ; cardiologist ; heart failure
P-728	-0.9429 -0.0194 -0.5613 -0.0156 -0.0635 -0.6275 -0.3858 -0.6052 -0.4515 -0.3166 -0.0509 -0.1214 -0.1581 -0.2350 -0.1058 -0.8290 -0.1017
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp ; antibodies ; nonterminal epitopes
H-1519	-0.4543716311454773	▁circula ting ▁NT - pro b NP ▁; ▁anti bo dies ▁; ▁non gly cos yla ted ▁; ▁non termin al ▁e pito pes
D-1519	-0.4543716311454773	circulating NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
P-1519	-1.4784 -0.0964 -1.0476 -0.0753 -0.0239 -0.6742 -0.6684 -0.9386 -0.0229 -0.0568 -1.2167 -1.1250 -0.0911 -0.6327 -0.6833 -0.3431 -0.2232 -0.8704 -0.0265 -0.7530 -0.0085 -0.0529 -0.0610 -0.3175 -0.2413 -0.0849
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv failure ; diagnostic ; left ventricular dysfunction
H-1093	-0.8593524098396301	▁ RV ▁failure ▁; ▁diagnosti ▁procedure s ▁; ▁management ▁; ▁intr in sic ▁left ▁vent ri cular ▁dys function
D-1093	-0.8593524098396301	RV failure ; diagnosti procedures ; management ; intrinsic left ventricular dysfunction
P-1093	-2.1216 -1.1381 -2.2340 -0.3149 -3.1872 -3.7124 -0.0690 -0.3813 -0.4148 -0.6162 -0.2991 -0.1328 -0.0169 -0.1759 -0.0434 -2.2684 -0.2896 -0.0303 -0.1995 -0.2850 -0.1161
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd ; diuretic ; peripheral edema ; functional class
H-899	-0.5214974880218506	▁PD ▁; ▁weight ▁loss ▁; ▁di ure tic ▁response ▁; ▁per i pher al ▁ed ema
D-899	-0.5214974880218506	PD ; weight loss ; diuretic response ; peripheral edema
P-899	-0.2608 -1.0212 -0.6023 -1.3426 -0.5650 -0.1848 -0.2132 -0.7427 -0.4965 -0.4362 -0.0247 -0.1713 -0.0334 -0.0487 -0.2953 -0.0169 -2.8504 -0.0810
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic heart failure ; yield ; atrial ; cells
H-1334	-0.9053784608840942	▁Chro nic ▁heart ▁failure ▁; ▁transform ing ▁growth ▁factor ▁; ▁at rial
D-1334	-0.9053784608840942	Chronic heart failure ; transforming growth factor ; atrial
P-1334	-0.5471 -0.1314 -0.7454 -0.1818 -0.4386 -1.7381 -0.0461 -0.5538 -0.1497 -0.4928 -5.9343 -0.0309 -1.5867 -0.0985
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients ; hfpef ; kccq ; health ; prognostic
H-791	-0.9141248464584351	▁ HF p EF ▁; ▁ cc q
D-791	-0.9141248464584351	HFpEF ; ccq
P-791	-1.3811 -0.3850 -0.0694 -0.6078 -0.2772 -2.4466 -0.4035 -1.8880 -1.5546 -0.1283
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients ; heartmate ii ; lvad ; centrimag ; rvad
H-298	-0.4561261832714081	▁Heart Mate ▁II ▁l VAD ▁; ▁Centri Mag ▁r VAD
D-298	-0.4561261832714081	HeartMate II lVAD ; CentriMag rVAD
P-298	-0.5375 -0.0806 -0.6366 -0.2131 -0.0244 -0.5852 -0.1581 -0.9143 -1.8159 -0.0814 -0.3246 -0.1019
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods study ; exercise ; patients ; heart failure
H-615	-2.2304153442382812	▁voordelen ▁; ▁cardiovascular ▁; ▁heart ▁failure
D-615	-2.2304153442382812	voordelen ; cardiovascular ; heart failure
P-615	-6.0133 -0.5306 -5.3835 -2.8036 -2.4631 -0.2125 -0.3148 -0.1219
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf ; mi ; reduced ejection fraction ; ef
H-1100	-0.5414730310440063	HF ▁; ▁MI ▁; ▁pres er ved ▁; ▁reduce d ▁e je ction ▁ fraction ▁; EF
D-1100	-0.5414730310440063	HF ; MI ; preserved ; reduced ejection fraction ;EF
P-1100	-1.3049 -0.5585 -0.8000 -0.5152 -1.8751 -0.0535 -0.4491 -0.6480 -1.8199 -0.0280 -0.0551 -0.1008 -0.0565 -0.3431 -0.0096 -0.5038 -0.8150 -0.2408 -0.1111
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality ; inpatient ; admissions ; hospital ; emergency department
H-1623	-0.6830453276634216	▁in patient ▁ad missions ▁; ▁hospital ▁days ▁; ▁emergency ▁department ▁; ED
D-1623	-0.6830453276634216	inpatient admissions ; hospital days ; emergency department ;ED
P-1623	-5.2507 -0.1163 -0.4924 -0.2092 -0.4097 -0.1628 -0.4811 -0.3255 -0.0796 -0.0374 -0.4582 -1.1557 -0.2548 -0.1293
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard ; tnf antagonist ; baseline ; covariates
H-606	-0.40054431557655334	▁n b DM ARD ▁; ▁t NF ▁anta gon ist
D-606	-0.40054431557655334	nbDMARD ; tNF antagonist
P-606	-0.0406 -0.0312 -0.2835 -0.9287 -0.2614 -2.2790 -0.2292 -0.1207 -0.0066 -0.1554 -0.3344 -0.1359
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab ; adjuvant ; outcomes ; cardiotoxicity ; congestive heart failure ; chf
H-670	-0.5670078992843628	▁tras tuz um ab ▁; ▁cardio toxic iteit ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-670	-0.5670078992843628	trastuzumab ; cardiotoxiciteit ; congestive heart failure ;CHf
P-670	-0.1213 -0.0453 -0.0190 -0.8051 -0.3172 -0.2564 -0.5602 -1.7653 -0.1911 -0.0347 -0.1624 -1.9752 -0.4163 -0.1680 -0.3300 -1.6502 -1.6130 -0.2489 -0.0933
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac ; sympathovagal balance
H-1138	-0.3210991621017456	▁py rido stig mine ▁; ▁met hy la tropi ne ▁; ▁propra no lol ▁; ▁cardiac ▁sympa t hova gal ▁balance
D-1138	-0.3210991621017456	pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
P-1138	-0.0097 -0.0288 -0.0088 -0.1463 -1.2665 -0.4500 -0.1683 -0.5576 -0.0069 -1.8628 -0.3067 -0.0256 -0.0150 -0.0942 -0.5257 -0.0510 -0.1042 -0.2901 -0.0833 -0.4129 -0.5555 -0.3194 -0.0959
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr ; protein kinase r-like er kinase ; perk ; calreticulin ; chop ; hf
H-1084	-0.4235363006591797	▁u PR ▁effect ors ▁; ▁protein ▁kina se ▁; ▁r - like ▁ER ▁kina se ▁; per k ▁; ▁cal ret icul in ▁; ▁CHO p ▁; ▁ HF ▁tissu es
D-1084	-0.4235363006591797	uPR effectors ; protein kinase ; r-like ER kinase ;perk ; calreticulin ; CHOp ; HF tissues
P-1084	-2.2506 -0.2916 -0.3220 -0.3489 -0.4609 -0.0789 -0.0141 -0.1786 -1.2897 -0.8794 -0.1491 -0.6691 -0.6797 -0.0103 -0.1269 -0.5920 -0.6442 -0.6296 -0.2224 -0.0035 -0.4038 -0.0031 -0.4977 -0.4187 -0.0743 -0.2767 -0.2899 -1.1330 -0.4937 -0.1506 -0.0690 -0.2354 -0.0894
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin ; protein-c ; phosphorylation ; troponin i ; phosphorylation ; hf
H-1427	-0.7749828696250916	▁my os in ▁ binding ▁; ▁protein - c ▁ phos phor y lation ▁; ▁ser 23 /24 ▁trop onin ▁I ▁ phos phor y lation ▁; ▁ HF
D-1427	-0.7749828696250916	myosin binding ; protein-c phosphorylation ; ser23/24 troponin I phosphorylation ; HF
P-1427	-1.4891 -0.0593 -0.9207 -0.5814 -0.0039 -0.8632 -0.2577 -0.1550 -0.9824 -0.3091 -0.0852 -2.4610 -2.2804 -0.1105 -0.3193 -1.0555 -0.3738 -0.0161 -0.0373 -0.0736 -2.6854 -0.1353 -0.0572 -2.6958 -2.5703 -0.1126 -0.3511 -2.1616 -0.5308 -0.1768 -0.1131
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory
H-1324	-0.5673641562461853	▁e cho car dio graphic ▁; ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s
D-1324	-0.5673641562461853	echocardiographic ; natriuretic peptide ; inflammatory markers
P-1324	-1.4044 -0.2371 -0.1442 -0.7295 -0.5581 -0.7642 -1.9515 -0.7029 -0.3594 -1.4912 -0.8737 -0.1488 -0.3961 -0.2895 -0.0615 -0.4482 -0.5925 -0.1341 -0.3080 -0.2132 -0.1066
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
H-1207	-0.5089513659477234	▁Pho s pho dies tera se -2 ▁; ▁fail ing ▁heart s ▁; ▁blu nts ▁beta - ad r energi c ▁response s ▁; ▁cardio my o cy tes
D-1207	-0.5089513659477234	Phosphodiesterase-2 ; failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
P-1207	-0.4128 -0.0970 -0.0915 -2.7607 -0.0375 -0.1048 -0.2212 -0.6839 -3.6942 -0.0757 -1.1691 -0.1199 -0.3998 -1.6229 -0.1548 -0.6718 -0.0355 -0.1525 -0.5530 -0.7215 -0.0951 -0.2268 -0.1868 -0.2902 -0.0269 -0.2699 -0.2558 -0.0421 -0.1386 -0.3367 -0.1287
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol ; thromboembolic events ; patients ; heart failure ; β2-receptor haplotype
H-1120	-0.46295255422592163	▁car vedi lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure ▁; ▁β 2- recept or ▁ha plo type
D-1120	-0.46295255422592163	carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype
P-1120	-0.0052 -0.0402 -0.1093 -0.6046 -0.4655 -0.7512 -1.1734 -0.5902 -0.2285 -0.4863 -1.0814 -0.3141 -1.3240 -0.1670 -0.3800 -0.0299 -0.0471 -0.0325 -0.0269 -0.0202 -0.0819 -0.0437 -3.0074 -0.1005
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref ; exercise ; resting hr ; bpm ; beta-blocker ; therapy
H-1946	-0.6135492324829102	▁h Fr EF ▁; ▁exercise ▁performance ▁; ▁rest ing ▁; ▁HR ▁; ▁beta - block er ▁ therapy
D-1946	-0.6135492324829102	hFrEF ; exercise performance ; resting ; HR ; beta-blocker therapy
P-1946	-2.1504 -1.6846 -1.6800 -0.3227 -0.6960 -0.2882 -0.2162 -1.2651 -0.0916 -1.5505 -0.5321 -0.5914 -0.1700 -0.0712 -0.1330 -0.0593 -0.2963 -0.0186 -0.3441 -0.1095
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline ; follow-up ; paf ; activity ; metabolic ; enzymes ; patients ; heart failure ; healthy
H-1266	-0.6275976896286011	▁pa f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure
D-1266	-0.6275976896286011	paf ; metabolic enzymes ; heart failure
P-1266	-1.6242 -2.3018 -0.4832 -0.0926 -0.0677 -0.0750 -0.1568 -0.4508 -0.9752 -0.1829 -0.9721 -0.1490
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo inhibition ; cardiomyocyte bioenergetics ; lv function ; chronic acf
H-472	-0.36029142141342163	▁ XO ▁inhibi tion ▁; ▁cardio my o cy te ▁bio ener ge tics ▁; ▁LV ▁function ▁; ▁chronic ▁a CF ▁; ▁rat
D-472	-0.36029142141342163	XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic aCF ; rat
P-472	-1.3811 -0.0274 -0.1068 -0.6775 -0.1981 -0.0233 -0.4650 -0.4390 -0.1138 -0.1494 -0.0138 -0.4124 -0.8266 -0.2566 -0.1642 -0.0395 -0.7307 -0.1203 -0.0227 -0.9315 -0.8734 -0.7271 -0.0201 -0.2038 -0.0832
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled trials ; rcts ; observational cohort studies ; contemporaneous control group
H-152	-1.464184284210205	RC t s
D-152	-1.464184284210205	RCts
P-152	-3.2626 -0.4846 -2.6501 -0.8158 -0.1078
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox hazard models ; esrd ; death ; composite end point ; esrd ; death ; esrd
H-391	-0.8314747214317322	▁co x ▁hazard ▁models ▁; ▁ES RD ▁; ▁to ▁death ▁; ▁ES RD ▁; ▁death ▁; ▁ES RD
D-391	-0.8314747214317322	cox hazard models ; ESRD ; to death ; ESRD ; death ; ESRD
P-391	-0.4091 -0.0148 -0.1402 -0.4045 -0.2120 -3.2720 -0.7883 -0.2930 -3.8999 -0.3842 -0.2622 -1.8204 -0.5682 -0.2613 -0.8639 -0.2225 -1.7362 -0.7345 -0.2549 -0.0876
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative ; renal dysfunction ; stroke ; myocardial infarction ; heart failure ; cabg
H-970	-0.2940434217453003	▁renal ▁dys function ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca BG
D-970	-0.2940434217453003	renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
P-970	-0.4793 -0.0450 -0.0715 -0.1570 -0.3971 -0.1501 -0.5350 -0.5562 -0.2526 -0.6230 -0.0353 -0.2327 -0.1484 -0.1637 -0.3190 -0.0827 -0.2247 -0.8416 -0.5765 -0.1899 -0.0936
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients ; heart failure ; hf ; cardiopulmonary exercise test ; anaerobic threshold
H-1753	-0.542701005935669	▁heart ▁failure ▁; HF ▁; ▁cardio pul mon ary ▁exercise ▁test ▁; ▁ana ero bic ▁thre s hold ▁; AT
D-1753	-0.542701005935669	heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
P-1753	-2.0819 -0.2674 -0.3197 -0.1462 -0.3552 -0.3884 -0.5127 -1.3183 -0.5285 -1.1688 -1.1735 -0.3356 -0.0487 -0.2673 -0.6469 -0.0856 -0.2006 -0.5899 -0.8786 -0.1565 -0.3577 -0.1113
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients ; heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortality
H-1896	-0.7828850746154785	▁heart ▁failure ▁; ▁heart ▁failure ▁nurse s ▁; ▁follow - up ▁; ▁card i ology ▁services
D-1896	-0.7828850746154785	heart failure ; heart failure nurses ; follow-up ; cardiology services
P-1896	-1.8672 -0.1714 -0.5444 -2.5228 -0.1145 -1.4128 -0.0574 -0.2834 -1.9537 -0.1115 -0.0208 -0.6338 -0.4929 -0.4246 -0.1874 -1.3144 -1.8550 -0.1240
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
H-1144	-0.38290929794311523	HF ▁rat s ▁; ▁py rido stig mine ▁; ▁stroke ▁volume ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁output ▁; ▁contract ility ▁; ▁left ▁vent ric le
D-1144	-0.38290929794311523	HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
P-1144	-2.5461 -1.7168 -0.0944 -0.5244 -0.0322 -0.0134 -0.0108 -0.3529 -0.1850 -1.2864 -0.6598 -0.1664 -0.0460 -0.1104 -0.0392 -0.2680 -0.0096 -0.1476 -0.0301 -0.0042 -0.1247 -0.0372 -0.2051 -0.2611 -0.1021 -0.0625 -1.1458 -0.9584 -0.2760 -0.0707
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac deaths ; atherosclerotic cad
H-1907	-0.5704707503318787	▁recrea tional ▁ath letes ▁; ▁sud den ▁cardiac ▁death s ▁; ▁male s ▁; ▁a ther os cle ro tic ▁CAD
D-1907	-0.5704707503318787	recreational athletes ; sudden cardiac deaths ; males ; atherosclerotic CAD
P-1907	-3.6016 -0.1878 -1.4238 -0.0415 -1.0230 -0.4545 -0.0191 -0.0198 -0.3869 -0.2970 -0.6661 -1.9443 -0.1234 -0.5528 -0.1339 -0.4220 -0.6007 -0.1618 -0.1408 -0.4738 -0.0629 -0.2558 -0.1275
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery ; rheumatic ; surgery ; mva
H-359	-0.7454293966293335	▁rhe u matic ▁; ▁MS
D-359	-0.7454293966293335	rheumatic ; MS
P-359	-1.6423 -0.1163 -0.0739 -0.1425 -0.8267 -2.3312 -0.0852
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health ; followed up ; hf ; hospitalization ; death ; contact
H-687	-0.992315948009491	▁women s ▁Health ▁Initiative ▁; ▁ HF ▁hospital ization
D-687	-0.992315948009491	womens Health Initiative ; HF hospitalization
P-687	-1.6259 -2.8622 -1.3834 -0.4116 -0.7660 -0.5117 -0.7457 -1.5916 -0.2948 -0.5985 -0.1241
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted ; left ventricle end-diastolic pressure
H-1340	-0.5919644236564636	▁CHF - develop ed ▁in far cted ▁animals ▁; ▁left ▁vent ric le ▁end - dia sto lic ▁pressure
D-1340	-0.5919644236564636	CHF-developed infarcted animals ; left ventricle end-diastolic pressure
P-1340	-0.7541 -0.3330 -0.0671 -0.0551 -0.0106 -0.0822 -1.7595 -0.6187 -0.6783 -0.3880 -0.0406 -0.8992 -0.4015 -2.4935 -0.1063 -0.0256 -0.2027 -0.1344 -0.5952 -2.7127 -0.0729
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv ; pathophysiologic ; rv dysfunction
H-1094	-0.6796201467514038	▁ RV ▁; ▁pat ho phy si ologic ▁mechanism s ▁; ▁ RV ▁dys function
D-1094	-0.6796201467514038	RV ; pathophysiologic mechanisms ; RV dysfunction
P-1094	-1.9024 -0.9554 -0.5556 -1.2309 -0.6603 -0.8629 -2.3431 -0.0728 -0.0715 -0.2797 -0.4524 -0.7924 -0.3112 -0.5506 -0.1508 -0.2301 -0.1315
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients ; hf ; crt ; implantation ; complications
H-912	-0.5222403407096863	▁di al ysis - dependent ▁patients ▁; ▁ HF ▁; ▁c RT ▁implant ation
D-912	-0.5222403407096863	dialysis-dependent patients ; HF ; cRT implantation
P-912	-0.8823 -0.0400 -0.0157 -0.1238 -0.0439 -0.6195 -0.7967 -1.2960 -0.3710 -0.3374 -0.6222 -2.0049 -0.2865 -0.6530 -0.1901 -0.0729
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak oxygen consumption ; pulse ; patients
H-1918	-0.4770541191101074	▁Peak ▁oxygen ▁consum p tion ▁; ▁oxygen ▁puls e
D-1918	-0.4770541191101074	Peak oxygen consumption ; oxygen pulse
P-1918	-0.2289 -0.9272 -0.4741 -0.1324 -1.4835 -0.3689 -0.9197 -0.0571 -0.2510 -0.3171 -0.0877
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic ; nhs ; chronic ; disease ; exercise ; acute ; hospital
H-613	-0.5426332950592041	▁economic ▁climate ▁; ▁NH s ▁; ▁behaviour al - change ▁; ▁chronic ▁disease ▁; ▁exercise ▁programme s
D-613	-0.5426332950592041	economic climate ; NHs ; behavioural-change ; chronic disease ; exercise programmes
P-613	-1.0128 -1.5190 -0.2271 -0.5514 -0.6140 -0.3494 -1.2535 -0.0658 -0.1632 -0.1240 -0.6773 -0.1581 -0.1479 -0.5940 -0.1805 -0.5093 -0.1901 -1.8558 -0.1167
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf ; patients ; hct ; city of hope
H-1452	-0.6288051009178162	▁post - h CT ▁CHF ▁; ▁h CT ▁; ▁City ▁of ▁Hope
D-1452	-0.6288051009178162	post-hCT CHF ; hCT ; City of Hope
P-1452	-1.8401 -0.0287 -0.7937 -0.6118 -0.2755 -0.4882 -1.1350 -0.4213 -0.5021 -0.9689 -0.1343 -1.3139 -0.2172 -0.0727
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.6506320238113403	
D-557	-0.6506320238113403	
P-557	-1.1549 -0.1464
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior vena cava ; ivc
H-321	-0.9489267468452454	▁pig s ▁; ▁ca va ▁; ▁i cc ▁; ▁snar ed ▁; ▁co
D-321	-0.9489267468452454	pigs ; cava ; icc ; snared ; co
P-321	-2.4852 -0.1566 -0.5890 -2.6042 -0.1055 -0.3110 -1.4464 -1.0005 -0.3722 -1.6599 -0.3850 -0.5930 -2.2395 -0.1920 -0.0939
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin ; resistin
H-932	-0.47050127387046814	▁do xor ubi cin ▁; ▁i p ▁; ▁se rum ▁resist in ▁levels ▁; ▁Hum - re t n ▁mi ce
D-932	-0.47050127387046814	doxorubicin ; ip ; serum resistin levels ; Hum-retn mice
P-932	-0.0373 -0.0496 -0.0389 -0.2544 -0.3981 -0.8921 -0.0197 -0.5216 -0.2312 -0.3187 -0.1205 -0.4532 -0.9554 -0.4183 -0.0859 -0.1234 -3.4055 -0.8339 -0.0358 -0.6499 -0.4759 -0.3574 -0.1448
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs ; physicians ; hospital
H-1729	-0.8890631198883057	▁kosten ▁; ▁high - volu me ▁physician s
D-1729	-0.8890631198883057	kosten ; high-volume physicians
P-1729	-2.2699 -1.6998 -2.6120 -0.0832 -0.0472 -0.0889 -0.2383 -0.1705 -1.5888 -0.0920
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf ; proteins
H-1361	-1.0016385316848755	▁CHF ▁; ▁car bo hydrat es
D-1361	-1.0016385316848755	CHF ; carbohydrates
P-1361	-0.7859 -0.7391 -2.3738 -0.1149 -0.2171 -0.2007 -3.4907 -0.0908
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.2879188060760498	▁de activa tion
D-1864	-0.2879188060760498	deactivation
P-1864	-0.2739 -0.1423 -0.4215 -0.5215 -0.0805
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone receptor antagonists ; randomized ; morbidity ; mortality ; symptomatic systolic heart failure
H-438	-0.3760087490081787	▁al do ster one ▁receptor ▁anta gon ists ▁; ▁morbi d iteit ▁; ▁mortal ity ▁; ▁sy sto lic ▁heart ▁failure
D-438	-0.3760087490081787	aldosterone receptor antagonists ; morbiditeit ; mortality ; systolic heart failure
P-438	-0.2909 -0.1504 -0.0898 -0.4360 -0.0106 -0.1008 -0.0123 -0.9310 -0.6794 -0.4759 -0.0554 -1.7140 -0.3807 -0.0456 -1.2764 -0.3209 -0.1701 -0.0639 -0.1717 -0.6940 -0.2080 -0.2885 -0.0818
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a ; upr ; downregulation ; cardiac ; genes ; hf
H-1089	-0.568175733089447	▁s cn 5 a ▁tran script ▁; ▁u PR ▁; ▁cardiac ▁gene s ▁; ▁ HF
D-1089	-0.568175733089447	scn5a transcript ; uPR ; cardiac genes ; HF
P-1089	-0.7485 -0.2186 -0.2706 -0.1872 -0.2584 -0.0574 -0.2107 -2.5757 -0.7519 -0.4300 -1.0946 -0.4453 -0.1656 -0.2324 -1.2412 -1.0053 -0.2128 -0.1210
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east ; rhythm control therapy ; diagnosis ; cardiovascular ; complications
H-1655	-0.30663782358169556	▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1655	-0.30663782358169556	east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
P-1655	-0.7250 -0.5719 -0.4313 -0.1146 -0.3038 -0.2276 -0.2447 -0.0208 -0.3514 -0.3475 -0.3626 -0.0466 -0.0054 -0.2597 -0.8004 -0.4076 -0.1814 -0.1171
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin ; inflammation ; hepatic ; prognosis ; patients ; lvad ; implantation
H-540	-0.3850410282611847	▁album in ▁levels ▁; ▁nutrition ▁; ▁ inflammation ▁; ▁he pati c ▁function ▁; ▁l VAD ▁implant ation
D-540	-0.3850410282611847	albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD implantation
P-540	-0.3669 -0.5490 -1.4244 -0.4108 -1.5681 -0.2043 -0.1191 -0.0654 -0.3481 -0.0238 -0.1253 -0.2477 -0.0867 -0.3762 -0.5530 -0.0223 -0.4207 -0.4196 -0.2569 -0.1124
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right ventricular ; rv ; left ventricular assist device ; lvad ; outcomes
H-294	-0.6287108063697815	▁Right ▁vent ri cular ▁; RV ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-294	-0.6287108063697815	Right ventricular ;RV ; left ventricular assist device ; lVAD
P-294	-1.0483 -0.0605 -2.0102 -0.1765 -0.6321 -0.8483 -0.6074 -1.4191 -0.0707 -2.5997 -0.2262 -0.5706 -0.2582 -0.3569 -0.0416 -0.0154 -0.2737 -0.1014
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse ; pasp ; downward ; regression line ; shift ; pasp ; tapse
H-496	-1.4169830083847046	▁pas p ▁; ▁pas p
D-496	-1.4169830083847046	pasp ; pasp
P-496	-3.1864 -1.3297 -0.5790 -1.8145 -0.6101 -2.2852 -0.1139
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox proportional hazards models ; health ; health ; hazard ratios ; confidence intervals
H-689	-0.5832223892211914	▁co x ▁proportion al ▁hazard s
D-689	-0.5832223892211914	cox proportional hazards
P-689	-0.0536 -0.0641 -0.0647 -0.0207 -0.1515 -0.5073 -3.7205 -0.0833
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis ; expenditure ; b natriuretic peptides ; nps
H-10	-0.46277955174446106	▁li poly sis ▁; ▁energie ▁ex pendi ture ▁; ▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁CC
D-10	-0.46277955174446106	lipolysis ; energie expenditure ; natriuretic peptides ;NPs ; CC
P-10	-0.3394 -0.0679 -0.3752 -0.2556 -1.4511 -0.1165 -0.1435 -1.9228 -0.4964 -0.1129 -0.6302 -0.4428 -1.7982 -0.3242 -0.1445 -0.1561 -0.2970 -0.0495 -0.0472 -0.3916 -0.8296 -0.1445 -0.1070
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths ; stroke ; hospitalisations ; heart failure ; follow-up
H-816	-0.7155081629753113	▁non - fa tal ▁stroke ▁; ▁hospital isation s ▁; ▁heart ▁failure
D-816	-0.7155081629753113	non-fatal stroke ; hospitalisations ; heart failure
P-816	-3.5119 -0.0941 -0.3026 -0.3487 -0.6888 -0.4173 -2.2186 -0.0702 -0.1232 -1.1843 -0.6235 -0.1274 -0.1948 -0.1117
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts ; mena ; cardiac injury ; mena ; hf ; pathophysiology
H-1817	-0.5575396418571472	▁heart s ▁; ▁men a ▁; ▁cardiac ▁injury ▁; ▁men a ▁; ▁ HF ▁pat ho phy si ology
D-1817	-0.5575396418571472	hearts ; mena ; cardiac injury ; mena ; HF pathophysiology
P-1817	-1.9461 -0.1504 -0.5179 -0.8925 -0.1466 -0.5536 -0.3939 -0.1709 -0.1924 -0.8340 -0.1331 -0.2058 -0.5867 -0.3266 -0.7594 -0.4579 -0.3834 -2.3399 -0.2890 -0.3451 -0.0831
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic ; biomarkers ; molecular dysfunction ; chronic hf
H-1477	-0.2046167403459549	▁bio mark ers ▁; ▁molecular ▁dys function ▁; ▁chronic ▁ HF
D-1477	-0.2046167403459549	biomarkers ; molecular dysfunction ; chronic HF
P-1477	-0.2592 -0.1992 -0.2181 -0.4457 -0.1002 -0.0115 -0.0501 -0.2367 -0.0654 -0.4088 -0.3342 -0.2320 -0.0987
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 ; c statistic ; net reclassification improvement ; integrated discrimination improvement
H-705	-0.6710485219955444	▁ST 2 ▁; ▁re class ification ▁; ▁risk ▁; ▁c ▁statistic ▁; ▁net ▁re class ification ▁; ▁discrimina tion
D-705	-0.6710485219955444	ST2 ; reclassification ; risk ; c statistic ; net reclassification ; discrimination
P-705	-1.2231 -0.0649 -0.4062 -2.7340 -0.2012 -0.4678 -1.1356 -1.1701 -0.2787 -0.5844 -0.3808 -0.2882 -0.9550 -0.1312 -0.2937 -0.5318 -0.6181 -0.2236 -1.3022 -0.9907 -0.1109
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome ; gls ; beat ; cox proportional hazards analyses
H-814	-0.4474261999130249	▁g ls ▁; ▁index ▁beat ▁method ▁; ▁CV ▁events ▁; ▁co x ▁proportion al ▁hazard s ▁analyse s
D-814	-0.4474261999130249	gls ; index beat method ; CV events ; cox proportional hazards analyses
P-814	-1.6209 -1.6867 -0.2501 -0.0153 -0.0100 -0.6177 -0.3369 -0.5262 -1.0882 -0.5892 -0.0882 -0.0564 -0.0555 -0.0121 -0.0487 -0.4904 -0.8320 -0.3180 -0.2299 -0.0762
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ; ischemic heart failure ; biomarkers ; heart failure
H-1615	-0.515214741230011	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1615	-0.515214741230011	non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
P-1615	-1.7063 -0.0763 -0.0666 -0.2105 -1.4163 -0.1874 -0.0426 -0.3961 -2.1703 -0.1551 -0.3804 -0.1412 -0.1032 -0.2361 -0.3691 -1.6512 -0.1268 -0.2261 -0.1275
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients ; vad ; patients ; ecmo ; vad ; patients ; ecmo
H-1389	-1.3043041229248047	▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁ec mo ▁group
D-1389	-1.3043041229248047	VAD group ; ecmo+VAD group ; ecmo group
P-1389	-1.4896 -0.1148 -3.0444 -0.2838 -0.6309 -2.1358 -2.8125 -0.0807 -1.6520 -0.4297 -1.1522 -1.6057 -3.5754 -0.4055 -0.1516
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air ; cardiovascular ; health ; acute myocardial infarction
H-1806	-0.5729218125343323	▁Ambient ▁air ▁pollution ▁; ▁cardiovascular ▁health ▁; ▁a cute ▁my o card ial ▁in far ction
D-1806	-0.5729218125343323	Ambient air pollution ; cardiovascular health ; acute myocardial infarction
P-1806	-0.0471 -0.1126 -0.2771 -0.2861 -0.7706 -1.4871 -0.3477 -1.9481 -0.0281 -1.7714 -0.7285 -0.3331 -0.6985 -0.0714 -0.4043 -0.5588 -0.3230 -0.1192
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq ; kaplan-meier curves ; death ; all-cause hospitalization
H-784	-0.7264312505722046	▁ cc q ▁; ▁ka plan - me ier ▁cur ves ▁; ▁death ▁; ▁hospital ization
D-784	-0.7264312505722046	ccq ; kaplan-meier curves ; death ; hospitalization
P-784	-2.0481 -0.2356 -1.5352 -0.8922 -0.2942 -0.0214 -0.0470 -0.6197 -0.0849 -0.2150 -2.3800 -0.9683 -0.7962 -1.1610 -0.4385 -1.0328 -0.1598 -0.1459
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ; ras ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
H-1599	-0.3371259868144989	▁ RAS ▁; ▁do pp ler ▁ultra son ography ▁; ▁com put ed ▁to mo graphic ▁ang i ography ▁; ▁magnetic ▁res on ance ▁ang i ography
D-1599	-0.3371259868144989	RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
P-1599	-2.3173 -0.0216 -0.4835 -0.3530 -0.0283 -1.0922 -0.0548 -0.0371 -0.3854 -0.2893 -0.0432 -0.0106 -0.1294 -0.0398 -0.2754 -0.3306 -0.6610 -0.4828 -0.1710 -0.3422 -0.0858 -0.1530 -0.1196 -0.2432 -0.4503 -0.5463 -0.1314 -0.3877 -0.1108
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone ; double-blind ; randomized
H-1316	-0.8828117847442627	▁Test o ster one ▁ therapy ▁; ▁exercise ▁rehabilita tion ▁; ▁chronic ▁heart ▁failure ▁; ▁testosteron e ▁status
D-1316	-0.8828117847442627	Testosterone therapy ; exercise rehabilitation ; chronic heart failure ; testosterone status
P-1316	-3.5474 -0.5885 -0.0725 -0.6307 -1.4245 -0.0630 -1.2695 -1.0181 -0.0650 -0.9144 -0.6738 -4.1806 -0.9391 -0.1800 -0.5514 -1.0161 -0.0525 -0.0984 -0.2604 -0.1103
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic ; renal underperfusion ; renin- angiotensin-aldosterone pathway
H-1596	-0.5294661521911621	▁pat ho phy si ologic ▁mechanism ▁; ▁renal ▁under per fusion ▁; ▁re nin - ▁ang io ten sin - al do ster one
D-1596	-0.5294661521911621	pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone
P-1596	-1.6015 -0.7172 -0.9196 -1.9739 -0.0866 -0.0746 -0.5809 -0.0481 -1.1491 -0.1892 -0.1015 -0.4238 -0.0489 -0.1984 -0.0353 -0.7513 -0.4411 -0.0603 -0.5532 -0.1861 -0.0287 -0.1584 -0.0201 -0.3508 -2.9182 -0.1494
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ; ami ; complications ; heart failure ; kidney infection ; uti ; complications ; rehospitalization
H-1718	-0.5638335943222046	AMI ▁; ▁heart ▁failure ▁; ▁ki dne y ▁infection ▁; UTI
D-1718	-0.5638335943222046	AMI ; heart failure ; kidney infection ;UTI
P-1718	-1.3707 -0.9265 -2.0501 -0.1349 -0.2776 -0.0607 -0.2550 -0.0860 -0.2141 -0.1536 -1.3911 -0.2966 -0.1129
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
H-869	-0.2774408459663391	▁prote o mics ▁; ▁path way ▁analysis ▁; ▁pressure - over load - indu ced ▁heart ▁failure ▁; ▁mito cho ndri al - tar get ed ▁pe pti des
D-869	-0.2774408459663391	proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
P-869	-0.7592 -1.1885 -0.0065 -0.2581 -0.8548 -0.0560 -0.1871 -0.9104 -0.1137 -0.0810 -0.0203 -0.0992 -0.2144 -0.1014 -0.1637 -1.1312 -0.1322 -0.3711 -0.0393 -0.3913 -0.2969 -0.0270 -0.0811 -0.1545 -0.1053 -0.0550 -0.2525 -0.0602 -0.1777 -0.2186 -0.0922
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil ; cardioprotection ; apoptotic signaling pathway ; dna fragmentation ; mitochondrial
H-965	-0.2936496436595917	▁nic oran dil ▁; ▁cardio protec tion ▁; ▁apo pto tic ▁signal ing ▁path way ▁; ▁DNA ▁fragment ation ▁; ▁mito cho ndri al ▁ultra struct ural
D-965	-0.2936496436595917	nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural
P-965	-0.0407 -0.0340 -0.3082 -0.3234 -0.2515 -0.2770 -0.7721 -0.3943 -0.0773 -0.0748 -1.0319 -0.0630 -0.3453 -0.2612 -0.2296 -0.4728 -0.0539 -0.0775 -0.3718 -0.3140 -0.0020 -0.5835 -0.1396 -0.0181 -0.2523 -0.1399 -0.0430 -1.4692 -0.0937
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ; ic ; multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy
H-103	-0.28728294372558594	▁IC ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁tri al - Card iac ▁re syn chron ization ▁Therapy
D-103	-0.28728294372558594	IC ; multicenter Automatic Defibrillator Implantation trial-Cardiac resynchronization Therapy
P-103	-1.0066 -0.4454 -0.3390 -0.0315 -0.3862 -0.0211 -0.4897 -0.0518 -0.5452 -0.0390 -0.2112 -0.2850 -0.7736 -0.0370 -0.0407 -0.4726 -0.0963 -0.3651 -0.0381 -0.0074 -0.6879 -0.1796 -0.2521 -0.0928
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted county ; minnesota ; mi ; diagnosed ; hf ; followed-up
H-1102	-0.3374783396720886	▁Ol m sted ▁County ▁; ▁Minnesota ▁; ▁MI ▁diagnose d ▁; ▁ HF
D-1102	-0.3374783396720886	Olmsted County ; Minnesota ; MI diagnosed ; HF
P-1102	-1.8464 -0.0966 -0.0590 -0.0724 -0.5898 -0.0498 -0.2800 -0.3260 -0.3127 -0.0179 -0.2200 -0.4001 -0.6278 -0.1031 -0.0605
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health buddy program ; admissions ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
H-1627	-0.5214134454727173	▁Health ▁Budd y ▁Program ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁mortal ity ▁; ▁con ges tive ▁heart ▁failure
D-1627	-0.5214134454727173	Health Buddy Program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
P-1627	-1.1707 -0.0739 -0.0366 -0.8179 -0.5686 -0.2714 -0.8665 -0.2977 -0.7802 -0.0172 -0.1535 -0.4253 -0.2461 -0.2046 -1.6313 -0.2389 -0.1686 -0.2767 -2.1349 -0.8225 -0.3568 -0.3399 -0.0929
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected ; clinical ; death ; medical ; hospitalization ; hf ; clinic ; outpatients
H-379	-1.3818614482879639	▁ HF
D-379	-1.3818614482879639	HF
P-379	-3.9056 -0.6907 -0.7567 -0.1744
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence ; adjusted odds ratio ; hazard ratio ; death ; hf ; ami ; admission ; discharge
H-1308	-0.8919346928596497	▁odds ▁ratio ▁; haz ard ▁ratio ▁; ▁death ▁; HF ▁; ▁ AMI ▁ad mission
D-1308	-0.8919346928596497	odds ratio ;hazard ratio ; death ;HF ; AMI admission
P-1308	-1.9268 -0.0386 -1.8643 -0.0234 -0.0065 -0.0071 -0.5194 -1.2607 -0.3761 -2.0893 -0.4233 -1.8725 -1.1822 -1.1945 -0.9114 -1.3479 -0.1187
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration ; neurohumoral blockers ; hf ; hospitalization ; patients ; co-morbidity
H-184	-0.5804883241653442	▁neuro hu moral ▁block ers ▁; ▁ HF ▁hospital ization ▁; ▁co - mor bid ity ▁burde n
D-184	-0.5804883241653442	neurohumoral blockers ; HF hospitalization ; co-morbidity burden
P-184	-0.1984 -0.0136 -0.7331 -0.5556 -0.3514 -0.4463 -0.8531 -0.1796 -2.0328 -0.7621 -1.2798 -1.4825 -0.0626 -0.1659 -0.5211 -1.2305 -0.2282 -0.1845 -0.2328 -0.0958
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left ventricular ejection fraction ; mortality ; patients ; heart failure ; heart failure survey ; israel
H-110	-0.7936152815818787	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁is ra el
D-110	-0.7936152815818787	left ventricular ejection fraction ; heart failure ; Heart Failure Survey ; israel
P-110	-1.7231 -0.1009 -2.3830 -0.7567 -0.2438 -0.1916 -0.1619 -1.3877 -0.0503 -0.5408 -4.2298 -0.2659 -0.4109 -0.5961 -0.4225 -1.6817 -0.4958 -0.6362 -1.2482 -0.1061 -0.0132 -0.4460 -0.1607
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular endothelial growth factor ; vegf ; transition ; compensatory hypertrophy ; cardiac failure
H-450	-0.5280982851982117	▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ve GF ▁; ▁compensa tory ▁hyper trop hy ▁; ▁cardiac ▁failure
D-450	-0.5280982851982117	vascular endothelial growth factor ;veGF ; compensatory hypertrophy ; cardiac failure
P-450	-2.8418 -0.3243 -0.0087 -1.3239 -0.0827 -0.0106 -0.3021 -0.1932 -0.8876 -1.6615 -0.4749 -0.8025 -0.1126 -0.0846 -0.1200 -0.0149 -1.3286 -0.5801 -0.0064 -0.2327 -0.1610 -0.0635
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective ; patients ; rule ; sensitivity ; specificity ; cad ; sensitivity ; cad
H-1192	-0.832485020160675	▁CAD ▁; ▁CAD
D-1192	-0.832485020160675	CAD ; CAD
P-1192	-0.4112 -0.9969 -1.6028 -1.0304 -0.1210
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia ; postoperative ; mortality ; patients ; left ventricular assist device ; lvad ; implantation
H-530	-0.36384284496307373	▁hypo album in emia ▁; ▁post operativ e ▁mortal ity ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-530	-0.36384284496307373	hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
P-530	-0.0447 -0.0901 -0.3534 -0.2925 -0.3684 -0.0529 -0.0984 -0.1825 -0.0487 -1.5073 -0.3829 -0.1768 -0.0436 -2.5618 -0.2091 -0.3425 -0.1560 -0.4155 -0.0537 -0.0082 -0.5017 -0.1139
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis ; pathogenesis ; heart failure
H-173	-0.8027217984199524	▁apo pto sis ▁; ▁heart ▁failure
D-173	-0.8027217984199524	apoptosis ; heart failure
P-173	-0.7941 -0.3425 -1.0191 -0.4312 -3.1793 -0.1056 -0.4477 -0.1022
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients ; terminal ; diagnostic ; follow-up
H-1819	-1.161125898361206	▁diagnose ▁; ▁alternatieve ▁treatment s
D-1819	-1.161125898361206	diagnose ; alternatieve treatments
P-1819	-2.5559 -1.4993 -2.1830 -1.0670 -0.4131 -0.2773 -0.1323
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic ; neurohormonal ; symptoms ; fluid overload
H-1201	-0.6077401041984558	▁di ure tic ▁ef fica cy ▁; ▁neuro hormon al ▁activa tion
D-1201	-0.6077401041984558	diuretic efficacy ; neurohormonal activation
P-1201	-0.6495 -0.4280 -1.3026 -0.8912 -0.3263 -0.2231 -0.5892 -0.0509 -0.0492 -0.0605 -0.0182 -0.5129 -3.3312 -0.0756
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr ; mrna splice ; cardiac ; hf
H-1088	-0.5917680263519287	▁u PR ▁; ▁na + ▁channel ▁m RNA ▁sp lice ▁; ▁cardiac ▁; ▁na + ▁current ▁; ▁human ▁ HF
D-1088	-0.5917680263519287	uPR ; na+ channel mRNA splice ; cardiac ; na+ current ; human HF
P-1088	-3.1491 -1.8500 -0.4561 -0.1866 -1.1227 -0.0262 -0.0148 -0.1517 -0.0111 -0.3632 -0.5299 -0.1590 -1.6175 -0.1775 -0.7330 -0.0157 -0.2357 -1.1391 -0.3622 -0.3838 -0.2409 -0.0932
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients ; preserved lvef ; lvef
H-114	-0.2749395966529846	▁LV EF ▁; ▁LV EF
D-114	-0.2749395966529846	LVEF ; LVEF
P-114	-0.1818 -0.3963 -0.4807 -0.1262 -0.4184 -0.2099 -0.1113
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence ; lvad ; transplantation ; patients ; budget
H-316	-0.6512579321861267	▁l VAD ▁; ▁transplant ation ▁; ▁budget
D-316	-0.6512579321861267	lVAD ; transplantation ; budget
P-316	-0.2568 -0.0854 -0.7952 -0.2112 -0.7468 -3.1320 -0.2213 -0.3197 -0.0931
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets ; transcriptional pause release ; pathological
H-1052	-0.4387386441230774	▁bet s ▁; ▁tran scription al ▁pause ▁release ▁; ▁tran scription ▁; ▁path ological ▁stress
D-1052	-0.4387386441230774	bets ; transcriptional pause release ; transcription ; pathological stress
P-1052	-1.9550 -0.4455 -0.6819 -0.0961 -0.1433 -0.2097 -0.1480 -0.1107 -0.2982 -0.3051 -0.0594 -1.6885 -0.1251 -0.5709 -0.2702 -0.2382 -0.1128
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg ; atherosclerotic cad ; cardiac death
H-1910	-0.40106505155563354	▁e CG ▁; ▁a ther os cle ro tic ▁CAD ▁; ▁sud den ▁cardiac ▁death
D-1910	-0.40106505155563354	eCG ; atherosclerotic CAD ; sudden cardiac death
P-1910	-0.4678 -0.8385 -0.3844 -1.4333 -0.5809 -0.4152 -0.2335 -0.1074 -0.3654 -0.1028 -0.4542 -0.6303 -0.0303 -0.0083 -0.3871 -0.2456 -0.1333
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ; ami ; hazard ratio ; mortality
H-1313	-0.7859532237052917	▁ HF ▁; ▁index ▁ AMI ▁; ▁hazard ▁ratio
D-1313	-0.7859532237052917	HF ; index AMI ; hazard ratio
P-1313	-1.9246 -0.9862 -0.4346 -0.0438 -1.2025 -0.1480 -0.8765 -1.2466 -0.0353 -1.6268 -0.1207
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d ; therapy
H-107	-0.60784912109375	▁c RT - d ▁; ▁IE ▁; ▁de fi br illa tor - on ly ▁ therapy ▁; HR
D-107	-0.60784912109375	cRT-d ; IE ; defibrillator-only therapy ;HR
P-107	-0.2657 -3.4046 -0.0884 -0.6535 -0.5523 -1.4778 -1.0024 -0.1629 -0.0528 -0.1917 -0.2278 -0.0490 -0.2030 -0.2946 -1.2277 -0.1609 -0.1068 -1.5990 -0.7215 -0.1941 -0.1282
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr variability ; risk stratification
H-1587	-0.803047776222229	▁HR ▁dynamic s ▁; ▁HR ▁variabil iteit ▁; ▁risk ▁strat ification
D-1587	-0.803047776222229	HR dynamics ; HR variabiliteit ; risk stratification
P-1587	-0.5649 -0.2766 -0.1771 -0.3216 -2.8473 -0.8679 -2.3754 -0.6823 -0.7291 -0.4734 -0.7539 -0.2336 -0.1365
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary exercise testing ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
H-1174	-0.5085452198982239	▁cardio pul mon ary ▁exercise ▁; ▁e cho car dio graphic ▁assessment ▁; ▁my o card ial ▁function ▁; ▁left ▁vent ri cular ▁fill ing
D-1174	-0.5085452198982239	cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling
P-1174	-2.4593 -0.3982 -1.3969 -0.3188 -0.6755 -0.4112 -0.0503 -0.0523 -0.0403 -0.4344 -0.5459 -0.6806 -0.4019 -0.5106 -0.1856 -0.4469 -0.8916 -0.4293 -0.2173 -0.1862 -0.0301 -1.4101 -0.2123 -0.6258 -0.0781 -0.5723 -0.0690
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle tracking echocardiography ; ste ; bivp ; acute ; right ventricular pressure overload ; rvpo
H-320	-0.4982351064682007	▁spec kle ▁track ing ▁e cho card i ography ▁; ▁ste ▁; ▁Bi VP ▁; ▁right ▁vent ri cular ▁pressure ▁over load ▁; RV PO
D-320	-0.4982351064682007	speckle tracking echocardiography ; ste ; BiVP ; right ventricular pressure overload ;RVPO
P-320	-0.0460 -0.8089 -0.0138 -0.0826 -0.4463 -0.0685 -0.1407 -0.7782 -0.1643 -0.4453 -1.2345 -1.8622 -0.7976 -0.1106 -0.4696 -1.3884 -0.0525 -1.2959 -0.3805 -0.1359 -0.1677 -0.0508 -0.3279 -0.8579 -0.8679 -0.3699 -0.0881
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary endpoints ; therapy ; atrial fibrillation ; atrial tachyarrhythmias ; atp ; shock therapy
H-860	-0.33838918805122375	▁at rial ▁fi bril lation ▁; ▁at rial ▁ta chy ar rhythm ias ▁; ▁ATP ▁; ▁shock ▁ therapy
D-860	-0.33838918805122375	atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
P-860	-2.4364 -0.0221 -0.2022 -0.0222 -0.0665 -0.3300 -0.2554 -0.0512 -0.2045 -0.4878 -0.0234 -0.0911 -1.3181 -0.3780 -0.0857 -0.2463 -0.0103 -0.4176 -0.0221 -0.3228 -0.1123
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous ; coronary revascularization ; hemodynamically ; stable ; patient ; intensive care unit ; icu
H-1293	-0.607536256313324	▁per cuta ne ous ▁corona ry ▁re vas cular ization ▁; ▁hem o dynamic ally
D-1293	-0.607536256313324	percutaneous coronary revascularization ; hemodynamically
P-1293	-0.3019 -0.0028 -0.8464 -1.0799 -0.0897 -2.1844 -0.0511 -0.2861 -0.5191 -0.9493 -0.6671 -0.5105 -0.1602 -0.0089 -0.7969 -1.8037 -0.0703
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity ; diabetes mellitus ; metabolic ; comorbidities ; heart failure with preserved ejection fraction
H-760	-0.588960587978363	▁diabetes ▁mell itus ▁; ▁metabol ic ▁risk ▁factors ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-760	-0.588960587978363	diabetes mellitus ; metabolic risk factors ; heart failure ; preserved ejection fraction
P-760	-4.9969 -0.0207 -0.0716 -0.5425 -0.2706 -0.0512 -0.6730 -0.4742 -0.2568 -2.5368 -0.1260 -0.4231 -0.6656 -0.0678 -0.6386 -0.0253 -0.1003 -0.0654 -0.4018 -0.0230 -0.3670 -0.1589
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef ; bnp ; hf ; patients ; prognostic ; significance ; bnp ; ef
H-188	-0.8146547079086304	▁sex ▁; ▁EF ▁; ▁b NP ▁; ▁ HF ▁; ▁b NP ▁; ▁sex ▁; ▁EF
D-188	-0.8146547079086304	sex ; EF ; bNP ; HF ; bNP ; sex ; EF
P-188	-1.3838 -0.1403 -0.4089 -0.1643 -0.8344 -0.8898 -0.1704 -1.7131 -0.4459 -0.5629 -1.8470 -0.7130 -0.2167 -3.8420 -0.1985 -0.8191 -0.1896 -0.1241
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk ; scn5a ; kv4.3 ; mrna ; mrna splice
H-1087	-0.49373334646224976	▁per k ▁inhibi tion ▁; ▁s cn 5 a ▁; ▁kv 4.3 ▁m RNA ▁levels ▁; ▁na + ▁channel ▁m RNA ▁sp lice
D-1087	-0.49373334646224976	perk inhibition ; scn5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
P-1087	-1.9113 -0.9063 -0.2580 -0.4411 -0.4292 -1.0532 -0.3338 -0.9344 -0.2183 -0.3718 -0.9273 -0.1753 -0.0095 -0.0915 -0.6667 -0.4585 -0.0917 -0.9096 -0.0227 -0.0131 -0.1525 -0.0637 -0.4663 -1.3495 -0.0882
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential effect ; lvef ; mortality ; hospitalization ; acute ; decompensated hf
H-112	-0.5450490713119507	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁hospital ization ▁; ▁a cute ▁de com pensa ted ▁ HF
D-112	-0.5450490713119507	LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
P-112	-0.3378 -0.8584 -0.8880 -3.8916 -0.1092 -0.1381 -0.0883 -1.7305 -0.7047 -0.3479 -0.4823 -0.6348 -0.2835 -0.0360 -0.0217 -0.1144 -0.0745 -0.2990 -0.3043 -0.3142 -0.2193 -0.1125
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated ; mena expression ; correlates ; hf ; mena ; cardiac ; pathophysiology
H-1812	-0.6674996018409729	▁Men a ▁expression ▁; ▁ HF ▁; ▁men a ▁; ▁cardiac ▁pat ho phy si ology
D-1812	-0.6674996018409729	Mena expression ; HF ; mena ; cardiac pathophysiology
P-1812	-1.4444 -0.0543 -0.0890 -0.2130 -1.0508 -1.0075 -0.2467 -2.3323 -0.0862 -0.4793 -0.0829 -0.4295 -0.8672 -0.3663 -2.6843 -0.2298 -0.2455 -0.1061
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt loading ; uninephrectomy ; ang ii infusion ; cardiac function ; hf
H-282	-0.4247221052646637	▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion ▁mouse ▁model ▁; ▁cardiac ▁function ▁; ▁mi ce ▁; ▁ HF
D-282	-0.4247221052646637	salt loading ; uninephrectomy ; ANG II infusion mouse model ; cardiac function ; mice ; HF
P-282	-0.0402 -0.0375 -0.0438 -0.1377 -0.0069 -1.1621 -0.8383 -0.1229 -0.0579 -1.4567 -0.1723 -0.2298 -0.3717 -0.0036 -0.0074 -1.4253 -0.9800 -0.1405 -0.0188 -0.1235 -0.3171 -1.7684 -0.1120 -0.4538 -1.3317 -0.3309 -0.1366 -0.0650
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination ; echocardiographic ; lv reverse remodeling ; sensitivity ; specificity
H-433	-0.2588493227958679	▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing
D-433	-0.2588493227958679	echocardiographic score ; LV reverse remodeling
P-433	-0.0903 -0.1440 -0.1071 -0.4883 -0.8754 -0.5618 -0.2767 -0.0247 -0.4655 -0.0455 -0.0441 -0.0853 -0.3082 -0.1070
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients ; atrial fibrillation ; heart failure ; hf ; stroke ; anticoagulation ; patients
H-1353	-0.3361837565898895	▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; HF ▁; ▁stroke ▁; ▁antico ag ulation
D-1353	-0.3361837565898895	atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
P-1353	-1.3433 -0.0391 -0.4534 -0.0256 -0.1267 -0.5925 -0.8864 -0.3153 -0.5004 -0.1425 -0.2433 -0.1644 -0.2401 -0.5377 -0.2912 -0.2241 -0.0725 -0.1184 -0.3065 -0.1003
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration ; hr reduction ; bpm ; p value
H-1942	-1.401387095451355	▁HR ▁re duction
D-1942	-1.401387095451355	HR reduction
P-1942	-4.3394 -1.6544 -0.1485 -0.7036 -0.1611
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck stent ; myocardial infarction ; antiplatelet medication
H-508	-0.22767172753810883	▁bottle ne ck ▁sten t ▁; ▁my o card ial ▁in far ction ▁; ▁anti plate let ▁medication
D-508	-0.22767172753810883	bottleneck stent ; myocardial infarction ; antiplatelet medication
P-508	-0.2781 -0.1486 -0.0244 -0.0323 -0.1084 -0.2975 -0.6239 -0.3012 -0.3528 -0.6794 -0.0286 -0.2373 -0.0610 -0.4765 -0.0081 -0.0592 -0.1472 -0.2870 -0.2969 -0.1050
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv fractional shortening ; lung ; incidence
H-278	-0.9071611762046814	ANS ▁mi ce ▁; ▁LV ▁; ▁lung ▁weight
D-278	-0.9071611762046814	ANS mice ; LV ; lung weight
P-278	-2.8318 -2.1456 -0.4719 -0.4705 -0.4834 -0.4005 -1.6255 -0.3004 -0.2421 -0.0998
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan failure ; circulatory ; hemodynamic ; portal hypertension ; cardiac output
H-234	-0.23985536396503448	▁Font an ▁failure ▁; ▁circula tory ▁de rang ement ▁; ▁hem o dynamic ▁; ▁portal ▁hyper tension ▁; ▁cardiac ▁output
D-234	-0.23985536396503448	Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
P-234	-0.2198 -0.0487 -0.1591 -0.3028 -0.0060 -0.1809 -0.1562 -0.0265 -1.3758 -0.5898 -0.2277 -0.3714 -0.0039 -0.6935 -0.0200 -0.0787 -0.0143 -0.3234 -0.1377 -0.0098 -0.2581 -0.0726
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab ; chf ; nontrastuzumab users ; hazard ratio
H-679	-0.4800722002983093	▁Tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab ▁users ▁; haz ard ▁ratio ▁; HR
D-679	-0.4800722002983093	Trastuzumab ; CHF ; nontrastuzumab users ;hazard ratio ;HR
P-679	-1.0389 -0.2987 -0.0971 -0.5392 -0.6957 -0.1546 -0.3634 -0.5333 -0.2070 -0.2099 -0.2605 -1.6856 -1.8652 -0.6224 -0.3794 -0.0044 -0.0187 -0.3149 -0.1217 -0.5444 -0.1266
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic heart failure ; spironolactone ; hospitalization ; death
H-446	-0.2301567643880844	▁sy sto lic ▁heart ▁failure ▁; ▁spi rono lac tone
D-446	-0.2301567643880844	systolic heart failure ; spironolactone
P-446	-0.3128 -0.1606 -0.1309 -0.6757 -0.1432 -0.4565 -0.0633 -0.0187 -0.0389 -0.0546 -0.5787 -0.1278
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction ; rad variant ; q66p ; congestive heart failure
H-1673	-0.45659229159355164	▁Rad ▁variant ▁; Q 66 p ▁; ▁con ges tive ▁heart ▁failure ▁; ▁humans
D-1673	-0.45659229159355164	Rad variant ;Q66p ; congestive heart failure ; humans
P-1673	-0.6010 -0.0504 -0.2680 -1.4377 -0.3345 -0.1876 -0.2035 -0.0591 -0.3431 -1.5445 -0.4499 -0.1595 -1.0479 -0.3225 -0.2188 -0.0774
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional enrichment analysis ; regulation ; cell death ; degs
H-1614	-0.37086135149002075	▁functional ▁en rich ment ▁analysis ▁; ▁programme d ▁cell ▁death
D-1614	-0.37086135149002075	functional enrichment analysis ; programmed cell death
P-1614	-0.2495 -0.0888 -0.3537 -0.6437 -0.6229 -0.5236 -0.1277 -0.0288 -0.2334 -0.2058 -1.2812 -0.0913
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes ; patients ; atrial fibrillation ; early treatment of atrial fibrillation for stroke prevention trial
H-1642	-0.4967781901359558	▁at rial ▁fi bril lation ▁; ▁At rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁tri al
D-1642	-0.4967781901359558	atrial fibrillation ; Atrial fibrillation ; Stroke prevention trial
P-1642	-2.8214 -0.0916 -0.6118 -0.1190 -0.2195 -0.4173 -3.1291 -0.0401 -0.5217 -0.0958 -0.1490 -0.2867 -0.2447 -0.1062 -0.2806 -0.0047 -0.4686 -0.0562 -0.1784 -0.0932
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology ; comorbidities ; patients ; outcomes
H-564	-0.4315875470638275	▁et i ology ▁; ▁como rbi di ties
D-564	-0.4315875470638275	etiology ; comorbidities
P-564	-0.8170 -0.4185 -0.1799 -0.3491 -0.3058 -0.0545 -1.1374 -0.0776 -0.8564 -0.1196
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence ; intestinal ; patients ; chf
H-1358	-0.7911009788513184	▁intestinal ▁ morph ology ▁; ▁per me ability ▁; ▁ab sor p tion ▁function ▁; ▁CHF
D-1358	-0.7911009788513184	intestinal morphology ; permeability ; absorption function ; CHF
P-1358	-6.3687 -0.3229 -0.0768 -0.6560 -0.1929 -2.2258 -0.0778 -0.3288 -0.4054 -0.0062 -0.2616 -0.9738 -1.2832 -0.1291 -0.2940 -0.2657 -0.2431 -0.1280
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients ; exercise ; anaerobic metabolism ; peak respiratory quotient
H-1756	-1.077337384223938	▁ana ero bic ▁metabolism ▁; ▁respirator y
D-1756	-1.077337384223938	anaerobic metabolism ; respiratory
P-1756	-5.2863 -0.7062 -0.3201 -0.1966 -0.6946 -0.1806 -0.2584 -1.9212 -0.1320
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni ; cardiovascular mortality ; hospitalization ; heart failure ; quality of life
H-1969	-0.6454756855964661	▁AR NI ▁; ▁cardiovascular ▁mortal ity ▁; ▁hospital ization ▁; ▁heart ▁failure
D-1969	-0.6454756855964661	ARNI ; cardiovascular mortality ; hospitalization ; heart failure
P-1969	-1.1901 -0.7729 -0.6367 -0.2144 -0.1011 -1.6412 -0.3360 -0.5857 -0.5120 -1.1177 -0.3523 -0.2176 -1.2033 -0.1554
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial dd ; muscle ; titin hypophosphorylation
H-768	-0.5063757300376892	▁my o card ial ▁ DD ▁; ▁muscle ▁strip ▁sti ff ness ▁; ▁titi n ▁hypo phos phor y lation
D-768	-0.5063757300376892	myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
P-768	-1.0791 -0.1802 -0.1452 -0.2806 -0.9563 -0.1371 -0.5088 -1.7967 -0.2143 -1.0647 -0.0827 -1.5255 -0.2550 -0.0956 -0.1037 -0.0427 -0.0801 -1.1758 -1.0612 -0.0758 -0.1988 -0.0802
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined training ; peak work rate ; peak quadriceps force
H-1917	-0.7636160254478455	▁quadri cep s ▁force
D-1917	-0.7636160254478455	quadriceps force
P-1917	-3.3170 -0.3958 -0.0964 -0.2005 -0.4283 -0.1437
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins ; expression ; cardiac hypertrophy ; proteins ; nucleolin
H-95	-0.5121390223503113	▁protein s ▁; ▁cardiac ▁hyper trop hy ▁; ▁nu cle olin
D-95	-0.5121390223503113	proteins ; cardiac hypertrophy ; nucleolin
P-95	-1.5196 -0.2532 -0.5671 -0.3505 -0.2081 -0.0571 -1.4882 -0.3380 -1.3641 -0.0090 -0.1298 -0.2465 -0.1264
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based ; prognosis ; idiopathic dilated cardiomyopathy
H-1750	-0.4239935576915741	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1750	-0.4239935576915741	idiopathic dilated cardiomyopathy
P-1750	-1.7321 -0.7086 -0.0453 -0.1411 -0.2129 -0.1933 -0.1220 -0.9828 -0.5936 -0.0302 -0.2336 -0.0925
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients ; physicians ; readmission ; hospital
H-1728	-0.8787835240364075	▁high - volu me ▁physician s ▁; ▁read mission ▁rates
D-1728	-0.8787835240364075	high-volume physicians ; readmission rates
P-1728	-3.3547 -0.0756 -0.0775 -0.1406 -0.4201 -0.1982 -1.1004 -1.1959 -1.9031 -0.6930 -1.2890 -0.0971
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc ; nps ; clinical
H-1024	-0.7043704390525818	▁ NP ▁measure ment ▁; ▁PO c ▁measure ment ▁; NP s
D-1024	-0.7043704390525818	NP measurement ; POc measurement ;NPs
P-1024	-1.6312 -0.0725 -1.6893 -0.1546 -0.2998 -0.3373 -1.4840 -1.5930 -0.1093 -0.2965 -1.3466 -0.2018 -0.5569 -0.0884
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized ; follow-up
H-1751	-0.4171454906463623	▁benefits ▁; ▁follow - up
D-1751	-0.4171454906463623	benefits ; follow-up
P-1751	-0.5988 -1.6256 -0.0310 -0.1771 -0.0441 -0.3616 -0.0819
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas city cardiomyopathy questionnaire ; kccq ; hf with reduced ef ; patients ; hfpef
H-781	-0.5430087447166443	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁k cc q ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-781	-0.5430087447166443	Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; EF ; HFpEF
P-781	-0.0299 -0.8147 -1.4155 -0.0895 -0.0949 -1.1782 -0.0594 -0.3095 -0.0093 -0.3998 -1.9717 -0.0605 -1.8856 -0.1606 -0.7273 -0.4914 -0.2072 -0.4293 -0.2599 -1.8669 -0.4160 -0.0910 -0.2615 -0.2415 -0.1042
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; right ventricular contractile function ; prognosis
H-491	-0.2935097813606262	▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; ▁heart ▁failure ▁; ▁index ▁; ▁right ▁vent ri cular ▁contract ile
D-491	-0.2935097813606262	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index ; right ventricular contractile
P-491	-0.0339 -0.0416 -0.0151 -0.1236 -0.0034 -0.0417 -0.0457 -0.2037 -0.0959 -0.4606 -0.0624 -0.2613 -0.0053 -0.0487 -0.0143 -0.0206 -0.0957 -0.1199 -1.5828 -0.3013 -1.2909 -0.3255 -0.2628 -0.0689 -1.1131 -0.1215 -0.0993 -1.4336 -0.2156 -0.0197 -0.0710 -0.9964 -0.0900
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients ; biventricular support ; heartmate ii ; lvad ; centrimag ; right ventricular assist device ; rvad
H-296	-0.5559543967247009	▁bi ven tri cular ▁support ▁; ▁hybrid ▁system ▁; ▁Heart Mate ▁II ▁l VAD ▁; ▁Centri Mag ▁right ▁vent ri cular ▁assist ▁device ▁; ▁r VAD
D-296	-0.5559543967247009	biventricular support ; hybrid system ; HeartMate II lVAD ; CentriMag right ventricular assist device ; rVAD
P-296	-2.1354 -0.0750 -2.4632 -0.8108 -1.7221 -0.4158 -0.0604 -0.1094 -0.2627 -1.2344 -0.0405 -0.5234 -0.1285 -0.0124 -0.1784 -0.2623 -0.3610 -0.2984 -0.0325 -1.6747 -0.2999 -0.2914 -0.1561 -0.1896 -1.4266 -0.0749 -0.2358 -0.0911
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
H-521	-0.2598845660686493	▁Blood ▁pressure ▁; ▁arm ▁cu ff ▁; ▁stroke ▁volume ▁; SV ▁; ▁e je ction ▁ fraction ▁; ▁end - dia sto lic ▁volume ▁; ▁e cho card i ography
D-521	-0.2598845660686493	Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
P-521	-0.1626 -0.1671 -0.2877 -1.0842 -0.2135 -0.1168 -0.0796 -0.1266 -0.1494 -0.2970 -0.9782 -0.2515 -0.1907 -0.0807 -0.0261 -0.2185 -0.0063 -0.4136 -1.2739 -0.0692 -0.0232 -0.1496 -0.0686 -0.1313 -0.3183 -0.0821 -0.1073 -0.1770 -0.5416 -0.2161 -0.2277 -0.0801
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis ; heart failure ; myocardial tissue ; left ventricular ; trichrome blue histologic analysis
H-1060	-0.45829424262046814	▁fibro sis ▁; ▁heart ▁failure ▁; ▁my o card ial ▁tissu e ▁; ▁left ▁vent ri cular ▁tissu e ▁; ▁tri ch rom e ▁blue ▁his t ologic ▁analysis
D-1060	-0.45829424262046814	fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic analysis
P-1060	-0.0179 -0.4227 -0.9828 -0.9520 -0.1582 -0.3756 -1.6282 -0.6525 -0.6793 -1.0410 -0.1355 -0.2089 -0.4015 -0.3994 -0.0770 -2.2755 -0.3109 -0.0574 -0.1194 -0.5360 -0.0128 -0.0374 -0.0022 -0.0160 -0.0775 -1.2899 -0.2412 -0.1131 -0.5405 -0.3465 -0.0982
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped ; snp ; rs10927887 ; ka renal chloride channel gene ; clcnka
H-1802	-0.5832831263542175	▁Cau ca sian ▁; ▁geno type d ▁; ▁s NP ▁rs 109 27 887 ▁; ▁ka ▁renal ▁chlor ide ▁channel ▁gene ▁; CL cn ka
D-1802	-0.5832831263542175	Caucasian ; genotyped ; sNP rs10927887 ; ka renal chloride channel gene ;CLcnka
P-1802	-0.7871 -0.0204 -0.4164 -0.3743 -4.2066 -0.0131 -0.1364 -0.2472 -0.3126 -0.2892 -1.3541 -0.0342 -0.9493 -0.0638 -0.2956 -0.2017 -0.0029 -0.1018 -0.1885 -0.0450 -1.5768 -0.2350 -0.4838 -1.7430 -1.3131 -0.2637 -0.0930
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise ; training ; outcomes ; hf ; patients ; exercise ; training ; therapy ; clinical
H-1934	-0.9116783738136292	▁exercise ▁training ▁; HF ▁patients ▁; ▁exercise ▁training ▁ therapy
D-1934	-0.9116783738136292	exercise training ;HF patients ; exercise training therapy
P-1934	-2.0112 -1.2259 -0.4570 -1.2818 -1.8217 -0.9748 -1.3609 -0.7926 -0.5933 -0.0278 -0.2715 -0.1217
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile function ; lv dilatation ; lv end-diastolic pressure ; wall stress ; lung
H-476	-0.4583582282066345	▁contract ile ▁function ▁; ▁LV ▁di la tation ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight
D-476	-0.4583582282066345	contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
P-476	-0.0093 -0.0696 -0.1763 -0.3008 -0.3734 -0.4741 -0.3248 -0.0514 -0.3617 -1.1021 -2.3059 -2.8814 -0.0450 -0.0279 -0.1768 -0.0631 -0.2087 -0.5178 -0.9433 -0.2125 -0.1383 -0.1363 -0.1970 -0.2586 -0.1028
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp ; plasma ; patients ; dyspnea ; left ventricular dysfunction ; admission
H-265	-0.44036927819252014	▁NT - pro b NP ▁; ▁plasma ▁; ▁dys pne a ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ED
D-265	-0.44036927819252014	NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; ED
P-265	-0.5878 -0.0938 -0.0223 -0.7210 -0.9982 -1.5054 -0.1485 -0.4095 -0.2527 -0.0136 -0.1985 -0.3582 -0.0646 -0.0699 -2.1991 -0.5469 -0.0600 -0.1978 -0.4279 -0.5034 -0.1968 -0.1120
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological ; remodelling ; heart ; cardiac hypertrophy ; hf ; death ; fibrosis ; inflammation
H-1035	-0.6438631415367126	▁heart ▁; ▁cardiac ▁hyper trop hy ▁; ▁ HF ▁; ▁death ▁; ▁fibro sis ▁; ▁ inflammation
D-1035	-0.6438631415367126	heart ; cardiac hypertrophy ; HF ; death ; fibrosis ; inflammation
P-1035	-4.3734 -0.4410 -0.1207 -0.1615 -0.0267 -1.4000 -0.2075 -0.8341 -0.1753 -0.3636 -2.4004 -0.4507 -0.0074 -0.1966 -0.5042 -0.1363 -0.0530 -0.2613 -0.1197
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action ; correlation ; baseline ; hgb ; baseline ; hrqol ; kccq
H-842	-0.5267155170440674	▁ HF - ac TION ▁co hor t ▁; ▁h gb ▁; ▁base line ▁HR Qo L ▁; ▁k cc q
D-842	-0.5267155170440674	HF-acTION cohort ; hgb ; baseline HRQoL ; kccq
P-842	-1.1916 -0.4192 -0.0423 -0.4535 -1.6435 -0.0410 -0.7253 -0.0554 -0.2965 -0.7472 -0.1680 -0.1947 -0.6322 -0.0114 -0.2570 -0.0055 -1.2245 -0.1818 -1.3788 -0.1270 -2.0116 -0.2169 -0.0894
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating progenitor cells ; cpcs ; endothelial ; prognostic ; cardiovascular diseases
H-120	-0.4362201392650604	▁circula ting ▁pro gen itor ▁cell s ▁; ▁c ▁pc s ▁; ▁en dot heli al ▁repair ▁; ▁cardiovascular
D-120	-0.4362201392650604	circulating progenitor cells ; c pcs ; endothelial repair ; cardiovascular
P-120	-0.0696 -0.2767 -0.0923 -0.2460 -0.2789 -0.4591 -0.1770 -0.4164 -0.1787 -1.8080 -0.1624 -0.4126 -0.0476 -0.3406 -0.1642 -0.0126 -0.1544 -0.2642 -0.0593 -3.4427 -0.0974
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right ventricular ; rv ; prognosis ; patients ; heart failure ; hf
H-1158	-0.687183678150177	▁right ▁vent ri cular ▁; RV ▁; ▁body ▁composition ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1158	-0.687183678150177	right ventricular ;RV ; body composition ; advanced heart failure ;HF
P-1158	-1.1227 -0.0521 -1.6399 -0.1609 -0.4995 -0.6540 -0.4730 -2.8952 -0.1360 -0.1783 -2.5736 -0.3327 -0.1636 -0.2649 -0.1753 -0.2336 -0.1268
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular assist device ; vad ; extracorporeal membrane oxygenation ; ecmo ; renal function
H-1385	-0.35839924216270447	▁vent ri cular ▁assist ▁device ▁; VAD ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁renal ▁function
D-1385	-0.35839924216270447	ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
P-1385	-0.0263 -2.0044 -0.1542 -0.6357 -0.2389 -0.3984 -0.0263 -0.2589 -0.0153 -0.0466 -0.6328 -0.1043 -0.0141 -0.0543 -0.0998 -0.3217 -0.3445 -0.4415 -1.4949 -0.2254 -0.0137 -0.3064 -0.6569 -0.0863
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american college of cardiology ; american heart association ; patients ; ras ; patients ; ras
H-1604	-0.9814459681510925	▁American ▁college ▁of ▁Card i ology ▁; American ▁Heart ▁association ▁; ▁ RAS
D-1604	-0.9814459681510925	American college of Cardiology ;American Heart association ; RAS
P-1604	-2.5146 -0.7952 -0.2970 -1.8100 -0.1786 -0.0719 -0.4916 -0.6092 -1.5491 -0.5060 -0.6206 -3.1008 -0.1098 -1.9825 -0.0848
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-375	-0.2337656021118164	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-375	-0.2337656021118164	functional MS ; valve plasty ; degenerative MR ; LV
P-375	-0.1991 -0.1500 -0.3044 -0.6634 -0.0194 -0.0431 -0.3281 -0.2899 -0.0143 -0.0131 -0.1756 -0.1004 -0.3630 -0.0219 -0.9877 -0.0670
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus ; cells ; functional capacity ; mortality ; nondiabetic ; patients
H-131	-0.892261266708374	▁ EO - c FU s ▁; ▁cd 34 + ve g FR 2 ▁; ▁cell s ▁; ▁non dia be tic ▁patients
D-131	-0.892261266708374	EO-cFUs ; cd34+vegFR2 ; cells ; nondiabetic patients
P-131	-3.0909 -0.2252 -0.0824 -1.2001 -0.6609 -0.5442 -0.3124 -0.9453 -0.4247 -2.9015 -0.5450 -1.5446 -1.1311 -0.2984 -1.7525 -0.2759 -0.1928 -0.6258 -3.2213 -0.0096 -0.1140 -0.8630 -0.9820 -0.2694 -0.0937
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable cardioverter-defibrillator ; physicians ; heart failure ; patients
H-1857	-0.5027440786361694	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁heart ▁failure ▁patients
D-1857	-0.5027440786361694	implantable cardioverter-defibrillator deactivation ; heart failure patients
P-1857	-1.9635 -0.0739 -0.2160 -0.0391 -0.3375 -0.1236 -0.1482 -0.1639 -0.4078 -0.1771 -0.0898 -0.1991 -0.0837 -1.0619 -0.5204 -2.4445 -0.1374 -1.1727 -0.5380 -0.1569
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional ms ; patients ; valve plasty ; degenerative mr ; dilated ; disease
H-340	-0.19269290566444397	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁ann ular ▁size ▁re duction ▁; ▁de genera tive ▁MR ▁; ▁LV
D-340	-0.19269290566444397	functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
P-340	-0.1470 -0.0825 -0.2976 -0.7734 -0.0208 -0.0341 -0.2718 -0.1781 -0.0169 -0.0022 -0.4871 -0.1262 -0.0177 -0.2494 -0.0234 -0.0091 -0.2099 -0.0721 -0.2723 -0.0315 -0.8556 -0.0606
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty ; prognostic ; heart failure ; hf ; biological phenotype
H-1001	-0.7442911863327026	▁fra il ty ▁; ▁heart ▁failure ▁; HF
D-1001	-0.7442911863327026	frailty ; heart failure ;HF
P-1001	-1.2277 -0.8882 -0.2259 -0.4336 -2.1719 -0.1973 -0.2945 -0.6512 -1.2379 -0.1147
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv remodeling ; diastolic ; xo inhibition ; symptoms ; hospitalizations ; patients ; severe heart failure
H-478	-0.47250425815582275	▁LV ▁remodel ing ▁; ▁dia sto lic ▁properties ▁; ▁ XO ▁inhibi tion ▁; ▁heart ▁failure
D-478	-0.47250425815582275	LV remodeling ; diastolic properties ; XO inhibition ; heart failure
P-478	-0.0173 -1.2200 -0.0673 -0.2684 -0.0125 -0.2194 -0.0418 -0.3199 -0.5410 -0.2332 -0.0510 -0.0286 -0.3532 -0.4450 -4.0975 -0.3177 -0.1696 -0.1019
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt ; atrial pacing
H-1442	-0.8002007603645325	▁SD QT ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁h Nor m ▁group ▁; ▁fixed - rate ▁at rial ▁pa cing
D-1442	-0.8002007603645325	SDQT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
P-1442	-0.0444 -0.9053 -0.2733 -0.9045 -0.7324 -0.9346 -0.5766 -0.5018 -0.8483 -1.5917 -0.5492 -1.2484 -4.7869 -0.0335 -2.3111 -1.0468 -0.2526 -0.1424 -0.1986 -0.9455 -0.2124 -0.0116 -0.5727 -0.2762 -0.1042
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ; ef
H-192	-1.2503005266189575	▁border line ▁; ▁female ▁; ▁pres er ved
D-192	-1.2503005266189575	borderline ; female ; preserved
P-192	-4.0941 -0.0794 -0.7081 -0.5400 -0.6744 -0.5569 -0.1134 -0.8540 -4.7448 -0.1380
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping ; myocardial ; heart failure
H-1063	-0.6537822484970093	▁t 1- ma pping ▁techniek ▁; ▁diffuse ▁my o card ial ▁changes ▁; ▁heart ▁failure ▁; ▁contrast ▁agent ▁; ▁breath - hold ing
D-1063	-0.6537822484970093	t1-mapping techniek ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
P-1063	-3.5168 -0.1797 -0.5715 -0.3431 -2.1481 -0.4591 -0.3088 -0.6861 -0.3692 -0.5446 -0.9436 -2.4295 -0.3667 -0.8270 -0.3131 -0.3040 -0.2296 -0.0086 -0.7435 -0.1362 -0.1698 -0.1853 -0.1122 -0.3218 -0.1268
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical ; bnp ; inhospital ; mortality
H-196	-0.6127856373786926	▁b NP ▁; ▁in hospital ▁mortal ity
D-196	-0.6127856373786926	bNP ; inhospital mortality
P-196	-0.6264 -1.6817 -0.7383 -0.0526 -0.0421 -0.1151 -1.7248 -0.4342 -0.0999
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies ; crt-d ; heart failure ; death
H-108	-0.8360222578048706	▁IE s ▁; ▁c RT - d ▁recipient s ▁; ▁heart ▁failure ▁; ▁death
D-108	-0.8360222578048706	IEs ; cRT-d recipients ; heart failure ; death
P-108	-4.2531 -0.3492 -0.4052 -0.2430 -1.5771 -0.0881 -0.5835 -0.9547 -0.1588 -0.3507 -2.0501 -0.3535 -1.0713 -0.6995 -0.1398 -0.0987
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure ; health ; income ; hf
H-1800	-0.8255658149719238	▁ex pendi ture ▁; ▁health ▁per ▁capita ▁; ▁gross ▁national ▁income ▁per ▁capita ▁; ▁ HF ▁; ▁la
D-1800	-0.8255658149719238	expenditure ; health per capita ; gross national income per capita ; HF ; la
P-1800	-4.0978 -0.1416 -1.4214 -0.7408 -1.5105 -0.7802 -0.0347 -0.2373 -0.2682 -0.9094 -0.3348 -0.8074 -0.0231 -0.3998 -0.9485 -0.4372 -0.8435 -0.5262 -1.9658 -0.0831
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt ; dt ; btt ; patients
H-314	-0.9698930382728577	▁b t ▁; ▁ DT ▁; ▁b t
D-314	-0.9698930382728577	bt ; DT ; bt
P-314	-1.3563 -1.4423 -0.3527 -0.8118 -0.3796 -0.8263 -1.3522 -1.0634 -1.9439 -0.1705
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals ; patients ; hfpef
H-952	-0.5400105714797974	▁AF ▁; ▁ pharma ce u tical s ▁; ▁h FP EF
D-952	-0.5400105714797974	AF ; pharmaceuticals ; hFPEF
P-952	-0.3895 -0.7322 -0.3008 -0.2448 -0.6523 -0.3517 -0.0419 -0.2800 -0.2983 -1.5475 -1.2244 -1.0517 -0.2994 -0.1458
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood pressure ; therapy ; patients ; ras
H-1600	-0.4135320782661438	▁blood ▁pressure ▁control ▁; ▁lipid - lo wering ▁ therapy ▁; ▁smoking ▁ces s ation ▁; RAS
D-1600	-0.4135320782661438	blood pressure control ; lipid-lowering therapy ; smoking cessation ;RAS
P-1600	-0.4756 -0.2678 -1.5682 -0.1853 -0.7918 -0.0806 -0.0665 -0.0486 -0.6784 -0.0687 -0.2503 -0.0543 -0.1620 -0.0758 -0.5375 -0.4503 -1.8754 -0.1241 -0.0959
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-0.8909296989440918	▁virtual ▁co hor ts
D-2014	-0.8909296989440918	virtual cohorts
P-2014	-1.9923 -0.0466 -0.8317 -0.2219 -2.1583 -0.0947
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac magnetic resonance ; amyloidotic ; diagnosis ; multiple myeloma ; osteomedullary biopsy
H-999	-0.31957247853279114	▁cardiac ▁magnetic ▁res on ance ▁; ▁a my lo ido tic ▁pattern ▁; ▁multiple ▁mye loma ▁; ▁osteo me dulla ry ▁bio psy
D-999	-0.31957247853279114	cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
P-999	-0.0152 -0.0616 -0.1910 -0.2451 -0.2782 -0.3026 -0.0775 -0.4388 -0.1037 -0.1142 -1.9592 -0.4003 -0.2196 -0.2450 -0.0657 -0.2466 -0.3916 -0.0309 -0.0621 -0.0478 -2.0638 -0.0024 -0.0481 -0.3112 -0.0675
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable cardioverter-defibrillators ; icds ; mortality ; cardiac resynchronization therapy ; crt ; symptoms ; mortality
H-1068	-0.5065333843231201	▁implant able ▁cardio ver ter - de fi br illa tors ▁; ▁i cc s ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-1068	-0.5065333843231201	implantable cardioverter-defibrillators ; iccs ; cardiac resynchronization therapy ; cRT
P-1068	-0.8018 -0.0284 -0.0707 -0.0264 -0.4317 -0.1119 -0.1064 -0.0934 -0.5698 -0.3123 -0.5527 -0.5467 -0.5998 -1.0854 -1.0669 -0.3894 -0.7641 -0.0788 -0.0796 -0.0138 -1.2217 -0.5702 -0.0167 -0.3084 -0.5960 -3.1484 -0.4830 -0.1086
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular endothelial growth factor blockade ; beta-blocker ; therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
H-448	-0.40748971700668335	▁Vas cular ▁en dot heli al ▁growth ▁factor ▁block ade ▁; ▁beta - block er ▁ therapy ▁; ▁cardiac ▁function ▁; ▁ang io gene sis ▁; ▁remodel ing ▁; ▁heart ▁failure
D-448	-0.40748971700668335	Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
P-448	-1.1659 -0.0785 -0.0120 -0.8740 -0.0795 -0.0083 -0.2870 -0.3641 -2.2694 -0.3904 -0.4713 -0.2851 -0.0255 -0.1709 -0.0964 -0.4998 -0.0294 -0.5196 -0.0155 -0.1119 -0.4193 -0.4805 -0.8277 -0.2560 -0.7342 -0.3570 -1.0684 -0.0572 -0.8031 -0.1604 -0.1598 -0.2797 -0.0891
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure with preserved ejection fraction
H-915	-0.2795588970184326	▁Low - so dium ▁DAS h ▁die t ▁; ▁dia sto lic ▁function ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-915	-0.2795588970184326	Low-sodium DASh diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
P-915	-1.2220 -0.0424 -0.0156 -0.0080 -0.0565 -0.1635 -1.6471 -0.0880 -0.4361 -0.0213 -0.0794 -0.0408 -0.2230 -0.2745 -0.0177 -1.7053 -0.1149 -0.2148 -0.1584 -0.0737 -0.0693 -0.3184 -0.2903 -0.3118 -0.1077 -0.0625 -0.4750 -0.1201 -0.4600 -0.2780 -0.0793 -0.0585 -0.4659 -0.0062 -0.2754 -0.0826
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis ; hfpef ; clinical ; echo-doppler cardiography ; invasive haemodynamic assessment
H-1303	-0.37235984206199646	▁ HF p EF ▁; ▁e cho - d opp ler ▁card i ography ▁; ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.37235984206199646	HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
P-1303	-1.5695 -0.4642 -0.0514 -0.7904 -0.2971 -0.0975 -0.0433 -0.0417 -2.1340 -0.0292 -0.6959 -0.1955 -0.4126 -0.2307 -0.2893 -0.0811 -0.1029 -0.0175 -0.5998 -0.0106 -0.0476 -0.2841 -0.0784
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker ; uptitrations ; patients ; hfref ; hfpef ; hospital ; admission
H-177	-0.9250348806381226	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁h Fr EF ▁; ▁ HF p EF
D-177	-0.9250348806381226	RAS- ; β-blocker uptitrations ; hFrEF ; HFpEF
P-177	-1.7434 -0.0546 -0.0644 -3.6661 -0.0587 -0.0656 -0.8546 -0.0911 -4.3547 -0.6924 -2.9096 -0.5506 -0.5172 -1.3588 -0.5600 -1.4371 -0.4401 -0.3611 -0.4049 -0.0921 -0.5946 -0.2732 -0.1308
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients ; exercise-induced pasp ; pasp ; patients ; pasp
H-827	-0.9283257126808167	▁pas p ▁; ▁pas p
D-827	-0.9283257126808167	pasp ; pasp
P-827	-1.3302 -0.2457 -0.8709 -2.5290 -0.2938 -1.1204 -0.1082
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal muscle ; sarcomere ; patients ; heart failure ; type 2 diabetes
H-1243	-0.3521234095096588	▁skelet al ▁muscle ▁sar com ere ▁structure ▁; ▁heart ▁failure ▁; ▁type ▁2 ▁diabetes ▁; ▁e pica tech in - rich ▁coco a
D-1243	-0.3521234095096588	skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
P-1243	-0.4589 -0.1203 -0.3437 -0.3984 -0.1901 -0.4035 -2.4774 -0.2735 -1.4450 -0.1642 -0.1697 -0.5754 -0.3053 -0.0142 -0.4943 -0.0769 -0.0109 -0.0951 -0.0486 -0.1475 -0.0088 -0.1474 -0.0369 -0.2649 -0.1322
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician ; outcomes ; patients ; outcomes ; medically ; diseases ; hf
H-1722	-0.6779329180717468	▁Physic ian ▁volume ▁; ▁med ically ▁managed ▁disease s ▁; ▁ HF
D-1722	-0.6779329180717468	Physician volume ; medically managed diseases ; HF
P-1722	-0.5995 -1.4152 -0.1439 -0.5418 -2.5441 -0.6060 -0.0905 -0.3211 -0.1286 -0.4173 -1.9356 -0.4200 -0.2111 -0.1164
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal flow pump ; hemocompatibility ; blood-flow ; pulse
H-1994	-0.3723936378955841	▁centri fu gal ▁flow ▁pump ▁; ▁hem o com pati bility ▁; ▁magnet ically ▁le vita ted ▁ro tor ▁; ▁blood - flow ▁path s ▁; ▁artificial ▁puls e
D-1994	-0.3723936378955841	centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
P-1994	-0.0809 -1.3396 -0.3707 -0.5876 -1.1431 -0.4503 -0.7624 -0.2991 -0.1304 -0.0883 -0.5981 -0.2619 -0.0510 -0.2952 -0.0240 -0.0109 -0.2659 -0.0328 -0.0224 -0.6873 -2.0097 -0.0598 -0.0597 -0.1966 -0.0607 -0.3564 -0.4723 -0.1714 -0.3340 -0.2432 -0.0784
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone ; patients ; hf-ref ; hyperkalemia ; patients
H-1224	-0.455484002828598	▁e pler en one ▁; ▁ HF - re f ▁; ▁hyper kal emia ▁; ▁w RF
D-1224	-0.455484002828598	eplerenone ; HF-ref ; hyperkalemia ; wRF
P-1224	-0.0464 -0.0449 -0.1605 -0.6954 -0.4601 -0.6525 -0.2770 -0.0309 -1.0396 -2.5883 -0.5731 -0.2922 -0.1984 -0.3951 -0.2444 -0.1533 -0.3968 -0.2770 -0.1282
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial complex v activity ; phosphocreatine ; atp
H-1786	-0.632472574710846	▁mito cho ndri al ▁complex ▁; ▁a ac ▁; ▁ phos pho creati ne ▁; ▁ATP
D-1786	-0.632472574710846	mitochondrial complex ; aac ; phosphocreatine ; ATP
P-1786	-0.0842 -1.1811 -0.4948 -0.0472 -0.0823 -1.6339 -2.7676 -0.2211 -0.4427 -0.4517 -0.0284 -0.3137 -0.9274 -1.4943 -0.8114 -0.0894 -0.2113 -0.1019
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients ; sst2 ; sst2 ; odds ratios ; cardiovascular events
H-409	-0.5448854565620422	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB ▁; ▁cardiovascular ▁events
D-409	-0.5448854565620422	sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
P-409	-0.6283 -1.4788 -0.2561 -0.1867 -0.0461 -0.5828 -0.2131 -1.1114 -0.5522 -0.1862 -1.4069 -0.2012 -1.0156 -0.0672 -0.9704 -0.1186 -0.8179 -0.6955 -0.3365 -0.7963 -0.2042 -0.1153
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients ; frail ; frail ; biological phenotype
H-1007	-0.4683619737625122	▁fra il ▁; ▁intermedi ate ▁fra il
D-1007	-0.4683619737625122	frail ; intermediate frail
P-1007	-0.1117 -0.1187 -0.7967 -0.1843 -2.1744 -0.0513 -0.2172 -0.4628 -0.0982
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs morphology ; cardiac resynchronization therapy ; crt
H-880	-0.47076281905174255	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-880	-0.47076281905174255	QRs morphology ; cardiac resynchronization therapy ; cRT
P-880	-0.3208 -0.7617 -0.4673 -0.0833 -0.5499 -0.1974 -0.0835 -0.0575 -0.2273 -0.0335 -1.3092 -0.7268 -0.0273 -0.2979 -0.7510 -2.2539 -0.2199 -0.1055
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients ; hfpef ; longitudinal ; cardiac event
H-738	-1.1335618495941162	▁h FP EF ▁; ▁cardiac ▁event
D-738	-1.1335618495941162	hFPEF ; cardiac event
P-738	-1.2618 -2.2172 -0.9410 -0.5336 -2.2736 -1.4581 -0.2718 -0.1115
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm ; outcomes ; discharged ; admission ; heart failure
H-149	-1.0046876668930054	▁RM ▁; ▁dis charge d ▁; ▁heart ▁failure
D-149	-1.0046876668930054	RM ; discharged ; heart failure
P-149	-1.1025 -1.1803 -1.9182 -0.0556 -0.0389 -0.4244 -4.7896 -0.1960 -0.2176 -0.1238
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient ; emergency department ; acute heart failure ; ahf ; clinical
H-57	-0.6651756167411804	▁a cute ▁heart ▁failure ▁; ▁a HF
D-57	-0.6651756167411804	acute heart failure ; aHF
P-57	-1.2948 -0.0413 -0.6906 -0.1557 -0.3070 -0.9585 -2.0461 -0.3564 -0.1362
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene ; pathological ; heart disease ; transcription factors ; driving ; gene
H-639	-0.7355077862739563	▁em bry o nic ▁gene ▁programs ▁; ▁path ological ▁heart ▁disease ▁; ▁tran scription ▁factors ▁; ▁gene ▁programs
D-639	-0.7355077862739563	embryonic gene programs ; pathological heart disease ; transcription factors ; gene programs
P-639	-3.1539 -0.2988 -0.3631 -1.5253 -2.0589 -0.7180 -0.5925 -0.1302 -0.5628 -0.8905 -0.2526 -0.7261 -0.0521 -0.0292 -0.2836 -0.9092 -1.2635 -0.4146 -0.3453 -0.1401
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard error of measurement ; mdc ; clinical ; change
H-807	-0.439453125	▁m DC
D-807	-0.439453125	mDC
P-807	-0.3012 -0.9134 -0.4315 -0.1118
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients ; lbbb ; implantable ; primary outcome ; primary outcome
H-887	-0.45035865902900696	LB b ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - c RT
D-887	-0.45035865902900696	LBb ; implantable cardioverter defibrillator-cRT
P-887	-0.8909 -2.0681 -0.5711 -0.3739 -0.0530 -0.0825 -0.0334 -0.0904 -0.2473 -0.0404 -0.1384 -0.1317 -0.0270 -0.1655 -0.8926 -1.5279 -0.6727 -0.0997
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart rate ; ivabradine ; afterload ; patients ; systolic heart failure
H-516	-0.3274708390235901	▁isola ted ▁heart ▁rate ▁; HR ▁; ▁i va bra dine ▁; ▁sy sto lic ▁heart ▁failure
D-516	-0.3274708390235901	isolated heart rate ;HR ; ivabradine ; systolic heart failure
P-516	-0.1646 -0.2662 -0.7301 -0.1693 -0.4774 -0.3716 -0.4006 -0.0930 -0.0280 -0.1823 -0.1081 -0.1985 -1.6909 -0.0906 -0.0812 -0.6063 -0.1569 -0.2891 -0.1172
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients ; followed up ; composite primary outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
H-1650	-0.42226681113243103	▁cardiovascular ▁death ▁; ▁stroke ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1650	-0.42226681113243103	cardiovascular death ; stroke ; heart failure ; myocardial infarction
P-1650	-1.1315 -1.1151 -0.1410 -0.3843 -0.1329 -0.7302 -0.1365 -0.1999 -0.7673 -0.3473 -0.1831 -0.8435 -0.0901 -0.2073 -0.3338 -0.2932 -0.1415
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical treatment ; heart failure
H-336	-0.5196719765663147	▁heart ▁failure ▁; ▁hyper tension ▁; ▁mit ral ▁re gur gi tation ▁; ▁mit ral ▁sten osis ▁; ▁heart ▁failure
D-336	-0.5196719765663147	heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; heart failure
P-336	-2.0210 -0.1996 -0.2929 -1.9561 -0.0576 -0.2394 -0.0815 -0.0383 -0.0362 -0.1448 -0.1620 -0.1144 -0.4169 -0.0741 -0.0335 -0.0210 -0.0078 -0.2554 -4.7350 -0.2386 -0.2105 -0.0963
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization therapy ; crt ; morbidity ; mortality ; chronic systolic heart failure ; wide qrs complex
H-845	-0.682233989238739	▁Card iac - re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁chronic ▁sy sto lic ▁heart ▁failure ▁; ▁QR s
D-845	-0.682233989238739	Cardiac-resynchronization therapy ; cRT ; chronic systolic heart failure ; QRs
P-845	-1.8372 -0.2173 -0.0591 -0.5830 -0.2078 -0.0339 -1.7904 -0.9897 -0.0748 -0.3719 -0.9493 -3.1797 -0.4016 -2.2536 -0.0365 -0.0942 -0.1726 -0.5651 -0.2232 -0.8223 -0.0062 -0.6607 -0.7316 -0.1121
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk ; scn5a ; kv4.3 ; mrnas ; transient receptor potential cation channel m7 ; trpm7 ; mrna
H-1086	-0.44157806038856506	▁per k ▁activa tion ▁; ▁s cn 5 a ▁; ▁Kv 4.3 ▁channel ▁m RNA s ▁; ▁trans ient ▁receptor ▁potential ▁ cation ▁channel ▁m 7 ▁; TR PM 7 ▁channel ▁m RNA
D-1086	-0.44157806038856506	perk activation ; scn5a ; Kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7 channel mRNA
P-1086	-2.0155 -1.1708 -0.0635 -0.4390 -0.6640 -0.4153 -0.2127 -0.8098 -0.1539 -0.2917 -1.0462 -0.0402 -0.1163 -0.0281 -0.0628 -0.3601 -0.3949 -0.0173 -0.0568 -0.0372 -0.7058 -0.0785 -0.0126 -0.2297 -0.7590 -0.0536 -0.2608 -0.8878 -1.6692 -1.5433 -0.3327 -0.0194 -0.1078 -0.3014 -0.0973
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients ; implantable cardioverter-defibrillator ; heart function clinic ; university health network ; toronto ; canada
H-1861	-0.5696070790290833	▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁Heart ▁Fun ction ▁Clinic ▁; ▁university ▁health ▁network ▁; ▁tor onto ▁; ▁Canada
D-1861	-0.5696070790290833	implantable cardioverter-defibrillator ; Heart Function Clinic ; university health network ; toronto ; Canada
P-1861	-0.4561 -0.0536 -0.2011 -0.0346 -0.2736 -0.0725 -0.2812 -0.1803 -0.4622 -0.2555 -0.0720 -0.5436 -1.3711 -0.1779 -0.0015 -0.7463 -0.5545 -1.5011 -0.9518 -1.4964 -0.4316 -1.0143 -0.0010 -2.1640 -1.6630 -0.3371 -0.0817
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced pasp ; clinical ; prognostic ; pulmonary hypertension ; patients ; right ventricular contractile reserve
H-831	-0.42539361119270325	▁pas p ▁; ▁pulmonar y ▁hyper tension ▁; ▁vent ri cular ▁contract ile ▁reserve
D-831	-0.42539361119270325	pasp ; pulmonary hypertension ; ventricular contractile reserve
P-831	-2.2380 -0.2233 -0.3693 -0.0230 -0.2270 -0.1242 -0.0275 -0.8827 -0.1690 -1.5525 -0.3207 -0.0291 -0.2039 -0.0328 -0.2848 -0.0984
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi ; metoprolol ; elevated ; plasma norepinephrine ; dopamine ; elevated ; epinephrine
H-1550	-0.3942096531391144	▁MI ▁; ▁met o pro lol ▁; ▁plasma ▁no re pine ph rine ▁; ▁dop amine ▁; ▁e pine ph rine
D-1550	-0.3942096531391144	MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
P-1550	-0.9550 -1.9996 -0.9300 -0.4614 -0.0676 -0.4079 -0.3438 -0.2004 -0.1854 -0.2967 -0.0628 -0.9329 -0.2517 -0.2561 -0.0040 -0.0653 -0.2117 -0.0448 -0.0150 -0.7622 -0.2880 -0.2290 -0.0956
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis ; biomedical ; biomedical ; patients ; dcm ; heart failure
H-1264	-0.39556777477264404	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1264	-0.39556777477264404	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
P-1264	-0.0701 -0.2071 -0.0318 -1.1422 -0.4895 -1.6077 -0.2582 -0.4332 -0.0441 -0.0848 -0.0360 -0.5403 -0.6592 -0.2559 -0.2233 -0.3056 -0.8244 -0.1998 -0.3517 -0.1465
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ; hf
H-696	-0.3441961109638214	▁ST 2 ▁; ▁cardio protec tive ▁signal ing ▁; ▁my o car dium ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; HF
D-696	-0.3441961109638214	ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
P-696	-0.9084 -0.1116 -0.4282 -0.2283 -0.3486 -1.4371 -0.5660 -0.5570 -0.3490 -0.3402 -0.1297 -0.0349 -0.1077 -0.2242 -0.0100 -0.0885 -0.2923 -0.6366 -0.3002 -0.1346 -0.2143 -0.4386 -0.2788 -0.0961
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular outcomes in renal atherosclerotic lesions ; coral ; stenting ; ras
H-1602	-0.3636151850223541	▁Card io vas cular ▁Out com es ▁; ▁Ren al ▁Ath eros cle ro tic ▁Les ions ▁; co RAL ▁; ▁sten ting ▁; RAS
D-1602	-0.3636151850223541	Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;coRAL ; stenting ;RAS
P-1602	-0.4721 -1.0893 -0.0683 -0.2446 -1.0533 -0.0524 -0.0986 -0.6982 -0.0686 -0.0767 -0.0806 -0.0672 -0.1099 -0.4579 -0.8341 -0.5730 -0.2046 -0.2627 -0.7358 -0.1184 -0.2922 -0.1929 -0.1531 -0.2302 -1.2727 -0.2476 -0.0627
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality ; heart failure ; hf ; implantable cardioverter defibrillators ; icds
H-60	-0.6036229729652405	▁mortal iteit ▁; ▁heart ▁failure ▁; HF ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ic d s
D-60	-0.6036229729652405	mortaliteit ; heart failure ;HF ; implantable cardioverter defibrillators ;icds
P-60	-4.7569 -2.2733 -0.4504 -1.0273 -0.2156 -0.2092 -0.2195 -0.2757 -0.2944 -0.0492 -0.0882 -0.0210 -0.1855 -0.8399 -0.0446 -0.1984 -0.1798 -0.2383 -0.3924 -1.4270 -0.4340 -0.2118 -0.3611 -0.0935
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic ; interatrial shunting ; patients ; heart failure with reduced ejection fraction
H-1950	-0.44409042596817017	▁left - to - right ▁inter at rial ▁sh unting ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1950	-0.44409042596817017	left-to-right interatrial shunting ; heart failure ; ejection fraction
P-1950	-3.2814 -0.1038 -0.2090 -0.2414 -0.2967 -0.0518 -0.0335 -0.1963 -0.3582 -0.9640 -0.5735 -1.1610 -0.0877 -0.6028 -0.1418 -0.0932 -0.0782 -0.4586 -0.0110 -0.2812 -0.1008
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary approaches to stop hypertension ; dash ; mortality ; postmenopausal ; hf
H-686	-0.5390712022781372	▁Mediterrane an ▁and ▁Diet ary ▁App ro ach es ▁to ▁Stop ▁Hyper tension ▁; DAS h ▁; ▁die t ▁score s ▁; ▁mortal iteit ▁; ▁post meno paus al ▁women ▁; HF
D-686	-0.5390712022781372	Mediterranean and Dietary Approaches to Stop Hypertension ;DASh ; diet scores ; mortaliteit ; postmenopausal women ;HF
P-686	-0.4724 -0.0290 -2.0806 -0.1910 -0.1779 -0.8217 -0.3149 -3.0819 -0.1417 -0.1948 -0.4725 -0.2739 -0.0262 -0.4499 -0.1121 -0.1349 -0.2250 -2.8374 -0.0361 -0.0444 -0.0628 -0.4937 -0.0900 -1.3239 -0.3044 -0.0213 -0.0434 -0.0116 -0.0462 -1.2860 -0.3541 -1.9025 -0.1784 -0.0918
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic ; patients ; reverse remodeling ; crt ; clinical ; outcomes
H-436	-0.4340534210205078	▁multi para metric ▁e cho car dio graphic ▁score ▁; ▁rever se ▁remodel ing ▁; ▁c RT
D-436	-0.4340534210205078	multiparametric echocardiographic score ; reverse remodeling ; cRT
P-436	-0.1622 -0.0938 -0.1118 -0.1321 -0.2916 -0.0785 -0.9321 -1.3284 -0.6046 -0.4173 -0.2419 -0.0379 -0.0415 -0.0418 -0.3830 -0.6895 -2.3365 -0.2321 -0.0905
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire ; implanted ; pacemakers ; ventricularly ; beats ; heart failure
H-1056	-0.45621728897094727	▁York shire ▁s win e ▁; ▁pace makers ▁; ▁vent ri cular ly ▁pace d ▁; ▁heart ▁failure
D-1056	-0.45621728897094727	Yorkshire swine ; pacemakers ; ventricularly paced ; heart failure
P-1056	-0.2297 -0.0203 -0.0464 -0.1216 -0.3501 -0.4623 -1.1253 -0.1088 -0.4910 -0.0948 -1.1979 -0.0811 -0.1057 -0.1057 -0.1695 -0.4288 -3.4744 -0.1357 -0.2809 -0.0943
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; clinical ; outcomes ; chf
H-636	-0.27656784653663635	▁anta gon ists ▁; ▁inhibi tors ▁; ▁re nin - angi oten sin - al do ster one ▁; ▁sympa the tic ▁ner vous ▁systems ▁; ▁CHF
D-636	-0.27656784653663635	antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
P-636	-0.4383 -0.0170 -0.4966 -0.3756 -0.0026 -0.1617 -0.5907 -0.0385 -0.3060 -0.0750 -0.0022 -0.1295 -0.6040 -0.1601 -0.0287 -0.1792 -0.0194 -0.5719 -0.2547 -0.0046 -0.6708 -0.9422 -0.3242 -0.8787 -0.1090 -0.3922 -0.0415 -0.1198 -0.0857
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf ; hf ; epidemiology ; rheumatic fever
H-1799	-0.5928495526313782	▁ HF ▁; ▁ HF ▁; ▁epidemi ology ▁; ▁SH ▁; ▁c ' d ▁; ▁rhe u matic ▁fe ver
D-1799	-0.5928495526313782	HF ; HF ; epidemiology ; SH ; c'd ; rheumatic fever
P-1799	-2.0934 -0.4639 -0.4394 -0.8773 -0.2843 -0.5205 -2.1690 -0.4639 -0.2576 -0.2850 -0.2408 -0.3438 -3.4902 -0.0411 -0.1470 -0.0887 -0.0859 -0.3540 -0.0530 -0.0335 -0.2144 -0.0959
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality ; readmissions ; costs ; patient ; physician ; hospital
H-1725	-0.6883171200752258	▁mortal ity ▁; ▁read missions ▁; ▁costs
D-1725	-0.6883171200752258	mortality ; readmissions ; costs
P-1725	-2.1869 -1.4548 -0.3242 -0.0610 -0.1059 -0.3339 -1.2075 -0.4216 -0.0991
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise ; training ; exercise ; exercise capacity ; qol ; obese ; patients ; hfpef
H-1976	-0.4624679982662201	▁calor ic ▁restriction ▁; diet ▁; ▁aero bic ▁exercise ▁training ▁; exe rci se ▁; ▁exercise ▁capacity ▁; ▁Q OL ▁; ▁obes e ▁older ▁patients ▁; ▁h FP EF
D-1976	-0.4624679982662201	caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese older patients ; hFPEF
P-1976	-1.3817 -0.2889 -0.3005 -0.1910 -0.0568 -0.2230 -0.0142 -0.1365 -0.2472 -1.0462 -0.1833 -0.5278 -0.0467 -0.2050 -0.1831 -1.0463 -0.4832 -0.1537 -1.6572 -0.2285 -0.1723 -0.6394 -0.0933 -0.3659 -0.6279 -0.4038 -1.2618 -1.0609 -0.6576 -0.3332 -0.1194
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic heart failure ; hf ; hemodynamic ; syndrome ; dysfunction ; molecular pathways
H-1472	-0.39025700092315674	▁chronic ▁heart ▁failure ▁; HF ▁; ▁hem o dynamic ▁disorder ▁; ▁syndrome
D-1472	-0.39025700092315674	chronic heart failure ;HF ; hemodynamic disorder ; syndrome
P-1472	-0.5883 -1.0873 -0.1616 -0.2831 -0.3550 -0.4061 -0.2822 -0.3072 -0.0046 -0.2564 -0.4468 -0.0096 -1.1996 -0.0759
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications ; patients ; heart failure and reduced ejection fraction ; outpatient
H-667	-0.7111683487892151	▁medication s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-667	-0.7111683487892151	medications ; heart failure ; ejection fraction
P-667	-3.4565 -0.2898 -0.7958 -1.0434 -0.0858 -0.2884 -1.5867 -0.1511 -0.0582 -0.4839 -0.0109 -0.8653 -0.1294
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms ; hfpef ; diastolic filling time ; heart rate ; symptoms
H-1172	-0.5020290613174438	▁ HF p EF ▁; ▁dia sto lic ▁fill ing ▁time ▁; ▁heart ▁rate
D-1172	-0.5020290613174438	HFpEF ; diastolic filling time ; heart rate
P-1172	-0.7261 -0.6021 -0.1128 -0.9920 -0.4457 -0.0776 -0.1127 -0.0710 -0.6707 -0.0647 -2.1169 -0.2031 -1.2382 -0.2376 -0.2581 -0.1033
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac ; myocyte-specific mena overexpression ; cardiac ; pathology
H-1813	-0.3551402688026428	▁mi ce ▁; ▁cardiac ▁my o cy te - specific ▁Men a ▁over expression ▁; TTA ▁; ▁t g t et Men a ▁; ▁cardiac ▁path ology
D-1813	-0.3551402688026428	mice ; cardiac myocyte-specific Mena overexpression ;TTA ; tgtetMena ; cardiac pathology
P-1813	-0.9699 -0.3559 -0.6616 -0.0345 -0.8673 -0.2728 -0.0623 -0.0700 -0.5356 -0.0486 -1.0914 -0.0242 -0.0372 -0.0479 -0.2130 -0.4971 -0.7793 -1.6452 -0.0947 -0.1553 -0.0088 -0.4134 -0.0047 -0.3910 -0.0268 -0.1938 -0.5209 -0.1905 -0.0855
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk stratification ; antiplatelet agents ; combination ; anticoagulants ; vascular diseases
H-1355	-0.31449100375175476	▁anti plate let ▁agents ▁; ▁antico a gul ants ▁; ▁vas cular ▁disease s
D-1355	-0.31449100375175476	antiplatelet agents ; anticoagulants ; vascular diseases
P-1355	-0.1625 -0.1814 -0.2780 -0.3305 -0.5894 -0.3597 -0.1899 -0.5536 -0.2791 -0.5530 -0.4460 -0.1551 -0.3415 -0.1346 -0.3800 -0.0976
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international right heart foundation working group ; step ; syndrome ; right heart failure
H-1458	-0.9031385183334351	▁international ▁Right ▁Heart ▁foundation ▁Work ing ▁Group ▁; ▁syndrome ▁; ▁right ▁heart ▁failure
D-1458	-0.9031385183334351	international Right Heart foundation Working Group ; syndrome ; right heart failure
P-1458	-3.0385 -0.6326 -0.7282 -0.9971 -1.7613 -0.0292 -1.3933 -0.5816 -1.6176 -1.5394 -0.2245 -0.2704 -0.4610 -0.1754 -0.0970
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc ; diagnostic
H-1025	-0.6401192545890808	▁PO c ▁systems ▁; ▁me as uring ▁ NP ▁levels
D-1025	-0.6401192545890808	POc systems ; measuring NP levels
P-1025	-0.4927 -1.6639 -0.5396 -1.3597 -0.8707 -0.1652 -0.0614 -0.3473 -0.0668 -1.1140 -0.9091 -0.0911
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients ; lbbb ; qrs ; implantable
H-890	-0.6299975514411926	▁l b ▁; ▁QR s ▁; ▁cardio ver ter ▁; ▁de fi br illa tor - c RT
D-890	-0.6299975514411926	lb ; QRs ; cardioverter ; defibrillator-cRT
P-890	-1.3143 -1.2014 -1.0714 -1.1543 -1.2201 -0.1687 -1.7367 -0.0165 -0.1122 -1.0263 -0.0306 -0.0148 -0.0517 -0.1341 -0.0210 -0.1621 -1.0409 -1.7157 -0.3193 -0.0880
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography ; cardiac ; cardiac function
H-453	-0.3528440296649933	▁e cho card i ography ▁; ▁cardiac ▁diameter s ▁; ▁cardiac ▁function
D-453	-0.3528440296649933	echocardiography ; cardiac diameters ; cardiac function
P-453	-0.0803 -0.0842 -0.2568 -1.0529 -0.3322 -0.5219 -0.0851 -0.1229 -0.2698 -0.3200 -0.1936 -0.2281 -1.3304 -0.0617
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline ; embase ; psycinfo
H-151	-0.5122630596160889	▁electronic ▁database s ▁; ▁med line ▁; ▁ EMBA se ▁; ▁Psy c INFO
D-151	-0.5122630596160889	electronic databases ; medline ; EMBAse ; PsycINFO
P-151	-3.3815 -0.2121 -0.1420 -0.2202 -0.5190 -0.8198 -0.2554 -1.2697 -0.0512 -0.3173 -0.1240 -0.4355 -0.0603 -0.0034 -0.3313 -0.0536
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality of life ; functional capacity
H-618	-0.7585318088531494	▁functional ▁capacity
D-618	-0.7585318088531494	functional capacity
P-618	-1.1061 -1.3963 -0.3650 -0.1667
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized ; medical
H-1977	-1.6634339094161987	
D-1977	-1.6634339094161987	
P-1977	-3.2346 -0.0923
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients ; systolic hf ; cxl-1020 ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
H-423	-0.5039277076721191	▁sy sto lic ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁; ▁right ▁heart ▁fill ing ▁pressure s ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁cardiac ▁; ▁stroke ▁volume ▁index
D-423	-0.5039277076721191	systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
P-423	-0.2352 -0.1927 -0.0157 -0.7772 -0.3858 -0.2423 -0.4637 -0.4042 -0.1210 -0.0729 -0.8339 -0.7092 -1.9727 -0.4500 -1.1260 -2.5185 -0.1012 -1.1488 -0.3021 -0.3379 -0.0550 -0.5477 -0.0542 -0.4627 -0.1479 -0.0900 -0.5330 -0.0608 -0.6775 -0.2482 -1.2964 -0.0422 -0.3864 -0.1207
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic ; patients ; severe heart failure ; financial
H-1242	-0.7894037365913391	▁AF ▁; ▁severe ▁heart ▁failure ▁; ▁financiële ▁burde n
D-1242	-0.7894037365913391	AF ; severe heart failure ; financiële burden
P-1242	-0.8343 -0.7286 -3.2205 -0.3775 -0.1306 -0.4364 -1.1561 -1.3092 -0.1317 -0.2551 -0.1034
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow up ; ffm ; patients
H-16	-1.1405102014541626	▁follow ▁up ▁body ▁weight ▁; ▁FM ▁; ▁f m ▁; ▁f m ▁; cc
D-16	-1.1405102014541626	follow up body weight ; FM ; fm ; fm ;cc
P-16	-2.5764 -1.9993 -1.4073 -0.4277 -0.5881 -1.7564 -0.5599 -0.4643 -1.7280 -0.9404 -1.5940 -1.1253 -0.8592 -1.6046 -0.4948 -0.1225
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential analysis ; cluster analysis
H-1610	-0.2694522738456726	▁r . ▁Clu ster ▁analysis
D-1610	-0.2694522738456726	r. Cluster analysis
P-1610	-0.2540 -0.5321 -0.4905 -0.0135 -0.3307 -0.2010 -0.0644
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1260	-0.5137176513671875	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1260	-0.5137176513671875	left ventricular ejection fraction ; left ventricular diastolic end diameter
P-1260	-1.6278 -0.0840 -2.3640 -0.3595 -0.3478 -0.2494 -0.1222 -0.6099 -0.0216 -0.3040 -0.1948 -0.0611 -2.4059 -0.2687 -0.0801 -0.1082 -0.0544 -1.0396 -0.0860 -0.2869 -0.1125
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence ; clinical ; outcomes ; concentric left ventricular hypertrophy ; heart failure with preserved ejection fraction
H-1523	-0.3326275646686554	▁ecce n tric ▁; ▁concentr ic ▁left ▁vent ri cular ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1523	-0.3326275646686554	eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
P-1523	-0.1785 -0.0290 -0.1050 -1.0582 -0.0243 -0.0286 -0.6388 -0.0588 -1.9609 -0.4428 -0.1757 -0.0267 -1.0703 -0.2644 -0.2643 -0.1050 -0.3282 -0.1820 -0.1117 -0.0786 -0.4638 -0.0063 -0.2709 -0.1104
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients ; left ventricular ejection fraction ; heart failure with preserved ejection fraction ; hfpef
H-1887	-0.3636589050292969	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1887	-0.3636589050292969	left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
P-1887	-0.4718 -0.0643 -1.6343 -0.2440 -0.2203 -0.2258 -0.1089 -0.4996 -0.0208 -0.2965 -1.0541 -0.1399 -0.5320 -0.0980 -0.1198 -0.4963 -0.0376 -0.2833 -0.0903 -0.3301 -0.0150 -0.3288 -1.5492 -0.0390 -0.4755 -0.3083 -0.1351
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
H-451	-0.3408434987068176	▁β - ad r energi c ▁receptor ▁block er ▁ therapy ▁; ▁my o card ial ▁per fusion ▁; ▁neo angi ogen es is ▁; ▁fail ing ▁heart
D-451	-0.3408434987068176	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
P-451	-0.0191 -0.0457 -0.0774 -0.3071 -0.7264 -0.0263 -0.0231 -0.5091 -0.1325 -1.3061 -0.0412 -0.4733 -0.8345 -0.2329 -0.4771 -1.2171 -0.2419 -0.0229 -0.2655 -0.0781 -0.0163 -0.0954 -0.1073 -0.1247 -0.2430 -1.6539 -0.0546 -0.5244 -0.2480 -0.1005
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
H-1780	-0.45697492361068726	▁cardiac ▁hyper trop hy ▁; ▁pressure - over load ▁; ▁abdominal ▁a or tic ▁con stri ction ▁; ▁a ac
D-1780	-0.45697492361068726	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
P-1780	-1.9792 -0.2275 -0.0518 -1.2869 -0.3797 -0.3444 -0.1282 -0.0430 -0.1363 -0.5458 -0.0860 -0.1649 -0.3041 -0.9793 -0.0330 -1.5870 -0.1205 -0.6883 -0.3118 -0.2931 -0.2444 -0.1182
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline ; hgb ; correlated ; baseline ; kccq ; hgb ; exercise ; training ; hrqol
H-839	-0.6866343021392822	▁h gb ▁; ▁k cc q ▁scale s ▁; ▁h gb ▁; ▁exercise ▁training ▁; ▁HR Qo L
D-839	-0.6866343021392822	hgb ; kccq scales ; hgb ; exercise training ; HRQoL
P-839	-1.7301 -0.3357 -0.2063 -2.3399 -0.0685 -1.4879 -1.1644 -0.0831 -0.1779 -0.7916 -0.2718 -0.1520 -1.0578 -1.0531 -0.2576 -0.6690 -0.0086 -1.4733 -0.2966 -0.1075
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient ; patients ; heart failure ; hospital ; discharge ; readmissions ; patient ; follow-up
H-722	-1.0716136693954468	▁heart ▁failure ▁; ▁hospital ▁dis charge ▁; ▁read missions
D-722	-1.0716136693954468	heart failure ; hospital discharge ; readmissions
P-722	-4.9992 -0.4137 -0.6953 -2.1646 -1.2962 -0.0941 -0.8284 -0.5508 -0.2275 -0.3863 -0.1316
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; svr ; cardiac index
H-225	-0.3777076005935669	▁Font an ▁failure ▁; ▁hem o dynamic ally ▁; ▁heart ▁failure ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁s VR ▁; ▁index ▁; ▁pres er ved ▁cardiac ▁index
D-225	-0.3777076005935669	Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; index ; preserved cardiac index
P-225	-0.4452 -0.1098 -0.2497 -0.2539 -0.9108 -0.2849 -0.0070 -0.3759 -0.6610 -2.8358 -0.1111 -0.2255 -0.1086 -0.3493 -0.0990 -0.5830 -0.0877 -0.0508 -0.2621 -0.8356 -0.5012 -0.3595 -0.3557 -0.2136 -0.6033 -0.0553 -0.3935 -0.0546 -0.0101 -0.2440 -0.0715
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous hf
H-1156	-0.3735307455062866	▁my o fi ber ▁dynamic s ▁; ▁my o fi ber ▁; ▁EM d ▁; ▁dys syn chron ous ▁ HF
D-1156	-0.3735307455062866	myofiber dynamics ; myofiber ; EMd ; dyssynchronous HF
P-1156	-0.9460 -0.4187 -0.0719 -0.2791 -0.1207 -0.0966 -0.3887 -0.3815 -0.2738 -0.0891 -0.2640 -0.8342 -1.7434 -0.6072 -0.1748 -0.0561 -0.0225 -0.0039 -0.8562 -0.2486 -0.3081 -0.3104 -0.0956
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial index ; pulse-wave ; coronary artery calcium scores
H-1562	-0.25753358006477356	▁cru de ▁; ▁an kle - bra chi al ▁index ▁; ▁puls e - wa ve ▁veloci ty ▁; ▁corona ry ▁arter y ▁calci um ▁score s
D-1562	-0.25753358006477356	crude ; ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
P-1562	-0.2902 -0.0804 -0.2348 -0.9381 -0.3908 -0.1628 -0.2554 -0.6398 -0.0939 -0.0480 -0.4117 -0.0683 -0.2234 -0.0688 -0.1648 -0.0914 -0.1990 -0.0934 -0.3853 -0.0425 -1.0452 -0.0138 -0.4644 -0.1779 -0.0373 -0.1666 -0.3284 -0.2739 -0.0785
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate ; unfolded protein response ; upr ; scn5a ; remodeling ; hf
H-1081	-0.4130761921405792	▁tru nca ted ▁na + ▁channel s ▁; ▁un fold ed ▁protein ▁response ▁; ▁u PR ▁; ▁s cn 5 a ▁electric ▁remodel ing ▁; ▁ HF
D-1081	-0.4130761921405792	truncated na+ channels ; unfolded protein response ; uPR ; scn5a electric remodeling ; HF
P-1081	-0.7697 -0.1934 -0.0882 -0.1049 -0.7557 -0.0412 -0.1577 -0.6437 -0.0164 -0.0051 -0.0540 -0.1129 -0.0949 -0.2019 -1.4829 -0.6095 -0.1619 -2.2865 -0.2235 -0.1622 -0.2626 -0.4002 -0.0397 -0.0359 -0.1808 -1.5086 -1.0234 -0.2863 -0.0755
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary endpoint ; intermacs ; interagency registry for mechanically assisted circulatory support
H-1996	-0.9240809082984924	▁inter ma cs ▁; ▁inter age ncy ▁Registr y ▁for ▁Mechanic ally ▁Assist ed ▁circula tory ▁Support
D-1996	-0.9240809082984924	intermacs ; interagency Registry for Mechanically Assisted circulatory Support
P-1996	-1.5737 -2.8397 -4.1860 -0.7147 -2.4958 -0.6228 -0.0276 -0.8532 -0.1053 -0.5928 -0.1535 -0.6570 -0.2555 -0.8075 -0.2870 -0.1878 -0.6333 -0.4365 -0.1279
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol ; lv contractile function ; xo-mediated ros ; myofilament ; sensitivity
H-477	-0.4469991624355316	▁allo puri nol ▁; ▁LV ▁contract ile ▁function ▁; ▁efficiency ▁; ▁ XO - media ted ▁ ROS ▁effects ▁; ▁my o fila ment
D-477	-0.4469991624355316	allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS effects ; myofilament
P-477	-0.0158 -0.0150 -0.4276 -0.1912 -1.0256 -0.0162 -0.0802 -0.3669 -0.2827 -1.0736 -0.2085 -0.3806 -0.0759 -0.0194 -0.0738 -0.1257 -0.1199 -0.2308 -2.1095 -0.4778 -0.6050 -0.1167 -0.0057 -0.7456 -2.7366 -0.0958
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic function ; hfpef ; patients ; long axis function ; exercise
H-1888	-0.48815783858299255	▁techniek ▁; ▁sy sto lic ▁function ▁; ▁ HF p EF ▁; ▁long ▁a xis ▁function ▁; ▁exercise
D-1888	-0.48815783858299255	techniek ; systolic function ; HFpEF ; long axis function ; exercise
P-1888	-3.6709 -0.3715 -0.1817 -0.1697 -0.1533 -0.1148 -0.2087 -1.6001 -0.2901 -0.0698 -0.2776 -0.5333 -0.5155 -0.0920 -0.0441 -0.0567 -0.4712 -0.6298 -0.1995 -0.1128
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians ; patients ; heart failure ; equitable ; therapeutic
H-1823	-1.2662413120269775	▁physician s ▁; ▁advanced ▁heart ▁failure
D-1823	-1.2662413120269775	physicians ; advanced heart failure
P-1823	-3.7457 -0.1456 -0.9544 -3.0191 -0.6109 -0.1401 -1.3870 -0.1271
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf ; multivariate-adjusted odds ratio ; mortality ; hazard ratio ; mortality
H-1312	-1.0735135078430176	▁con current ▁ HF ▁; ▁mortal ity ▁; ▁hazard ▁ratio
D-1312	-1.0735135078430176	concurrent HF ; mortality ; hazard ratio
P-1312	-4.2948 -0.0901 -0.3654 -0.3177 -0.8439 -1.4041 -2.2731 -0.7463 -0.1136 -0.0587 -2.2281 -0.1463
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas ; hf ; hyperkalemia ; hypokalemia ; spironolactone ; clinical
H-1708	-0.5293484330177307	▁AA s ▁; ▁ HF ▁; ▁hyper kal emia ▁; ▁hypo kal emia ▁; ▁spi rono lac tone
D-1708	-0.5293484330177307	AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
P-1708	-1.1956 -0.5041 -0.7472 -1.4073 -0.9097 -0.4560 -0.7421 -0.3975 -0.3781 -0.2433 -0.0741 -0.5585 -0.5916 -0.2292 -0.0357 -0.0207 -0.0354 -0.0486 -1.9200 -0.0923
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors ; g-protein-coupled receptor ; kinase-2 ; downregulation
H-1407	-0.26457345485687256	▁receptor s ▁; ▁g - prote in - co up led ▁receptor ▁kina se -2
D-1407	-0.26457345485687256	receptors ; g-protein-coupled receptor kinase-2
P-1407	-0.4092 -0.5116 -0.8474 -0.1996 -0.1214 -0.0259 -0.2340 -0.1011 -0.0279 -0.1281 -0.6604 -0.0231 -0.0593 -0.0427 -0.0447 -0.9657 -0.0958
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp ; nonterminal epitopes ; central glycosylated region
H-1522	-0.4603528380393982	▁NT - pro b NP ▁as say ▁; ▁non termin al ▁e pito pes ▁; ▁gly cos yla ted
D-1522	-0.4603528380393982	NT-probNP assay ; nonterminal epitopes ; glycosylated
P-1522	-0.0803 -0.0696 -0.0230 -0.5034 -0.8999 -0.2334 -0.1984 -0.8138 -0.6850 -0.9152 -0.0101 -0.0637 -0.1324 -0.8047 -0.8674 -0.1235 -0.4489 -0.5465 -0.1688 -1.9642 -0.1152
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a ; angii ; hypoxia ; expression ; upr ; downregulation
H-1085	-0.6629326939582825	▁s cn 5 a ▁; ▁Ang II ▁; ▁hypo xia ▁; ▁u PR ▁; ▁na + ▁current
D-1085	-0.6629326939582825	scn5a ; AngII ; hypoxia ; uPR ; na+ current
P-1085	-1.1844 -0.1919 -0.5862 -0.1606 -0.4150 -0.9712 -0.6479 -0.1405 -0.0763 -0.0157 -0.1757 -3.1229 -0.9634 -0.6073 -1.7835 -1.2507 -0.0292 -0.1705 -0.1029
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients ; heart transplant ; prospectively ; ecct
H-710	-0.6387522220611572	▁isola ted ▁heart ▁transplant ▁; ▁ec CT
D-710	-0.6387522220611572	isolated heart transplant ; ecCT
P-710	-0.3248 -0.6084 -1.4084 -0.0720 -0.7981 -0.2902 -1.9174 -0.1914 -0.1381
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate logistic regression analysis ; bnp ; patients ; diastolic dysfunction
H-1571	-0.38379746675491333	▁b NP ▁; ▁dia sto lic ▁dys function
D-1571	-0.38379746675491333	bNP ; diastolic dysfunction
P-1571	-0.8314 -1.5459 -0.3094 -0.0297 -0.0511 -0.3507 -0.0931 -0.3245 -0.2023 -0.0998
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate ratio ; therapy ; patient ; comorbidities
H-663	-0.9429879188537598	▁ therapy ▁; ▁como rbi di ties
D-663	-0.9429879188537598	therapy ; comorbidities
P-663	-2.5215 -0.5577 -1.1409 -2.8873 -0.0397 -0.8762 -0.1028 -0.2182 -0.1425
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization ; medicare ; hospital ; medicare ; policy
H-1715	-0.40780577063560486	▁re hospital ization ▁; ▁Medica re ▁hospital ▁claims ▁; ▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1715	-0.40780577063560486	rehospitalization ; Medicare hospital claims ; Medicare ; post-acute care transfer policy
P-1715	-1.8276 -0.1023 -0.5933 -0.5457 -0.0250 -0.0176 -1.7953 -0.4879 -0.2026 -0.0488 -0.0191 -0.6888 -0.0413 -0.0284 -0.1195 -0.0347 -0.5892 -0.3902 -0.6611 -0.2225 -0.1230
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart failure ; compliance ; etidronate ; alendronate
H-1543	-0.2373049259185791	▁heart ▁failure ▁; ▁re fill ▁compliance ▁; ▁et id rona te ▁; ▁ale ndr onate
D-1543	-0.2373049259185791	heart failure ; refill compliance ; etidronate ; alendronate
P-1543	-1.2910 -0.2319 -0.2144 -0.1831 -0.1169 -0.8499 -0.1132 -0.0146 -0.0545 -0.0216 -0.0356 -0.1319 -0.3350 -0.0178 -0.1007 -0.2479 -0.0742
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis ; metabolic exercise ; cardiac ; kidney
H-1762	-0.40638571977615356	▁AT ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score
D-1762	-0.40638571977615356	AT ; metabolic exercise ; cardiac ; kidney index score
P-1762	-0.2197 -1.3799 -0.0447 -0.0543 -0.2461 -0.2360 -0.0167 -1.4679 -0.0719 -0.4148 -0.0818 -0.0141 -0.0677 -1.6821 -0.0981
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical ; activity ; crf ; hf ; mortality
H-1776	-0.6355728507041931	▁physical ▁activity ▁; ▁c RF ▁; ▁ HF ▁mortal ity
D-1776	-0.6355728507041931	physical activity ; cRF ; HF mortality
P-1776	-2.4553 -0.8886 -0.2858 -0.1846 -0.6351 -0.2903 -0.8523 -0.3470 -0.1258 -1.2234 -0.2404 -0.0984
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular pathways ; patients ; chronic heart failure ; chf
H-249	-0.8168851733207703	▁et ▁; ▁HD L - media ted ▁protect ive ▁effects ▁; ▁molecular ▁path ways ▁; ▁chronic ▁heart ▁failure ▁; CH f
D-249	-0.8168851733207703	et ; HDL-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
P-249	-0.8147 -0.9104 -5.9513 -1.9907 -0.0990 -0.1204 -0.1022 -1.0475 -0.2970 -0.7093 -0.3506 -0.7503 -0.1059 -0.1116 -0.5521 -0.5988 -0.5641 -0.3107 -0.2823 -1.1989 -1.5611 -0.2621 -0.0972
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo ; dopamine ; nesiritide ; secondary end points ; renal function ; clinical ; outcomes
H-82	-0.388496071100235	▁dop amine ▁; ▁nesi riti de ▁; ▁renal ▁function
D-82	-0.388496071100235	dopamine ; nesiritide ; renal function
P-82	-0.3736 -0.1650 -0.1573 -0.0418 -0.0339 -0.2371 -0.4292 -1.9607 -0.5197 -0.2638 -0.0913
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia ; medline ; cochrane library
H-31	-0.48387089371681213	▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁med line ▁; ▁co ch rane ▁Library
D-31	-0.48387089371681213	anemia ; iron deficiency ; medline ; cochrane Library
P-31	-4.2146 -0.2667 -0.6920 -0.0230 -0.0845 -0.0800 -0.0083 -0.3613 -0.0659 -0.7225 -0.8597 -0.7795 -0.2705 -0.0545 -0.1915 -0.0680 -0.0573 -0.2631 -0.1307
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq ; patients ; hfpef
H-790	-0.8812524080276489	▁k cc q ▁; ▁interne ▁consiste ncy ▁; ▁ HF p EF ▁; ▁ ron bach
D-790	-0.8812524080276489	kccq ; interne consistency ; HFpEF ; ronbach
P-790	-2.0676 -0.0742 -1.3454 -0.6195 -1.9635 -0.7325 -0.0472 -0.2921 -0.9112 -0.4130 -0.0793 -0.4481 -0.3604 -1.5170 -3.9874 -0.0355 -0.8911 -0.0775
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable ; patients ; qrs duration
H-891	-0.4767015874385834	▁implant able ▁cardio ver ter ▁de fi br illa tor - c RT ▁; ▁non - LB bb ▁; ▁QR s
D-891	-0.4767015874385834	implantable cardioverter defibrillator-cRT ; non-LBbb ; QRs
P-891	-0.4009 -0.0574 -0.0813 -0.0249 -0.0873 -0.7520 -0.0171 -0.1066 -0.0615 -0.0258 -0.1297 -1.3246 -1.7574 -0.3600 -1.7204 -0.0496 -0.0596 -1.0388 -1.0912 -0.0229 -0.7278 -0.9613 -0.1061
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal ; diagnostic ; clinical
H-1304	-1.171639323234558	
D-1304	-1.171639323234558	
P-1304	-2.2566 -0.0867
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up ; patients
H-1538	-0.5804589986801147	▁ale ndr onate ▁; ▁et id rona te - ▁; ▁ra lo xi fen e - tre ated
D-1538	-0.5804589986801147	alendronate ; etidronate- ; raloxifene-treated
P-1538	-2.6198 -0.0276 -0.0416 -2.9108 -0.0059 -0.0286 -0.0089 -0.0220 -0.7130 -2.1454 -0.3877 -0.0276 -0.1401 -0.0201 -0.1244 -0.1737 -0.0139 -0.6139 -1.4571 -0.1272
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy ; trastuzumab ; comorbidities ; chf ; international classification of diseases ; healthcare common procedure coding system codes
H-674	-0.2898859679698944	▁che mo therapy ▁; ▁tras tuz um ab ▁; ▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁health care ▁common ▁procedure ▁co ding ▁system ▁code s
D-674	-0.2898859679698944	chemotherapy ; trastuzumab ; CHF ; international Classification of Diseases ; healthcare common procedure coding system codes
P-674	-0.7645 -0.4993 -0.0315 -0.1996 -0.0740 -0.0517 -0.0239 -0.4646 -0.4598 -0.7658 -0.4691 -0.3442 -0.0894 -0.0568 -0.0942 -0.0460 -0.0388 -0.3094 -0.7982 -0.0303 -0.6598 -0.2651 -1.0045 -0.0468 -0.3332 -0.0597 -0.0936 -0.2373 -0.0954
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart failure ; hf ; therapies ; outcomes ; patients ; hf ; preserved left ventricular ejection fraction ; lvef
H-111	-0.5906482338905334	▁con tempor ary ▁heart ▁failure ▁; HF ▁; ▁ therapie s ▁; ▁ HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF
D-111	-0.5906482338905334	contemporary heart failure ;HF ; therapies ; HF ; left ventricular ejection fraction ;LVEF
P-111	-1.5469 -0.0033 -0.3060 -0.5855 -0.0836 -0.4218 -0.2736 -0.3393 -1.8933 -1.3744 -0.1505 -0.4410 -2.0219 -0.4952 -0.2482 -1.5755 -0.0423 -1.9552 -0.3139 -0.1099 -0.2864 -0.1691 -0.7424 -0.0191 -0.5484 -0.6799 -0.1811 -0.2220 -0.0991
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart ; patients ; hfpef ; hf with reduced ejection fraction ; hfref
H-240	-0.5525939464569092	▁h ART ▁; ▁ HF p EF ▁; ▁ HF ▁met ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF
D-240	-0.5525939464569092	hART ; HFpEF ; HF met reduced ejection fraction ;HFrEF
P-240	-1.8021 -0.0513 -0.3219 -0.9799 -0.3089 -0.2218 -0.4338 -0.2058 -1.4744 -0.4245 -3.2468 -1.1599 -0.0600 -0.0325 -0.1749 -0.0655 -0.2012 -0.0129 -0.2722 -1.0409 -0.1464 -0.2839 -0.2399 -0.1005
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced hf ; cxl-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
H-421	-0.5506196618080139	▁ conscious ▁dog s ▁; ▁ta chy pac ing - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁contract ility ▁; ▁elastan ce ▁; ▁ve no arte rial ▁di lation
D-421	-0.5506196618080139	conscious dogs ; tachypacing-induced HF ; cXL-1020 ; contractility ; elastance ; venoarterial dilation
P-421	-1.9659 -0.3662 -1.0076 -0.1285 -0.5880 -0.5332 -1.1765 -0.0170 -0.1340 -0.0974 -0.0301 -0.1157 -0.3306 -0.6820 -0.2331 -0.5719 -0.5211 -0.1644 -0.0559 -0.8944 -0.0041 -0.1066 -0.3939 -5.3161 -1.1173 -0.5216 -0.8769 -0.0424 -0.0563 -0.0786 -0.1886 -0.0590 -0.2610 -0.0856
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone morphogenetic protein 4 ; expression ; rrna transcription ; shift ; heterochromatic chromatin
H-98	-0.43863168358802795	▁bone ▁mor pho gene tic ▁protein ▁; ▁r RNA ▁tran scription ▁; ▁hetero ch ro matic ▁chr omat in
D-98	-0.43863168358802795	bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
P-98	-0.4207 -0.4451 -0.4485 -1.5787 -1.9539 -0.2440 -0.4125 -0.0137 -0.0342 -0.0318 -0.0186 -0.8634 -0.4082 -0.2762 -0.0909 -0.4134 -0.0139 -0.0468 -1.0773 -0.3097 -0.1097
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ; gluconeogenesis ; citrate cycle
H-873	-0.2639940679073334	▁act in ▁cy tos kelet on ▁; ▁mito cho ndri al ▁function ▁; ▁intermedi ate ▁metabolism ▁; ▁gly col ysis ▁; glu cone ogen es is ▁; ▁cit rate ▁cycle
D-873	-0.2639940679073334	actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
P-873	-0.0136 -0.8278 -0.3713 -1.0624 -0.1430 -0.2961 -0.3302 -0.0143 -0.8638 -0.2325 -0.0272 -0.1681 -0.2097 -0.1328 -0.7855 -0.1440 -0.1718 -0.0191 -0.0430 -0.2223 -0.5458 -0.0700 -0.0420 -0.5139 -0.0766 -0.1388 -0.2892 -0.0618 -0.0811 -0.2425 -0.2116 -0.0961
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated ; resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
H-939	-0.43291184306144714	▁resist in ▁; ▁an thra cycli ne - indu ced ▁cardio toxic iteit ▁; ▁heart ▁failure ▁; ▁macro pha ges
D-939	-0.43291184306144714	resistin ; anthracycline-induced cardiotoxiciteit ; heart failure ; macrophages
P-939	-1.2512 -0.4768 -0.4012 -0.3698 -0.0210 -0.1823 -1.1017 -0.3270 -0.0489 -0.1265 -0.0466 -0.4009 -2.0392 -0.2810 -0.5639 -0.1290 -0.5209 -0.1433 -0.0252 -0.7253 -0.2501 -0.0924
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular matrix ; left ventricular ; biopsies ; tissuefaxs ; correlated ; t1 time
H-741	-0.4405846893787384	▁extra cel lular ▁matri x ▁; ▁left ▁vent ri cular ▁bio psi es ▁; ▁t issue FAX s ▁technology
D-741	-0.4405846893787384	extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
P-741	-0.4889 -0.0625 -0.0698 -0.0141 -0.2058 -0.8335 -0.0521 -0.0658 -2.2847 -0.4346 -0.0642 -0.3260 -0.4355 -0.3324 -2.0094 -0.0068 -0.1063 -0.7095 -0.2754 -0.3947 -0.0804
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients ; systolic hf ; the danish heart failure database ; esrd ; danish registry on dialysis
H-389	-0.5938864350318909	▁sy sto lic ▁ HF ▁; ▁Danish ▁Heart ▁Fail ure ▁database ▁; ▁ES RD ▁; ▁Danish ▁Registr y ▁on ▁Dia lys is
D-389	-0.5938864350318909	systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
P-389	-0.1731 -0.1391 -0.0307 -0.2891 -0.3093 -0.4135 -2.6959 -0.4665 -0.2393 -0.5100 -0.0639 -0.1540 -1.5163 -0.8514 -0.2820 -2.2580 -1.9338 -0.1791 -0.1695 -0.8475 -0.1035 -0.2543 -0.2842 -0.0893
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left ventricular assist devices ; lvads ; patients ; heart failure ; incidence ; pump dysfunction ; pump
H-773	-0.4868077337741852	▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁advanced ▁heart ▁failure ▁; ▁pump ▁dys function ▁; ▁pump ▁replace ment
D-773	-0.4868077337741852	left ventricular assist devices ; lVADs ; advanced heart failure ; pump dysfunction ; pump replacement
P-773	-0.0601 -0.0468 -2.0302 -0.1508 -0.5668 -0.2526 -0.5145 -0.0721 -0.0318 -0.1749 -0.5087 -4.0588 -0.6408 -0.2356 -0.3194 -0.3344 -0.0529 -0.0284 -0.2489 -0.2794 -0.3180 -0.4226 -0.2310 -0.1040
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable models ; st2 ; outcomes ; clinical ; amino-terminal pro-b-type natriuretic peptide
H-704	-0.4745853841304779	▁ST 2 ▁; ▁amino - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de
D-704	-0.4745853841304779	ST2 ; amino-terminal pro-b-type natriuretic peptide
P-704	-0.4029 -0.1066 -1.0021 -1.1817 -0.0800 -0.1011 -0.0137 -0.5334 -0.0382 -1.1848 -0.0289 -0.0074 -0.0257 -0.4444 -0.7981 -1.9136 -0.8574 -0.2048 -0.7197 -0.2280 -0.0937
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular pacing ; bivp ; cardiac output ; cardiac ; surgery ; patients
H-319	-0.867416501045227	▁Bi ven tri cular ▁pa cing ▁; Bi VP ▁; ▁cardiac ▁output ▁; co ▁; ▁cardiac ▁surgery
D-319	-0.867416501045227	Biventricular pacing ;BiVP ; cardiac output ;co ; cardiac surgery
P-319	-3.0587 -0.1611 -4.2657 -0.7732 -0.0332 -0.7379 -0.4667 -2.3558 -0.3648 -0.4101 -0.0932 -0.0283 -0.2407 -1.3740 -0.4235 -0.0857 -0.0446 -1.4308 -0.1328
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully magnetically levitated lvas ; mortality ; seattle ; heart failure
H-2002	-0.5436013340950012	▁fully ▁magnet ically ▁le vita ted ▁l VAS ▁; ▁Seattle ▁Heart ▁Fail ure
D-2002	-0.5436013340950012	fully magnetically levitated lVAS ; Seattle Heart Failure
P-2002	-3.1470 -0.0496 -0.2211 -0.0321 -0.0286 -0.2818 -0.1918 -0.2760 -0.7122 -1.4851 -0.4277 -0.2003 -0.6669 -0.3343 -0.0995
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients ; new york heart association ; nyha ; chronic heart failure ; reduced ejection fraction
H-1952	-0.5706546902656555	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁chronic ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction ▁; ▁Canadian ▁special ▁access ▁programme
D-1952	-0.5706546902656555	New York Heart association ;NYha ; chronic heart failure ; reduced ejection fraction ; Canadian special access programme
P-1952	-1.1345 -0.5874 -1.5730 -0.3021 -0.3526 -0.5382 -0.7800 -0.7334 -0.9868 -0.3740 -0.1838 -0.7070 -1.5724 -0.0280 -0.0243 -0.1088 -0.0389 -0.2636 -0.0116 -1.0510 -1.8008 -0.9630 -0.1635 -0.1519 -0.3076 -0.0990
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa ; immunoassays ; antibodies ; c termini ; nt-probnp
H-1518	-0.5009370446205139	▁Alpha LIS a ▁immun o assa ys ▁; ▁anti bo dies ▁; ▁termini ▁; ▁circula ting ▁NT - pro b NP
D-1518	-0.5009370446205139	AlphaLISa immunoassays ; antibodies ; termini ; circulating NT-probNP
P-1518	-0.0544 -0.3564 -0.4138 -0.0601 -0.4442 -0.1669 -1.8085 -0.3391 -0.0428 -0.0424 -0.9198 -0.9073 -3.4908 -0.2283 -0.0014 -0.0599 -0.6034 -0.0535 -0.0588 -0.9399 -0.2700 -0.1903 -0.0697
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine ; bnp ; furosemide ; dobutamine ; norepinephrine ; outcome
H-587	-0.2904481589794159	▁creati nine ▁; ▁b NP ▁; ▁fur os em ide ▁dose ▁; ▁oxygen ▁flow ▁; ▁dobu tamine ▁; ▁no re pine ph rine
D-587	-0.2904481589794159	creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
P-587	-0.3549 -0.2783 -0.2154 -0.8986 -1.3088 -0.1889 -0.4703 -0.2498 -0.0577 -0.0996 -0.1367 -0.1116 -0.2085 -0.1177 -0.1582 -0.0323 -0.0405 -0.1256 -0.0111 -0.0474 -0.0118 -0.7154 -0.0453 -1.2944 -0.0825
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule ; expression ; regulation ; rad ; q66p ; rgk protein ; in vivo
H-1678	-0.6172632575035095	▁mis tar ge ting ▁; ▁alter ed ▁regula tion ▁; ▁Rad ▁Q 66 p ▁; ▁r GK ▁protein ▁; ▁ef fica cy ▁in ▁vivo
D-1678	-0.6172632575035095	mistargeting ; altered regulation ; Rad Q66p ; rGK protein ; efficacy in vivo
P-1678	-3.2811 -0.1563 -0.1939 -0.0918 -0.1725 -1.4527 -0.0559 -0.2351 -0.2305 -0.3024 -2.0974 -0.6994 -0.4493 -0.2238 -0.2004 -0.4818 -0.2389 -0.2018 -1.3790 -1.8320 -0.1867 -0.0843 -1.4111 -0.0023 -0.3145 -0.0739
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte hypertrophy ; heart failure ; global gene expression ; dna ; genomic
H-89	-0.6095647215843201	▁My o cy te ▁hyper trop hy ▁antecede nt ▁to ▁heart ▁failure ▁; ▁gene ▁expression ▁; ▁DNA
D-89	-0.6095647215843201	Myocyte hypertrophy antecedent to heart failure ; gene expression ; DNA
P-89	-0.6738 -0.1126 -0.0852 -0.0405 -0.0964 -0.0246 -0.7401 -1.1522 -0.0206 -0.8715 -1.1012 -0.2906 -0.6618 -2.5106 -0.3411 -0.9210 -0.4040 -1.4234 -0.1106
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change ; correlation ; hospitals ; longitudinal
H-138	-1.315968632698059	▁hospital s
D-138	-1.315968632698059	hospitals
P-138	-3.9385 -0.5018 -0.7141 -0.1095
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical ; biomedical ; patients ; dcm ; heart failure ; pubmed
H-1259	-0.3408088982105255	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure ▁; ▁Pub Med
D-1259	-0.3408088982105255	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure ; PubMed
P-1259	-0.0657 -0.1110 -0.0127 -0.7967 -0.4919 -1.0039 -0.3532 -0.5858 -0.0194 -0.0606 -0.0170 -0.4426 -0.7681 -0.1408 -0.2378 -0.2291 -0.7492 -0.1542 -1.1474 -0.0685 -0.1128 -0.1779 -0.0924
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 ; sst2 ; odds ratio ; cardiovascular event
H-408	-0.8534418940544128	▁s st 2/ high - dos e ▁BB ▁; ▁s st 2 ▁; ▁BB ▁; ▁cardiovascular ▁event
D-408	-0.8534418940544128	sst2/high-dose BB ; sst2 ; BB ; cardiovascular event
P-408	-0.2340 -1.5637 -0.9621 -1.2531 -0.0663 -0.8425 -0.2570 -1.6946 -1.0248 -0.0568 -1.7464 -0.1056 -0.7837 -2.9212 -1.0449 -0.3601 -1.0097 -0.1735 -0.1156
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones ; adipokines ; fat free mass ; ffm ; fat mass
H-11	-0.3580019176006317	▁neuro hormon es ▁; ▁adi pok ines ▁; cc ▁; ▁fat ▁free ▁mass ▁; ▁f m ▁; ▁fat ▁mass ▁; FM
D-11	-0.3580019176006317	neurohormones ; adipokines ;cc ; fat free mass ; fm ; fat mass ;FM
P-11	-0.0529 -0.0538 -0.2389 -0.2483 -0.0134 -0.0669 -0.1846 -0.3047 -1.2854 -0.2471 -1.3653 -0.2276 -0.0895 -0.2874 -1.6272 -0.3245 -0.4746 -0.1691 -0.0729 -0.4850 -0.0574 -0.2594 -0.0982
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac plasma membrane ; s1pr1 ; β1ar ; heart failure
H-1411	-0.629270613193512	▁cardiac ▁plasma ▁membran e ▁; ▁s 1 PR 1 ▁; ▁β 1 AR ▁over stimul ation ▁; ▁heart ▁failure
D-1411	-0.629270613193512	cardiac plasma membrane ; s1PR1 ; β1AR overstimulation ; heart failure
P-1411	-2.2896 -0.0850 -0.0054 -0.0548 -0.9215 -0.8010 -0.6171 -0.7179 -2.5471 -0.5504 -0.3430 -1.1284 -1.0452 -0.0869 -0.1049 -0.7930 -0.3775 -0.2599 -0.1386 -0.2368 -0.1107
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley ; randomized ; acf ; allopurinol
H-473	-0.47681501507759094	▁Spr a gue - ▁da w ley ▁rat s ▁; ▁sham ▁; ▁a CF ▁; ▁allo puri nol
D-473	-0.47681501507759094	Sprague- dawley rats ; sham ; aCF ; allopurinol
P-473	-0.4910 -0.3273 -0.2569 -0.0365 -0.4778 -0.0056 -0.4608 -0.9270 -0.1144 -0.7492 -0.1086 -0.2561 -0.9808 -1.2644 -0.5046 -0.0978 -0.0240 -0.6944 -1.6395 -0.1197
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 ; myocardial collagen ; myocardial
H-1064	-0.39100971817970276	▁my o card ial ▁collage n ▁; ▁my o card ial ▁de lay ed ▁enhance ment ▁imagin g
D-1064	-0.39100971817970276	myocardial collagen ; myocardial delayed enhancement imaging
P-1064	-1.8693 -0.3501 -0.4635 -0.7145 -0.0874 -0.2132 -0.3079 -0.9187 -0.3116 -0.4718 -1.0382 -0.0317 -0.0533 -0.0751 -0.3361 -0.1059 -0.0757 -0.1057 -0.2222 -0.0681
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin ; sitagliptin ; follow-up
H-1833	-0.8392311334609985	▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁follow - up
D-1833	-0.8392311334609985	saxagliptin ; sitagliptin ; follow-up
P-1833	-0.2671 -0.0291 -0.4655 -3.0184 -0.5914 -2.1326 -0.4322 -0.3564 -2.8305 -1.2653 -0.0776 -0.2972 -0.0457 -0.6836 -0.0957
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter ablation ; patients ; compensated hfpef ; left ventricular ; ejection fraction
H-944	-0.42915472388267517	▁Cat heter ▁ab lation ▁; ▁AF ▁; ▁compensa ted ▁H FP EF ▁; ▁le ft ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-944	-0.42915472388267517	Catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV ; ejection fraction
P-944	-1.3778 -0.0563 -0.0193 -0.1482 -0.8796 -0.1919 -0.4845 -0.1079 -0.0899 -1.5173 -0.5135 -0.6618 -0.3198 -1.3144 -0.0286 -0.0427 -2.0072 -0.0761 -0.2410 -0.3998 -0.3943 -0.0251 -0.1233 -0.0488 -0.5774 -0.0079 -0.2683 -0.0936
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy ; sst2 ; patients ; chronic heart failure
H-411	-0.6267521381378174	▁BB ▁ therapy ▁; ▁s st 2 ▁measure ment ▁; ▁chronic ▁heart ▁failure ▁; ▁BB
D-411	-0.6267521381378174	BB therapy ; sst2 measurement ; chronic heart failure ; BB
P-411	-0.7937 -0.8646 -0.0812 -0.6992 -0.2371 -0.9265 -0.0295 -1.1479 -0.3162 -0.5491 -0.3622 -0.4712 -0.2539 -1.1121 -2.0929 -0.5745 -0.1428
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths ; crt ; hazard ratio
H-853	-1.187105417251587	▁c RT ▁; ▁control ▁group ▁; ▁hazard ▁ratio
D-853	-1.187105417251587	cRT ; control group ; hazard ratio
P-853	-0.4059 -4.1354 -1.3043 -3.4809 -0.8575 -0.5540 -0.1409 -0.0203 -0.8374 -0.1344
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd ; outpatients ; systolic hf ; patients ; egfr
H-396	-0.6702093482017517	▁ES RD ▁; ▁sy sto lic ▁ HF ▁; ▁e G FR
D-396	-0.6702093482017517	ESRD ; systolic HF ; eGFR
P-396	-2.9792 -0.8269 -0.4071 -0.6136 -0.0746 -0.0402 -0.3975 -0.3605 -0.3485 -0.1311 -2.4813 -0.2877 -0.2803 -0.1545
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse ; pasp ; step ; rv function ; lv dysfunction
H-501	-0.7887338995933533	▁pas p ▁; ▁length - force ▁relationship ▁; ▁ RV ▁function ▁evaluation ▁; ▁LV ▁dys function
D-501	-0.7887338995933533	pasp ; length-force relationship ; RV function evaluation ; LV dysfunction
P-501	-7.2801 -0.3938 -0.8340 -0.0848 -0.1107 -0.1013 -0.3747 -0.2732 -0.4168 -0.4082 -0.1206 -1.3808 -0.2353 -0.0825 -1.7548 -0.0573 -0.1947 -0.0936
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel ; apoptotic cells ; tunel-positive cells
H-172	-0.5357689261436462	▁tu nel ▁as say ▁; ▁apo pto tic ▁cell s ▁; ▁tu nel - posi tive ▁cell s
D-172	-0.5357689261436462	tunel assay ; apoptotic cells ; tunel-positive cells
P-172	-1.3936 -1.4457 -0.2149 -0.2785 -0.4281 -0.7132 -0.3068 -0.8228 -0.4580 -0.1397 -0.4678 -0.9901 -1.4216 -0.1608 -0.0025 -0.5433 -0.3126 -0.1123 -0.4116 -0.0915
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno donor ; myocardial function ; evidence ; hf
H-425	-0.9123120307922363	▁pure ▁H no ▁donor ▁; ▁my o card ial ▁function ▁; ▁ HF
D-425	-0.9123120307922363	pure Hno donor ; myocardial function ; HF
P-425	-4.9437 -1.1881 -0.8725 -0.1834 -0.3591 -1.0760 -0.3255 -0.2681 -1.3054 -0.2122 -0.2554 -1.6185 -0.7236 -0.2056 -0.1476
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular support ; rvads ; explanted
H-301	-0.8915960788726807	▁bi ven tri cular ▁support ▁; ▁r VAD s ▁; ▁ex plant ed
D-301	-0.8915960788726807	biventricular support ; rVADs ; explanted
P-301	-2.4779 -0.0935 -2.7018 -0.4535 -1.5561 -0.4475 -1.5215 -0.4900 -0.4210 -1.2709 -0.4728 -0.0594 -1.1104 -0.1922 -0.1054
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions ; readmission ; patients ; congestive heart failure ; south dakota
H-1583	-0.533898115158081	▁con ges tive ▁heart ▁failure ▁; ▁Mid we stern ▁state ▁; ▁South ▁da kota
D-1583	-0.533898115158081	congestive heart failure ; Midwestern state ; South dakota
P-1583	-0.4700 -0.6147 -1.3680 -0.4767 -0.1546 -0.5769 -1.3597 -0.0816 -0.2702 -0.6111 -0.2949 -1.2485 -0.3305 -0.0174 -0.5089 -0.1587
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes ; myocardium ; conditions
H-990	-0.37656688690185547	▁cardio my o cy tes ▁; ▁mechanic al ▁; ▁humor al ▁stimul i ▁; ▁my o car dium
D-990	-0.37656688690185547	cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
P-990	-0.1634 -0.3643 -0.2356 -0.1572 -0.1028 -0.5197 -1.4645 -0.0179 -0.6215 -0.0533 -0.0633 -0.2985 -0.5982 -0.3607 -0.4752 -0.0887 -0.0255 -0.2086 -1.6203 -0.0925
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation ; consultation ; consultation ; operation
H-1283	-1.4456355571746826	▁m t
D-1283	-1.4456355571746826	mt
P-1283	-1.6073 -2.3669 -1.7330 -0.0753
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox proportional hazards models ; death ; transplantation ; lv assist device implantation ; heart failure ; hospitalization ; follow-up
H-431	-0.5049061179161072	▁co x ▁proportion al ▁hazard s ▁; ▁transplant ation ▁; ▁LV ▁assist ▁device ▁implant ation ▁; ▁heart ▁failure ▁hospital ization
D-431	-0.5049061179161072	cox proportional hazards ; transplantation ; LV assist device implantation ; heart failure hospitalization
P-431	-0.1535 -0.0502 -0.0635 -0.0123 -0.0375 -0.4167 -0.8664 -4.7352 -0.6541 -0.2005 -0.0473 -0.2719 -0.0622 -0.3213 -0.4770 -0.3088 -0.5090 -0.2420 -0.8491 -0.5713 -0.1590 -0.0991
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity
H-964	-0.4709240198135376	▁Nico rand il ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se
D-964	-0.4709240198135376	Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase
P-964	-0.0013 -0.1152 -0.0829 -0.3763 -0.2319 -0.0631 -0.2094 -0.3409 -1.7267 -0.5192 -0.0218 -0.0176 -2.1100 -0.0652 -0.1702 -0.0859 -0.8842 -0.0147 -0.3902 -0.1477 -0.0264 -0.0268 -0.1168 -0.3591 -0.0388 -2.2129 -1.7603 -0.0854 -1.7880 -0.4114 -0.0041 -0.4280 -0.0026 -0.0562 -1.9689 -0.0935
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass correlation coefficient ; icc ; kappa coefficient ; standard error of measurement ; minimal detectable change ; mdc
H-801	-0.2661094069480896	▁intra class ▁corre lation ▁co e ffi cient ▁; ▁i cc ▁; ▁ka ppa ▁co e ffi cient ▁; ▁m d
D-801	-0.2661094069480896	intraclass correlation coefficient ; icc ; kappa coefficient ; md
P-801	-0.5041 -0.1080 -0.0743 -0.1914 -0.0627 -0.4164 -0.2621 -0.1862 -0.3387 -0.5628 -0.3568 -0.3845 -0.0233 -0.1944 -0.0312 -0.2339 -0.1337 -0.0793 -0.4250 -0.2489 -0.8629 -0.3348 -0.1051
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized ; heart failure ; saxagliptin ; sitagliptin ; antihyperglycemic drugs ; retrospective cohort study
H-1826	-0.5702651143074036	▁Hospital ized ▁Heart ▁Fail ure ▁; ▁Sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁Drug s
D-1826	-0.5702651143074036	Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
P-1826	-3.2307 -0.0923 -0.2450 -0.1150 -0.5443 -0.2813 -0.0287 -0.0172 -0.4902 -2.6433 -0.2348 -1.2590 -0.1713 -0.1043 -2.0203 -0.1624 -0.0867 -0.3118 -0.0911 -0.9146 -0.5425 -0.3208 -0.3625 -0.0555 -0.4164 -0.0848
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise ; training ; outcomes ; chronic heart failure ; heart failure - a controlled trial investigating outcomes in exercise training ; hf-action
H-1629	-0.647389829158783	▁race ▁; ▁exercise ▁training ▁; ▁chronic ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁; ▁tri al ▁Investiga ting ▁Out com es ▁in ▁Exerci se ▁Tra i N ing ▁; HF - ac TION
D-1629	-0.647389829158783	race ; exercise training ; chronic heart failure ; Heart Failure ; trial Investigating Outcomes in Exercise TraiNing ;HF-acTION
P-1629	-2.2298 -0.2684 -0.3103 -0.7694 -0.2230 -1.2087 -0.3709 -0.1745 -0.3738 -1.1592 -0.3067 -0.8500 -0.1401 -3.2373 -0.0312 -0.4359 -0.0542 -0.3949 -0.0499 -0.0389 -0.8148 -0.2224 -0.0685 -0.3258 -0.6922 -3.2962 -0.1451 -0.2851 -0.9264 -0.0405 -0.6034 -1.5965 -0.2701 -0.0971
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient ; primary end point ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cabg
H-972	-0.30267760157585144	▁Swedish ▁national ▁in patient ▁Registr y ▁; ▁re hospital ization ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca BG
D-972	-0.30267760157585144	Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
P-972	-0.3341 -0.6513 -0.0624 -0.1449 -1.1194 -0.1264 -0.3264 -0.1758 -0.0112 -0.4378 -0.3597 -0.2893 -0.1473 -0.3542 -0.5146 -0.1800 -0.5171 -0.0180 -0.2451 -0.1150 -0.1726 -0.4301 -0.0830 -0.3482 -0.4274 -0.5834 -0.2200 -0.0803
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients ; heart failure with preserved ejection fraction ; hfpef ; heart failure ; obese
H-1974	-0.4681304395198822	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF ▁; ▁heart ▁failure ▁; ▁over weight ▁; ▁obes e
D-1974	-0.4681304395198822	heart failure ; preserved ejection fraction ; hFPEF ; heart failure ; overweight ; obese
P-1974	-2.3999 -0.1864 -0.5911 -0.1089 -0.1290 -0.8230 -0.0441 -0.2032 -0.0413 -0.3693 -0.0185 -0.3459 -0.7463 -1.6517 -0.9573 -0.2733 -0.9280 -0.2539 -0.3146 -0.5623 -0.1243 -0.6955 -0.0174 -0.0695 -0.2080 -0.1090
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal dialysis ; pd ; diuretic ; volume overload ; heart failure ; hf
H-894	-0.3242892026901245	▁Peri tone al ▁di al ysis ▁; PD ▁; ▁di ure tic ▁resist ant ▁volume ▁over load ▁; ▁heart ▁failure ▁; HF
D-894	-0.3242892026901245	Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
P-894	-0.3254 -0.5154 -0.1092 -0.2233 -0.0619 -0.1741 -0.4361 -0.1478 -0.4368 -0.4338 -0.4417 -1.1833 -0.3817 -0.0328 -0.1966 -0.0583 -0.1179 -0.5121 -0.4513 -0.1650 -0.2181 -0.6187 -0.4448 -0.0969
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal dysfunction ; prognostic ; heart failure ; hf ; dysfunction ; end-stage renal disease ; esrd
H-387	-0.663754940032959	▁Ren al ▁dys function ▁; ▁heart ▁failure ▁; HF ▁; ▁renal ▁disease ▁; ▁e RD
D-387	-0.663754940032959	Renal dysfunction ; heart failure ;HF ; renal disease ; eRD
P-387	-3.3943 -0.3318 -0.1126 -0.2110 -0.3122 -2.1786 -0.2306 -0.2916 -0.3295 -0.2068 -0.1289 -0.1893 -0.1651 -1.3820 -1.4475 -0.2655 -0.1065
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression analysis ; echocardiographic ; lv reverse remodeling ; lv end-systolic volume
H-430	-0.3592391908168793	▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing ▁; ▁LV ▁end - sy sto lic ▁volume
D-430	-0.3592391908168793	echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
P-430	-0.6188 -0.2508 -0.0908 -0.7479 -0.5576 -0.4416 -0.1791 -0.0970 -0.3575 -0.0391 -0.0584 -0.0815 -0.2434 -0.4516 -2.3536 -0.0629 -0.6916 -0.1227 -0.0388 -0.1845 -0.1659 -0.0684
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral artery disease ; pad ; heart failure ; hf ; prevalence ; hf ; patients ; pad
H-1567	-0.5026480555534363	▁Peri pher al ▁arter y ▁disease ▁; PAD ▁; ▁heart ▁failure ▁; HF ▁; HF ▁; ▁ HF ▁; PAD
D-1567	-0.5026480555534363	Peripheral artery disease ;PAD ; heart failure ;HF ;HF ; HF ;PAD
P-1567	-0.0803 -0.0264 -0.1586 -0.0326 -0.6520 -0.3538 -0.2351 -0.1480 -0.1676 -0.5956 -0.2088 -0.2526 -0.3099 -0.1952 -1.7457 -0.2095 -2.3890 -0.4534 -0.2376 -2.2747 -0.1873 -0.1444
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission ; disease ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia
H-137	-0.6734922528266907	▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia
D-137	-0.6734922528266907	heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
P-137	-6.9431 -0.4333 -0.3025 -0.2739 -0.2000 -0.2991 -0.0100 -0.9199 -0.6760 -0.2320 -0.9873 -0.0204 -0.4019 -0.1743 -0.4888 -0.3986 -0.3556 -0.0306 -0.5038 -0.3571 -0.1351
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; fontan circulation
H-1492	-0.3116682171821594	▁per i pher al ▁muscle ▁pump ▁; ▁cardiac ▁fill ing ▁; ▁sub pul mon ary ▁vent ric le ▁; ▁Font an ▁circulation
D-1492	-0.3116682171821594	peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
P-1492	-0.2546 -0.1146 -0.0416 -0.0833 -0.4035 -0.7589 -0.3677 -0.3276 -0.1711 -0.0638 -0.5278 -1.1048 -0.2718 -0.9979 -0.0977 -0.0174 -0.6445 -0.3277 -0.3807 -0.0869 -0.0291 -0.0377 -0.2711 -0.0984
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological phenotype ; clinically ; deficit index ; medical ; frailty
H-1013	-0.866572916507721	▁bi ological ▁ph eno type ▁; ▁deficit ▁index ▁; ▁medical ▁records
D-1013	-0.866572916507721	biological phenotype ; deficit index ; medical records
P-1013	-3.5193 -0.4468 -1.1466 -0.7100 -0.0070 -0.8828 -1.5796 -0.0386 -0.8047 -0.2975 -0.1931 -1.5410 -0.0984
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt ; elevated ; acute ; β-adrenoceptor blockade ; esmolol
H-1444	-0.6997137069702148	▁SD QT ▁; ▁ HF VT ▁; ▁h Nor m ▁; ▁β - ad re no cept or ▁block ade ▁; ▁es mol ol
D-1444	-0.6997137069702148	SDQT ; HFVT ; hNorm ; β-adrenoceptor blockade ; esmolol
P-1444	-0.0331 -0.7204 -0.2693 -1.5077 -1.0190 -1.6857 -0.3713 -1.4253 -3.5074 -0.0437 -1.8845 -0.8539 -0.0604 -0.0863 -0.5381 -0.2773 -0.4809 -0.2746 -0.3811 -0.4040 -0.6847 -0.9657 -0.0043 -0.2898 -0.3421 -0.0818
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology ; national cardiovascular disease registry practice innovation and clinical excellence registry
H-660	-0.6861289143562317	▁Card i ology ▁practice s ▁; ▁national ▁Card io vas cular ▁Disease ▁Registr y ▁; ▁practice ▁Innovation ▁; ▁Clinic al ▁Excellence ▁registr y
D-660	-0.6861289143562317	Cardiology practices ; national Cardiovascular Disease Registry ; practice Innovation ; Clinical Excellence registry
P-660	-1.1728 -1.0907 -0.4201 -0.9727 -0.0583 -0.3530 -2.7052 -0.8036 -1.3896 -0.1068 -0.6294 -0.2333 -1.0889 -0.0304 -1.3559 -0.6182 -1.3689 -1.0686 -0.6013 -0.0095 -0.2340 -0.4632 -0.0689 -0.2165 -0.0932
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts ; hh ; medical ; all-cause mortality ; discharged ; patients ; heart failure
H-162	-1.1780688762664795	▁s ts ▁ HH ▁; ▁TM ▁; ▁medical ▁support ▁; ▁all - ca use ▁mortal ity ▁; ▁dis charge d ▁patients ▁; ▁heart ▁failure
D-162	-1.1780688762664795	sts HH ; TM ; medical support ; all-cause mortality ; discharged patients ; heart failure
P-162	-1.3391 -1.8940 -1.9190 -0.1959 -0.2925 -0.7205 -0.9925 -4.8348 -3.1582 -0.7865 -5.5996 -0.0660 -0.0266 -0.3427 -0.0270 -1.8406 -0.3300 -1.6117 -0.1074 -0.0460 -0.7479 -2.0690 -1.0146 -0.1901 -0.3393 -0.1383
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically ; myocardial infarction ; heart failure ; randomized ; bisoprolol
H-452	-0.6047425270080566	▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁bis o pro lol ▁; ▁vehicle
D-452	-0.6047425270080566	myocardial infarction ; heart failure ; bisoprolol ; vehicle
P-452	-4.9853 -0.3936 -0.2775 -0.8065 -0.0275 -0.2749 -0.1293 -0.4313 -0.3219 -0.0765 -0.5805 -0.6073 -0.3450 -0.0625 -0.2670 -1.1313 -0.3507 -0.2996 -0.1219
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions ; training ; patients ; out-patient ; follow-up ; patient ; health care
H-1579	-1.229203462600708	▁in - patient ▁follow - up ▁; ▁health
D-1579	-1.229203462600708	in-patient follow-up ; health
P-1579	-6.2611 -0.3203 -0.1934 -0.0839 -0.2332 -0.0861 -0.7189 -1.9048 -2.3483 -0.1422
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf ; phenotype ; cardiac ; explant ; progenitors ; regulation
H-1337	-0.316112220287323	▁CHF ▁; ▁cardiac ▁ex plant
D-1337	-0.316112220287323	CHF ; cardiac explant
P-1337	-0.2223 -0.5122 -0.2859 -0.0503 -0.0128 -1.0684 -0.0608
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia ; intravenous ; atropine ; cardiac ; vagal tone
H-1380	-0.4605574905872345	▁ta chy car dia ▁; ▁intra ven ous ▁a tropi ne ▁; ▁cardiac ▁va gal ▁tone ▁; ▁CHF - DN x ▁; ▁CHF - in v
D-1380	-0.4605574905872345	tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
P-1380	-0.2841 -1.0317 -0.0743 -0.0347 -0.4755 -0.4816 -0.0149 -3.1234 -0.0753 -0.0991 -1.7879 -0.3771 -0.0768 -0.0356 -0.1975 -0.0461 -0.7183 -0.0586 -0.0676 -0.6567 -0.2216 -0.6895 -0.0325 -0.0797 -0.7367 -0.3924 -0.9239 -0.1027
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report ; stable ; hno donor ; cxl-1020 ; myoctyes ; hearts ; patients ; heart failure ; hf
H-415	-0.5544905662536621	▁h no ▁donor ▁; ▁c XL -10 20 ▁; ▁isola ted ▁my oc ty es ▁; ▁intact ▁heart s ▁; ▁heart ▁failure ▁; HF
D-415	-0.5544905662536621	hno donor ; cXL-1020 ; isolated myoctyes ; intact hearts ; heart failure ;HF
P-415	-3.1766 -0.9361 -0.2709 -0.1769 -0.5846 -0.4064 -0.1554 -1.7378 -0.4216 -2.1183 -0.0563 -0.4059 -0.0691 -0.0501 -0.2894 -0.3734 -0.0218 -0.3225 -0.1122 -0.2031 -1.7109 -0.0588 -0.1672 -0.2690 -0.2058 -0.1164
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.85350501537323	
D-947	-0.85350501537323	
P-947	-1.5905 -0.1165
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet ; patient ; subvalvular ; annular ms
H-374	-0.5720309019088745	▁MS ▁; ▁sub val vu lar ▁; ▁dynamic ▁; ▁MS
D-374	-0.5720309019088745	MS ; subvalvular ; dynamic ; MS
P-374	-0.7114 -0.7226 -0.1670 -0.1343 -0.0019 -0.0722 -0.2340 -1.3828 -0.2712 -0.9216 -2.1615 -0.0839
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes ; chronic heart failure ; hf ; exercise ; training
H-1630	-0.655083954334259	▁race ▁; ▁chronic ▁heart ▁failure ▁; HF ▁; ▁exercise ▁training ▁response
D-1630	-0.655083954334259	race ; chronic heart failure ;HF ; exercise training response
P-1630	-1.2061 -0.3510 -0.4983 -0.6269 -0.1336 -0.3664 -0.2885 -1.1455 -1.3073 -1.2745 -0.9783 -0.2334 -0.1063
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological ; capillary ; coronary perfusion
H-457	-0.8822858929634094	▁his t ological ▁analysis ▁; ▁cap illa ry ▁; ▁corona ry ▁per fusion ▁; ▁ad - f lk ▁rat s
D-457	-0.8822858929634094	histological analysis ; capillary ; coronary perfusion ; ad-flk rats
P-457	-3.3770 -0.9865 -0.5919 -0.7317 -0.7540 -0.6078 -0.0870 -2.1364 -0.7628 -0.1357 -1.7203 -0.3959 -0.0379 -0.8267 -0.7774 -0.1346 -1.6554 -0.1646 -0.5374 -0.1025 -2.7665 -0.1205
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician ; mortality ; internists ; cardiologists
H-1730	-0.5595325827598572	▁physician ▁volume ▁; ▁mortal iteit ▁; ▁intern ists ▁; ▁cardio logist s
D-1730	-0.5595325827598572	physician volume ; mortaliteit ; internists ; cardiologists
P-1730	-1.2714 -0.4408 -0.6022 -0.0949 -1.8687 -0.4197 -0.0326 -1.4602 -0.3306 -0.3211 -0.2492 -0.3532 -0.2970 -0.0918
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle walk test ; hand ; baseline
H-1322	-0.5425418615341187	▁shu ttle ▁walk ▁test ▁; ▁body ▁mass ▁; ▁hand ▁grip ▁strength
D-1322	-0.5425418615341187	shuttle walk test ; body mass ; hand grip strength
P-1322	-0.2638 -0.0021 -0.3594 -0.6763 -0.5300 -0.7307 -0.2850 -0.4367 -0.8364 -0.5899 -0.5455 -1.6211 -0.1762
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc ; frame ; patient ; consultation ; patients
H-1027	-0.8494521379470825	▁PO c ▁testing ▁; ▁ NP ▁; ▁ED
D-1027	-0.8494521379470825	POc testing ; NP ; ED
P-1027	-1.0155 -1.5955 -1.0697 -0.4735 -1.1015 -0.0732 -0.3414 -1.6058 -1.0503 -0.1682
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical ; outcomes ; heart failure ; charm ; candesartan in heart failure assessment of reduction in mortality and morbidity
H-554	-0.5547928214073181	▁heart ▁failure ▁; ▁CHA r ▁programme ▁; Can des ar tan ▁in ▁Heart ▁Fail ure ▁assessment ▁; ▁Mor t ality ▁; ▁Morbi d ity
D-554	-0.5547928214073181	heart failure ; CHAr programme ;Candesartan in Heart Failure assessment ; Mortality ; Morbidity
P-554	-4.2838 -0.1832 -0.3197 -0.8800 -1.6268 -0.2093 -0.2992 -0.1956 -0.0234 -0.0157 -0.0051 -0.1266 -0.6113 -0.3093 -1.0569 -0.3031 -1.4936 -0.4556 -0.1138 -0.0121 -0.5738 -0.0029 -0.0395 -0.9589 -0.2327 -0.0926
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk in communities
H-284	-0.6317674517631531	▁Tro ponin ▁t ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; ▁at hero sc ler osis
D-284	-0.6317674517631531	Troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis
P-284	-1.1907 -0.0194 -2.1251 -0.3291 -0.7656 -0.0388 -0.0927 -0.0043 -0.0318 -0.0315 -0.8324 -0.0422 -0.0127 -0.0679 -0.5786 -0.7331 -1.8613 -1.3407 -0.2982 -0.7362 -0.5250 -0.7311 -0.1224 -0.1095 -0.7519 -0.8098 -0.0938 -1.1272 -2.7147 -0.1844 -0.0358 -2.4471 -0.0635 -1.1407 -0.1224
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial shunting ; patients ; heart failure with reduced ejection fraction ; proof-of-principle cohort study
H-1948	-0.6639096736907959	▁left - to - right ▁inter at rial ▁sh unting ▁; ▁patients ▁met ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1948	-0.6639096736907959	left-to-right interatrial shunting ; patients met heart failure ; ejection fraction
P-1948	-3.0665 -0.0982 -0.1364 -0.1673 -0.2024 -0.0889 -0.0230 -0.1583 -0.6148 -1.1740 -0.9431 -2.0725 -2.8850 -1.0421 -0.1210 -0.7817 -0.3049 -0.1377 -0.1672 -0.5228 -0.0216 -0.4373 -0.1032
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical examination ; patient ; bmi ; heart rate ; rhythm ; blood pressure ; auscultation ; rule ; valvular disease ; pulmonary congestion
H-1894	-0.44470351934432983	▁b mi ▁; ▁weight ▁; ▁heart ▁rate ▁; ▁ rhythm ▁; ▁ly ing ▁; ▁standing ▁blood ▁pressure ▁; ▁aus cul tation ▁; ▁val vu lar ▁disease ▁; ▁pulmonar y ▁con gestion
D-1894	-0.44470351934432983	bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
P-1894	-1.9013 -1.9741 -0.3391 -1.4184 -0.2791 -1.3130 -0.2880 -0.4056 -0.1519 -0.2209 -0.2440 -0.0380 -0.0970 -0.2352 -0.1641 -1.1944 -0.4169 -0.2083 -1.4615 -0.0308 -0.0708 -0.3587 -0.1373 -0.0433 -0.1878 -0.3917 -0.1994 -0.0049 -0.2960 -0.0194 -0.0806 -0.3779 -0.1259
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial extracellular matrix ; cardiac magnetic resonance ; t1 mapping ; pathobiology ; pathophysiology ; prognosis
H-735	-0.46691563725471497	▁my o card ial ▁extra cel lular ▁matri x ▁; ▁cardiac ▁magnetic ▁res on ance ▁t 1 ▁ma pping ▁; ▁path obi ology
D-735	-0.46691563725471497	myocardial extracellular matrix ; cardiac magnetic resonance t1 mapping ; pathobiology
P-735	-1.3287 -0.2532 -0.2577 -0.3622 -0.2269 -0.1957 -0.0612 -0.0447 -0.6129 -0.4421 -0.0122 -0.1005 -0.7239 -0.1912 -0.2171 -2.2355 -0.3562 -0.3727 -0.0894 -0.8833 -0.1158 -0.0563 -0.4281 -2.0172 -0.0882
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone antagonist ; therapy ; chronic advanced heart failure ; patients ; post-myocardial infarction ; heart failure ; patients
H-1738	-0.5324898362159729	▁al do ster one ▁anta gon ist ▁ therapy ▁; ▁chronic ▁advanced ▁heart ▁failure ▁patients ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁patients ▁; ▁e je ction
D-1738	-0.5324898362159729	aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction ; heart failure patients ; ejection
P-1738	-0.1990 -0.1007 -0.0824 -0.4223 -0.1194 -0.0059 -0.4213 -0.8850 -0.0271 -0.3480 -1.7781 -1.8173 -0.7373 -0.1260 -1.2768 -0.4024 -0.0447 -0.0453 -0.2115 -0.7574 -0.3376 -0.5304 -0.0378 -0.3184 -0.1522 -1.9311 -0.9175 -0.0947 -1.0685 -1.2153 -1.5126 -0.1487 -0.2373 -0.2107 -0.1164
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil ; heart rate ; aortic ; blood flow ; mitochondrial ; oxidative stress ; doxorubicin ; cardiotoxicity
H-963	-0.3595840632915497	▁Nico rand il ▁; ▁heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁mito cho ndri al ▁oxid ative ▁stress ▁; ▁do xor ubi cin ▁cardio toxic iteit
D-963	-0.3595840632915497	Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxiciteit
P-963	-0.0031 -0.0784 -0.0484 -0.3963 -3.2907 -0.6188 -0.2140 -0.0332 -0.0660 -0.3724 -0.3201 -0.2032 -0.2057 -0.0060 -0.4444 -0.1855 -0.0138 -0.0213 -0.0608 -0.1916 -0.2086 -0.0754 -0.0029 -0.0155 -0.2968 -0.4585 -0.5035 -2.1320 -0.2504 -0.0701
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed ; heart failure ; left ventricular ejection fraction ; spironolactone ; kaiser permanente ; northern california
H-440	-0.40057244896888733	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁; ▁spi rono lac tone ▁; ▁Kaiser ▁Permanent e ▁Northern ▁California
D-440	-0.40057244896888733	heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
P-440	-2.2974 -0.1362 -0.2671 -0.1081 -0.0521 -2.2234 -0.2953 -0.0828 -0.1527 -0.0646 -0.9131 -0.0573 -0.0124 -0.0356 -0.0139 -0.7663 -0.4543 -0.2895 -0.0751 -0.4032 -0.0802 -0.3355 -0.0970
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative ; renal dysfunction ; cardiovascular events ; stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
H-968	-0.40952181816101074	▁renal ▁dys function ▁; ▁cardiovascular ▁events ▁; stro ke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁death ▁; ▁isola ted ▁corona ry ▁arter y ▁by pass ▁graf ting
D-968	-0.40952181816101074	renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
P-968	-0.3971 -0.0320 -0.0718 -0.2397 -0.0458 -0.3599 -0.3276 -0.2715 -0.1224 -1.1624 -0.2875 -0.5221 -0.2163 -0.4683 -0.0334 -0.1850 -0.0544 -0.1956 -0.3140 -0.0844 -0.2148 -3.4627 -0.3549 -0.0488 -0.1290 -0.0304 -1.2300 -0.0095 -0.5751 -1.6847 -0.0520 -0.0418 -0.7236 -0.2800 -0.1051
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum ; systolic ; lv posterior wall ; lv internal diameter ; metoprolol
H-1549	-0.7500734329223633	▁sept um ▁; sy sto lic ▁; ▁thi ck ness ▁; ▁LV ▁posterior ▁wall ▁thi ck ness ▁; ▁LV ▁internal ▁diameter ▁; ▁met o pro lol
D-1549	-0.7500734329223633	septum ;systolic ; thickness ; LV posterior wall thickness ; LV internal diameter ; metoprolol
P-1549	-0.2586 -0.0160 -1.1306 -0.5750 -0.3291 -0.0458 -0.8909 -5.5942 -0.0428 -2.0478 -0.2358 -0.7322 -0.8332 -0.8162 -2.9130 -0.0482 -1.3253 -0.2425 -0.1712 -1.3029 -0.0207 -0.4785 -0.0277 -0.2396 -0.0387 -0.3354 -0.2263 -0.0837
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american college of physicians ; acp ; evidence ; clinical ; anemia ; patients ; heart disease
H-30	-0.5937207341194153	▁American ▁college ▁of ▁Physic ians ▁; ▁a CP ▁; ▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁heart ▁disease
D-30	-0.5937207341194153	American college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
P-30	-3.2786 -1.2220 -0.2527 -0.2014 -0.4268 -0.4356 -0.7895 -0.9554 -0.5153 -1.4819 -0.2098 -0.2447 -0.0395 -0.0818 -0.0613 -0.0210 -0.5005 -0.0375 -0.2700 -2.0392 -0.2725 -0.2152 -0.1034
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese ; patients ; clinically ; stable ; hfpef ; exercise ; training ; peak vo2
H-1990	-0.6252225041389465	▁obes e ▁older ▁patients ▁; ▁h FP EF ▁; ▁calor ic ▁restriction ▁; ▁aero bic ▁exercise ▁training ▁; ▁VO 2
D-1990	-0.6252225041389465	obese older patients ; hFPEF ; caloric restriction ; aerobic exercise training ; VO2
P-1990	-1.7747 -0.1079 -1.9299 -0.8186 -0.4535 -1.1745 -1.5898 -0.8921 -0.3996 -0.1913 -0.3012 -0.2930 -0.1321 -0.0317 -0.2609 -0.2103 -1.5386 -0.3270 -0.9057 -0.0309 -0.2638 -0.1277
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2007	-0.9397894740104675	▁economic ▁analysis ▁; ▁Patient ▁management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁; ▁kosten - effect ive ness ▁; ▁disease ▁management ▁; ▁heart ▁failure
D-2007	-0.9397894740104675	economic analysis ; Patient management Interventions ; Heart Failure ; kosten-effectiveness ; disease management ; heart failure
P-2007	-2.7848 -0.6313 -0.8426 -0.5038 -0.5274 -0.8969 -0.0956 -1.4937 -0.5307 -0.5208 -1.0425 -0.6351 -5.3648 -0.0989 -1.7777 -0.5669 -1.3777 -0.5571 -0.3833 -0.0593 -1.3059 -1.0861 -0.1300 -0.1737 -0.1082
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective ; hf ; patients ; hf with reduced ef ; ef ; hfpef ; ef
H-782	-0.7796748876571655	▁ HF ▁registr y ▁; ▁ HF ▁; ▁EF ▁; EF ▁; ▁ HF p EF ▁; EF
D-782	-0.7796748876571655	HF registry ; HF ; EF ;EF ; HFpEF ;EF
P-782	-0.6279 -0.8715 -0.4449 -0.2129 -0.4517 -1.1217 -0.9842 -0.5015 -1.5504 -0.3570 -2.1117 -1.0580 -0.7672 -0.5778 -0.3036 -0.6425 -0.9097 -0.9317 -1.0227 -0.1447
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat ; n-terminal pro-brain natriuretic peptide ; hospitalized ; hf
H-1877	-0.5846903324127197	▁BAT ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁ HF
D-1877	-0.5846903324127197	BAT ; n-terminal pro-brain natriuretic peptide ; HF
P-1877	-0.0275 -1.4432 -2.5988 -0.0581 -0.1564 -0.0160 -0.0247 -0.0799 -0.1381 -0.2323 -0.0973 -0.5005 -0.7026 -1.4949 -0.8959 -0.1510 -0.4816 -0.4362 -1.9043 -1.1145 -0.2194 -0.0901
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients ; hr variability ; mortality ; ami ; diagnosis ; chf ; lv dysfunction
H-1586	-0.5791863799095154	▁HR ▁variabil ity ▁; ▁mortal ity ▁; ▁ AMI ▁; ▁CHF ▁; LV ▁dys function
D-1586	-0.5791863799095154	HR variability ; mortality ; AMI ; CHF ;LV dysfunction
P-1586	-0.8106 -0.1384 -1.4293 -0.4731 -0.1724 -1.3899 -0.4329 -1.2241 -0.1387 -0.2656 -0.2240 -2.0823 -0.2223 -0.3748 -0.1227 -0.2461 -0.0991
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence ; exercise ; cell senescence ; active ; osteoporosis
H-1901	-0.43639418482780457	▁exercise ▁; ▁cell ▁se nesc ence ▁; ▁malign a ncies ▁; ▁cancer ▁; ▁prostat e ▁; ▁colon ▁; ▁osteo por osis ▁; ▁depression ▁; ▁dem entia
D-1901	-0.43639418482780457	exercise ; cell senescence ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
P-1901	-2.6203 -0.4139 -1.2367 -0.2123 -0.2875 -0.6702 -0.3336 -1.5375 -0.5711 -0.1534 -0.2695 -0.2790 -0.7288 -0.0621 -0.0908 -0.1720 -0.5478 -0.4029 -0.0268 -0.2868 -0.0633 -0.2004 -0.1542 -0.4347 -0.1706 -0.0131 -0.2074 -0.0723
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended criteria cardiac transplant ; ecct ; transplant ; donors ; transplant ; comorbidity
H-708	-0.6488413214683533	▁cardiac ▁transplant ▁; ▁ec t ▁; ▁transplant ▁pool ▁; ▁donor s ▁; ▁recipient s
D-708	-0.6488413214683533	cardiac transplant ; ect ; transplant pool ; donors ; recipients
P-708	-0.3032 -0.1135 -0.4398 -0.1410 -2.0034 -0.4379 -0.2066 -0.7372 -0.6690 -0.6241 -0.1453 -0.5258 -0.3605 -0.1265 -3.4638 -0.0838
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic ; pediatric fontan ; patients ; catheterization
H-227	-0.46384748816490173	▁as ym pto matic ▁pediatr ic ▁Font an ▁; PF ▁; ▁cat heter ization
D-227	-0.46384748816490173	asymptomatic pediatric Fontan ;PF ; catheterization
P-227	-0.4507 -0.2596 -0.0919 -0.4183 -0.0877 -0.1176 -0.4125 -0.2154 -0.6491 -0.3124 -1.1558 -1.1381 -0.0340 -1.6026 -0.3831 -0.0928
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ; ventricular assist devices ; cardiac ; nurses ; gastrointestinal bleeding
H-1660	-0.45657622814178467	▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse s ▁; ▁gastro inte stin al ▁ble ed ing
D-1660	-0.45657622814178467	ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
P-1660	-0.0264 -2.9251 -0.2364 -0.6560 -0.3463 -0.5889 -0.3703 -0.0516 -0.0743 -0.5077 -0.8440 -0.1358 -0.5012 -0.0738 -0.0622 -0.6204 -0.2807 -0.2660 -0.1080
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the lancet ; anoop shah ; air ; heart failure ; morbidity ; mortality
H-1807	-0.38141128420829773	▁Lance t ▁; ▁Ano op ▁Shah ▁; ▁air ▁pollution ▁; ▁heart ▁failure ▁; ▁morbi d iteit ▁; ▁mortal ity
D-1807	-0.38141128420829773	Lancet ; Anoop Shah ; air pollution ; heart failure ; morbiditeit ; mortality
P-1807	-0.1535 -0.0221 -0.1422 -0.5597 -0.1160 -0.1398 -0.4256 -0.1538 -0.2092 -0.3220 -0.4369 -0.1231 -0.4744 -0.2984 -0.0352 -1.6204 -0.3484 -0.0219 -1.0936 -1.2391 -0.0744
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia ; hf ; health-related quality of life ; hrqol ; hf
H-835	-0.6725537180900574	▁an emia ▁; ▁ HF ▁; ▁health - related ▁quality ▁of ▁life ▁; HR Qo L ▁; ▁ HF
D-835	-0.6725537180900574	anemia ; HF ; health-related quality of life ;HRQoL ; HF
P-835	-1.2870 -0.1349 -0.4386 -1.6217 -0.6823 -0.5863 -1.9258 -0.1726 -0.1089 -0.2630 -0.4762 -0.5031 -0.2343 -0.9636 -0.0120 -1.1711 -0.3558 -1.7946 -1.0734 -0.2087 -0.1095
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell therapy ; chronic heart failure ; chf ; disease ; progenitor cells
H-1336	-0.38696521520614624	▁cell ▁ therapy ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁disease ▁; ▁ex plant - der i ved ▁pro gen itor ▁cell s
D-1336	-0.38696521520614624	cell therapy ; chronic heart failure ;CHf ; disease ; explant-derived progenitor cells
P-1336	-0.5233 -0.3294 -0.0345 -0.4444 -0.1419 -0.5207 -0.1370 -0.2155 -1.5236 -2.0886 -0.3251 -0.6747 -0.4234 -0.0585 -0.0029 -0.0701 -0.0677 -0.4260 -0.2533 -0.1820 -0.0537 -0.1006 -0.9356 -0.1212 -0.3122 -0.0953
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous nonfailing ; hf ; combinations ; remodeling
H-1152	-0.39894917607307434	▁m RI - based ▁models ▁; ▁dys syn chron ous ▁non fail ing ▁; ▁ HF ▁; ▁can ine ▁electro me chan ics
D-1152	-0.39894917607307434	mRI-based models ; dyssynchronous nonfailing ; HF ; canine electromechanics
P-1152	-0.4709 -1.3222 -0.1101 -0.0439 -0.5360 -0.9199 -0.0071 -0.0499 -0.0300 -1.1313 -0.1016 -0.1016 -0.0939 -0.2125 -0.4643 -0.4438 -0.6356 -1.0103 -0.4473 -0.0317 -0.0708 -0.0794 -1.0449 -0.5301 -0.0846
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients ; acute rv failure ; chronic pulmonary arterial hypertension ; pah ; acute ; pulmonary embolism
H-1095	-0.5474612712860107	▁a cute ▁ RV ▁failure ▁; ▁chronic ▁pulmonar y ▁arterial ▁hyper tension ▁; PA h ▁; ▁pulmonar y ▁e mbol ism
D-1095	-0.5474612712860107	acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; pulmonary embolism
P-1095	-3.0269 -0.0831 -0.2132 -0.3890 -0.3916 -0.4249 -0.4573 -0.0180 -0.1125 -0.0103 -0.2691 -0.0261 -0.3788 -2.2245 -0.6015 -0.3830 -0.9166 -0.1421 -0.2724 -0.0881 -1.6692 -0.3605 -0.1330
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute rv failure ; pulmonary embolism ; mortality ; diagnostic
H-1097	-0.576664924621582	▁a cute ▁ RV ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁mortal iteit
D-1097	-0.576664924621582	acute RV failure ; pulmonary embolism ; mortaliteit
P-1097	-1.9329 -0.0641 -0.1725 -0.3441 -0.5363 -0.1936 -0.0451 -0.1360 -0.2322 -0.1580 -1.6883 -0.8645 -0.3033 -2.1999 -0.2559 -0.0999
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin ; chemotherapy ; elevated ; cardiotoxicity
H-937	-0.5931805372238159	▁se rum ▁resist in ▁; ▁women ▁; ▁an thra cycli ne - conta ining ▁che mo therapy ▁; ▁cardio toxic iteit
D-937	-0.5931805372238159	serum resistin ; women ; anthracycline-containing chemotherapy ; cardiotoxiciteit
P-937	-0.2148 -0.6608 -0.2860 -0.7019 -1.4893 -1.4768 -0.6756 -0.2624 -0.1061 -0.5035 -1.4279 -0.2689 -0.1212 -0.9047 -0.1489 -0.4623 -0.0808 -0.5109 -0.1014 -0.5631 -2.3371 -0.2272 -0.1114
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients ; sst2 ; titrated ; cardiovascular event
H-405	-0.8723537921905518	▁s st 2 ▁; ▁BB ▁; ▁cardiovascular ▁event ▁rate
D-405	-0.8723537921905518	sst2 ; BB ; cardiovascular event rate
P-405	-0.1385 -1.6124 -0.0989 -0.4677 -2.9430 -0.7045 -0.0721 -0.7960 -1.7451 -0.9281 -0.0896
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad ; q66p ; cardiomyopathy
H-1677	-0.6368284821510315	▁Rad ▁Q 66 p ▁; ▁cardio my o pathy
D-1677	-0.6368284821510315	Rad Q66p ; cardiomyopathy
P-1677	-0.8435 -1.6010 -0.4725 -0.1821 -0.2612 -0.2414 -0.8820 -0.5083 -0.0278 -1.8920 -0.0932
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular ; wall stiffness
H-1148	-0.7929415702819824	▁vent ri cular ▁structure ▁; ▁ge ometr y ▁; ▁fiber ▁; she et ▁ orientation ▁; ▁handling ▁; ▁slow ed ▁con duction
D-1148	-0.7929415702819824	ventricular structure ; geometry ; fiber ;sheet orientation ; handling ; slowed conduction
P-1148	-0.2046 -2.4831 -0.3223 -1.2063 -0.3411 -1.9697 -0.0366 -0.4537 -0.2616 -0.0332 -1.5449 -0.1029 -0.0240 -0.5430 -0.0453 -0.5831 -1.1187 -0.3886 -1.4878 -1.0138 -0.0192 -0.0823 -4.6003 -0.1645
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.9782666563987732	▁SD QT - to - SD RR ▁ratio ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁h Nor m
D-1441	-0.9782666563987732	SDQT-to-SDRR ratio ; HFVT ; HFVT ; hNorm
P-1441	-1.1427 -0.8416 -0.1457 -0.1130 -0.0556 -0.7416 -2.8777 -0.9619 -0.3058 -1.0776 -0.6302 -1.0510 -0.5990 -1.2265 -1.3347 -1.9601 -0.4513 -1.3377 -3.6229 -0.0429 -0.8946 -0.1076
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration ; renin-angiotensin system blocker ; beta-blocker ; therapy ; patients ; hospitalized ; heart failure ; preserved left ventricular ejection fractions
H-174	-0.3983292579650879	▁re nin - angi oten sin ▁system ▁block er ▁; ▁beta - block er ▁ therapy ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction
D-174	-0.3983292579650879	renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection
P-174	-0.0503 -0.6574 -0.0680 -0.0121 -0.6379 -0.4255 -0.0535 -0.6621 -0.1844 -0.4217 -0.1057 -0.0444 -0.2564 -0.0996 -0.8385 -0.0144 -0.4615 -0.8440 -0.1445 -0.3852 -0.5156 -0.0632 -1.7911 -0.3802 -0.2279 -0.2244 -0.1971 -1.6428 -0.1421
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestion
H-1180	-0.458748459815979	▁Exerci se ▁; ▁Medical ▁Therapie s ▁; ▁Card iac ▁Fun ction ▁; ▁Breath ▁; ▁Lung ▁con gestion
D-1180	-0.458748459815979	Exercise ; Medical Therapies ; Cardiac Function ; Breath ; Lung congestion
P-1180	-0.5777 -0.0994 -0.3377 -0.2548 -0.2068 -0.0786 -0.8336 -0.6573 -0.1633 -0.0675 -0.0044 -0.4963 -2.5947 -0.3428 -0.2816 -0.3849 -0.0553 -1.2047 -0.0746
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional electrical stimulation ; peripheral muscles ; endothelial function ; clinical ; heart failure ; patients ; preserved left ventricular ejection fraction
H-1326	-0.5467316508293152	▁function al ▁electric al ▁stimul ation ▁; ▁per i pher al ▁muscle s ▁; ▁en dot heli al ▁function ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1326	-0.5467316508293152	functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; left ventricular ejection fraction
P-1326	-3.8489 -0.0816 -0.2543 -0.0179 -0.1306 -0.7674 -0.7339 -0.1024 -0.2476 -0.1027 -0.1899 -0.7092 -0.1695 -0.4353 -0.1853 -0.9799 -0.1701 -0.0104 -0.4658 -0.2359 -2.2091 -0.1242 -0.5485 -1.4938 -0.0766 -1.6181 -0.2974 -0.2194 -0.2257 -0.2562 -1.1301 -0.0101 -0.4193 -0.1216
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
H-1139	-0.44282397627830505	▁ta chy car dic ▁response ▁; ▁met hy la tropi ne ▁; ▁va gal ▁tone ▁; ▁bra dy car dic ▁response ▁; ▁propra no lol ▁; ▁sympa the tic ▁tone
D-1139	-0.44282397627830505	tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol ; sympathetic tone
P-1139	-0.4264 -1.7561 -0.1508 -0.4153 -0.7142 -0.4461 -0.0252 -0.2219 -0.8232 -0.0107 -1.6901 -0.3837 -0.0960 -0.0743 -0.2867 -0.3333 -0.1691 -0.8251 -0.1364 -0.6899 -1.2872 -0.2378 -0.0929 -0.0160 -0.0876 -0.5095 -0.0395 -0.6992 -1.1034 -0.2229 -0.1299 -0.0699
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac resynchronization therapy ; crt ; mild heart failure ; hf ; patients ; qrs prolongation ; ejection fraction ; ef
H-751	-0.4500449597835541	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁mild ▁heart ▁failure ▁; HF ▁; ▁QR s ▁prolong ation ▁; ▁e je ction ▁ fraction ▁; EF
D-751	-0.4500449597835541	cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction ;EF
P-751	-0.7402 -0.0748 -0.2453 -0.0410 -1.2111 -1.3412 -0.0695 -0.4312 -0.7836 -2.9190 -0.3502 -0.2318 -0.1956 -0.1139 -0.1761 -0.3406 -0.2314 -0.3519 -0.6128 -0.4291 -0.8785 -0.3716 -0.0093 -0.1126 -0.0521 -0.4152 -0.0063 -0.4225 -0.3388 -0.3198 -0.1345
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ; lad
H-509	-0.3399694859981537	▁fra ction al ▁flow ▁reserve ▁; ▁posi tron ▁e mission ▁tom ography ▁imagin g ▁; ▁ ische mia ▁; ▁bottle ne ck ▁sten ting ▁; ▁left ▁vent ric le ▁; ▁proxima l ▁ LAD
D-509	-0.3399694859981537	fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD
P-509	-1.1197 -0.0074 -0.0692 -0.0873 -0.0595 -0.3260 -0.0976 -0.1478 -0.1194 -0.6501 -0.8046 -0.4115 -1.9879 -0.2387 -0.3865 -0.6612 -0.0298 -0.5008 -0.3969 -0.0271 -0.0685 -0.0142 -0.0323 -0.1882 -0.4183 -0.0783 -0.0444 -1.3077 -0.7245 -0.3288 -0.2052 -0.0436 -0.1138 -0.0912 -0.3822 -0.0686
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity ; oxidative stress ; dna fragmentation
H-962	-0.37327319383621216	▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se ▁activity ▁; ▁oxid ative ▁stress ▁marker s ▁; ▁DNA ▁fragment ation
D-962	-0.37327319383621216	mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
P-962	-0.0082 -0.5664 -0.1324 -0.0266 -0.0961 -0.1084 -0.2870 -0.0799 -1.8308 -2.0189 -0.0837 -1.2726 -0.3242 -0.0106 -0.2699 -0.0016 -0.0663 -0.9754 -0.2396 -0.0205 -0.1316 -0.1851 -0.0919 -0.1670 -0.5816 -0.1043 -0.1781 -0.5551 -0.6990 -0.0854
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox regression ; covariates ; spironolactone ; death ; hospitalization ; hyperkalemia ; acute kidney injury
H-442	-0.3688250780105591	▁co x ▁re gression ▁; ▁spi rono lac tone ▁; ▁death ▁; ▁hyper kal emia ▁; ▁ki dne y ▁injury
D-442	-0.3688250780105591	cox regression ; spironolactone ; death ; hyperkalemia ; kidney injury
P-442	-0.1035 -0.1396 -0.0314 -0.0213 -0.5291 -0.1428 -0.0344 -0.1085 -0.0743 -1.2275 -2.2618 -0.2357 -0.8700 -0.3531 -0.2040 -0.3080 -0.4519 -0.4502 -0.1124 -0.1050 -0.2392 -0.1104
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes ; mortality ; hospitalization ; mortality ; cardiovascular mortality ; hf ; hospitalization ; cox models ; exercise ; training
H-1633	-0.7705307006835938	▁mortal ity ▁; hospital ization ▁; ▁mortal ity ▁; ▁cardiovascular ▁mortal ity ▁; HF ▁hospital ization ▁; ▁co x ▁; ▁exercise ▁training
D-1633	-0.7705307006835938	mortality ;hospitalization ; mortality ; cardiovascular mortality ;HF hospitalization ; cox ; exercise training
P-1633	-3.9779 -1.5769 -0.6977 -0.9838 -0.7262 -0.3592 -0.6931 -1.4152 -0.2314 -0.0329 -0.0785 -1.5067 -0.1861 -0.8862 -0.5034 -0.4775 -0.4120 -0.5695 -0.0710 -1.7285 -0.2539 -0.7972 -0.2179 -0.1101
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin inhibitors ; natriuretic peptide ; atrial natriuretic peptide ; b-type natriuretic peptide
H-1462	-0.8065919280052185	▁ne pri ly sin ▁inhibi tors ▁; ▁na tri ure tic ▁pe pti de ▁system ▁; ▁at rial ▁na tri ure tic ▁pe pti de ▁; ▁na tri ure tic ▁pe pti de
D-1462	-0.8065919280052185	neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; natriuretic peptide
P-1462	-1.0743 -0.2519 -0.7135 -0.5334 -0.1337 -0.2990 -0.3258 -0.0872 -1.2206 -1.3413 -2.5834 -1.4258 -0.2368 -0.7629 -0.6472 -0.3761 -1.4934 -0.0312 -0.1437 -1.4450 -1.4423 -2.2213 -1.1259 -0.1350 -0.6450 -0.5156 -0.2494 -1.1110 -1.2383 -2.1679 -1.2684 -0.1246 -0.5502 -0.1958 -0.1136
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse ; pasp ; downward ; hfref ; hfpef ; prognostic ; resolution
H-500	-0.7607196569442749	▁T AP se ▁; ▁pas p ▁; ▁non sur viv ors ▁; ▁h Fr EF ▁; ▁ HF p EF
D-500	-0.7607196569442749	TAPse ; pasp ; nonsurvivors ; hFrEF ; HFpEF
P-500	-5.0301 -0.4480 -1.1185 -1.6826 -0.9930 -0.2365 -0.6439 -0.2398 -0.0712 -0.0158 -0.6288 -0.2222 -1.1813 -0.7176 -1.1517 -0.1931 -0.1914 -0.5002 -0.1298 -0.5234 -0.7321 -0.0849
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action ; randomized ; patients ; hf ; ejection fraction ; exercise ; training
H-1632	-0.7887526750564575	▁ HF - ac TION ▁; ▁ HF ▁; ▁e je ction ▁ fraction ▁; ▁exercise ▁training
D-1632	-0.7887526750564575	HF-acTION ; HF ; ejection fraction ; exercise training
P-1632	-1.0235 -0.5137 -0.1497 -0.6812 -2.2036 -0.6367 -1.6105 -0.6506 -0.8572 -0.8299 -0.5047 -0.0779 -0.7111 -0.0239 -1.3867 -2.2632 -0.4169 -0.3123 -0.1333
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic ; proteins ; histone acetyltransferases ; epigenetic ; histone deacetylases ; cardiac ; disease
H-1041	-0.3925038278102875	▁epi gene tic ▁; writer ▁; ▁protein s ▁; hi stone ▁a ce tyl transfer as es ▁; ▁epi gene tic ▁; eras ers ▁; hi stone ▁de ace ty las es ▁; ▁cardiac
D-1041	-0.3925038278102875	epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
P-1041	-1.7148 -0.2732 -0.6437 -0.7904 -1.4591 -0.7915 -0.1965 -0.1551 -0.3418 -0.0645 -0.0146 -0.0478 -0.5601 -0.6658 -0.0145 -0.0582 -0.1817 -0.4066 -0.2463 -0.1619 -1.0403 -0.8813 -0.0236 -0.0841 -0.3653 -0.0651 -0.0744 -0.0652 -0.3400 -0.2667 -0.0095 -0.0898 -0.5003 -0.0137 -1.4201 -0.1022
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated ; nt-probnp ; admission ; all-cause mortality ; patients ; acute hf ; admission
H-270	-0.46931853890419006	▁NT - pro b NP ▁; ▁mortal iteit ▁; ▁a cute ▁ HF
D-270	-0.46931853890419006	NT-probNP ; mortaliteit ; acute HF
P-270	-0.0684 -0.0536 -0.0281 -0.4744 -0.4590 -0.7316 -0.3603 -2.3491 -0.3464 -1.2367 -0.0533 -0.2322 -0.3254 -0.1557 -0.1657
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic cell transplantation ; hct ; congestive heart failure ; chf ; anthracyclines
H-1449	-0.8546376824378967	▁ha e mato po ie tic ▁cell ▁transplant ation ▁; ▁h CT ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁h CT ▁; ▁an thra cycli nes
D-1449	-0.8546376824378967	haematopoietic cell transplantation ; hCT ; congestive heart failure ;CHf ; hCT ; anthracyclines
P-1449	-0.1285 -0.6501 -0.1509 -0.2045 -0.9211 -1.3213 -0.4025 -0.0579 -0.4687 -0.6311 -1.5836 -1.2608 -0.3936 -0.2577 -1.0020 -2.6188 -0.8059 -0.1665 -0.3456 -1.5589 -1.5901 -0.2851 -2.3197 -1.0329 -0.6852 -1.4384 -0.1264 -0.2871 -3.3470 -0.3254 -0.1266
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; administration ; doxorubicin
H-956	-0.28769004344940186	▁cardio protec tive ▁effect ▁; ▁nic oran dil ▁; ▁hem o dynamic ▁altera tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁cum ul ative ▁administration ▁; ▁do xor ubi cin
D-956	-0.28769004344940186	cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; cumulative administration ; doxorubicin
P-956	-0.2535 -0.5827 -0.9412 -0.1670 -0.3700 -0.1100 -0.0747 -0.3079 -0.1905 -1.1593 -0.1964 -0.0065 -0.4614 -0.1657 -0.1989 -0.0019 -0.4913 -0.0715 -0.0276 -0.0151 -0.0748 -0.2681 -1.2789 -0.0267 -0.0262 -0.2546 -0.6183 -0.0697 -0.0065 -0.0283 -0.3747 -0.6018 -0.0718
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in vivo ; mir-25 ; antagomir ; cardiac dysfunction ; murine ; myocardium ; heart failure
H-643	-0.4163367450237274	▁in ▁vivo ▁inhibi tion ▁; ▁mi r -25 ▁; ▁anta go mir ▁; ▁cardiac ▁dys function ▁; ▁mur ine ▁my o car dium ▁; ▁heart ▁failure
D-643	-0.4163367450237274	in vivo inhibition ; mir-25 ; antagomir ; cardiac dysfunction ; murine myocardium ; heart failure
P-643	-0.1862 -0.0106 -0.1777 -0.6607 -0.5241 -0.0861 -1.8105 -0.0902 -0.3216 -0.3055 -0.0485 -0.2251 -0.4768 -0.6425 -0.0327 -0.0849 -0.3464 -0.1027 -2.0925 -0.3441 -0.1330 -0.0173 -0.1188 -1.0340 -1.0259 -0.1048 -0.5206 -0.1335
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine ; patients ; dilated cardiomyopathy ; dcm ; heart failure
H-1258	-0.46684905886650085	▁Chinese ▁herbal ▁medicine ▁; CH m ▁; ▁dil ated ▁cardio my o pathy ▁; ▁d m ▁; ▁heart ▁failure
D-1258	-0.46684905886650085	Chinese herbal medicine ;CHm ; dilated cardiomyopathy ; dm ; heart failure
P-1258	-0.5995 -0.0391 -0.0644 -0.1960 -1.7850 -0.3306 -0.2929 -1.4115 -0.2387 -0.0476 -0.9356 -1.1130 -0.0104 -0.2349 -0.5411 -0.8803 -0.2328 -0.3309 -0.1158 -0.2683 -0.1353
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension ; diabetes mellitus ; grade ; systolic ; diastolic murmurs ; apex
H-347	-0.1544504463672638	▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁sy sto lic ▁; ▁dia sto lic ▁mur mur s
D-347	-0.1544504463672638	hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
P-347	-0.5230 -0.0619 -0.2239 -0.4825 -0.0030 -0.0315 -0.3716 -0.0371 -0.0868 -0.0307 -0.2412 -0.0182 -0.0353 -0.0680 -0.1467 -0.0346 -0.3013 -0.1624 -0.0749
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative ; patients ; preoperative ; hypoalbuminemia ; albumin
H-533	-0.7544089555740356	▁post operativ e ▁; ▁hypo album in emia ▁; ▁album in ▁concentration
D-533	-0.7544089555740356	postoperative ; hypoalbuminemia ; albumin concentration
P-533	-2.1030 -0.0551 -0.0523 -3.2425 -0.7194 -0.3199 -0.4630 -0.4910 -0.4494 -1.4211 -0.3157 -0.2695 -0.5603 -0.0996
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left bundle branch block ; remodeling ; dyssynchronous heart failure ; hf ; heart
H-1147	-0.5846958756446838	▁elektri al ▁activa tion ▁; ▁dys syn chron ous ▁heart ▁failure ▁; HF ▁; ▁electro me chan ical ▁behavior ▁; ▁heart
D-1147	-0.5846958756446838	elektrial activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
P-1147	-3.2546 -0.4026 -0.1175 -0.3958 -0.3881 -0.0464 -0.0165 -0.0143 -1.2288 -1.1274 -0.2415 -0.2840 -0.3805 -0.2878 -0.0812 -0.0582 -0.0271 -0.3336 -1.8725 -0.3385 -2.2337 -0.2232 -0.0942
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients ; heart failure ; heart ; cardiologists ; cardiovascular ; surgeons ; medical ; patient
H-1822	-0.8897486329078674	▁advanced ▁heart ▁failure ▁; heart ▁team ▁; ▁cardio logist s ▁; ▁cardiovascular ▁surge ons ▁; ▁medical ▁staff
D-1822	-0.8897486329078674	advanced heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
P-1822	-5.5549 -1.3132 -0.5691 -0.5484 -2.7171 -0.3211 -0.4161 -0.2321 -0.1877 -0.2123 -0.3336 -0.0749 -0.1097 -1.5065 -1.0934 -0.5286 -0.6989 -0.3690 -0.1188
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex sensitivity ; heart rate variability ; hrv ; renal dnx
H-1376	-0.5436660647392273	▁Baro re flex ▁ sensitiv ity ▁; ▁time ▁domain ▁; ▁heart ▁rate ▁variabil ity ▁; HR v ▁; ▁CHF - in v ▁group ▁; ▁sham - in v ▁; ▁sham ▁levels ▁; ▁renal ▁DN x
D-1376	-0.5436660647392273	Baroreflex sensitivity ; time domain ; heart rate variability ;HRv ; CHF-inv group ; sham-inv ; sham levels ; renal DNx
P-1376	-0.0898 -0.2880 -0.0752 -0.5159 -0.0039 -1.5445 -0.3487 -0.1369 -0.0241 -2.0846 -0.3562 -0.3195 -0.0361 -1.8622 -0.3862 -1.5514 -2.6473 -0.3431 -0.0748 -0.0995 -0.6080 -0.4049 -1.9929 -0.2324 -0.0240 -0.1081 -0.9813 -0.3368 -0.3220 -0.2318 -1.0505 -0.2961 -0.0311 -0.3032 -0.0431 -0.2824 -0.0790
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
H-1542	-0.2238050401210785	▁bis phos phon ates ▁; ▁ale ndr onate ▁; ▁et id rona te ▁; ▁heart ▁failure ▁; ▁re fill ▁compliance
D-1542	-0.2238050401210785	bisphosphonates ; alendronate ; etidronate ; heart failure ; refill compliance
P-1542	-0.0563 -0.0298 -0.0748 -0.2801 -0.3125 -0.0417 -0.0122 -0.0268 -0.1656 -0.0078 -0.0464 -0.0171 -0.0253 -0.2522 -0.8923 -0.1614 -0.8401 -0.0160 -0.0640 -0.5768 -0.9372 -0.0871
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse ; hospitalization ; physician ; discharge ; patients ; hospitalized ; heart failure
H-206	-0.5813004970550537	▁nurse ▁assessment ▁; ▁cognitive ▁im pair ment ▁; ▁hospital ization ▁; ▁physician ▁; ▁dis charge ▁; ▁el der ly ▁patients ▁hospital ized ▁; ▁heart ▁failure
D-206	-0.5813004970550537	nurse assessment ; cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients hospitalized ; heart failure
P-206	-1.2121 -0.2837 -1.3126 -0.0346 -0.5833 -0.0767 -0.6296 -0.4870 -1.0313 -0.7143 -0.2879 -0.7917 -0.3446 -0.3629 -0.0249 -0.3119 -1.6086 -0.0386 -0.3688 -0.3731 -1.7120 -0.2531 -1.7857 -0.6601 -0.1354 -0.1823 -0.0886
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol ; nonselective β-blocker ; selective β-blocker ; metoprolol ; thromboembolic events ; heart failure
H-1111	-0.4380861520767212	▁car vedi lol ▁; ▁non sel ective ▁β - block er ▁; ▁β - block er ▁met o pro lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure
D-1111	-0.4380861520767212	carvedilol ; nonselective β-blocker ; β-blocker metoprolol ; thromboembolic events ; heart failure
P-1111	-0.0258 -0.0154 -0.0520 -0.5340 -2.0683 -0.1778 -0.0590 -0.1340 -0.1114 -0.6528 -0.3858 -0.5601 -1.1054 -0.0899 -0.5075 -0.3969 -1.2770 -0.5022 -0.0543 -0.1387 -0.4777 -0.3469 -0.8492 -0.8803 -0.4165 -0.0655 -0.5047 -0.4513 -0.4406 -0.5192 -0.2636 -0.2780 -0.1150
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline ; cardiac transplant ; ecct
H-716	-0.7758396863937378	▁cardiac ▁transplant ▁survival ▁; ▁ec CT
D-716	-0.7758396863937378	cardiac transplant survival ; ecCT
P-716	-0.7813 -0.0868 -2.2043 -0.4721 -0.2114 -2.1140 -0.2103 -0.1266
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ; ami ; pna ; mortality
H-1700	-1.0163357257843018	▁ HF ▁; ▁ AMI ▁; ▁p NA ▁; ▁mortal ity
D-1700	-1.0163357257843018	HF ; AMI ; pNA ; mortality
P-1700	-2.3886 -0.9573 -0.2049 -1.8852 -0.7200 -0.3304 -0.7349 -2.3499 -0.9169 -0.3531 -2.1035 -0.1554 -0.1124
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients ; heart failure ; hf ; evidence ; outcomes ; hf
H-685	-1.2435640096664429	▁heart ▁failure ▁; HF ▁; ▁ HF
D-685	-1.2435640096664429	heart failure ;HF ; HF
P-685	-6.0347 -0.2660 -0.4200 -0.3683 -0.9055 -1.9681 -0.3820 -0.6927 -0.1547
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling ; arrhythmia ; ami ; hr variability ; arrhythmia
H-1590	-0.6242811679840088	▁ar rhythm ia ▁substrat e ▁; AMI ▁; ▁HR ▁; ▁ar rhythm ia ▁events
D-1590	-0.6242811679840088	arrhythmia substrate ;AMI ; HR ; arrhythmia events
P-1590	-0.1786 -0.2078 -1.3326 -0.0206 -0.1166 -0.2876 -1.5673 -0.2733 -0.4135 -1.4757 -1.3028 -0.6440 -1.1842 -0.7231 -0.1851 -0.0757
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced cardiotoxicity ; resistin ; retn
H-933	-0.4947602450847626	▁do xor ubi cin - indu ced ▁cardio toxic iteit ▁; ▁Hum - re t n ▁; ▁litt er mate ▁; ▁resist in ▁; ▁re t n
D-933	-0.4947602450847626	doxorubicin-induced cardiotoxiciteit ; Hum-retn ; littermate ; resistin ; retn
P-933	-0.0255 -0.0174 -0.0128 -0.6053 -0.1302 -0.0262 -0.1286 -0.1275 -0.9349 -2.1959 -0.3385 -0.3972 -0.0540 -2.6310 -0.4285 -0.0537 -0.9152 -0.1328 -0.0206 -0.0631 -0.5279 -2.1633 -0.2090 -0.4353 -0.8586 -0.6175 -0.0300 -0.2000 -0.0676
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients ; hypertension ; compensated hfpef ; dash ; sodium
H-919	-0.5681822299957275	▁hyper tension ▁; ▁compensa ted ▁H FP EF ▁; ▁DAS h ▁; ▁s rd ▁; ▁so dium ▁; ▁kcal
D-919	-0.5681822299957275	hypertension ; compensated HFPEF ; DASh ; srd ; sodium ; kcal
P-919	-1.8878 -0.0937 -0.2988 -0.0867 -0.1663 -1.3101 -0.9939 -1.1685 -0.2271 -0.2250 -0.1253 -0.5622 -1.4271 -1.2624 -0.4183 -0.0165 -0.0958 -0.9381 -0.1859 -0.3511 -0.0911
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd ; dyssynchronous hf ; remodeling ; insignificantly
H-1154	-0.39828142523765564	▁EM d ▁; ▁dys syn chron ous ▁ HF
D-1154	-0.39828142523765564	EMd ; dyssynchronous HF
P-1154	-1.2450 -0.4807 -0.3033 -0.0129 -0.0258 -0.0104 -1.3175 -0.2336 -0.3905 -0.2493 -0.1120
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic dysfunction ; pathophysiology ; hfpef ; cardiovascular function
H-1302	-0.3771314322948456	▁dia sto lic ▁dys function ▁; ▁pat ho phy si ology ▁; ▁ HF p EF ▁; ▁non - dia sto lic ▁ab normal ities ▁; ▁cardiovascular ▁function
D-1302	-0.3771314322948456	diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
P-1302	-0.0609 -0.1523 -0.1544 -0.1859 -0.1489 -0.2302 -0.3661 -0.3681 -0.2238 -2.9584 -0.4911 -0.1952 -1.0160 -0.6981 -0.0673 -0.4036 -0.3401 -0.2658 -0.0583 -0.1212 -0.1733 -0.0685 -0.0439 -0.1053 -1.3119 -0.2484 -0.0481 -0.4772 -0.2388 -0.0929
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ; ejection fraction ; cardiac index ; inotropes ; medical ; transplant
H-1997	-0.5408186912536621	▁e je ction ▁ fraction ▁; ▁cardiac ▁index ▁; ▁in o trop es ▁; ▁in ot rope - dependent
D-1997	-0.5408186912536621	ejection fraction ; cardiac index ; inotropes ; inotrope-dependent
P-1997	-0.1699 -0.2177 -0.0848 -0.6468 -0.0307 -0.6371 -0.1481 -0.0122 -0.4889 -0.0674 -1.3202 -0.0886 -0.9857 -0.2942 -0.0704 -0.5831 -0.1221 -0.2682 -0.0271 -4.9637 -0.1304
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density lipoprotein ; hdl ; endothelial cell ; nitric oxide
H-246	-0.655113160610199	▁hoge - dens ity ▁lipo prote in ▁; HD L ▁; ▁en dot heli al - protec tive ▁effects ▁; ▁en dot heli al ▁cell ▁; ▁ec ▁; ▁ni tric ▁oxid e ▁; NO
D-246	-0.655113160610199	hoge-density lipoprotein ;HDL ; endothelial-protective effects ; endothelial cell ; ec ; nitric oxide ;NO
P-246	-2.0841 -0.2125 -0.9965 -2.0939 -0.0724 -0.1734 -1.3542 -0.8403 -0.5022 -3.6279 -0.7629 -0.0974 -0.7060 -0.1904 -0.0240 -0.9490 -0.2859 -1.5561 -1.6172 -0.7659 -0.0234 -0.7761 -0.1912 -0.0174 -0.2401 -0.4471 -0.2432 -0.8865 -0.0254 -0.0810 -0.0102 -0.1077 -0.4218 -0.6595 -0.4441 -0.0973
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort study ; saxagliptin ; sitagliptin ; antihyperglycemic agents
H-1840	-0.477931410074234	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁agents
D-1840	-0.477931410074234	hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
P-1840	-0.0478 -0.9831 -0.3843 -0.1009 -0.0071 -0.5434 -2.3060 -0.2194 -0.8918 -0.4082 -0.0749 -1.7013 -0.2755 -0.0128 -0.4640 -0.1595 -0.3539 -0.2881 -0.4774 -0.4447 -0.2712 -0.0991
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially expressed genes ; degs ; ischemic heart failure ; healthy ; diagnosis ; heart failure
H-1608	-0.8269863724708557	▁de g s ▁; ▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁heart ▁failure
D-1608	-0.8269863724708557	degs ; non-ischemic ; ischemic heart failure ; heart failure
P-1608	-2.7892 -2.8017 -0.1407 -0.3993 -0.6010 -0.0991 -0.0631 -0.2924 -1.5489 -0.2382 -0.0573 -0.5525 -1.9669 -0.1559 -0.6525 -2.8481 -0.1809 -0.1968 -0.1283
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin resistance ; type 2 diabetes ; insulin receptor substrates 1 ; irs1 ; irs2 ; cellular metabolism
H-653	-0.39573267102241516	▁in s ulin ▁resist ance ▁; ▁type ▁2 ▁diabetes ▁; ▁insulin ▁receptor ▁substrat es ▁; IR s 1 ▁; ▁i RS 2 ▁; ▁insulin - signal ing ▁component s ▁; ▁cel lular ▁metabolism
D-653	-0.39573267102241516	insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling components ; cellular metabolism
P-653	-1.4812 -0.5752 -0.0847 -0.1857 -0.0594 -0.2607 -0.1865 -0.3452 -0.0287 -0.1814 -0.0085 -0.0160 -0.0157 -0.1153 -0.3942 -2.7052 -0.0738 -0.8593 -0.2411 -0.3544 -0.3078 -0.8839 -0.5189 -0.0597 -0.1235 -0.0238 -0.1279 -0.9589 -0.6106 -0.7051 -0.8250 -0.0257 -0.0559 -0.3695 -0.0825
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome ; admission ; discharge ; hospitalized ; heart failure ; hf ; nursing outcomes classification ; noc
H-1398	-0.6179413795471191	▁ad mission ▁to ▁dis charge ▁; ▁older ▁adults ▁; ▁heart ▁failure ▁; HF ▁; ▁Nur sing ▁Out com es ▁Classifica tion ▁; no c
D-1398	-0.6179413795471191	admission to discharge ; older adults ; heart failure ;HF ; Nursing Outcomes Classification ;noc
P-1398	-2.6339 -0.5605 -0.3789 -0.1279 -0.0381 -0.5960 -0.8705 -0.1093 -2.3135 -0.5036 -0.1194 -0.3081 -0.6882 -0.1291 -0.4725 -0.1345 -2.8261 -0.1533 -0.0341 -0.0907 -0.0875 -0.3043 -1.4907 -0.7007 -0.2919 -0.1032
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp ; phosphomimic ; ser77 ; ser83 ; riα ; proteins ; riα
H-1432	-0.552968442440033	▁8- flu o - c AMP ▁ binding ▁; ▁wild ▁type ▁; ▁ phos pho mi mic ▁; ▁ser 77 ▁; ▁ser 83 ▁mu tant ▁; ▁RI α ▁protein s ▁; ▁double ▁mu tant ▁; ▁w t ▁RI α
D-1432	-0.552968442440033	8-fluo-cAMP binding ; wild type ; phosphomimic ; ser77 ; ser83 mutant ; RIα proteins ; double mutant ; wt RIα
P-1432	-0.1737 -0.2534 -0.3999 -0.0559 -0.0533 -0.1366 -1.4268 -0.0369 -0.2782 -1.1031 -0.0479 -0.1590 -0.0649 -0.0308 -0.0778 -0.2945 -0.5664 -2.3193 -0.9351 -0.5605 -0.1870 -0.6515 -2.5770 -2.4950 -0.4470 -0.1212 -0.8712 -0.2430 -0.5045 -0.2152 -0.2228 -0.8474 -0.2180 -0.2644 -0.2107 -0.4773 -0.0662 -2.4837 -0.3565 -0.1691 -0.0689
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate analysis ; preoperative ; albumin ; mortality ; lvad ; implantation ; hazard ratio ; confidence interval
H-535	-0.7708421349525452	▁pre operativ e ▁album in ▁; ▁l VAD ▁implant ation
D-535	-0.7708421349525452	preoperative albumin ; lVAD implantation
P-535	-3.8114 -0.1218 -0.0605 -0.3805 -0.6160 -0.6747 -1.9335 -0.0368 -0.4895 -0.5368 -0.4432 -0.1453
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients ; systolic heart failure ; qrs duration ; crt ; death ; hospitalization ; heart failure ; mortality
H-854	-0.892350435256958	▁sy sto lic ▁heart ▁failure ▁; ▁QR s ▁; ▁c RT ▁; ▁hospital ization ▁; ▁heart ▁failure
D-854	-0.892350435256958	systolic heart failure ; QRs ; cRT ; hospitalization ; heart failure
P-854	-0.2712 -0.2485 -0.1268 -0.9360 -0.2744 -0.2827 -0.2204 -1.3303 -0.2175 -0.8665 -3.7018 -0.3405 -4.4658 -0.8345 -0.5886 -0.5631 -0.2813 -1.2583 -0.1466
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox regression models ; propensity score ; oral ; glucocorticoid ; hf ; hospitalisations ; loop diuretics
H-605	-0.39244237542152405	▁co x ▁re gression ▁models ▁; ▁pro pens ity ▁score ▁; ▁oral ▁gluco cor tico id ▁dos age ▁; ▁ HF ▁hospital isation s ▁; ▁loop ▁di ure tics
D-605	-0.39244237542152405	cox regression models ; propensity score ; oral glucocorticoid dosage ; HF hospitalisations ; loop diuretics
P-605	-0.0440 -0.1800 -0.0254 -0.0302 -0.8751 -0.3245 -0.0141 -0.0555 -1.9104 -0.1003 -0.3364 -0.1130 -0.0149 -0.5159 -0.6115 -0.1813 -2.1417 -0.0367 -0.2559 -1.0092 -0.1688 -0.8912 -0.1067 -0.0756 -0.2570 -0.0062 -0.2372 -0.9356 -0.2502 -0.3829 -0.0783
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional electrical stimulation ; fes ; exercise capacity ; quality of life ; endothelial function ; chronic heart failure ; systolic function
H-1327	-0.33676114678382874	▁Fun ction al ▁electric al ▁stimul ation ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁stress ▁; ▁en dot heli al ▁function ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁function
D-1327	-0.33676114678382874	Functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; systolic function
P-1327	-0.6597 -0.0235 -0.0295 -0.1595 -0.0134 -0.1150 -0.7083 -0.6765 -1.2290 -0.8604 -0.4343 -0.7120 -0.7024 -0.2848 -0.2172 -0.3355 -0.2305 -0.0519 -0.3556 -0.0926 -0.0057 -0.0769 -0.2004 -0.9525 -0.7144 -0.1270 -0.2505 -0.0474 -0.0713 -0.1240 -0.1888 -0.3724 -0.0902
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis ; patients ; hf ; hospitalization ; all-cause hospitalization ; mortality ; hf ; hospitalization ; death
H-910	-0.9753629565238953	▁dia lys is ▁patients ▁; ▁ HF
D-910	-0.9753629565238953	dialysis patients ; HF
P-910	-0.9751 -0.1355 -0.2934 -2.0445 -0.7398 -1.1815 -0.3078 -2.9377 -0.1629
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse events ; reoperation ; bleeding ; driveline ; infection ; gastrointestinal bleeding ; stroke ; rankin score
H-2003	-0.37403061985969543	▁ble ed ing ▁; ▁drive line ▁infection ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁de bilitat ing ▁stroke ▁; ▁Rank in ▁Score
D-2003	-0.37403061985969543	bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke ; Rankin Score
P-2003	-2.2418 -0.5656 -0.4007 -0.4481 -0.2992 -0.0683 -0.1642 -0.3689 -0.0488 -0.1767 -0.5760 -0.1343 -0.1080 -0.8639 -0.3426 -0.2441 -0.1875 -0.0126 -0.1189 -0.3296 -0.6486 -0.1260 -0.4682 -0.3605 -0.2907 -0.1310
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta blockers ; all-cause mortality ; readmissions ; heart failure with reduced ejection fraction ; hfref ; heart rate
H-1936	-0.5236441493034363	▁Beta ▁block ers ▁; ▁read missions ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁heart ▁rate ▁; HR
D-1936	-0.5236441493034363	Beta blockers ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
P-1936	-0.5444 -0.5319 -0.2662 -0.6109 -3.8763 -0.1142 -0.5849 -0.5024 -0.0894 -0.2788 -0.1013 -0.1363 -0.0310 -0.3297 -0.0076 -0.3110 -1.2367 -0.1230 -0.8483 -0.2110 -1.4553 -0.2679 -0.4526 -0.1999 -0.4132 -0.0906
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous hf ; electromechanical delay ; emd ; myocyte depolarization ; myofiber shortening
H-1149	-0.34113919734954834	▁dys syn chron ous ▁ HF ▁; ▁electro me chan ical ▁de lay ▁; em d ▁; ▁my o cy te ▁de po lar ization ▁; ▁my o fi ber
D-1149	-0.34113919734954834	dyssynchronous HF ; electromechanical delay ;emd ; myocyte depolarization ; myofiber
P-1149	-0.2030 -0.0358 -0.0070 -0.8042 -0.5335 -0.4105 -0.2305 -0.0466 -0.1586 -0.0927 -0.4962 -0.1044 -0.1503 -0.3538 -3.9113 -0.1431 -0.2833 -0.3891 -0.1545 -0.1189 -0.1265 -0.0519 -0.0520 -0.1090 -0.3593 -0.4453 -0.3574 -0.1202 -0.0459 -0.1612 -0.3472 -0.1134
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs morphology ; outcomes ; cardiac resynchronization therapy ; resynchronization-defibrillation for ambulatory heart failure trial ; raft
H-879	-0.3418993055820465	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁re syn chron ization - Def i bril lation ▁; ▁amb ulator y ▁Heart ▁Fail ure ▁tri al ▁; RAF t
D-879	-0.3418993055820465	QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; ambulatory Heart Failure trial ;RAFt
P-879	-0.1365 -0.4917 -0.6429 -0.0547 -0.3602 -0.1975 -0.2781 -0.0420 -0.1302 -0.0323 -0.5729 -1.3753 -0.0354 -0.4481 -0.1625 -0.0780 -0.0534 -0.6408 -0.3271 -0.6994 -0.4772 -0.1513 -0.0409 -0.5427 -0.7964 -0.0846 -0.0391 -0.6044 -0.3748 -0.9571 -0.2051 -0.0176 -0.3431 -0.7467 -0.2882 -0.1425 -0.0795
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker ; clinical ; therapeutic
H-1478	-0.40292859077453613	▁bio mark er ▁studies ▁; ▁bio mark er - guide d ▁clinic al ▁trial
D-1478	-0.40292859077453613	biomarker studies ; biomarker-guided clinical trial
P-1478	-0.1641 -0.2583 -0.1352 -0.4521 -0.6849 -0.0827 -0.1679 -0.1300 -0.1958 -0.0112 -0.0233 -0.2434 -0.0940 -0.1932 -3.4997 -0.1110
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf ; incidence ; liver ; nodularity
H-231	-0.6228675842285156	▁ab normal ▁ liver ▁texture ▁; ▁no du lar ity
D-231	-0.6228675842285156	abnormal liver texture ; nodularity
P-231	-0.6998 -0.0449 -0.2340 -0.6239 -1.0993 -1.3800 -0.0696 -0.0078 -0.2793 -2.5973 -0.3064 -0.1320
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant ; patients ; pd ; hf ; clinical
H-896	-0.6675770282745361	▁transplant ▁; ▁PD ▁; ▁ HF ▁volume ▁management ▁; ▁post - PD ▁initiat ion
D-896	-0.6675770282745361	transplant ; PD ; HF volume management ; post-PD initiation
P-896	-0.3738 -1.2294 -2.0476 -0.3971 -0.7204 -0.4673 -0.1810 -0.1081 -0.9112 -2.6886 -0.0265 -0.1116 -0.9402 -0.0631 -0.3067 -0.1086
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty ; biological phenotype ; physical ; activity
H-1004	-0.7080699801445007	▁fra il ty ▁; ▁bi ological ▁ph eno type ▁; ▁we ak ▁grip ▁strength ▁; ▁physical ▁exhaust ion
D-1004	-0.7080699801445007	frailty ; biological phenotype ; weak grip strength ; physical exhaustion
P-1004	-0.7866 -0.4289 -0.2186 -0.7255 -3.4024 -0.3768 -0.6503 -0.5369 -0.0063 -0.6616 -0.0266 -0.0288 -0.1565 -1.3548 -0.2895 -0.4208 -0.1630 -0.0967 -3.7286 -0.1021
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d ; patients ; ic ; crt-d ; ies
H-109	-0.870380163192749	▁c RT - d ▁; ▁IE ▁; ▁IC ▁; ▁benefit ▁; ▁c RT - d ▁; ▁IE s
D-109	-0.870380163192749	cRT-d ; IE ; IC ; benefit ; cRT-d ; IEs
P-109	-0.7787 -2.2167 -0.0982 -0.8474 -0.3010 -2.3469 -0.2424 -0.5703 -0.3845 -3.9968 -0.3615 -0.3978 -2.2923 -0.1276 -0.6551 -0.5370 -0.4161 -0.4804 -0.2605 -0.0964
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds ; discharge ; patients ; heart failure ; outcomes ; driven ; readmissions
H-467	-1.0383455753326416	▁significant - volu me ▁ED s ▁; ▁dis charge ▁patients ▁; ▁heart ▁failure ▁; ▁ED ▁; ▁read missions ▁; ▁repeat ▁ED
D-467	-1.0383455753326416	significant-volume EDs ; discharge patients ; heart failure ; ED ; readmissions ; repeat ED
P-467	-6.2784 -1.5937 -0.0924 -0.2302 -0.2674 -0.3085 -0.5358 -1.7811 -0.0683 -0.9137 -1.9575 -0.4297 -0.0658 -1.1210 -2.0005 -1.9381 -1.0815 -0.0714 -0.2670 -0.8104 -0.2457 -1.7192 -0.1046
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute right heart failure ; therapy ; refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; ecmo ; cpr ; icu
H-1295	-0.46052905917167664	▁a cute ▁right ▁heart ▁failure ▁; ▁ therapy ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁heart ▁team ▁; ▁corpore al ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁c PR ▁; ICU
D-1295	-0.46052905917167664	acute right heart failure ; therapy refractory cardiogenic shock ; heart team ; corporeal membrane oxygenation ; ecmo ; cPR ;ICU
P-1295	-2.5670 -0.0172 -1.2394 -0.4207 -0.2662 -0.3940 -0.9154 -0.0287 -0.0507 -0.0605 -0.1789 -0.0590 -0.1386 -0.6023 -0.0817 -0.4024 -2.1564 -0.9519 -0.3273 -0.3472 -0.0401 -0.0352 -0.1157 -0.1870 -0.2722 -0.2514 -0.4580 -1.3356 -0.2654 -0.1873 -0.8570 -0.6302 -0.0143 -0.2015 -0.0619
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report ; patient ; right atrial myxoma ; massive embolism ; pulmonary arteries ; surgically ; right atrial ; pulmonary embolectomy
H-595	-0.3491513729095459	▁right ▁at rial ▁my xo ma ▁; ▁massive ▁e mbol ism ▁; ▁pulmonar y ▁arteri es ▁; ▁right ▁at rial ▁mass ▁remo val ▁; ▁pulmonar y ▁e mbol ecto my
D-595	-0.3491513729095459	right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
P-595	-1.0297 -0.3567 -0.0858 -1.1491 -0.0361 -0.2803 -0.2854 -1.2997 -0.0623 -0.0370 -1.1970 -0.4829 -0.0201 -0.1351 -0.0104 -0.1283 -0.5028 -0.2935 -0.4148 -0.1631 -0.0693 -0.1246 -0.0773 -0.2012 -0.0054 -0.0787 -0.1199 -0.0711 -0.1963 -1.8765 -0.3085 -0.0736
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency room ; undiagnosed ; heart disease ; symptoms ; hf ; surgical palliation
H-201	-0.8643007874488831	▁heart ▁disease ▁; ▁ HF ▁; ▁sur g ical ▁palli ation
D-201	-0.8643007874488831	heart disease ; HF ; surgical palliation
P-201	-5.4766 -0.3395 -0.2095 -1.5969 -0.2130 -0.8576 -1.2909 -0.1058 -0.3708 -0.0314 -0.4268 -0.2143 -0.1028
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart magnetic resonance imaging ; chelation ; patient ; compliance ; heart failure ; arrhythmias
H-745	-0.5831356048583984	▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-745	-0.5831356048583984	heart magnetic resonance imaging ; chelation choices ; heart failure ; arrhythmias
P-745	-2.3060 -0.1195 -0.5820 -0.2883 -0.5528 -0.1868 -0.1827 -0.4431 -0.0178 -0.0227 -0.6976 -0.1748 -0.2816 -4.0185 -0.3375 -0.2754 -0.0117 -0.2295 -1.1441 -0.2931 -0.0804
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection fraction ; ef ; patients ; nyha class iiib ; symptoms ; right ventricular dysfunction
H-897	-0.6766523718833923	▁e je ction ▁ fraction ▁; EF ▁; ▁pre - PD ▁; ▁NY ha ▁class ▁III b ▁; ▁right ▁vent ri cular ▁dys function
D-897	-0.6766523718833923	ejection fraction ;EF ; pre-PD ; NYha class IIIb ; right ventricular dysfunction
P-897	-0.0558 -0.3951 -0.0899 -0.4743 -0.0344 -0.3260 -0.8243 -0.2873 -5.0860 -0.0309 -0.1312 -0.3705 -0.9884 -1.1227 -0.8733 -0.0940 -0.2334 -0.8955 -1.4057 -0.1799 -2.2558 -0.6834 -0.0559 -0.3867 -0.2030 -0.1095
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs ; early-outgrowth colony-forming units ; eo-cfus ; cells
H-124	-0.7811678647994995	▁c ▁pc s ▁; ▁ec b ▁; ▁circula ting ▁; ▁cd 34 ▁; ▁v EG FR 2 ▁; ▁cd 133 + ▁cell s
D-124	-0.7811678647994995	c pcs ; ecb ; circulating ; cd34 ; vEGFR2 ; cd133+ cells
P-124	-0.1808 -2.2488 -0.1832 -0.4711 -2.2651 -1.2484 -1.1678 -1.0011 -0.2269 -1.7579 -0.8640 -0.6700 -1.1352 -0.0895 -0.8631 -0.4088 -0.2302 -0.8946 -0.8776 -0.2942 -1.5831 -0.3851 -0.1821 -0.2070 -0.0936
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene expression ; bax ; pacing ; bcl-2 ; mrna ; expression ; heart failure ; bcl-2 ; bax
H-168	-0.546978235244751	▁Gene ▁expression ▁; ▁Bax ▁; ▁b cl -2 ▁m RNA ▁expression ▁; ▁heart ▁failure ▁; ▁b cl - 2/ Ba x
D-168	-0.546978235244751	Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
P-168	-1.7275 -0.1634 -0.7300 -0.0380 -0.3007 -0.4200 -0.2190 -0.1380 -0.0054 -0.0855 -0.8104 -0.2848 -1.2221 -0.1472 -0.3617 -1.6909 -0.5324 -0.1506 -0.0291 -3.0417 -0.0825 -0.3009 -0.0987
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl ; hno ; inotropic ; lusitropic ; vasodilator ; in vivo ; camp
H-413	-0.4614754617214203	▁ni tro x yl ▁; ▁h no ▁; ▁Angeli s ▁salt ▁; ▁in o tropi c ▁; ▁ lusi tropi c ▁; ▁vaso dila tor ▁effects ▁; ▁c AMP
D-413	-0.4614754617214203	nitroxyl ; hno ; Angelis salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
P-413	-0.0167 -0.0926 -0.5001 -0.2097 -0.2745 -1.5140 -1.1505 -0.2406 -1.2024 -4.1382 -0.0198 -0.2401 -0.1621 -1.1744 -0.0090 -0.1287 -0.1904 -0.5520 -0.0068 -0.0142 -0.1240 -0.1974 -0.0112 -0.0033 -0.0547 -1.1962 -0.1880 -0.0953 -0.0708 -0.4407 -0.0872
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy ; anticoagulation ; rate control ; cardiovascular ; complications ; stroke ; cardiovascular death ; acute heart failure ; patients ; atrial fibrillation
H-1643	-0.3123994469642639	▁antico ag ulation ▁; ▁rate ▁control ▁; ▁cardiovascular ▁complica tions ▁; stro ke ▁; ▁cardiovascular ▁death ▁; ▁a cute ▁heart ▁failure ▁; ▁at rial ▁fi bril lation ▁; AF
D-1643	-0.3123994469642639	anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
P-1643	-1.1008 -0.1177 -0.1682 -0.2650 -0.1410 -0.4900 -0.3941 -0.2636 -0.0247 -0.5165 -0.3370 -0.6605 -0.1537 -0.7010 -0.0314 -0.5666 -0.1140 -0.0749 -0.0198 -0.2825 -0.1126 -0.2071 -1.0457 -0.0697 -0.3217 -0.0459 -0.1986 -0.3294 -0.4958 -0.3368 -0.0980
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence ; clinical ; continuous-flow lvads ; heartmate ii ; hm ii ; heartware ; btt ; dt ; patients
H-309	-0.5498203039169312	▁continuo us - flow ▁l VAD s ▁; ▁he art Mate ▁II ▁; HM ▁II ▁; ▁Heart War e ▁; ▁b t ▁; ▁ DT
D-309	-0.5498203039169312	continuous-flow lVADs ; heartMate II ;HM II ; HeartWare ; bt ; DT
P-309	-0.6408 -0.0676 -0.1755 -0.0713 -1.6084 -0.0635 -0.2612 -0.3607 -0.0376 -0.5887 -0.1196 -1.0114 -0.1027 -0.6820 -1.5224 -0.0974 -1.2155 -0.2302 -0.0564 -0.1786 -1.6327 -1.0667 -0.2286 -1.8386 -0.2306 -0.6400 -0.1167
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients ; baseline ; ef ; ef ; core
H-753	-0.7272273302078247	▁EF ▁; ▁EF
D-753	-0.7272273302078247	EF ; EF
P-753	-0.7941 -1.0827 -0.5051 -1.1252 -0.1289
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal muscle ; lean mass ; z-score
H-1499	-0.8278324604034424	▁skelet al ▁muscle ▁mass ▁; ▁appen di cular ▁lean ▁mass ▁index ▁; ▁z - s core
D-1499	-0.8278324604034424	skeletal muscle mass ; appendicular lean mass index ; z-score
P-1499	-4.8757 -0.1970 -0.6017 -0.2368 -0.8842 -2.8203 -0.2008 -0.3824 -1.2937 -0.1631 -0.0452 -2.1733 -0.2702 -0.1093 -0.1713 -0.2101 -0.1499 -0.1160
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash ; mortality ; hf ; nonsignificant
H-693	-0.5540512800216675	▁DAS h ▁die t ▁score s ▁; ▁mortal ity ▁; ▁ HF ▁; ▁Mediterrane an ▁die t ▁score s
D-693	-0.5540512800216675	DASh diet scores ; mortality ; HF ; Mediterranean diet scores
P-693	-0.0634 -0.1796 -2.0519 -0.1302 -0.0832 -0.1331 -0.3207 -0.9302 -1.6290 -0.1868 -2.1689 -0.4510 -0.4972 -0.4701 -0.3803 -1.0318 -0.4225 -0.0447 -0.1244 -0.2301 -0.1057
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality of life ; all-cause mortality ; mortality
H-561	-1.4445369243621826	▁quality ▁of ▁life ▁; ▁mortal iteit
D-561	-1.4445369243621826	quality of life ; mortaliteit
P-561	-3.0758 -1.6898 -1.4699 -1.1837 -1.1412 -2.2990 -0.5904 -0.1064
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef ; bnp ; bnp ; inhospital ; mortality
H-197	-1.0386618375778198	▁b NP ▁; ▁b NP ▁; ▁in hospital ▁mortal ity
D-197	-1.0386618375778198	bNP ; bNP ; inhospital mortality
P-197	-3.5626 -1.8375 -0.7294 -2.5247 -1.1185 -0.5017 -0.2669 -0.0708 -0.0927 -1.4430 -0.1966 -0.1195
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular diseases ; heart failure ; hf ; incidence ; hf
H-285	-0.3666515350341797	▁cardiovascular ▁disease s ▁; ▁heart ▁failure ▁; HF ▁; ▁ HF
D-285	-0.3666515350341797	cardiovascular diseases ; heart failure ;HF ; HF
P-285	-0.2193 -0.5969 -0.1510 -0.3621 -0.3455 -0.1651 -0.1652 -0.4356 -0.6211 -0.9759 -0.3785 -0.2460 -0.1041
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart failure ; left ventricular systolic dysfunction ; post hoc analysis
H-402	-0.7057984471321106	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁sy sto lic ▁dys function ▁; ▁BB
D-402	-0.7057984471321106	heart failure ; left ventricular systolic dysfunction ; BB
P-402	-2.7448 -0.3874 -0.3063 -1.0721 -0.1618 -2.8568 -0.2547 -0.0443 -0.1403 -0.2957 -0.0507 -0.2670 -0.4296 -1.9389 -0.2363 -0.1060
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka ; polymorphism ; rs10927887 ; p.arg83gly ; heart failure ; estimated glomerular filtration rate ; renastur
H-1801	-0.5419228672981262	▁CL cn ka ▁poly morph ism ▁; ▁p . ▁ar g 83 g ly ▁; ▁heart ▁failure ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁re NAS tur ▁co hor t
D-1801	-0.5419228672981262	CLcnka polymorphism ; p. arg83gly ; heart failure ; glomerular filtration rate ; reNAStur cohort
P-1801	-0.6079 -1.3710 -1.2626 -0.3385 -0.0124 -0.9524 -0.1475 -3.1629 -0.0862 -0.4807 -0.0478 -0.4368 -1.8886 -0.1487 -0.1723 -0.4993 -0.1579 -0.2121 -0.1218 -0.1828 -0.0699 -0.1021 -0.3867 -0.5974 -0.2567 -1.4245 -0.1191 -0.1917 -0.9391 -1.0765 -0.0979 -0.2580 -0.0738
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 ; functional capacity ; outcomes ; ambulatory ; patients ; hf
H-706	-0.7989636063575745	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁ HF
D-706	-0.7989636063575745	ST2 ; functional capacity ; HF
P-706	-1.1299 -0.1108 -0.6974 -0.6733 -0.7210 -0.3819 -3.3693 -0.4450 -0.3174 -0.1436
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac vegf expression ; endothelial no synthase activation ; hearts
H-455	-0.4670912027359009	▁cardiac ▁VE GF ▁expression ▁; ▁Akt ▁; ▁en dot heli al ▁no ▁synth ase ▁activa tion ▁; ▁fail ing ▁heart s
D-455	-0.4670912027359009	cardiac VEGF expression ; Akt ; endothelial no synthase activation ; failing hearts
P-455	-1.4598 -1.5913 -0.0826 -0.0680 -0.2217 -0.0202 -0.2579 -0.0405 -0.7968 -0.0711 -0.0058 -1.0334 -0.0532 -1.3073 -0.0050 -0.5314 -0.6638 -1.3101 -0.1122 -0.5242 -0.1850 -0.2996 -0.1019
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene expression ; cardiomyocytes ; jq1 ; drug ; genes
H-1046	-0.41137048602104187	▁Gene ▁expression ▁profil ing ▁; ▁culture d ▁cardio my o cy tes ▁; ▁j q 1 ▁; ▁drug ▁; ▁ phen yle ph rine - indu ced ▁gene s
D-1046	-0.41137048602104187	Gene expression profiling ; cultured cardiomyocytes ; jq1 ; drug ; phenylephrine-induced genes
P-1046	-2.4064 -0.1749 -0.1456 -0.0728 -0.3287 -0.4141 -0.0595 -0.1171 -1.0818 -0.8757 -0.2318 -0.0892 -0.3548 -0.2429 -0.9507 -1.4117 -0.2585 -0.3587 -0.6290 -0.2545 -0.0959 -0.8641 -0.3208 -0.0672 -0.1772 -0.0051 -0.0954 -0.2915 -0.1165 -0.2008 -0.0595
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced pasp ; right ventricular contractile reserve ; patients ; exercise-induced pasp
H-824	-0.7154941558837891	▁pas p ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pas p
D-824	-0.7154941558837891	pasp ; right ventricular contractile reserve ; pasp
P-824	-1.5310 -0.4679 -0.3408 -1.2667 -0.0554 -2.4301 -0.4131 -0.0230 -0.2951 -0.0141 -0.7615 -2.5549 -0.3758 -0.1180 -0.0851
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene expression profile ; gse9128 ; gene expression omnibus ; non-ischemic heart failure ; ischemic
H-1609	-0.4242744743824005	▁Gene ▁expression ▁profile ▁; ▁g se 91 28 ▁; ▁Gene ▁Express ion ▁Omni bus ▁; ▁non - ische mic ▁heart ▁failure ▁; ▁ ische mic ▁sample s
D-1609	-0.4242744743824005	Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic samples
P-1609	-0.5575 -0.3083 -0.2295 -1.3757 -0.4584 -1.1661 -0.2215 -0.1861 -0.3892 -0.4057 -0.0828 -0.0071 -0.1772 -0.2923 -0.3893 -0.5578 -0.0428 -0.0304 -0.2304 -0.8625 -0.1476 -2.6045 -0.2050 -0.0270 -0.3683 -0.3557 -0.2265 -0.2898 -0.1090
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac ; insulin-resistance ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose
H-1784	-0.23663531243801117	▁cardiac ▁insulin - re si stance ▁; ▁a ac ▁; ▁insulin - stimul ated ▁rates ▁; ▁gly col ysis ▁; ▁gluco se ▁oxid ation ▁; ▁plasma ▁membran e ▁trans location ▁; ▁gluco se ▁transporter
D-1784	-0.23663531243801117	cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
P-1784	-0.0596 -0.3841 -0.0641 -0.5782 -1.2507 -0.0219 -0.4423 -0.7398 -0.5736 -0.5161 -0.1273 -0.0972 -0.0148 -0.2083 -0.3308 -0.5803 -0.0074 -0.0414 -0.1841 -0.2402 -0.0356 -0.1357 -0.0171 -0.2900 -0.3282 -0.0112 -0.0115 -0.0342 -0.0216 -0.2273 -0.4427 -0.0189 -0.0631 -0.0434 -0.2880 -0.0882
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic ; invasively
H-920	-0.5091559290885925	▁post - DAS h ▁; ▁s rd ▁bra chi al ▁; ▁central ▁blood ▁pressure ▁; ▁radi al ▁arterial ▁ton ometr y ▁; ▁cardiovascular ▁function ▁; ▁e cho car dio graphic
D-920	-0.5091559290885925	post-DASh ; srd brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
P-920	-1.4415 -0.0450 -0.0182 -0.1414 -0.7560 -1.2025 -0.8985 -2.0195 -0.0857 -0.0323 -0.6909 -1.0154 -0.7051 -0.7166 -0.2691 -0.5371 -0.0264 -0.0557 -0.8434 -0.0533 -0.5648 -0.2488 -0.0581 -0.6884 -0.2634 -0.1041 -0.0597 -0.0309 -0.6222 -0.8070 -1.1858 -0.1061
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial ; exercise ; outcomes ; heart failure ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-1924	-0.5812644362449646	▁Psycho social ▁Factor s ▁; ▁Exerci se ▁Ad her ence ▁; ▁Heart ▁Fail ure ▁Patient s ▁; ▁Heart ▁Fail ure ▁; ▁Exerci se ▁Training ▁; HF - ac TION
D-1924	-0.5812644362449646	Psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Heart Failure ; Exercise Training ;HF-acTION
P-1924	-0.9290 -0.1021 -0.4720 -0.1677 -0.3223 -0.2292 -0.0975 -1.5125 -1.1479 -0.4086 -0.2643 -1.3382 -0.1360 -1.2554 -0.4124 -0.1558 -0.4294 -1.0318 -0.1417 -1.1890 -0.3127 -0.6654 -0.1132 -0.3778 -0.3270 -1.2917 -0.0507 -0.5805 -2.1496 -0.3148 -0.0931
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients ; coronary angiography ; diagnosis ; systolic hf ; etiology ; ejection fraction
H-1186	-0.3637765347957611	▁deriva tion ▁co hor t ▁; ▁corona ry ▁ang i ography ▁; ▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology
D-1186	-0.3637765347957611	derivation cohort ; coronary angiography ; systolic HF ; unclear etiology
P-1186	-1.1203 -0.4013 -0.0479 -0.5216 -0.0819 -0.7030 -0.1482 -1.6873 -0.4142 -0.8618 -0.2113 -0.4841 -0.0252 -0.0361 -0.0504 -0.2617 -0.1557 -0.5086 -0.1306 -0.0100 -0.0037 -0.2474 -0.1469 -0.7369 -0.0982
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees ; ea
H-922	-0.45919522643089294	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁e es
D-922	-0.45919522643089294	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees
P-922	-0.6983 -1.0540 -1.0145 -0.2475 -1.0014 -0.6508 -0.4773 -1.3903 -0.1302 -0.7363 -0.1237 -0.0551 -0.5215 -0.9137 -0.2112 -0.3817 -0.0556 -0.2083 -0.0472 -1.2279 -0.1347 -0.1612 -0.0267 -0.0308 -0.2845 -0.4386 -0.4854 -0.2478 -0.1084 -1.0749 -0.0954
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic ; rhythm
H-1653	-0.33459004759788513	▁ rhythm ▁control ▁ therapy ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁cat heter ▁ab lation ▁; ▁electro car dio graphic ▁device ▁; ▁ rhythm
D-1653	-0.33459004759788513	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
P-1653	-0.1744 -0.4692 -0.7604 -0.8015 -0.0510 -0.5145 -1.0574 -0.5370 -0.6597 -0.6275 -0.0350 -0.3695 -0.0300 -0.0990 -0.1213 -0.1890 -0.0343 -0.3345 -0.2094 -0.0055 -0.0150 -0.0596 -0.3094 -0.0155 -0.0359 -0.6079 -0.4679 -0.2105 -0.9057 -0.5913 -0.4509 -0.1787 -0.1131
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells ; angiotensin ii ; angii ; hypoxia ; scn5a ; mrna splicing ; scn5a
H-1083	-0.46099036931991577	▁ang io ten sin ▁II ▁; Ang II ▁; ▁hypo xia ▁; ▁activa tors ▁; ▁ab normal ▁s cn 5 a ▁m RNA ▁s plic ing ▁; ▁s cn 5 a ▁variant s
D-1083	-0.46099036931991577	angiotensin II ;AngII ; hypoxia ; activators ; abnormal scn5a mRNA splicing ; scn5a variants
P-1083	-2.1899 -1.6336 -0.0830 -1.1853 -0.8497 -0.2875 -0.2816 -0.6268 -0.1664 -0.0498 -0.0060 -0.2353 -0.0649 -0.1376 -0.5385 -1.2892 -0.0349 -1.0818 -0.2165 -0.3925 -0.3471 -0.0074 -0.0680 -0.4024 -0.2301 -0.0966 -0.3026 -1.1630 -0.3938 -0.4006 -0.3741 -0.0990 -0.4904 -0.3103 -0.0983
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence ; hf with reduced ejection fraction ; hfref ; hf with preserved ejection fraction ; hfpef
H-1488	-0.5733955502510071	▁ HF ▁with ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁treatment ▁; ▁ HF ▁met ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1488	-0.5733955502510071	HF with reduced ejection fraction ;HFrEF ; treatment ; HF met preserved ejection fraction ;HFpEF
P-1488	-2.4096 -0.1585 -2.6207 -0.7762 -0.0202 -0.0286 -0.2416 -0.0565 -0.3745 -0.0193 -0.4182 -1.3719 -0.1934 -0.3737 -0.1897 -2.1240 -0.3515 -1.6841 -0.2679 -2.1855 -0.1775 -0.0816 -0.4201 -0.0382 -0.2144 -0.0878 -0.3194 -0.0161 -0.2942 -0.9823 -0.2991 -0.3527 -0.2742 -0.0723
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal life support ; therapy ; patients ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion ; therapy
H-1298	-0.449746698141098	▁extra corp o real ▁life ▁support ▁; ▁ brid ging ▁ therapy ▁; ▁ ische mic ▁right ▁heart ▁failure ▁; ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁reper fusion ▁ therapy
D-1298	-0.449746698141098	extracorporeal life support ; bridging therapy ; ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
P-1298	-0.5203 -0.0186 -0.4769 -0.0252 -0.3848 -1.1696 -0.6723 -1.0268 -0.1662 -0.0245 -0.7521 -0.0136 -0.6295 -4.0078 -0.1231 -0.2916 -0.9752 -0.5099 -0.2082 -0.3595 -0.0111 -0.0220 -0.1622 -0.0351 -0.2471 -1.0309 -0.0922 -0.4689 -0.0029 -0.0120 -0.4390 -0.0110 -0.2953 -0.1061
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart failure ; reduced left ventricular ejection fraction ; fes ; exercise capacity ; quality of life ; endothelial function ; hfpef
H-1332	-0.5270474553108215	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁status ▁; ▁en dot heli al ▁function ▁; ▁ HF p EF
D-1332	-0.5270474553108215	heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
P-1332	-1.4219 -0.1952 -0.1405 -0.7402 -0.1007 -2.1055 -0.3993 -0.1397 -0.2405 -0.0771 -0.5399 -0.0113 -0.3599 -2.8124 -1.1139 -0.2324 -0.2801 -0.4061 -0.2282 -0.9017 -0.2096 -0.2136 -0.1072 -0.4625 -0.1351 -0.0116 -0.1010 -0.2253 -1.8946 -0.9391 -0.0785 -0.7449 -0.2532 -0.0966
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures ; hospitalizations ; noncardiovascular ; diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular ; drugs ; rate-control
H-1240	-0.2538068890571594	▁ex pendi tures ▁; ▁non car dio vas cular ▁diagnose s ▁; ▁implant able ▁cardiac ▁ar rhythm ia ▁devices ▁; ▁non car dio vas cular ▁drugs
D-1240	-0.2538068890571594	expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
P-1240	-1.4854 -0.0797 -0.2120 -0.4753 -0.0983 -0.0378 -0.3949 -0.2982 -0.3586 -0.1073 -0.0654 -0.2761 -0.1009 -0.0365 -0.0094 -0.0089 -0.0657 -0.6457 -0.1095 -0.3416 -0.0843 -0.0314 -0.4291 -0.3681 -0.4484 -0.0627 -0.3908 -0.0843
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.52745521068573	▁in tub ation
D-220	-0.52745521068573	intubation
P-220	-0.1499 -0.0336 -0.8787 -1.4503 -0.1248
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene ; heart failure
H-1541	-0.5659298300743103	▁ra lo xi fen e ▁; ▁mechanism ▁of ▁action ▁; ▁heart ▁failure
D-1541	-0.5659298300743103	raloxifene ; mechanism of action ; heart failure
P-1541	-1.5047 -0.0166 -0.1326 -0.0502 -0.6220 -0.3848 -0.3713 -0.9668 -0.0160 -0.5013 -1.2466 -0.3592 -1.6292 -0.1217
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts ; heart mass ; transgenic
H-1814	-0.762458086013794	▁heart s ▁; ▁t g t et Men a ▁; ▁litt er mates ▁; ▁heart ▁mass ▁; ▁trans ge nic ▁mi ce
D-1814	-0.762458086013794	hearts ; tgtetMena ; littermates ; heart mass ; transgenic mice
P-1814	-1.4430 -0.2198 -0.4937 -4.6372 -0.5286 -0.0743 -0.0722 -0.6982 -0.0152 -1.4900 -2.2618 -0.0461 -0.2458 -0.3913 -2.8921 -0.3285 -0.2143 -0.0298 -0.1105 -0.7362 -0.7926 -0.2752 -0.2389 -0.0638
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients ; hfref ; exercise ; respiratory gas analysis ; baseline
H-1938	-0.7984663248062134	▁h Fr EF ▁; ▁exercise ▁protocol ▁; ▁respirator y ▁gas ▁analysis
D-1938	-0.7984663248062134	hFrEF ; exercise protocol ; respiratory gas analysis
P-1938	-2.2627 -1.7927 -1.7543 -0.5726 -1.7939 -0.4419 -0.6885 -0.1049 -0.1537 -0.0347 -0.3684 -0.2579 -0.1537
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients ; drugs ; heart failure ; biomedical ; nonprescribing ; patients
H-1126	-0.49020248651504517	▁drugs ▁; ▁heart ▁failure ▁; ▁chart ▁review ▁; ▁bio medic al ▁reasons ▁; ▁non pre scribi ng
D-1126	-0.49020248651504517	drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
P-1126	-2.7846 -1.4874 -0.6157 -0.0783 -0.6008 -0.0630 -0.0369 -0.5774 -0.0080 -0.0563 -0.0113 -0.2051 -1.3447 -0.6527 -0.0607 -0.0994 -0.2118 -0.2687 -0.1509
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean mass ; adverse outcome ; adipose tissue ; cardioprotective ; hf
H-1169	-0.6735853552818298	▁fat ▁; ▁lean ▁mass ▁; ▁fat ▁loss ▁; ▁cata bol ism ▁; ▁adi pose ▁tissu e ▁; ▁cardio protec tive ▁; ▁ HF
D-1169	-0.6735853552818298	fat ; lean mass ; fat loss ; catabolism ; adipose tissue ; cardioprotective ; HF
P-1169	-3.5496 -0.2918 -0.4078 -0.1036 -0.3540 -0.6213 -1.1886 -0.2596 -4.2962 -0.3059 -0.4387 -0.2010 -0.0047 -0.0178 -0.0112 -0.1123 -0.1573 -0.6854 -0.2177 -0.6883 -0.2669 -1.7927 -0.6624 -0.1195 -0.0852
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
H-97	-0.30882343649864197	▁heart s ▁; ▁fish ▁; ▁nu cle olin ▁; ▁cha mber ▁pattern ing ▁; ▁functional ▁deficit s ▁; ▁cardiac ▁loop ing ▁; ▁my o cy te ▁differenti ation
D-97	-0.30882343649864197	hearts ; fish ; nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
P-97	-1.4922 -0.1421 -0.5202 -0.8497 -0.5371 -0.5200 -0.0083 -0.1163 -0.4119 -0.0409 -0.0033 -0.1530 -0.3773 -0.1905 -1.2978 -0.4436 -0.3473 -0.1877 -0.0840 -0.0034 -0.0681 -0.1877 -0.4421 -0.1074 -0.0678 -0.0524 -0.1475 -0.1716 -0.2130 -0.0804
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients ; chronic hf ; prevalence ; exercise ; hf ; hospitalization ; mortality ; exercise ; training
H-1641	-0.7107509970664978	▁black ▁race ▁; ▁chronic ▁ HF ▁; ▁exercise ▁performance ▁; ▁ HF ▁hospital ization ▁; ▁mortal ity ▁; ▁exercise ▁training
D-1641	-0.7107509970664978	black race ; chronic HF ; exercise performance ; HF hospitalization ; mortality ; exercise training
P-1641	-0.5031 -0.0880 -0.2487 -2.4532 -0.4318 -0.1771 -0.4350 -3.2255 -0.1997 -0.2038 -0.7364 -0.4845 -1.7026 -0.6625 -0.4541 -0.6946 -1.3259 -0.4707 -0.4333 -0.3175 -0.2470 -0.1416
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse event ; acute myocardial infarction ; congestive heart failure ; adverse events
H-4	-0.5951843857765198	▁advers e ▁event ▁rates ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure
D-4	-0.5951843857765198	adverse event rates ; acute myocardial infarction ; congestive heart failure
P-4	-3.7776 -0.0565 -0.2396 -1.3064 -0.3579 -0.2292 -0.0587 -1.1701 -0.5238 -0.2710 -0.5045 -0.0300 -0.3921 -0.1805 -0.2252 -0.0315 -0.2915 -1.0842 -0.4087 -0.0865 -1.7772 -0.0911
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages ; cardiomyocytes ; doxorubicin ; in vitro ; resistin ; mrna ; protein expression
H-935	-0.4235519468784332	▁Mac rop hage s ▁; ▁cardio my o cy tes ▁; ▁Hum - re t n ▁mi ce ▁; ▁do xor ubi cin ▁; ▁h Re t n ▁; human ▁resist in ▁; ▁m RNA ▁; ▁protein ▁expression
D-935	-0.4235519468784332	Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin ; hRetn ;human resistin ; mRNA ; protein expression
P-935	-0.7113 -0.1554 -0.0381 -0.1075 -0.1981 -0.0584 -0.4248 -0.4304 -0.1341 -0.0741 -0.3772 -0.4930 -0.1010 -2.5025 -0.5286 -0.0550 -1.8328 -0.3590 -0.5778 -0.7886 -0.0553 -0.0359 -0.2311 -0.4497 -0.2840 -2.8166 -0.0528 -0.0207 -0.2502 -1.0232 -0.0965 -0.1336 -0.3695 -0.0013 -0.0269 -0.6983 -0.0536 -0.0742 -0.2346 -0.0866
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads ; heartmate ii ; thoratec corp ; pleasanton ; calif ; hvad ; heartware ; framingham
H-546	-0.40286552906036377	▁l VAD s ▁; ▁CF ▁devices ▁; ▁Heart Mate ▁II ▁devices ▁; ▁tho r a tec ▁Corp ▁; ▁Ple asan ton ▁cali f ▁; ▁h VAD ▁devices ▁; ▁Heart War e ▁in t l ▁; ▁in t l ▁; ▁fram ing ham ▁; ▁Mass
D-546	-0.40286552906036377	lVADs ; CF devices ; HeartMate II devices ; thoratec Corp ; Pleasanton calif ; hVAD devices ; HeartWare intl ; intl ; framingham ; Mass
P-546	-0.2794 -0.0297 -0.2134 -0.2338 -0.3519 -0.5687 -0.1229 -1.9071 -0.0561 -0.3526 -0.1128 -0.1063 -0.0992 -0.8001 -0.6599 -0.0035 -0.0973 -0.2074 -0.4935 -0.0047 -0.0048 -1.6627 -0.0670 -0.0463 -1.0212 -0.1662 -0.9574 -0.0899 -1.6980 -0.1734 -0.0276 -0.0805 -0.0603 -0.0178 -0.3464 -2.4254 -0.7760 -0.0210 -0.2543 -0.9298 -0.0330 -0.0082 -0.5193 -0.1066 -0.2801 -0.0581
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma nps ; adiponectin ; baseline ; ffm ; correlate ; nps ; adiponectin ; follow up
H-19	-0.6757847666740417	▁FM ▁; ▁plasma ▁ NP s ▁; ▁total ▁adi pon ect in ▁; ▁FM ▁; ▁f FM ▁; ▁ NP s ▁; ▁adi pon ect in
D-19	-0.6757847666740417	FM ; plasma NPs ; total adiponectin ; FM ; fFM ; NPs ; adiponectin
P-19	-1.2887 -0.3801 -0.7443 -0.9516 -0.0398 -0.0516 -0.3264 -2.4014 -0.1414 -0.0347 -1.0867 -1.2744 -0.4761 -1.5486 -0.3518 -0.7001 -1.9899 -0.2988 -2.2021 -0.2348 -0.0713 -0.2182 -0.1509 -0.0280 -1.0508 -0.5777 -0.2100 -0.0917
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic tone ; parasympathetic tone ; heart rate ; intravenous bolus ; metoprolol ; atropine
H-1378	-0.5034216046333313	▁sympa the tic ▁tone ▁; ▁para sy mpa the tic ▁tone ▁; ▁heart ▁rate ▁response ▁; ▁met o pro lol ▁; ▁a tropi ne
D-1378	-0.5034216046333313	sympathetic tone ; parasympathetic tone ; heart rate response ; metoprolol ; atropine
P-1378	-0.1035 -1.5095 -0.8840 -0.1664 -0.2249 -0.2335 -0.4768 -0.5227 -1.9663 -1.4438 -0.2017 -0.2658 -1.2734 -0.3250 -0.7716 -0.3156 -0.3123 -0.5047 -0.0453 -0.1267 -0.2781 -0.0404 -0.0079 -0.7887 -0.2261 -0.0742
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef ; pathophysiologically ; hf with reduced ef ; hfref ; hfref ; therapy
H-1533	-0.8058426976203918	▁EH ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁EF ▁; HF r EF ▁; ▁h Fr EF ▁ therapy
D-1533	-0.8058426976203918	EH ; HFpEF ; HF ; EF ;HFrEF ; hFrEF therapy
P-1533	-0.8925 -0.2376 -1.5894 -0.7524 -0.1504 -0.7539 -0.1431 -1.4281 -1.0877 -0.4953 -3.6537 -0.1359 -1.8394 -0.1007 -0.3648 -0.2050 -0.7495 -1.0588 -0.8383 -1.6907 -0.0412 -0.2423 -0.0838
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma ; collected ; hf ; patients ; immunoreactive ; nt-probnp ; c-terminally ; nt-probnp
H-1520	-0.6493521928787231	▁plasma ▁collect ed ▁; ▁ HF ▁patients ▁; ▁immun ore active ▁NT - pro b NP ▁; ▁NT - pro b NP
D-1520	-0.6493521928787231	plasma collected ; HF patients ; immunoreactive NT-probNP ; NT-probNP
P-1520	-0.6395 -0.4270 -0.6932 -0.5197 -1.4137 -0.4304 -0.6463 -0.2641 -0.0024 -1.2489 -0.1971 -1.3563 -0.1384 -0.1191 -1.7496 -0.4731 -0.6972 -1.2400 -0.0576 -0.1278 -1.6958 -0.6643 -0.6838 -0.0990
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt interval ; ecgs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine ; infusion
H-1438	-0.3138810396194458	▁beat - to - beat ▁ QT ▁interval ▁; ▁e CG s ▁; at rial ▁pa cing ▁; ▁es mol ol ▁; ▁iso pren a line ▁; ▁a tropi ne ▁in fusion
D-1438	-0.3138810396194458	beat-to-beat QT interval ; eCGs ;atrial pacing ; esmolol ; isoprenaline ; atropine infusion
P-1438	-0.0455 -0.0720 -0.1340 -0.1223 -0.1507 -0.6054 -0.3793 -0.0594 -0.5274 -1.3449 -0.8751 -0.2311 -0.7099 -1.1192 -0.0193 -0.0021 -0.1948 -0.1796 -0.9120 -0.0069 -0.1453 -0.3143 -0.0082 -0.1476 -0.1337 -0.0638 -0.4904 -0.0530 -0.0228 -1.1103 -0.0236 -0.0289 -0.3398 -0.0994
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence interval
H-803	-0.4300873577594757	
D-803	-0.4300873577594757	
P-803	-0.7400 -0.1201
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power spectral analysis ; hf ; dnx
H-1377	-0.5031301379203796	▁power ▁spec tral ▁analysis ▁; ▁low - fre quen ncy ▁; high - fre quen ncy ▁; LF ▁; HF ▁; ▁CHF - in v ▁; ▁sham - in v ▁; ▁sham ▁levels ▁; ▁DN x
D-1377	-0.5031301379203796	power spectral analysis ; low-frequenncy ;high-frequenncy ;LF ;HF ; CHF-inv ; sham-inv ; sham levels ; DNx
P-1377	-0.0842 -0.8751 -0.0207 -0.2968 -0.3902 -0.1796 -0.0803 -0.1080 -2.7611 -0.3798 -1.6461 -1.4681 -0.1545 -0.1792 -2.1087 -0.3571 -0.3285 -0.0649 -1.0858 -0.4534 -0.5551 -0.1161 -0.1235 -0.5886 -0.6515 -0.1690 -0.0886 -0.1893 -0.6820 -0.5341 -0.2512 -0.1080 -0.9075 -0.4003 -0.2826 -0.0866 -0.2772 -0.0857
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ; ventricular-arterial coupling ; patients
H-524	-0.524544894695282	▁contract ility ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁SV
D-524	-0.524544894695282	contractility ; ventricular-arterial coupling ; SV
P-524	-0.0218 -0.7567 -0.4215 -0.0496 -1.8323 -0.2778 -0.2108 -0.0468 -0.0650 -0.3864 -0.7799 -0.6944 -0.3593 -1.8714 -0.0943
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change ; follow-up ; readmissions ; hospital ; follow-up
H-721	-0.860048234462738	▁follow - up ▁visit s
D-721	-0.860048234462738	follow-up visits
P-721	-0.3173 -0.1987 -0.0904 -0.8435 -0.1641 -4.2995 -0.1068
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal pro-b-type natriuretic peptide ; nt-probnp ; misdiagnosis ; heart failure ; hf
H-1511	-0.6030751466751099	▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁mis diagnos is ▁; ▁heart ▁failure ▁; HF
D-1511	-0.6030751466751099	n-terminal pro-b-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
P-1511	-5.1818 -0.0589 -0.1660 -0.0380 -0.1802 -0.0269 -0.7658 -0.0328 -0.0044 -0.0218 -0.5761 -0.5860 -1.5204 -0.9346 -0.1942 -0.6427 -0.4748 -2.2322 -0.0229 -0.0395 -0.4136 -0.4546 -0.3970 -1.1456 -0.1072 -0.4548 -1.3510 -0.2936 -0.1590 -0.3474 -0.7501 -0.2165 -0.1110
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac magnetic resonance postcontrast t1 time ; prognosis ; hfpef ; postcontrast t1 ; biomarker ; hfpef
H-743	-0.5979775786399841	▁cardiac ▁magnetic ▁res on ance ▁; ▁post contra st ▁t 1 ▁; ▁h FP EF ▁; ▁post contra st ▁t 1 ▁; ▁bio mark er ▁; ▁h FP EF
D-743	-0.5979775786399841	cardiac magnetic resonance ; postcontrast t1 ; hFPEF ; postcontrast t1 ; biomarker ; hFPEF
P-743	-0.1758 -0.1013 -0.3560 -0.2348 -0.2332 -0.3460 -1.6859 -0.1284 -0.0498 -2.7736 -0.3599 -0.6276 -0.8153 -1.4105 -0.8278 -0.2236 -0.4713 -0.1991 -0.0644 -1.5081 -0.4427 -0.2639 -0.1057 -0.1320 -0.2536 -0.1841 -1.1126 -1.8229 -1.2813 -0.2432 -0.1028
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action ; randomized ; patients ; left ventricular ejection fraction ; new york heart association class ii ; hf ; exercise ; training
H-698	-0.8779222369194031	▁ HF - ac TION ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁New ▁York ▁Heart ▁association ▁class ▁II ▁to ▁IV ▁ HF
D-698	-0.8779222369194031	HF-acTION ; left ventricular ejection fraction ; New York Heart association class II to IV HF
P-698	-2.2427 -0.8839 -0.1711 -1.4771 -2.9281 -0.6569 -0.8095 -0.0833 -2.9030 -0.5370 -0.2585 -0.3659 -0.2470 -1.0029 -0.0230 -0.3216 -0.7727 -0.5065 -0.8650 -0.4079 -2.6248 -0.2856 -2.0896 -0.0943 -0.3155 -0.6515 -0.9258 -0.1312
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial dd ; collagen deposition ; titin ; obese ; diabetic ; zsf1 ; heart failure with preserved ejection fraction
H-762	-0.3128904700279236	▁my o card ial ▁ DD ▁; ▁collage n ▁de position ▁; ▁titi n ▁modification ▁; ▁obes e ▁; ▁diabet ic ▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-762	-0.3128904700279236	myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; ejection fraction
P-762	-0.6247 -0.1760 -0.2159 -0.4023 -1.1981 -0.0352 -0.4155 -0.0280 -0.1446 -0.0443 -0.3397 -0.2683 -0.0901 -0.1027 -0.2270 -0.2505 -0.5733 -0.0503 -0.3473 -0.0185 -0.0248 -1.4554 -0.0853 -0.9748 -0.0848 -0.0662 -0.7117 -0.6857 -0.0529 -0.3996 -0.2800 -0.0532 -0.0429 -0.6345 -0.0039 -0.4068 -0.0622
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac ; jq1 ; bet ; pathological ; cardiac ; gene expression
H-1049	-0.48817700147628784	▁tran scription al ▁analysis ▁; ▁cardiac ▁tissu e ▁; ▁mi ce ▁; ▁ TAC - ▁; ▁sham - opera ted ▁; ▁j q 1 ▁; ▁vehicle ▁; ▁ BET ▁inhibi tion ▁; ▁path ological ▁cardiac ▁gene ▁expression ▁programme
D-1049	-0.48817700147628784	transcriptional analysis ; cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
P-1049	-2.9332 -0.1359 -0.0646 -0.6458 -1.1329 -0.0670 -0.1591 -0.2291 -0.4808 -0.5485 -0.4236 -0.4879 -1.9727 -0.6482 -0.0599 -1.8182 -0.0098 -0.0586 -0.0301 -0.2128 -0.4295 -0.1160 -1.3475 -0.9163 -0.2819 -0.0449 -0.4686 -0.8169 -0.3324 -0.1216 -0.4104 -0.3552 -0.3564 -0.4416 -0.0976 -0.4100 -0.0821 -0.0361 -0.2520 -0.0913
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional hazard models ; negative binomial regression models ; health
H-1624	-0.33091577887535095	▁co x - propor tional ▁hazard ▁models ▁; ▁negative ▁bi nom ial ▁re gression ▁models
D-1624	-0.33091577887535095	cox-proportional hazard models ; negative binomial regression models
P-1624	-0.1761 -0.1036 -0.0219 -0.0569 -0.0679 -0.0851 -0.9666 -0.4713 -0.0369 -0.7222 -0.8422 -0.2201 -0.0574 -0.0119 -0.5496 -1.1686 -0.0673
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic blood pressure ; elevated ; left ventricular ; hypertrophy
H-277	-0.5890309810638428	▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁hyper trop hy ▁; ▁AT ▁; ▁AN ▁; ▁AS ▁; ▁ ANS
D-277	-0.5890309810638428	systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
P-277	-1.3297 -0.3221 -0.0756 -0.4957 -0.5734 -0.4365 -0.8744 -0.0986 -1.5866 -0.2235 -0.6407 -0.3304 -0.9085 -0.2348 -0.0444 -1.3892 -0.5850 -0.3110 -0.6881 -0.2990 -0.7580 -0.2189 -0.4390 -1.5583 -0.4587 -0.9241 -0.0997
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 ; hypertrophy ; fibrosis ; ventricular dysfunction ; gene
H-642	-0.3477177321910858	▁hand 2 ▁; ▁pressure - over load - indu ced ▁hyper trop hy ▁; ▁fibro sis ▁; ▁vent ri cular ▁dys function ▁; ▁fet al ▁gene ▁program
D-642	-0.3477177321910858	hand2 ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
P-642	-0.4956 -0.3836 -1.3992 -0.6138 -0.1113 -0.0441 -0.1365 -0.4046 -0.0514 -0.1223 -0.0821 -0.0226 -1.2607 -0.4194 -0.0030 -0.3984 -0.2567 -0.0093 -1.2510 -0.3445 -0.0474 -0.0820 -0.3667 -0.0241 -0.0270 -0.7024 -0.6505 -0.2555 -0.1181
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission ; nt-probnp ; patients ; acute hf ; diagnosis
H-264	-0.6768085360527039	▁cut off ▁value ▁; ▁ad mission ▁NT - pro b NP ▁; ▁ED ▁; ▁a cute ▁ HF ▁ diagnos is
D-264	-0.6768085360527039	cutoff value ; admission NT-probNP ; ED ; acute HF diagnosis
P-264	-2.8771 -0.0921 -0.9552 -0.2542 -0.6396 -0.4499 -2.3799 -0.0712 -0.0360 -0.6289 -0.4129 -0.2467 -1.6340 -0.7160 -1.1097 -0.0320 -0.1367 -0.6350 -1.2772 -0.1739 -0.3479 -0.3235 -0.1370
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak oxygen consumption ; vo2max ; resting hr ; bpm ; p value
H-1943	-0.6988170742988586	▁Peak ▁oxygen ▁consum p tion ▁; VO 2 max ▁; ▁rest ing ▁; ▁HR
D-1943	-0.6988170742988586	Peak oxygen consumption ;VO2max ; resting ; HR
P-1943	-0.8589 -0.5541 -0.5253 -0.1517 -1.1139 -0.5999 -0.4664 -0.1511 -0.0509 -0.4500 -2.2017 -0.1690 -1.0800 -1.3193 -1.4011 -0.0879
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up ; patients ; combined end point ; death ; heart failure ; death ; cardiac transplant
H-1747	-0.7345600724220276	▁heart ▁failure ▁; ▁sud den ▁death ▁; ▁non card iac ▁; ▁cardiac ▁transplant
D-1747	-0.7345600724220276	heart failure ; sudden death ; noncardiac ; cardiac transplant
P-1747	-7.2085 -0.1463 -1.1472 -0.2735 -0.0332 -0.7411 -0.2322 -0.1112 -0.0602 -0.0393 -0.4678 -0.0661 -0.1310 -0.2079 -0.1532
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty ; health abc short physical performance battery ; habc battery ; gill index ; hf
H-625	-0.4546020030975342	▁fra il ty ▁; ▁health ▁ABC ▁Short ▁Physic al ▁performance ▁Bat tery ▁; ▁h ABC ▁Bat tery ▁; ▁Gill ▁index ▁; ▁ HF
D-625	-0.4546020030975342	frailty ; health ABC Short Physical performance Battery ; hABC Battery ; Gill index ; HF
P-625	-0.6425 -0.3754 -0.5743 -0.4084 -1.4365 -0.3128 -0.6038 -0.3586 -0.0137 -0.2893 -0.3589 -0.0128 -0.1452 -0.8724 -1.4636 -0.5722 -0.0127 -0.2082 -0.1646 -0.0090 -0.1674 -1.8678 -0.2739 -0.1299 -0.0910
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic ; cardiac ; cardiac ; gene ; signal transduction ; pathological ; gene expression ; hf
H-1053	-0.37440893054008484	▁epi gene tic ▁readers ▁; ▁cardiac ▁bi ology ▁; ▁cardiac ▁gene ▁control ▁; ▁chr omat in - dependent ▁signal ▁trans duction ▁; ▁path ological ▁gene ▁expression ▁; ▁ HF ▁progression
D-1053	-0.37440893054008484	epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
P-1053	-0.7074 -0.2112 -0.6331 -0.1019 -0.5778 -0.0650 -1.2500 -0.4691 -0.3085 -0.6503 -0.8370 -0.9460 -0.2652 -0.0266 -0.0124 -0.6622 -0.1604 -0.0139 -0.2815 -0.0347 -0.3433 -0.3708 -0.0770 -0.4240 -0.4726 -0.3082 -0.1519 -0.9715 -0.1857 -0.0480 -0.3192 -0.0947
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical ; rule ; patients ; cad ; angiography ; patients ; systolic hf ; cost
H-1193	-0.4012552499771118	▁CAD ▁; ▁ang i ography ▁; ▁sy sto lic ▁ HF
D-1193	-0.4012552499771118	CAD ; angiography ; systolic HF
P-1193	-0.5094 -0.3434 -1.5354 -0.3397 -0.2249 -0.4221 -0.0599 -0.0444 -0.0584 -0.3202 -0.1335 -1.0677 -0.1574
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic response ; heart rate ; exercise ; baseline ; follow-up ; tests ; heart rate ; exercise
H-1176	-0.9052317142486572	▁chr ono tropi c ▁response ▁; ▁heart ▁rate ▁; ▁follow - up ▁tests ▁; ▁heart ▁rate
D-1176	-0.9052317142486572	chronotropic response ; heart rate ; follow-up tests ; heart rate
P-1176	-3.9421 -0.0986 -0.2494 -0.1248 -0.9698 -0.4462 -2.5703 -0.7200 -0.9808 -1.0787 -0.1589 -0.0388 -0.3692 -0.6993 -2.4063 -0.6820 -0.6707 -0.0883
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient ; hospital ; gastrointestinal bleeding ; patient ; ventricular tachycardia ; terminal heart failure
H-1961	-0.42353710532188416	▁gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁ta chy car dia ▁storm ▁; ▁terminal ▁heart ▁failure
D-1961	-0.42353710532188416	gastrointestinal bleeding ; ventricular tachycardia storm ; terminal heart failure
P-1961	-1.9916 -0.2292 -1.4164 -0.0610 -0.0495 -0.2868 -0.1767 -0.4061 -0.7371 -1.5921 -0.1577 -0.1713 -0.1310 -0.0481 -0.0293 -0.0026 -0.3652 -0.5191 -0.4964 -0.1582 -0.1906 -0.1017
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous ; revascularization ; angioplasty ; stenting ; clinical ; patients ; randomized ; clinical
H-1601	-0.7067332863807678	▁per cuta ne ous ▁re vas cular ization ▁; ▁ang io plast y ▁; ▁sten ting
D-1601	-0.7067332863807678	percutaneous revascularization ; angioplasty ; stenting
P-1601	-2.5395 -0.0049 -0.8281 -2.2427 -0.0289 -0.0970 -0.4414 -0.8713 -1.0246 -0.6133 -1.1852 -0.0820 -0.6165 -0.5461 -0.0131 -0.3929 -1.0908 -0.1028
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients ; hf ; t2d ; erc ; vo2max ; maximum oxygen consumption ; skm ; biopsies
H-1251	-0.3913045823574066	▁ HF ▁; ▁t 2 d ▁; ▁ ERC ▁; ▁tre ad m ill ▁testing ▁; VO 2 max ▁; ▁oxygen ▁consum p tion ▁; ▁Sk m ▁bio psi es
D-1251	-0.3913045823574066	HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
P-1251	-2.3250 -0.2918 -0.1649 -1.0425 -0.0113 -0.3596 -0.1524 -1.2742 -0.3921 -0.2356 -0.1331 -0.0090 -0.4639 -0.2837 -1.3537 -0.0766 -0.3782 -0.0586 -0.0270 -0.2154 -0.4847 -0.1875 -0.1123 -0.7719 -0.4576 -0.1944 -0.1493 -0.0923 -0.1670 -0.3006 -0.2661 -0.0894
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild hf ; qrs prolongation ; lvef ; crt ; reverse remodeling ; clinical ; systolic dysfunction
H-758	-0.525759220123291	▁ HF ▁; ▁QR s ▁prolong ation ▁; ▁LV EF ▁; ▁c RT ▁; ▁rever se ▁remodel ing ▁; ▁LV ▁sy sto lic ▁dys function
D-758	-0.525759220123291	HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; LV systolic dysfunction
P-758	-0.7581 -0.3804 -0.2139 -0.1212 -0.9907 -0.1756 -0.7391 -0.2723 -0.5921 -0.3684 -0.1178 -1.7661 -3.8677 -0.2982 -0.1021 -0.0231 -0.0228 -0.0712 -0.1972 -1.3761 -0.9945 -0.0840 -0.0996 -0.0636 -0.1284 -0.2872 -0.0839
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients ; rv support ; lvad ; patients ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
H-295	-0.6180694699287415	▁ RV ▁; ▁l VAD ▁ insertion ▁; ▁cardio ge nic ▁shock ▁; ▁my o card ial ▁in far ction ▁; ▁chronic ▁de com pensa ted ▁heart ▁failure
D-295	-0.6180694699287415	RV ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
P-295	-2.0623 -0.8472 -1.4465 -0.8319 -0.0237 -2.8941 -0.0310 -0.6432 -0.1006 -0.0992 -1.5790 -0.1074 -0.6508 -0.7823 -0.3633 -0.3241 -0.9629 -0.0461 -0.4089 -0.1599 -0.4748 -1.4399 -0.0587 -0.1513 -0.2032 -0.4424 -0.6835 -0.1765 -0.3798 -0.1678
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up ; patients
H-268	-0.8207568526268005	
D-268	-0.8207568526268005	
P-268	-1.4977 -0.1438
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty ; gill index ; hf
H-628	-0.7204306125640869	▁non - fra il ▁; HR ▁; ▁fra il ty ▁; HR ▁; ▁Gill ▁index ▁; ▁ HF
D-628	-0.7204306125640869	non-frail ;HR ; frailty ;HR ; Gill index ; HF
P-628	-2.4349 -0.0389 -0.0110 -0.0890 -1.7926 -1.9568 -1.0479 -0.8697 -0.1283 -0.4393 -0.4109 -2.0330 -0.6662 -0.3090 -0.0064 -0.3341 -1.1427 -0.3539 -0.1833 -0.1607
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence ; hf ; ami ; adjusted odds ratio
H-1310	-1.034528374671936	▁ HF ▁; ▁ AMI ▁; ▁odds ▁ratio
D-1310	-1.034528374671936	HF ; AMI ; odds ratio
P-1310	-1.6903 -0.5798 -0.4223 -2.3820 -0.9546 -1.1943 -0.4998 -0.0416 -2.4747 -0.1058
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic heart failure ; chf ; multisystem disease ; comorbidities ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
H-1357	-0.5313163995742798	▁Chro nic ▁heart ▁failure ▁; CH f ▁; ▁multi system ▁disease ▁; ▁an emia ▁; ▁insulin ▁resist ance ▁; ▁autonomi c ▁dys balance ▁; ▁cardiac ▁cache xia
D-1357	-0.5313163995742798	Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
P-1357	-2.2238 -0.6825 -0.8277 -0.1669 -0.2578 -2.0375 -2.1011 -0.2581 -2.8030 -1.2634 -0.4840 -0.2265 -0.3326 -0.1419 -0.2019 -0.0038 -0.0550 -0.0453 -0.2079 -0.0030 -0.3102 -0.0333 -0.0687 -0.1422 -0.0260 -0.0295 -0.0280 -0.3363 -0.1105
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic ; β-ar ; catecholamine ; infusions ; pde2 ; expression ; camp ; activity ; correlated ; cardiac ; β-ar responsiveness
H-1214	-0.48488718271255493	▁β - AR ▁stimul ation ▁; ▁cate chol amine ▁in fusion s ▁; ▁rat s ▁; ▁p de 2 ▁expression ▁; ▁c AMP ▁hydro ly tic ▁activity ▁; ▁blu n ted ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.48488718271255493	β-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
P-1214	-2.5647 -0.0713 -0.6887 -0.4588 -1.0364 -1.1770 -0.0182 -0.0720 -0.1738 -0.0586 -0.0146 -0.3666 -0.4834 -0.7309 -0.0971 -0.9142 -0.4887 -2.5418 -0.0420 -0.0661 -0.2884 -0.0786 -0.1336 -0.0268 -0.5194 -1.4901 -0.4497 -0.3495 -0.1488 -0.1985 -0.3811 -0.0087 -0.2230 -0.0338 -0.4969 -0.1284 -1.4169 -0.3539 -0.1196
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic pah ; clinical ; hospitalized ; patients ; acute ; rv decompensation ; pharmacologic ; therapies ; rv failure ; pah
H-1096	-0.6088910102844238	▁chronic ▁P AH ▁; ▁hospital ized ▁patients ▁; ▁ RV ▁de com pensa tion ▁; ▁ pharma c ologic ▁ therapie s ▁; ▁ RV ▁failure ▁management ▁; ▁p AH
D-1096	-0.6088910102844238	chronic PAH ; hospitalized patients ; RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
P-1096	-0.2947 -2.4703 -0.0532 -0.4939 -2.2213 -0.1161 -0.6268 -0.3632 -0.5680 -1.0468 -0.2516 -0.4096 -0.2937 -0.5309 -0.4848 -0.2838 -1.2127 -0.0539 -0.0704 -1.4349 -0.2419 -0.2871 -0.3585 -1.1921 -0.6909 -0.5808 -0.1134 -0.3106 -1.8874 -0.0834 -0.3223 -0.1354
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese ; zsf1 ; heart failure with preserved ejection fraction ; lung ; preserved left ventricular ejection fraction ; left ventricular dd
H-767	-0.6407045722007751	▁obes e ▁; ▁z SF 1 ▁groups ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁lung ▁weight ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁ DD
D-767	-0.6407045722007751	obese ; zSF1 groups ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
P-767	-1.8500 -0.0467 -2.2421 -0.3040 -0.1723 -1.5011 -1.0234 -0.5158 -2.2839 -0.1659 -0.2318 -1.6010 -0.2149 -0.1194 -0.4732 -0.0268 -0.2350 -0.3506 -0.2419 -0.1280 -2.1878 -0.0824 -1.7391 -0.2892 -0.3549 -0.4071 -0.2410 -0.6820 -0.0245 -0.2246 -0.2066 -0.0704 -1.7789 -0.3346 -1.2446 -0.4120 -0.2399 -0.0993
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine oxidase ; xo ; left ventricular ; myocytes ; volume overload ; vo ; mitral regurgitation ; aortocaval fistula ; acf
H-470	-0.40124619007110596	▁Xan thi ne ▁oxid ase ▁; XO ▁; ▁rat ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁my o cy tes ▁; ▁volume ▁over load ▁; VO ▁; ▁mit ral ▁re gur gi tation ▁; ▁a orto ca val ▁fi stu la ▁; ▁ac f
D-470	-0.40124619007110596	Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
P-470	-0.0049 -0.3182 -0.8381 -0.0120 -0.4928 -0.6018 -0.2650 -0.3578 -3.2993 -1.2409 -0.1834 -0.0638 -1.4401 -0.2355 -0.2932 -0.7484 -0.2214 -0.2074 -0.1228 -0.0375 -0.0399 -0.5671 -0.1872 -0.0454 -0.0677 -0.2997 -0.4530 -0.3518 -0.1394 -0.1354 -0.0174 -0.0567 -0.1127 -0.0894 -0.2325 -0.0272 -0.0184 -0.0349 -0.0371 -0.0795 -0.0067 -1.1268 -0.4190 -0.9308 -2.1288 -0.1876 -0.0823
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse ; myocardial t1 ; heart failure
H-1055	-0.39116495847702026	▁free - bre a thing ▁puls e ▁se que nce ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁model ▁; ▁ta chy car dia - indu ced ▁heart ▁failure
D-1055	-0.39116495847702026	free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
P-1055	-1.2555 -0.1040 -0.0259 -0.0710 -1.1585 -0.1133 -0.1873 -0.6652 -2.1565 -1.1484 -0.3717 -0.3003 -0.2553 -0.2458 -0.2839 -1.2862 -0.4543 -0.5127 -0.7187 -0.0467 -0.0570 -0.2598 -0.4092 -0.2558 -0.0541 -0.0319 -0.0234 -0.0839 -0.0084 -0.0866 -0.3083 -0.0615 -0.2014 -0.0975
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic ; new york heart association classes ; saf
H-229	-0.825853705406189	▁ PF ▁co hor t ▁; New ▁York ▁Heart ▁association ▁; SAF ▁; PF
D-229	-0.825853705406189	PF cohort ;New York Heart association ;SAF ;PF
P-229	-2.3717 -0.6340 -0.1875 -0.6158 -0.0716 -0.2247 -1.2543 -0.5428 -1.2806 -0.6600 -1.1987 -1.0019 -0.4186 -2.5456 -0.1247 -0.0812
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians ; patients ; patient ; clinician ; medication ; patient
H-1129	-0.9420328736305237	▁medication
D-1129	-0.9420328736305237	medication
P-1129	-2.2323 -0.4050 -0.1889
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients ; physicians ; mortality ; physicians ; hospitals
H-1727	-0.6741570830345154	▁physician s ▁; ▁mortal iteit ▁; ▁low - volu me ▁physician s ▁; ▁low - volu me ▁hospital s
D-1727	-0.6741570830345154	physicians ; mortaliteit ; low-volume physicians ; low-volume hospitals
P-1727	-2.9565 -0.3221 -0.8236 -1.3894 -2.4233 -0.5786 -0.6736 -0.0929 -0.1513 -0.0921 -0.3029 -0.2578 -0.8691 -1.8998 -0.0949 -0.2918 -0.1031 -0.3041 -0.2963 -0.1369 -0.0972
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western ; administrative ; health ; patients ; hf ; hospitalized ; ami
H-1307	-0.8967644572257996	▁Western ▁Australian ▁link ed ▁administrative ▁health ▁; ▁ HF ▁; ▁index ▁; ▁ AMI
D-1307	-0.8967644572257996	Western Australian linked administrative health ; HF ; index ; AMI
P-1307	-0.2862 -1.3410 -3.6516 -0.0609 -0.5519 -1.0284 -1.2049 -1.3788 -1.7596 -0.6893 -0.3148 -0.4976 -0.7030 -0.4975 -0.2334 -0.1494
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report ; connection ; patients ; disease ; healthcare ; conditions ; turkey
H-1825	-1.8837506771087646	▁Turkey
D-1825	-1.8837506771087646	Turkey
P-1825	-5.1720 -0.3325 -0.1467
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective cohort ; eds ; diagnosis ; heart failure
H-463	-1.2362252473831177	▁ED s ▁; ▁heart ▁failure ▁; ▁ED
D-463	-1.2362252473831177	EDs ; heart failure ; ED
P-463	-3.1453 -0.5740 -0.6032 -3.0820 -0.2723 -1.8178 -0.3478 -1.1172 -0.1664
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome ; prospective ; hospitalized ; hf ; nursing ; outcomes
H-1403	-1.126037836074829	▁science ▁; ▁older ▁adults ▁hospital ized ▁; ▁ HF
D-1403	-1.126037836074829	science ; older adults hospitalized ; HF
P-1403	-3.7296 -0.2722 -2.2942 -0.1420 -1.9160 -0.2752 -1.4437 -1.1125 -0.2562 -0.8151 -0.1296
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas ; rnas ; expression ; genes ; messenger rna ; repression
H-1482	-0.42740577459335327	▁mi RNA s ▁; ▁non co ding ▁ RNA s ▁; ▁ binding ▁; ▁messenger ▁ RNA
D-1482	-0.42740577459335327	miRNAs ; noncoding RNAs ; binding ; messenger RNA
P-1482	-0.5849 -0.0629 -0.1967 -0.6923 -0.4820 -0.0327 -0.4111 -0.2653 -0.0596 -0.1979 -0.5310 -2.4832 -0.2280 -0.7500 -0.1466 -0.1934 -0.0867 -0.6401 -0.0764
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients ; hfpef ; ivabradine ; placebo ; double-blind
H-1173	-0.7020964622497559	▁ HF p EF ▁; ▁i va bra dine ▁; ▁i va bra dine
D-1173	-0.7020964622497559	HFpEF ; ivabradine ; ivabradine
P-1173	-0.9992 -1.2183 -0.1820 -1.1053 -0.3946 -0.0430 -0.0486 -0.4199 -0.2578 -1.1412 -3.1779 -0.0688 -0.5922 -0.2143 -1.2606 -0.1098
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac ; cells ; cardiac ; cells ; cardiac functions ; myocardial infarction
H-1335	-0.5598357319831848	▁Card iac ▁c - K it ▁; ▁cell s ▁; ▁cardiac ▁ex plant - der i ved ▁cell s ▁; ▁cardiac ▁function s ▁; ▁my o card ial ▁in far ction
D-1335	-0.5598357319831848	Cardiac c-Kit ; cells ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
P-1335	-2.5040 -0.1486 -0.0900 -0.0860 -1.7148 -0.0257 -2.0555 -0.2857 -0.1636 -0.7058 -0.3451 -0.8779 -0.0089 -0.2060 -0.1128 -0.8347 -0.1756 -1.3287 -0.2074 -0.5671 -0.4448 -0.2304 -0.2918 -0.5757 -1.3713 -0.3125 -0.3659 -1.1244 -0.0459 -0.4622 -0.3371 -0.3370 -0.1313
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps ; adverse outcomes ; patients ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
H-1022	-0.4983210265636444	NP s ▁; ▁heart ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁diabetes ▁; ▁che mo therapy
D-1022	-0.4983210265636444	NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
P-1022	-1.0472 -0.2851 -0.6609 -4.3409 -0.2198 -0.3779 -0.0060 -0.1054 -0.1217 -0.0284 -1.1109 -0.1431 -0.0353 -0.2763 -0.1872 -0.1497 -0.0337 -0.2389 -0.0997
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses ; pathophysiology ; hf ; nursing ; medical ; symptoms ; pathophysiologic
H-2022	-0.8651908040046692	▁pat ho phy si ology ▁; ▁ HF ▁; ▁medical ▁management ▁; ▁pat ho phy si ologic
D-2022	-0.8651908040046692	pathophysiology ; HF ; medical management ; pathophysiologic
P-2022	-2.2994 -1.0349 -0.4812 -3.0281 -0.4309 -0.2690 -1.4607 -0.4999 -0.2694 -0.4878 -0.1166 -0.2538 -1.0817 -0.4340 -0.7265 -2.1884 -0.0678 -1.2134 -0.0950
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia ; pna
H-1691	-0.508833110332489	▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia ▁; ▁p NA
D-1691	-0.508833110332489	heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pNA
P-1691	-5.4683 -0.1286 -0.1799 -0.4316 -0.1291 -0.4551 -0.0163 -0.6040 -0.5045 -0.1718 -0.6473 -0.0213 -0.2198 -0.1151 -0.2410 -0.3560 -0.1291 -0.0145 -0.4882 -0.2632 -0.2195 -0.9240 -0.3449 -0.1389
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
H-1618	-0.4939808249473572	▁mortal ity ▁; ▁health care ▁utiliza tion ▁; ▁combinatie d ▁care ▁management ▁; ▁tele health ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁mell itus
D-1618	-0.4939808249473572	mortality ; healthcare utilization ; combinatied care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
P-1618	-1.0864 -2.0445 -0.2982 -0.2534 -0.1180 -0.5435 -0.5567 -0.9084 -4.6092 -0.3798 -0.5380 -0.0866 -0.1902 -0.2174 -0.2733 -0.2864 -0.0835 -0.3258 -1.7278 -0.5400 -0.0809 -0.1731 -0.0115 -0.3639 -0.1699 -0.2401 -0.0078 -0.2773 -0.2684 -0.1517 -0.0244 -0.0042 -0.0185 -0.3330 -0.0976
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 ; bets ; chromatin ; downstream signalling ; rna ; polymerase ii ; pol ii
H-1043	-0.4368826746940613	▁inhibi tor ▁j q 1 ▁; ▁ BET s ▁; ▁chr omat in ▁; ▁down stream ▁signal ling ▁; ▁ RNA ▁poly mera se ▁II ▁; Pol ▁II
D-1043	-0.4368826746940613	inhibitor jq1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;Pol II
P-1043	-1.0503 -0.0306 -1.5359 -0.9118 -0.9233 -0.4682 -1.0653 -0.8715 -0.5014 -0.6062 -0.0567 -0.0372 -0.6692 -0.2834 -0.9480 -0.0036 -0.2815 -0.4593 -0.3731 -0.3679 -0.0257 -0.0359 -0.0508 -0.0316 -0.1261 -0.2243 -0.8032 -0.1189 -0.1829 -0.0627
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction ; hfpef
H-942	-0.35138413310050964	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF
D-942	-0.35138413310050964	catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hFPEF
P-942	-1.1755 -0.1309 -0.0611 -0.1084 -0.6953 -0.3137 -0.0762 -0.3951 -0.0554 -0.0591 -0.3592 -0.7302 -0.2200 -0.7361 -0.0757 -0.3318 -0.1017 -0.0757 -0.5077 -0.0291 -0.1342 -0.0685 -0.2934 -0.0047 -0.3586 -0.8086 -1.5411 -0.7037 -0.2798 -0.1110
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic ; heart failure with preserved ejection fraction ; hfpef ; patients ; health ; symptoms ; quality of life
H-780	-0.5471311211585999	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-780	-0.5471311211585999	heart failure ; preserved ejection fraction ;HFpEF
P-780	-2.5943 -0.1616 -0.4703 -0.2765 -0.0744 -0.7642 -0.0352 -0.1415 -0.0607 -0.3347 -0.0197 -0.2871 -1.2405 -0.0436 -0.6625 -2.0298 -0.1045
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate cox proportional hazards regression modeling ; hospitalization ; acute coronary syndromes ; coronary interventions ; patients
H-104	-0.4874003827571869	▁co x ▁proportion al ▁hazard s ▁re gression ▁model ing ▁; ▁IE ▁; ▁a cute ▁corona ry ▁syndrome s ▁; ▁corona ry ▁intervention s
D-104	-0.4874003827571869	cox proportional hazards regression modeling ; IE ; acute coronary syndromes ; coronary interventions
P-104	-0.0751 -0.1464 -0.0488 -0.0337 -0.0767 -0.4041 -0.2648 -0.0077 -0.9749 -0.2891 -0.4484 -3.4896 -0.3997 -1.6644 -0.0248 -0.0792 -1.6870 -0.0027 -0.0954 -0.4107 -0.0367 -1.4642 -0.0682 -0.0834 -0.2813 -0.1153
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic adenosine monophosphate ; camp ; cyclic guanosine monophosphate ; cgmp ; hearts
H-1209	-0.6930117011070251	▁di minis hed ▁ cycli c ▁ad enos ine ▁mono phos pha te ▁; ▁c AMP ▁; ▁aug mente d ▁ cycli c ▁gua no sine ▁mono phos pha te ▁; ▁c ▁g m ▁; ▁heart s
D-1209	-0.6930117011070251	diminished cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; c gm ; hearts
P-1209	-4.6702 -0.2055 -0.3418 -0.0761 -0.1028 -0.4039 -0.4176 -0.3109 -2.7219 -0.0027 -0.0256 -0.0902 -0.2112 -0.6499 -0.8166 -0.3234 -0.4461 -2.6220 -0.0269 -0.0043 -0.0689 -0.0665 -0.7503 -0.5612 -0.0427 -0.8639 -0.0022 -0.0375 -0.0576 -0.1679 -0.4714 -0.3359 -2.7021 -0.8294 -0.5358 -4.0857 -0.4143 -0.4188 -0.1456
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra ; methotrexate ; tnf antagonist ; non-biological disease modifying antirheumatic drug ; nbdmard
H-604	-0.4264705777168274	▁RA ▁; ▁met ho tre xa te ▁; ▁t NF ▁anta gon ist ▁; ▁non - bi ological ▁disease ▁; ▁anti r heu matic ▁drug ▁; ▁n b DM ARD
D-604	-0.4264705777168274	RA ; methotrexate ; tNF antagonist ; non-biological disease ; antirheumatic drug ; nbDMARD
P-604	-0.4491 -0.5015 -0.0781 -0.3020 -0.0529 -0.5750 -0.1330 -0.3791 -2.5520 -0.1702 -0.0857 -0.0029 -0.1944 -0.2725 -0.1572 -0.0617 -1.3997 -0.2695 -0.1055 -0.6220 -0.0378 -0.8304 -0.5063 -0.3107 -0.1642 -0.5282 -1.2357 -0.0065 -0.4286 -0.8448 -0.2674 -0.1227
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal dysfunction ; intestinal ; lead ; chronic ; inflammatory ; catabolic ; anabolic ; cardiac cachexia ; terminal ; chf ; prognosis
H-1360	-0.4210912883281708	▁intestinal ▁dys function ▁; ▁disturb ed ▁intestinal ▁barrier ▁; ▁infla mma tory ▁state ▁; ▁cata bo lic ▁; ana bo lic ▁im balance ▁; ▁cardiac ▁cache xia ▁; ▁CHF
D-1360	-0.4210912883281708	intestinal dysfunction ; disturbed intestinal barrier ; inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
P-1360	-0.4412 -0.5980 -0.1292 -0.1871 -1.0374 -0.0707 -0.2423 -0.3477 -0.4382 -4.0064 -0.4497 -0.1656 -0.7031 -0.2159 -0.1034 -0.0147 -0.0610 -2.0003 -0.0880 -0.0161 -0.0525 -0.9426 -0.0226 -0.1978 -0.0125 -0.0163 -0.0111 -0.1933 -0.0836 -0.1113 -0.0943
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report ; patient ; diagnosis ; ischemic-hypertensive cardiomyiopathy ; angina ; myocardial ischemia ; coronary arteries
H-998	-0.3701978921890259	▁ ische mic - hy per tensi ve ▁cardio my io pathy ▁; ▁ang ina ▁; ▁induc ible ▁my o card ial ▁ ische mia ▁; ▁corona ry ▁arteri es
D-998	-0.3701978921890259	ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
P-998	-0.8008 -0.1907 -0.2135 -0.0941 -0.1576 -0.0363 -0.1501 -0.0328 -0.1618 -0.5813 -1.6857 -0.0781 -0.4225 -1.0843 -0.5997 -0.2694 -0.0173 -0.6321 -0.8467 -0.1925 -0.3496 -0.5297 -0.2065 -0.0969 -0.4798 -0.3769 -0.0308 -0.8743 -0.0189 -0.2481 -0.3075 -0.0800
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate receptor 1 ; s1pr1 ; β1-adrenergic receptor ; β1ar ; g-protein-coupled receptors ; heart
H-1405	-0.5796574950218201	▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁β 1- ad r energi c ▁receptor ▁; β 1 AR ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁heart
D-1405	-0.5796574950218201	sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
P-1405	-0.0137 -2.2374 -1.4064 -3.8965 -1.3362 -0.3159 -0.0210 -0.0686 -0.2102 -0.0434 -0.9358 -0.5687 -0.5791 -1.1204 -2.6604 -0.0871 -0.2949 -0.2499 -0.4061 -0.6889 -0.1130 -0.0431 -0.5993 -0.2799 -0.6061 -0.9450 -0.4682 -1.1048 -0.0922 -0.0126 -0.2299 -0.0995 -0.0237 -0.0372 -0.3581 -0.0945 -0.2846 -0.2903 -0.5825 -0.2614 -0.0993
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal ; correlated ; pcwp ; p values
H-484	-1.0965912342071533	▁e - sept al ▁; ▁pc WP ▁; ▁e / e ' lateral ▁; ▁e / e ' me an
D-484	-1.0965912342071533	e-septal ; pcWP ; e/e'lateral ; e/e'mean
P-484	-0.5666 -5.1496 -0.0446 -0.0502 -0.4803 -0.0768 -1.4759 -0.3964 -0.3860 -2.2006 -0.1117 -5.0746 -0.0243 -0.3698 -0.4517 -2.0450 -0.1343 -4.4505 -0.0928 -0.0511 -0.3437 -0.1483
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-864	-0.5194666385650635	▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-864	-0.5194666385650635	atrial fibrillation ; carvedilol ; metoprolol
P-864	-3.2522 -0.0876 -0.7690 -0.1159 -0.2179 -0.4801 -0.0211 -0.0714 -0.1438 -0.4729 -0.1288 -1.0728 -0.0585 -0.2872 -0.9928 -0.1394
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia ; intravenous ; metoprolol ; cardiac ; sympathetic tone
H-1379	-0.44174379110336304	▁Brad y car dia ▁; ▁intra ven ous ▁met o pro lol ▁; ▁cardiac ▁sympa the tic ▁tone ▁; ▁CHF - in v ▁rabbi ts ▁; ▁sham - in v ▁; ▁CHF - DN x
D-1379	-0.44174379110336304	Bradycardia ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
P-1379	-0.0587 -0.1704 -0.0566 -0.0460 -0.7391 -1.1655 -0.0114 -3.5808 -0.0392 -0.4147 -0.0702 -0.5398 -0.2905 -0.0256 -0.1194 -0.6167 -0.9800 -0.0389 -0.5591 -0.9027 -0.0628 -0.7509 -0.5037 -0.3581 -0.2652 -0.4244 -0.0213 -0.1012 -0.8913 -0.3487 -0.5199 -0.0684 -0.0702 -0.9447 -0.2119 -0.2733 -0.1031
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized ; walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; severe heart failure
H-569	-0.6905577182769775	▁Nordic ▁walking ▁; ▁standard ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-569	-0.6905577182769775	Nordic walking ; standard cardiac rehabilitation ; functional capacity ; heart failure
P-569	-0.9047 -0.8456 -0.1688 -0.7222 -0.0392 -0.0543 -0.4832 -0.6401 -0.4590 -1.1387 -0.3653 -3.9816 -0.2167 -0.2329 -0.1060
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes ; patients ; prescribed ; pharmacological ; discharge ; left ventricular function
H-1849	-0.6327046751976013	▁c PG - re com mend ed ▁ pharma c ological ▁treatment ▁; ▁device ▁consideration ▁; ▁left ▁vent ri cular ▁function ▁assessment
D-1849	-0.6327046751976013	cPG-recommended pharmacological treatment ; device consideration ; left ventricular function assessment
P-1849	-5.4285 -0.5187 -0.2305 -0.0502 -0.1003 -0.0182 -0.0734 -0.1028 -0.1887 -0.0863 -0.6893 -0.8731 -0.3337 -0.4312 -1.1710 -0.2904 -1.2883 -0.0551 -2.2425 -0.3627 -0.1466 -0.0573 -0.3027 -0.1432
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls ; lvef ; prognostic ; clinical ; echocardiographic ; systolic
H-820	-0.4831746220588684	▁g LS ▁; ▁LV EF ▁; ▁sa ▁; ▁CV ▁events ▁; ▁e cho car dio graphic ▁sy sto lic ▁parameter s ▁; ▁AF
D-820	-0.4831746220588684	gLS ; LVEF ; sa ; CV events ; echocardiographic systolic parameters ; AF
P-820	-0.1990 -1.5461 -0.2119 -0.3350 -0.8539 -0.1350 -0.3689 -0.5298 -0.5393 -2.5753 -0.2705 -1.6930 -0.0710 -0.0772 -0.4707 -0.4030 -0.0355 -0.0318 -0.1126 -0.6857 -0.0986 -0.3151 -0.2696 -0.1607 -0.0902
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc ; dapc protein ; sarcomeric microstructure ; skm ; myofibre regeneration
H-1254	-0.4387868046760559	ERC ▁; ▁DAP c ▁protein ▁levels ▁; ▁sar come ric ▁micro structure ▁; ▁Sk m ▁; ▁my o fi bre ▁regenera tion
D-1254	-0.4387868046760559	ERC ; DAPc protein levels ; sarcomeric microstructure ; Skm ; myofibre regeneration
P-1254	-0.9600 -1.0561 -0.1693 -0.6458 -1.0901 -1.4857 -0.2662 -0.0107 -0.4612 -0.4980 -0.0124 -0.1325 -0.2866 -0.3457 -0.1926 -0.4210 -0.8944 -0.0846 -0.0392 -0.0520 -0.1521 -0.9839 -0.2046 -0.0862
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas ; expression ; bhlh ; transcription factor ; hand2 ; myocardium ; gene ; heart failure
H-644	-0.3409818112850189	▁signal ling ▁casca des ▁; ▁micro RNA s ▁; ▁b HL h ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁post na tal ▁mamma lian ▁my o car dium ▁; ▁em bry o nic ▁gene ▁programs ▁; ▁heart ▁failure
D-644	-0.3409818112850189	signalling cascades ; microRNAs ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
P-644	-2.3712 -0.2987 -0.0142 -0.0161 -0.4501 -0.0098 -0.0226 -0.1409 -0.4472 -0.1062 -0.1865 -0.1939 -0.3191 -0.0422 -0.2164 -0.6364 -0.1231 -0.0959 -0.2250 -0.0093 -1.3487 -0.0300 -0.0108 -0.3325 -1.0965 -0.1703 -0.0362 -0.2091 -0.3482 -1.2542 -0.0206 -0.1861 -0.7400 -0.3159 -0.1707 -0.7098 -0.1616 -0.2312 -0.2510 -0.0910
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad ; q66p ; rad ; cav1.2 ; cav1.3 ; l-type channel ; isoforms ; heart
H-1674	-0.47403421998023987	▁Rad ▁Q 66 p ▁; ▁inhibi tory ▁actions ▁; ▁Rad ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁l - type ▁channel ▁iso form s ▁; ▁heart
D-1674	-0.47403421998023987	Rad Q66p ; inhibitory actions ; Rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
P-1674	-0.8189 -1.6843 -1.0830 -0.1882 -0.2404 -0.7556 -0.2408 -0.5587 -0.3144 -0.8668 -1.5472 -0.1486 -1.3184 -0.3832 -0.3096 -0.2226 -1.0581 -0.1346 -0.3161 -0.3504 -0.0463 -0.0042 -0.0400 -0.0204 -0.0544 -0.1642 -0.2056 -0.8732 -0.1768 -0.0960
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef ; lcx ; lad ; stenting ; infarcted ; left ventricle ; lcx ; lad
H-512	-0.7131760120391846	▁EF ▁; LC x ▁; ▁ LAD ▁; ▁sten ting ▁; ▁left ▁vent ric le ▁; ▁ LC x ▁; ▁ LAD
D-512	-0.7131760120391846	EF ;LCx ; LAD ; stenting ; left ventricle ; LCx ; LAD
P-512	-0.2042 -0.3594 -1.4541 -1.7537 -0.8197 -1.3901 -0.4111 -0.5429 -0.1241 -0.3494 -0.4068 -0.5645 -0.0521 -1.3774 -0.3975 -0.2942 -2.1268 -0.4433 -2.1687 -0.3698 -0.8392 -0.1949 -0.3635 -0.1088
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv compliance ; lv end-diastolic volume ; lv end-diastolic pressure ; β coefficient
H-1531	-1.0247362852096558	▁EH ▁; ▁LV ▁compliance ▁; ▁CH ▁; LV ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁h g ▁β ▁co e ffi cient
D-1531	-1.0247362852096558	EH ; LV compliance ; CH ;LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg β coefficient
P-1531	-0.6348 -0.2719 -1.6685 -2.3124 -0.1966 -3.0876 -0.4912 -4.0531 -2.2278 -3.5374 -0.2026 -0.0743 -0.2940 -0.1506 -0.2594 -0.4955 -2.8477 -1.8684 -2.7431 -0.1559 -0.1064 -0.1984 -0.1383 -0.6798 -0.7499 -2.3423 -0.0723 -1.4496 -0.0401 -0.4250 -0.0758 -0.2193 -0.6610 -0.1100
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva ; surgical ; implantation ; leaflet ; leaflet ; edge-to-edge anastomosis
H-360	-0.3905317485332489	▁m va ▁; ▁sur g ical ▁ring ▁implant ation ▁; ▁le a flet ▁motion ▁; ▁le a flet ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is
D-360	-0.3905317485332489	mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
P-360	-0.1011 -2.3390 -0.3122 -1.8114 -0.1426 -0.5375 -0.0429 -0.3449 -0.3553 -0.2489 -0.0544 -0.0568 -0.0317 -0.3761 -0.1477 -0.1034 -0.0393 -0.0971 -2.3438 -0.0470 -0.3653 -0.8925 -0.0250 -0.0833 -0.2877 -0.0492 -0.0802 -0.1578 -0.0025 -0.5780 -0.5235 -0.2189 -0.0906
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart ; patients ; new york heart association ; nyha ; hospitalized ; hf ; primary outcome ; death ; hf ; hospitalization
H-239	-0.6344128847122192	▁h ART ▁; ▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁ HF ▁; ▁self - management ▁counsel ing ▁; ▁death ▁; ▁ HF ▁hospital ization
D-239	-0.6344128847122192	hART ; New York Heart association ;NYha ; HF ; self-management counseling ; death ; HF hospitalization
P-239	-2.1487 -0.1239 -0.4158 -1.1138 -0.6124 -1.2530 -0.3838 -0.2876 -0.5434 -0.7683 -0.2807 -2.1945 -1.2850 -0.5258 -0.2321 -0.0461 -0.0134 -0.0367 -0.0756 -0.3607 -1.4802 -0.1387 -0.4967 -0.5433 -1.5794 -0.5980 -0.1273 -0.0987
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in vivo ; cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
H-1783	-0.32405632734298706	▁cardiac ▁function ▁; ▁e cho card i ography ▁; ▁dia sto lic ▁dys function ▁; ▁sy sto lic ▁dys function ▁; ▁e je ction ▁ fraction
D-1783	-0.32405632734298706	cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
P-1783	-1.8145 -0.2749 -0.1904 -0.0631 -0.2516 -0.2049 -0.6719 -0.3100 -0.3476 -0.0293 -0.0704 -0.2416 -0.1522 -0.1146 -0.2690 -1.8141 -0.1145 -0.2904 -0.0906 -0.1228 -0.3256 -0.0806 -0.2741 -0.1044 -0.4844 -0.0129 -0.2568 -0.0965
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; hf ; pathogenesis ; hf
H-1038	-0.5149846076965332	▁ BET ▁; ▁bro modo main ▁protein s ▁; ▁bet s ▁; ▁a ce tyl - ly sine ▁reader ▁protein s ▁; ▁ HF
D-1038	-0.5149846076965332	BET ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; HF
P-1038	-1.7168 -0.2972 -1.6747 -0.0456 -0.0474 -0.6590 -0.6740 -0.2101 -0.3961 -1.2761 -0.1244 -0.1651 -0.1724 -0.2279 -0.1559 -0.0797 -1.3506 -0.8673 -0.0393 -0.6751 -0.1137 -0.2046 -0.5555 -0.3437 -1.2024 -0.1151
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood transfusions ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
H-42	-0.34943869709968567	▁blood ▁trans fusion s ▁; ▁ir on ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁adults ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease ▁; ▁trans fusion
D-42	-0.34943869709968567	blood transfusions ; iron ; erythropoiesis-stimulating agents ; adults ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
P-42	-1.2667 -0.0188 -0.0206 -0.1995 -0.4637 -0.0275 -0.0651 -0.3593 -0.1193 -0.3941 -0.5625 -0.4505 -1.7239 -0.2099 -0.2243 -0.0289 -0.3321 -0.6218 -0.3879 -0.7284 -0.7926 -0.1755 -0.0655 -0.1748 -0.0141 -0.3801 -1.3649 -0.2745 -0.0801 -0.1054 -0.0081 -0.8914 -0.3031 -0.2850 -0.2468 -0.0119 -0.0488 -0.1003 -0.1004
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade ; clinical
H-202	-0.5419712662696838	▁Grad ing ▁of ▁re com mend ations ▁assessment ▁; ▁development ▁and ▁evaluat ion ▁; GRAD e
D-202	-0.5419712662696838	Grading of recommendations assessment ; development and evaluation ;GRADe
P-202	-0.3030 -0.3793 -0.7483 -0.5462 -0.1420 -0.1062 -0.0124 -1.4588 -0.9040 -0.8591 -0.5858 -0.3456 -2.1498 -0.3418 -0.0918 -0.0986 -0.6218 -0.0609
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf ; hospitalization
H-563	-0.7557234168052673	▁ HF
D-563	-0.7557234168052673	HF
P-563	-1.1630 -0.8568 -0.8219 -0.1812
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right heart circulatory failure ; disease ; right heart
H-1460	-0.7949128150939941	▁right ▁heart ▁circula tory ▁failure ▁; ▁mechanism s ▁of ▁disease ▁; ▁right ▁heart
D-1460	-0.7949128150939941	right heart circulatory failure ; mechanisms of disease ; right heart
P-1460	-3.6980 -0.5854 -0.0202 -0.1151 -0.0961 -0.4716 -2.5838 -0.1310 -1.7307 -0.7941 -0.4039 -0.7084 -0.3269 -0.1507 -0.1075
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular action potentials ; excitation-contraction ; myocardium
H-1671	-0.6311652064323425	▁l - type ▁volta ge - ga ted ▁ca (2 +) ▁channel s ▁; ▁vent ri cular ▁action ▁potential s ▁; ▁excita tion - con traction ▁; ▁ec ▁; ▁coup ling ▁; ▁my o car dium
D-1671	-0.6311652064323425	l-type voltage-gated ca(2+) channels ; ventricular action potentials ; excitation-contraction ; ec ; coupling ; myocardium
P-1671	-3.5587 -0.0814 -0.0025 -0.0116 -0.1564 -0.0696 -0.0626 -0.2367 -3.1261 -1.2384 -0.0044 -0.0900 -0.2917 -0.5837 -0.0974 -2.3685 -0.6704 -0.0443 -2.2995 -0.2346 -0.4180 -1.2087 -0.5892 -0.0852 -0.0605 -0.3118 -0.3008 -1.1238 -0.8228 -1.4306 -0.1901 -0.5249 -0.8088 -0.0793 -0.0191 -0.3350 -0.3232 -0.1241
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine ; exercise capacity ; left ventricular filling ; patients ; heart failure with preserved ejection fraction ; hfpef
H-1171	-0.2937528192996979	▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁fill ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1171	-0.2937528192996979	ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
P-1171	-0.0267 -0.0339 -0.1901 -0.1923 -0.3361 -0.4861 -0.3016 -0.1525 -0.0707 -0.0331 -1.7418 -0.1654 -0.8139 -0.0766 -0.1741 -1.0757 -0.0927 -0.2257 -0.0695 -0.0509 -0.3835 -0.0111 -0.0887 -0.0446 -0.2848 -0.0035 -0.2861 -1.0693 -0.0784 -0.4089 -0.3193 -0.1124
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; patients ; systolic dysfunction
H-1733	-0.4235366880893707	▁al do ster one ▁anta gon ism ▁; ▁heart ▁failure ▁; ▁al do ster one ▁; ▁neuro hormon e ▁; ▁electro ly tes ▁; ▁heart ▁failure ▁; ▁sy sto lic ▁dys function
D-1733	-0.4235366880893707	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
P-1733	-0.5986 -0.1555 -0.1267 -0.3568 -0.3548 -0.0092 -1.0126 -0.4787 -1.0912 -0.3989 -0.6031 -1.5863 -0.1544 -0.0837 -0.4518 -0.4055 -0.0705 -0.0629 -0.1429 -0.4877 -0.0094 -0.4759 -0.0287 -0.3423 -3.2798 -0.3471 -0.3841 -0.0686 -0.0725 -0.1616 -0.0384 -0.1322 -0.3201 -0.1076
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate analysis ; bnp ; estimated glomerular filtration rate ; hypertension ; transmitral ; e-wave ; diastolic mitral annular velocity
H-1570	-0.3879784643650055	▁b NP ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁hyper tension ▁; ▁transmit ral ▁e - wa ve ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1570	-0.3879784643650055	bNP ; glomerular filtration rate ; hypertension ; transmitral e-wave ; diastolic mitral annular velocity
P-1570	-0.8062 -2.0143 -0.4440 -0.2053 -0.1508 -0.0467 -0.1270 -0.7068 -1.0732 -0.3579 -0.1439 -0.0141 -0.2433 -0.0263 -0.3035 -2.1980 -0.0421 -0.0906 -0.0217 -0.2563 -0.6154 -0.0752 -0.0225 -0.1362 -0.0419 -0.9536 -0.0099 -0.3147 -0.0516 -0.4301 -0.1042
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1 receptors ; neprilysin ; renin-angiotensin-aldosteron ; ras ; vasodilatory ; diuretic ; natriuretic peptides
H-1967	-0.37375277280807495	▁AT 1 ▁receptor s ▁; ▁nepri ly sin ▁block s ▁; ▁re nin - angi oten sin - al do ster on ▁; RAS ▁; ▁vaso dila tory ▁; ▁di ure tic ▁; ▁na tri ure tic ▁pe pti des
D-1967	-0.37375277280807495	AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic ; natriuretic peptides
P-1967	-0.1650 -0.4899 -0.0204 -0.2956 -0.4204 -0.0541 -0.1746 -0.9795 -0.1176 -0.2150 -0.5656 -0.0288 -0.1031 -0.0512 -0.0005 -0.1275 -1.3569 -0.1018 -0.0170 -0.2382 -0.0381 -0.1827 -0.4443 -0.0419 -0.9890 -0.4496 -0.0108 -0.1819 -0.3775 -0.3372 -0.1892 -1.4760 -1.9991 -0.0168 -0.1318 -0.6210 -1.4262 -0.7237 -0.0623 -0.1855 -0.1954 -0.0950
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade ; halt ; disease ; protein kinase ; pka ; β-adrenergic receptor
H-1425	-0.44620460271835327	▁β - block ade ▁; ▁c AMP - dependent ▁protein ▁kina se ▁; ▁p ka ▁; ▁β - ad r energi c ▁receptor ▁activa tion
D-1425	-0.44620460271835327	β-blockade ; cAMP-dependent protein kinase ; pka ; β-adrenergic receptor activation
P-1425	-0.3517 -0.1311 -1.1284 -0.5795 -0.6267 -0.3958 -0.1539 -0.1191 -0.0142 -0.1083 -0.0050 -0.1084 -0.6489 -0.6073 -1.1602 -0.7860 -2.8088 -0.0337 -0.0725 -0.5431 -0.6379 -0.0610 -0.0275 -0.0498 -0.5379 -0.2392 -0.1117
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence ; erythropoiesis-stimulating agent ; therapy ; venous thromboembolism
H-47	-0.5682041645050049	▁er y thro po ies is - stimul ating ▁agent ▁ therapy ▁; ▁benefits ▁; ▁ve nous ▁ thro mbo e mbol ism
D-47	-0.5682041645050049	erythropoiesis-stimulating agent therapy ; benefits ; venous thromboembolism
P-47	-0.9471 -0.3532 -0.6896 -0.5791 -2.5068 -0.1862 -0.1512 -0.0369 -0.3400 -0.0122 -0.5920 -0.0369 -0.5934 -0.8044 -0.3481 -2.5454 -0.1952 -0.1975 -0.5134 -0.6831 -0.1911 -0.0876 -1.2996 -0.2313 -0.0835
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable adjustment ; mortality ; hospitalization ; hazard ratio ; cardiovascular mortality ; hf ; hospitalization
H-1638	-0.6697741150856018	▁black ▁race ▁; ▁mortal ity ▁; hospital ization ▁; haz ard ▁ratio ▁; HR ▁; ▁cardiovascular ▁mortal ity ▁; HF ▁hospital ization
D-1638	-0.6697741150856018	black race ; mortality ;hospitalization ;hazard ratio ;HR ; cardiovascular mortality ;HF hospitalization
P-1638	-0.0156 -0.2092 -0.4223 -2.5380 -1.7194 -1.0292 -0.8501 -1.1001 -0.4652 -0.0366 -0.0108 -0.0158 -0.2023 -0.4754 -0.3411 -0.0653 -0.1222 -1.6945 -0.2789 -1.0375 -1.3534 -0.9683 -0.9481 -0.1753
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous ; chronic myocardial ischemia ; stent ; polytetrafluoroethylene
H-504	-0.5530555248260498	▁chronic ▁my o card ial ▁ ische mia ▁; ▁sten t ▁; ▁poly te tra flu oro e thy lene ▁tube
D-504	-0.5530555248260498	chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
P-504	-4.2844 -1.5455 -0.2544 -0.3183 -0.6926 -0.1556 -0.1799 -0.8488 -0.5072 -0.0095 -0.0652 -1.0845 -0.4037 -0.1169 -0.9287 -0.0188 -0.0360 -0.1983 -0.0118 -0.1465 -0.2119 -0.6207 -0.0813
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical ; genetic ; chf ; area under the curve ; auc ; genetic ; auc ; clinical ; auc
H-1456	-0.7698330879211426	▁genetic ▁; ▁CHF ▁; ▁cur ve ▁; AU c ▁; ▁genetic ▁; AU c ▁; ▁clinic al
D-1456	-0.7698330879211426	genetic ; CHF ; curve ;AUc ; genetic ;AUc ; clinical
P-1456	-3.6911 -0.6480 -0.1566 -0.9627 -2.4913 -0.1252 -0.2379 -0.3935 -1.8366 -0.1446 -0.1467 -0.2258 -0.2593 -1.4921 -0.8707 -0.1103 -0.0488 -0.6927 -0.0933
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney ; prognostic ; hf index
H-1760	-0.6779356598854065	▁oxygen ▁up take ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score ▁; ▁ HF ▁index
D-1760	-0.6779356598854065	oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; HF index
P-1760	-5.9630 -2.3764 -0.2014 -0.3619 -0.0986 -0.0532 -0.2453 -0.2320 -0.0190 -1.2371 -0.0481 -0.4671 -0.0497 -0.0313 -0.3555 -0.4919 -1.1944 -0.4254 -0.0668 -0.2244 -0.0942
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart failure ; hf ; tumor necrosis factor ; tnf ; tnf antagonists ; disease ; severe hf
H-601	-0.44703587889671326	▁heart ▁failure ▁; HF ▁; ▁tumor ▁nec rosi s ▁factor ▁; TN f ▁; α ▁; ▁t NF ▁anta gon ists ▁; ▁ HF
D-601	-0.44703587889671326	heart failure ;HF ; tumor necrosis factor ;TNf ;α ; tNF antagonists ; HF
P-601	-0.6962 -0.2133 -0.2500 -0.2751 -0.3196 -0.0307 -0.1336 -0.0077 -0.1213 -0.0691 -0.5682 -0.4683 -1.7811 -0.8797 -0.5384 -0.6192 -0.9907 -0.0600 -0.1909 -0.0047 -0.1791 -0.3147 -2.0906 -0.5698 -0.1703 -0.0808
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers for medicare and medicaid services ; cms ; hospital ; outcomes ; reported ; mortality ; readmission ; penalties
H-1031	-0.577672004699707	▁Center s ▁for ▁Medica re ▁and ▁Medica id ▁Services ▁; ▁c ms ▁; ▁mortal ity ▁; ▁read mission ▁rates ▁; ▁penal ties
D-1031	-0.577672004699707	Centers for Medicare and Medicaid Services ; cms ; mortality ; readmission rates ; penalties
P-1031	-0.6169 -0.1148 -0.4464 -0.0287 -0.0199 -0.5761 -0.0213 -0.0075 -0.3897 -0.5947 -0.4235 -0.7462 -0.9633 -3.1898 -1.3439 -0.3053 -1.0074 -1.2027 -0.4404 -0.6074 -0.4233 -0.0774 -0.2059 -0.1117
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox proportional hazard models ; covariates ; follow-up ; physician ; discharge ; primary outcome ; death ; all-cause readmission
H-1416	-0.4501466155052185	▁co x ▁proportion al ▁hazard ▁; ▁follow - up ▁; ▁physician ▁; ▁dis charge
D-1416	-0.4501466155052185	cox proportional hazard ; follow-up ; physician ; discharge
P-1416	-0.0736 -0.0735 -0.0209 -0.0124 -0.0253 -1.8342 -0.0384 -0.1544 -0.0284 -0.5918 -0.5218 -0.6834 -0.5698 -0.0869 -2.3786 -0.1088
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate logistic regression analysis ; rule ; cad ; stenosis ; 3-vessel cad ; 2-vessel cad ; left anterior descending artery
H-1187	-0.7039205431938171	▁significant ▁re gression ▁analysis ▁; ▁CAD ▁; ▁diameter ▁sten osis ▁; ▁left ▁main ▁; ▁CAD ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁arter y
D-1187	-0.7039205431938171	significant regression analysis ; CAD ; diameter stenosis ; left main ; CAD ; proximal left anterior descending artery
P-1187	-5.4948 -0.2863 -0.0116 -0.2505 -0.4591 -3.1033 -0.4123 -0.1515 -0.0300 -0.0352 -0.4458 -1.2328 -0.0223 -0.2568 -0.7765 -0.3239 -2.0942 -0.0699 -0.6686 -1.4073 -0.0659 -0.0753 -0.0183 -0.2666 -0.2547 -0.0885
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate ; signal transduction ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
H-1040	-0.31449592113494873	▁signal ▁trans duction ▁casca de ▁; ▁tran scription ▁factors ▁; ▁cardio my o cy tes ▁; ▁tran scription ▁factors ▁; ▁chr omat in ▁structure
D-1040	-0.31449592113494873	signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; chromatin structure
P-1040	-0.4544 -0.0491 -1.0279 -0.2176 -0.0994 -0.4157 -0.4121 -0.0585 -0.3690 -0.3803 -0.0877 -0.5729 -0.7167 -0.0851 -0.0467 -0.4454 -0.4125 -0.1150 -0.3453 -0.3294 -0.1673 -0.0326 -0.6598 -0.3273 -0.2254 -0.1236
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients ; hypertensive hfpef ; dash ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
H-926	-0.3907158672809601	▁hyper tensi ve ▁H FP EF ▁; ▁so dium - re strict ed ▁DAS h ▁die t ▁; ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling
D-926	-0.3907158672809601	hypertensive HFPEF ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
P-926	-1.4594 -0.3643 -0.0306 -1.7495 -1.3465 -1.0362 -0.2208 -0.0164 -0.0280 -0.0156 -0.0554 -0.0349 -0.0475 -0.1276 -0.2188 -1.5880 -0.0562 -0.2287 -0.0265 -1.8235 -0.1173 -0.0134 -0.0587 -0.0448 -0.1173 -0.2580 -0.0475 -0.1955 -0.0890 -0.2089 -0.0289 -1.9359 -0.2584 -0.2159 -0.0714 -0.0515 -0.1712 -0.9053 -0.2820 -0.0834
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular dilatation
H-334	-0.25443777441978455	▁mechanism ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁di la tation
D-334	-0.25443777441978455	mechanism ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
P-334	-0.2858 -0.4546 -0.4558 -0.0926 -0.0297 -0.1135 -0.0662 -0.1917 -0.2053 -0.0217 -0.3121 -0.0875 -0.4569 -0.2156 -0.0753 -0.0389 -0.0136 -0.1030 -0.3236 -1.2786 -0.8301 -0.2298 -0.2082 -0.0254 -0.2198 -0.3570 -0.3670 -0.0933 -0.0491 -0.4444 -0.0542 -0.0250 -1.1797 -0.1418 -0.1974 -0.2689 -0.0589 -0.2631 -0.0880
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized aldactone evaluation study ; symptomatic chronic advanced heart failure ; patients ; aldosterone antagonist ; spironolactone ; mortality ; placebo
H-1735	-0.5352085828781128	▁Rand om ized ▁al da cto ne ▁Evalua tion ▁Study ▁; ▁chronic ▁advanced ▁heart ▁failure ▁patients ▁; ▁al do ster one ▁anta gon ist ▁; ▁spi rono lac tone ▁; ▁mortal iteit
D-1735	-0.5352085828781128	Randomized aldactone Evaluation Study ; chronic advanced heart failure patients ; aldosterone antagonist ; spironolactone ; mortaliteit
P-1735	-1.8117 -0.8488 -0.0768 -0.2941 -0.2004 -0.2205 -0.7506 -1.5317 -0.2354 -0.4122 -0.3936 -2.1325 -1.8603 -0.8877 -0.0779 -1.0982 -0.3104 -0.0850 -0.2259 -0.1147 -0.4407 -0.2041 -0.0016 -0.4774 -0.2409 -0.0110 -0.0101 -0.0534 -0.0616 -0.7194 -0.2663 -1.8466 -0.1969 -0.0989
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence ; mortality ; outcomes ; heart failure ; acute myocardial infarction ; patients ; acute myocardial infarction ; western australia
H-1305	-0.9609023332595825	▁heart ▁failure ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁Western ▁Australia
D-1305	-0.9609023332595825	heart failure ; acute myocardial infarction ; acute myocardial infarction ; Western Australia
P-1305	-3.2979 -0.2374 -0.3804 -0.7411 -0.0664 -2.0920 -1.0045 -1.1660 -1.4270 -0.0653 -0.5405 -0.2530 -0.4062 -4.7367 -0.1851 -1.4656 -0.7718 -1.1803 -1.6744 -0.0648 -0.4502 -0.2754 -0.4769 -1.3810 -1.1729 -0.2950 -0.1367
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf ; hct ; polymorphisms ; genes ; anthracycline ; metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
H-1450	-0.30254095792770386	▁CHF ▁; ▁h CT ▁; ▁poly morph ism s ▁; ▁an thra cycli ne ▁metabolism ▁; ▁ir on ▁home osta sis ▁; ▁anti - oxid ant ▁de fen ce ▁; ▁my o card ial ▁remodel ling
D-1450	-0.30254095792770386	CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
P-1450	-0.0517 -0.4828 -1.7403 -0.8018 -0.2725 -0.5610 -0.0086 -0.3906 -0.1640 -0.3692 -0.3087 -0.0376 -0.2221 -1.1992 -0.0493 -0.2607 -0.2202 -0.0127 -0.2779 -0.0768 -0.3254 -0.2549 -0.0077 -0.0391 -0.0071 -0.1285 -0.1268 -0.0129 -0.6260 -0.2623 -0.3880 -0.1431 -0.4653 -0.5244 -0.0336 -0.2447 -0.3132 -0.0858
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.6471446752548218	▁medication ▁; ▁no nadh er ence
D-559	-1.6471446752548218	medication ; nonadherence
P-559	-0.7043 -0.8899 -2.0424 -3.7267 -0.0932 -2.4916 -3.0923 -0.1369
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological ; diagnostic ; prognostic
H-1278	-1.2165534496307373	▁pat ho phy si ological
D-1278	-1.2165534496307373	pathophysiological
P-1278	-0.7763 -1.0559 -0.4849 -2.5993 -0.7276 -2.7887 -0.0832
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad ; surgery ; patients ; albumin ; hypoalbuminemia ; surgery
H-534	-0.698129415512085	▁l VAD ▁; ▁album in ▁levels ▁; ▁hypo album in emia
D-534	-0.698129415512085	lVAD ; albumin levels ; hypoalbuminemia
P-534	-0.3065 -0.0402 -1.7925 -1.6273 -0.3522 -2.4580 -0.5619 -0.0817 -0.1771 -0.2570 -0.1937 -1.1059 -0.1217
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate model ; creatinine ; hazard ratio ; confidence interval ; mortality
H-717	-0.40758267045021057	▁creati nine ▁; haz ard ▁ratio ▁; ▁post - trans plant ▁mortal ity
D-717	-0.40758267045021057	creatinine ;hazard ratio ; post-transplant mortality
P-717	-0.0636 -0.5187 -0.7419 -0.4055 -0.0040 -0.0110 -0.6135 -1.0218 -0.0686 -0.1036 -0.0239 -0.1640 -2.0233 -0.1808 -0.1695
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death ; patients ; estimated glomerular filtration rate ; odds ratio ; confidence interval
H-977	-1.051368236541748	▁glo mer ular ▁filtr ation ▁rate
D-977	-1.051368236541748	glomerular filtration rate
P-977	-4.0067 -0.3304 -0.0981 -0.1798 -0.9071 -1.7177 -1.0390 -0.1322
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical ; hm ii ; heartware ; patients ; economic ; hm ii
H-310	-0.6964079737663269	▁scientific ▁literature ▁; ▁ HM ▁II ▁; ▁Heart War e ▁patients ▁; ▁economic ▁evaluation s ▁; HM ▁II
D-310	-0.6964079737663269	scientific literature ; HM II ; HeartWare patients ; economic evaluations ;HM II
P-310	-2.1413 -1.2185 -0.1852 -1.9111 -0.1653 -1.4347 -0.2087 -0.7237 -0.0765 -0.0382 -0.4051 -0.1693 -1.1175 -0.9346 -0.1207 -0.1897 -0.6029 -1.3030 -0.8536 -0.1288
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine ; nesiritide ; renal function ; patients ; acute heart failure ; renal dysfunction
H-72	-0.28092846274375916	▁dop amine ▁; ▁nesi riti de ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-72	-0.28092846274375916	dopamine ; nesiritide ; renal function ; acute heart failure ; renal dysfunction
P-72	-0.1402 -0.1500 -0.1840 -1.1717 -0.0448 -0.3393 -0.4831 -0.0492 -0.1873 -0.3775 -0.8116 -0.0250 -0.3451 -0.1074 -0.2759 -0.0175 -0.2379 -0.1714 -0.3717 -0.1279
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized ; hr variability ; hr variability ; clinical ; risk stratification ; cardiac ; patients
H-1591	-1.3077821731567383	▁HR ▁variabil ity ▁; tur bul ence ▁; ▁HR ▁variabil ity ▁; tur bul ence ▁; ▁cardiac ▁patients
D-1591	-1.3077821731567383	HR variability ;turbulence ; HR variability ;turbulence ; cardiac patients
P-1591	-1.0805 -0.2120 -2.2886 -3.2348 -1.1036 -1.2828 -3.2386 -0.5576 -0.9080 -0.0867 -2.5747 -2.3985 -1.3692 -0.9962 -2.9215 -0.7524 -0.2784 -0.5412 -0.1920 -0.1385
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications ; implantation ; lvad therapy ; transplantation ; btt ; dt ; medical therapy
H-313	-0.5224940776824951	▁l VAD ▁ therapy ▁; ▁transplant ation ▁e ligi bility ▁status ▁; ▁device ▁; ▁b t ▁; ▁d t ▁; ▁medical ▁ therapy
D-313	-0.5224940776824951	lVAD therapy ; transplantation eligibility status ; device ; bt ; dt ; medical therapy
P-313	-1.4713 -0.0246 -1.9546 -0.0371 -0.6088 -0.2711 -0.6213 -0.8867 -0.0344 -0.4786 -0.0961 -0.3570 -0.1674 -0.4984 -1.4248 -0.9657 -0.1652 -1.5748 -0.1460 -0.4195 -0.1541 -0.2782 -0.0367 -0.2565 -0.1335
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical ; artery tonometry ; prospectively ; admission ; patients ; icu ; clinical
H-580	-0.6912950277328491	▁radi al ▁arter y ▁ton ometr y ▁; ▁PH ▁; ▁ ICU
D-580	-0.6912950277328491	radial artery tonometry ; PH ; ICU
P-580	-1.3329 -0.0673 -0.0306 -0.5283 -0.1337 -0.0369 -0.3815 -0.7586 -3.3010 -1.2331 -1.4625 -0.0279 -0.2470 -0.1370
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully magnetically levitated centrifugal-flow chronic lvas ; adverse event ; quality of life ; functional status
H-2006	-0.37249019742012024	▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic ▁l VAS
D-2006	-0.37249019742012024	magnetically levitated centrifugal-flow chronic lVAS
P-2006	-0.8920 -0.3403 -0.0303 -0.0208 -0.3927 -0.2701 -1.3461 -0.2283 -0.1428 -0.0987 -0.4352 -0.6302 -0.1588 -0.5034 -0.0977
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome complex ; scaffold protein ; drives ; kinases ; phosphorylation ; effector molecules
H-995	-0.558746337890625	▁e RK 1/2 ▁signal ling ▁; ▁signal o some ▁complex ▁; ▁sc af fold ▁protein ▁; ▁kina ses ▁; ▁sequenti al ▁ phos phor y lation
D-995	-0.558746337890625	eRK1/2 signalling ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
P-995	-0.6626 -0.1061 -0.1987 -0.4873 -0.5743 -0.4574 -0.7913 -0.9711 -1.7721 -0.4657 -0.3553 -0.5872 -0.7582 -0.1262 -0.4670 -0.4003 -0.1643 -1.4538 -0.3823 -0.0867 -0.0723 -0.1269 -0.1629 -1.6573 -1.3930 -0.0603 -0.8226 -0.0816
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast cancer ; patients ; medicare ; diagnosed ; breast cancer ; chemotherapy ; seer-medicare ; texas ; medicare
H-672	-0.463167667388916	▁breast ▁cancer ▁patients ▁; ▁full ▁Medica re ▁coverage ▁; ▁breast ▁cancer ▁; ▁che mo therapy ▁; ▁s EER - Medic are ▁; ▁Texas ▁Cancer ▁Registr y - Medic are ▁database s
D-672	-0.463167667388916	breast cancer patients ; full Medicare coverage ; breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare databases
P-672	-1.2807 -0.2133 -0.7686 -0.6733 -0.4311 -0.0207 -0.0249 -0.0958 -0.5463 -1.1919 -0.1455 -0.4914 -0.1927 -0.2860 -0.0537 -0.4040 -1.3836 -0.2222 -0.0285 -0.1475 -0.4432 -0.1608 -0.3129 -1.5677 -0.5435 -0.0371 -1.7512 -0.2189 -0.3477 -0.7786 -0.1853 -0.2325 -0.1037
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection fraction ; b-type natriuretic peptide ; patients ; hospitalized ; heart failure ; inhospital ; outcomes ; get with the guideline-heart failure registry
H-186	-0.5501899719238281	▁e je ction ▁ fraction ▁; ▁na tri ure tic ▁pe pti de ▁; ▁heart ▁failure ▁; ▁in hospital ▁outcome s ▁; ▁get ▁With ▁the ▁guide line - ▁he art ▁Fail ure ▁Registr y
D-186	-0.5501899719238281	ejection fraction ; natriuretic peptide ; heart failure ; inhospital outcomes ; get With the guideline- heart Failure Registry
P-186	-0.2750 -0.2970 -0.0351 -0.3565 -0.0304 -0.2927 -0.6310 -1.1871 -0.9424 -1.4526 -0.7137 -0.0588 -0.2835 -1.0073 -1.6805 -0.1138 -0.5802 -0.1531 -0.0451 -0.6305 -0.1431 -0.5045 -0.3393 -1.1732 -0.8056 -1.9096 -0.0328 -0.0767 -1.0149 -0.5688 -0.4825 -0.5748 -0.9152 -0.1021 -0.2540 -0.1435
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased ; cardiomyocytes ; pde2 ; activity ; cgmp synthesis ; nitric oxide ; donors ; pde2 inhibition ; β-ar responsiveness
H-1215	-0.5261020660400391	▁cardio my o cy tes ▁; ▁p de 2 ▁; ▁c g MP ▁synth es is ▁; ▁ni tric ▁oxid e ▁donor s ▁; ▁p de 2 ▁inhibi tion ▁; ▁β - AR ▁responsive ness
D-1215	-0.5261020660400391	cardiomyocytes ; pde2 ; cgMP synthesis ; nitric oxide donors ; pde2 inhibition ; β-AR responsiveness
P-1215	-0.1565 -1.0470 -0.5666 -0.1736 -0.0870 -0.4794 -1.2881 -2.0512 -0.0683 -1.2736 -0.0291 -1.6808 -0.9796 -0.5885 -0.0595 -0.1916 -0.6514 -0.0216 -0.0376 -0.0115 -0.1118 -0.0270 -0.1541 -0.4162 -0.8459 -1.6064 -0.1092 -0.6618 -0.6236 -0.6273 -0.0351 -0.0180 -0.6167 -0.0717 -1.7336 -0.2627 -0.1022
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko ; cardiac ; irs1 ; irs2 ; proteins ; heart failure ; cardiac energy metabolism gene expression ; p38α ; mitogen-activated protein kinase ; p38
H-656	-0.4123222529888153	▁l - d ko ▁mi ce ▁; ▁cardiac ▁I RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁heart ▁failure ▁; ▁cardiac ▁energy ▁metabolism ▁; ▁p 38 α ▁mit ogen - activa ted ▁protein ▁kina se
D-656	-0.4123222529888153	l-dko mice ; cardiac IRS1 ; iRS2 proteins ; heart failure ; cardiac energy metabolism ; p38α mitogen-activated protein kinase
P-656	-0.8744 -0.1865 -0.4934 -0.5467 -1.7133 -0.3864 -0.6607 -0.1570 -1.5955 -0.1028 -1.8189 -0.6217 -0.9796 -0.1798 -0.0657 -0.7822 -0.1317 -0.3261 -0.5021 -0.1239 -0.3126 -0.3565 -0.5871 -0.0240 -0.1749 -0.0096 -0.1267 -0.1355 -0.4047 -0.1263 -0.2299 -0.0332 -0.2439 -0.0806 -0.0037 -0.0841 -0.3784 -0.1081
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs ; hdl ; phosphorylation
H-251	-0.5852425694465637	▁ec s ▁; ▁HD L ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁e NOS - Th r ▁; ▁PK c - β II - Ser ▁; ▁p 70 s 6 k - Ser
D-251	-0.5852425694465637	ecs ; HDL ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser ; p70s6k-Ser
P-251	-1.2455 -0.8103 -0.4757 -0.6917 -3.3570 -0.3301 -0.0828 -0.1564 -0.7478 -1.4601 -0.1381 -0.2903 -0.0482 -0.0622 -0.1071 -0.3941 -0.4554 -0.1046 -0.0567 -0.0636 -3.0588 -0.0032 -0.3844 -0.1547 -0.7594 -0.0943 -0.1049 -1.4575 -0.1276 -0.1457 -1.2627 -0.0155 -0.6826 -0.2733 -0.4367 -2.7136 -0.0350 -0.1972 -0.2923 -0.1327
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp ; 6-minute walking distance ; peak o2
H-829	-1.035111665725708	▁pas p
D-829	-1.035111665725708	pasp
P-829	-1.9054 -0.7293 -1.3462 -0.1595
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts ; patients ; sts ; hh ; sts
H-155	-1.4289212226867676	▁s ts ▁; HH ▁; ▁h m ▁; ▁TM ▁; ▁s TS ▁; ▁TM
D-155	-1.4289212226867676	sts ;HH ; hm ; TM ; sTS ; TM
P-155	-3.4732 -1.7646 -0.3116 -2.0615 -0.2951 -2.0977 -1.3399 -0.2485 -3.1416 -1.5067 -0.7327 -2.4517 -0.6526 -2.3427 -0.2729 -0.1697
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular myocytes ; sarcomere ; shortening
H-417	-0.5325132012367249	▁mouse ▁vent ri cular ▁my o cy tes ▁; ▁sar com ere
D-417	-0.5325132012367249	mouse ventricular myocytes ; sarcomere
P-417	-0.5461 -0.0856 -1.4572 -0.1755 -1.0540 -0.2216 -0.1319 -0.1461 -0.4179 -0.3501 -0.1396 -0.1686 -2.4675 -0.0933
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative ; alberta ; discharged ; hospital ; diagnosis ; heart failure
H-1415	-0.7149072885513306	▁administratie ▁; ▁Albert a ▁; ▁dis charge d ▁ali ve ▁; ▁hospital ▁; ▁heart ▁failure
D-1415	-0.7149072885513306	administratie ; Alberta ; discharged alive ; hospital ; heart failure
P-1415	-3.0052 -1.9578 -0.4192 -0.2079 -0.6620 -0.9333 -0.0600 -0.0250 -0.3027 -0.0257 -1.7815 -0.1707 -0.4848 -1.7455 -0.1152 -0.1760 -0.0808
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart failure ; histologically ; myocardial collagen ; healthy ; heart failure
H-1062	-0.9636911749839783	▁heart ▁failure ▁; ▁my o card ial ▁collage n ▁; ▁tissu e ▁; ▁heart ▁failure
D-1062	-0.9636911749839783	heart failure ; myocardial collagen ; tissue ; heart failure
P-1062	-4.4239 -0.3739 -0.4333 -0.9834 -0.7432 -0.3875 -0.4959 -0.0475 -0.1623 -0.4449 -0.9059 -0.0624 -0.4624 -5.9105 -0.2745 -0.1709 -0.1003
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates ; crt ; death ; hf ; hospitalization ; hazard ratio ; lvef
H-757	-0.5917189121246338	▁c RT ▁on ▁assign ment ▁; ▁time ▁to ▁death ▁; ▁ HF ▁hospital ization ▁; haz ard ▁ratio ▁; ▁LV EF
D-757	-0.5917189121246338	cRT on assignment ; time to death ; HF hospitalization ;hazard ratio ; LVEF
P-757	-0.2060 -2.8778 -2.6619 -0.1244 -0.2462 -0.5254 -1.4616 -0.1238 -0.3060 -0.1962 -0.8202 -0.7131 -0.4391 -0.5910 -0.3809 -0.2740 -0.0104 -0.0099 -0.4775 -0.1383 -0.7155 -0.2067 -0.1038
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor 1 ; s1pr1 ; downregulation ; cardiac ; hypertrophic ; heart failure ; s1pr1 ; cardiac ; gene ; therapy
H-1404	-0.5234264135360718	▁beta 1- ad r energi c ▁receptor ▁; ▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁reciproc al ▁down regul ation ▁; ▁cardiac ▁hyper trop hic ▁response ▁; ▁heart ▁failure ▁; ▁s 1 PR 1 ▁cardiac ▁gene ▁ therapy
D-1404	-0.5234264135360718	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
P-1404	-0.6383 -0.3715 -0.1637 -0.2272 -0.3874 -0.0839 -0.0173 -0.3550 -0.0138 -1.4038 -0.6443 -3.1931 -1.3087 -0.4032 -0.0061 -0.0218 -0.1760 -0.0220 -0.7176 -1.0027 -0.7521 -1.9787 -1.4863 -0.1073 -0.0123 -0.5083 -0.1026 -0.8138 -0.2594 -0.0120 -0.1577 -0.0127 -1.0206 -0.1363 -0.1885 -1.1359 -0.1438 -0.3566 -0.8817 -0.3739 -0.6487 -1.8593 -0.1223 -0.3543 -0.2642 -0.0183 -0.1927 -0.0667
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative risk ; rr ; heart failure ; bisphophonates ; rr ; confidence interval ; hazard ratio
H-1540	-0.8155978918075562	▁ RR ▁; ▁heart ▁failure ▁; ▁bis pho phon ates ▁; ▁cru de ▁ RR ▁; ▁confidence ▁interval ▁; CI ▁; ▁hazard ▁ratio ▁; HR
D-1540	-0.8155978918075562	RR ; heart failure ; bisphophonates ; crude RR ; confidence interval ;CI ; hazard ratio ;HR
P-1540	-5.3648 -0.4607 -0.4568 -1.7584 -0.3753 -0.3127 -0.2357 -0.1416 -0.2984 -1.0145 -0.6046 -0.0857 -0.0724 -0.6677 -0.3404 -0.5079 -2.9932 -0.0369 -0.4282 -2.8184 -0.4043 -1.0576 -0.0353 -0.4640 -0.6302 -0.3269 -0.1283
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare ; centers for medicare and medicaid services ; clinics ; propensity-score
H-1621	-0.4979875683784485	▁hoog - co st ▁Medica re ▁; ▁fee - for - service ▁; ▁Center s ▁for ▁Medica re ▁; ▁Medica id ▁Services
D-1621	-0.4979875683784485	hoog-cost Medicare ; fee-for-service ; Centers for Medicare ; Medicaid Services
P-1621	-4.1620 -0.0499 -0.0696 -0.0695 -0.0444 -0.0777 -0.9377 -1.0081 -0.0370 -0.0679 -0.1069 -0.0920 -1.4531 -0.5289 -0.4563 -0.6260 -0.0267 -0.0236 -1.3823 -0.0089 -0.0234 -0.2180 -0.3341 -0.1477
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician ; heart failure ; clinical practice guideline ; cpg ; outcomes ; heart failure ; hf
H-1841	-0.7538027763366699	▁physician ▁ad her ence ▁; ▁guide line ▁recommendations ▁; ▁heart ▁failure ▁; ▁Clinic al ▁practice ▁Guide line ▁; CP g ▁; ▁heart ▁failure ▁; HF
D-1841	-0.7538027763366699	physician adherence ; guideline recommendations ; heart failure ; Clinical practice Guideline ;CPg ; heart failure ;HF
P-1841	-3.7965 -0.7335 -0.6925 -1.1423 -0.9373 -0.5674 -0.0496 -1.1839 -1.1080 -0.5121 -0.0954 -0.4909 -0.8005 -0.0271 -0.2719 -0.7407 -0.0592 -0.2637 -1.6081 -1.0742 -0.2682 -2.5726 -0.1196 -0.1987 -0.6779 -0.2454 -0.1156
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil ; heart failure ; hemodynamic ; mitochondrial dysfunction ; antitumor ; activity
H-967	-0.21440045535564423	▁nic oran dil ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁hem o dynamic ▁perturba tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁anti tum or ▁activity
D-967	-0.21440045535564423	nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
P-967	-0.0383 -0.0206 -0.2196 -0.3237 -0.1368 -0.0066 -0.0145 -0.7757 -0.1524 -0.0433 -0.1173 -0.5358 -0.1447 -0.2794 -0.1076 -0.0653 -0.5309 -0.2333 -0.1370 -0.0058 -0.0088 -0.1002 -0.2663 -0.0018 -0.3692 -0.0553 -0.0321 -0.0462 -0.0384 -0.2102 -0.5681 -0.4112 -0.0540 -1.4003 -0.1909 -0.0769
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq ; new york heart association class ; patients ; hfpef ; hf with reduced ef
H-788	-0.7094884514808655	▁ cc q ▁summary ▁score s ▁; ▁New ▁York ▁Heart ▁association ▁class ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁EF
D-788	-0.7094884514808655	ccq summary scores ; New York Heart association class ; HFpEF ; HF ; EF
P-788	-2.4783 -0.3421 -1.3955 -1.6984 -0.1603 -0.1377 -0.2490 -0.4723 -0.4372 -1.2520 -0.4908 -1.0534 -0.1848 -0.4882 -0.5115 -0.1232 -0.1873 -0.2110 -0.6134 -1.3938 -0.6653 -2.1073 -0.2750 -0.0999
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm control therapy ; diagnosis ; atrial ; sinus rhythm ; rhythm control ; symptoms ; rate control
H-1646	-0.40955793857574463	▁ Rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁at rial ▁structure ▁; ▁function ▁; ▁sinus ▁ rhythm ▁; ▁de lay ed ▁ rhythm ▁control ▁; ▁rate ▁control
D-1646	-0.40955793857574463	Rhythm control therapy ; AF ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
P-1646	-0.8718 -0.4049 -0.5137 -0.5160 -0.0318 -0.4769 -0.6840 -0.3362 -0.6057 -0.0713 -0.0899 -0.1212 -2.0587 -0.1084 -0.2084 -0.5249 -0.4114 -0.3303 -0.2899 -0.0289 -0.0418 -0.0686 -0.6049 -0.5132 -0.5240 -0.8089 -0.2613 -0.2999 -0.0705
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic ; therapy
H-83	-0.3471132218837738	▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁dop amine ▁; ▁nesi riti de ▁; ▁renal ▁function ▁; ▁di ure tic ▁ therapy
D-83	-0.3471132218837738	acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic therapy
P-83	-1.9056 -0.0307 -0.4702 -0.0612 -0.2299 -0.0121 -0.0703 -0.0949 -0.5010 -0.0280 -0.1650 -0.2198 -0.6638 -0.0427 -0.1884 -0.1998 -0.1307 -0.2932 -0.5257 -0.1656 -0.5779 -1.4403 -0.4187 -0.0838 -0.3851 -0.1206
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf ; prospective ; dual-energy x-ray absorptiometry ; echocardiography ; blood
H-1161	-0.6500311493873596	▁ HF ▁; ▁body ▁composition ▁; s kin fold ▁thi ck ness ▁; ▁dual - ener gy ▁X - ray ▁ab sor pti ometr y ▁; ▁e cho card i ography ▁; ▁blood ▁testing
D-1161	-0.6500311493873596	HF ; body composition ;skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
P-1161	-1.8997 -1.1839 -0.5907 -3.5325 -0.6066 -0.4724 -2.7448 -2.4602 -0.1853 -0.5868 -0.0302 -1.1831 -0.4573 -0.0224 -0.0975 -0.2628 -0.1608 -1.7220 -0.0758 -0.2441 -0.0359 -0.5018 -0.5037 -0.1313 -0.6626 -0.2598 -0.0862 -0.1302 -0.4118 -0.8300 -0.2056 -0.3493 -0.0570 -0.2869 -0.2974 -0.1330
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients ; heart failure
H-1744	-1.3329014778137207	▁heart ▁failure ▁treatment
D-1744	-1.3329014778137207	heart failure treatment
P-1744	-3.6021 -0.3626 -1.9818 -0.4987 -0.2194
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp ; red blood cell transfusion ; hemoglobin ; hemoglobin ; hospitalized ; patients ; coronary heart disease
H-36	-0.9740710258483887	▁a CP ▁; ▁red ▁blood ▁cell ▁trans fusion ▁; ▁hem o glob in ▁thre s hold ▁; ▁hem o glob in ▁levels ▁; ▁corona ry ▁heart ▁disease
D-36	-0.9740710258483887	aCP ; red blood cell transfusion ; hemoglobin threshold ; hemoglobin levels ; coronary heart disease
P-36	-1.7680 -2.7736 -0.8484 -0.9039 -0.3450 -0.6949 -0.0786 -0.0298 -1.8017 -2.0273 -1.2367 -0.6376 -1.9670 -1.1070 -0.2120 -0.7043 -0.2923 -1.2057 -1.0504 -0.3611 -1.3983 -2.5311 -0.4269 -0.4805 -1.8785 -0.4289 -0.6277 -0.2512 -0.1795
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals ; patients ; hospitalized ; heart failure ; hf ; conditions ; acute myocardial infarction ; pneumonia ; conditions
H-1032	-0.6406205892562866	▁hospital s ▁; ▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁pneu monia
D-1032	-0.6406205892562866	hospitals ; heart failure ;HF ; acute myocardial infarction ; pneumonia
P-1032	-3.9865 -0.7043 -0.4647 -2.4333 -0.1045 -0.2677 -0.1948 -0.3070 -2.2965 -0.0068 -0.8857 -0.3729 -0.1258 -0.7577 -0.0179 -0.0982 -0.1624 -0.3203 -0.0095 -0.1979 -0.2455 -0.1336
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted ; interatrial shunt ; clinical ; haemodynamic ; outcomes ; patients ; heart failure with reduced ejection fraction
H-1962	-0.4834999442100525	▁left - to - right ▁inter at rial ▁shu nt ▁; ▁ha emo dynamic ▁outcome s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1962	-0.4834999442100525	left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure ; ejection fraction
P-1962	-5.1456 -0.0464 -0.1289 -0.1785 -0.2890 -0.0952 -0.0487 -0.4202 -0.1401 -0.1844 -0.7354 -0.0480 -0.2019 -0.0051 -1.9027 -0.1243 -0.3926 -0.8464 -0.0964 -0.4774 -0.1925 -0.1395 -0.2110 -0.5705 -0.0173 -0.2777 -0.1389
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1 time ; correlated ; right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
H-742	-0.6089255213737488	▁right ▁vent ri cular - pul mon ary ▁arterial ▁coup ling ▁; pul mon ary ▁vas cular ▁resist ance ▁; ▁right ▁vent ri cular ▁e je ction ▁ fraction
D-742	-0.6089255213737488	right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
P-742	-1.1020 -0.0758 -2.1774 -0.2583 -0.2741 -0.8824 -0.8231 -0.2613 -0.0636 -0.4449 -0.6176 -0.3033 -2.9305 -0.9794 -0.1930 -0.0667 -0.4711 -0.2127 -0.1176 -0.5059 -0.7624 -0.0500 -2.0959 -0.4076 -0.3345 -0.3336 -0.1691 -1.4524 -0.0363 -0.3441 -0.1302
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left ventricular assist devices ; lvads ; chronic end-stage heart failure ; bridge to transplantation ; btt ; patients ; destination therapy ; dt
H-308	-0.4414542615413666	▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁chronic ▁end - s tage ▁heart ▁failure ▁; bridge ▁to ▁transplant ation ▁; ▁b t ▁; ▁transplant - ine ligi ble ▁patients ▁; ▁de stin ation ▁ therapy ▁; ▁d t
D-308	-0.4414542615413666	ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ; dt
P-308	-0.9723 -2.7499 -0.1959 -0.5181 -0.2362 -0.4694 -0.0641 -0.0296 -0.1533 -0.4100 -1.6146 -1.4395 -0.0683 -0.1449 -0.0391 -0.8184 -0.1696 -0.2252 -0.0999 -0.0965 -0.1951 -0.6293 -0.4214 -0.9434 -0.9109 -0.1941 -0.3221 -0.0995 -0.7342 -0.0227 -0.2449 -0.2977 -0.3659 -0.3102 -0.0716 -0.1254 -0.2029 -0.0152 -0.7247 -0.7196 -0.6643 -0.1648 -0.0879
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise ; training ; peak oxygen consumption ; quality of life ; obese ; patients ; heart failure with preserved ejection fraction ; randomized ; clinical
H-1973	-0.38326317071914673	▁Cal o ric ▁re stri ction ▁; ▁aero bic ▁Exerci se ▁Training ▁; ▁Peak ▁o xy gen ▁Consum p tion ▁; ▁Quality ▁of ▁Life ▁; ▁Old er ▁Patient s ▁; ▁Heart ▁Fail ure ▁; ▁Pres er ved ▁e je ction ▁Fra ction
D-1973	-0.38326317071914673	Caloric restriction ; aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Older Patients ; Heart Failure ; Preserved ejection Fraction
P-1973	-0.1557 -0.8792 -0.3127 -0.6130 -0.5634 -0.0664 -0.2625 -0.6041 -0.1527 -0.2690 -0.2114 -0.4795 -0.7351 -0.0079 -0.4071 -0.1236 -0.0621 -0.1511 -0.1210 -0.1839 -0.2872 -2.0304 -0.2740 -0.1596 -0.4097 -1.5729 -0.0252 -0.1533 -0.0972 -1.4462 -0.4263 -0.0509 -0.5368 -0.9716 -0.2113 -0.0591 -0.4493 -0.5884 -0.0926 -0.0230 -0.3284 -0.0124 -0.2168 -0.0794
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol ; metoprolol ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-855	-0.31031322479248047	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD it - c RT ▁trial ▁; Mul ti center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-855	-0.31031322479248047	carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-cRT trial ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
P-855	-0.0164 -0.0541 -0.0420 -0.2765 -0.0127 -0.2777 -0.0274 -0.1299 -0.3465 -0.5218 -0.0340 -0.6519 -0.0262 -0.3939 -0.0915 -0.3314 -0.2520 -0.6225 -0.2218 -0.1468 -0.4717 -0.0155 -0.3356 -0.1378 -0.7105 -0.0183 -1.1053 -2.5978 -0.3344 -0.1436 -0.9004 -0.2092 -0.0239 -0.2190 -0.0294 -0.1417 -0.0233 -0.2323 -0.0377 -0.2201 -0.4420 -0.9774 -0.2874 -0.0246 -0.4780 -0.0502 -0.0045 -0.5702 -0.2455 -0.2672 -0.0947
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral ; glucocorticoids ; hf
H-610	-0.7516521215438843	▁Oral ▁gluco cor tico ids ▁; ▁ HF ▁; ▁HR
D-610	-0.7516521215438843	Oral glucocorticoids ; HF ; HR
P-610	-1.1217 -0.1008 -0.3560 -1.0887 -0.7868 -0.6237 -0.8136 -0.5297 -1.2531 -1.2897 -0.9326 -0.1233
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ; ea ; tac ; placebo
H-523	-0.4759557545185089	▁HR ▁; ▁i va bra dine ▁group ▁; ▁Ea ▁; ▁ TAC
D-523	-0.4759557545185089	HR ; ivabradine group ; Ea ; TAC
P-523	-0.7166 -0.3856 -0.0399 -0.0301 -0.2625 -0.0655 -1.5409 -0.2387 -1.5504 -0.1949 -0.7984 -0.2200 -0.5227 -0.0972
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol ; therapy ; metoprolol ; hazard ratio ; confidence interval
H-862	-0.4694301187992096	▁car vedi lol ▁; ▁met o pro lol ▁; haz ard ▁ratio ▁; HR
D-862	-0.4694301187992096	carvedilol ; metoprolol ;hazard ratio ;HR
P-862	-0.0377 -0.1273 -0.1069 -0.7144 -0.8082 -0.7825 -0.0796 -0.1845 -1.0157 -0.1293 -0.0050 -0.0058 -0.3131 -0.2723 -2.7827 -0.1459
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up ; systemic ; adverse events ; patients ; dcm ; heart failure
H-1265	-0.6283832788467407	▁CH m ▁; ▁ad ju nc tive ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1265	-0.6283832788467407	CHm ; adjunctive treatment ; dCM ; heart failure
P-1265	-2.5983 -0.2897 -0.3310 -3.6420 -0.4267 -0.0103 -0.2503 -0.5958 -0.2318 -0.1947 -0.2506 -0.2301 -0.5042 -0.1024 -0.2937 -0.1026
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone supplementation ; exercise rehabilitation ; health ; outcomes ; patients ; chf ; testosterone
H-1325	-0.6057778596878052	▁testosteron e ▁supplement ation ▁; ▁exercise ▁rehabilita tion ▁; ▁CHF ▁; ▁testosteron e ▁status
D-1325	-0.6057778596878052	testosterone supplementation ; exercise rehabilitation ; CHF ; testosterone status
P-1325	-0.3473 -0.0702 -1.3772 -1.2190 -0.7415 -1.0510 -0.1506 -0.6315 -0.4958 -0.9369 -0.5373 -1.5442 -0.0620 -0.1262 -0.2991 -0.1023
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change ; peak vo2 ; correlated ; change ; lean body mass ; change ; thigh ; muscle
H-1987	-0.6118396520614624	▁VO 2 ▁; ▁lean ▁body ▁mass ▁; ▁th igh ▁muscle ▁; inter mus cular ▁fat ▁ratio
D-1987	-0.6118396520614624	VO2 ; lean body mass ; thigh muscle ;intermuscular fat ratio
P-1987	-0.9984 -0.0584 -0.3505 -0.3094 -0.8465 -0.2612 -0.2760 -3.6088 -0.8283 -0.3804 -0.7137 -0.1598 -0.8044 -0.2963 -0.5473 -0.1179 -0.3202 -0.1356
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals ; get with the guidelines-heart failure ; hf ; patients ; ef ; ef ; ef ; ef
H-189	-0.7636383175849915	▁get ▁With ▁the ▁Guide lines - ▁he art ▁Fail ure ▁; ▁ HF ▁; EF ▁; ▁border line ▁; EF ▁; ▁EF
D-189	-0.7636383175849915	get With the Guidelines- heart Failure ; HF ;EF ; borderline ;EF ; EF
P-189	-1.3860 -1.7999 -1.1727 -0.8312 -0.1717 -0.0340 -1.2609 -0.1986 -0.3316 -0.3369 -0.3540 -0.8966 -0.8679 -1.1907 -1.4033 -0.6159 -0.6406 -0.0171 -0.5958 -0.8086 -0.6938 -2.3341 -0.2516 -0.1335
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2017	-0.9685818552970886	▁Tools ▁for ▁economic ▁analysis ▁of ▁Patient ▁management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁; ▁kosten - ef ective ness ▁model ▁; ▁disease ▁management ▁programs ▁; ▁heart ▁failure
D-2017	-0.9685818552970886	Tools for economic analysis of Patient management Interventions in Heart Failure ; kosten-efectiveness model ; disease management programs ; heart failure
P-2017	-2.5962 -0.6495 -1.1252 -0.2861 -2.2378 -0.3001 -0.6485 -0.5465 -0.0617 -0.5948 -0.6462 -0.3884 -1.2343 -0.4739 -4.2952 -0.0968 -2.0694 -0.0840 -0.8831 -2.0625 -0.2633 -3.8917 -0.0589 -0.4118 -1.3518 -0.4007 -0.1375 -0.1706 -0.1221
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi ; death ; medical ; hospitalization ; hf ; clinic ; outpatients ; hf ; health
H-385	-0.9569265246391296	▁ HF PSI ▁; ▁death ▁; ▁medical ▁hospital ization ▁; ▁ HF ▁; ▁clinic ▁out patient s ▁; ▁ HF ▁resources ▁; ▁health ▁systems
D-385	-0.9569265246391296	HFPSI ; death ; medical hospitalization ; HF ; clinic outpatients ; HF resources ; health systems
P-385	-1.0714 -1.3933 -0.6324 -0.5577 -5.2838 -0.2790 -1.4338 -0.4082 -0.5008 -0.2119 -0.9418 -0.5272 -1.6800 -0.6461 -1.8998 -0.0183 -0.1050 -0.5387 -0.7442 -0.8692 -2.9055 -1.2656 -0.3305 -0.1267 -0.3664 -0.1429
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; hypertrophy ; heart failure
H-1787	-0.4118514358997345	▁cardiac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁oxid ative ▁metabolism ▁; ▁cardiac ▁hyper trop hy ▁; ▁energy ▁deficit ▁; ▁hyper trop hy ▁; ▁heart ▁failure
D-1787	-0.4118514358997345	cardiac insulin-resistance ; mitochondrial oxidative metabolism ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
P-1787	-0.2499 -0.1803 -0.0645 -0.2903 -2.5554 -0.0126 -0.2098 -0.0489 -0.6178 -0.0769 -0.0164 -0.0276 -0.0988 -0.0696 -0.2809 -0.8672 -0.3043 -0.0365 -1.6227 -0.2770 -0.4235 -0.0130 -0.2982 -0.2594 -0.1434 -2.5687 -0.2657 -0.3509 -0.1785 -0.2664 -0.0925
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate cox model ; pasp ; exercise ; peak o2 ; prognostic ; hazard ratio ; peak o2 ; pasp
H-830	-1.1452531814575195	▁co x ▁model ▁analysis ▁; ▁pas p ▁; ▁exercise ▁; ▁ha ard ▁ratio ▁; ▁pas p
D-830	-1.1452531814575195	cox model analysis ; pasp ; exercise ; haard ratio ; pasp
P-830	-0.1159 -0.2046 -0.3258 -0.6697 -0.5723 -2.2716 -0.6432 -1.0859 -2.9718 -0.5556 -4.7181 -0.6914 -0.0927 -0.8010 -3.3004 -0.8367 -0.6412 -0.1169
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology ; heart failure with preserved ejection fraction ; hfpef ; myocardial extracellular matrix
H-734	-0.5136409997940063	▁pat ho phy si ology ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF ▁; ▁my o card ial ▁extra cel lular ▁matri x ▁accumula tion
D-734	-0.5136409997940063	pathophysiology ; heart failure ; preserved ejection fraction ; hFPEF ; myocardial extracellular matrix accumulation
P-734	-0.9104 -1.0463 -0.2611 -2.9949 -0.3306 -0.4047 -0.6964 -0.1002 -0.4569 -0.0835 -0.0508 -0.6396 -0.0409 -0.1249 -0.0622 -0.5772 -0.0174 -0.2649 -0.8583 -2.0447 -1.6854 -0.3371 -0.4979 -0.1132 -0.2447 -0.2941 -0.2012 -0.2060 -0.0691 -0.0200 -0.4140 -0.1598 -1.3395 -0.3234 -0.1063
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular ; dilatation
H-338	-0.27070990204811096	▁mechanism ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁; LV
D-338	-0.27070990204811096	mechanism ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
P-338	-0.2667 -0.4589 -0.3689 -0.0919 -0.0338 -0.1149 -0.0688 -0.2218 -0.1903 -0.0258 -0.3194 -0.0945 -0.4600 -0.1703 -0.0793 -0.0343 -0.0134 -0.1059 -0.3366 -1.1769 -0.8038 -0.2179 -0.2084 -0.0245 -0.2025 -0.3091 -0.3126 -0.0842 -0.0464 -0.4855 -0.0385 -0.0247 -0.8830 -0.0504 -0.5231 -0.1628 -1.1870 -0.0901
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ; pvf ; implanted ; cardioverter-defibrillator device
H-1346	-0.35832762718200684	▁breath ing ▁control ▁; ▁cardiac ▁arrest ▁; ▁humans ▁; ▁puls e less ▁vent ri cular ▁fi bril lation ▁; pv f ▁; ▁cardio ver ter - de fi br illa tor ▁device
D-1346	-0.35832762718200684	breathing control ; cardiac arrest ; humans ; pulseless ventricular fibrillation ;pvf ; cardioverter-defibrillator device
P-1346	-1.1755 -0.2314 -0.8369 -0.3913 -0.3320 -0.0427 -0.2492 -0.7184 -0.3283 -0.0365 -0.1567 -0.5248 -0.0295 -1.0330 -0.1738 -0.4885 -0.1127 -0.1231 -0.2575 -1.0359 -1.6894 -0.1649 -0.2132 -0.0209 -0.2083 -0.0686 -0.1882 -0.0580 -0.2606 -0.2375 -0.0545 -0.3952 -0.2599 -0.0860
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad ; rgk ; rem ; rem2 ; rad ; monomeric g proteins ; ventricular action potential ; gain ; cardiac ; l-type channel ; activity
H-1672	-0.41201314330101013	▁r GK ▁; ▁re m ▁; ▁rem 2 ▁; ▁rad ▁; ▁gem ▁; Kir ▁; ▁mono me ric ▁g ▁protein s ▁; ▁vent ri cular ▁action ▁; ▁ec ▁coup ling ▁; ▁cardiac ▁l - type ▁channel ▁activity
D-1672	-0.41201314330101013	rGK ; rem ; rem2 ; rad ; gem ;Kir ; monomeric g proteins ; ventricular action ; ec coupling ; cardiac l-type channel activity
P-1672	-1.5117 -1.1678 -0.1577 -1.7031 -0.2648 -0.4008 -0.2271 -0.0449 -0.1316 -0.6333 -0.2917 -0.6929 -1.0850 -0.3632 -0.3822 -0.0229 -0.0810 -0.1010 -0.1596 -0.1642 -0.0643 -0.2539 -0.0411 -1.6951 -0.3771 -0.0538 -1.0119 -0.8882 -0.1739 -0.1154 -0.2916 -0.2385 -0.6437 -0.0270 -0.0045 -0.0227 -0.2716 -0.2252 -0.0823
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hf ; myocardial infarction
H-1136	-0.4193210303783417	▁a ce tyl cho line ster ase ▁inhibi tor ▁py rido stig mine ▁; ▁sympa t hova gal ▁balance ▁; ▁cardiac ▁remodel ing ▁; ▁cardiac ▁function ▁; HF ▁; ▁my o card ial ▁in far ction
D-1136	-0.4193210303783417	acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ;HF ; myocardial infarction
P-1136	-0.3374 -2.0463 -0.2581 -0.4368 -0.1007 -0.2750 -0.6132 -0.1052 -0.0626 -0.5267 -0.0129 -0.0024 -0.5370 -0.3868 -0.0400 -0.1376 -0.1022 -0.2297 -0.2668 -0.2073 -0.0139 -0.1504 -0.0526 -0.2132 -0.0833 -0.2749 -0.2037 -1.7745 -0.5991 -1.3852 -0.8767 -0.6400 -1.5218 -0.0831 -0.2711 -0.6682 -0.3353 -0.1023
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac sympathetic activity ; β-blocker
H-1112	-0.4236117899417877	▁cardiac ▁sympa the tic ▁activity ▁; ▁i - meta - i odob enz yl guan i dine ▁; ▁i - mi BG ▁; ▁β - block er
D-1112	-0.4236117899417877	cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
P-1112	-0.5929 -0.1911 -0.8646 -1.0047 -0.6630 -0.5879 -1.2655 -0.4631 -0.0107 -0.0625 -0.2756 -0.1389 -0.2856 -0.7580 -0.0041 -0.2964 -0.0572 -0.4110 -0.3550 -0.4088 -0.4416 -1.1275 -0.6007 -0.1653 -0.0574 -0.5040 -0.1936 -0.3573 -0.1406
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based ; heart disease ; therapies ; patients ; cabg ; sweden
H-971	-0.5776205062866211	▁Swedish ▁Web - system ▁for ▁en han ce ment ▁and ▁development ▁of ▁e viden ce - based ▁care ▁in ▁Heart ▁disease ▁Evalua ted ▁According ▁to ▁Reco mmende d ▁Therapie s ▁registr y ▁; ▁ca BG ▁; ▁Sweden
D-971	-0.5776205062866211	Swedish Web-system for enhancement and development of evidence-based care in Heart disease Evaluated According to Recommended Therapies registry ; caBG ; Sweden
P-971	-0.5893 -1.2537 -0.0550 -1.4297 -0.5920 -0.1461 -0.4873 -2.3334 -0.1456 -0.4064 -1.0702 -0.1632 -1.4606 -0.0767 -0.7162 -0.0509 -0.0346 -0.7780 -0.8294 -0.4128 -0.1190 -1.6658 -0.1855 -1.7429 -0.1614 -0.0143 -0.0012 -0.0230 -0.1037 -0.0452 -0.0351 -0.0333 -0.5270 -1.2427 -0.9841 -0.7905 -1.4618 -0.2928 -0.0668
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef ; clinical ; reverse remodeling ; death ; hf ; hospitalization ; hazard ratio
H-756	-0.5893832445144653	▁LV EF ▁; ▁rever se ▁remodel ing ▁parameter s ▁; ▁time ▁to ▁death ▁; ▁ HF ▁hospital ization ▁; haz ard ▁ratio
D-756	-0.5893832445144653	LVEF ; reverse remodeling parameters ; time to death ; HF hospitalization ;hazard ratio
P-756	-0.1366 -0.6160 -0.4546 -4.4323 -0.0419 -0.2332 -0.0785 -0.2794 -0.0992 -0.4123 -2.2147 -0.1583 -0.1956 -0.1618 -1.3079 -0.3433 -0.9103 -0.6481 -0.9806 -0.0153 -0.0156 -0.0713 -0.2226 -0.1156
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients ; brain natriuretic peptide ; bnp ; bnp ; patients ; bnp ; bnp
H-1569	-0.9715706706047058	▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁b NP ▁; ▁b NP
D-1569	-0.9715706706047058	brain natriuretic peptide ; bNP ; bNP ; bNP
P-1569	-0.6305 -0.0420 -0.8897 -0.6332 -2.4165 -0.8681 -0.3398 -1.0107 -0.3380 -1.1704 -0.7444 -0.5510 -1.5231 -0.9235 -1.0463 -1.5846 -0.7057 -2.8956 -0.1467
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes ; coprimary end points ; end point ; change ; serum cystatin c ; renal function ; end point
H-79	-0.5438632965087891	▁cum ul ative ▁urin e ▁volume ▁; ▁de con gestion ▁end ▁point ▁; ▁se rum ▁cyst atin ▁c ▁; ▁en roll ment ▁; ren al ▁function
D-79	-0.5438632965087891	cumulative urine volume ; decongestion end point ; serum cystatin c ; enrollment ;renal function
P-79	-1.9726 -0.2342 -0.1263 -0.9947 -0.1351 -0.3660 -0.3218 -0.1397 -0.0531 -0.1061 -2.5554 -1.0769 -0.7012 -0.2971 -0.2019 -0.0163 -0.2127 -1.2696 -0.3912 -0.1238 -0.1548 -0.4227 -0.4738 -0.6280 -0.1227 -0.1802 -1.8285 -0.1216
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse ; longitudinal rv fiber shortening ; pasp ; rv ; in vivo ; rv ; prognosis
H-493	-0.7003152966499329	▁t AP se ▁; long itud in al ▁ RV ▁fiber ▁short en ing ▁; ▁pas p ▁; force ▁; ▁ RV ▁; ▁in ▁vivo ▁ RV ▁; ▁length - force
D-493	-0.7003152966499329	tAPse ;longitudinal RV fiber shortening ; pasp ;force ; RV ; in vivo RV ; length-force
P-493	-3.8429 -0.7934 -1.0036 -0.3165 -0.7119 -0.1092 -1.1060 -0.0712 -0.3989 -0.6820 -0.4481 -0.4369 -0.0704 -0.1565 -0.2795 -1.3118 -0.2549 -0.2580 -0.4696 -0.4653 -2.4383 -0.8058 -0.4088 -0.5251 -0.0161 -0.6817 -0.5156 -1.5628 -1.5385 -0.0873 -0.1299 -1.1061 -0.1079
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde ; pde2 ; cgmp ; leading ; camp hydrolysis ; cross talk ; cgmp ; camp signaling
H-1210	-0.5562332272529602	▁p de ▁super family ▁; ▁p de 2 ▁; ▁c g MP ▁; ▁c AMP ▁hydro lys is ▁; ▁negative ▁cross ▁talk ▁; ▁c g MP ▁; ▁c AMP ▁signal ing
D-1210	-0.5562332272529602	pde superfamily ; pde2 ; cgMP ; cAMP hydrolysis ; negative cross talk ; cgMP ; cAMP signaling
P-1210	-0.3885 -0.8579 -1.7728 -0.0648 -0.3450 -0.2956 -0.9817 -0.0198 -0.3404 -0.0372 -2.3785 -0.9377 -0.2585 -0.0306 -1.2085 -0.0193 -0.0345 -0.0969 -0.2799 -2.1561 -0.1090 -0.0817 -0.3241 -0.0238 -3.3368 -0.6950 -0.2222 -0.0121 -0.3695 -0.2581 -0.1544 -0.1740 -0.0906
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal probnp ; nt-probnp ; midregional proanp ; mr-proanp ; adiponectin ; elevated ; chf ; correlated ; bmi
H-14	-0.5937773585319519	▁pro b NP ▁; NT - pro b NP ▁; ▁mid region al ▁pro AN p ▁; MR - pro AN p ▁; ▁total ▁adi pon ect in ▁; ▁CHF ▁; ▁b mi ▁; ▁FM
D-14	-0.5937773585319519	probNP ;NT-probNP ; midregional proANp ;MR-proANp ; total adiponectin ; CHF ; bmi ; FM
P-14	-1.1129 -1.8404 -0.8723 -0.3831 -3.7004 -0.0290 -0.0395 -1.6002 -0.6236 -0.3423 -0.4311 -0.0929 -0.0172 -0.0234 -0.7044 -0.5737 -0.1940 -0.5561 -0.0282 -0.0204 -0.9854 -0.4141 -0.2701 -0.7805 -0.0239 -0.0134 -0.3770 -0.6188 -0.2685 -0.0558 -0.3013 -2.8532 -1.0076 -0.1781 -0.3360 -0.2046 -0.0963
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization ; admissions ; patient
H-900	-0.5020519495010376	▁re - hospital ization ▁; ▁ad missions
D-900	-0.5020519495010376	re-hospitalization ; admissions
P-900	-0.2592 -0.1835 -0.0475 -0.7819 -1.5061 -0.4621 -0.1885 -1.0016 -0.0879
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides ; szeto-schiller ; ss ; ss20 ; cardiac function ; proteomic remodeling ; signaling pathways
H-870	-0.39342960715293884	▁mito cho ndri al - tar get ed ▁antioxidant ▁; ▁Sze to - sch iller ▁; SS ▁; ▁SS 20 ▁; ▁cardiac ▁function ▁; ▁prote om ic ▁remodel ing
D-870	-0.39342960715293884	mitochondrial-targeted antioxidant ; Szeto-schiller ;SS ; SS20 ; cardiac function ; proteomic remodeling
P-870	-0.2282 -0.6316 -0.1683 -0.0336 -0.0623 -0.1603 -0.2864 -0.0334 -0.2241 -0.2926 -1.9762 -0.0856 -0.0330 -0.9733 -0.1430 -0.6281 -0.9699 -1.0249 -0.6760 -0.2130 -0.5379 -0.0776 -0.1348 -0.3879 -0.0488 -0.3667 -1.1752 -0.0393 -0.0400 -0.4493 -0.0952
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical ; cardiac arrest ; cardiopulmonary resuscitation ; cpr ; diagnosis ; posterior wall infarction ; hospitalized ; cardiac
H-1291	-0.4426549971103668	▁cardiac ▁arrest ▁; ▁cardio pul mon ary ▁res uscita tion ▁; ▁c PR ▁; ▁posterior ▁wall ▁in far ction ▁; ▁cardiac ▁centre
D-1291	-0.4426549971103668	cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
P-1291	-2.5265 -0.0943 -0.1901 -0.0673 -0.6506 -1.9447 -0.5289 -0.2319 -0.0531 -0.6200 -0.3140 -0.4276 -0.4967 -0.3825 -0.0127 -0.3425 -0.0224 -0.1526 -0.0987 -0.5045 -0.0979 -0.4127 -0.3304 -0.1212
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence ; hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorticoid receptor antagonists ; heart failure ; hf
H-1702	-0.5536038279533386	▁hyper kal emia ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁race ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁heart ▁failure ▁; HF
D-1702	-0.5536038279533386	hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
P-1702	-0.5566 -0.4081 -0.6308 -0.5131 -0.1888 -0.7495 -1.6549 -2.1457 -0.3243 -0.0258 -0.2423 -0.0161 -0.4819 -0.5348 -0.1058 -0.1596 -0.4360 -0.7200 -1.6874 -2.8815 -0.2810 -0.0337 -0.2921 -0.0331 -0.5360 -0.3811 -0.4275 -0.1448 -0.2204 -0.6171 -0.1822 -0.1033
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade ; evidence ; acp ; erythropoiesis-stimulating agents ; patients ; anemia ; congestive heart failure ; coronary heart disease
H-37	-0.8197714686393738	▁a CP ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease
D-37	-0.8197714686393738	aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
P-37	-3.4360 -2.6608 -0.6480 -0.6141 -0.4711 -1.3479 -0.7990 -2.9404 -0.1512 -0.5910 -0.0698 -0.9046 -1.1099 -0.4604 -0.8393 -0.1534 -0.2079 -0.0396 -0.5189 -2.0726 -0.4313 -0.0985 -0.1241 -0.0163 -1.5763 -0.6209 -0.4988 -0.2121 -0.1592
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients ; patients ; type 2 diabetes ; therapy ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; insulin
H-1831	-0.46359753608703613	▁diabetes ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁sul fon yl ure as ▁; ▁insulin ▁products
D-1831	-0.46359753608703613	diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin products
P-1831	-2.0015 -0.4974 -0.2104 -0.0070 -0.4668 -2.2432 -0.4274 -0.5280 -0.1075 -0.0912 -2.3191 -0.3119 -0.0898 -0.0155 -0.0477 -0.0875 -0.3338 -0.6434 -0.0268 -0.2354 -0.1754 -0.0273 -0.1615 -0.0563 -0.9969 -0.3029 -0.1054
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr ; scn5a ; ventricular systolic hf ; human induced pluripotent stem cell-derived cardiomyocytes ; hipsc-cms
H-1082	-0.420356422662735	▁u PR ▁; ▁s cn 5 a ▁; ▁vent ri cular ▁sy sto lic ▁ HF ▁tissu e ▁sample s ▁; ▁induc ed ▁pluri potent ▁stem ▁cell - der i ved ▁cardio my o cy tes ▁; hi PS c - CM s
D-1082	-0.420356422662735	uPR ; scn5a ; ventricular systolic HF tissue samples ; induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
P-1082	-3.2137 -1.7055 -0.2364 -0.3220 -0.2468 -0.4610 -0.1080 -0.4096 -0.1873 -2.8029 -0.3328 -0.0222 -0.0791 -0.0526 -0.5040 -0.6993 -0.7722 -0.1008 -0.1513 -0.1270 -0.2389 -0.8079 -0.0730 -0.0102 -0.0007 -0.0009 -0.1416 -0.0805 -0.0773 -0.4425 -0.2226 -0.0837 -0.8007 -0.6734 -0.0516 -0.0653 -0.4949 -0.5600 -0.5546 -0.3428 -0.0534 -0.1134 -0.0335 -0.3637 -0.0942
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory ; patients ; heart failure ; hf ; reduced ejection fraction ; renin-angiotensin system ; ras ; β-blockers ; all-cause mortality ; readmissions
H-175	-0.43456488847732544	▁heart ▁failure ▁; HF ▁; ▁e je ction ▁ fraction ▁; ▁r EF ▁; ▁re nin - angi oten sin ▁system ▁; RAS ▁; ▁β - block ers
D-175	-0.43456488847732544	heart failure ;HF ; ejection fraction ; rEF ; renin-angiotensin system ;RAS ; β-blockers
P-175	-4.0383 -0.1361 -0.3470 -0.2003 -0.2218 -0.1790 -0.2054 -0.0452 -0.4903 -0.0169 -0.3589 -1.2053 -0.2446 -0.1626 -0.0037 -0.4444 -0.0720 -0.0016 -0.1823 -0.7751 -0.0341 -0.5822 -0.1510 -0.5207 -0.0410 -0.0251 -0.1028 -0.1072 -2.0093 -0.1327
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial ; cochrane effective practice and organisation of care taxonomy
H-1847	-0.35019057989120483	▁co ch rane ▁Effective ▁practice ▁; ▁Organisation ▁of ▁Care ▁Tax ono my
D-1847	-0.35019057989120483	cochrane Effective practice ; Organisation of Care Taxonomy
P-1847	-0.3419 -0.3928 -0.0969 -0.1562 -0.2467 -0.3392 -0.7763 -0.0528 -0.2318 -0.7434 -0.0722 -0.8797 -0.4671 -0.1057
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd ; chf ; crf ; icc ; kappa coefficients
H-802	-0.6160953044891357	▁co PD ▁; ▁CHF ▁; ▁c RF ▁; ▁ICC ▁; ▁ka ppa ▁co ef fici ents
D-802	-0.6160953044891357	coPD ; CHF ; cRF ; ICC ; kappa coefficients
P-802	-1.1143 -1.9730 -0.4286 -0.0078 -0.3744 -0.3433 -1.4704 -0.4521 -0.6383 -1.0236 -0.0102 -0.0849 -0.1260 -0.0243 -0.0214 -2.6330 -0.2424 -0.1215
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients ; stable heart failure ; left ventricular ejection fraction ; training ; training
H-1913	-0.7620973587036133	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁; ▁aero bic ▁training ▁; ▁dynamic ▁resist ance ▁training ▁; ▁lower ▁lim bs
D-1913	-0.7620973587036133	heart failure ; left ventricular ejection ; aerobic training ; dynamic resistance training ; lower limbs
P-1913	-5.2367 -0.3053 -0.2915 -0.8033 -0.1130 -2.3732 -0.4520 -0.1429 -0.2198 -0.1020 -1.3868 -0.6482 -0.2821 -1.5585 -1.1751 -0.2758 -0.1957 -0.1154 -1.1885 -0.3857 -0.0803 -0.0135 -1.2192 -0.3588 -0.1290
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient ; implantable cardioverter-defibrillator ; implant ; change ; clinical
H-1865	-0.4091077148914337	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant
D-1865	-0.4091077148914337	implantable cardioverter-defibrillator deactivation ; implant
P-1865	-1.8399 -0.1135 -0.2939 -0.0394 -0.3262 -0.0912 -0.1186 -0.1072 -0.3784 -0.1265 -0.0646 -0.2632 -0.0758 -0.7758 -0.6757 -0.2593 -1.7127 -0.1021
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients ; heart failure ; myocardial function ; dilated ; contracting ; ventricles ; aetiologies
H-987	-0.8312861323356628	▁heart ▁failure ▁; ▁my o card ial ▁function ▁; ▁dil ated ▁poor ly ▁contract ing ▁vent ric les
D-987	-0.8312861323356628	heart failure ; myocardial function ; dilated poorly contracting ventricles
P-987	-4.0546 -0.2716 -0.2821 -0.8151 -0.4292 -0.5545 -1.3424 -0.1314 -0.4816 -3.3596 -0.0742 -2.2349 -0.1346 -0.0027 -0.0887 -0.0491 -0.8454 -1.0462 -0.3228 -0.1049
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients ; implantable cardioverter-defibrillator ; patients ; implantable cardioverter-defibrillator
H-1866	-0.421197772026062	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁shock s
D-1866	-0.421197772026062	implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
P-1866	-0.9677 -0.0997 -0.1740 -0.0518 -0.3987 -0.0910 -0.1587 -0.2855 -0.7002 -0.1895 -0.1085 -0.1867 -0.0906 -0.9987 -0.9872 -2.8599 -0.1482 -0.3031 -0.0544 -0.4711 -0.0886 -0.1053 -0.2661 -0.4240 -0.2867 -0.0691 -1.3279 -0.2148 -0.4084 -0.1197
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global left ventricular longitudinal systolic strain ; gls ; left ventricular ; cardiovascular ; atrial fibrillation
H-809	-0.41316166520118713	▁global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁g LS ▁; ▁left ▁vent ri cular ▁mechanic s ▁; ▁cardiovascular ▁; CV ▁; ▁at rial ▁fi bril lation ▁; AF
D-809	-0.41316166520118713	global left ventricular longitudinal systolic strain ; gLS ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
P-809	-0.6007 -0.5085 -0.0565 -1.7758 -0.2902 -0.0139 -0.1758 -0.0295 -0.0349 -0.1275 -0.0873 -0.0466 -0.4844 -0.0940 -0.8473 -0.2855 -1.7823 -0.0908 -2.1880 -0.3239 -0.6039 -0.0976 -0.2609 -0.0534 -0.3724 -0.0376 -0.2421 -1.5057 -0.0156 -0.5249 -0.0573 -0.1962 -0.3313 -0.4428 -0.1974 -0.0914
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad ; q65p ; murine ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type rad
H-1675	-0.6918845772743225	▁mouse ▁Rad ▁Q 65 p ▁; ▁mur ine ▁equivalent ▁; ▁human ▁Rad ▁Q 66 p ▁; ▁current s ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁channel s ▁; ▁wild - type ▁Rad
D-1675	-0.6918845772743225	mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
P-1675	-0.1415 -1.4079 -3.6897 -0.5315 -0.2983 -0.2498 -0.1386 -2.3311 -0.9239 -0.5923 -1.1911 -1.7967 -1.6515 -0.7247 -0.3155 -0.3213 -0.8877 -0.2164 -0.6249 -0.2867 -0.7016 -0.2222 -0.3233 -0.3546 -0.6526 -0.1101 -0.9132 -0.2121 -0.4087 -0.7424 -0.0432 -0.0108 -0.7802 -0.3319 -0.0879
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient ; mi ; hazard ratios ; hf
H-1108	-1.1004265546798706	▁MI ▁; ▁hazard ▁ratio s ▁; HF
D-1108	-1.1004265546798706	MI ; hazard ratios ;HF
P-1108	-0.9104 -1.3734 -0.7952 -0.0958 -0.5260 -0.4226 -5.4590 -0.1552 -0.1662
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare ; patients ; acute ; hospital ; hf ; ami ; pna
H-1693	-0.9070745706558228	▁Medica re ▁; ▁older ▁patients ▁; ▁a cute ▁care ▁hospital ▁; HF ▁; ▁ AMI ▁; ▁p NA
D-1693	-0.9070745706558228	Medicare ; older patients ; acute care hospital ;HF ; AMI ; pNA
P-1693	-1.0174 -0.0688 -0.7357 -2.8914 -0.3528 -0.8972 -0.4756 -0.0685 -0.6577 -0.2572 -0.3689 -2.2484 -0.3253 -2.0996 -2.2220 -0.4428 -0.5530 -2.0404 -0.2511 -0.1676
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular events ; baseline ; sst2 ; metoprolol succinate
H-404	-0.546103835105896	▁cardio vas cular ▁events ▁; ▁s st 2 ▁status ▁; ▁BB ▁dose ▁; ▁met o pro lol ▁suc cina te
D-404	-0.546103835105896	cardiovascular events ; sst2 status ; BB dose ; metoprolol succinate
P-404	-2.5885 -0.3798 -0.4881 -0.8269 -0.8879 -0.0187 -1.7562 -0.1295 -0.3982 -0.3920 -1.5174 -0.5800 -0.3230 -0.1764 -0.7307 -0.0633 -0.3302 -0.0422 -0.0350 -0.0570 -0.2223 -0.0709
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt ; nt-probnp ; aric ; hf ; aucs ; nris
H-289	-0.4352773427963257	▁c t n t ▁; ▁NT - pro b NP ▁; ▁a RIC ▁ HF ▁model ▁; AU c s ▁; ▁NR Is
D-289	-0.4352773427963257	ctnt ; NT-probNP ; aRIC HF model ;AUcs ; NRIs
P-289	-0.0110 -0.2410 -0.0185 -0.2857 -0.0921 -0.0518 -0.0609 -0.0242 -0.7849 -0.7180 -0.1392 -0.2270 -1.1556 -0.1916 -0.7932 -0.7289 -0.4536 -0.2652 -1.3313 -0.3891 -0.2357 -0.3102 -1.6763 -0.6115 -0.0855
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf ; hf with reduced ef ; hf with preserved ef ; change ; hf ; mi
H-1109	-1.0281398296356201	▁ HF ▁; ▁ HF ▁; ▁EF ▁; ▁ HF ▁; ▁EF ▁; ▁ HF ▁; ▁EF ▁; ▁ HF ▁; ▁mix ▁; ▁ HF ▁; ▁MI
D-1109	-1.0281398296356201	HF ; HF ; EF ; HF ; EF ; HF ; EF ; HF ; mix ; HF ; MI
P-1109	-0.9551 -0.5814 -0.4346 -2.9898 -0.3544 -0.4064 -0.6142 -0.2134 -1.4454 -0.6116 -0.3506 -4.1269 -0.3391 -1.4537 -0.5580 -0.4331 -3.6038 -0.3646 -1.1768 -1.2310 -0.4750 -3.7733 -0.9037 -0.6187 -0.8537 -0.3430 -0.1158 -0.3852 -0.1035
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl ; nyha-iiib ; phosphorylation ; phosphorylation ; hdl ; healthy
H-255	-0.6892125606536865	▁ec ▁; ▁HD L ▁; NY ha - III b ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁ phos phor y lation ▁; ▁e NOS - Th r ▁; ▁HD L
D-255	-0.6892125606536865	ec ; HDL ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDL
P-255	-0.8934 -0.3796 -1.7641 -3.5268 -0.2726 -1.0226 -0.5740 -0.1000 -0.1219 -0.0106 -0.4027 -0.1148 -0.2701 -1.4847 -1.9449 -0.1950 -0.3829 -0.1457 -0.0279 -0.0812 -0.1952 -1.0482 -0.2696 -0.4262 -2.2064 -1.7737 -0.1192 -0.3084 -0.2437 -0.0403 -0.0486 -1.2352 -0.0026 -0.5634 -0.6240 -2.8562 -0.3997 -0.1141
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol ; von willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
H-1118	-0.449981689453125	▁car vedi lol ▁; ▁Will e brand ▁factor ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1118	-0.449981689453125	carvedilol ; Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
P-1118	-0.1497 -0.1667 -0.2928 -0.9850 -3.8198 -0.3246 -0.1480 -0.1925 -0.3531 -0.1849 -0.8277 -0.0878 -0.4916 -0.7338 -0.4680 -0.1057 -0.2422 -0.4022 -0.9059 -0.0534 -0.0188 -0.1095 -0.1718 -0.0240 -0.3121 -0.1282
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart failure ; hf ; hypertensive heart disease ; hhd ; pathophysiology ; therapeutic ; hhd ; stable ; phenotypes
H-274	-0.4858866333961487	▁mouse ▁heart ▁failure ▁; HF ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁h HD ▁; ▁ therapeut ic ▁target s ▁; ▁h HD
D-274	-0.4858866333961487	mouse heart failure ;HF ; hypertensive heart disease ; hHD ; therapeutic targets ; hHD
P-274	-0.0333 -0.5024 -0.0949 -0.1958 -0.2848 -0.1344 -0.2911 -0.1409 -0.0606 -1.0562 -0.3270 -0.1441 -0.7679 -0.8443 -0.3318 -2.3875 -1.2178 -0.4778 -0.9484 -0.1413 -0.1612 -0.5598 -0.7793 -0.1991 -0.0655
2021-01-18 15:09:03 | INFO | fairseq.logging.progress_bar | :    101 / 142 wps=214
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic reticular ; protein ; phospholamban ; infarcted ; hearts ; metoprolol
H-1551	-0.4039536118507385	▁sar co plas mic ▁reti cular ▁; SR ▁; ▁ca (2 +) - up take ▁; ▁protein ▁content ▁; ▁SR ▁; ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁in far cted ▁heart s ▁; ▁met o pro lol
D-1551	-0.4039536118507385	sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein content ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
P-1551	-0.0328 -0.2823 -0.8175 -1.3363 -0.0048 -0.3133 -0.3576 -0.3433 -0.5940 -0.2091 -0.5840 -0.0050 -0.1150 -0.1756 -0.6032 -0.2834 -0.6504 -2.1333 -0.1729 -0.1020 -1.8317 -0.3480 -0.5727 -0.0110 -0.0576 -0.1177 -0.2139 -0.3196 -0.0709 -0.1572 -1.1257 -0.2958 -0.2696 -0.0621 -0.1582 -1.6200 -0.4235 -0.1423 -0.2618 -0.1136 -0.2032 -0.0729 -0.2956 -0.2371 -0.0804
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug ; patients ; chronic obstructive pulmonary disease ; copd ; chronic heart failure ; chf ; chronic renal failure ; crf
H-794	-0.7820859551429749	▁Time d ▁up ▁& ▁go ▁; ▁tu g ▁; ▁advanced ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; co PD ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁chronic ▁renal ▁failure ▁; cr f
D-794	-0.7820859551429749	Timed up & go ; tug ; advanced chronic obstructive pulmonary disease ;coPD ; chronic heart failure ;CHf ; chronic renal failure ;crf
P-794	-0.8043 -0.6429 -1.2057 -1.9436 -1.6251 -0.3951 -0.2815 -2.4023 -0.4052 -3.3106 -0.1426 -0.5212 -0.1896 -0.4901 -0.0046 -0.0992 -0.2213 -0.2113 -1.5692 -1.2645 -0.1571 -0.1257 -0.3728 -0.0923 -0.1532 -1.5865 -1.7211 -0.1065 -0.0805 -0.0496 -0.2725 -0.2280 -1.7233 -3.3614 -0.2435 -0.1512
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise ; intramuscular testosterone supplementation ; patients ; chronic heart failure ; chf ; testosterone ; collected ; health ; outcomes
H-1317	-0.8751674890518188	▁exercise ▁; ▁intra mus cular ▁testosteron e ▁supplement ation ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁low ▁testosteron e ▁status
D-1317	-0.8751674890518188	exercise ; intramuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status
P-1317	-5.7797 -0.2861 -1.1293 -0.1107 -0.1896 -0.0892 -0.0519 -1.1448 -0.6885 -0.3251 -5.0256 -0.7942 -0.1208 -0.2593 -1.1594 -1.1496 -0.1482 -0.5983 -0.0771 -0.0859 -0.0895 -0.7243 -0.1019
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients ; hospitalized ; hf ; preserved lvef ; mortality ; patients ; lvef ; lvef ; mortality
H-117	-0.719452977180481	▁ HF ▁; ▁LV EF ▁; ▁LV EF ▁; ▁LV EF
D-117	-0.719452977180481	HF ; LVEF ; LVEF ; LVEF
P-117	-2.5825 -0.4797 -0.3862 -0.3984 -0.3565 -0.4102 -0.8387 -0.3139 -0.8037 -0.4092 -0.2994 -1.9519 -0.1227
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls ; left ventricular ejection fraction ; lvef ; systolic mitral annulus velocity ; multivariate models
H-818	-0.45243531465530396	▁g LS ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF ▁; ▁sy sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁sa ▁; ▁CV
D-818	-0.45243531465530396	gLS ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; CV
P-818	-0.1655 -1.3147 -0.6171 -0.7676 -0.0631 -2.2504 -0.5216 -0.2786 -0.2767 -0.1747 -0.6726 -0.0339 -0.4213 -0.7019 -0.5667 -0.2007 -0.0129 -0.0583 -0.0822 -0.2522 -0.1409 -0.8637 -0.3381 -0.3880 -0.0464 -0.2834 -0.1133 -0.9399 -0.4405 -0.9462 -0.0927
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart failure ; hf ; plasma b-type natriuretic peptide ; bnp ; preserved ejection fraction ; ef ; hf
H-187	-0.6324211955070496	▁heart ▁failure ▁; HF ▁; ▁plasma b - type ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁e je ction ▁ fraction ▁; EF ▁; ▁ HF
D-187	-0.6324211955070496	heart failure ;HF ; plasmab-type natriuretic peptide ; bNP ; ejection fraction ;EF ; HF
P-187	-1.1757 -0.1554 -0.3021 -0.6520 -0.3341 -0.0744 -2.9163 -0.2459 -0.0105 -0.0453 -0.5321 -0.5714 -1.8945 -0.5698 -0.1399 -0.8629 -0.4780 -0.8140 -0.9351 -0.4011 -1.6939 -0.1441 -0.0319 -0.3081 -0.0059 -0.4389 -0.8845 -0.2640 -0.9853 -0.6487 -1.6319 -0.0901
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm ; telemonitoring ; implanted ; medical ; structured telephone support ; sts ; human-to-human contact ; hh ; human-to-machine interface
H-153	-0.5224714279174805	▁RM ▁; ▁home ▁tele monitor ing ▁; TM ▁; ▁implant ed ▁monitoring ▁devices ▁; ▁medical ▁support ▁; ▁telephone ▁support ▁; ▁s s ▁; ▁human - to - human ▁contact ▁; HH ▁; ▁human - to - machine ▁interface ▁; HM
D-153	-0.5224714279174805	RM ; home telemonitoring ;TM ; implanted monitoring devices ; medical support ; telephone support ; ss ; human-to-human contact ;HH ; human-to-machine interface ;HM
P-153	-0.6865 -0.7572 -1.4588 -0.9122 -0.2656 -0.1516 -0.5307 -1.5597 -0.8225 -0.0435 -0.1493 -0.0115 -0.3570 -0.7299 -1.4089 -1.4386 -0.5851 -1.3870 -0.7706 -0.3621 -2.4778 -0.6184 -0.3469 -1.2819 -0.0423 -0.0514 -0.2710 -0.0449 -0.0025 -0.4049 -0.1713 -0.2989 -0.0755 -0.0301 -0.0569 -0.0945 -0.0716 -0.0013 -0.3837 -0.4653 -0.2847 -0.0797
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox regression analysis ; patients ; beta-blockers ; beta-blockers ; primary endpoint ; therapy ; antitachycardia pacing ; atp ; shock therapy
H-859	-0.31358200311660767	▁co x ▁re gression ▁analysis ▁; ▁beta - block ers ▁; ▁beta - block ers ▁; ▁anti ta chy car dia ▁pa cing ▁; ▁a TP ▁; ▁shock ▁ therapy
D-859	-0.31358200311660767	cox regression analysis ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
P-859	-0.1081 -0.1618 -0.0444 -0.0155 -0.2612 -0.7041 -0.7749 -0.0916 -0.6535 -0.1251 -0.3460 -0.4299 -0.0903 -0.5218 -0.1494 -0.3617 -0.3099 -1.3075 -0.2261 -0.0403 -0.0249 -0.0051 -0.2511 -0.2087 -0.9922 -0.8203 -0.3704 -0.0442 -0.2973 -0.0259 -0.1666 -0.1049
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically ; legal ; decisions
H-1680	-0.9750882387161255	▁et h ically ▁; ▁pediatr ics ▁; ▁religious ▁belief s ▁; ▁life - s usta ining ▁treatment ▁; ▁legal ▁majority
D-1680	-0.9750882387161255	ethically ; pediatrics ; religious beliefs ; life-sustaining treatment ; legal majority
P-1680	-0.1574 -0.1600 -1.1960 -2.1217 -0.1452 -0.8441 -0.4148 -1.3913 -0.8573 -0.2017 -0.3303 -5.2334 -0.0410 -0.8053 -0.7510 -1.1325 -0.5647 -0.3951 -2.5006 -1.0556 -1.0702 -0.0826
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient ; prescribing ; medications ; medical
H-1122	-1.50494384765625	▁medication s ▁; ▁medical ▁records
D-1122	-1.50494384765625	medications ; medical records
P-1122	-5.0709 -0.3831 -1.1254 -1.7103 -0.1240 -2.0192 -0.1016
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost ; patient ; rhythm-control ; rate-control
H-1241	-0.777421772480011	▁cost ▁; ▁ rhythm - control ▁; ▁rate - control
D-1241	-0.777421772480011	cost ; rhythm-control ; rate-control
P-1241	-0.9470 -0.9347 -0.5668 -1.9885 -0.5005 -0.0409 -0.5090 -2.4164 -0.4242 -0.0500 -0.7222 -0.2288
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left ventricular ejection fraction ; egfr
H-393	-1.038358449935913	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁e G FR
D-393	-1.038358449935913	left ventricular ejection fraction ; eGFR
P-393	-4.4706 -0.1208 -1.9974 -0.3759 -0.3151 -0.4122 -0.2941 -1.3665 -0.0402 -0.8819 -0.4168 -3.4692 -0.6005 -0.5825 -0.2317
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf ; hazard ratios ; body mass index ; obese
H-1773	-0.4534137547016144	▁fit ▁; ▁un fit ▁; ▁c RF ▁; ▁hazard ▁ratio s ▁; ▁fit ▁; ▁un fit ▁; ▁over weight ▁body ▁mass ▁index ▁; ▁obes e ▁men
D-1773	-0.4534137547016144	fit ; unfit ; cRF ; hazard ratios ; fit ; unfit ; overweight body mass index ; obese men
P-1773	-0.0609 -0.6917 -0.0123 -0.1587 -0.2986 -0.1898 -0.4589 -0.7767 -2.1758 -0.0340 -0.7271 -0.4355 -1.2278 -0.2140 -0.0596 -0.1136 -0.9217 -0.3337 -0.1973 -1.7249 -0.0841 -0.0077 -0.5770 -0.4884 -0.1153 -0.3306 -0.1791 -0.1009
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary outcome ; patients ; crt ; hazard ratio ; confidence interval
H-852	-1.1727508306503296	▁c RT ▁; ▁hazard ▁ratio ▁; ▁95% ▁confidence ▁interval
D-852	-1.1727508306503296	cRT ; hazard ratio ; 95% confidence interval
P-852	-0.3314 -3.0886 -1.4869 -1.4727 -0.0573 -0.5958 -2.1728 -0.1343 -0.0374 -3.3978 -0.1252
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi ; blood urea nitrogen ; b-type natriuretic peptide ; new york heart association class ; diabetes ; atrial fibrillation ; all-cause hospitalization
H-382	-0.46142491698265076	▁ HF PSI ▁model ▁; ▁blood ▁u rea ▁nit rogen ▁; ▁na tri ure tic ▁pe pti de ▁; ▁New ▁York ▁Heart ▁association ▁class ▁; ▁diabetes ▁status ▁; ▁at rial ▁fi bril lation ▁; flu tter
D-382	-0.46142491698265076	HFPSI model ; blood urea nitrogen ; natriuretic peptide ; New York Heart association class ; diabetes status ; atrial fibrillation ;flutter
P-382	-1.2870 -0.8777 -1.3031 -1.2783 -0.1949 -0.1513 -0.1720 -0.5279 -0.1689 -0.0440 -0.2239 -0.3022 -0.7633 -0.6702 -1.5983 -0.5218 -0.1267 -0.6004 -0.1632 -0.1776 -0.2855 -1.5146 -0.3511 -1.1568 -0.0844 -0.0299 -0.3723 -0.1383 -0.4765 -0.0315 -0.1288 -0.0566 -0.0896 -1.0966 -0.1100 -0.0263 -0.3526 -0.0799
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare patient safety monitoring system ; mpsms ; adverse event ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
H-2	-0.4397527575492859	▁Medica re ▁Patient ▁Safety ▁monitoring ▁system ▁; ▁m SMS ▁; ▁advers e ▁event ▁rates ▁; ▁patients ▁hospital ized ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁pneu monia ▁; ▁surgery
D-2	-0.4397527575492859	Medicare Patient Safety monitoring system ; mSMS ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
P-2	-0.0859 -0.0166 -0.2843 -0.4964 -0.1586 -0.5035 -0.4853 -0.5627 -1.5457 -0.5775 -0.9826 -0.0398 -0.2548 -1.5039 -0.6332 -1.2951 -0.9957 -0.1905 -1.5186 -0.1448 -0.0081 -0.9062 -0.4304 -0.1937 -0.5652 -0.0190 -0.1857 -0.1123 -0.3047 -0.0193 -0.2326 -1.2957 -0.3175 -0.0581 -0.1738 -0.0333 -0.1695 -0.4335 -0.0431 -0.1705 -0.0823
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells ; functional capacity ; cells ; peak vo2
H-127	-1.02021324634552	▁cd 34 ▁; ve g FR 2 ▁; ▁cell s ▁; ▁functional ▁capacity ▁; ▁10- cell ▁; ▁cd 34 ▁; ve g FR 2 ▁; ▁cell s ▁; ▁VO 2
D-127	-1.02021324634552	cd34 ;vegFR2 ; cells ; functional capacity ; 10-cell ; cd34 ;vegFR2 ; cells ; VO2
P-127	-0.8366 -0.4002 -2.7067 -0.6156 -1.7391 -1.0511 -0.3444 -2.1208 -0.6447 -0.1775 -0.4943 -0.7462 -0.8995 -0.2178 -4.0057 -0.1911 -0.3550 -1.9867 -0.6892 -2.5746 -1.2455 -1.7160 -1.2150 -0.2086 -1.8710 -0.1676 -0.1313 -0.3821 -2.5165 -0.1249 -0.1733 -0.0983
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients ; heart failure and reduced ejection fraction ; patient
H-659	-0.9272022247314453	▁treatment ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-659	-0.9272022247314453	treatment ; outpatients ; heart failure ; reduced ejection fraction
P-659	-7.0139 -0.5498 -3.3333 -0.0112 -0.0911 -1.6970 -0.5850 -0.0719 -0.2176 -0.6934 -0.0163 -0.0260 -0.1143 -0.0439 -0.3226 -0.0138 -1.7760 -0.1125
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality rate ; patients ; hf ; hf ; case-fatality rate
H-1311	-0.7521795034408569	▁concurrent ▁ HF ▁; ▁concurrent ▁ HF
D-1311	-0.7521795034408569	concurrent HF ; concurrent HF
P-1311	-1.6001 -0.3957 -0.3088 -0.8581 -0.0709 -0.5147 -0.7141 -2.1461 -0.1611
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame ; chf ; anthracycline ; stem cell ; allogeneic ; autologous ; follow-up
H-1453	-0.5479469299316406	▁CHF ▁; ▁an thra cycli ne ▁exposure ▁; ▁stem ▁cell ▁source ▁; allo gene ic
D-1453	-0.5479469299316406	CHF ; anthracycline exposure ; stem cell source ;allogeneic
P-1453	-0.1447 -0.9890 -3.1761 -0.2040 -0.2988 -0.7852 -0.2848 -0.3044 -0.0131 -0.2383 -0.1381 -0.6643 -0.0068 -0.2016 -0.1147 -1.6621 -0.0889
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting tension ; fpassive ; muscle ; kcl-ki ; titin ; titin ; extracellular matrix ; fpassive
H-765	-0.4795420467853546	▁rest ing ▁tension ▁; ▁f pass ive - sar com ere ▁length ▁; ▁muscle ▁strip s ▁; ▁k c l - KI ▁treatment ▁; ▁titi n ▁; ▁extra cel lular ▁matri x ▁; ▁f pass ive
D-765	-0.4795420467853546	resting tension ; fpassive-sarcomere length ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; fpassive
P-765	-3.5222 -0.1049 -0.0535 -0.2967 -2.5530 -0.1206 -0.1288 -3.1132 -0.1298 -0.0739 -0.0649 -0.4624 -1.0235 -0.7208 -0.1855 -0.0946 -0.5394 -1.3237 -0.4886 -0.1270 -0.0227 -0.0233 -0.2600 -0.4297 -0.0673 -0.0381 -0.2739 -0.0502 -0.0825 -0.0270 -0.0035 -0.0462 -0.6599 -0.7793 -0.0429 -0.1032 -0.1204 -0.0654
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart failure ; myocardial infarction ; mi ; β-adrenoceptor blockade ; infarcted ; metoprolol
H-1547	-0.47669947147369385	▁heart ▁failure ▁; ▁my o card ial ▁in far ction ▁; MI ▁; ▁β - ad re no cept or ▁block ade ▁; ▁in far cted ▁rat s ▁; ▁met o pro lol
D-1547	-0.47669947147369385	heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
P-1547	-4.0471 -0.2098 -0.3337 -0.6185 -0.5450 -0.3755 -1.0760 -0.0649 -0.3322 -0.1237 -0.3189 -2.9995 -0.2752 -0.0866 -0.0193 -0.0392 -0.1633 -0.3125 -0.4441 -0.1048 -0.1252 -0.1439 -0.3253 -0.0395 -0.1307 -1.4930 -0.2125 -0.0906 -0.4604 -0.0478 -0.3217 -0.0682 -0.3016 -0.3540 -0.0804
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training ; exercise capacity ; muscle ; quality of life ; cardiac ; nt-probnp ; inflammatory ; il6 ; hscrp ; biomarkers
H-1922	-0.5701887607574463	▁aero bic ▁; ▁resist ance ▁; ▁exercise ▁capacity ▁; ▁muscle ▁strength ▁; ▁cardiac ▁; NT - pro b NP ▁; ▁infla mma tory ▁; IL 6 ▁; ▁h s cr p
D-1922	-0.5701887607574463	aerobic ; resistance ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ;IL6 ; hscrp
P-1922	-0.1651 -0.3673 -0.6779 -0.0638 -0.1254 -1.9987 -4.6499 -0.9615 -0.2226 -0.3124 -0.3348 -0.2507 -0.1328 -0.3386 -2.5424 -0.0245 -0.9093 -0.7499 -0.5707 -0.3430 -0.1342 -0.3607 -0.0796 -0.2149 -0.8046 -0.1998 -0.3183 -0.0050 -0.0168 -0.0714 -0.3716 -0.3743 -0.1238
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital ; readmission ; all-cause readmission ; acr ; potential preventable readmission ; ppr ; medicare ; medicaid ; readmission ; cms
H-135	-0.6576519012451172	▁read mission ▁; ▁a cr ▁; ▁Potential ▁Prev en table ▁Read mission ▁; ▁p PR ▁; ▁Center s ▁for ▁Medica re ▁; ▁Medica id ▁30- day ▁read mission ▁; ▁c ms
D-135	-0.6576519012451172	readmission ; acr ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid 30-day readmission ; cms
P-135	-3.8373 -1.4831 -1.1049 -0.5847 -0.5324 -0.2901 -0.5878 -1.1476 -0.1529 -0.4943 -0.7911 -0.4381 -0.2096 -0.0791 -0.7970 -0.2875 -0.3477 -0.6546 -0.4563 -0.0168 -0.0090 -1.2117 -0.0180 -0.0071 -1.7296 -0.1748 -1.3683 -1.1372 -0.2122 -0.2940 -0.7884 -0.3224 -0.1370
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive heart failure ; correlation coefficient
H-218	-1.1574019193649292	▁con ges tive ▁heart ▁failure ▁visit s ▁; ▁ED
D-218	-1.1574019193649292	congestive heart failure visits ; ED
P-218	-2.7872 -0.3930 -1.2140 -0.8932 -0.2056 -3.3432 -0.1497 -0.6423 -0.9106 -2.0831 -0.1094
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise ; rehabilitation ; walking ; minnesota quality of life ; exercise
H-1882	-2.0623252391815186	▁walking ▁; ▁Minnesota ▁; ▁quality ▁of ▁life
D-1882	-2.0623252391815186	walking ; Minnesota ; quality of life
P-1882	-6.6886 -0.7944 -2.4846 -2.2363 -3.0015 -1.2279 -1.0382 -0.9726 -0.1169
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine vasopressin ; avp ; physiologic ; chf ; avp ; vasopressin receptor antagonist ; therapy ; therapeutic ; chf
H-637	-0.40526196360588074	▁argi nine ▁vaso press in ▁; ▁a VP ▁; ▁CHF ▁; ▁a VP ▁; ▁vaso press in ▁receptor ▁anta gon ist ▁ therapy ▁; ▁CHF
D-637	-0.40526196360588074	arginine vasopressin ; aVP ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
P-637	-0.3027 -0.5165 -0.0874 -0.1697 -1.0977 -0.5867 -0.6381 -0.5008 -0.3744 -0.3540 -0.7840 -1.1993 -1.0823 -0.3380 -0.5467 -0.1282 -0.4390 -0.0220 -0.0657 -0.0017 -0.2327 -0.5921 -0.0260 -0.4296 -0.0795 -0.2155 -0.1318
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; β-blockers ; patients ; heart failure and reduced ejection fraction
H-661	-0.5435116291046143	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-661	-0.5435116291046143	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
P-661	-6.5581 -1.8327 -0.1586 -1.3526 -0.4581 -0.0342 -0.0937 -0.3178 -0.1287 -0.0623 -0.0714 -0.5679 -0.8111 -0.1240 -0.1295 -0.7156 -0.0127 -0.2572 -0.0903 -0.2823 -0.0418 -0.0413 -0.2397 -0.1285 -0.3785 -2.3932 -0.2456 -0.3064 -0.0624 -0.1065 -0.1422 -0.5176 -0.0167 -0.2386 -0.1051
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies ; medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; risk stratification ; patient ; heart failure ; therapies ; disease
H-1205	-0.3636792302131653	▁medication ▁; ▁physical ▁ therapy ▁; ▁implant able ▁de fi br illa tors ▁; ▁circula tory ▁support ▁; ▁transplant ation ▁; ▁heart ▁failure
D-1205	-0.3636792302131653	medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure
P-1205	-2.1931 -0.2569 -0.0516 -0.3318 -0.0235 -0.4583 -0.3147 -0.0387 -0.0419 -0.0597 -0.3862 -0.1511 -0.2735 -0.4094 -0.0004 -0.0789 -0.1551 -0.3625 -0.0963 -0.2425 -0.3276 -1.2998 -0.0937 -1.3266 -0.1181
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary approaches to stop hypertension ; dash ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hfpef
H-918	-0.41156643629074097	▁so dium - re strict ed ▁dieta ry ▁; ▁hyper tension ▁die t ▁; DAS h ▁; ▁s rd ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁h FP EF
D-918	-0.41156643629074097	sodium-restricted dietary ; hypertension diet ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hFPEF
P-918	-0.0360 -0.0260 -0.0151 -0.0390 -0.0463 -0.0312 -1.0027 -1.5897 -1.4261 -1.8451 -0.0328 -0.9483 -0.0815 -0.2029 -0.0815 -0.0904 -0.1483 -0.9334 -0.9733 -0.2733 -0.1696 -0.0272 -2.1054 -0.1046 -0.0164 -0.0329 -0.0306 -0.0797 -0.2467 -0.0733 -0.2109 -0.0514 -0.2074 -0.0209 -2.0318 -0.2079 -0.1855 -0.0664 -0.0252 -0.0373 -0.3601 -0.1825 -0.2892 -0.0990 -0.0352 -1.7491 -1.1246 -0.6713 -0.2430 -0.0705
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right ventricular pacing ; gene expressions ; bax ; bcl-2 ; caspase-3 ; rtq-pcr ; interventricular septum ; biopsies ; heart failure
H-166	-0.33874690532684326	▁right ▁vent ri cular ▁pa cing ▁; ▁Bax ▁; ▁b cl -2 ▁; ▁Cas pas e -3 ▁; ▁RT q - ▁pc r ▁; ▁interven tri cular ▁sept um ▁bio psi es ▁; ▁beag le ▁dog s ▁; ▁heart ▁failure
D-166	-0.33874690532684326	right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq- pcr ; interventricular septum biopsies ; beagle dogs ; heart failure
P-166	-3.7213 -0.0430 -1.5028 -0.1846 -0.0122 -0.2817 -0.3509 -0.2043 -0.2101 -0.1550 -0.2882 -0.2034 -0.2113 -0.0532 -0.0292 -0.0404 -0.1038 -0.3257 -0.3233 -1.6416 -0.0563 -0.4993 -0.0449 -0.3334 -0.0077 -1.0220 -0.1251 -0.0331 -0.0144 -0.0110 -0.0390 -0.1548 -0.2962 -0.0232 -0.0255 -0.2620 -0.0703 -0.6014 -0.3009 -0.1791 -0.1652 -0.0769
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; bax ; caspase 3 ; expression
H-961	-0.35136711597442627	▁Rat s ▁; ▁heart s ▁; ▁cas pas e -3 ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁cy to ch rom e ▁c ▁; ▁b cl 2 ▁; ▁Bax ▁; ▁cas pas e ▁3 ▁expression
D-961	-0.35136711597442627	Rats ; hearts ; caspase-3 ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
P-961	-0.7478 -0.1312 -0.4019 -3.1727 -0.1231 -0.3439 -0.7117 -0.0474 -0.3411 -0.2073 -1.8479 -0.4073 -0.0363 -0.2407 -0.1932 -0.8302 -0.3708 -0.0493 -0.0189 -1.0178 -0.0229 -0.1601 -0.0372 -0.3418 -0.1355 -0.0621 -0.1784 -0.0019 -0.0663 -0.6845 -0.4462 -0.1019 -0.0595 -0.0421 -0.1051 -0.0018 -0.1071 -0.0526 -0.0616 -0.1567 -1.0754 -0.0983 -0.1377 -0.0827
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol ; carvedilol ; sympathetic activity ; von willebrand factor
H-1119	-0.5534680485725403	▁met o pro lol ▁; ▁car vedi lol ▁; ▁sympa the tic ▁activity ▁; ▁von ▁Will e brand ▁factor ▁; ▁ar g 16 ▁; ▁g l n 27 ▁; ▁g ly 16
D-1119	-0.5534680485725403	metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor ; arg16 ; gln27 ; gly16
P-1119	-0.0905 -0.7099 -0.0297 -0.2803 -0.4322 -0.0053 -0.4471 -0.3157 -0.5777 -0.1081 -0.7631 -0.9756 -1.0516 -0.4024 -1.1448 -1.1014 -0.1161 -0.1948 -0.1081 -1.4460 -0.3554 -0.0887 -0.3399 -1.2599 -0.3698 -1.0863 -0.0177 -0.5069 -0.3986 -0.2407 -0.4197 -0.1745 -3.1634 -0.0961
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute hf ; relax-ahf ; astronaut ; pronto ; patient ; patients ; end points
H-1017	-0.5771758556365967	▁a cute ▁ HF ▁; ▁RELA x - a HF ▁; ▁ AST RON AUT ▁; ▁PR ONTO ▁; ▁patient ▁en roll ment
D-1017	-0.5771758556365967	acute HF ; RELAx-aHF ; ASTRONAUT ; PRONTO ; patient enrollment
P-1017	-0.2679 -0.0971 -0.3821 -0.4220 -0.4242 -0.3679 -1.2879 -0.0253 -0.2445 -1.5264 -0.1316 -1.8650 -1.7359 -0.4138 -0.0461 -0.1447 -1.0071 -0.0201 -1.5974 -0.6037 -0.0187 -0.2910 -0.4285 -0.9770 -0.1036
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized ; hf ; international classification of diseases ; clinical ; principal ; discharge ; diagnosis
H-1832	-0.38710373640060425	▁hospital ized ▁ HF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision ▁; ▁Clinic al ▁Modifica tion ▁code s ▁; ▁dis charge
D-1832	-0.38710373640060425	hospitalized HF ; international Classification of Diseases ; Ninth revision ; Clinical Modification codes ; discharge
P-1832	-2.3319 -0.1437 -0.5706 -0.5943 -0.3592 -0.2220 -0.1366 -0.0541 -0.0732 -0.0611 -0.0293 -0.4167 -0.0171 -0.0084 -0.8703 -0.0764 -0.3700 -0.6761 -0.0050 -0.3374 -0.2345 -0.0373 -0.1304 -0.7033 -1.1382 -0.1037 -1.0405 -0.0977
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
H-1959	-0.5843150615692139	▁Pul mon ary ▁cap illa ry ▁we dge ▁pressure ▁; ▁h g ▁; SD ▁; ▁h g ▁; ▁right ▁at rial ▁pressure ▁; ▁pulmonar y ▁arterial ▁pressure ▁; ▁pulmonar y ▁resist ance
D-1959	-0.5843150615692139	Pulmonary capillary wedge pressure ; hg ;SD ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
P-1959	-1.1133 -2.0927 -0.8137 -0.5078 -0.2609 -0.5357 -0.1576 -0.1947 -0.8361 -0.4255 -1.9452 -0.2399 -0.3233 -2.1543 -0.8060 -2.3822 -0.1346 -0.2609 -0.2099 -1.0136 -0.1910 -0.7035 -0.2455 -0.0160 -0.0946 -0.0149 -0.7802 -0.3497 -0.0067 -0.2727 -0.2494 -0.1690 -0.2695 -0.0958
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad ; q65p ; movement ; wild-type rad ; q65p ; l-type channel ; rgk proteins
H-1676	-0.7144280672073364	▁Rad ▁; ▁Q 65 p ▁; ▁wild - type ▁Rad ▁; ▁Q 65 p ▁substitut ion ▁; ▁l - type ▁channel ▁inhibi tion ▁; ▁r GK ▁protein s
D-1676	-0.7144280672073364	Rad ; Q65p ; wild-type Rad ; Q65p substitution ; l-type channel inhibition ; rGK proteins
P-1676	-0.9678 -1.1087 -2.6718 -0.5776 -0.4401 -0.4080 -5.0701 -0.0312 -0.0071 -1.3524 -0.2630 -1.8883 -0.1939 -0.4873 -2.8958 -0.0312 -0.3093 -0.3972 -0.0475 -0.0070 -0.0624 -0.0854 -0.6018 -0.2850 -0.4117 -0.1773 -0.1896 -0.1393 -0.2439 -0.0811
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 ; heart failure ; proteomics ; actin cytoskeleton ; ss20 ; mitochondrial ; metabolic pathways
H-876	-0.5426601767539978	▁heart ▁failure ▁; ▁prote o mics ▁; ▁act in ▁cy tos kelet on ▁path ways ▁; ▁SS 20 ▁; ▁mito cho ndri al ▁; ▁metabol ic ▁path ways
D-876	-0.5426601767539978	heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
P-876	-5.2839 -0.4663 -0.4046 -0.7692 -1.1732 -0.0222 -0.8334 -0.3667 -0.2308 -0.3701 -0.6094 -0.0717 -0.1976 -0.6643 -0.0959 -0.7514 -0.3120 -0.3819 -0.8842 -0.0245 -0.5478 -0.0850 -0.0325 -0.6296 -0.0336 -0.1570 -0.2846 -0.1312 -0.3565 -0.1085
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic insufficiency ; mechanical circulatory support ; continuous flow ; left ventricular assist devices ; lvads ; pulsatile devices
H-542	-0.31280267238616943	▁a or tic ▁insu ffi cie ncy ▁; AI ▁; ▁mechanic al ▁circula tory ▁support ▁; ▁continuo us ▁flow ▁; CF ▁; ▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁pulsa tile ▁devices
D-542	-0.31280267238616943	aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
P-542	-0.2006 -0.1582 -1.3623 -0.0512 -0.2039 -1.6287 -0.1123 -0.3873 -0.7401 -0.5365 -0.2856 -0.0232 -0.0034 -0.2319 -0.2559 -0.4058 -0.0445 -0.2732 -0.1647 -0.2052 -0.5611 -0.2340 -0.0650 -0.0420 -1.3723 -0.1260 -0.3252 -0.1637 -0.2473 -0.0725 -0.0083 -0.2239 -0.4307 -0.0313 -0.0432 -0.1442 -0.4131 -0.1085
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration ; pyridostigmine ; coronary artery ligation ; cardiac ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hf
H-1145	-0.2705315351486206	▁py rido stig mine ▁; ▁corona ry ▁arter y ▁liga tion ▁; ▁cardiac ▁va gal ▁; ▁sympa the tic ▁tone ▁; ▁cardiac ▁remodel ing ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ HF
D-1145	-0.2705315351486206	pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
P-1145	-0.0779 -0.0176 -0.0084 -0.2492 -0.4581 -0.0461 -0.8142 -0.0172 -0.2713 -0.0999 -0.9690 -0.3007 -0.2423 -0.0065 -0.0320 -0.2309 -0.0249 -0.5176 -0.5788 -0.0386 -0.2115 -0.0852 -0.0322 -0.0799 -0.1802 -0.0859 -0.0415 -1.4540 -0.3327 -0.0375 -0.1751 -0.1998 -1.1392 -0.3374 -0.2785 -0.0671
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge ; patients ; follow-up ; physician ; physician
H-1418	-1.2002592086791992	▁follow - up
D-1418	-1.2002592086791992	follow-up
P-1418	-3.0750 -0.4047 -0.0699 -2.3286 -0.1230
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life expectancy ; heart failure ; patients ; disease ; terminal heart failure
H-1665	-0.9199976325035095	▁heart ▁failure ▁; ▁re frac tory ▁; ▁terminal ▁heart ▁failure
D-1665	-0.9199976325035095	heart failure ; refractory ; terminal heart failure
P-1665	-4.9058 -0.2247 -0.3350 -3.0000 -0.0758 -0.1862 -0.5277 -0.2082 -1.1219 -0.1770 -0.1565 -0.1213
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart failure ; discharges ; university of connecticut health center ; patients ; follow-up
H-723	-0.7974147200584412	▁heart ▁failure ▁dis charge s ▁; ▁University ▁of ▁Connect i cut ▁health ▁Center
D-723	-0.7974147200584412	heart failure discharges ; University of Connecticut health Center
P-723	-3.8332 -0.1583 -1.2610 -0.0448 -0.1731 -0.3021 -1.3706 -0.0445 -0.9602 -0.0334 -0.0850 -0.9490 -0.6840 -1.9706 -0.0913
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes ; patients ; new york heart association ; nyha ; heart failure ; eplerenone ; placebo ; heart failure ; medicines ; emphasis-hf
H-1229	-0.6923314929008484	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁Class ▁II ▁Heart ▁Fail ure ▁; ▁e pler en one ▁; ▁Place bo ▁; ▁Standard ▁Heart ▁Fail ure ▁Medicine s ▁; EMP ha SIS - HF ▁Study
D-1229	-0.6923314929008484	New York Heart association ;NYha ; Class II Heart Failure ; eplerenone ; Placebo ; Standard Heart Failure Medicines ;EMPhaSIS-HF Study
P-1229	-2.6892 -1.0718 -2.8460 -0.3568 -0.1580 -0.9881 -0.9915 -0.4475 -1.3108 -0.2389 -0.7313 -0.1919 -1.0303 -0.2591 -0.4246 -0.0275 -0.1092 -0.2312 -0.1185 -0.4276 -0.0058 -0.1858 -1.5342 -0.5457 -0.1239 -1.1279 -0.0773 -0.0703 -0.1439 -0.6568 -2.6112 -1.6855 -0.0783 -0.4253 -1.0298 -0.5340 -0.1308
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; ivc occlusion ; bivp ; ste ; rs
H-324	-0.43875014781951904	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁base ▁; ▁mid pap illa ry ▁; ▁ap ex ▁; ▁base line ▁; ▁IV c ▁oc clusi on ▁; ▁Bi VP ▁; ▁ STE ▁analysis ▁; ▁twist ▁; ▁bas al ▁rota tions ▁; ▁CS ▁; ▁RS
D-324	-0.43875014781951904	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; IVc occlusion ; BiVP ; STE analysis ; twist ; basal rotations ; CS ; RS
P-324	-0.6774 -0.0823 -0.1094 -0.5142 -0.0090 -0.4224 -0.4347 -0.4614 -0.0748 -1.5850 -0.0901 -0.3172 -0.2767 -0.1647 -0.0859 -0.1015 -0.4947 -0.3364 -0.6445 -0.1977 -0.6042 -3.3734 -0.0357 -0.2544 -0.0857 -0.7422 -0.0036 -0.0037 -0.1251 -0.2647 -0.5151 -0.2505 -0.6177 -2.4956 -1.7727 -0.6217 -0.3308 -0.2375 -0.3131 -0.6219 -0.0072 -0.0044 -0.0395 -0.1903 -0.1616 -0.2249 -0.0230 -0.4262 -0.0724
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence ; drugs ; drugs ; raas ; renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
H-1490	-0.29363834857940674	▁drugs ▁; ▁RA as ▁; ▁direct ▁re nin ▁inhibi tors ▁; ▁neutral ▁en dop ep tida se ▁inhibi tors ▁; ▁vaso pe pti das e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers
D-1490	-0.29363834857940674	drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
P-1490	-0.4060 -0.3512 -0.2350 -0.2887 -0.2930 -0.0079 -0.0205 -1.6875 -0.0833 -0.1437 -0.3674 -0.1041 -0.0166 -0.2154 -2.1167 -0.0093 -0.0258 -0.0182 -0.1761 -0.2799 -0.0078 -0.2307 -0.1248 -1.1580 -0.0571 -0.0382 -0.2409 -0.2838 -0.3409 -0.2445 -0.0653 -0.3979 -0.0060 -0.2262 -0.0804 -0.3793 -0.1366
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute heart failure ; hf ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
H-1015	-0.33141031861305237	▁a cute ▁heart ▁failure ▁; HF ▁; ▁ pharma c ologic ▁studies ▁; ▁calci um - sensi t izing ▁agents ▁; ▁en do the lin ▁; ▁vaso press in ▁; ▁ad enos ine
D-1015	-0.33141031861305237	acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
P-1015	-0.3936 -0.0866 -0.6266 -0.1211 -0.3250 -0.3817 -0.2771 -0.5710 -0.4645 -0.0973 -0.1171 -0.9409 -0.4360 -0.4677 -0.0144 -0.0726 -0.0721 -1.7308 -0.0219 -0.3815 -0.2937 -0.1572 -0.0514 -0.2008 -0.9953 -0.2178 -0.0011 -0.0234 -0.2998 -0.2421 -0.1001 -0.0410 -0.9952 -0.2760 -0.1052
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in vivo ; hf ; phenylephrine ; haemodynamic ; surgical ; transverse aortic constriction ; tac ; jq1 ; pathological ; cardiac hypertrophy
H-1047	-0.5297508835792542	▁ HF ▁; ▁ phen yle ph rine ▁; ▁ha emo dynamic ▁stress ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁j q 1 ▁; ▁cardiac ▁hyper trop hy
D-1047	-0.5297508835792542	HF ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
P-1047	-2.4737 -0.5330 -0.5398 -1.3993 -1.2328 -0.5471 -0.1334 -0.1527 -0.2044 -0.0034 -0.0762 -0.0027 -0.1978 -0.1274 -0.5889 -0.4815 -0.0687 -0.1315 -1.0858 -0.0594 -1.2880 -0.0603 -0.3145 -0.2294 -0.5406 -0.2862 -1.0500 -0.8882 -0.6717 -0.2989 -0.5037 -0.0273 -2.0961 -0.1807 -0.0662
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; fontan
H-1502	-0.39387282729148865	▁mus cle ▁aero bic ▁capacity ▁; ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis ▁; ▁Font an ▁adults
D-1502	-0.39387282729148865	muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan adults
P-1502	-0.7173 -0.3295 -0.1610 -0.2372 -0.4996 -0.3409 -0.1785 -0.0240 -0.1098 -0.5236 -0.2483 -0.0365 -0.3156 -0.6401 -1.4811 -0.0378 -0.0759 -0.8288 -1.0359 -0.4219 -0.1429 -0.0370 -1.0407 -0.2992 -0.0836
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
H-1117	-0.5663401484489441	▁i i - mi BG ▁cardiac ▁was hout ▁; ▁car vedi lol ▁; ▁met o pro lol ▁treatment ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1117	-0.5663401484489441	ii-miBG cardiac washout ; carvedilol ; metoprolol treatment ; β2-adrenergic receptor haplotype
P-1117	-0.1000 -1.2818 -0.3279 -0.2864 -3.1830 -0.9363 -3.0339 -0.8853 -0.4478 -0.0407 -0.1747 -0.2137 -0.5310 -0.0773 -0.8064 -0.0841 -0.4015 -1.3858 -0.6296 -0.3022 -0.1320 -0.1810 -0.3755 -0.8264 -0.0634 -0.0466 -0.1154 -0.1864 -0.0222 -0.3365 -0.1418
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute myocardial infarction ; ami ; incidence ; deaths ; heart failure ; hf ; ami
H-1306	-0.7162458300590515	▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁death s ▁; ▁heart ▁failure ▁; HF ▁; ▁ AMI
D-1306	-0.7162458300590515	acute myocardial infarction ;AMI ; deaths ; heart failure ;HF ; AMI
P-1306	-3.5338 -0.0794 -1.3189 -0.4690 -0.3019 -0.8088 -0.0438 -0.2407 -0.1662 -0.4448 -0.7733 -0.3704 -3.4522 -0.3654 -0.3955 -0.6062 -0.0875 -0.2120 -0.4640 -0.2066 -2.0647 -0.4424 -0.2287 -0.1136
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; cardiac metabolic gene expression ; atp
H-655	-0.5462058782577515	▁h - d ko ▁; ▁vent ri cular ▁mass ▁; ▁cardiac ▁apo pto sis ▁; ▁fibro sis ▁; ▁Akt ▁; for k head ▁box ▁; ▁o -1 ▁signal ing ▁; ▁cardiac ▁metabol ic ▁gene ▁expression ▁; ▁ATP
D-655	-0.5462058782577515	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ;forkhead box ; o-1 signaling ; cardiac metabolic gene expression ; ATP
P-655	-1.4188 -0.2535 -0.3527 -0.7218 -0.4866 -0.1803 -2.3900 -0.6079 -0.1740 -0.1201 -0.2237 -0.1388 -0.1843 -0.8592 -0.3946 -0.0037 -0.1258 -0.3740 -0.2586 -3.4264 -0.7101 -0.1144 -1.1187 -0.1166 -0.7870 -0.3762 -1.0390 -0.9135 -0.2017 -0.2294 -0.0848 -0.0181 -0.1031 -0.7822 -0.1740 -0.1678 -0.2569 -1.3101 -0.1034
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck stent ; implanted ; lad ; circumflex artery ; lcx ; lcx ; lad
H-505	-0.3983543813228607	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁; LAD ▁; ▁proxima l ▁circum flex ▁arter y ▁; LC x ▁; ▁proxima l ▁ LC x ▁; ▁mid ▁ LAD ▁; ▁pig s
D-505	-0.3983543813228607	bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCx ; proximal LCx ; mid LAD ; pigs
P-505	-0.1443 -0.1136 -0.0180 -0.0382 -0.1240 -0.5856 -1.4995 -0.1259 -0.2494 -0.1707 -0.0579 -0.0337 -0.3445 -0.1522 -0.3427 -0.0460 -0.1571 -0.0143 -0.0230 -0.0204 -0.2563 -0.5264 -1.1423 -2.0896 -0.2906 -0.1748 -0.0979 -0.2109 -0.2091 -1.3696 -0.3681 -2.2445 -0.2123 -0.1472 -0.9951 -0.6085 -0.0737 -0.1637 -0.0941
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized ; heart failure ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
H-1827	-0.5352416634559631	▁post marketing ▁; ▁hospital ized ▁heart ▁failure ▁; ▁h HF ▁; ▁di pe pti dy l ▁pep tida se -4 ▁; ▁d PP -4 ▁; ▁inhibi tors ▁; ▁anti hy per gly ce mic ▁agents
D-1827	-0.5352416634559631	postmarketing ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dPP-4 ; inhibitors ; antihyperglycemic agents
P-1827	-1.8544 -0.2240 -0.5787 -2.1431 -0.1599 -0.8074 -0.2224 -0.2787 -0.3343 -0.8826 -0.1803 -0.0948 -0.0241 -0.0712 -3.9551 -1.9551 -0.0035 -0.0373 -0.2304 -0.0604 -0.3910 -0.0890 -0.9479 -0.0636 -0.5723 -0.4033 -0.2108 -0.3255 -0.0197 -0.5485 -0.0587 -0.3684 -0.2499 -0.4805 -0.5791 -0.3023 -0.0957
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox modeling ; heart failure patient severity index ; hfpsi ; university of michigan ; hf ; clinic ; primary outcome
H-380	-0.6121698617935181	▁co x ▁model ing ▁; ▁Heart ▁Fail ure ▁Patient ▁Sever ity ▁index ▁; HF PSI ▁; ▁University ▁of ▁Michigan ▁ HF ▁clinic ▁; UM ▁co hor t
D-380	-0.6121698617935181	cox modeling ; Heart Failure Patient Severity index ;HFPSI ; University of Michigan HF clinic ;UM cohort
P-380	-0.5905 -0.1241 -0.9916 -0.1803 -0.2940 -0.6719 -0.2735 -0.4426 -0.2354 -0.7833 -1.3435 -0.1131 -0.2246 -1.5767 -0.8196 -0.1441 -0.8294 -0.0250 -0.0725 -2.7912 -0.9392 -0.6283 -0.2735 -1.7508 -0.3967 -0.7776 -0.0399 -0.3145 -0.1054
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 ; healthy ; cardiomyocytes ; camp ; inotropic effect ; acute ; β-ar ; contractility
H-1216	-0.3482566475868225	▁p de 2 ▁over expression ▁; ▁healthy ▁cardio my o cy tes ▁; ▁c AMP ▁; ▁l - type ▁ca 2 ▁; ▁in o tropi c ▁effect ▁; ▁β - AR ▁stimul ation ▁; ▁bas al ▁contract ility
D-1216	-0.3482566475868225	pde2 overexpression ; healthy cardiomyocytes ; cAMP ; l-type ca2 ; inotropic effect ; β-AR stimulation ; basal contractility
P-1216	-0.8266 -0.6781 -0.0427 -0.2499 -0.0369 -0.2526 -0.9759 -0.0885 -0.5994 -0.6245 -0.1969 -0.1031 -0.2450 -0.0192 -0.1019 -1.1536 -1.2426 -0.0333 -0.0037 -0.2475 -0.0657 -0.7242 -0.5018 -0.6072 -0.0208 -0.1106 -0.1110 -0.3120 -0.1111 -0.0129 -0.6981 -0.2668 -0.6432 -0.6202 -0.0087 -0.0421 -0.0112 -0.9501 -0.2955 -0.0949
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp ; shock therapy
H-863	-0.8098500370979309	▁ATP ▁; HR ▁; ▁in appropria te ▁shock ▁ therapy ▁; HR
D-863	-0.8098500370979309	ATP ;HR ; inappropriate shock therapy ;HR
P-863	-1.1296 -0.3522 -4.4878 -0.5703 -0.7293 -0.0939 -0.2160 -0.3750 -0.2284 -0.0294 -1.0713 -1.7789 -0.1435 -0.1324
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac resynchronization therapy ; crt ; patients ; heart failure ; hf ; outcomes ; crt ; dialysis ; reported
H-904	-0.667154848575592	▁Card iac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁c RT ▁; ▁di al ysis
D-904	-0.667154848575592	Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF ; cRT ; dialysis
P-904	-1.3545 -0.4535 -0.0274 -0.1270 -0.0171 -1.2947 -0.9035 -0.0421 -0.4265 -0.7341 -3.1836 -0.4571 -1.2568 -0.0780 -0.0630 -0.2439 -0.0599 -0.6554 -1.2754 -0.4893 -0.1477 -0.3382 -0.7091 -0.4444 -0.7859 -3.0867 -0.4102 -1.7010 -0.1910 -0.1352 -0.1422 -0.1147
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ; hf ; mortality ; cardiovascular ; hf ; mortality
H-1766	-0.5378462076187134	▁cardio re spira tory ▁fitness ▁; cr f ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁; HF ▁; ▁mortal ity ▁; ▁cardiovascular ▁risk ▁factors ▁; ▁ HF ▁mortal ity ▁; ▁fit ▁; ▁un fit ▁men
D-1766	-0.5378462076187134	cardiorespiratory fitness ;crf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
P-1766	-1.1230 -0.1991 -0.2304 -0.1521 -1.0161 -0.2943 -1.1062 -2.7572 -0.2278 -0.0650 -0.0669 -0.0039 -0.2039 -0.6661 -0.2370 -0.2441 -0.6026 -0.4860 -0.1581 -1.3886 -0.3197 -0.0393 -0.5582 -0.3079 -0.1602 -1.1222 -0.3780 -0.8462 -1.0343 -0.2771 -0.2856 -1.9467 -0.0069 -0.0353 -0.8164 -0.4239 -0.1142
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; eplerenone ; patients ; hospitalization ; heart failure
H-1221	-0.4787469506263733	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁EM PHA SIS - HF ▁; ▁e pler en one ▁; ▁hospital ization ▁; ▁Sur v I val ▁Study ▁in ▁Heart ▁Fail ure
D-1221	-0.4787469506263733	eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; hospitalization ; SurvIval Study in Heart Failure
P-1221	-0.0755 -0.3236 -0.2361 -1.4509 -0.2317 -0.5771 -0.4188 -0.2617 -0.1533 -0.0336 -0.1345 -0.3327 -0.7891 -0.1882 -0.3528 -0.0527 -0.2594 -0.9826 -0.2149 -0.2143 -0.3224 -0.6925 -0.3361 -1.7429 -0.9331 -0.3302 -0.9149 -0.0897 -2.5957 -0.0127 -0.2521 -0.5035 -0.3308 -0.1639 -0.8667 -0.2115 -0.1315
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart rate ; cardiac ; patients ; patients ; acute myocardial infarction ; ami ; patients ; congestive heart failure ; chf ; left ventricular ; dysfunction
H-1585	-0.4752179682254791	▁Heart ▁rate ▁; HR ▁; ▁cardiac ▁patients ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁left ▁vent ri cular ▁; LV
D-1585	-0.4752179682254791	Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
P-1585	-1.1935 -0.4677 -0.5947 -0.4414 -0.5973 -0.3010 -0.4089 -0.4129 -0.9148 -0.0408 -1.0499 -0.5799 -0.2343 -1.0702 -0.0374 -0.3018 -0.1775 -0.5259 -0.1331 -0.4094 -0.1170 -0.3824 -1.4589 -0.3771 -0.0771 -0.1843 -0.9423 -1.4825 -0.1221 -0.0241 -0.0676 -1.3109 -0.1487 -0.4805 -0.0598 -0.3446 -0.1109
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular cardiomyocytes ; chronic ; insulin ; irs1 ; irs2 ; proteins ; insulin ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
H-657	-0.3138289451599121	▁ne ona tal ▁rat ▁vent ri cular ▁cardio my o cy tes ▁; ▁chronic ▁insulin ▁exposure ▁; ▁i RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁insulin ▁action ▁; ▁p 38 ▁; ▁cardiac ▁dys function ▁; ▁insulin ▁resist ance ▁; ▁type ▁2 ▁diabetes
D-657	-0.3138289451599121	neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
P-657	-0.0476 -0.0261 -0.0589 -0.0449 -0.4013 -1.2344 -0.3255 -0.0837 -1.3165 -0.6334 -0.1635 -0.0938 -0.4133 -0.7742 -0.2487 -0.1801 -0.2044 -0.9737 -0.0369 -1.1675 -0.3899 -0.7019 -0.1497 -0.0385 -0.2001 -0.1092 -0.2964 -0.1295 -0.1308 -0.4316 -0.4110 -0.1299 -0.6134 -0.7395 -0.0419 -0.0422 -0.2187 -0.0125 -0.0902 -0.0235 -0.2513 -0.0360 -0.3644 -0.0256 -0.3314 -0.0986
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms ; left ventricular ; midpapillary ; atrioventricular delay ; avd ; interventricular delay ; vvd ; ste ; circumferential strain ; radial strain ; rs
H-323	-0.44947144389152527	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁mid pap illa ry ▁level ▁; ▁at rio ven tri cular ▁de lay ▁; AV d ▁; ▁interven tri cular ▁de lay ▁; ▁v d ▁; ▁ste ▁analysis ▁; ▁circum fer ential ▁strain ▁; CS ▁; ▁radi al ▁strain ▁; RS
D-323	-0.44947144389152527	echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ;AVd ; interventricular delay ; vd ; ste analysis ; circumferential strain ;CS ; radial strain ;RS
P-323	-1.1177 -0.0974 -0.1658 -0.5080 -0.0150 -0.4758 -0.4341 -0.4126 -0.0654 -1.7548 -0.1729 -0.5972 -0.1548 -0.2539 -0.8436 -0.1671 -0.2510 -0.5912 -0.1544 -0.0305 -2.9071 -0.5902 -0.1030 -0.0664 -0.3514 -0.8963 -0.5098 -0.1715 -0.0067 -2.0071 -0.1930 -0.0596 -0.1389 -0.3082 -0.2068 -0.4674 -0.1755 -1.9400 -0.2014 -0.9971 -0.3968 -0.2578 -0.7919 -0.0305 -0.2772 -0.7128 -0.2117 -0.0063 -0.0489 -0.0897 -0.4060 -0.0643 -0.3641 -0.0532
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients ; new york heart association ; nyha ; functional class ; hf ; ejection fractions ; chronic ; stable ; guideline-directed medical therapy ; gdmt ; united states ; canada ; europe
H-1870	-0.3844153583049774	▁New ▁York ▁heart ▁association ▁; NY ha ▁; ▁functional ▁class ▁III ▁ HF ▁; ▁e je ction ▁ fraction s ▁; ▁chronic ▁stable ▁guide line - direct ed ▁medical ▁ therapy ▁; GD m
D-1870	-0.3844153583049774	New York heart association ;NYha ; functional class III HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDm
P-1870	-0.8038 -0.6084 -1.5628 -0.2313 -0.3583 -0.5382 -0.7933 -0.2119 -0.0707 -0.0794 -0.2876 -0.2941 -0.6897 -0.1576 -0.0445 -0.1203 -0.0397 -0.2580 -0.0042 -0.1601 -0.1926 -0.1312 -0.9118 -0.9893 -0.0259 -0.0769 -0.0040 -0.1149 -0.0688 -0.1307 -0.0237 -0.1767 -0.4550 -1.7535 -1.3966 -0.0732
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients ; qrs ; hazard ratio ; primary outcome ; patients ; qrs ; hazard ratio
H-889	-0.5847448706626892	▁non - LB bb ▁; ▁QR s ▁; ▁hazard ▁ratio
D-889	-0.5847448706626892	non-LBbb ; QRs ; hazard ratio
P-889	-0.6112 -0.0732 -0.1756 -0.8571 -0.2334 -0.0822 -1.5139 -0.9768 -1.1466 -0.0535 -1.1658 -0.1276
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous hf ; myofiber shortening ; septum ; myofiber shortening ; stretch ; wall
H-1155	-0.5560678839683533	▁ca (2 +) ▁handling ▁; ▁dys syn chron ous ▁ HF ▁; ▁my o fi ber ▁; ▁sept um ▁; ▁my o fi ber ▁; ▁stretch ▁rate ▁; ▁lateral ▁wall
D-1155	-0.5560678839683533	ca(2+) handling ; dyssynchronous HF ; myofiber ; septum ; myofiber ; stretch rate ; lateral wall
P-1155	-1.8175 -0.3356 -0.0070 -0.8845 -0.7599 -0.0336 -0.0354 -0.0179 -1.3402 -0.2611 -0.3160 -0.3336 -1.3594 -0.3908 -0.0949 -0.3585 -0.6063 -2.2654 -0.0307 -0.3218 -0.9289 -0.2503 -0.0838 -0.3233 -0.8722 -0.2207 -0.9845 -0.8987 -0.4148 -0.9294 -0.1964 -0.1211
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics ; proteomics ; transverse aortic constriction ; tac ; heart failure ; signaling pathway ; ingenuity pathway analysis
H-871	-0.5522688031196594	▁label - free ▁shot gun ▁; ▁prote o mics ▁; ▁global ▁prote o mics ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁heart ▁failure
D-871	-0.5522688031196594	label-free shotgun ; proteomics ; global proteomics ; transverse aortic constriction ;TAC ; heart failure
P-871	-1.0097 -0.0813 -0.0640 -0.0509 -0.0401 -1.2770 -0.2447 -1.3882 -0.0235 -0.4571 -2.4648 -0.4348 -1.1521 -0.0221 -0.3106 -0.0042 -0.1786 -0.0624 -0.2103 -1.2598 -0.0764 -2.5367 -0.0749 -0.3136 -0.2708 -0.5473 -1.1926 -0.0884 -0.6446 -0.0865
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells ; transforming growth factor-β ; tgf-β ; epithelial ; mesenchymal ; transition ; expression ; pluripotency markers
H-1342	-0.415923148393631	▁c - K it + ▁cell s ▁; ▁growth ▁factor - β ▁; ▁t GF - β ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker s ▁; ▁sham s
D-1342	-0.415923148393631	c-Kit+ cells ; growth factor-β ; tGF-β ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
P-1342	-0.1345 -0.0765 -2.6805 -0.0184 -1.0370 -0.2009 -0.1856 -0.6674 -3.1655 -0.1872 -0.2141 -0.0699 -0.7816 -1.3745 -0.5768 -0.0765 -0.0487 -0.7943 -0.2918 -0.0965 -0.1326 -0.0091 -0.6562 -0.0244 -0.1344 -0.1868 -1.2624 -0.0822 -0.0788 -0.0893 -0.3423 -0.1989 -0.0361 -0.0467 -0.0710 -0.0748 -0.4319 -0.0258 -0.1760 -0.2262 -0.0889
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka ; change ; riiα ; cα ; expression ; riiα ; ser96 ; cα ; thr197 ; phosphorylation ; hf
H-1428	-0.6254158616065979	▁p ka ▁; ▁type ▁II ▁regulator y ▁; RI i α ▁; ▁cata ly tic ▁; ▁c α ▁; ▁sub un it ▁expression ▁; ▁r II α ▁; ▁ser 96) ▁; ▁c α ▁; ▁ phos phor y lation ▁; HF
D-1428	-0.6254158616065979	pka ; type II regulatory ;RIiα ; catalytic ; cα ; subunit expression ; rIIα ; ser96) ; cα ; phosphorylation ;HF
P-1428	-0.5958 -0.9256 -0.7341 -2.3230 -0.1965 -0.3778 -0.1524 -0.2300 -1.9288 -0.3896 -0.2727 -0.2192 -0.0344 -0.1856 -0.2615 -0.4677 -0.9824 -0.6667 -0.4558 -2.2049 -0.0991 -0.0653 -0.1176 -0.2797 -0.3310 -1.6847 -0.5065 -0.2465 -0.7310 -0.2939 -0.8190 -0.3413 -0.3051 -0.1484 -2.5014 -0.1941 -1.0782 -0.7981 -0.0952 -0.1787 -2.1772 -0.2162 -0.0805
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients ; hfref ; left ventricular ejection fraction ; hfpef ; left ventricular ejection fraction ; β-blocker ; hf ; hospitalization
H-178	-0.6896004676818848	▁h Fr EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF p EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ RAS - ▁; ▁β - block er ▁; ▁index ▁ HF
D-178	-0.6896004676818848	hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; β-blocker ; index HF
P-178	-0.7978 -1.0683 -0.9590 -0.8499 -0.1787 -0.1288 -3.0451 -1.4148 -0.4268 -0.5440 -0.5735 -0.9771 -0.0633 -0.4185 -0.6649 -0.8710 -0.1775 -0.3158 -0.7333 -0.2329 -0.1740 -3.5067 -1.3945 -0.3578 -0.8414 -0.6220 -0.7532 -0.0736 -0.8651 -0.8188 -0.1815 -0.0589 -2.0920 -0.0138 -0.0834 -0.1523 -0.0497 -1.4701 -0.4338 -0.3500 -0.2432 -0.5257 -0.1505
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross talk ; g-protein-coupled receptors ; physiological ; significance ; regulation ; hearts ; chronic ; β-adrenergic receptor ; postischemic heart failure
H-1410	-0.37851253151893616	▁g - prote in - co up led ▁receptor s ▁; ▁reciproc al ▁regula tion ▁; ▁mouse ▁heart s ▁; ▁β - ad r energi c ▁receptor ▁; ▁post ische mic ▁heart ▁failure
D-1410	-0.37851253151893616	g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor ; postischemic heart failure
P-1410	-0.6565 -0.1185 -0.0482 -0.3844 -0.0987 -0.0271 -0.1607 -0.5963 -0.1302 -0.4153 -0.6919 -2.1317 -0.0434 -0.5895 -0.5292 -0.2892 -0.1077 -0.2912 -0.1014 -0.4091 -0.7128 -0.0521 -0.1806 -0.4199 -0.4369 -0.0470 -0.0362 -1.5981 -0.4710 -0.0417 -0.3568 -0.6422 -0.1260 -0.2341 -0.0722
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric remodeling ; concentric hypertrophy ; left ventricular ; remodeling ; heart failure with preserved ejection fraction ; hfpef ; eccentric hypertrophy ; patients
H-1524	-0.35721635818481445	▁concentr ic ▁remodel ing ▁; cr ▁; ▁concentr ic ▁hyper trop hy ▁; CH ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁remodel ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁ecce n tric ▁hyper trop hy ▁; EH
D-1524	-0.35721635818481445	concentric remodeling ;cr ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
P-1524	-0.0297 -0.0342 -0.3413 -0.0798 -0.3849 -0.5588 -0.5290 -0.0416 -0.0558 -0.1361 -0.1531 -1.2494 -0.6329 -0.8869 -0.4234 -0.2785 -0.0581 -1.3153 -0.2149 -0.3584 -0.0977 -0.2761 -3.2943 -0.0370 -0.5950 -0.3956 -0.0416 -0.5639 -0.0248 -0.0440 -0.4004 -0.0167 -0.0699 -0.0338 -0.3645 -0.0050 -0.3202 -0.3564 -0.0680 -0.5573 -0.1492 -0.0130 -0.0401 -0.1815 -0.1936 -0.0792 -1.2648 -0.2147 -0.4338 -0.2236 -0.1002
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise ; exercise
H-1989	-1.490782618522644	▁weight ▁; SD ▁; ▁exercise ▁group ▁; SD
D-1989	-1.490782618522644	weight ;SD ; exercise group ;SD
P-1989	-2.2772 -0.8208 -0.7396 -0.8593 -2.9881 -2.3286 -0.8643 -1.4122 -2.4399 -0.1779
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv dysfunction ; hazard ratio ; confidence interval ; cachexia ; hazard ratio ; multivariate analyses
H-1166	-0.8283177018165588	RV ▁dys function ▁; haz ard ▁ratio ▁; ▁confidence ▁interval ▁; CI ▁; ▁cache xia ▁; haz ard ▁ratio
D-1166	-0.8283177018165588	RV dysfunction ;hazard ratio ; confidence interval ;CI ; cachexia ;hazard ratio
P-1166	-2.8482 -1.0777 -0.1423 -0.3575 -2.9421 -0.0214 -0.3835 -0.5973 -1.8066 -0.0860 -0.3678 -1.2527 -0.4031 -0.0540 -0.1488 -0.9479 -2.5343 -0.0744 -0.2474 -0.9231 -0.1786
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients ; resting hr ; follow-up ; baseline ; vo2max ; patients ; resting hr ; p value
H-1945	-1.4066991806030273	▁rest ing ▁HR ▁; ▁VO 2 max ▁; ▁rest ing ▁HR
D-1945	-1.4066991806030273	resting HR ; VO2max ; resting HR
P-1945	-2.8256 -0.1765 -1.4551 -0.6604 -4.6819 -0.1558 -0.0718 -0.5992 -5.3006 -0.1733 -1.6171 -0.4237 -0.1461
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β ; cell ; phenotype ; in vitro ; cardiac progenitor function ; cell ; clinical
H-1344	-0.536082923412323	▁t GF - β ▁inhibi tion ▁; ▁c - K it + ▁cell ▁ph eno type ▁; ▁function ▁in ▁vi tro ▁; ▁cardiac ▁pro gen itor ▁function ▁; ▁cell ▁exp an sion ▁protocol s
D-1344	-0.536082923412323	tGF-β inhibition ; c-Kit+ cell phenotype ; function in vitro ; cardiac progenitor function ; cell expansion protocols
P-1344	-2.5247 -0.9953 -0.0706 -0.1202 -0.3059 -0.7220 -0.3016 -0.0089 -0.1061 -2.7758 -0.0078 -1.1033 -0.3488 -0.4821 -0.1606 -0.0068 -0.3051 -0.8945 -1.7574 -0.0296 -0.0139 -0.5243 -0.1915 -0.1145 -0.1425 -0.3846 -0.1514 -0.2403 -0.2528 -0.0477 -0.3198 -2.4150 -0.8388 -0.2239 -0.3171 -0.0939
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp ; inflammatory ; biomarkers ; hscrp ; il6 ; patients ; hscrp
H-1920	-0.3729652762413025	▁NT - pro b NP ▁; ▁infla mma tory ▁bio mark ers ▁; ▁h s cr p ▁; ▁IL ▁6 ▁; ▁h s cr p
D-1920	-0.3729652762413025	NT-probNP ; inflammatory biomarkers ; hscrp ; IL 6 ; hscrp
P-1920	-0.0700 -0.1971 -0.6536 -0.7191 -0.7288 -0.3388 -0.1313 -0.4614 -0.4697 -0.0601 -0.1802 -0.3298 -0.3660 -0.1367 -0.0184 -0.1206 -0.6240 -0.2381 -0.8385 -0.9746 -0.8297 -0.2327 -0.0187 -0.1794 -0.4676 -0.5555 -0.1296
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets ; in vitro ; neurohormonally ; heart disease ; nanomolar ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological ; gene induction
H-1044	-0.2890504002571106	▁bet s ▁; ▁neuro hormon ally ▁induc ed ▁heart ▁disease ▁; ▁na nomo lar ▁dos es ▁; ▁j q 1 ▁; ▁ phen yle ph rine - media ted ▁hyper trop hy ▁; ▁cardio my o cy tes ▁; ▁path ological ▁gene ▁in duction
D-1044	-0.2890504002571106	bets ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
P-1044	-1.7598 -0.1407 -0.2959 -0.1051 -0.0236 -0.5563 -0.0272 -0.1021 -0.8615 -0.3313 -0.3003 -0.3036 -0.0077 -0.1106 -0.3651 -0.0153 -0.4134 -0.1142 -1.2793 -1.2669 -0.4997 -0.4084 -0.0243 -0.2357 -0.1112 -0.0431 -0.0985 -0.0350 -0.0268 -0.0186 -0.0076 -1.3120 -0.2926 -0.0315 -0.2158 -0.2519 -0.0360 -0.0351 -0.4383 -0.0109 -0.2821 -0.0714 -0.0456 -0.0061 -0.3124 -0.0655
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat ; functional status ; quality of life ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; patients ; nyha functional class iii ; hf
H-1878	-0.616610050201416	▁BAT ▁; ▁exercise ▁capacity ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁burde n ▁; ▁heart ▁failure ▁hospital ization s ▁; ▁g m - tre ated ▁NY ha ▁functional ▁class ▁III ▁ HF
D-1878	-0.616610050201416	BAT ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; burden ; heart failure hospitalizations ; gm-treated NYha functional class III HF
P-1878	-0.0375 -0.8961 -2.7372 -0.5561 -0.2827 -3.6184 -0.0333 -0.1837 -0.0098 -0.0251 -0.0485 -0.0666 -0.1160 -0.0258 -0.2912 -0.5125 -1.1384 -0.5984 -0.0775 -0.2591 -0.3098 -3.1405 -0.0419 -0.6968 -0.3026 -0.0577 -1.4085 -0.7108 -0.1652 -0.2335 -2.1707 -1.0315 -0.3290 -0.0031 -0.3980 -0.8619 -1.0905 -0.8715 -0.1256 -0.5827 -0.2729 -0.4103 -0.2922 -0.1102
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated ; p70s6k ; pkc-βii ; hdl ; nyha-iiib ; malondialdehyde ; bound ; hdl ; nyha-iiib ; hdl ; healthy
H-257	-0.7080430388450623	▁p 70 s 6 k ▁; ▁PK c - β II ▁; ▁HD L ▁; ▁ny ha - III b ▁; ▁malo ndi alde hy de ▁; ▁HD L ▁; ▁ny ha - III b ▁; ▁HD L
D-257	-0.7080430388450623	p70s6k ; PKc-βII ; HDL ; nyha-IIIb ; malondialdehyde ; HDL ; nyha-IIIb ; HDL
P-257	-1.1641 -0.4119 -0.2789 -0.3149 -2.6510 -0.2318 -0.0427 -0.7070 -0.0503 -0.0423 -0.4604 -0.1466 -1.9401 -2.6034 -0.2394 -1.4754 -0.6775 -0.2200 -0.6163 -0.0358 -0.3633 -0.0366 -0.0599 -0.0346 -0.7920 -0.2282 -0.3204 -1.8511 -2.4037 -0.3408 -1.6557 -0.3974 -0.1107 -0.5887 -0.0180 -0.5185 -0.4173 -2.5559 -1.2315 -0.0878
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change ; exercise ; exercise
H-1986	-1.065293312072754	▁m HF ▁; ▁exercise ▁; ▁die t ▁; ▁exercise ▁; ▁die t
D-1986	-1.065293312072754	mHF ; exercise ; diet ; exercise ; diet
P-1986	-1.4434 -3.3494 -1.1667 -3.6459 -0.2505 -0.4959 -0.1394 -0.8916 -0.9725 -0.2748 -1.6416 -0.1441 -0.3331 -0.1652
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx ; dnx
H-1374	-0.8616235852241516	▁non pa ce ▁; ▁non - DN x ▁; ▁stam - I nner vat ed ▁; ▁s ham - in v ▁; ▁non pa ce ▁; ▁DN x ▁; ▁s ham - DN x ▁; ▁pace ▁non - DN x ▁; ▁cm f - in v ▁; ▁pace ▁; ▁DN x ▁; ▁cm f - DN x
D-1374	-0.8616235852241516	nonpace ; non-DNx ; stam-Innervated ; sham-inv ; nonpace ; DNx ; sham-DNx ; pace non-DNx ; cmf-inv ; pace ; DNx ; cmf-DNx
P-1374	-0.7740 -0.1385 -0.4451 -1.1063 -0.1780 -0.1615 -1.0309 -0.9375 -0.8980 -3.6879 -0.1335 -3.3440 -0.0005 -0.0588 -0.1138 -0.4752 -2.3533 -0.3048 -0.1112 -0.3081 -0.4046 -0.7688 -0.4367 -0.0606 -0.1464 -1.8135 -0.8006 -0.2041 -0.5053 -3.6252 -0.2949 -0.0819 -2.9874 -0.3606 -0.2983 -0.3767 -2.4842 -0.0836 -1.6597 -0.4549 -0.3137 -1.5931 -2.3580 -0.0763 -0.1650 -0.2959 -0.3133 -1.9376 -1.8303 -0.3476 -0.1607 -0.5352 -2.0152 -1.9057 -0.0665 -1.6499 -0.4371 -0.3082 -0.1178
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc battery ; hf ; health abc hf model ; death
H-629	-1.0455929040908813	▁h ABC ▁Bat tery ▁score ▁; ▁ HF ▁; ▁health ▁ABC ▁; ▁ HF ▁model ▁; ▁h b ▁; ▁SD ▁; ▁death
D-629	-1.0455929040908813	hABC Battery score ; HF ; health ABC ; HF model ; hb ; SD ; death
P-629	-2.3191 -1.1456 -0.5859 -0.0244 -0.2106 -0.2453 -0.7958 -0.2833 -0.9085 -1.6953 -0.2561 -1.6189 -1.0499 -0.4935 -0.8124 -0.2486 -1.4143 -2.6540 -0.2231 -0.8854 -0.7290 -4.1329 -2.2509 -0.1115
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection fraction ; patients ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
H-1010	-0.7377436757087708	▁e je ction ▁ fraction ▁; ▁fra il ▁; ▁bi ological ▁ph eno type ▁; ▁fra il ty
D-1010	-0.7377436757087708	ejection fraction ; frail ; biological phenotype ; frailty
P-1010	-0.5054 -0.1883 -0.0328 -0.5611 -0.0178 -0.4772 -0.1044 -0.0652 -0.3659 -2.4429 -0.2965 -0.3904 -0.1675 -0.0075 -0.4760 -3.5544 -0.2128 -0.6102 -4.1897 -0.0889
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin ; hgb ; hrqol ; hrqol ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-836	-0.6464480757713318	▁hem o glob in ▁; ▁h gb ▁; ▁HR Qo L ▁; ▁HR Qo L ▁; ▁Heart ▁Fail ure ▁; ▁Exerci se ▁Training ▁; HF - ac TION
D-836	-0.6464480757713318	hemoglobin ; hgb ; HRQoL ; HRQoL ; Heart Failure ; Exercise Training ;HF-acTION
P-836	-0.8720 -0.4578 -0.1324 -1.0750 -0.4850 -1.4140 -0.2164 -0.2384 -0.4272 -0.0250 -2.6080 -0.1867 -0.7494 -0.0212 -2.3184 -0.1897 -2.0583 -0.1148 -0.5088 -0.3127 -1.5795 -0.0530 -0.3690 -0.2583 -0.4216 -0.0286 -0.6460 -1.2845 -0.2448 -0.0971
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial fibrillation ; congestive heart failure ; health care ; expenditures ; patients ; québec ; randomized ; rhythm ; rate-control
H-1234	-0.6706058979034424	▁At rial ▁Fi bril lation ▁; ▁con ges tive ▁Heart ▁Fail ure ▁trial ▁; ▁health ▁care ▁ex pendi tures ▁; ▁Québec ▁; ▁ rhythm ▁; ▁rate - control ▁treatment
D-1234	-0.6706058979034424	Atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; Québec ; rhythm ; rate-control treatment
P-1234	-1.2754 -0.0107 -0.5808 -0.0609 -0.0440 -0.5929 -0.1432 -0.2993 -1.3674 -0.5788 -0.3623 -0.9957 -1.9914 -0.3316 -1.8432 -1.9199 -0.1107 -0.0427 -0.3755 -0.3815 -2.5535 -0.4834 -0.2051 -0.5267 -0.7549 -0.2181 -0.2004 -0.0192 -0.9844 -1.3861 -0.1494
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart failure ; patient ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
H-1668	-0.38650649785995483	▁heart ▁failure ▁; ▁my o card ial ▁is cha emia ▁; ▁bra dy ar rhythm ias ▁; ▁val vu lar ▁re gur gi tation ▁; ▁pulmonar y ▁e mbol ism ▁; ▁infection ▁; ▁renal ▁dys function
D-1668	-0.38650649785995483	heart failure ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
P-1668	-4.0589 -0.1461 -0.3341 -0.5344 -0.2480 -0.3390 -0.5610 -0.3071 -0.0535 -0.3665 -0.3681 -1.9541 -0.8086 -0.0322 -0.0904 -0.4302 -0.2710 -0.3629 -0.0969 -0.1195 -0.0268 -0.1221 -0.1848 -0.1501 -0.2547 -0.0017 -0.1379 -0.1199 -0.0191 -0.9984 -0.2895 -0.0314 -0.3369 -0.0014 -0.0510 -0.0695 -0.3233 -0.0863
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report ; calcineurin ; nfat ; mir-25 ; expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dhand ; hand2 ; diseased ; myocardium
H-640	-0.41070786118507385	▁calci ne uri n ▁; ▁n fat ▁signal ling ▁; ▁mi R -25 ▁expression ▁; ▁heli x - loop - heli x ▁; ▁b HL h ▁; ▁tran scription ▁factor ▁d HAND ▁; ▁hand ▁; ▁human ▁; ▁mouse ▁my o car dium
D-640	-0.41070786118507385	calcineurin ; nfat signalling ; miR-25 expression ; helix-loop-helix ; bHLh ; transcription factor dHAND ; hand ; human ; mouse myocardium
P-640	-0.0500 -0.5172 -0.0211 -0.1205 -0.7355 -2.4573 -0.1496 -1.1160 -0.3177 -0.2616 -0.4017 -1.2704 -0.0392 -0.1215 -0.3605 -0.1886 -0.2394 -0.0587 -0.0231 -0.1232 -0.0187 -0.3264 -0.6366 -0.9446 -0.2841 -0.4624 -0.1960 -0.0243 -0.0154 -0.0336 -0.6895 -0.9558 -0.1606 -0.2461 -1.0022 -0.8480 -0.3217 -0.0718 -1.6037 -0.0814 -0.0148 -0.1636 -0.3096 -0.0878
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise ; correlated ; psss ; btes ; exercise ; psss ; btes
H-1929	-1.1551133394241333	▁ps s ▁; ▁b tes ▁; ▁exercise ▁time ▁; ▁ps s ▁; ▁b tes
D-1929	-1.1551133394241333	pss ; btes ; exercise time ; pss ; btes
P-1929	-2.4339 -0.5211 -0.7160 -1.9381 -0.2572 -0.3912 -2.7656 -1.7604 -0.3294 -2.9442 -0.5424 -0.7044 -2.4923 -0.3094 -0.2550 -0.1212
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp ; admission ; sensitivity ; specificity ; confidence interval ; area under the curve
H-269	-0.6702640056610107	▁NT - pro b NP ▁cut off ▁point ▁; ▁ sensitiv iteit ▁; ▁confidence ▁interval
D-269	-0.6702640056610107	NT-probNP cutoff point ; sensitiviteit ; confidence interval
P-269	-0.3970 -0.0983 -0.0518 -0.5260 -1.4749 -1.0248 -0.2082 -0.9907 -1.0054 -2.0070 -0.0292 -1.5745 -0.6346 -0.2713 -0.0993 -0.9167 -0.0849
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic ; r-r interval ; hr variability ; short-term fractal scaling exponent ; prognostic
H-1588	-0.362720251083374	▁prognos tic ▁power ▁; ▁r - r ▁interval ▁os cilla tions ▁; ▁non - line ar ▁HR ▁variabil ity ▁; ▁fra c tal ▁scal ing ▁ex ponent
D-1588	-0.362720251083374	prognostic power ; r-r interval oscillations ; non-linear HR variability ; fractal scaling exponent
P-1588	-1.0825 -0.9227 -0.1902 -0.3989 -0.1216 -0.2048 -0.7746 -0.0181 -2.0086 -0.0697 -0.2119 -0.3948 -0.5030 -0.0368 -0.0205 -0.0086 -0.3866 -0.0756 -0.9311 -0.4684 -0.3300 -0.0623 -0.0916 -0.3604 -0.1051 -0.1704 -0.0753 -0.4038 -0.0907
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic function ; diastolic filling formalism ; relaxation ; doppler mitral inflow velocity ; e-wave
H-921	-0.3051701486110687	▁dia sto lic ▁function ▁; ▁dia sto lic ▁fill ing ▁formal ism ▁; ▁relax ation ▁; vis co ela stic ▁; ▁passiv e ▁; sti ff ness ▁; ▁do pp ler ▁mit ral ▁in flow ▁veloci ty ▁; ▁e - wa ve
D-921	-0.3051701486110687	diastolic function ; diastolic filling formalism ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
P-921	-0.1364 -0.1255 -0.0259 -0.1307 -0.4063 -0.0942 -0.1343 -0.0812 -0.6962 -0.0752 -2.1408 -0.3993 -0.2588 -0.0788 -0.1449 -0.8499 -0.0418 -0.0109 -0.0072 -0.0223 -0.4297 -0.2239 -0.0309 -1.5249 -1.2052 -0.0982 -0.7153 -0.2461 -0.4850 -0.0183 -1.0371 -0.0741 -0.0650 -0.0401 -0.0537 -0.1960 -0.0718 -0.3582 -0.2265 -0.0255 -0.0902 -0.1142 -0.1526 -0.0842
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart failure ; hf ; patients ; spontaneous ventricular tachycardia ; hf ; patients ; spontaneous vt ; hearts
H-1437	-0.7033982276916504	▁heart ▁failure ▁; HF ▁; ▁vent ri cular ▁ta chy car dia ▁; HF VT ▁; ▁ HF ▁patients ▁; ▁spontane ous ▁ VT ▁; HF VT ▁; ▁structura lly ▁normal ▁heart s ▁; ▁h Nor m
D-1437	-0.7033982276916504	heart failure ;HF ; ventricular tachycardia ;HFVT ; HF patients ; spontaneous VT ;HFVT ; structurally normal hearts ; hNorm
P-1437	-1.8988 -0.2394 -0.2863 -0.3340 -0.3631 -0.7782 -2.4645 -0.3389 -0.6569 -0.3015 -0.1166 -0.0512 -0.1837 -0.6603 -1.8391 -0.3042 -1.2251 -0.5097 -2.5458 -0.7128 -0.6394 -1.1233 -0.4959 -0.2711 -0.1662 -0.6685 -1.4192 -0.2546 -0.6595 -0.1227 -0.3095 -0.2630 -0.0875 -0.1916 -2.6872 -1.7625 -0.0328 -0.3706 -0.0971
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; estimated glomerular filtration rate ; lvef
H-819	-0.2823001742362976	▁g LS ▁; ▁co x ▁model ▁; ▁chronic ▁heart ▁failure ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁prior ▁stroke ▁score ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁LV EF ▁; ▁sa ▁; ▁CV
D-819	-0.2823001742362976	gLS ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa ; CV
P-819	-0.1156 -1.2827 -0.3061 -0.0471 -0.0878 -0.0801 -0.6749 -0.5226 -0.3918 -0.1119 -0.2758 -0.0474 -0.0173 -0.1860 -0.0601 -0.1361 -0.0148 -0.2091 -0.0639 -0.2005 -0.0674 -0.1311 -0.0734 -0.1184 -0.4450 -0.2092 -0.2361 -0.1106 -0.3810 -0.1538 -0.4124 -0.7551 -0.6819 -1.2087 -0.0649
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient ; vad ; patients ; ventricular assist device ; ecmo ; patients ; extracorporeal membrane oxygenation ; ecmo ; vad ; patients ; ecmo ; vad
H-1387	-1.003676414489746	▁vent ri cular ▁assist ▁device ▁support ▁; ▁ec mo ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁membran e ▁support ▁; ▁ec mo ▁; ▁ec mo ▁; ▁ec mo ▁; ▁ VAD
D-1387	-1.003676414489746	ventricular assist device support ; ecmo ; extracorporeal membrane oxygenation membrane support ; ecmo ; ecmo ; ecmo ; VAD
P-1387	-1.0730 -2.2907 -0.1396 -0.5903 -0.1087 -2.8779 -0.1958 -0.4408 -2.8818 -1.1772 -0.7618 -0.1024 -0.8363 -0.2310 -0.0460 -0.0477 -0.5054 -0.7013 -0.0708 -0.0641 -3.1430 -0.2892 -0.7004 -2.7905 -0.9852 -1.4026 -2.9776 -0.7338 -0.9933 -2.7013 -0.6318 -1.4572 -0.3789 -0.6091 -0.1921
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic events ; ies ; patients ; ischemic cardiomyopathy ; ic ; cardiac resynchronization therapy ; defibrillator ; crt-d
H-102	-0.5083482265472412	▁ ische mic ▁events ▁; IE s ▁; ▁ ische mic ▁cardio my o pathy ▁; ▁i cc ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁c RT - d
D-102	-0.5083482265472412	ischemic events ;IEs ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; cRT-d
P-102	-1.1177 -0.1263 -0.7194 -0.5572 -0.3976 -1.7795 -0.0899 -0.3803 -0.9100 -0.1070 -0.4410 -0.1201 -1.0380 -1.3769 -0.0249 -0.3083 -0.5527 -2.2898 -0.3694 -0.0505 -0.0363 -0.0488 -0.0169 -0.9681 -0.8378 -0.0141 -0.4301 -0.0486 -0.0270 -0.1219 -0.1619 -0.0779 -0.2404 -0.2719 -1.9633 -0.0562 -0.7185 -0.9151 -0.1145
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart failure ; disease ; evidence-based ; health care
H-2016	-1.1667585372924805	▁heart ▁failure ▁disease ▁management ▁; ▁treatment s
D-2016	-1.1667585372924805	heart failure disease management ; treatments
P-2016	-4.0843 -0.2068 -0.4800 -0.3318 -1.5044 -2.8099 -0.2396 -0.7369 -0.1070
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin ; heart failure ; murine ; resistin ; transgenic ; retn ; gene ; resistin
H-930	-0.5919042825698853	▁resist in ▁; ▁heart ▁failure ▁; ▁mouse ▁; ▁mur ine ▁resist in ▁; ▁trans ge nic ▁; ▁Ret n ▁gene ▁; ▁h um - re t n ▁mi ce ▁; ▁ inflammation - stimul ated ▁resist in ▁; ▁humans
D-930	-0.5919042825698853	resistin ; heart failure ; mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice ; inflammation-stimulated resistin ; humans
P-930	-3.9909 -0.6071 -1.2580 -0.5544 -0.1060 -0.3269 -3.2748 -0.7442 -0.0249 -1.6984 -0.2611 -0.8330 -0.1995 -0.0290 -0.0637 -0.1204 -0.2059 -1.1934 -0.0091 -0.1777 -0.1627 -0.9867 -0.0266 -0.0293 -1.9304 -0.1793 -0.0069 -0.3330 -0.1354 -0.6366 -0.9550 -0.0880 -0.0369 -0.0125 -0.3234 -0.1746 -0.3093 -1.7179 -0.2592 -0.2085 -0.0772
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients ; angiotensin-converting enzyme inhibitors ; angiotensin receptors blockers ; β-blockers
H-1745	-0.5614703297615051	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor s ▁block ers ▁; ▁β - block ers ▁; ▁devices
D-1745	-0.5614703297615051	angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers ; devices
P-1745	-3.7856 -1.8756 -0.2630 -1.8892 -0.5457 -0.0414 -0.1358 -0.4903 -0.1998 -0.0652 -0.0614 -0.5829 -1.1169 -0.0281 -0.1162 -0.7260 -0.0119 -0.1619 -1.2686 -0.1981 -0.4183 -0.0386 -0.0458 -0.2455 -0.1821 -1.0124 -0.2308 -0.3694 -0.1763
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ; tac
H-1815	-0.4314208924770355	▁t t t et Men a ▁; ▁cardiac ▁injury ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁heart ▁di la tation ▁; ▁hyper trop hy ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC
D-1815	-0.4314208924770355	tttetMena ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
P-1815	-4.3290 -0.7277 -0.3293 -0.3511 -0.6265 -0.0295 -0.7318 -0.3799 -0.1246 -0.2727 -0.1153 -0.0646 -0.0514 -0.4756 -0.0069 -0.2339 -1.0771 -0.0011 -0.0273 -2.4161 -0.0319 -0.1926 -0.2873 -0.6018 -0.3273 -0.3142 -0.0373 -0.3090 -0.0605 -0.0150 -0.9135 -0.2437 -0.0005 -0.1430 -0.0648 -0.2538 -0.7614 -0.0300 -0.8309 -0.1392 -0.6128 -0.2147 -0.1518 -0.0742
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation for ambulatory heart failure trial ; implantable ; primary end point ; all-cause mortality ; heart failure ; hospitalization
H-882	-0.5044680833816528	▁re syn chron ization - Def i bril lation ▁; ▁amb ulator y ▁Heart ▁Fail ure ▁tri al ▁; ▁implant able ▁cardio ver ter ▁; ▁de fi br illa tor - c RT ▁; ▁mortal iteit ▁; ▁heart ▁failure
D-882	-0.5044680833816528	resynchronization-Defibrillation ; ambulatory Heart Failure trial ; implantable cardioverter ; defibrillator-cRT ; mortaliteit ; heart failure
P-882	-0.1356 -0.0893 -0.0460 -0.7409 -0.0984 -0.2223 -0.3779 -0.1932 -0.0230 -1.1668 -0.6631 -0.0900 -0.0532 -0.4957 -0.3503 -1.0336 -0.3475 -0.0524 -0.3145 -0.2027 -0.0569 -0.0684 -0.0245 -0.0965 -2.1757 -0.0219 -0.0318 -0.0899 -0.0528 -0.0233 -0.0995 -0.7113 -2.0647 -0.4885 -3.9261 -1.8441 -0.1211 -0.5203 -0.3391 -1.1468 -0.0835
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart failure ; patients ; italy ; confirmatory factor analysis ; cfa ; schfi v.6.2 ; self-care maintenance ; self-care management ; self-care confidence
H-1505	-0.5709683299064636	▁heart ▁failure ▁patients ▁; ▁Italy ▁; ▁confirma tory ▁factor ▁analysis ▁; ▁c fa ▁; ▁ SCH fi ▁; Sel f - Car e ▁Main ten ance ▁; ▁Self - Car e ▁management ▁; ▁Self - Car e ▁Confi den ce
D-1505	-0.5709683299064636	heart failure patients ; Italy ; confirmatory factor analysis ; cfa ; SCHfi ;Self-Care Maintenance ; Self-Care management ; Self-Care Confidence
P-1505	-2.6549 -0.1730 -1.1104 -0.3775 -0.6897 -0.6129 -0.0168 -0.0331 -0.0699 -0.1926 -0.2808 -0.5832 -1.2048 -0.2343 -0.4904 -1.4076 -1.8725 -0.4074 -1.7272 -0.6345 -0.1106 -2.0248 -0.0571 -0.8144 -0.1815 -0.1498 -0.1701 -0.1430 -0.0428 -1.5874 -0.0592 -0.4971 -0.1391 -0.1070 -0.0299 -1.4153 -0.0744 -0.9820 -0.0894 -0.2107 -0.2371 -0.0846
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional status ; 6-mwt ; nyha class ; patients ; hfpef ; hfref ; prescribed ; therapy ; patients ; hfpef ; death ; hf ; hospitalization
H-244	-0.6106445789337158	▁functional ▁status ▁; ▁mw t ▁; ▁NY ha ▁class ▁; ▁ HF p EF ▁; ▁h Fr EF ▁; ▁ therapy ▁; ▁ HF p EF ▁; ▁death ▁; ▁ HF ▁hospital ization
D-244	-0.6106445789337158	functional status ; mwt ; NYha class ; HFpEF ; hFrEF ; therapy ; HFpEF ; death ; HF hospitalization
P-244	-2.1053 -0.1136 -0.3023 -1.3593 -0.0273 -0.1549 -0.5374 -0.3604 -0.7431 -0.2433 -0.4488 -0.5022 -0.0858 -0.2697 -0.1694 -1.1479 -0.6801 -0.5373 -0.2474 -0.7995 -2.4669 -0.2986 -1.0558 -0.6212 -0.1435 -0.1740 -0.2604 -2.3859 -0.1330 -0.3819 -0.4973 -1.1902 -0.6204 -0.2117 -0.0968
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; follow-up ; mortality ; ischemic cardiomyopathy
H-69	-0.31385380029678345	▁renal ▁dys function ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i CD ▁shock s ▁; ▁mortal ity ▁; ▁ ische mic ▁cardio my o pathy ▁; ▁male ▁sex
D-69	-0.31385380029678345	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy ; male sex
P-69	-0.0213 -0.0208 -0.1012 -0.1874 -0.0172 -0.3930 -0.1941 -0.7431 -0.0065 -0.1878 -0.4125 -0.1978 -0.0563 -0.1800 -0.0176 -0.1833 -0.0467 -0.1190 -0.0547 -0.1534 -0.1720 -0.2057 -0.1782 -0.0766 -1.6499 -0.2845 -0.0867 -0.1648 -0.1004 -0.6849 -0.0199 -0.3538 -0.3804 -0.3270 -0.0530 -0.0670 -0.3233 -1.1956 -1.5399 -0.1209 -0.7225 -0.0223 -0.3440 -0.0442 -0.8156 -0.8387 -0.0368 -1.3947 -0.0469 -0.4132 -0.2616 -0.1014
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold proteins ; cardiac remodelling ; field ; therapeutic
H-996	-0.43817588686943054	▁Raf - MEK 1/2 - er k 1/2 ▁sc af fold ▁protein s ▁; ▁cardiac ▁remodel ling
D-996	-0.43817588686943054	Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
P-996	-0.0263 -0.2064 -0.0166 -0.1372 -0.0808 -0.6415 -0.3436 -0.3695 -2.3757 -1.2544 -0.2419 -0.8663 -0.1770 -0.4384 -0.1958 -0.0353 -0.1150 -0.7341 -0.0695
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients ; chf ; testosterone ; exercise ; testosterone ; placebo
H-1318	-0.8333591222763062	▁CHF ▁; ▁SD ▁testosteron e ▁; ▁n mol
D-1318	-0.8333591222763062	CHF ; SD testosterone ; nmol
P-1318	-0.1049 -0.5214 -0.3446 -0.2536 -0.0652 -1.4016 -1.0674 -0.0199 -4.4629 -0.0920
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional ms ; lv dilatation ; heart failure ; hf ; functional ms ; hf ; prolapse ; degenerative mitral valve
H-341	-0.3969487249851227	▁functional ▁MS ▁; ▁LV ▁di la tation ▁; ▁treatment ▁; ▁heart ▁failure ▁; HF ▁; ▁LV ▁; ▁functional ▁MS ▁; ▁ HF ▁; ▁MR ▁; ▁de genera tive ▁mit ral ▁val ve
D-341	-0.3969487249851227	functional MS ; LV dilatation ; treatment ; heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
P-341	-0.2354 -0.1888 -0.2949 -0.3948 -0.6417 -0.1876 -0.0201 -0.3395 -1.5658 -2.3256 -0.2864 -0.0316 -0.2154 -0.8896 -0.1647 -0.6474 -0.3232 -0.1725 -0.3664 -0.3276 -1.1828 -0.4312 -0.1355 -0.1543 -0.3384 -0.7635 -0.0110 -0.2447 -0.0288 -0.0409 -0.0486 -0.0774 -0.3470 -0.0729
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new york heart association class ; kccq ; symptom ; spearman correlations ; 2-way anova ; patients ; hf with reduced ef ; hfpef
H-783	-0.5345137119293213	▁New ▁York ▁Heart ▁association ▁class ▁; ▁k cc q ▁over all ▁Summa ry ▁; ▁symptom ▁domain s ▁; ▁Spe ar man ▁corre lation s ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-783	-0.5345137119293213	New York Heart association class ; kccq overall Summary ; symptom domains ; Spearman correlations ; HF ; EF ; HFpEF
P-783	-1.1815 -0.5969 -1.2847 -0.2309 -1.8239 -0.2464 -0.9323 -0.0586 -1.6489 -2.2566 -0.0856 -0.1550 -0.1630 -0.4471 -1.8440 -0.2657 -0.1396 -0.5561 -0.0332 -0.0017 -0.0123 -0.0358 -0.0085 -0.0624 -0.3434 -1.3971 -1.1022 -0.3636 -0.6196 -0.2813 -0.3053 -0.3119 -0.0920 -0.1311 -0.1465 -0.0779
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; patients ; heart failure ; medications ; medical
H-1130	-0.7527289390563965	▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure
D-1130	-0.7527289390563965	angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
P-1130	-4.5076 -2.9192 -0.2629 -1.0915 -0.0754 -0.0876 -0.0682 -0.0636 -0.1461 -0.1822 -0.2462 -1.9267 -2.0079 -0.5085 -1.9512 -0.5988 -0.0976 -0.2141 -0.8368 -0.3275 -0.3780 -0.1196 -0.0666 -0.3062 -0.2655 -0.5572 -1.1992 -0.1950 -1.1831 -0.1922
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang ii infusion ; ang ii infusion ; uninephrectomy ; ang ii infusion ; salt loading ; ang ii infusion ; uninephrectomy ; salt loading
H-276	-0.7914668917655945	▁c 57 BL ▁; ▁ANG ▁II ▁in fusion ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion ▁; ▁salt ▁load ing ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁salt ▁load ing ▁; ANS
D-276	-0.7914668917655945	c57BL ; ANG II infusion ; ANG II infusion ; uninephrectomy ; ANG II infusion ; salt loading ; ANG II infusion ; uninephrectomy ; salt loading ;ANS
P-276	-0.8105 -1.5931 -1.7902 -0.5196 -1.8307 -0.7998 -0.0111 -0.0266 -0.2881 -4.5585 -1.4061 -0.0140 -0.0315 -0.2044 -0.0255 -2.2464 -1.8372 -0.3083 -0.1362 -1.2041 -0.2759 -2.4637 -1.5461 -0.0233 -0.0617 -0.2006 -0.3328 -0.0893 -0.0744 -0.1900 -2.7868 -1.4764 -0.0173 -0.0376 -0.1857 -0.0287 -1.9256 -1.6824 -0.3017 -0.2773 -0.9984 -0.3151 -0.1273 -0.1761 -0.0885 -0.7526 -2.0699 -0.5479 -0.0873
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral blood flow velocity ; tissue doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcwp ; patients ; decompensated systolic heart failure ; hf
H-480	-0.38719820976257324	▁early ▁transmit ral ▁blood ▁flow ▁veloci ty ▁; ▁tissu e ▁; ▁do pp ler ▁; ▁dia sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁; ▁pc p ▁; ▁de com pensa ted ▁sy sto lic ▁heart ▁failure ▁; HF
D-480	-0.38719820976257324	early transmitral blood flow velocity ; tissue ; doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; decompensated systolic heart failure ;HF
P-480	-1.6558 -0.6766 -0.9095 -0.6814 -0.0932 -2.1874 -0.0388 -0.4095 -0.5536 -0.1821 -0.5952 -0.3301 -0.0139 -0.6617 -1.0984 -1.1713 -0.1680 -0.0413 -0.2399 -0.0993 -0.9139 -0.2217 -0.8614 -0.0262 -0.1618 -0.0062 -0.0315 -0.0608 -0.0600 -0.3365 -0.0199 -0.0955 -0.2433 -0.1812 -0.0915 -1.4594 -0.2031 -0.6782 -0.0294 -0.1349 -0.2646 -0.0131 -0.0901 -0.1030 -0.3693 -0.1073 -0.2070 -0.3002 -0.2103 -0.0717
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic ; lv ejection fraction ; lv strain ; strain ; systole ; diastolic ; lv strain rate ; diastole ; transmitral flow ; patients ; sinus rhythm ; follow-up
H-951	-0.48482295870780945	▁sy sto lic ▁indice s ▁; LV ▁e je ction ▁ fraction ▁; ▁LV ▁strain ▁; stra in ▁rate ▁; ▁sy stol e ▁; ▁dia sto lic ▁indice s ▁; ▁LV ▁strain ▁rate ▁; ▁dia stol e ▁; ▁early ▁transmit ral ▁flow ▁; ▁sinus ▁ rhythm
D-951	-0.48482295870780945	systolic indices ;LV ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow ; sinus rhythm
P-951	-3.2130 -0.6509 -0.0236 -0.1458 -0.0428 -0.2731 -0.1599 -0.7395 -0.3308 -0.0498 -0.3060 -0.0199 -0.3090 -0.6715 -1.2005 -1.5992 -0.9657 -0.1188 -0.1090 -0.3819 -0.1900 -0.3500 -0.4506 -0.3366 -0.0892 -0.5032 -0.0485 -0.2185 -0.0520 -0.1935 -2.0867 -1.6385 -0.2797 -0.2335 -0.1320 -0.0884 -0.3850 -1.0103 -1.3997 -0.3227 -0.2962 -0.3241 -0.4849 -0.0815 -0.1578 -0.2319 -0.2968 -0.0793
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak vo2 ; exercise
H-1984	-1.302420973777771	▁VO 2 ▁; ▁exercise ▁; ▁body ▁mass ▁; ▁die t
D-1984	-1.302420973777771	VO2 ; exercise ; body mass ; diet
P-1984	-3.0729 -0.1471 -0.7777 -2.3714 -0.6465 -1.7312 -0.1547 -1.4971 -2.1892 -0.2023 -2.6396 -0.1992
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard ratios ; confidence interval ; hf ; hf
H-1107	-1.181950330734253	▁hazard ▁ratio s ▁; ▁CI ▁; ▁early - ons et ▁ HF ▁; ▁ HF
D-1107	-1.181950330734253	hazard ratios ; CI ; early-onset HF ; HF
P-1107	-3.9930 -0.7785 -0.4619 -0.4316 -4.5051 -0.3470 -1.5297 -0.1746 -0.7815 -0.1643 -0.4946 -0.4573 -0.6258 -3.1763 -1.6580 -0.3821 -0.1322
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami ; patient ; hospital ; hospital compare ; p-value
H-1698	-1.034778118133545	▁ AMI ▁patient ▁; ▁hospital ▁; ▁hospital ▁Compar e
D-1698	-1.034778118133545	AMI patient ; hospital ; hospital Compare
P-1698	-1.7101 -0.2043 -2.6470 -0.7677 -0.2258 -1.1129 -1.4069 -0.5654 -0.0433 -2.5531 -0.1461
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass spectrometry ; c-terminally ; nt-probnp ; physiological ; proteolysis
H-1517	-0.6713470816612244	▁Mass ▁spec tro met ry ▁; ▁circula ting ▁NT - pro b NP ▁; ▁physio logic al ▁prote ol ysis ▁; ▁le u 3- g ly 4 ▁; ▁pro 6 - ▁g ly 7 ▁; ▁pro 75 - ▁ar g
D-1517	-0.6713470816612244	Mass spectrometry ; circulating NT-probNP ; physiological proteolysis ; leu3-gly4 ; pro6- gly7 ; pro75- arg
P-1517	-0.2174 -0.4961 -0.3412 -0.1068 -4.6514 -0.3393 -0.0258 -0.0876 -1.1579 -0.0523 -0.1174 -1.3621 -0.4146 -0.3535 -0.0272 -0.3488 -0.0269 -0.0379 -0.4820 -0.4189 -0.4420 -0.5546 -0.0056 -0.2107 -2.7577 -0.0683 -1.9688 -0.3286 -0.1613 -1.7002 -0.0303 -3.4471 -0.1599 -0.3682 -1.0902 -0.1502 -2.1176 -0.0118 -0.3150 -0.2032 -0.9517 -0.0884
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt ; nt-probnp ; report ; ctnt ; nt-probnp ; clinical ; hf
H-292	-0.3623894453048706	▁c t n t ▁; ▁NT - pro b NP ▁; ▁laborator y ▁report ▁; ▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF
D-292	-0.3623894453048706	ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF
P-292	-0.0557 -0.2680 -0.0991 -0.5061 -0.1914 -0.2023 -0.0944 -0.0672 -1.2149 -0.3787 -0.3236 -0.4471 -0.1052 -0.0681 -0.4248 -0.0269 -0.3716 -0.0371 -0.8138 -0.1804 -0.3102 -0.0775 -0.0890 -1.0578 -0.3989 -0.3729 -0.5016 -0.8482 -1.1893 -0.1498
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef ; patients ; new york heart association class ii ; ejection fraction ; fes ; placebo
H-1329	-0.8989121317863464	▁ HF p EF ▁; ▁New ▁York ▁Heart ▁association ▁; ▁mean ▁e je ction ▁ fraction
D-1329	-0.8989121317863464	HFpEF ; New York Heart association ; mean ejection fraction
P-1329	-0.4926 -2.2108 -0.1749 -0.7011 -0.8298 -2.6155 -1.0474 -1.3989 -0.5333 -0.9235 -2.7804 -0.0892 -0.1929 -0.0620 -0.5391 -0.0154 -1.4639 -0.1095
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left ventricular ; systolic pressure ; ejection fraction ; fractional shortening ; cardiac output ; lv end-diastolic pressure ; mi ; metoprolol
H-1548	-0.43090537190437317	▁de press ed ▁left ▁vent ri cular ▁; LV ▁; ▁sy sto lic ▁pressure ▁; ▁pressure ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁cardiac ▁output ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁met o pro lol
D-1548	-0.43090537190437317	depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; metoprolol
P-1548	-0.6107 -0.0209 -0.0792 -0.1306 -0.0386 -1.2504 -0.1203 -0.3729 -0.2532 -0.4171 -0.0488 -0.2615 -0.1392 -1.0999 -0.2599 -0.8801 -0.3883 -0.0741 -0.0950 -0.0516 -0.4395 -0.0098 -0.2206 -3.3236 -0.0035 -0.0647 -0.2655 -0.0417 -0.2521 -0.3105 -0.1748 -0.0097 -0.3060 -0.2128 -0.7877 -2.7483 -0.0687 -0.0286 -0.1436 -0.0784 -0.4413 -0.2838 -3.0567 -0.2707 -0.0485 -0.2227 -0.2024 -0.0749
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction ; clinical ; carotid ; baroreflex activation therapy ; bat ; heart failure ; hf
H-1867	-0.5977984070777893	▁bar ore flex ▁Activ ation ▁Therapy ▁; ▁Heart ▁Fail ure ▁With ▁a ▁Red u ced ▁e je ction ▁Fra ction ▁; ▁caro tid ▁baro re flex ▁activa tion ▁ therapy ▁; BAT ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1867	-0.5977984070777893	baroreflex Activation Therapy ; Heart Failure With a Reduced ejection Fraction ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
P-1867	-4.6498 -1.7143 -0.1779 -1.2791 -0.1419 -0.1135 -0.4377 -0.7853 -0.3048 -0.7454 -2.4778 -0.3119 -0.7511 -0.0345 -0.5612 -0.2831 -0.0209 -0.0086 -0.7132 -0.0051 -0.3729 -0.4917 -0.1617 -0.9155 -2.5607 -0.1722 -0.0353 -0.4975 -0.7930 -0.0234 -0.1430 -0.1186 -0.1254 -1.0033 -0.2127 -0.1037 -0.1942 -0.1973 -0.1960 -0.0767
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome ; hazard ratio
H-1748	-0.8852076530456543	haz ard ▁ratio ▁; HR ▁; HR
D-1748	-0.8852076530456543	hazard ratio ;HR ;HR
P-1748	-4.9013 -0.0180 -0.0224 -0.2350 -0.1816 -1.1335 -0.6314 -0.6609 -0.1827
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf ; blood glucose ; obesity ; systemic hypertension ; rheumatic fever ; disease
H-1793	-0.4611090123653412	▁ HF ▁; ▁raised ▁blood ▁gluco se ▁levels ▁; ▁obes ity ▁; ▁to ba cco ▁; ▁system ic ▁hyper tension ▁; SH ▁; ▁rhe u matic ▁fe ver ▁; ▁cha gas ▁; ▁disease ▁; ▁la
D-1793	-0.4611090123653412	HF ; raised blood glucose levels ; obesity ; tobacco ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; la
P-1793	-2.1714 -0.3168 -0.2642 -0.1240 -0.3054 -0.0082 -0.0783 -0.3901 -0.2201 -0.2385 -3.1451 -0.1983 -0.0112 -0.9176 -0.0938 -0.2001 -0.0422 -0.1688 -0.0647 -0.0155 -0.1732 -0.1737 -0.0892 -0.0173 -0.0618 -0.2215 -0.0702 -0.0459 -0.1503 -0.9282 -0.0089 -2.5567 -0.2383 -0.1679 -1.2419 -1.8438 -0.0980
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard ratios ; crf ; obese ; body mass index
H-1772	-0.40679022669792175	▁c RF ▁; ▁over weight ▁; ▁obes e ▁body ▁mass ▁index
D-1772	-0.40679022669792175	cRF ; overweight ; obese body mass index
P-1772	-0.6614 -1.3932 -0.6629 -0.3876 -0.1847 -0.3139 -0.1003 -0.0967 -0.8133 -0.1340 -0.0134 -0.4067 -0.1202
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq ; patients ; hfpef ; log rank ; ef
H-789	-0.9621261358261108	▁ cc q ▁; ▁ HF p EF ▁; log ▁rank ▁; ▁EF
D-789	-0.9621261358261108	ccq ; HFpEF ;log rank ; EF
P-789	-1.8342 -0.9444 -2.0983 -1.1948 -1.0832 -0.6022 -0.0659 -0.8505 -0.4387 -1.6855 -1.8544 -0.4258 -0.9372 -0.2519 -0.1646
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline ; egfr ; egfr ; egfr ; hypertension ; diuretics ; esrd
H-395	-0.7954471707344055	▁e g FR ▁group ▁II ▁; ▁e g FR ▁group ▁III ▁; ▁e g FR ▁group ▁IV ▁; ▁un control led ▁hyper tension ▁; ▁di ure tics ▁; ▁age ▁; ▁ES RD
D-395	-0.7954471707344055	egFR group II ; egFR group III ; egFR group IV ; uncontrolled hypertension ; diuretics ; age ; ESRD
P-395	-0.2194 -2.1603 -0.2516 -2.5324 -2.2465 -0.3157 -0.1044 -2.2586 -0.5366 -1.7773 -0.7157 -0.3290 -0.0679 -2.2985 -0.3498 -1.6186 -0.5053 -0.2964 -0.0085 -0.0053 -1.2198 -0.1200 -0.0553 -0.2437 -0.5057 -1.0977 -0.3291 -0.3070 -2.2540 -0.4854 -1.0594 -0.4189 -0.2199 -0.1315
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial ; phosphodiesterase-2 ; pde2 ; heart failure ; hf ; beta-adrenergic receptor ; β-ar ; healthy ; diseased ; cardiomyocytes
H-1208	-0.4413539469242096	▁my o card ial ▁ phos pho dies tera se -2 ▁; ▁p de 2 ▁; ▁heart ▁failure ▁; HF ▁; ▁p de 2- media ted ▁effects ▁; ▁beta - ad r energi c ▁receptor ▁; β - AR ▁; ▁cardio my o cy tes
D-1208	-0.4413539469242096	myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
P-1208	-0.9726 -0.2905 -0.3948 -1.2614 -0.2112 -0.0262 -0.3961 -3.0235 -0.0512 -0.3652 -0.3592 -0.2996 -0.2222 -1.4953 -0.9906 -0.2044 -0.6825 -0.0602 -0.2259 -0.6058 -0.2080 -0.3339 -0.9846 -0.1014 -0.3364 -0.0660 -0.3146 -0.9547 -0.0764 -0.0397 -0.0539 -0.3358 -0.9313 -0.1110 -0.0089 -0.5830 -0.1843 -0.0108 -0.7098 -0.4924 -0.1495 -0.6109 -0.3650 -0.1316 -0.1082 -0.3113 -0.0919
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart failure ; patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator ; carvedilol ; atp ; shock therapy ; metoprolol
H-866	-0.2999986410140991	▁heart ▁failure ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁; ▁car vedi lol ▁; ▁ATP ▁; ▁shock ▁ therapy ▁; ▁met o pro lol
D-866	-0.2999986410140991	heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
P-866	-1.8716 -0.1450 -1.0400 -0.0915 -0.0484 -0.1439 -0.0261 -0.9739 -1.5420 -0.0447 -0.4756 -0.0223 -0.1040 -0.6433 -0.3819 -0.2498 -0.3991 -0.2566 -0.0312 -0.1105 -0.0296 -0.2169 -0.0984 -0.1573 -0.0847 -0.6535 -0.3351 -0.1524 -0.3704 -0.3405 -0.0036 -0.0343 -0.0578 -0.3244 -0.1606 -0.3008 -0.0268 -0.3906 -0.0239 -0.4177 -0.0374 -0.2505 -0.0483 -0.1363 -0.4470 -0.0999
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich cocoa ; skm ; mitochondrial structure ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; murphy ; naviaux ; hogan ; ceballos ; maisel ; henry
H-1245	-0.2570357918739319	ERC ▁; ▁e pica tech in - rich ▁coco a ▁; ▁Sk m ▁mito cho ndri al ▁structure ▁; ▁ta ub ▁; ▁Ram i rez - s anche z ▁; ▁ci ar aldi ▁; ▁per kin s ▁; ▁Murphy ▁; ▁na vi aux ▁; ▁Hoga n ▁; ▁ce ball os ▁; ▁Mais el ▁; ▁Henry
D-1245	-0.2570357918739319	ERC ; epicatechin-rich cocoa ; Skm mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
P-1245	-1.8126 -0.4672 -0.4889 -0.0179 -0.1899 -0.1851 -0.0989 -0.0193 -0.0695 -0.0135 -0.4075 -0.2472 -0.3256 -0.1274 -0.7379 -0.4522 -0.0187 -0.3791 -0.2284 -0.3102 -0.1187 -0.3635 -1.0376 -0.0220 -0.0081 -0.0218 -1.5132 -0.0036 -0.0088 -0.3443 -0.0100 -0.0040 -0.0061 -0.2907 -0.5116 -0.5163 -0.0201 -0.1471 -0.2512 -0.0995 -0.0037 -0.0053 -0.0059 -0.2181 -0.0464 -0.0179 -0.2441 -0.0398 -0.2586 -0.1268 -0.1931 -0.7312 -0.0033 -0.2553 -0.0080 -0.5391 -0.0595
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up ; death ; readmission ; patients ; physician ; physicians
H-1420	-1.046264410018921	▁follow - up ▁visit s ▁; ▁urgent ▁read mission
D-1420	-1.046264410018921	follow-up visits ; urgent readmission
P-1420	-0.3908 -0.2333 -0.0516 -2.3281 -0.1490 -0.8150 -3.0709 -1.3912 -0.9542 -2.0232 -0.1016
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena overexpression ; tac ; surgery ; mena ; cardiac hypertrophy ; cardiac
H-1816	-0.6196098327636719	▁ TTA ▁; ▁t g t et Men a ▁; ▁ TAC ▁surgery ▁; ▁cardiac ▁hyper trop hy ▁; ▁ TTA ▁; ▁t g t et Men a ▁; ▁post - TAC ▁cardiac ▁functional ▁deteriora tion
D-1816	-0.6196098327636719	TTA ; tgtetMena ; TAC surgery ; cardiac hypertrophy ; TTA ; tgtetMena ; post-TAC cardiac functional deterioration
P-1816	-2.1029 -1.5258 -1.2854 -1.9346 -0.1273 -0.1039 -0.1286 -0.2312 -0.0394 -0.7897 -1.2670 -0.1746 -0.4676 -0.2283 -0.1608 -0.2304 -0.0204 -1.1751 -0.3157 -1.3372 -0.2400 -1.2499 -1.4036 -0.1446 -0.1151 -0.0451 -0.3316 -0.0144 -0.5614 -1.7629 -0.0201 -0.4122 -0.3889 -0.4749 -1.1946 -1.2676 -0.1815 -0.0907
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography ; lv end-diastolic volume ; mitral valve opening ; mva
H-357	-0.528668999671936	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁; ▁m 2 ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁m VA ▁; ▁pressure ▁gradi ent
D-357	-0.528668999671936	echocardiography ; LV ; end-diastolic volume ; m2 ; MR ; mitral valve opening ; mVA ; pressure gradient
P-357	-0.0552 -0.1432 -0.1640 -0.7062 -0.3039 -0.5094 -1.2049 -1.5532 -2.1575 -0.0627 -0.0151 -0.0795 -0.0399 -0.1529 -0.3967 -0.3400 -3.9675 -0.3179 -0.3911 -0.3496 -0.0475 -0.0359 -0.0525 -0.0827 -1.0761 -0.3482 -0.0705 -1.6472 -0.2850 -0.3693 -0.0083 -0.1147 -0.8486 -0.0776
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd ; diuretic ; hf ; outcomes ; clinical ; hospitalizations ; pdrelated ; complications
H-901	-0.742285430431366	▁PD ▁; ▁di ure tic ▁re frac tory ▁; ▁ HF ▁; ▁PD related ▁complica tions
D-901	-0.742285430431366	PD ; diuretic refractory ; HF ; PDrelated complications
P-901	-1.8436 -0.3255 -0.2643 -0.2762 -1.0222 -0.0292 -0.0582 -0.1969 -0.4945 -1.8085 -0.5638 -0.7714 -2.5508 -2.3200 -0.0184 -0.5511 -0.1857 -0.0809
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial ; glycolysis
H-1785	-0.286602258682251	▁ATP ▁; ▁mito cho ndri al ▁oxid ation ▁; ▁gluco se ▁; ▁lac tate ▁; ▁fa tty ▁acid s ▁; ▁my o card ial ▁gly col ysis
D-1785	-0.286602258682251	ATP ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
P-1785	-0.1685 -1.6584 -0.1471 -0.6593 -0.1796 -0.0122 -0.0256 -0.3282 -0.3200 -0.0173 -0.1107 -0.2970 -0.0018 -0.0835 -0.2500 -0.0592 -0.1081 -0.0107 -0.1053 -0.3036 -0.6902 -0.2311 -0.4061 -1.1422 -0.0216 -0.0894 -0.1603 -0.6156 -0.1088
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients ; eplerenone ; potassium ; potassium ; hospitalization ; hyperkalemia ; medication ; adverse events
H-1226	-0.5232682824134827	▁e pler en one ▁; ▁po tas s ium ▁; ▁po tas s ium ▁; ▁hyper kal emia ▁; ▁medication
D-1226	-0.5232682824134827	eplerenone ; potassium ; potassium ; hyperkalemia ; medication
P-1226	-0.0574 -0.0744 -0.0926 -0.8844 -0.4251 -0.7463 -0.7524 -0.6845 -0.4747 -0.3084 -1.1952 -0.9631 -0.4966 -0.6574 -0.3931 -1.1538 -0.2882 -0.2417 -0.5881 -0.7333 -0.1970 -0.1041
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient ; new york heart association class iii ; heart failure ; hf ; left ventricular ejection fraction ; periodic breathing ; pb ; report
H-1347	-0.6475250124931335	▁New ▁York ▁Heart ▁association ▁class ▁III ▁heart ▁failure ▁; HF ▁; ▁vent ri cular ▁e je ction ▁; ▁permanent ▁periodic ▁breath ing ▁; ▁p b
D-1347	-0.6475250124931335	New York Heart association class III heart failure ;HF ; ventricular ejection ; permanent periodic breathing ; pb
P-1347	-2.4388 -0.8153 -1.6898 -0.5217 -1.6730 -0.0563 -0.6777 -0.1981 -0.2238 -0.8619 -0.2416 -0.7874 -2.1082 -0.2833 -0.0836 -0.1300 -0.0239 -1.7102 -1.4917 -0.0914 -0.4017 -0.1203 -0.1852 -0.0805 -0.3614 -0.1429 -0.0832
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation ; bottleneck stent ; lad ; lcx ; myocardial ischemia ; stent ; ischemic heart failure ; stent ; therapeutic
H-514	-0.3808458149433136	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁ LAD ▁; ▁ LC x ▁; ▁por cine ▁model ▁; ▁rever sible ▁my o card ial ▁ ische mia ▁; open ▁sten t ▁; ▁ ische mic ▁heart ▁failure ▁; ▁sten t
D-514	-0.3808458149433136	bottleneck stent ; proximal LAD ; LCx ; porcine model ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
P-514	-0.8133 -0.1628 -0.0140 -0.0644 -0.1102 -0.4949 -0.0548 -0.0491 -0.2531 -0.0942 -0.2973 -1.9063 -0.4511 -1.3306 -0.3370 -2.8431 -0.1157 -0.0603 -0.7997 -0.0048 -0.0149 -0.4839 -0.2678 -0.1497 -0.3887 -0.1691 -0.0733 -0.5119 -0.2757 -0.5965 -0.0839 -0.1043 -0.1720 -0.4260 -0.0300 -0.1062 -0.2938 -0.0523 -0.1532 -1.4567 -0.0477 -0.1754 -0.0868
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium ; spironolactone ; aas
H-1705	-0.6153254508972168	▁Po tas s ium ▁; ▁spi rono lac tone ▁; ▁AA s
D-1705	-0.6153254508972168	Potassium ; spironolactone ; AAs
P-1705	-2.4207 -0.1592 -0.2277 -0.0840 -0.4742 -0.1711 -0.0700 -0.1133 -0.1289 -0.3874 -1.1599 -0.3879 -2.7198 -0.1102
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese ; body mass index ; chronic ; stable ; hfpef
H-1978	-0.8404241800308228	▁obes e ▁; SD ▁; ▁body ▁mass ▁index ▁; ▁h FP EF
D-1978	-0.8404241800308228	obese ;SD ; body mass index ; hFPEF
P-1978	-2.0233 -0.1377 -1.1728 -0.7148 -0.4333 -0.5310 -0.0904 -0.0065 -0.3043 -3.3502 -1.8107 -0.7345 -0.3270 -0.1294
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic ; vegf pathway ; intravenously ; injected ; adenoviral ; vegf receptor ; adenovirus
H-456	-0.4729611277580261	▁pro angi ogen ic ▁effects ▁; ▁b ▁; ▁VE GF ▁path way ▁; ▁rat s ▁; ▁a den ovi ral ▁ve ctor ▁; ▁de co y ▁VE GF ▁receptor ▁; ▁ad - f lk ▁; ▁ade no virus ▁; ▁ad - c ▁; ▁treatment
D-456	-0.4729611277580261	proangiogenic effects ; b ; VEGF pathway ; rats ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; adenovirus ; ad-c ; treatment
P-456	-0.1853 -0.0551 -0.2506 -0.1407 -0.8347 -0.4590 -0.8146 -0.5900 -3.2571 -0.0862 -0.1344 -0.0691 -0.4044 -2.2782 -0.0898 -0.5519 -0.4224 -0.0590 -0.1621 -0.1958 -0.9114 -0.0058 -0.2816 -0.0679 -0.0011 -0.0602 -1.9723 -0.0726 -0.0254 -0.2060 -0.4243 -0.0713 -0.7460 -0.0455 -0.1804 -0.2623 -0.0426 -0.0117 -0.2056 -0.5012 -0.0411 -0.3868 -0.8358 -0.8536 -2.4243 -0.0787
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical ; post-lvad ai ; aortic valve ; leaflet ; bioprosthetic aortic valve replacement ; functional capacity ; lvad ; patients ; symptomatic
H-552	-0.5736885666847229	▁post - ▁l VAD ▁AI ▁; ▁a or tic ▁val ve ▁; ▁le a flet ▁repair ▁; ▁bio pro sthetic ▁a or tic ▁val ve ▁replace ment ▁; ▁CF ▁l VAD ▁; ▁AI
D-552	-0.5736885666847229	post- lVAD AI ; aortic valve ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; AI
P-552	-2.3541 -0.0233 -1.9380 -0.0424 -2.0342 -1.1890 -0.0747 -0.1238 -0.9765 -0.3841 -0.1761 -1.1887 -0.0559 -0.0163 -0.0345 -0.4811 -0.0955 -0.0057 -0.0471 -0.0289 -0.8634 -0.1075 -1.0461 -0.4688 -0.2158 -1.0076 -0.2926 -0.2355 -0.3745 -0.7431 -0.0357 -0.4473 -2.4920 -0.3573 -0.1221
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced pulmonary artery systolic pressure ; pasp ; stress doppler echocardiography ; right ventricular contractile reserve ; patients ; pulmonary hypertension ; right heart failure
H-822	-0.36400580406188965	▁pulmonar y ▁arter y ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁do pp ler ▁e cho card i ography ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension ▁; ▁right ▁heart ▁failure
D-822	-0.36400580406188965	pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
P-822	-2.2640 -0.1325 -0.0528 -0.1164 -0.2316 -0.1196 -0.0929 -0.3664 -0.4396 -0.6456 -0.3551 -0.3394 -1.6656 -0.0111 -0.5156 -0.0644 -0.2128 -0.3624 -0.3378 -0.1588 -0.3232 -0.3521 -0.0420 -2.2436 -0.2622 -0.0229 -0.1563 -0.0188 -0.1867 -0.0632 -0.1229 -0.2320 -0.0252 -0.1768 -0.5231 -0.2241 -0.2538 -0.3931 -0.0899
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline ; embase ; healthstar ; cinahl ; cochrane library ; campbell collaboration ; joanna briggs institute evidence based practice ; centre for reviews and dissemination ; evidence based practice centres
H-1844	-0.525342583656311	▁med line ▁; EMBA se ▁; ▁he al th star ▁; ▁c INA HL ▁; ▁co ch rane ▁Library ▁; ▁Campbell ▁Col labora tion ▁; ▁Joan na ▁Brig gs ▁institut e ▁voor ▁review s ▁and ▁Disse mination ▁; ▁e viden ce ▁based ▁practice ▁Centre s
D-1844	-0.525342583656311	medline ;EMBAse ; healthstar ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institute voor reviews and Dissemination ; evidence based practice Centres
P-1844	-1.0901 -0.5662 -0.2878 -0.9463 -0.9561 -0.1674 -0.2800 -0.1276 -1.8224 -1.0023 -0.2161 -1.6183 -2.1192 -0.5441 -0.1875 -0.0415 -0.0947 -0.0177 -0.0850 -0.1568 -0.0358 -0.5581 -0.0666 -0.0286 -0.1855 -0.0588 -0.4632 -0.1353 -0.0443 -0.2830 -0.1768 -2.8206 -0.7304 -0.7248 -0.4962 -0.0537 -0.0182 -0.7875 -0.7709 -0.0069 -0.2858 -1.0180 -0.5221 -1.3332 -0.5611 -0.1231 -0.0756
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods study ; health care ; systolic heart failure ; prescribed ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
H-1123	-0.5945912599563599	▁sy sto lic ▁heart ▁failure ▁; ▁β - block er ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block er
D-1123	-0.5945912599563599	systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
P-1123	-5.3949 -0.2195 -0.1055 -0.6726 -0.2997 -0.3323 -0.3593 -0.0405 -0.4235 -0.2412 -0.2737 -3.1212 -1.0614 -0.2774 -0.7825 -0.0479 -0.0846 -0.0268 -0.0643 -0.1037 -0.0455 -0.2633 -0.4312 -1.1462 -0.3198 -1.3985 -0.2862 -0.1349 -0.1050 -0.7689 -0.2654 -0.4095 -0.1144
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ; angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
H-647	-0.3414958715438843	▁heart ▁failure ▁; ▁neuro - hormon al ▁system ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁in tolerance ▁; ▁beta ▁receptor ▁block ers ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists
D-647	-0.3414958715438843	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
P-647	-3.0228 -0.2389 -0.3725 -0.0383 -0.0543 -0.0215 -0.0210 -0.0607 -0.4537 -0.9512 -0.5621 -0.1783 -1.2347 -0.0769 -0.1833 -0.0385 -0.0996 -0.1000 -0.2909 -0.3018 -0.0503 -0.2941 -0.9687 -0.0226 -0.3338 -0.0983 -0.1935 -0.8073 -0.6631 -0.1458 -0.8756 -0.1072 -0.2214 -0.0569 -0.1142 -0.0723 -0.2929 -0.4787 -0.0177 -0.2248 -0.0634 -0.0139 -0.4366 -0.1105 -0.2227 -0.0087 -0.2441 -0.8436 -1.3039 -0.1306 -0.0029 -0.1203 -0.0016 -0.7106 -0.4723 -0.0973
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest ; rs ; rs synchrony ; ste ; noninvasive ; rvpo ; rs synchrony ; strain ; bivp
H-330	-0.5188891291618347	▁open ▁che st ▁model ▁; ▁twist ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁ STE ▁; ▁ rv PO ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁Bi VP ▁; ▁CO
D-330	-0.5188891291618347	open chest model ; twist ; RS ; RS synchrony ; CS ; STE ; rvPO ; RS synchrony ; CS ; BiVP ; CO
P-330	-0.0137 -0.2515 -0.0306 -0.2277 -0.2008 -0.0034 -0.2079 -0.0331 -0.2995 -0.0409 -0.0053 -0.2750 -0.1629 -1.2126 -0.2798 -0.9305 -2.2384 -0.2347 -1.8950 -1.6432 -1.4269 -0.1596 -0.2849 -0.0063 -0.3904 -0.1442 -0.3873 -0.2049 -1.1958 -0.3017 -0.6990 -1.9867 -0.1734 -0.0946
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse ; pasp ; tapse ; pasp ; cox regression ; kaplan-meier analyses ; tapse ; pasp
H-498	-0.910653293132782	▁T AP se ▁; ▁pas p ▁; ▁t AP se - to - pas p ▁ratio ▁; TA PS e ▁; PAS p ▁; ▁co x ▁re gression ▁; ▁ka plan - me ier ▁analyse s ▁; ▁
D-498	-0.910653293132782	TAPse ; pasp ; tAPse-to-pasp ratio ;TAPSe ;PASp ; cox regression ; kaplan-meier analyses ;
P-498	-4.4871 -0.4037 -1.2213 -0.5115 -1.2087 -0.5797 -0.4337 -3.5430 -0.6457 -0.7895 -0.0949 -0.2130 -0.1091 -1.1567 -0.9719 -0.6871 -0.3676 -2.9455 -1.0741 -0.4825 -0.9661 -1.0766 -0.7624 -0.4835 -0.1794 -0.1287 -0.0307 -0.0127 -0.2649 -0.1843 -0.0353 -0.0623 -0.5767 -0.0824 -0.4180 -0.1992 -0.4926 -3.9436 -3.6899
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom ; cpet ; patients ; chf ; patients ; exercise ; exercise ; patients ; exercise ; rehabilitation
H-1880	-0.7399871349334717	▁c PET ▁; ▁CHF ▁; ▁exercise ▁; ▁exercise
D-1880	-0.7399871349334717	cPET ; CHF ; exercise ; exercise
P-1880	-1.0512 -0.9382 -0.4953 -0.0425 -0.7702 -1.1156 -0.6032 -0.7973 -1.4572 -0.1291
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart failure ; hf ; mrna splicing ; cardiac ; scn5a ; endoplasmic reticulum
H-1080	-0.32767894864082336	▁human ▁heart ▁failure ▁; HF ▁; ▁m RNA ▁s plic ing ▁; ▁volta ge - ga ted ▁cardiac ▁; ▁na + ▁channel ▁α - sub un it ▁; ▁s cn 5 a ▁; ▁en co ding ▁tru nca ted ▁; ▁non function al ▁channel s ▁; ▁en do plas mic ▁reti culum
D-1080	-0.32767894864082336	human heart failure ;HF ; mRNA splicing ; voltage-gated cardiac ; na+ channel α-subunit ; scn5a ; encoding truncated ; nonfunctional channels ; endoplasmic reticulum
P-1080	-3.4359 -0.2774 -0.1572 -0.2594 -0.6371 -0.3334 -0.0135 -0.0714 -0.5956 -0.0530 -0.1455 -0.3014 -0.0258 -0.0550 -0.0954 -0.0672 -0.3191 -0.0757 -1.6559 -0.0527 -0.7888 -0.0720 -0.7930 -0.0184 -0.0101 -0.0741 -0.0288 -0.2975 -0.3625 -0.2226 -0.4843 -0.1898 -0.2540 -0.3926 -0.1069 -0.1472 -0.1011 -0.0309 -0.0167 -1.2723 -1.1946 -0.0093 -0.0120 -0.0636 -0.0469 -0.4327 -0.0431 -0.1490 -0.0815 -1.0179 -0.0021 -0.0019 -0.2774 -0.0715
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart failure ; diagnosis ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; disease
H-988	-0.5547623038291931	▁pa e dia tric ▁heart ▁failure ▁; ▁my o card itis ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure ▁; ▁heart ▁failure ▁; ▁an thra cycli ne ▁; ▁malign ant ▁disease
D-988	-0.5547623038291931	paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; malignant disease
P-988	-0.2793 -0.1507 -0.1132 -0.9778 -1.9151 -0.3678 -0.3778 -1.1417 -0.3585 -0.4488 -0.5348 -0.3518 -0.0828 -0.0802 -0.0397 -0.4913 -0.4229 -0.0240 -0.3918 -1.7912 -0.1827 -0.2539 -3.8160 -0.2436 -0.2342 -0.1855 -0.0737 -0.3266 -0.6475 -0.3247 -1.3291 -0.3892 -0.3586 -0.6059 -0.1045
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; clinical ; evidence-based ; medications ; costs ; outcomes
H-2010	-0.7619717717170715	▁Tools ▁for ▁economic ▁analysis ▁of ▁Patient ▁management ▁Interven tions ▁in ▁Heart ▁Fail ure ▁; ▁cost - ef ective ness ▁model ▁; ▁medication s ▁; ▁costs
D-2010	-0.7619717717170715	Tools for economic analysis of Patient management Interventions in Heart Failure ; cost-efectiveness model ; medications ; costs
P-2010	-0.8727 -0.5427 -0.9209 -0.1882 -1.0671 -0.3335 -0.4935 -0.3459 -0.0468 -0.4453 -0.7635 -0.3116 -0.6067 -0.8619 -2.1445 -0.0461 -1.8333 -0.0595 -0.5623 -0.7789 -0.4857 -4.3070 -0.0446 -0.1956 -2.0883 -0.1517 -0.0757
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic peptides ; nps ; b-type np ; n-terminal pro-b-type np ; diagnosis ; acute heart failure ; patients ; emergency department ; acute dyspnea
H-1020	-0.4045398533344269	▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁b - type ▁ NP ▁; ▁n - termin al ▁pro - b - type ▁ NP ▁; ▁a cute ▁heart ▁failure ▁; ▁Emer gen cy ▁Department ▁; ED ▁; ▁a cute ▁dys pne a
D-1020	-0.4045398533344269	natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-b-type NP ; acute heart failure ; Emergency Department ;ED ; acute dyspnea
P-1020	-0.0129 -0.6907 -0.9443 -1.9640 -0.7138 -0.2747 -0.4529 -0.3564 -0.1176 -0.5778 -0.1925 -4.1300 -0.0753 -0.0254 -0.2837 -0.0534 -0.2945 -1.1753 -0.0406 -0.0374 -0.0058 -0.0526 -0.0217 -1.0383 -0.0271 -0.0050 -0.0879 -0.0441 -0.3649 -0.7660 -0.0710 -0.4827 -0.0879 -0.1804 -0.1545 -0.2826 -0.1207 -0.2158 -0.2625 -1.4027 -0.3775 -0.3004 -0.0237 -0.1186 -0.0058 -0.1573 -0.2365 -0.1106
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak oxygen consumption ; peak vo2 ; exercise ; exercise oscillatory ventilation ; eov ; partial pressure of end-tidal co2 ; petco2 ; gain ; cardiopulmonary exercise testing
H-1275	-0.6410558819770813	▁oxygen ▁consum p tion ▁; ▁VO 2 ▁; ▁v co 2 ▁s lope ▁; ▁exercise ▁; ▁os cilla tory ▁ventilation ▁; ▁e OV ▁; ▁pressure ▁; ▁end - ti dal ▁CO 2 ▁; PET co 2 ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-1275	-0.6410558819770813	oxygen consumption ; VO2 ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
P-1275	-2.1121 -0.4419 -0.1520 -1.0245 -0.3607 -3.1088 -0.8982 -0.2312 -0.7858 -1.5348 -0.0767 -0.3893 -0.1159 -0.2929 -0.3546 -1.7956 -0.1852 -0.0295 -0.1062 -0.0151 -0.1995 -0.2803 -0.3040 -0.1959 -3.6634 -0.3553 -1.4943 -0.0457 -0.0659 -0.0595 -1.2526 -0.0510 -0.2168 -0.1838 -0.6993 -1.1526 -0.3342 -0.1008 -0.2694 -1.1534 -0.5921 -1.0839 -0.6584 -0.3180 -0.1063
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective cohort study ; denmark ; bisphosphonates ; raloxifene
H-1536	-0.6290613412857056	▁Denmark ▁; ▁bis phos phon ates ▁; ▁ra lo xi fen e
D-1536	-0.6290613412857056	Denmark ; bisphosphonates ; raloxifene
P-1536	-4.5475 -0.3713 -0.1949 -0.0306 -0.1088 -0.6503 -0.4587 -0.9419 -0.0490 -0.1640 -0.0542 -0.4132 -0.7325 -0.0901
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension ; lv dilatation ; lv dysfunction ; mitral valve ; organic ; lesion ; systolic ; diastolic tethering ; etiology
H-365	-0.27713820338249207	▁hyper tension ▁; ▁LV ▁di la tation ▁; ▁LV ▁dys function ▁; ▁MR ▁; ▁MS ▁; ▁mit ral ▁val ve ▁; ▁sy sto lic ▁; ▁dia sto lic ▁te ther ing ▁; ▁MR ▁; ▁MS
D-365	-0.27713820338249207	hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; systolic ; diastolic tethering ; MR ; MS
P-365	-0.5072 -0.0506 -0.1584 -0.0752 -0.4402 -0.1673 -0.0305 -0.2517 -0.0260 -0.0723 -0.0602 -0.1122 -0.3407 -0.1089 -0.4689 -0.8061 -0.0795 -0.0304 -0.0880 -0.0857 -0.3373 -3.7555 -0.0567 -0.0239 -0.4195 -0.0050 -0.0461 -0.0365 -0.0055 -0.5223 -0.0515 -0.1493 -0.3412 -0.2585 -0.0524 -0.1627 -0.0705
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; patients ; diuretic ; therapy ; serum sodium ; systolic function
H-1196	-0.5001131296157837	▁to lv ap tan ▁; ▁hypo na trem ia ▁; ▁United ▁States ▁; ▁japan ▁; ▁con ges tive ▁heart ▁failure ▁; ▁di ure tic ▁ therapy ▁; ▁so dium ▁levels ▁; ▁sy sto lic ▁function
D-1196	-0.5001131296157837	tolvaptan ; hyponatremia ; United States ; japan ; congestive heart failure ; diuretic therapy ; sodium levels ; systolic function
P-1196	-0.0496 -0.4672 -0.4537 -0.0895 -0.3431 -0.7432 -0.8215 -0.0484 -0.9505 -0.3185 -2.7702 -1.0193 -0.3488 -1.5561 -0.3429 -0.1202 -0.2445 -1.1507 -0.3477 -0.0460 -1.1076 -0.3751 -0.9238 -0.7663 -0.6482 -0.0372 -0.6734 -0.2231 -0.0110 -0.2334 -0.1922 -0.0038 -0.0508 -0.0852 -0.4906 -0.3781 -0.0728
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal ; strain ; left ventricle ; echocardiographic ; patients ; baseline ; echocardiography ; crt ; follow-up ; echocardiograms
H-429	-0.5801113247871399	▁longitud in al ▁strain ▁; ▁left ▁vent ric le ▁; ▁e cho car dio graphic ▁measure ments ▁; ▁base line ▁e cho card i ography ▁; ▁c RT ▁; ▁follow - up ▁e cho card i ogram s
D-429	-0.5801113247871399	longitudinal strain ; left ventricle ; echocardiographic measurements ; baseline echocardiography ; cRT ; follow-up echocardiograms
P-429	-2.5839 -0.4651 -0.0359 -0.1928 -0.9338 -0.2389 -0.1262 -1.6170 -0.7856 -0.3168 -0.1574 -0.1281 -0.1162 -0.9483 -0.4728 -1.6219 -0.9406 -0.4504 -2.1898 -0.0170 -0.0572 -0.1452 -0.5520 -1.3935 -0.2765 -0.2529 -0.3885 -2.5270 -0.2414 -0.0099 -0.1255 -0.0391 -0.1563 -0.1559 -0.3718 -1.3525 -0.0371 -0.4645 -0.2413 -0.0779
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating factor ; paf ; metabolic ; enzymes ; follow-up ; patients ; diagnosed ; heart failure ; hf ; healthy
H-1267	-0.6614009141921997	▁plate let - activa ting ▁factor ▁; pa f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure ▁; HF
D-1267	-0.6614009141921997	platelet-activating factor ;paf ; metabolic enzymes ; heart failure ;HF
P-1267	-0.8045 -0.7737 -0.2084 -0.1187 -0.4033 -0.1800 -0.6853 -2.1726 -2.4196 -0.2962 -0.0306 -0.0629 -0.0465 -0.0861 -0.4075 -2.3548 -0.2368 -0.2705 -1.6359 -0.6088 -0.0868
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute care surgery ; acs ; consultations ; oht ; transplantation ; medical therapy ; intravenous ; inotropes ; ventricular assist devices ; vads
H-1281	-0.43085429072380066	▁a cute ▁care ▁surgery ▁; ▁ac s ▁; ▁o HT ▁; ▁transplant ation ▁; ▁medical ▁ therapy ▁; ▁m t ▁; ▁intra ven ous ▁in o trop es ▁; ▁vent ri cular ▁assist ▁devices ▁; VAD s
D-1281	-0.43085429072380066	acute care surgery ; acs ; oHT ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
P-1281	-0.0303 -0.0400 -1.1663 -0.1952 -0.3214 -1.3865 -0.2215 -0.5349 -0.4812 -2.5600 -0.3187 -0.1290 -0.4285 -0.3447 -0.1575 -0.2412 -0.0129 -0.2268 -0.4538 -0.2261 -0.2196 -0.1436 -0.0099 -2.6875 -0.0250 -0.6250 -0.0412 -0.3533 -0.2678 -0.0053 -1.1254 -0.1168 -0.1922 -0.0403 -0.3824 -0.0335 -0.6500 -0.3041 -0.1038
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients ; hfpef ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1178	-0.5453801155090332	▁ HF p EF ▁; ▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁; ▁exercise ▁; ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1178	-0.5453801155090332	HFpEF ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; diastolic mitral flow velocity ; diastolic mitral annular velocity
P-1178	-2.0316 -0.8148 -0.1723 -0.9334 -0.3943 -0.0797 -0.0567 -0.3383 -0.2248 -0.2459 -1.9552 -0.8905 -0.2936 -0.4314 -0.0455 -1.9445 -0.0862 -1.4382 -0.0612 -0.4672 -0.8861 -0.4728 -0.5067 -0.2034 -0.0766 -0.0327 -0.1998 -0.0728 -1.3888 -1.8269 -0.1202 -0.3963 -0.6244 -0.0825 -0.1213 -0.3288 -0.2069 -2.0766 -0.0056 -0.4538 -0.1333 -0.2413 -0.0884
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone system ; raas ; hfref ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpef
H-1489	-0.36516013741493225	▁re nin - angi oten sin - al do ster one ▁system ▁; RA as ▁; ▁h Fr EF ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁al do ster one ▁block ade ▁; ▁ HF p EF
D-1489	-0.36516013741493225	renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
P-1489	-0.0216 -0.5029 -0.0818 -0.0031 -0.1559 -0.8781 -0.0806 -0.0376 -0.2147 -0.1031 -0.7372 -0.0503 -0.5477 -1.1640 -0.2269 -0.2362 -2.1550 -1.3121 -0.9579 -0.2216 -0.3344 -0.7099 -0.1766 -1.0974 -0.1848 -0.0133 -0.0487 -0.1179 -0.0208 -0.0530 -0.0407 -0.2250 -0.2113 -0.2315 -0.7251 -0.1326 -0.5737 -0.2175 -0.1833 -0.0688 -0.1220 -0.0536 -0.1337 -0.1044 -0.4125 -0.3453 -0.2577 -0.3539 -0.6662 -0.5940 -0.1030 -1.2066 -0.2409 -0.0704
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission ; lvet ; patients ; outcome ; tonometric
H-583	-0.6831648349761963	▁l VET ▁; ▁to no metric ▁indice s
D-583	-0.6831648349761963	lVET ; tonometric indices
P-583	-0.3369 -1.5682 -0.7827 -1.8443 -0.1518 -0.1664 -1.4626 -0.1015 -0.2693 -0.1479
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart rate ; blood pressure ; renal function ; spironolactone ; ras blockers ; β-blockers
H-182	-0.5556109547615051	▁heart ▁rate ▁; ▁blood ▁pressure ▁; ▁renal ▁function ▁; ▁spi rono lac tone ▁; ▁ RAS ▁block ers ▁; ▁β - block ers
D-182	-0.5556109547615051	heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
P-182	-2.9398 -0.5061 -0.3696 -0.2994 -0.5432 -0.2354 -0.0174 -0.2025 -0.3085 -0.0233 -0.0261 -0.0742 -0.0335 -0.4068 -1.1244 -0.1735 -0.9588 -0.1720 -0.3076 -3.0797 -0.0993 -0.2660 -0.5427 -1.0390 -0.1414
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac ; β-adrenoceptor blockade ; heart failure ; reverse ; cardiac remodeling ; elevated ; plasma catecholamines
H-1553	-0.3159392178058624	▁cardiac ▁performance ▁; ▁β - ad re no cept or ▁block ade ▁; ▁heart ▁failure ▁; ▁SR ▁ca (2 +) - pump ▁function ▁; ▁cardiac ▁remodel ing ▁; ▁plasma ▁cate chol amine s
D-1553	-0.3159392178058624	cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; cardiac remodeling ; plasma catecholamines
P-1553	-1.2320 -0.1538 -0.2501 -0.0258 -0.0367 -0.1140 -0.3996 -0.6675 -0.7670 -0.2159 -0.2768 -0.3376 -0.3518 -0.6408 -0.1883 -0.4011 -0.0876 -0.6491 -0.5105 -0.0060 -0.0622 -0.0730 -0.5707 -0.3793 -1.0502 -0.0316 -0.0960 -0.5619 -0.0329 -0.0881 -0.0306 -0.1890 -0.2215 -0.2742 -0.0844
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate ratio ; confidence interval ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; therapy ; confidence interval ; β-blockers ; therapy
H-666	-0.599613606929779	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁ therapy
D-666	-0.599613606929779	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers therapy
P-666	-4.8519 -2.0563 -0.1497 -1.0263 -0.4180 -0.0205 -0.0759 -0.1534 -0.1025 -0.0613 -0.0612 -0.3544 -0.7067 -0.0311 -0.1933 -0.3802 -0.0256 -0.3812 -0.1319 -1.2957 -1.4964 -0.0491 -0.2580 -0.1387 -1.5622 -0.0746 -0.5468 -0.1863
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 ; congestive heart failure ; phenotypes ; mitochondrial ; tac ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
H-874	-0.4492720663547516	▁SS 31 ▁; ▁con ges tive ▁heart ▁failure ▁ph eno type s ▁; ▁mito cho ndri al ▁damage ▁; TAC ▁; ▁mito cho ndri al ▁prote ome ▁; ▁mito cho ndri al ▁; ▁non mi to cho ndri al ▁protein
D-874	-0.4492720663547516	SS31 ; congestive heart failure phenotypes ; mitochondrial damage ;TAC ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
P-874	-0.0942 -0.8825 -1.0375 -0.1455 -0.5262 -1.7481 -0.9660 -0.1092 -0.5370 -0.0418 -0.0077 -0.1203 -0.2462 -0.0342 -1.1787 -0.5030 -0.0578 -1.4972 -0.3534 -0.6563 -0.3164 -0.0804 -0.7353 -0.4282 -0.0541 -0.0918 -0.0420 -1.1090 -0.0716 -0.6066 -0.2700 -0.0438 -0.7891 -0.3948 -0.1007 -0.0933 -0.8367 -0.1985 -0.0344 -0.2475 -1.5189 -0.0633
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar ; atpase ; activity ; mrna ; phospholamban ; α-myosin heavy chain ; mrna ; β-myosin heavy chain ; metoprolol
H-1552	-0.35491976141929626	▁my o fi bril lar ▁ca (2 +) - stimul ated ▁ATP ase ▁activity ▁; ▁m RNA ▁levels ▁; ▁SR ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁α - my os in ▁heavy ▁chain ▁; ▁m RNA ▁level ▁; ▁β - my os in ▁heavy ▁chain ▁; ▁met o pro lol
D-1552	-0.35491976141929626	myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA level ; β-myosin heavy chain ; metoprolol
P-1552	-1.1890 -0.5309 -0.0707 -0.1111 -0.2321 -1.1031 -0.4796 -0.0092 -0.0318 -0.0919 -0.3611 -1.7184 -1.2067 -1.0257 -0.3645 -0.0042 -0.0755 -1.1565 -0.3218 -0.1471 -0.7829 -0.4320 -0.0096 -0.0634 -0.2062 -0.2685 -0.3682 -0.1000 -0.1881 -1.0701 -0.2816 -0.4038 -0.1609 -0.0283 -0.2127 -0.1693 -0.5793 -0.2976 -0.0153 -0.4281 -0.0058 -0.1216 -0.4385 -0.2875 -0.4219 -0.0242 -0.2698 -0.1466 -0.2892 -0.2633 -0.0098 -0.5464 -0.0874 -0.3379 -0.0923 -0.5128 -0.3421 -0.0912
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl ; healthy ; hdl ; healthy ; patients ; chf-nyha-iii ; hdl ; nyha-iiib ; patients ; chf-nyha-ii ; hdl ; nyha-ii
H-250	-0.9759107232093811	▁HD L ▁; health y ▁; ▁CHF - NY ha - III ▁; HD L ▁; NY ha - III b ▁; ▁et h ▁; ▁CHF - NY ha - II ▁; HD l ▁; NY ha - II
D-250	-0.9759107232093811	HDL ;healthy ; CHF-NYha-III ;HDL ;NYha-IIIb ; eth ; CHF-NYha-II ;HDl ;NYha-II
P-250	-2.0764 -3.5478 -0.5601 -5.4296 -0.0433 -0.4815 -0.5386 -0.1613 -0.1107 -0.8758 -0.1246 -0.1223 -0.5317 -1.5050 -3.1081 -0.5159 -2.9919 -0.6794 -0.0802 -0.2001 -0.1031 -0.3396 -1.7099 -0.4826 -0.9814 -0.4091 -0.1206 -0.2359 -0.9506 -0.0787 -0.5684 -0.4469 -1.7226 -3.2644 -0.9447 -1.6764 -0.7192 -0.0917 -0.9742 -0.4172 -0.0905
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized ; coronary microembolization-induced hf ; cxl-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
H-420	-0.46927610039711	▁in est het ized ▁dog s ▁; ▁corona ry ▁micro e mbol ization - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁vent ri cular ▁end - dia sto lic ▁pressure ▁; ▁my o card ial ▁oxygen ▁consum p tion ▁; ▁e je ction ▁ fraction ▁; ▁vent ri cular ▁power ▁index
D-420	-0.46927610039711	inesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
P-420	-2.7911 -0.1761 -1.6332 -0.2592 -0.4014 -0.0809 -1.0076 -0.0752 -0.7124 -0.0167 -0.4698 -0.0225 -0.5785 -0.3165 -0.0117 -0.0548 -0.2435 -0.4408 -0.2021 -1.5033 -0.4659 -0.2305 -0.1102 -0.5177 -0.3998 -0.0487 -1.9047 -0.1952 -2.2061 -0.0718 -0.0249 -0.0936 -0.0544 -0.3583 -0.2045 -0.4797 -0.1448 -0.3752 -0.6527 -0.2832 -0.3316 -0.0440 -1.0282 -0.2450 -0.0500 -0.1418 -0.1070 -1.3669 -0.0107 -0.2519 -0.2180 -2.0862 -0.6192 -0.0667 -0.0369 -0.2456 -0.0797
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard error of measurement ; mdc ; mdc
H-805	-0.6129277348518372	▁m DC ▁; ▁confidence ▁level ▁; ▁m DC ▁; ▁m DC ▁; ▁95% ▁confidence ▁level ▁; ▁m DC
D-805	-0.6129277348518372	mDC ; confidence level ; mDC ; mDC ; 95% confidence level ; mDC
P-805	-0.1333 -0.6123 -0.3902 -2.6262 -0.0396 -0.1550 -0.0521 -0.6557 -0.8020 -0.0816 -0.7244 -0.8704 -2.6544 -0.1501 -0.0401 -0.3428 -0.0748 -0.6389 -1.1062 -0.1084
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline ; heart failure ; t1-mapping ; administration ; administration
H-1061	-1.3946555852890015	▁heart ▁failure ▁; ▁contrast ▁agent ▁; ▁after ▁contrast ▁agent ▁administration
D-1061	-1.3946555852890015	heart failure ; contrast agent ; after contrast agent administration
P-1061	-4.4248 -0.3682 -0.5785 -2.8029 -0.0228 -1.1596 -3.6923 -1.1974 -0.0211 -2.1185 -0.2082 -0.1414
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies ; hf ; idiopathic dilated cardiomyopathy ; ischemic ; valvular
H-1794	-0.5922917127609253	▁ HF ▁; ▁LA ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁c ' d ▁; ▁ ische mic ▁; ▁SH ▁; ▁val vu lar ▁; ▁alcohol
D-1794	-0.5922917127609253	HF ; LA ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
P-1794	-1.9924 -1.1139 -0.3672 -3.2046 -1.7251 -1.2951 -0.0911 -0.0230 -0.1788 -0.2624 -0.1050 -0.1041 -0.7888 -0.5686 -0.0099 -0.3637 -0.1552 -3.2731 -0.1330 -0.1696 -0.1971 -0.0496 -0.1267 -0.2918 -0.1906 -0.4154 -0.0478 -0.0068 -0.1448 -0.4369 -0.3117 -1.2681 -0.1338
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 ; functional capacity ; clinical ; outcomes ; ambulatory ; patients ; hf ; heart failure ; outcomes ; exercise ; training ; hf-action ; randomized ; exercise ; training ; hf
H-697	-0.5267444849014282	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁ambula tory ▁patients ▁; ▁ HF ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - ac TION ▁; ▁exercise ▁training ▁; ▁ HF
D-697	-0.5267444849014282	ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; controlled trial Investigating Outcomes of Exercise Training ;HF-acTION ; exercise training ; HF
P-697	-0.2499 -0.1056 -1.2701 -0.1696 -0.6371 -0.3339 -0.2794 -0.1913 -0.3240 -0.5799 -0.5475 -0.6818 -0.2668 -1.3288 -0.1433 -0.4143 -0.3783 -2.3841 -0.7830 -0.3194 -0.0234 -0.5597 -0.1220 -0.7328 -0.0963 -0.0758 -0.2391 -0.2484 -0.2083 -0.4195 -0.2810 -1.3883 -0.1148 -0.6004 -1.4323 -0.4202 -0.9470 -0.3758 -0.3989 -1.4120 -0.8720 -0.1855 -0.1087
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ; exercise rehabilitation ; patient ; chronic heart failure ; chf ; clinical ; cardiopulmonary exercise testing ; cpet ; exercise rehabilitation ; china
H-1879	-0.9594829678535461	▁cardio pul mon ary ▁exercise ▁testing ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁with ▁chronic ▁heart ▁failure ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁Card io P ul mon ary ▁Exerci se ▁test ing ▁; ▁c PET ▁; ▁exercise ▁rehabilita tion ▁; ▁China
D-1879	-0.9594829678535461	cardiopulmonary exercise testing ; exercise rehabilitation ; patients with chronic heart failure ; chronic heart failure ;CHf ; CardioPulmonary Exercise testing ; cPET ; exercise rehabilitation ; China
P-1879	-0.4056 -1.1572 -2.1379 -0.6190 -0.8604 -0.6972 -0.3668 -2.9189 -0.5333 -0.6005 -0.4720 -1.1441 -2.2450 -0.3730 -0.4734 -0.2703 -0.2427 -5.0619 -1.3847 -0.3071 -0.1837 -1.0052 -1.8200 -0.2007 -0.5698 -0.7188 -4.0805 -0.3874 -1.4854 -0.1783 -0.4197 -0.1628 -1.7482 -0.2911 -0.1305 -0.6668 -0.7307 -0.2678 -0.5288 -0.1842 -0.4905 -0.9260 -3.1536 -0.4432 -0.1320
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ; ischemic hf ; pathogenesis ; nyha functional class iv ; estimated glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
H-1704	-0.38871127367019653	▁AA ▁; ▁ ische mic ▁ HF ▁path ogen es is ▁; ▁NY ha ▁functional ▁class ▁IV ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁heart ▁rate ▁; ▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁my o card ial ▁in far ction
D-1704	-0.38871127367019653	AA ; ischemic HF pathogenesis ; NYha functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
P-1704	-1.8929 -1.1330 -0.5053 -0.1126 -0.1177 -0.2341 -0.3703 -1.6930 -0.1455 -0.0855 -0.4761 -0.2931 -0.5449 -1.0626 -0.1553 -0.0752 -0.1163 -0.4296 -0.1053 -0.1312 -0.0469 -0.0616 -0.4593 -0.6001 -0.2541 -0.8605 -0.6469 -0.1465 -0.2590 -0.0142 -0.0900 -0.0195 -0.0013 -0.0084 -0.2394 -0.7362 -0.5926 -0.2456 -0.7978 -0.0547 -0.2752 -0.3172 -0.5735 -0.1234
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action ; randomized ; exercise ; training ; patients ; hf ; left ventricular ejection fractions ; hrqol ; kansas city cardiomyopathy questionnaire ; kccq ; baseline
H-837	-0.5807233452796936	▁ HF - ac tion ▁; ▁exercise ▁training ▁; HF ▁; ▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction s ▁; ▁HR Qo L ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁k cc q
D-837	-0.5807233452796936	HF-action ; exercise training ;HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
P-837	-1.9935 -0.2719 -0.0725 -0.3324 -2.3598 -0.4572 -1.1050 -0.7306 -0.3126 -2.1962 -0.3085 -1.1911 -0.8769 -0.1245 -1.8673 -0.4324 -0.0847 -0.2586 -0.1016 -0.6757 -0.0066 -0.1430 -0.2516 -0.2732 -0.0087 -1.5962 -0.1717 -0.0114 -0.1909 -0.8286 -0.1213 -0.1196 -0.9635 -0.0597 -0.1914 -0.0100 -0.1985 -1.3346 -0.1289 -1.8290 -0.1057 -0.0933
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt ; systolic dysfunction ; outcomes ; resynchronization reverses remodeling in systolic left ventricular dysfunction ; reverse ; patients ; left ventricular ; ejection fraction ; lvef
H-752	-0.4691429138183594	▁c RT ▁; ▁sy sto lic ▁dys function ▁; ▁re syn chron ization ▁re ve rse s ▁re model ing ▁in ▁Sy sto lic ▁left ▁v ▁en tri cular ▁dys function ▁; ▁re vers e ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; LV EF
D-752	-0.4691429138183594	cRT ; systolic dysfunction ; resynchronization reverses remodeling in Systolic left v entricular dysfunction ; reverse ; left ventricular ;LV ; ejection fraction ;LVEF
P-752	-0.1832 -3.0678 -0.3307 -0.1073 -0.0870 -0.1778 -0.1780 -0.1473 -0.2466 -0.2749 -0.1909 -0.0208 -0.7211 -0.0462 -0.5466 -0.1314 -0.0634 -0.3051 -0.7898 -0.0389 -1.1662 -0.5427 -0.0139 -0.0870 -0.3408 -0.0766 -1.7573 -2.7899 -0.2599 -0.0448 -0.1941 -0.1742 -1.5355 -2.5778 -0.2799 -0.3005 -0.4009 -0.0325 -1.0465 -0.0920 -0.2832 -0.4861 -0.7755 -0.0143 -0.1280 -0.0424 -0.4944 -0.0189 -0.2562 -0.2408 -0.4598 -0.2108 -0.0861
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated glomerular filtration rate ; egfr ; type 2 diabetes ; cholesterol ; ldl-cholesterol ; clcnka ; genotype
H-1803	-0.5015938878059387	▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR ▁; ▁diabetes ▁; ▁total ▁cholesterol ▁; ▁l DL - ch olesterol ▁; ▁CL cn ka ▁ gg ▁geno type
D-1803	-0.5015938878059387	glomerular filtration rate ; egFR ; diabetes ; total cholesterol ; lDL-cholesterol ; CLcnka gg genotype
P-1803	-0.2274 -0.4122 -0.1300 -0.4094 -0.9308 -0.6949 -0.4798 -0.1518 -3.1766 -0.8252 -0.3323 -0.1988 -0.1661 -0.2251 -0.1631 -0.2252 -0.3976 -0.3419 -0.2176 -0.7324 -0.0031 -0.2216 -0.1580 -1.9314 -1.0224 -0.3950 -0.9758 -0.0995 -0.0037 -0.1978 -0.1032
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography ; lv end-diastolic dimension ; lv end-diastolic pressure ; wall stress ; lung ; acf
H-474	-0.6381620168685913	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight ▁; ▁un tre ated ▁a CF ▁; ▁sham ▁group
D-474	-0.6381620168685913	echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; untreated aCF ; sham group
P-474	-0.4426 -0.1500 -0.3031 -0.7842 -0.2714 -0.4002 -1.9759 -1.8993 -0.8896 -0.1609 -0.0765 -0.3357 -0.2295 -0.9388 -0.0976 -0.2746 -1.4595 -1.6006 -1.4487 -0.1521 -0.0767 -0.3018 -0.1881 -0.6866 -0.7662 -1.1592 -0.2952 -0.1721 -0.4266 -0.2208 -0.1621 -1.4627 -0.0138 -0.4504 -1.5280 -0.5926 -1.7371 -0.0762 -1.4095 -0.4273 -0.1211
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic ; patients ; auc ; auc
H-488	-1.418116807937622	▁diagnosti ▁performance ▁; ▁s ' lateral ▁; ▁a UC
D-488	-1.418116807937622	diagnosti performance ; s'lateral ; aUC
P-488	-4.1492 -1.8289 -0.3660 -0.0710 -3.8469 -0.1004 -0.4296 -0.6206 -2.1963 -1.8033 -0.1870
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients ; follow-up ; patients ; spironolactone ; hospitalization ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval
H-443	-0.6927134990692139	▁spi rono lac tone
D-443	-0.6927134990692139	spironolactone
P-443	-0.1670 -0.0382 -0.0467 -0.0705 -3.6683 -0.1655
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control ; patients ; cardiac ; driven ; cardioversions ; costs ; antiarrhythmic drugs ; cad ; patient ; confidence interval ; patient
H-1239	-0.6341781616210938	▁cardiac ▁procedure s ▁; ▁cardio version s ▁; ▁kosten ▁; ▁anti ar rhythm ic ▁drugs ▁; CAD
D-1239	-0.6341781616210938	cardiac procedures ; cardioversions ; kosten ; antiarrhythmic drugs ;CAD
P-1239	-1.4996 -1.3906 -0.1319 -0.5796 -0.2578 -0.0605 -0.3079 -0.4032 -2.0630 -0.5012 -0.0422 -0.1398 -0.1923 -0.1506 -0.1204 -0.5481 -0.3821 -3.0902 -0.1885
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients ; bundle branch morphology ; diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin ii receptor blocker
H-906	-0.31989941000938416	▁diabetes ▁mell itus ▁; ▁cardio my o pathy ▁origin ▁; ▁β - block er ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin ▁II ▁receptor ▁block er
D-906	-0.31989941000938416	diabetes mellitus ; cardiomyopathy origin ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
P-906	-1.1479 -0.0085 -0.0633 -0.2353 -0.0117 -0.3792 -0.7881 -0.0230 -0.2739 -0.2219 -0.0553 -0.0285 -0.3813 -0.1540 -0.2465 -1.1275 -0.6637 -0.3580 -1.2431 -0.2603 -0.0214 -0.0647 -0.0793 -0.0464 -0.0531 -0.0551 -0.0644 -0.2398 -0.3504 -0.6145 -0.2206 -0.7136 -0.6385 -0.0107 -0.3856 -0.1642 -0.6422 -0.1211
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone post myocardial infarction heart failure efficacy and survival study ; ephesus ; post-myocardial infarction ; patients ; heart failure ; mortality ; hospitalizations ; patients ; randomized ; aldosterone antagonist ; eplerenone
H-1737	-0.5953215956687927	▁e pler en one ▁post ▁my o card ial ▁in far ction ▁; ▁Heart ▁failure ▁Ef fica cy ▁; ▁su rvi val ▁Study ▁; ▁eura s ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁al do ster one ▁anta gon ist ▁e pler en one
D-1737	-0.5953215956687927	eplerenone post myocardial infarction ; Heart failure Efficacy ; survival Study ; euras ; post-myocardial infarction ; heart failure ; aldosterone antagonist eplerenone
P-1737	-0.1697 -0.0183 -0.1052 -0.4751 -1.1965 -1.1877 -0.9010 -0.8584 -1.3835 -0.0557 -0.3956 -0.1928 -1.9279 -1.9011 -0.0626 -1.0767 -0.1327 -0.0763 -0.2636 -0.8144 -0.0626 -0.0168 -0.5264 -0.1907 -5.0106 -1.0617 -0.2860 -0.0230 -0.0867 -0.7126 -0.8335 -1.2738 -1.1752 -0.0478 -0.5365 -0.1757 -0.8314 -1.6042 -0.1173 -0.2691 -0.4453 -0.1084 -0.0963 -0.3310 -0.1090 -0.0012 -0.4247 -0.3723 -0.0478 -0.1147 -1.1127 -0.2417 -0.1109
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol ; metoprolol ; endpoint ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-856	-0.3899291157722473	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD it - cr t ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁With ▁Card iac ▁re syn chron ization ▁Therapy
D-856	-0.3899291157722473	carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-crt ; multicenter Automatic Defibrillator Implantation With Cardiac resynchronization Therapy
P-856	-0.0416 -0.0937 -0.0711 -0.2164 -0.0228 -0.2293 -0.0344 -0.1389 -0.2660 -0.4226 -0.0391 -0.6130 -0.0370 -0.3922 -0.0819 -0.3100 -0.1906 -0.6216 -0.2678 -0.1145 -0.5091 -0.0146 -0.1629 -0.1484 -1.5839 -0.0144 -2.8599 -2.0799 -0.1887 -0.7941 -0.0377 -0.4986 -0.0326 -0.2401 -0.0514 -0.3519 -0.0273 -0.2591 -0.4127 -2.1618 -0.1677 -0.0345 -0.4810 -0.0781 -0.0142 -0.9763 -0.3643 -0.2878 -0.0692
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence interval ; heart ; mortality ; death
H-1749	-0.9141467809677124	HR ▁; ▁heart ▁failure - related ▁mortal ity ▁; ▁sud den ▁death ▁; ▁HR
D-1749	-0.9141467809677124	HR ; heart failure-related mortality ; sudden death ; HR
P-1749	-1.4391 -0.7778 -4.0010 -0.5246 -0.4132 -0.1483 -0.1250 -1.4247 -0.3995 -1.2915 -0.0384 -0.6473 -1.0221 -1.7587 -0.4916 -0.1234
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash ; clinic ; brachial systolic pressure ; central end-systolic pressure
H-924	-0.7636165618896484	▁DAS h ▁; ▁s rd ▁; ▁bra chi al ▁sy sto lic ▁pressure ▁; ▁centrale ▁end - sy sto lic ▁pressure
D-924	-0.7636165618896484	DASh ; srd ; brachial systolic pressure ; centrale end-systolic pressure
P-924	-0.0128 -0.0982 -0.7137 -1.0417 -1.2416 -0.4826 -0.2678 -0.1802 -0.3704 -0.0500 -0.2665 -0.2407 -0.7976 -0.3004 -3.5717 -3.3687 -0.3308 -2.0817 -0.2643 -0.1480 -0.6157 -1.0062 -0.1121
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients ; hf ; obese ; body mass index ; idiopathic-dilated cardiomyopathy
H-558	-0.5201708674430847	▁ HF ▁; ▁obes e ▁; ▁body ▁mass ▁index ▁; ▁black ▁et hni city ▁; ▁ idio pathi c - dila ted ▁cardio my o pathy
D-558	-0.5201708674430847	HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
P-558	-2.1333 -0.5645 -0.8116 -1.1519 -0.1875 -0.4363 -1.2918 -0.2048 -0.0094 -0.6738 -1.5907 -0.0351 -0.3930 -0.6249 -0.2581 -0.5389 -0.1576 -0.0925 -0.4320 -0.2919 -0.0070 -0.2241 -0.1002 -1.0773 -0.8765 -0.0235 -0.2605 -0.1159
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause mortality ; hospitalization ; hf ; lvef ; patients ; heart failure survey ; israel
H-113	-0.892730176448822	▁ HF ▁; ▁LV EF ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁is ra el
D-113	-0.892730176448822	HF ; LVEF ; Heart Failure Survey ; israel
P-113	-2.9462 -1.0106 -0.7207 -0.0860 -0.5639 -0.1973 -3.6748 -0.2790 -1.1418 -0.4083 -0.6826 -1.7184 -0.3987 -0.0314 -0.2799 -0.1441
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients ; left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography ; followed up
H-1743	-0.5472301840782166	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁world ▁health ▁Organization ▁criteri a ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁negative ▁corona ry ▁ang i ography
D-1743	-0.5472301840782166	left ventricular ejection fraction ; world health Organization criteria ; idiopathic dilated cardiomyopathy ; negative coronary angiography
P-1743	-1.5233 -0.0815 -2.3369 -0.2765 -0.1165 -0.1847 -0.0901 -0.6451 -0.0179 -0.4210 -0.6824 -2.0234 -1.2600 -0.6120 -0.0384 -1.2675 -0.3535 -0.0228 -0.0448 -0.2301 -0.1465 -0.1840 -0.0923 -1.3967 -1.0455 -0.0292 -0.1727 -0.0409 -0.2031 -1.6612 -0.3587 -0.8280 -0.2359 -0.4173 -0.1125
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european society of cardiology ; hfpef ; symptoms ; heart failure ; preserved lv ejection fraction ; non-dilated left ventricle ; evidence ; diastolic dysfunction ; lv relaxation ; lv diastolic stiffness ; elevated ; lv filling pressures
H-27	-0.5115901827812195	▁ europe se ▁Society ▁of ▁Card i ology ▁guidelines ▁; ▁h FP EF ▁; ▁heart ▁failure ▁; ▁LV ▁e je ction ▁ fraction ▁; ▁non - dila ted ▁left ▁vent ric le ▁; ▁dia sto lic ▁dys function ▁; ▁LV ▁relax ation ▁; ▁dia sto lic ▁sti ff ness ▁; ▁LV ▁fill ing ▁pressure s
D-27	-0.5115901827812195	europese Society of Cardiology guidelines ; hFPEF ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ; LV relaxation ; diastolic stiffness ; LV filling pressures
P-27	-1.1676 -0.0042 -0.0227 -2.5740 -0.2204 -0.8517 -0.2406 -0.2235 -1.9891 -0.2560 -1.1752 -2.2099 -0.8918 -0.2977 -0.8515 -0.0856 -0.1918 -1.6421 -0.1677 -0.0755 -0.0210 -1.4419 -0.0079 -0.3207 -2.3036 -0.0213 -0.0022 -0.0460 -0.0802 -0.0316 -1.0980 -0.3580 -0.2858 -0.0206 -0.0657 -0.0652 -0.0886 -0.0429 -0.1725 -2.4633 -0.7731 -0.2017 -0.1097 -0.4342 -0.0805 -0.0978 -0.0452 -0.3390 -1.7285 -0.2185 -0.0828 -0.1877 -0.0605 -0.1417 -0.1219 -0.3968 -0.0655
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars ; s1pr1s ; myocyte ; camp ; report ; receptors ; g-protein-coupled receptor ; kinase-2
H-1408	-0.37228262424468994	▁β 1 AR s ▁; ▁s 1 PR 1 s ▁; ▁my o cy te ▁; ▁c AMP ▁production ▁; ▁receptor s ▁; ▁regulator y ▁; ▁g - prote in - co up led ▁receptor ▁kina se -2
D-1408	-0.37228262424468994	β1ARs ; s1PR1s ; myocyte ; cAMP production ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
P-1408	-1.1563 -1.3862 -0.7962 -0.3673 -0.3605 -0.6054 -0.4074 -0.4210 -1.5254 -0.2242 -0.2473 -0.6025 -0.1644 -0.1034 -0.0826 -0.2231 -0.1023 -0.1630 -0.8299 -0.2976 -0.7141 -0.2726 -0.3968 -0.4986 -0.0869 -1.0894 -0.2738 -0.0868 -0.0405 -0.1554 -0.0599 -0.0326 -0.0614 -0.4770 -0.0139 -0.0337 -0.0245 -0.0810 -0.3454 -0.0810
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up ; paf-cpt ; paf ; lyso-paf-at ; downregulated ; paf-ah ; lp-pla2 ; elevated
H-1270	-0.9187876582145691	▁follow - up ▁; ▁PA f - c PT ▁; ▁PA F ▁; ▁lys o - pa f - AT ▁; ▁pa f - AH ▁; ▁l p - PLA 2
D-1270	-0.9187876582145691	follow-up ; PAf-cPT ; PAF ; lyso-paf-AT ; paf-AH ; lp-PLA2
P-1270	-5.9089 -0.2091 -0.0390 -0.6424 -1.1391 -1.6568 -0.1930 -0.9386 -1.8308 -0.3314 -1.1165 -2.5978 -1.3160 -0.8702 -0.2528 -0.0867 -0.6524 -1.7998 -0.6207 -1.1118 -0.3653 -2.1664 -2.3422 -0.1760 -0.8931 -0.3259 -0.1364 -0.0130 -0.0686 -0.0159 -0.0501 -0.3302 -0.1232
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients ; heart failure ; ejection fraction ; cardiac rehabilitation ; walking ; exercise
H-570	-0.6814720630645752	▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁standard ▁cardiac ▁rehabilita tion ▁; ▁Nordic ▁walking
D-570	-0.6814720630645752	heart failure ; ejection fraction ; standard cardiac rehabilitation ; Nordic walking
P-570	-3.1472 -0.1987 -0.3216 -1.0869 -0.2218 -0.0333 -0.3616 -0.0083 -0.3568 -1.9039 -0.0711 -0.0474 -0.6280 -1.1253 -1.5000 -0.7464 -0.3935 -0.1147
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
H-1836	-0.9394142627716064	▁d RS - stra t ified ▁hazard ▁ratio s ▁; ▁ci ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁si tag lip tin ▁; ▁sul fon yl ure as ▁; ▁ci ▁; ▁si tag lip tin ▁; ▁insulin
D-1836	-0.9394142627716064	dRS-stratified hazard ratios ; ci ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; ci ; sitagliptin ; insulin
P-1836	-1.2359 -1.0068 -0.0965 -0.0200 -0.0601 -0.1800 -0.4739 -0.3621 -0.3201 -0.4712 -2.7491 -1.6549 -2.7985 -0.5794 -0.5294 -2.9094 -0.7672 -0.5017 -0.0965 -0.1346 -0.1142 -0.2659 -3.6850 -1.2562 -0.5903 -3.1059 -0.4971 -0.0914 -0.0285 -0.2675 -0.5050 -0.0813 -0.2860 -2.0967 -1.1396 -2.6492 -1.1098 -0.7753 -3.7649 -0.7423 -0.0266 -0.2157 -0.1530
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal muscle ; t-score ; fontan ; sarcopenic range muscle wasting ; t-score ; clinically ; t-score
H-1501	-0.8969883918762207	▁skelet al ▁muscle ▁mass ▁; ▁t - s core ▁; ▁Font an ▁; ▁sar co pen ic ▁range ▁; ▁muscle ▁was ting ▁; ▁t - s core
D-1501	-0.8969883918762207	skeletal muscle mass ; t-score ; Fontan ; sarcopenic range ; muscle wasting ; t-score
P-1501	-0.4069 -0.0708 -0.7460 -0.3757 -0.8716 -1.5955 -0.1628 -0.3765 -0.5403 -0.3271 -6.4489 -0.0275 -0.4008 -0.9568 -0.0760 -0.2151 -0.4274 -0.0097 -1.3745 -1.6906 -2.8510 -0.1197 -0.2430 -2.1038 -0.0952 -0.2842 -0.6003 -2.5350 -0.0797
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise ; testosterone ; baseline ; peak oxygen uptake ; beck depression inventory ; leg ; medical outcomes study short-form ; quality of life ; exercise ; placebo
H-1323	-0.5678133368492126	▁testosteron e ▁group ▁; ▁oxygen ▁up take ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁leg ▁strength ▁; ▁Medical ▁Out com es ▁Study ▁Short - Form ▁quality ▁of ▁life ▁domain s ▁; ▁exercise ▁; ▁place bo ▁group
D-1323	-0.5678133368492126	testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes Study Short-Form quality of life domains ; exercise ; placebo group
P-1323	-1.6564 -0.0556 -1.4832 -0.4757 -0.6923 -2.4115 -0.1826 -0.2095 -0.0683 -0.2243 -0.0206 -0.3411 -0.1215 -0.0304 -0.2954 -0.8053 -0.9212 -0.1653 -0.4458 -0.9990 -0.0870 -0.0216 -0.2381 -0.2006 -0.0212 -0.7141 -0.1012 -0.3340 -0.3088 -1.0228 -0.1351 -0.5539 -2.3387 -2.0810 -0.4928 -0.0126 -1.4006 -0.3512 -0.1242
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker ; uptitrations ; composite end-point ; all-cause mortality ; hf ; readmissions ; hfref ; hazard ratio ; confidence interval
H-181	-0.9933082461357117	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁all - ca use ▁mortal ity ▁; ▁ HF ▁; ▁read missions ▁; ▁h Fr EF ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁ci
D-181	-0.9933082461357117	RAS- ; β-blocker uptitrations ; all-cause mortality ; HF ; readmissions ; hFrEF ;hazard ratio ;HR ; confidence interval ; ci
P-181	-1.6711 -0.1498 -0.0684 -3.2676 -0.0171 -0.0295 -0.3392 -0.0323 -5.4977 -0.6665 -2.3575 -0.4632 -0.7420 -2.8014 -0.0292 -0.0351 -0.3482 -0.0637 -2.1365 -0.2344 -0.4757 -0.3736 -1.7832 -1.7062 -0.3190 -0.2863 -0.7278 -0.9535 -1.9195 -0.3311 -0.8086 -0.0217 -0.0108 -0.1764 -1.6146 -0.7462 -2.8447 -0.0100 -0.2665 -2.0036 -3.2837 -0.1058
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients ; heart failure ; outcomes ; exercise ; training ; hf-action ; exercise ; perceived social support score ; psss ; barriers to exercise score ; btes
H-1927	-0.6236002445220947	▁Heart ▁Fail ure ▁; ▁tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - ac tion ▁; ▁social ▁support ▁; ▁barrier s ▁to ▁exercise ▁; ▁p s s s ▁; ▁barrier s ▁to ▁exercise ▁score ▁; ▁b tes
D-1927	-0.6236002445220947	Heart Failure ; trial Investigating Outcomes of Exercise Training ;HF-action ; social support ; barriers to exercise ; psss ; barriers to exercise score ; btes
P-1927	-2.2500 -0.4112 -0.4520 -0.3612 -2.4116 -0.0497 -0.7301 -0.1115 -0.7245 -0.1143 -0.0280 -0.2541 -0.3911 -0.1523 -0.4017 -0.3636 -1.5129 -0.0623 -0.4812 -1.9495 -0.4012 -1.0294 -0.3683 -0.4049 -0.8642 -0.0488 -0.1695 -0.2722 -1.0308 -2.1004 -1.0502 -0.0979 -0.7384 -0.1967 -1.7876 -0.0511 -0.1479 -0.5370 -0.0770 -0.2664 -1.9671 -0.2469 -0.2693 -0.1026
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable analysis ; st2 ; death ; hospitalization ; hazard ratio ; cardiovascular death ; hf ; hospitalization ; hazard ratio ; all-cause mortality ; hazard ratio ; hazard ratios
H-703	-0.8458480834960938	▁ST 2 ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; haz ard ▁ratio ▁; ▁all - ca use ▁mortal ity ▁; haz ard ▁ratio ▁; ▁log 2
D-703	-0.8458480834960938	ST2 ; cardiovascular death ; HF hospitalization ;hazard ratio ; all-cause mortality ;hazard ratio ; log2
P-703	-1.1541 -0.2129 -0.6269 -2.4933 -0.9055 -0.1057 -0.5267 -0.5837 -0.9842 -1.3580 -0.2621 -2.5292 -0.0610 -0.1906 -0.4706 -3.2738 -0.0949 -0.0311 -0.2908 -0.0311 -2.3536 -0.6571 -2.8143 -0.1459 -0.1501 -1.4463 -0.5270 -0.1170 -0.7779 -0.1998
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients ; new york heart association class i ; fontan ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dxa ; calf ; muscle ; magnetic resonance spectroscopy ; healthy
H-1495	-0.4960402250289917	▁New ▁York ▁heart ▁association ▁; ▁Font an ▁adults ▁; ▁cardio pul mon ary ▁exercise ▁testing ▁; ▁lean ▁mass ▁quant ification ▁; ▁dual ▁x - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁cal f ▁muscle ▁; ▁magnetic ▁res on ance ▁spec tros copy
D-1495	-0.4960402250289917	New York heart association ; Fontan adults ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
P-1495	-1.3378 -0.8635 -2.3842 -0.3502 -1.5528 -0.8847 -0.0325 -1.3790 -0.3086 -0.0069 -0.7564 -1.8582 -0.7136 -0.3521 -1.7073 -0.2260 -0.0176 -0.1551 -0.3163 -0.1709 -0.2642 -0.0197 -0.1258 -0.1024 -0.1500 -0.0252 -0.7298 -0.6653 -0.1654 -0.4347 -0.3678 -0.1144 -0.2960 -0.2070 -0.0230 -0.0254 -0.1335 -0.1908 -0.2737 -0.4796 -0.4643 -0.4279 -0.2336 -0.1299 -1.5155 -0.2897 -0.0856
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo ; dopamine ; nesiritide ; bolus ; diuretic ; therapy ; renal function ; patients ; acute heart failure ; renal dysfunction
H-73	-0.5614823698997498	▁dop amine ▁; ▁nesi riti de ▁; ▁di ure tic ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-73	-0.5614823698997498	dopamine ; nesiritide ; diuretic ; renal function ; acute heart failure ; renal dysfunction
P-73	-0.5372 -0.1432 -0.2065 -0.4214 -0.0293 -0.2153 -0.2610 -1.4909 -0.7901 -0.9451 -3.9806 -1.0641 -0.6110 -0.4825 -0.4169 -0.0313 -0.2363 -0.1045 -0.2827 -0.0138 -0.2018 -0.3766 -0.5214 -0.1120
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized ; crt ; patients ; new york heart association class iii ; heart failure ; left ventricular ejection fraction ; qrs duration ; echocardiographic ; evidence ; left ventricular dyssynchrony
H-847	-0.6902786493301392	▁c RT ▁; ▁New ▁York ▁Heart ▁association ▁class ▁III ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁; ▁QR s ▁; ▁e cho car dio graphic ▁; ▁left ▁vent ri cular ▁dys syn chron y
D-847	-0.6902786493301392	cRT ; New York Heart association class III ; heart failure ; left ventricular ejection ; QRs ; echocardiographic ; left ventricular dyssynchrony
P-847	-0.6911 -3.2133 -0.3193 -1.3297 -0.8531 -1.3676 -0.3995 -1.6994 -0.1244 -0.8016 -2.7204 -0.2923 -0.1829 -0.2180 -0.1517 -2.5978 -0.3427 -0.1504 -0.1696 -0.0674 -0.8548 -0.0504 -0.5479 -0.2441 -0.2953 -0.0625 -0.0348 -0.3757 -0.4301 -1.0734 -0.3154 -0.1227 -3.0848 -0.7977 -0.0753 -0.0749 -0.0038 -0.9031 -0.4720 -0.1006
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients ; left ventricular ; ejection fraction ; stable hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
H-482	-0.31874069571495056	▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁right - side d ▁cardiac ▁cat heter ization ▁; ▁trans t hora cic ▁e cho card i ography ▁; ▁transmit ral ▁flow ▁; ▁mit ral ▁ann ulus ▁veloci ties ▁; ▁sy stol e ▁; ▁dia stol e
D-482	-0.31874069571495056	left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
P-482	-0.1436 -0.0711 -1.5856 -0.1645 -0.4038 -0.3493 -0.3240 -0.2796 -0.1482 -0.0607 -1.2726 -0.0273 -0.3265 -0.9606 -0.8883 -0.2522 -0.7075 -0.0872 -0.2517 -0.0656 -0.0192 -0.3751 -0.0366 -1.2108 -0.2007 -0.0040 -0.1832 -0.0505 -0.0646 -0.1106 -0.2357 -0.2169 -0.4075 -0.1652 -0.2228 -0.0391 -0.4265 -0.1809 -1.6194 -0.2964 -0.0579 -0.2230 -0.0916 -0.7650 -0.0229 -0.1706 -0.0798 -0.0373 -0.4236 -0.2432 -0.0133 -0.0220 -0.4965 -0.3706 -0.0778
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients ; acute coronary syndromes ; patients ; stable ; cad ; bnp ; nt-probnp ; cad ; prognostic ; clinical ; outcome
H-1367	-0.46575507521629333	▁a cute ▁corona ry ▁syndrome s ▁; ▁CAD ▁; ▁b NP ▁; ▁NT - pro b NP ▁; ▁CAD
D-1367	-0.46575507521629333	acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
P-1367	-0.2485 -0.0345 -0.0827 -1.8645 -0.0045 -0.1292 -0.5919 -0.3908 -0.8671 -1.2446 -0.4061 -0.3890 -0.0387 -0.1221 -0.0190 -0.5625 -0.5194 -1.6115 -0.2949 -0.2066 -0.1528
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline ; patients ; hf ; lyso-paf-at ; paf-cpt ; paf ; paf-ah ; lp-pla2
H-1269	-0.8692072629928589	▁ HF ▁; ▁lys o - pa f - at ▁; ▁pa f - c pt ▁; ▁PA f ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1269	-0.8692072629928589	HF ; lyso-paf-at ; paf-cpt ; PAf ; PAf-AH ; lp-PLA2
P-1269	-2.0474 -0.4389 -0.6044 -0.6075 -0.1777 -0.1099 -0.5438 -1.8587 -0.3369 -1.1533 -0.2786 -1.1782 -2.0321 -0.1609 -1.5334 -1.4955 -0.2690 -1.1274 -2.1379 -2.1133 -2.3003 -1.4799 -0.4722 -1.7788 -0.2717 -0.6543 -0.0164 -0.0723 -0.0134 -0.0505 -0.3582 -0.1418
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical therapy ; patients ; redo sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; patients ; transcatheter aortic valve procedure ; surgery ; aortic valve
H-549	-0.513967752456665	▁redo ▁ster no to my ▁; ▁a or tic ▁val ve ▁procedure s ▁; ▁bio pro sthetic ▁val ve ▁replace ment ▁; ▁da cro n ▁patch ▁ closure ▁; ▁a or tic ▁val ve ▁repair s ▁; ▁trans cat heter ▁a or tic ▁val ve ▁procedure ▁; ▁open ▁surgery ▁; ▁a or tic ▁val ve ▁replace ment
D-549	-0.513967752456665	redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
P-549	-2.5241 -0.6658 -0.1479 -0.4230 -1.3916 -0.4274 -0.0651 -0.1371 -1.8608 -0.6694 -0.2001 -1.9128 -0.3339 -0.3095 -0.0099 -0.1400 -0.1105 -0.6882 -0.1907 -2.8765 -0.6910 -0.3092 -0.2137 -0.0030 -0.0206 -0.0252 -0.3054 -0.0089 -0.2719 -0.1117 -0.1716 -1.2964 -0.4299 -0.2580 -1.0978 -0.3752 -0.3040 -0.0050 -0.1942 -0.0118 -0.8584 -0.1359 -1.5968 -0.3537 -0.2118 -0.8313 -0.3812 -0.0396 -0.1402 -0.4829 -0.1190 -0.0898 -1.4714 -0.4198 -0.2681 -0.6880 -0.5420 -0.3876 -0.1176
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma n-terminal pro-b-type natriuretic peptide ; nt-probnp ; patients ; acute heart failure ; hf ; admission ; emergency department
H-263	-0.5607399940490723	▁plasma ▁; ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁a cute ▁heart ▁failure ▁; HF ▁; ▁emergency ▁department ▁; ED
D-263	-0.5607399940490723	plasma ; pro-b-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ;ED
P-263	-2.3560 -0.7243 -3.6377 -0.0346 -0.6857 -0.0513 -0.0038 -0.0101 -0.7319 -0.7101 -1.3590 -0.7895 -0.1031 -0.4332 -0.3388 -1.4141 -0.0201 -0.0379 -0.4891 -0.3696 -0.3503 -0.6661 -0.1113 -0.3334 -0.1151 -0.1983 -0.4472 -0.2667 -0.2168 -0.0740 -0.3204 -1.3348 -0.2131 -0.1178
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac troponin t ; ctnt ; n-terminal pro-b-type natriuretic peptide ; nt-probnp ; biomarkers ; hf ; hf ; atherosclerosis risk in communities ; aric
H-286	-0.4309404194355011	▁cardiac ▁trop onin ▁t ▁; ▁c t n t ▁; ▁as say ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁bio mark ers ▁; ▁incident ▁ HF ▁; ▁ HF ▁; ▁Ath eros cle rosi s ▁Risk ▁in ▁Communi ties ▁; ARI c
D-286	-0.4309404194355011	cardiac troponin t ; ctnt ; assay ; n-terminal pro-b-type natriuretic peptide ;NT-probNP ; biomarkers ; incident HF ; HF ; Atherosclerosis Risk in Communities ;ARIc
P-286	-0.0500 -0.0518 -0.0831 -1.3499 -0.3680 -0.3868 -0.0621 -0.0174 -0.3346 -0.2963 -3.0574 -0.1178 -0.2098 -1.5060 -0.0199 -0.2001 -0.0072 -0.1373 -0.0208 -1.1220 -0.0239 -0.0024 -0.0021 -0.3434 -0.3384 -1.0546 -0.3941 -0.1526 -0.5333 -0.2966 -1.8317 -0.0100 -0.0358 -0.5409 -0.2728 -0.1540 -0.6838 -0.0734 -0.2576 -0.2196 -0.6797 -0.2754 -0.2788 -0.1434 -1.3771 -0.1883 -1.0599 -1.6123 -0.0541 -0.6804 -0.1511 -0.0426 -0.1715 -0.3754 -0.2674 -0.0140 -0.2363 -0.7942 -1.0409 -0.1493 -0.0758
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body mass index ; fat mass ; fat-free mass
H-1167	-0.900813639163971	▁body ▁mass ▁index ▁; HR ▁; ▁fat ▁mass ▁; ▁fat - free ▁mass ▁index
D-1167	-0.900813639163971	body mass index ;HR ; fat mass ; fat-free mass index
P-1167	-3.3083 -0.5129 -0.0659 -0.7242 -1.7571 -0.9667 -3.1280 -0.4384 -0.8258 -1.3338 -0.5385 -0.2455 -0.1650 -0.0789 -0.1957 -0.1284
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile range ; body mass index ; interquartile range ; copd ; chf ; crf
H-797	-0.9109918475151062	▁inter quart ile ▁range ▁; ▁body ▁mass ▁index ▁; inter quart ile ▁range ▁; ▁COP d ▁; ▁CHF ▁; ▁c RF
D-797	-0.9109918475151062	interquartile range ; body mass index ;interquartile range ; COPd ; CHF ; cRF
P-797	-6.5884 -0.3755 -0.0908 -0.0130 -0.7434 -1.8656 -0.1864 -0.0208 -0.6893 -1.2526 -0.2738 -0.1063 -0.0070 -0.4799 -2.7056 -1.8376 -0.2805 -0.0577 -0.3052 -0.9836 -1.5594 -0.3227 -0.2077
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse remodeling ; ejection fraction ; mortality ; all-cause hospitalizations ; hf ; hospitalizations ; dialysis ; patients
H-911	-0.5477007627487183	▁rever se ▁remodel ing ▁; ▁e je ction ▁ fraction ▁; ▁mortal ity ▁; ▁ HF ▁; ▁di al ysis ▁patients
D-911	-0.5477007627487183	reverse remodeling ; ejection fraction ; mortality ; HF ; dialysis patients
P-911	-0.1590 -0.1272 -0.1297 -0.0771 -0.3867 -0.0414 -0.1620 -0.0716 -0.4302 -0.0182 -0.4278 -0.2474 -2.1202 -0.3753 -2.7850 -0.9584 -1.4831 -1.2980 -0.0434 -0.1001 -0.7650 -0.2691 -0.1213
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates ; lv contractility ; lvef ; β coefficient ; confidence interval ; systolic blood pressure ; end-systolic volume ; β coefficient
H-1530	-1.113839864730835	▁EH ▁; ▁LV ▁contract ility ▁; ▁CH ▁; ▁LV EF ▁; ▁significant ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁end - sy sto lic ▁volume ▁; β ▁co e ffi cient
D-1530	-1.113839864730835	EH ; LV contractility ; CH ; LVEF ; significant ; systolic blood pressure ; end-systolic volume ;β coefficient
P-1530	-1.1606 -0.2343 -1.6581 -0.0954 -0.1787 -0.2574 -5.1933 -0.5500 -1.0461 -1.1256 -0.2906 -7.5615 -2.5998 -2.9412 -0.1350 -0.1151 -0.4966 -0.4669 -0.4025 -2.2420 -0.1004 -0.7014 -0.4540 -0.1768 -0.2213 -1.1382 -2.6884 -0.2019 -0.5847 -0.1478 -0.4525 -1.0225 -0.1159
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography ; dilated lv ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mva
H-348	-0.47312384843826294	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁m L ▁; ▁m 2 ▁; ▁LV ▁; ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁MS ▁; ▁m VA ▁; ▁pressure ▁gradi ent
D-348	-0.47312384843826294	echocardiography ; LV ; end-diastolic volume index ; mL ; m2 ; LV ; ejection fraction ; MR ; mitral valve opening ; MS ; mVA ; pressure gradient
P-348	-0.7413 -0.0876 -0.2600 -0.6753 -0.2125 -0.4073 -3.9948 -0.4712 -1.4759 -0.0560 -0.0214 -0.1198 -0.0359 -0.0826 -0.0748 -0.2943 -0.2356 -1.8863 -1.4223 -0.2020 -0.3034 -0.2254 -0.3677 -1.3068 -0.1671 -0.1178 -0.0376 -0.8116 -0.0124 -0.3247 -0.4376 -0.2217 -0.1191 -0.0195 -0.0781 -0.0706 -0.2983 -0.1597 -0.1553 -0.3029 -0.1142 -2.1383 -0.3398 -0.3730 -0.0122 -0.1103 -1.2490 -0.0788
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind ; clinical ; renal optimization strategies evaluation ; rose ; hospitalized ; patients ; acute heart failure ; renal dysfunction ; estimated glomerular filtration rate ; randomized ; admission
H-74	-0.4763337969779968	▁re nal ▁Optim ization ▁strategie s ▁Evalua tion ▁; ROS e ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁glo mer ular ▁filtr ation ▁rate
D-74	-0.4763337969779968	renal Optimization strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate
P-74	-3.5059 -0.4185 -1.0653 -0.4253 -0.6139 -0.0151 -1.3530 -0.2277 -0.3279 -0.3595 -0.1376 -0.3426 -1.5730 -0.0155 -0.2590 -0.0604 -0.1930 -0.0053 -0.0305 -0.0843 -0.4310 -0.1006 -0.1840 -0.0516 -0.0882 -0.5226 -0.4947 -0.7870 -0.1410
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets ; signal transduction ; pol ii ; transcription factor ; hf ; pathogenesis ; nuclear factor of activated t cells ; nfat ; nuclear factor-κb ; nf-κb ; transcription factor ; gata4
H-1051	-0.4731633961200714	▁bet s ▁; ▁chr omat in - media ted ▁signal ▁trans duction ▁; ▁Pol ▁II ▁; ▁tran scription ▁factor ▁network s ▁; ▁ HF ▁path ogen es is ▁; ▁nuclear ▁factor ▁of ▁activa ted ▁T ▁cell s ▁; ▁n FAT ▁; ▁nuclear ▁factor - κ b ▁; NF - κ b ▁; ▁tran scription ▁factor ▁g ATA 4
D-1051	-0.4731633961200714	bets ; chromatin-mediated signal transduction ; Pol II ; transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; nFAT ; nuclear factor-κb ;NF-κb ; transcription factor gATA4
P-1051	-3.2556 -0.3449 -0.6158 -0.4313 -0.0047 -0.5374 -0.0961 -0.0358 -0.1202 -0.1702 -0.0126 -0.2137 -0.7400 -1.1071 -0.1525 -0.4543 -0.4436 -0.0897 -0.1117 -2.2275 -0.1392 -0.3637 -1.0898 -0.7291 -0.4735 -0.2117 -0.0782 -0.1773 -0.3336 -0.0572 -0.0858 -1.0987 -0.0036 -0.0830 -1.1927 -0.1090 -0.0508 -0.2768 -2.3076 -0.1896 -0.1572 -0.1570 -0.1893 -0.4127 -0.5062 -0.4932 -0.1741 -0.7018 -0.1039 -0.3754 -0.3172 -0.1503 -0.4480 -0.2559 -0.1747 -2.8741 -0.1142 -0.1475 -0.3386 -0.0827
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes ; mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
H-33	-0.5523101091384888	▁cardiovascular ▁events ▁; ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁ex ace rb ation ▁; ▁ar rhythm ia ▁; ▁cardiac ▁death ▁; ▁hyper tension ▁; ▁ve nous ▁ thro mbo e mbol ic ▁events ▁; ▁ ische mic ▁cerebro vas cular ▁events
D-33	-0.5523101091384888	cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
P-33	-7.7680 -1.0576 -0.2031 -0.6310 -0.3350 -0.1530 -0.5735 -0.0281 -0.1869 -0.1040 -0.3501 -0.0193 -0.4645 -1.2362 -0.4674 -0.1065 -1.7449 -0.0678 -0.0147 -0.2319 -0.2347 -0.0073 -0.1138 -1.4380 -0.1263 -0.0332 -0.4616 -0.2637 -0.2745 -0.0283 -0.1489 -0.4731 -0.0529 -0.2318 -0.1581 -1.2598 -0.5722 -0.0333 -0.5237 -0.8330 -0.2505 -1.1541 -0.0242 -0.5147 -0.1576 -0.0749 -0.4347 -1.4416 -0.4374 -0.1141
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular mortality ; multivariable adjustment ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-562	-0.7012183666229248	▁cardiovascular ▁mortal iteit ▁; ▁hazard ▁ratio
D-562	-0.7012183666229248	cardiovascular mortaliteit ; hazard ratio
P-562	-0.6129 -0.0915 -2.2321 -1.2391 -0.5468 -0.1332 -0.6245 -0.1296
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus ; diabetes ; patients ; diabetes ; peak vo2 ; patients ; diabetes ; eo-cfus ; peak vo2
H-128	-1.0197398662567139	▁ EO - c FU s ▁; ▁diabetes ▁; ▁eu - c FU ▁; ▁ EO - c FU ▁; ▁VO 2 ▁; ▁diabetes ▁; ▁ EO - c FU s ▁; ▁VO 2
D-128	-1.0197398662567139	EO-cFUs ; diabetes ; eu-cFU ; EO-cFU ; VO2 ; diabetes ; EO-cFUs ; VO2
P-128	-2.2692 -0.3430 -0.1001 -1.2558 -1.2987 -0.4054 -0.4694 -0.0725 -0.3195 -4.3311 -0.1289 -1.7364 -0.8951 -0.5293 -4.6743 -0.4325 -0.1587 -1.6960 -0.9555 -0.5642 -1.9439 -0.0971 -0.4558 -0.2937 -0.4989 -2.1531 -0.4421 -0.1402 -1.7050 -0.9484 -1.1480 -0.5045 -3.3408 -0.1167 -0.1768 -0.1098
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting ; video edge detection ; epifluorescence microscopy ; myocardial tissues ; cardiomyocytes ; hf
H-1212	-0.4486822783946991	▁immun o blo tting ▁; ▁radio en zy matic - ▁; ▁fluor esc ence ▁res on ance ▁; ▁energy ▁transfer - based ▁as say s ▁; ▁video ▁edge ▁det ection ▁; ▁epi flu o resc ence ▁micro s copy ▁; ▁ca 2 ▁; ▁my o card ial ▁tissu es ▁; ▁isola ted ▁cardio my o cy tes ▁; ▁h b
D-1212	-0.4486822783946991	immunoblotting ; radioenzymatic- ; fluorescence resonance ; energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; isolated cardiomyocytes ; hb
P-1212	-0.1350 -0.3957 -0.0371 -0.9294 -0.2057 -0.1805 -0.3600 -0.2355 -0.2581 -0.3260 -2.6329 -0.0344 -1.3665 -1.4939 -0.3808 -0.1438 -0.3864 -0.6515 -0.8284 -0.3255 -0.1618 -0.0364 -0.0730 -0.1138 -0.3018 -0.2595 -0.4730 -0.0785 -0.3806 -0.2654 -0.2042 -0.0944 -0.0253 -1.0087 -0.3635 -1.6483 -0.0270 -0.1322 -0.6007 -0.2267 -0.4387 -0.0630 -0.3987 -0.5818 -0.1539 -0.1461 -0.5955 -0.0197 -0.0750 -0.1899 -1.5031 -0.0447 -0.0219 -0.6664 -0.6184 -0.2143 -0.0557 -0.1274 -1.7560 -2.1105 -0.1858 -0.0699
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east ; early treatment of atrial fibrillation for stroke prevention trial ; randomize ; patients ; stroke ; rhythm control therapy ; prospective ; randomized ; outcome
H-1649	-0.7234688401222229	▁e ast ▁; ▁At rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁tri al ▁; ▁AF ▁; ▁stroke ▁; CHA 2 DS 2 VAS c ▁score ▁; ▁usual ▁care ▁; ▁early ▁ rhythm ▁control ▁ therapy
D-1649	-0.7234688401222229	east ; Atrial fibrillation ; Stroke prevention trial ; AF ; stroke ;CHA2DS2VASc score ; usual care ; early rhythm control therapy
P-1649	-0.5000 -0.4201 -0.3164 -4.3448 -0.0205 -0.3676 -0.0541 -0.0588 -0.6790 -1.2268 -0.1540 -0.3865 -0.0092 -0.5997 -0.0197 -0.6116 -0.1945 -0.5044 -3.9155 -0.4646 -2.4766 -0.1020 -2.3548 -0.1538 -0.2814 -0.1088 -0.9493 -0.5413 -3.3797 -1.0127 -0.1707 -0.3277 -0.0510 -0.2007 -0.2266 -0.3198 -0.0249 -0.5917 -0.0939
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes ; exercise capacity ; peak oxygen consumption ; vo2 ; co-primary outcome ; qol ; minnesota ; heart failure ; heart ; qol ; co-primary outcome
H-1980	-0.8055451512336731	▁Exerci se ▁capacity ▁; ▁oxygen ▁consum p tion ▁; VO 2 ▁; ▁Q OL ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁; ML HF ▁; ▁Question naire ▁; ▁heart ▁failure - related ▁Q OL
D-1980	-0.8055451512336731	Exercise capacity ; oxygen consumption ;VO2 ; QOL ; Minnesota Living with Heart Failure ;MLHF ; Questionnaire ; heart failure-related QOL
P-1980	-1.8996 -0.2771 -0.2711 -0.3137 -1.9491 -0.2330 -0.0933 -1.0582 -0.3768 -0.4761 -0.0971 -0.3310 -4.5725 -0.8670 -0.1494 -0.0610 -0.1096 -0.4660 -0.2863 -0.4714 -1.3564 -0.2052 -1.7251 -1.2310 -0.7127 -4.1607 -0.0157 -0.3838 -2.1382 -0.2925 -0.3526 -0.0928 -0.9251 -0.7574 -0.1756 -0.1153
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic ; mitochondrial-targeted peptide ; ss31 ; mitochondrial function ; tac ; clinical ; mitochondrial-targeted peptide ; drugs ; heart failure
H-878	-0.5280649065971375	▁ TAC - indu ced ▁prote om ic ▁altera tions ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁SS 31 ▁; ▁mito cho ndri al ▁function ▁; ▁ TAC ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁drugs ▁; ▁heart ▁failure
D-878	-0.5280649065971375	TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; mitochondrial function ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
P-878	-0.9455 -0.1004 -0.2238 -0.0945 -0.3640 -0.1437 -0.2357 -0.3326 -1.8347 -0.1661 -0.3047 -0.2319 -1.8905 -0.5987 -0.0989 -0.1612 -0.6496 -0.7250 -0.0615 -1.1924 -0.1539 -0.6198 -1.6493 -0.5789 -0.3128 -1.0948 -1.0270 -0.3469 -0.0629 -0.2242 -0.2856 -0.9737 -0.2183 -0.2565 -0.1605 -0.9692 -0.6060 -0.1348 -0.2234 -0.7360 -0.8968 -0.0627 -2.0510 -0.1083 -0.3741 -0.9149 -0.3118 -0.8935 -0.0997 -0.1579 -0.0710
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients ; left ventricular ejection fraction ; patients ; hf ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; epidemic ; medical ; financial costs
H-55	-0.8854469060897827	▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁hospital ▁; ▁physician s
D-55	-0.8854469060897827	low left ventricular ejection fraction ; HF ; preserved left ventricular ejection fraction ; hospital ; physicians
P-55	-2.5788 -0.9551 -0.1451 -2.4540 -0.9847 -0.2320 -0.3991 -0.1319 -0.8639 -0.0294 -0.3798 -2.4233 -0.4161 -0.8640 -3.3880 -0.0332 -0.6780 -0.2553 -0.1227 -2.8744 -0.7278 -0.1954 -0.3744 -0.1531 -0.6491 -0.0200 -0.5916 -0.5703 -0.4527 -1.6015 -0.0710 -3.5038 -0.1001
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf ; patients ; hfref ; left ventricular ; ejection fraction ; hfpef ; echo-doppler ; n-terminal pro-brain-type natriuretic peptide ; adverse events
H-494	-0.6076214909553528	▁ HF ▁patients ▁; HF r EF ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁e cho - D opp ler ▁studies ▁; ▁pro - bra in - type ▁na tri ure tic ▁pe pti de
D-494	-0.6076214909553528	HF patients ;HFrEF ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; pro-brain-type natriuretic peptide
P-494	-1.4513 -0.6313 -3.1834 -0.4498 -1.4135 -1.4492 -0.3707 -0.2538 -1.2363 -0.0660 -2.0149 -0.1977 -0.3728 -0.2792 -0.3377 -0.0268 -0.1608 -0.0522 -0.4645 -0.0188 -0.2301 -1.0377 -1.0527 -0.6760 -0.2202 -0.1247 -0.0880 -0.0408 -1.9317 -0.0161 -0.4037 -0.1259 -0.2295 -1.3845 -0.0377 -0.1932 -0.0814 -0.0284 -0.0022 -0.0147 -0.2749 -1.0445 -2.3378 -1.2413 -0.0575 -0.5844 -1.1700 -0.1053
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds ; comorbidities ; hospitalized ; adjusted odds ratio ; aor ; confidence interval ; eds ; aor
H-464	-0.8143802285194397	▁low - volu me ▁ED s ▁; ▁hospital ized ▁; ▁medium - volu me ▁ED s ▁; ▁a OR
D-464	-0.8143802285194397	low-volume EDs ; hospitalized ; medium-volume EDs ; aOR
P-464	-1.3858 -0.0883 -0.0923 -0.2723 -0.6432 -0.2931 -0.6256 -1.0685 -0.4902 -0.4492 -3.1664 -3.2035 -0.4042 -0.1702 -1.0263 -0.3056 -1.0285 -1.1954 -0.1796 -0.8677 -0.1461
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients ; cardiac transplant ; ecct ; patients ; diabetes mellitus ; chronic kidney disease ; estimated glomerular filtration rate
H-715	-0.38495582342147827	▁cardiac ▁transplant ▁; ▁ec CT ▁; ▁diabetes ▁mell itus ▁; ▁chronic ▁ki dne y ▁disease ▁; ▁glo mer ular ▁filtr ation
D-715	-0.38495582342147827	cardiac transplant ; ecCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
P-715	-0.1366 -0.0935 -0.4910 -0.2289 -1.3160 -0.8403 -0.1585 -0.0021 -0.0315 -0.2614 -0.1745 -0.0507 -0.4219 -0.1929 -0.3330 -0.3253 -0.1314 -0.2302 -0.0637 -0.1899 -1.0500 -1.9597 -0.1710
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc battery ; health abc hf risk model ; change ; c-index ; net-reclassification-improvement ; hf
H-631	-0.67595374584198	▁h ABC ▁Bat tery ▁score s ▁; ▁health ▁ABC ▁ HF ▁Risk ▁model ▁; ▁discrimina tion ▁; ▁c - index ▁; ▁re class ified ▁; ▁ HF
D-631	-0.67595374584198	hABC Battery scores ; health ABC HF Risk model ; discrimination ; c-index ; reclassified ; HF
P-631	-1.9776 -1.2535 -0.4247 -0.0195 -0.5640 -0.0701 -0.2372 -1.5182 -0.2963 -1.2824 -0.1830 -0.7075 -0.4684 -0.3388 -0.4126 -1.1409 -0.4230 -0.3202 -0.1548 -0.0204 -0.4246 -1.5184 -0.0783 -1.5906 -0.8511 -0.7563 -2.2299 -0.2365 -0.1037
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi ; rmsea ; self-care maintenance ; cfi ; rmsea ; self-care management ; cfi ; rmsea ; self-care confidence
H-1507	-0.8592485189437866	▁c fi ▁; ▁RM se a ▁; ▁Self - Car e ▁Main ten ance ▁Scal e ▁; ▁c fi ▁; ▁RM se a ▁; ▁Self - Car e ▁management ▁Scal e ▁; ▁c fi ▁; ▁RM se a ▁; ▁Self - Car e ▁confi den ce ▁scale
D-1507	-0.8592485189437866	cfi ; RMsea ; Self-Care Maintenance Scale ; cfi ; RMsea ; Self-Care management Scale ; cfi ; RMsea ; Self-Care confidence scale
P-1507	-1.0850 -3.0097 -0.1457 -1.7175 -1.3467 -0.3348 -0.1087 -0.3808 -0.1151 -2.3334 -0.2014 -2.3833 -0.6670 -0.3430 -0.2543 -0.0623 -0.0894 -0.7889 -3.0741 -0.1202 -2.2534 -1.1604 -0.2371 -0.0928 -0.2753 -0.1244 -2.4170 -0.1852 -0.3906 -0.3700 -0.0311 -0.0866 -0.6452 -3.3492 -0.1257 -2.8610 -1.1630 -0.2976 -0.1266 -0.3577 -0.1156 -2.4624 -0.2172 -2.5291 -0.2667 -0.5323 -0.5174 -0.2157 -0.1358
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients ; bat ; patients ; quality-of-life ; nyha functional class ; change
H-1876	-0.7783189415931702	▁BAT ▁; ▁quality - of - life ▁score ▁; ▁ny ha ▁functional ▁class ▁ranking
D-1876	-0.7783189415931702	BAT ; quality-of-life score ; nyha functional class ranking
P-1876	-0.0950 -1.1923 -2.5804 -0.3082 -0.0358 -0.7580 -0.6459 -0.5465 -0.6701 -2.5695 -0.6309 -0.6513 -0.1688 -1.0809 -0.3497 -0.1696
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients ; preoperative ; hypoalbuminemia ; postoperative ; albumin ; hypoalbuminemia ; albumin ; lvad
H-537	-0.5809324383735657	▁hypo album in emia ▁; ▁post operativ e ▁; ▁album in ▁levels ▁; ▁hypo album in emia ▁; ▁album in ▁levels ▁; ▁l VAD
D-537	-0.5809324383735657	hypoalbuminemia ; postoperative ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
P-537	-1.7325 -0.4019 -0.6383 -0.2255 -0.3322 -0.7863 -0.2645 -0.1572 -2.5719 -0.7882 -0.5995 -0.6148 -0.3984 -0.4734 -0.3392 -0.6483 -0.3198 -0.2544 -1.3302 -0.4698 -0.6711 -0.3387 -0.2772 -0.0166 -0.3534 -0.1011
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization ; confidence interval ; acute myocardial infarction ; ami ; complications ; kidney infection ; urinary tract infection ; uti ; complications
H-1717	-0.5773679614067078	▁re hospital ization ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁complica tions ▁; ▁ki dne y ▁infection ▁; ▁urin ary ▁tract ▁infection ▁; UTI
D-1717	-0.5773679614067078	rehospitalization ; acute myocardial infarction ;AMI ; complications ; kidney infection ; urinary tract infection ;UTI
P-1717	-3.4257 -0.0194 -1.0057 -0.4359 -4.1172 -0.1195 -1.1358 -0.6728 -0.2709 -0.5772 -0.0437 -0.1642 -0.2381 -0.3593 -0.1942 -0.4084 -1.9571 -0.3790 -0.3342 -0.5215 -0.5126 -0.1126 -0.2252 -0.1311 -0.0055 -0.2591 -0.1602 -0.1183 -0.2589 -0.0174 -0.1528 -0.1422
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients ; heart failure ; hf ; ischemic ; nonischemic cardiomyopathies ; pharmacological ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
H-54	-0.39373812079429626	▁heart ▁failure ▁; HF ▁; ▁ ische mic ▁; ▁non ische mic ▁cardio my o pathi es ▁; ▁ pharma c ological ▁arma ment arium ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cardiac ▁transplant ation ▁; ▁left ▁; ▁vent ri cular ▁assist ▁devices
D-54	-0.39373812079429626	heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; ventricular assist devices
P-54	-4.6123 -0.1088 -0.2773 -0.3418 -0.2478 -1.3187 -0.0590 -0.2406 -0.9309 -0.1248 -0.0890 -0.5703 -0.1620 -0.6266 -0.6575 -0.0201 -0.3588 -0.3694 -1.3537 -0.1283 -0.0819 -0.3253 -0.0778 -0.0482 -0.0012 -0.1835 -0.8912 -0.0265 -0.3537 -0.0264 -0.1650 -0.1492 -0.0594 -0.2261 -0.0775 -0.2445 -0.2677 -0.0144 -0.0387 -0.0447 -0.0061 -0.7347 -0.6706 -0.0190 -0.2820 -0.0462 -0.0361 -0.3084 -0.1838 -0.1055 -1.8742 -0.9949 -0.9394 -0.0768 -0.1844 -0.0907 -0.3138 -0.0698
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf ; catheterization ; central venous pressure ; svr ; cardiac index
H-230	-1.5206125974655151	▁ SAF ▁; PF ▁; ▁centrale ▁ve nous ▁pressure ▁; ▁h g ▁; ▁s VR ▁index ▁; ▁dyn ▁; ▁cardiac ▁index
D-230	-1.5206125974655151	SAF ;PF ; centrale venous pressure ; hg ; sVR index ; dyn ; cardiac index
P-230	-3.7549 -0.4937 -1.0818 -0.7513 -1.1294 -5.9954 -3.9245 -0.5625 -0.8585 -0.8113 -2.0120 -0.4533 -0.4682 -1.8668 -0.8970 -0.1066 -0.6851 -2.1975 -3.3469 -3.1013 -0.0446 -0.2540 -0.1777
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission ; bnp ; reduced ef ; preserved ef ; bnp ; ef
H-193	-1.349751353263855	▁ad mission ▁media n ▁; ▁b NP ▁; ▁EF ▁; ▁pres er ved ▁EF ▁; ▁b NP ▁; ▁EF
D-193	-1.349751353263855	admission median ; bNP ; EF ; preserved EF ; bNP ; EF
P-193	-5.1202 -1.4709 -0.2859 -0.0339 -2.2748 -0.7498 -0.9917 -0.6512 -1.4346 -0.3198 -4.6732 -0.0760 -0.6106 -1.0865 -0.3760 -2.7183 -1.1074 -0.3005 -3.0760 -0.8107 -0.1768
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart failure ; admission ; heart transplantation ; lv assist device ; death ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval ; ischemic ; functional class
H-435	-0.6926385760307312	▁heart ▁failure ▁ad mission ▁; ▁heart ▁transplant ation ▁; LV ▁assist ▁device ▁; ▁death ▁; haz ard ▁ratio ▁; ▁death
D-435	-0.6926385760307312	heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio ; death
P-435	-3.1306 -0.4472 -2.0558 -0.5544 -0.2103 -1.2212 -0.1614 -0.6479 -0.4375 -0.1173 -0.5290 -0.1449 -0.2331 -0.1781 -0.4506 -1.2588 -0.0238 -0.3179 -0.5428 -1.8982 -0.5486 -0.1287
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv ejection fraction ; shortening ; systolic elastance ; contractile efficiency ; acf ; acf ; allopurinol ; cardiomyocytes ; extracellular flux analyzer
H-475	-0.2861206829547882	▁e je ction ▁ fraction ▁; ▁circum fer ential ▁short en ing ▁; ▁sy sto lic ▁elastan ce ▁; ▁contract ile ▁efficiency ▁; ▁a cf ▁; ▁allo puri nol ▁rat s ▁; ▁o 2 ▁consum p tion ▁rate ▁; ▁isola ted ▁cardio my o cy tes ▁; ▁extra cel lular ▁flux ▁anal y zer
D-475	-0.2861206829547882	ejection fraction ; circumferential shortening ; systolic elastance ; contractile efficiency ; acf ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
P-475	-0.7338 -0.2305 -0.0566 -0.5058 -0.0288 -0.3011 -1.1796 -1.1643 -0.5839 -0.1459 -0.0515 -0.2395 -0.3864 -0.2167 -0.1012 -0.0297 -0.0659 -0.6561 -0.1817 -0.0083 -0.1640 -0.2180 -0.1440 -0.6481 -0.9879 -0.0874 -0.8899 -0.0185 -0.3893 -0.1370 -0.0626 -0.2545 -0.3074 -0.0464 -0.0764 -0.1454 -0.7385 -0.3325 -0.1201 -0.8390 -0.0225 -0.0128 -0.6987 -0.4969 -0.0838 -0.0591 -0.1998 -0.0078 -0.1160 -0.0166 -0.0014 -0.1776 -0.1714 -0.0521 -0.3572 -0.0747
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively ; patients ; hfpef ; lv hypertrophy ; lvh ; relative wall thickness ; rwt ; lvh ; rwt ; lvh ; rwt ; lvh ; rwt
H-1526	-0.7188605666160583	▁ HF p EF ▁; ▁LV ▁structure ▁; ▁normal ▁ge ometr y ▁; ▁LV ▁hyper trop hy ▁; LV h ▁; ▁relative ▁wall ▁thi ck ness ▁; RW t ▁; ▁CR ▁; ▁LV h ▁; ▁r w t ▁; ▁CH ▁; LV h ▁; ▁r w t ▁; ▁eh ▁; LV h ▁; ▁r w t
D-1526	-0.7188605666160583	HFpEF ; LV structure ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rwt ; CH ;LVh ; rwt ; eh ;LVh ; rwt
P-1526	-1.7739 -0.7964 -0.0747 -0.5982 -0.4843 -0.6462 -3.7646 -0.4978 -2.4300 -0.1009 -0.0558 -0.6622 -0.2856 -0.6067 -0.6361 -0.0637 -0.9074 -0.1688 -0.3119 -1.9084 -0.1675 -1.2560 -0.8493 -0.3363 -0.0261 -1.1504 -0.2231 -0.4325 -0.0305 -0.2131 -0.6002 -0.1148 -1.0725 -1.4999 -0.0858 -0.3559 -0.2315 -0.1009 -0.2278 -3.4045 -0.2522 -2.1669 -1.2458 -0.1651 -0.8235 -0.3720 -0.1362 -0.4068 -0.6145 -0.2043 -2.4138 -1.9163 -0.2935 -0.8338 -0.2906 -0.1397 -0.1618 -0.1048
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 ; angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist ; valsartan ; hypertension ; heart failure with preserved ejection fraction ; outcomes ; heart failure with reduced ejection fraction
H-1463	-0.5338993072509766	▁l CZ 696 ▁; ▁ang io ten sin ▁receptor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁pro drug ▁; ▁ang io ten sin ▁receptor ▁anta gon ist ▁val sar tan ▁; ▁hyper tension ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1463	-0.5338993072509766	lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction ; heart failure ; ejection fraction
P-1463	-2.5822 -0.5154 -0.1331 -0.3536 -1.4438 -1.7524 -0.3217 -1.9806 -0.0441 -1.1267 -0.0653 -0.4109 -1.2236 -0.0444 -0.0472 -0.3763 -0.1867 -0.4041 -1.5515 -0.0609 -0.0649 -1.5936 -0.1258 -0.0327 -0.1788 -1.6578 -1.2277 -0.3605 -1.4192 -0.0247 -0.1195 -0.0015 -0.2208 -0.1749 -0.1453 -0.0340 -0.2406 -0.1131 -0.0293 -0.2188 -0.9156 -0.0779 -0.8431 -0.3647 -0.0517 -0.6602 -0.0239 -0.1742 -0.0816 -0.3419 -0.0105 -0.5987 -1.1600 -0.2433 -1.2716 -2.6835 -0.1414 -0.1329 -0.4038 -0.0171 -0.1955 -0.1007
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood pressure ; mitral valve plasty ; degenerative mr ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; physio ring 30 ; edwards lifesciences ; irvine
H-343	-0.29250434041023254	▁blood ▁pressure ▁; ▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁p 3 ▁pro lapse ▁; ▁chor dal ▁rup tures ▁; ▁tri ang ular ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is ▁; ▁ring ▁ann ulo plast y ▁; ▁Ph y sio ▁ring ▁; Ed ward s ▁life science s ▁; ▁ir vine
D-343	-0.29250434041023254	blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring ;Edwards lifesciences ; irvine
P-343	-0.2741 -0.1949 -0.2793 -0.2754 -0.0568 -0.0860 -0.0558 -0.1309 -0.7749 -0.2126 -0.0163 -0.0127 -0.3641 -0.1142 -0.4116 -1.0198 -0.0868 -0.0504 -0.0394 -0.5140 -0.0389 -0.0599 -0.0171 -0.0420 -0.3235 -0.0257 -0.0256 -0.0078 -0.2001 -0.0400 -0.3529 -0.4388 -0.0356 -0.0888 -0.3656 -0.0333 -0.1095 -0.0867 -0.0033 -0.7434 -0.1717 -0.2950 -0.0071 -0.2769 -0.3897 -0.0599 -0.3389 -0.1586 -0.9771 -0.0144 -0.0204 -0.3591 -1.1488 -3.0869 -0.0062 -0.0100 -0.8839 -0.0300 -0.0091 -0.2613 -0.1629 -0.0021 -1.9827 -0.0590
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes ; incremental shuttle walk test ; peak oxygen uptake ; muscular ; echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory ; beck depression inventory ; health-related quality of life ; minnesota living with heart failure questionnaire ; medical outcomes study short-form
H-1320	-0.43260103464126587	▁shu ttle ▁walk ▁test ▁; ▁oxygen ▁up take ▁; ▁muscular ▁strength ▁; ▁e cho car dio graphic ▁measure s ▁; ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s ▁; ▁depression ▁; ▁be ck ▁de pression ▁in ven tory ▁; Min nes ota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Medical
D-1320	-0.43260103464126587	shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic measures ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ;Minnesota Living with Heart Failure Questionnaire ; Medical
P-1320	-0.0450 -0.0006 -0.1765 -0.3131 -0.3211 -1.0508 -2.6467 -0.1675 -0.2828 -0.0333 -0.8207 -0.1627 -0.0576 -0.0752 -0.0630 -0.5741 -0.4499 -1.4864 -0.0690 -0.2548 -0.2850 -0.4245 -0.3831 -1.1434 -0.8190 -0.0699 -0.4714 -0.2123 -0.0125 -0.5345 -0.0967 -0.0485 -0.0627 -0.1476 -0.1058 -0.1171 -0.3304 -0.0121 -0.0920 -0.0729 -0.2132 -0.1518 -0.0219 -0.5519 -4.2040 -1.2877 -0.0794 -0.2508 -0.3773 -0.4281 -0.2568 -0.8613 -0.1395 -0.0115 -0.3023 -0.3647 -0.9814 -0.1150
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction term analysis ; lvef ; patients ; patients ; mortality ; lvef ; p value
H-116	-1.4000906944274902	▁LV EF ▁; HR ▁; ▁long - term ▁mortal ity ▁; ▁pres er ved ▁; ▁LV EF
D-116	-1.4000906944274902	LVEF ;HR ; long-term mortality ; preserved ; LVEF
P-116	-2.9862 -0.3989 -0.4655 -6.3338 -0.7301 -4.9723 -0.1723 -0.2288 -0.1039 -1.5497 -0.6036 -3.9777 -0.2830 -0.6466 -0.5291 -0.8570 -0.4525 -1.1914 -0.1194
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto ; zsf1 ; obese ; zsf1 ; obese ; zsf1 ; followed up ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
H-763	-0.7434986233711243	▁we star - k yo to ▁; ▁lean ▁z SF ▁; ▁obes e ▁z SF ▁; ▁z SF 1 ▁; ▁high - fat ▁die t ▁; ▁metabol ic ▁; ▁renal ▁; ▁e cho car dio graphic ▁; ▁hem o dynamic ally ▁; ▁eu than ization
D-763	-0.7434986233711243	westar-kyoto ; lean zSF ; obese zSF ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
P-763	-1.2179 -0.0815 -0.0556 -5.0524 -0.4418 -0.0808 -0.3171 -0.0812 -2.2016 -0.8190 -1.9255 -0.8460 -0.0674 -1.4746 -0.9621 -1.9042 -1.4336 -0.8187 -2.7447 -0.4613 -1.1793 -0.0591 -0.2195 -0.4477 -0.1361 -0.4015 -0.2680 -0.0296 -0.3817 -0.0018 -0.3503 -0.0570 -0.1308 -0.0627 -0.4786 -0.9278 -1.2058 -1.2260 -0.1352 -0.0131 -0.6245 -1.9543 -0.0009 -0.2378 -1.1487 -0.1894 -0.0899
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; patients
H-384	-0.9312883615493774	▁ka plan - me ier ▁cur ves ▁; ▁log - rank ▁testing ▁; ▁UM / VA / ▁va - RT ▁co hor ts
D-384	-0.9312883615493774	kaplan-meier curves ; log-rank testing ; UM/VA/ va-RT cohorts
P-384	-0.2812 -0.0122 -0.0813 -0.8458 -0.1710 -0.4444 -2.8995 -0.4253 -0.4933 -0.0979 -0.2836 -1.3346 -0.5408 -0.8090 -1.7684 -1.5580 -2.9395 -1.4180 -0.5455 -2.9276 -0.8791 -0.7470 -0.3981 -1.1983 -0.1827
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate cox regression analyses ; hypertension ; sinus rhythm ; hazard ratio ; confidence interval
H-950	-0.740827739238739	▁multi varia te ▁co x ▁re gression ▁analyse s ▁; ▁AF ▁type ▁; ▁hyper tension ▁; ▁sinus ▁ rhythm ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁ci ▁; ▁HR
D-950	-0.740827739238739	multivariate cox regression analyses ; AF type ; hypertension ; sinus rhythm ;hazard ratio ;HR ; confidence interval ; ci ; HR
P-950	-1.2907 -0.0379 -0.1653 -0.0927 -0.2748 -0.0787 -0.0181 -0.7779 -0.2627 -0.7618 -0.3150 -0.9066 -0.2671 -3.0029 -0.0633 -0.2760 -0.5832 -0.1997 -0.2661 -0.3235 -0.2937 -0.0104 -0.0044 -0.2118 -2.1915 -0.4603 -3.0736 -0.0189 -0.2195 -2.1902 -2.1717 -3.9137 -0.3395 -0.1251
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients ; chronic ; hf-ref ; nyha functional class ii ; egfr ; potassium ; eplerenone ; hyperkalemia
H-1228	-0.5668758153915405	▁chronic ▁ HF - re f ▁; ▁NY ha ▁functional ▁class ▁II ▁; ▁e g FR ▁; ▁po tas s ium ▁; ▁e pler en one ▁; ▁hyper kal emia ▁; ▁w RF
D-1228	-0.5668758153915405	chronic HF-ref ; NYha functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
P-1228	-1.0926 -0.4548 -0.4358 -0.0742 -1.7364 -2.6278 -0.3031 -0.8768 -0.9139 -0.2918 -0.0538 -0.5571 -0.3737 -0.2142 -3.1794 -1.0255 -0.1780 -0.6966 -0.5372 -0.3754 -0.1193 -0.2468 -0.1236 -0.2708 -0.0659 -0.3298 -0.3937 -0.5128 -0.2269 -0.3460 -0.1517 -0.1640 -0.5583 -0.1986 -0.1345
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm ; dual energy x-ray absorptiometry ; dxa ; patients ; chronic heart failure ; chf ; non-cachectic chf ; myocardial
H-12	-0.4468365013599396	▁f m ▁; ▁FM ▁; ▁body ▁fat ▁distribution ▁; ▁dual ▁energy ▁X - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁non - dia be tic ▁patients ▁; ▁chronic ▁heart ▁failure ▁; cc ▁; ▁non - ca che ctic ▁CHF ▁; ▁my o card ial ▁in far ction - bo th
D-12	-0.4468365013599396	fm ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;cc ; non-cachectic CHF ; myocardial infarction-both
P-12	-0.4388 -2.1214 -0.5179 -2.0916 -0.3823 -0.5934 -0.3427 -0.3777 -0.3804 -0.0298 -0.3180 -1.4602 -0.1149 -0.2334 -0.0474 -1.0041 -0.6436 -0.3684 -0.6785 -0.5538 -0.1965 -0.2600 -0.3162 -0.7230 -0.0501 -0.0050 -0.0981 -0.2147 -0.2742 -1.5487 -0.1087 -0.3698 -0.0895 -0.2116 -2.4675 -0.4834 -1.2628 -0.0297 -0.0062 -0.0824 -0.0437 -0.0123 -0.2669 -0.7410 -0.3637 -0.2186 -0.3743 -0.0490 -0.1261 -0.1682 -0.2283 -0.0460 -0.0779 -0.2851 -0.0789
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline ; drug ; spironolactone ; combined end point ; death ; hospitalization ; hf ; hazard ratio ; confidence interval ; aas ; hazard ratio ; confidence interval ; p value
H-1707	-0.7551034688949585	▁spi rono lac tone ▁; ▁sterf ▁; ▁hospital ization ▁; ▁ HF ▁; ▁ha ard ▁ratio ▁; ▁AA s ▁; haz ard ▁ratio
D-1707	-0.7551034688949585	spironolactone ; sterf ; hospitalization ; HF ; haard ratio ; AAs ;hazard ratio
P-1707	-0.4416 -0.0266 -0.0650 -0.1342 -0.5096 -5.4518 -0.7426 -0.1374 -0.8835 -0.2168 -0.8725 -0.3459 -0.3110 -3.5888 -0.3638 -0.1365 -0.3391 -0.6782 -0.1686 -1.1742 -1.2711 -0.0738 -0.3638 -0.4440 -0.1371
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective study ; patients ; invasively ; diagnosed ; pulmonary arterial hypertension ; inoperable ; chronic thromboembolic pulmonary hypertension ; right ventricular ; pump ; stable ; pulmonary arterial hypertension ; medication ; noninvasive ; stress echocardiography ; cardiopulmonary exercise testing
H-823	-0.2723710834980011	▁pulmonar y ▁arterial ▁hyper tension ▁; ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y ▁hyper tension ▁; ▁right ▁vent ri cular ▁pump ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁medication ▁; ▁stress ▁e cho card i ography ▁; ▁cardio pul mon ary ▁exercise
D-823	-0.2723710834980011	pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise
P-823	-0.6129 -0.1146 -0.0100 -0.2104 -0.0539 -0.1565 -0.2248 -0.1177 -0.4936 -0.0691 -0.1613 -0.1498 -0.4970 -0.0734 -0.0194 -0.1134 -0.0215 -0.2160 -0.3014 -0.0686 -0.2129 -0.7262 -0.0566 -1.7811 -0.0937 -0.3809 -0.4472 -0.1068 -0.1060 -0.0092 -0.2160 -0.0327 -0.9942 -0.1775 -0.3128 -0.1234 -0.0383 -0.0627 -0.1900 -0.3354 -0.2854 -0.2068 -0.0109 -0.3357 -0.6626 -0.3850 -0.1341 -1.1622 -0.0745
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular death ; hf ; hospitalization ; randomization ; btes ; btes ; cardiovascular death ; hf ; hospitalization ; exercise ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-1930	-0.6657078266143799	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁b tes ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁exercise ▁group ▁; haz ard ▁ratio
D-1930	-0.6657078266143799	cardiovascular death ; HF hospitalization ; btes ; cardiovascular death ; HF hospitalization ; exercise group ;hazard ratio
P-1930	-0.6462 -0.4137 -0.1500 -0.2818 -0.5925 -1.3207 -0.9600 -0.3751 -1.5311 -0.4807 -0.1720 -2.1213 -0.5748 -0.0965 -0.1971 -0.5515 -1.2276 -0.7049 -0.1861 -0.4941 -1.6930 -0.8534 -0.8863 -0.0333 -0.1836 -1.1347 -0.1121
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients ; hospitalized ; death ; all-cause readmission ; aor ; eds ; aor
H-466	-0.9761055111885071	▁index ▁ED ▁visit ▁; ▁low - volu me ▁ED ▁; ▁read mission ▁; ▁medium ▁; ▁a OR ▁; ▁high - volu me ▁ED s ▁; ▁a OR
D-466	-0.9761055111885071	index ED visit ; low-volume ED ; readmission ; medium ; aOR ; high-volume EDs ; aOR
P-466	-0.1379 -0.5889 -2.8982 -0.3839 -0.5933 -0.0821 -0.1388 -0.1431 -0.7767 -1.7346 -6.1019 -1.3090 -0.4474 -2.3459 -0.6805 -0.2695 -0.2966 -0.4711 -4.3052 -0.1188 -0.2457 -0.1258 -0.8122 -0.4061 -1.5313 -0.6191 -0.4102 -0.1969 -0.1362
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients ; implantable cardioverter-defibrillator ; implantation ; engage ; patients ; decisions ; implantable cardioverter-defibrillator
H-1863	-0.5419277548789978	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant ation ▁; ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1863	-0.5419277548789978	implantable cardioverter-defibrillator deactivation ; implantation ; cardioverter-defibrillator deactivation
P-1863	-1.0536 -0.1226 -0.2557 -0.0818 -0.6115 -0.1247 -0.1639 -0.4332 -0.8646 -0.2952 -0.1213 -0.2614 -0.2355 -1.2140 -0.8780 -0.6584 -1.6593 -0.6414 -3.1958 -0.0788 -0.5146 -0.1141 -0.0938 -0.3838 -0.7097 -0.2670 -0.0801 -0.1980 -0.2724 -1.1916 -0.4641 -0.1016
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac magnetic resonance ; t1 time ; hazard ratio ; confidence interval ; left atrial area ; hazard ratio ; confidence interval ; pulmonary vascular resistance ; hazard ratio ; confidence interval ; cardiac events
H-739	-0.8895318508148193	▁Card iac ▁magnetic ▁res on ance ▁; ▁left ▁at rial ▁area ▁; haz ard ▁ratio ▁; ▁pulmonar y ▁vas cular ▁resist ance
D-739	-0.8895318508148193	Cardiac magnetic resonance ; left atrial area ;hazard ratio ; pulmonary vascular resistance
P-739	-1.4782 -0.2555 -0.2148 -0.6680 -0.7718 -1.1543 -1.0864 -1.8197 -0.7271 -0.2454 -1.1425 -0.3217 -4.3700 -0.0291 -0.4780 -0.4090 -0.1703 -0.1196 -0.0522 -0.5368 -0.9543 -0.1568 -4.0054 -0.1819
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively ; followed up ; hf ; patients ; systolic ; left ventricular ejection fraction ; hf ; stable ; clinical ; conditions ; new york heart association class i ; clinical ; echocardiographic ; cardiopulmonary exercise test
H-1755	-0.494944304227829	▁ HF ▁unit s ▁; ▁sy sto lic ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁New ▁York ▁Heart ▁association ▁; ▁e cho car dio graphic ▁; ▁cardio pul mon ary ▁exercise ▁test
D-1755	-0.494944304227829	HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart association ; echocardiographic ; cardiopulmonary exercise test
P-1755	-1.0912 -1.2827 -0.9316 -0.1604 -0.4800 -0.1267 -0.0726 -0.0227 -0.3525 -1.4401 -0.0842 -0.0948 -1.7353 -0.2587 -0.1503 -0.1664 -0.1150 -0.6828 -0.0078 -0.2297 -0.8238 -1.3405 -0.1796 -0.4345 -0.3644 -0.7479 -0.4416 -1.7354 -0.6115 -0.0808 -0.0245 -0.5494 -0.4270 -0.1771 -0.0432 -0.3698 -0.9735 -0.3690 -0.1901 -0.8195 -0.5129 -0.0865
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients ; end stage heart failure ; abcd classification ; american college of cardiology ; acc ; american heart association ; aha ; new york heart association ; nyha ; heart disease ; symptoms ; heart failure ; physical ; medical treatment
H-1666	-0.891758918762207	▁heart ▁failure ▁; ▁ABC d ▁classifica tion ▁; ▁American ▁college ▁of ▁Card i ology ▁; ▁a cc ▁; American ▁heart ▁association ▁; AHA ▁; ▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁structura l ▁heart ▁disease ▁; ▁heart ▁failure
D-1666	-0.891758918762207	heart failure ; ABCd classification ; American college of Cardiology ; acc ;American heart association ;AHA ; New York Heart association ;NYha ; structural heart disease ; heart failure
P-1666	-7.3058 -0.8980 -0.5266 -0.7341 -0.2162 -0.4612 -0.1178 -0.2126 -2.7820 -1.0089 -0.3412 -1.4136 -0.3568 -0.1283 -0.1889 -0.2404 -0.1134 -0.2780 -1.2614 -1.7721 -0.2461 -0.3397 -1.8951 -0.1082 -1.4612 -0.4969 -1.5607 -0.3452 -0.2004 -0.7263 -0.8001 -0.4204 -2.5961 -0.8735 -0.4954 -0.5524 -0.1692 -1.8325 -0.5250 -0.4436 -0.1170
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva ; continuity equation ; lv end-diastolic volume ; lv end-systolic volume ; mitral filling flow ; mva ; mitral filling flow ; continuous wave doppler echocardiography ; mitral valve plasty
H-345	-0.4705466032028198	▁m va ▁; ▁continu ity ▁e qu ation ▁; LV ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁end - sy sto lic ▁volume ▁; ▁mit ral ▁fill ing ▁flow ▁volume ▁; ▁m va ▁; ▁veloci ty ▁time ▁integral ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁continuo us ▁wa ve ▁; ▁do pp ler ▁e cho card i ography ▁; ▁MR ▁; ▁mit ral ▁val ve ▁plast y
D-345	-0.4705466032028198	mva ; continuity equation ;LV ; end-diastolic volume ; LV end-systolic volume ; mitral filling flow volume ; mva ; velocity time integral ; mitral filling flow ; continuous wave ; doppler echocardiography ; MR ; mitral valve plasty
P-345	-0.3671 -2.4724 -0.4569 -0.5195 -1.0407 -0.0957 -0.1945 -0.9317 -0.4699 -1.3741 -1.5005 -1.4432 -0.0477 -0.1894 -0.1720 -0.0400 -0.1543 -0.2287 -0.9898 -2.5525 -0.0461 -1.1121 -0.1402 -0.0416 -0.2004 -0.1721 -0.3054 -0.1513 -0.5486 -0.1273 -0.5049 -1.7627 -0.1988 -0.1333 -2.9599 -0.3295 -0.8365 -0.0181 -0.8888 -0.4750 -0.4142 -0.1213 -0.0741 -0.4040 -0.0733 -0.2233 -0.2040 -0.2674 -0.0383 -0.0052 -0.0076 -0.8484 -0.1935 -0.0091 -0.4276 -0.0584 -0.0507 -0.1440 -0.4476 -0.1347 -0.2656 -0.0617 -1.0495 -0.2920 -0.0405 -0.3562 -0.0912 -0.0922 -0.5720 -0.1615 -0.0862
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance ; rm ; all-cause mortality ; sts ; hh ; cri ; cri ; cri
H-157	-1.565889596939087	▁r m ▁; ▁mortal ity ▁; ▁s ts ▁ HH ▁; ▁c r i ▁; ▁TM ▁; ▁office ▁hours ▁; ▁r m
D-157	-1.565889596939087	rm ; mortality ; sts HH ; cri ; TM ; office hours ; rm
P-157	-3.3353 -1.6450 -0.6526 -1.6411 -1.8309 -0.3483 -0.8998 -1.3752 -1.5074 -0.3462 -0.3276 -4.0722 -0.2680 -3.8088 -0.3499 -2.0651 -1.6443 -1.9760 -0.1906 -0.5747 -3.6227 -1.8333 -3.1358 -0.1305
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi ; hf ; clinic ; outcomes ; hfpsi ; outcomes ; tracking ; patients ; hfpsi
H-381	-0.6411083340644836	▁ HF PSI ▁; ▁Ann ▁ar bor ▁Veteran s ▁Affairs ▁; ▁ HF ▁clinic ▁; ▁va ▁co hor t ▁; ▁ HF PSI ▁; ▁va - RT ▁co hor t ▁; ▁va ▁patients ▁; ▁ HF PSI
D-381	-0.6411083340644836	HFPSI ; Ann arbor Veterans Affairs ; HF clinic ; va cohort ; HFPSI ; va-RT cohort ; va patients ; HFPSI
P-381	-0.9578 -1.5151 -0.6346 -0.2627 -0.0590 -0.1599 -0.0488 -0.5520 -0.0247 -2.5070 -1.2152 -1.5592 -0.7647 -0.6279 -0.1787 -0.2358 -0.6704 -0.8228 -0.0321 -0.2301 -0.5083 -1.2445 -0.6311 -0.2867 -0.1231 -0.3238 -1.9786 -0.2182 -1.0426 -0.0496 -0.3021 -0.2826 -0.6794 -0.3914 -0.7889 -1.3580 -1.0425 -0.5872 -0.1061
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas ; spironolactone ; hyperkalemia ; potassium ; hypokalemia ; potassium
H-1706	-0.4931989908218384	▁AA s ▁; ▁spi rono lac tone ▁dose ▁; ▁hyper kal emia ▁; po tas s ium ▁; ▁hypo kal emia ▁; po tas s ium
D-1706	-0.4931989908218384	AAs ; spironolactone dose ; hyperkalemia ;potassium ; hypokalemia ;potassium
P-1706	-0.5843 -0.4301 -0.6281 -0.5529 -0.0709 -0.1069 -0.1126 -0.1973 -0.2851 -0.5775 -0.3548 -0.1964 -0.3749 -0.7639 -0.9533 -0.7134 -0.4420 -0.6563 -1.2074 -0.5670 -0.2056 -0.9465 -0.5410 -0.6886 -0.5425 -0.5524 -0.4346 -0.1235
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate analysis ; patients ; preserved lvef ; mortality ; patients ; lvef ; hazard ratio ; lvef ; preserved lvef
H-115	-0.9548162817955017	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF ▁; haz ard ▁ratio ▁; HR ▁; ▁LV EF ▁; ▁pres er ved ▁LV EF ▁; HR
D-115	-0.9548162817955017	LVEF ; long-term mortality ; LVEF ;hazard ratio ;HR ; LVEF ; preserved LVEF ;HR
P-115	-4.1687 -0.5145 -0.4144 -5.8559 -0.1709 -0.1709 -0.1159 -1.8469 -0.4590 -0.6743 -0.3514 -0.5158 -0.3491 -0.0092 -0.0020 -0.2961 -0.6120 -0.6361 -1.7580 -0.5900 -0.6147 -2.4976 -0.2095 -1.4006 -0.3242 -0.5252 -1.3541 -1.9321 -0.1408 -0.1347
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients ; hfpef ; primary outcome ; odds ratio ; nyha class iii ; 6-minute walk test ; 6-mwt ; feet ; prescribed ; medications
H-242	-0.9446399807929993	▁ HF p EF ▁; odd s ▁ratio ▁; ▁ny ha ▁class ▁III ▁; ▁ny ha ▁; ▁walk ▁test ▁; ▁mw t
D-242	-0.9446399807929993	HFpEF ;odds ratio ; nyha class III ; nyha ; walk test ; mwt
P-242	-1.6155 -0.2976 -0.0616 -0.7173 -0.4635 -2.7785 -0.0366 -0.0106 -0.1919 -1.8557 -0.2666 -1.1356 -0.2400 -0.5450 -3.5300 -0.3115 -1.9815 -1.4099 -0.1611 -0.7762 -1.9674 -0.0552 -2.1108 -0.1521
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived pulmonary arterial systolic pressure ; pasp ; right ventricular ; rv ; tricuspid annular plane systolic excursion ; tapse ; diastole ; end-systole ; clinical ; follow-up ; heart failure ; hf ; patients ; cardiac
H-492	-0.3457532227039337	▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁right ▁vent ri cular ▁; RV ▁; ▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; TA PS e ▁; ▁dia stol e ▁; ▁end - sy stol e ▁; ▁heart ▁failure ▁; HF ▁; ▁cardiac ▁risk
D-492	-0.3457532227039337	pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
P-492	-0.4092 -0.1222 -0.0122 -0.0196 -0.0950 -0.1017 -0.2977 -0.2492 -0.5873 -0.7092 -0.2105 -0.3400 -0.0521 -1.2887 -0.1190 -0.2775 -1.3867 -0.3472 -0.0061 -0.0877 -0.0198 -0.0728 -0.0054 -0.2248 -0.0091 -0.0758 -0.1111 -0.3542 -0.0321 -0.2506 -2.2239 -1.0911 -0.7858 -0.1163 -0.0524 -0.0311 -0.3538 -0.5725 -0.2967 -0.1001 -0.8820 -0.1278 -0.1258 -0.2926 -1.2816 -0.0725 -0.1053 -0.2431 -0.3775 -0.3132 -0.7597 -0.1563 -0.0890
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad ; diabetes ; odds ratio ; electrocardiographic q waves ; left bundle branch block ; odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; odds ratio
H-1190	-0.413551926612854	▁CAD ▁; ▁diabetes ▁; ▁electro car dio graphic ▁Q ▁wa ves ▁; ▁left ▁bund le ▁bran ch ▁block ▁; ▁non dia bete s ▁risk ▁factors ▁; ▁dys li pide mia ▁; ▁hyper tension ▁; ▁to ba cco ▁use
D-1190	-0.413551926612854	CAD ; diabetes ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco use
P-1190	-1.6552 -0.1361 -0.1223 -0.1793 -0.0374 -0.0348 -0.3134 -0.1587 -2.2408 -0.0098 -0.5033 -0.1479 -0.0326 -0.0288 -0.4057 -0.0049 -0.0542 -0.2278 -0.2891 -0.5662 -0.0848 -0.0898 -0.0580 -1.9825 -0.2825 -0.3019 -0.1193 -0.0891 -0.0115 -0.5248 -0.2268 -0.0363 -0.0091 -0.1673 -0.0552 -1.2968 -0.8507 -2.3925 -0.6925 -0.1225
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area under the receiver operating characteristic curve ; auc ; pcwp ; confidence interval ; septal ; p values
H-485	-0.9268980622291565	▁receive r ▁operating ▁character istic ▁cur ve ▁; AU c ▁; ▁pc WP ▁; ▁confidence ▁interval ▁; CI ▁; ▁e - sept al ▁; ▁e / e lateral ▁; ▁e / eme an
D-485	-0.9268980622291565	receiver operating characteristic curve ;AUc ; pcWP ; confidence interval ;CI ; e-septal ; e/elateral ; e/emean
P-485	-2.4062 -0.0313 -1.2612 -0.2695 -0.1537 -0.7425 -0.2655 -0.2790 -1.5509 -2.5657 -0.1619 -0.1964 -1.5395 -0.3294 -1.0424 -0.0370 -0.1135 -2.3542 -0.1712 -0.7668 -5.7368 -0.0312 -0.0085 -0.2243 -1.2998 -3.8295 -0.1749 -0.2379 -0.5924 -1.0095 -2.7741 -0.0244 -0.0149 -0.1321 -0.1134
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients ; coronary artery disease ; hypertension ; trastuzumab ; administration ; chf
H-680	-0.9990324378013611	▁tras tuz um ab - tre ated ▁patients ▁; ▁corona ry ▁arter y ▁disease ▁; HR ▁; ▁hyper tension ▁; HR ▁; ▁week ly ▁tras tuz um ab ▁administration ▁; ▁CHF
D-680	-0.9990324378013611	trastuzumab-treated patients ; coronary artery disease ;HR ; hypertension ;HR ; weekly trastuzumab administration ; CHF
P-680	-2.4141 -0.2306 -0.1045 -2.0908 -1.1342 -0.1322 -1.3720 -1.1898 -0.4984 -3.0899 -1.2478 -0.0068 -0.2953 -0.3191 -0.2105 -2.2427 -0.3043 -0.4835 -0.0302 -0.2622 -2.0523 -0.5800 -2.9054 -0.6226 -1.1536 -0.0899 -0.2423 -1.4820 -2.2007 -0.1426 -3.4507 -0.2023 -0.1848
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef ; clinical ; crt ; crt ; systolic volume index ; lv mass
H-754	-0.8911179304122925	▁LV EF ▁; ▁clinic al ▁com posit e ▁response ▁; ▁c RT ▁on ▁; ▁c RT ▁OFF ▁; ▁LV ▁end ▁sy sto lic ▁volume ▁index ▁; ▁LV ▁mass
D-754	-0.8911179304122925	LVEF ; clinical composite response ; cRT on ; cRT OFF ; LV end systolic volume index ; LV mass
P-754	-1.8444 -0.8985 -0.3002 -3.5050 -0.0357 -0.0240 -0.0252 -0.0322 -0.4187 -0.3425 -0.3653 -1.6371 -2.5734 -0.8394 -0.4667 -2.4695 -0.7630 -0.3386 -1.1435 -3.9558 -0.0816 -0.0541 -0.1160 -0.1486 -0.0391 -0.2767 -2.9731 -0.7426 -0.2298 -0.0933
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β signaling ; tgf-β receptor type i ; cell ; yield ; epithelial ; mesenchymal ; transition ; pluripotency marker ; nanog ; cell ; cells ; in vitro
H-1343	-0.33737003803253174	▁t GF - β ▁signal ing ▁; ▁t GF - β ▁receptor ▁type ▁I ▁; ▁s mad ▁; ▁small - mo le cule ▁inhibi tors ▁; ▁c - K it + ▁cell ▁yi eld ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker ▁na nog ▁; ▁c - K it + ▁cell ▁differenti ation ▁; ▁cardio my o cy te - like ▁cell s
D-1343	-0.33737003803253174	tGF-β signaling ; tGF-β receptor type I ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
P-1343	-1.9303 -0.5708 -0.0933 -0.2124 -0.3958 -0.2420 -0.3353 -2.8995 -0.3423 -0.1330 -0.3632 -0.0721 -0.8945 -1.6675 -0.2571 -0.1421 -0.0334 -0.2027 -0.1091 -0.0493 -0.2165 -0.3082 -0.1069 -0.0229 -0.2036 -0.1852 -0.0263 -0.1247 -1.9635 -0.0326 -1.2434 -0.2107 -0.0050 -0.0006 -0.1780 -0.0155 -0.0837 -0.0803 -0.0060 -0.6985 -0.0140 -0.1491 -0.0965 -0.9341 -0.0275 -0.0530 -0.0772 -0.1390 -0.1011 -0.0429 -0.0252 -0.0287 -0.2138 -0.0140 -0.3075 -0.0117 -0.0669 -1.3818 -0.0349 -0.8778 -0.2387 -0.3465 -0.4683 -0.4162 -0.0108 -0.5122 -0.4414 -0.0833 -0.0660 -0.4310 -0.2428 -0.1228 -0.0566 -0.5511 -0.0607
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients ; hfref ; diuretics ; co-morbidities ; 6-mwt ; feet ; nyha class iii
H-243	-0.9822077751159668	▁h Fr EF ▁; ▁di ure tics ▁; ▁co - mor bid ities ▁; ▁w t ▁; ▁ny ha ▁class ▁III
D-243	-0.9822077751159668	hFrEF ; diuretics ; co-morbidities ; wt ; nyha class III
P-243	-1.8715 -1.6228 -2.0878 -0.2840 -0.5656 -1.3650 -0.6093 -0.5748 -0.3609 -0.0949 -0.1380 -0.2193 -2.3091 -0.4768 -2.2251 -1.6679 -0.7149 -2.7937 -0.4199 -0.4216 -0.2458 -1.3720 -0.1501
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery ; hf ; postoperative ; echocardiography ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mitral valve area ; mva
H-344	-0.434431254863739	▁ HF ▁; ▁post operativ e ▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁LV ▁; ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁mit ral ▁val ve ▁area ▁; ▁m VA ▁; ▁pressure ▁gradi ent
D-344	-0.434431254863739	HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mVA ; pressure gradient
P-344	-2.7428 -0.5011 -0.4036 -1.0094 -0.2522 -0.0680 -0.1965 -0.2515 -0.2498 -0.8189 -0.2109 -0.2516 -0.6419 -0.2967 -1.1805 -0.0692 -0.0239 -0.0481 -0.0269 -0.0761 -0.0387 -0.2173 -3.2519 -0.5281 -0.4810 -0.1803 -0.0399 -0.8924 -0.0067 -0.2408 -0.1847 -0.1753 -0.1430 -0.0497 -0.1035 -0.0673 -0.1671 -0.2424 -0.0921 -0.0727 -0.0635 -0.0815 -1.2769 -0.2340 -0.0490 -2.0291 -0.3494 -0.9433 -0.0182 -0.0500 -0.9402 -0.0606
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients ; systolic heart failure ; ejection fraction ; randomized ; placebo ; ivabradine ; shift ; systolic heart failure treatment with the if inhibitor ivabradine trial ; patients ; placebo ; ivabradine ; echocardiographic
H-519	-0.45018792152404785	▁sy sto lic ▁heart ▁failure ▁; ej ection ▁ fraction ▁; ▁i va bra dine ▁; ▁SHI ft ▁; ▁sy sto lic ▁Heart ▁Fail ure ▁Treatment ▁; ▁If ▁in hib itor ▁i va bra dine ▁tri al ▁; ▁i va bra dine ▁; ▁e cho car dio graphic ▁sub stu dy
D-519	-0.45018792152404785	systolic heart failure ;ejection fraction ; ivabradine ; SHIft ; systolic Heart Failure Treatment ; If inhibitor ivabradine trial ; ivabradine ; echocardiographic substudy
P-519	-1.1014 -0.2459 -0.1309 -1.2920 -0.1617 -0.2390 -3.8981 -0.0334 -0.0854 -0.0056 -0.2715 -0.1556 -0.1895 -0.6798 -0.5968 -0.1648 -0.1960 -0.8809 -0.3996 -0.3957 -0.0471 -0.1066 -0.9234 -0.7120 -0.5323 -0.2985 -0.8763 -1.2666 -0.1825 -0.0032 -0.0440 -0.7852 -0.0453 -0.2291 -0.1490 -0.2785 -0.0205 -0.2438 -0.6071 -0.1095 -0.7064 -0.2374 -0.6231 -0.2291 -0.0621 -0.0396 -0.4299 -1.1905 -0.9228 -0.0045 -0.5518 -0.2058 -0.0729
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard ratios ; multivariate regression ; tapse ; pasp ; hazard ratio ; tapse ; new york heart association functional class
H-499	-1.7453727722167969	▁Hazard ▁ratio s ▁; ▁p b ▁; ▁p b ▁; haz ard ▁ratio ▁; ▁p b ▁; ▁t AP se ▁; ▁New ▁York ▁Heart ▁association ▁functional ▁class
D-499	-1.7453727722167969	Hazard ratios ; pb ; pb ;hazard ratio ; pb ; tAPse ; New York Heart association functional class
P-499	-2.7605 -0.1467 -0.6806 -0.5137 -2.8224 -3.3958 -0.8136 -5.2449 -2.4792 -0.3967 -1.9632 -0.1050 -0.1032 -0.3426 -5.7260 -2.4538 -0.5032 -5.0282 -1.7046 -1.9491 -0.2148 -4.0555 -0.5857 -1.7651 -0.6177 -0.8250 -0.2157 -3.0628 -0.1407
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal function ; the chronic kidney disease epidemiology collaboration ; patients ; estimated glomerular filtration rate ; egfr
H-390	-0.7725383043289185	▁Ren al ▁function ▁; ▁Chro nic ▁Kid ney ▁Disease ▁Epidemi ology ▁Col labora tion ▁e qu ation ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR
D-390	-0.7725383043289185	Renal function ; Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; egFR
P-390	-2.2789 -0.1238 -0.1454 -0.6601 -0.0748 -0.6282 -0.0834 -1.1901 -0.2051 -0.4976 -0.3144 -3.0436 -0.0412 -0.0758 -1.3925 -0.1263 -1.1508 -0.5411 -0.2788 -0.6426 -0.1379 -0.1406 -0.8305 -0.3099 -0.6383 -0.1758 -2.9582 -2.0860 -2.2086 -0.1959
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective ; randomized ; paradigm-hf ; chronic heart failure ; systolic dysfunction ; lv ef ; functional class ; nyha ; elevated ; bnp ; nt-pro bnp ; primary endpoint ; cardiovascular death ; hospitalization ; heart failure ; arni ; lcz696 ; sacubiltril ; valsartan
H-1968	-0.4903063178062439	▁para dig m - HF ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; LV ▁EF ▁; ▁functional ▁class ▁NY ha ▁II - III ▁; ▁b NP ▁; ▁b NP ▁; ▁car dio vas cular ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure ▁; ▁ar ni ▁; ▁l z 696 ▁; ▁sa cubi lt ril ▁; ▁val sar tan
D-1968	-0.4903063178062439	paradigm-HF ; chronic heart failure ; systolic dysfunction ;LV EF ; functional class NYha II-III ; bNP ; bNP ; cardiovascular death ; hospitalization ; heart failure ; arni ; lz696 ; sacubiltril ; valsartan
P-1968	-1.5892 -0.8394 -0.5604 -0.0655 -0.4636 -0.6086 -0.9178 -1.0177 -0.1621 -0.6900 -0.0304 -0.0549 -0.1360 -0.0151 -0.0365 -0.2435 -0.5425 -1.4655 -0.2570 -0.5832 -0.0546 -0.5071 -0.7879 -0.3900 -0.0562 -0.0108 -0.2713 -1.2705 -0.7128 -0.3923 -3.1428 -0.7428 -0.2952 -0.6834 -0.1349 -0.2394 -0.3748 -0.4133 -0.1005 -0.1821 -0.6589 -1.4952 -0.4418 -0.1070 -0.2768 -0.3837 -1.2267 -0.1883 -0.4442 -2.8551 -0.0768 -0.1799 -0.0255 -0.0080 -0.0188 -0.0750 -0.2430 -0.0581 -0.0345 -0.0628 -0.4049 -0.0925
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv reverse remodeling ; lv end-diastolic dimension ; longitudinal ; strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial ; right ventricular fractional area ; change
H-432	-0.900509774684906	▁LV ▁rever se ▁remodel ing ▁; ▁pre - c RT ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁index ▁; ▁global ▁longitud in al ▁strain ▁; ▁left ▁vent ric le ▁; ▁left ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁end - dia sto lic ▁area ▁index ▁; ▁right ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁ fraction al ▁area
D-432	-0.900509774684906	LV reverse remodeling ; pre-cRT LV ; end-diastolic dimension index ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial area ; right ventricular fractional area
P-432	-0.8492 -0.5206 -0.0460 -0.1034 -0.1169 -0.3787 -5.8782 -0.0091 -1.0450 -2.6228 -3.6585 -1.1148 -3.5209 -0.1008 -0.0568 -0.6522 -0.1938 -0.8212 -0.3017 -0.5844 -0.3502 -3.0784 -0.0198 -0.1611 -0.0153 -0.1889 -0.7627 -0.1247 -0.2445 -1.4459 -0.6943 -0.3832 -0.2538 -1.4730 -0.2845 -1.0442 -0.4144 -1.3392 -0.1839 -2.1980 -0.2570 -4.3986 -0.1044 -0.0672 -0.5034 -0.3909 -1.7478 -0.9932 -0.2956 -0.7697 -2.1608 -0.2130 -1.2400 -0.6739 -1.0090 -0.2314 -2.3798 -0.6030 -0.9866 -0.0274 -0.0315 -0.5445 -0.6559 -0.1127
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia ; outcomes ; african americans ; aas ; new york heart association ; nyha ; hf ; left ventricular dysfunction ; randomized ; spironolactone ; titrated ; placebo ; randomized aldactone evaluation study ; rales
H-1703	-0.5314361453056335	▁hyper kal emia ▁; ▁African ▁American s ▁; ▁AA s ▁; ▁non - AA s ▁; ▁white ▁; ▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁class ▁III ▁; ▁ HF ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁spi rono lac tone ▁; ▁al da cto ne ▁Evalua tion ▁Study ▁; RAL es
D-1703	-0.5314361453056335	hyperkalemia ; African Americans ; AAs ; non-AAs ; white ; New York Heart association ;NYha ; class III ; HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
P-1703	-1.2865 -0.4653 -0.4608 -0.2636 -0.2310 -1.1206 -0.1752 -0.1938 -4.3368 -0.0967 -0.1142 -0.1742 -0.0507 -0.2704 -0.0195 -0.1327 -0.7139 -0.1985 -1.1343 -0.2096 -0.9219 -0.4221 -0.2007 -0.4659 -0.8007 -0.2098 -1.1300 -0.0525 -0.8777 -2.4845 -0.4196 -0.1507 -0.0192 -0.0559 -2.1337 -0.2659 -0.0124 -0.1611 -0.2456 -0.0296 -0.0066 -0.0349 -0.0250 -0.2932 -2.1879 -0.1217 -0.0566 -0.6180 -1.8652 -0.2120 -0.6172 -0.3266 -0.0205 -0.2712 -0.3146 -0.0814
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; irs1 ; irs2 ; heart-specific irs1 and irs2 gene double-knockout ; h-dko ; liver-specific irs1 and irs2 double-knockout ; l-dko
H-654	-0.6542272567749023	▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁; ▁hyper insu line mia ▁; ▁my o card ial ▁insulin ▁resist ance ▁; ▁cel lular ▁dys function ▁; ▁i RS 2 ▁; ▁i RS 1 ▁; ▁i RS 2 ▁gene ▁double - k no ckou t ▁; ▁l - d ko ▁; ▁ liver - specific ▁I RS 1 ▁; ▁i RS 2 ▁double - k no ckou t ▁; ▁l - d ko
D-654	-0.6542272567749023	iRS1 ; iRS2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS1 ; iRS2 gene double-knockout ; l-dko ; liver-specific IRS1 ; iRS2 double-knockout ; l-dko
P-654	-0.6031 -0.2395 -1.7021 -0.5835 -0.6252 -0.5373 -0.1072 -0.4495 -3.9029 -0.2892 -0.2735 -0.0108 -0.0876 -1.5534 -0.2463 -0.3811 -0.3055 -0.3687 -0.9181 -0.0315 -0.1888 -0.0425 -0.2044 -0.9924 -0.0167 -0.0636 -0.0928 -0.2349 -0.8850 -0.0652 -1.2806 -0.2534 -1.0836 -0.2184 -3.0819 -0.2673 -1.4283 -0.2550 -0.1246 -2.8589 -0.3476 -0.2501 -2.0127 -0.3962 -0.0943 -0.0107 -0.2814 -2.1391 -0.0685 -0.8179 -0.4768 -0.8883 -0.5793 -1.1648 -0.1155 -0.1158 -1.9615 -0.1224 -2.7540 -0.3921 -1.8728 -0.5243 -0.1153 -1.4090 -0.0810 -1.6269 -0.1874 -0.1831 -0.0108 -0.4125 -0.0822 -0.0320 -0.7202 -0.3409 -0.1902 -0.0894
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; diagnostic ; stable ; coronary artery disease ; b-type natriuretic peptide ; bnp ; nt-probnp ; ventricular cardiomyocytes ; ventricular ; wall stress ; myocardial ischemia
H-1364	-0.7988618016242981	▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁corona ry ▁arter y ▁disease ▁; ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁n - termin al ▁fragment ▁; nt - pro b NP ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁vent ri cular ▁wall ▁stress ▁; ▁my o card ial ▁ ische mia
D-1364	-0.7988618016242981	b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; coronary artery disease ; natriuretic peptide ; bNP ; n-terminal fragment ;nt-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
P-1364	-3.6356 -0.2388 -0.0683 -0.1585 -1.7120 -1.8840 -1.8833 -1.5617 -0.5576 -1.0228 -0.2970 -3.0862 -0.0270 -0.0982 -0.0084 -0.3252 -0.0517 -1.2937 -0.0752 -0.0195 -0.1317 -1.3471 -1.9108 -2.2418 -1.5741 -0.6776 -0.7197 -0.2866 -1.0762 -1.4741 -0.0295 -0.4007 -0.3391 -0.7327 -1.1146 -2.2396 -2.0364 -2.3663 -1.8060 -0.4573 -1.1627 -0.2416 -0.6249 -0.8135 -0.2992 -0.9802 -0.0229 -0.1108 -0.0027 -0.1120 -0.2809 -2.9712 -0.0115 -0.0235 -0.5967 -2.0437 -0.3764 -0.0349 -1.2370 -0.4940 -0.1632 -0.5743 -0.5012 -0.1340 -0.1324 -0.3566 -0.0202 -2.2168 -1.0266 -1.2389 -0.2560 -0.1301 -0.7884 -0.2958 -0.3150 -0.9017 -0.3208 -0.0925 -1.3355 -0.3918 -0.1093
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range ; interquartile range
H-665	-0.4768766164779663	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁inter quart ile ▁range ▁; ▁β - block ers
D-665	-0.4768766164779663	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; β-blockers
P-665	-4.9136 -1.6584 -0.1151 -1.0879 -0.2350 -0.0269 -0.0758 -0.1139 -0.0913 -0.0486 -0.0527 -0.2571 -0.7559 -0.0661 -0.1098 -0.3722 -0.0132 -0.5317 -0.1096 -0.6176 -0.2482 -0.0406 -0.0673 -0.0568 -0.6564 -0.3775 -0.0385 -0.1916 -0.1407 -1.5379 -0.1753
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ; ivabradine ; change ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; correlates ; exercise capacity ; therapy ; ivabradine ; correlated ; peak oxygen uptake
H-1177	-0.5640395283699036	▁i va bra dine ▁; ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty ▁; ▁exercise ▁capacity ▁; ▁i va bra dine ▁; ▁oxygen ▁up take
D-1177	-0.5640395283699036	ivabradine ; diastolic mitral flow velocity ; diastolic mitral annular velocity ; exercise capacity ; ivabradine ; oxygen uptake
P-1177	-0.5266 -0.0837 -0.3607 -0.4346 -0.4147 -0.5745 -0.1126 -0.0587 -0.4026 -0.1228 -2.1820 -1.2946 -0.0741 -0.3312 -0.3357 -0.1125 -0.0812 -0.2901 -0.1622 -2.4042 -0.0186 -0.1036 -0.0496 -0.4591 -1.5520 -0.5195 -0.3779 -0.3143 -0.0873 -0.5959 -0.4398 -0.2958 -2.0518 -2.9282 -0.4210 -0.1540 -0.1418
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence ; transfusion ; mortality ; relative risk ; mortality ; patients ; acute coronary syndrome
H-45	-0.7963747978210449	▁liberal ▁trans fusion ▁protocol s ▁; ▁mortal ity ▁rates ▁; ▁aggressiv e ▁protocol s ▁; ▁i 2 ▁; ▁mortal ity ▁rates ▁; ▁a cute ▁corona ry ▁syndrome
D-45	-0.7963747978210449	liberal transfusion protocols ; mortality rates ; aggressive protocols ; i2 ; mortality rates ; acute coronary syndrome
P-45	-0.4281 -0.0495 -0.1540 -0.9514 -0.1857 -0.5095 -5.0014 -2.3625 -1.4339 -0.5605 -0.6937 -0.0473 -0.0946 -0.1512 -0.4760 -1.9794 -0.0349 -0.4179 -0.5129 -2.0262 -1.9850 -0.6434 -0.1671 -0.0322 -0.0652 -1.6426 -0.0024 -0.3410 -0.1453
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death ; readmission ; patients ; physician ; hazard ratio ; confidence interval ; physician ; follow-up ; patients ; follow-up
H-1419	-0.9400460720062256	▁un plan ned ▁read mission ▁; ▁familiar ▁physician ▁; ▁hazard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; CI ▁; ▁un fa milia r ▁physician
D-1419	-0.9400460720062256	unplanned readmission ; familiar physician ; hazard ratio ;HR ; confidence interval ;CI ; unfamiliar physician
P-1419	-3.3903 -0.0652 -0.3188 -1.4813 -1.0981 -0.9872 -1.8913 -0.2742 -0.3546 -2.4131 -0.0135 -0.2550 -1.4846 -0.3782 -2.0869 -0.0290 -0.2468 -1.7104 -0.5492 -0.1598 -0.3126 -0.0551 -0.0381 -0.1138 -4.6000 -0.1342
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek ; human embryonic kidney ; cells ; β1ar ; s1pr1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1pr1 agonist ; s1pr1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
H-1409	-0.8702294230461121	▁h ek ▁; human ▁em bry o nic ▁ki dne y ▁; ▁cell s ▁over express ing ▁; ▁β 1 AR ▁; ▁s 1 PR 1 ▁; ▁β 1 AR ▁; ▁down regul ation ▁; ▁sp hing os ine -1 - phos pha te ▁; ▁s 1 PR 1 ▁ago nist ▁; ▁iso prot eren ol ▁; ▁β - ad r energi c ▁receptor ▁ago nist
D-1409	-0.8702294230461121	hek ;human embryonic kidney ; cells overexpressing ; β1AR ; s1PR1 ; β1AR ; downregulation ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; β-adrenergic receptor agonist
P-1409	-2.2032 -1.0425 -0.3423 -2.5690 -0.0989 -0.0633 -0.2881 -0.6449 -0.0300 -0.8682 -0.1506 -0.5016 -5.1950 -0.1202 -1.6022 -0.1141 -0.1311 -1.2297 -0.3221 -1.9094 -1.2037 -0.4350 -1.3745 -1.1908 -1.0580 -3.6643 -0.8424 -1.9047 -1.5117 -1.7288 -1.7104 -4.8804 -0.2898 -0.9569 -0.4928 -0.0574 -1.5636 -0.5823 -2.4942 -1.2606 -0.2447 -0.0092 -0.0112 -0.0945 -0.2833 -0.8638 -0.4765 -0.5075 -1.6705 -1.7081 -0.1221 -0.4244 -0.6999 -0.0389 -0.0972 -0.4383 -0.2558 -0.1006 -0.0654 -0.0508 -0.5866 -0.9943 -0.1305 -0.0303 -0.0804 -0.0541 -0.4095 -0.0985
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline ; training ; 6-minute walked distance ; quality of life ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; symptoms ; beck depression inventory ; zung self-rated depression scores ; b-type natriuretic peptide ; endothelial function ; flow-mediated dilatation ; left ventricular diastolic function
H-1330	-0.39736315608024597	▁kan sas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁ depressiv e ▁symptoms ▁; ▁be ck ▁de pression ▁in ven tory ▁; ▁z ung ▁self - rat ed ▁depression ▁score s ▁; ▁na tri ure tic ▁pe pti de ▁; ▁en dot heli al ▁function ▁; ▁vent ri cular ▁dia sto lic ▁function
D-1330	-0.39736315608024597	kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ; ventricular diastolic function
P-1330	-1.5330 -0.0025 -0.8644 -1.0843 -0.0740 -0.1565 -0.9177 -0.1191 -0.7075 -0.0274 -0.1377 -0.0230 -0.2817 -0.3106 -0.6855 -0.3127 -0.5828 -0.3087 -0.0265 -0.1774 -0.2091 -0.0178 -0.0480 -0.1985 -0.1246 -0.2124 -0.0039 -0.1182 -0.0600 -0.2759 -0.1049 -0.0096 -0.1385 -1.2825 -0.3256 -1.7305 -0.0021 -0.0129 -0.0097 -0.0634 -0.2685 -0.0781 -0.2934 -0.1278 -0.3254 -0.7615 -0.8147 -1.4100 -0.1376 -0.4697 -0.2479 -0.0704 -0.6135 -0.2018 -0.0085 -0.2461 -0.2073 -3.0984 -1.0087 -0.3514 -0.0513 -0.0505 -0.1284 -1.2929 -0.5713 -0.1096
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds ratios ; confidence intervals ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; patients ; estimated glomerular filtration rate ; nonsignificant ; acute kidney injury
H-976	-0.33163970708847046	▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁diabetes ▁mell itus ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁stroke ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁ki dne y ▁injury
D-976	-0.33163970708847046	cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; kidney injury
P-976	-2.7550 -0.7695 -0.4640 -1.1245 -0.0228 -0.4451 -0.0319 -0.1449 -0.3662 -0.1066 -0.0493 -1.5086 -0.2873 -0.0768 -0.1016 -0.0389 -0.4533 -0.0121 -0.2469 -0.0338 -0.0009 -0.0141 -0.1745 -0.0264 -0.0944 -0.0765 -0.0358 -0.0804 -0.0782 -0.1429 -0.1688 -0.2182 -0.2774 -0.2498 -0.5177 -0.0170 -0.1566 -0.1436 -0.1791 -0.2754 -0.0691 -0.1072 -0.0923 -0.2975 -0.0590 -0.1897 -0.0279 -0.0778 -0.5916 -1.1960 -0.5155 -2.9132 -0.3596 -0.1363 -0.0649 -0.1590 -0.0800
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic function ; ea ; ventricular-arterial coupling ; ees ; ea
H-925	-1.0552127361297607	▁dia sto lic ▁function ▁; ▁Ea ▁; ▁vent ri cular - arte rial ▁coup ling
D-925	-1.0552127361297607	diastolic function ; Ea ; ventricular-arterial coupling
P-925	-0.2834 -0.4025 -0.1293 -0.2982 -0.5598 -4.2380 -0.7824 -3.3657 -2.8843 -0.2708 -0.4595 -0.0885 -0.1083 -0.8080 -1.1544 -1.9398 -0.1657
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard ratios ; disease risk score ; drs ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
H-1835	-0.9554509520530701	▁disease ▁risk ▁score ▁; ▁d RS ▁; ▁ci ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁sax ag lip tin ▁; ▁pi og lita zone ▁; ▁sax ag lip tin ▁; ▁sul fon yl ure as ▁; ▁sax ag lip tin ▁; ▁insulin
D-1835	-0.9554509520530701	disease risk score ; dRS ; ci ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
P-1835	-1.8554 -0.8948 -0.1947 -0.3284 -0.0602 -0.4113 -0.4912 -2.3542 -2.7557 -1.5995 -0.0491 -1.2562 -2.8678 -0.7163 -1.7388 -0.8150 -0.7270 -2.6043 -0.2647 -1.7561 -0.0637 -1.3546 -2.7147 -0.4517 -0.7162 -0.0576 -0.0791 -0.0969 -0.2785 -1.0218 -0.0932 -1.5809 -3.0937 -0.4810 -0.0485 -0.0215 -0.2715 -0.5201 -0.0758 -0.3139 -2.8382 -0.0863 -1.6016 -3.2514 -0.6929 -0.0194 -0.1743 -0.1219
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients ; revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline ; electrocardiogram
H-106	-0.5550097227096558	▁i ▁; ▁re vas cular ization ▁; ▁co ron ary ▁arter y ▁by pass ▁surgery ▁; ▁hazard ▁ratio ▁; HR ▁; ▁per cuta ne ous ▁corona ry ▁intervention ▁; ▁HR ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁bund le ▁bran ch ▁block ▁pattern ▁; ▁base line ▁electro card i ogram ▁; ▁IE
D-106	-0.5550097227096558	i ; revascularization ; coronary artery bypass surgery ; hazard ratio ;HR ; percutaneous coronary intervention ; HR ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram ; IE
P-106	-1.7159 -2.9987 -0.2884 -0.0463 -0.1201 -0.5784 -0.4697 -1.4266 -1.3803 -0.7465 -0.0174 -0.2605 -0.9296 -0.1137 -0.2230 -0.2749 -0.9566 -0.0163 -0.1334 -1.2016 -0.3727 -0.1044 -0.0012 -0.5611 -0.5608 -0.2022 -1.3718 -0.0851 -0.2850 -1.0991 -0.4135 -0.0606 -0.0338 -0.0596 -0.2813 -0.5280 -0.2926 -4.6250 -0.0179 -0.3351 -0.0244 -0.1110 -0.3928 -0.1554 -0.2702 -0.2650 -0.0133 -0.0160 -0.2021 -0.5432 -0.0474 -0.4012 -2.3542 -0.4283 -0.1124
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical ; biomedical ; relative risk ; confidence interval ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1262	-0.6107134222984314	▁bio medic al ▁treatment ▁; ▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1262	-0.6107134222984314	biomedical treatment ; biomedical treatment ; CHm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
P-1262	-0.0151 -0.0983 -0.0141 -0.8998 -0.7373 -0.1382 -0.1403 -0.0207 -1.1530 -0.3913 -1.1913 -0.2874 -0.2945 -2.1074 -0.1059 -2.2148 -0.3818 -0.4157 -0.2455 -0.1798 -0.9515 -0.0269 -0.2716 -0.8756 -0.0949 -2.1781 -0.2757 -0.1768 -0.1390 -0.1424 -1.9155 -1.4361 -1.0935 -0.1546
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective ; randomized ; crossover study ; outcome ; stable heart failure ; patients ; left ventricular ejection fraction ; homozygous ; haplotype ; β2-receptor ; randomized ; carvedilol ; metoprolol
H-1114	-0.5645301342010498	▁open - label ▁cross over ▁study ▁; ▁heart ▁failure ▁patients ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ar g 16 ▁; ▁g l n 27 ▁; ▁g ly 16 ▁; ▁lim 27 ▁ha plo type ▁; ▁β 2- recept or ▁; ▁car vedi lol ▁; ▁met o pro lol
D-1114	-0.5645301342010498	open-label crossover study ; heart failure patients ; left ventricular ejection fraction ; arg16 ; gln27 ; gly16 ; lim27 haplotype ; β2-receptor ; carvedilol ; metoprolol
P-1114	-2.6689 -0.1184 -0.0999 -0.2653 -0.0200 -2.0664 -0.5192 -3.5518 -0.0623 -0.6824 -0.3094 -2.9204 -0.0530 -0.0805 -2.0554 -0.2727 -0.1090 -0.1908 -0.0796 -0.9219 -0.0078 -0.2708 -0.1807 -0.0755 -0.2079 -1.2052 -0.3279 -0.6653 -0.0276 -0.4337 -0.1276 -0.3533 -0.4030 -0.1043 -1.3704 -4.9634 -0.8400 -0.0356 -0.1316 -0.0578 -0.1575 -0.2062 -0.0332 -0.0421 -0.0808 -0.3527 -0.0177 -0.0403 -0.2239 -0.1954 -0.0263 -0.2581 -0.0610 -0.7230 -0.2704 -0.0887
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients ; death ; hospitalization ; aor ; aor ; aor ; aor
H-465	-1.1794830560684204	▁low - volu me ▁ED ▁cases ▁; ▁death ▁; hospital ization ▁; ED ▁visit ▁; ▁a OR ▁; ▁high - volu me ▁ED ▁; ▁a OR
D-465	-1.1794830560684204	low-volume ED cases ; death ;hospitalization ;ED visit ; aOR ; high-volume ED ; aOR
P-465	-3.2266 -0.1016 -0.1449 -0.2075 -1.2400 -2.8504 -0.6021 -3.5982 -1.4508 -0.3638 -0.7564 -0.5752 -1.6654 -2.0542 -0.4063 -0.9101 -0.2696 -0.4656 -5.4256 -0.1668 -0.3909 -0.1821 -1.5651 -2.5357 -0.9158 -0.4239 -0.3695 -0.1614
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health buddy program ; all-cause mortality ; hazard ratio ; confidence interval ; inpatient ; admissions ; baseline
H-1625	-0.5675248503684998	▁Health ▁Budd y ▁Program ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; CI ▁; ▁in patient ▁ad missions
D-1625	-0.5675248503684998	Health Buddy Program ;hazard ratio ;HR ; confidence interval ;CI ; inpatient admissions
P-1625	-2.2888 -0.2072 -0.0466 -1.2614 -0.6795 -3.4160 -0.0263 -0.0137 -0.4443 -0.2895 -0.3449 -0.2957 -0.0273 -0.4007 -0.5921 -0.5542 -0.2256 -0.0521 -0.4164 -0.1906 -0.5908 -0.1217
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted hazard ratios ; dash
H-691	-0.7419042587280273	▁multi vari able - ad just ed ▁hazard ▁ratio s ▁; ▁Mediterrane an ▁die t ▁score ▁; ▁DAS h
D-691	-0.7419042587280273	multivariable-adjusted hazard ratios ; Mediterranean diet score ; DASh
P-691	-1.4817 -0.0689 -0.2404 -0.2357 -0.0206 -0.0415 -0.0966 -0.3929 -0.1759 -0.2857 -0.4908 -5.6281 -0.3601 -0.8425 -0.1628 -0.1681 -0.4550 -1.1871 -0.1671 -2.9263 -0.1522
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt ; nt-probnp ; report ; aric ; hf ; systolic blood pressure ; antihypertensive medication ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hf ; area under the receiver operating characteristic curve ; auc ; integrated discrimination improvement ; net reclassification improvement ; nri
H-287	-0.3053157329559326	▁c t n t ▁; ▁NT - pro b NP ▁; labora tory ▁report ▁; ▁a RIC ▁ HF ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁anti hy per tensi ve ▁medication ▁; ▁smoking ▁; ▁diabetes ▁; ▁body ▁mass ▁index ▁; ▁corona ry ▁heart ▁disease ▁; ▁heart ▁rate ▁; ▁ HF ▁; ▁receive r ▁operating ▁character istic ▁cur ve ▁; AU c ▁; ▁discrimina tion ▁improvement ▁; ▁net ▁re class ification ▁improvement ▁; ▁n RI
D-287	-0.3053157329559326	ctnt ; NT-probNP ;laboratory report ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ;AUc ; discrimination improvement ; net reclassification improvement ; nRI
P-287	-0.0074 -0.0778 -0.0592 -0.3512 -0.1245 -0.0096 -0.0412 -0.0241 -0.4345 -0.6167 -0.3582 -0.2718 -0.0220 -0.0148 -0.4408 -0.3837 -0.5481 -0.8294 -0.8104 -0.5717 -0.1624 -0.0747 -0.0771 -0.1606 -0.3493 -0.1963 -0.0251 -0.4917 -0.0365 -0.0498 -0.0082 -0.0299 -0.5773 -0.3200 -0.1114 -0.0214 -0.1181 -0.0820 -0.0500 -0.0051 -0.1147 -0.0460 -0.5429 -0.1435 -0.2444 -0.0831 -0.4862 -0.2830 -0.1775 -1.3908 -2.2180 -0.1668 -0.5009 -0.0119 -0.1260 -0.0653 -0.0198 -0.1680 -0.0923 -0.2388 -1.5412 -2.3508 -0.1219 -0.3226 -0.3507 -0.3736 -0.0961 -0.0141 -0.0145 -0.0465 -0.2739 -0.6051 -0.0847 -0.6976 -0.0678 -0.4229 -0.0616
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; patients ; heart failure and reduced ejection fraction ; hf-ref ; new york heart association ; nyha ; functional class ; estimated glomerular filtration rate ; egfr ; serum potassium
H-1222	-0.4064587652683258	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁w RF ▁; ▁EM PHA SIS - HF ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF - re f ▁; ▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e ▁g FR ▁; ▁se rum ▁po tas s ium
D-1222	-0.4064587652683258	eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart association ;NYha ; glomerular filtration rate ; e gFR ; serum potassium
P-1222	-0.0835 -0.0798 -0.0882 -0.8072 -0.2285 -0.1657 -0.4448 -0.0832 -0.1320 -0.1836 -0.0964 -0.1704 -0.2627 -0.4995 -0.2181 -1.8074 -0.1862 -0.6249 -0.0366 -0.2721 -0.1496 -1.7907 -0.1041 -0.1011 -0.6963 -0.0170 -0.0077 -0.1909 -0.0186 -0.2565 -0.0086 -0.1451 -1.2206 -0.0490 -0.9779 -1.9249 -0.0531 -0.4348 -0.1322 -0.4485 -0.3418 -0.0843 -0.8378 -0.7730 -0.2475 -0.0254 -0.2042 -0.0491 -0.0505 -0.4962 -0.2544 -0.2024 -0.0976 -2.8233 -1.0667 -0.4407 -0.6501 -0.2592 -0.3886 -0.4334 -0.5820 -0.0779 -0.3392 -0.0902
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide ; nesiritide ; placebo ; change ; cystatin c ; nesiritide ; placebo
H-81	-1.2793699502944946	▁nesi riti de ▁; ▁cum ul ative ▁urin e ▁volume ▁; nesi riti de ▁; ▁m L ▁; ▁place bo ▁; ▁cyst atin ▁c ▁level ▁; nesi riti de
D-81	-1.2793699502944946	nesiritide ; cumulative urine volume ;nesiritide ; mL ; placebo ; cystatin c level ;nesiritide
P-81	-5.7459 -0.2421 -0.7174 -0.5785 -1.9014 -0.0695 -0.0414 -0.7791 -0.3519 -0.2434 -0.3302 -3.2960 -0.4969 -0.7904 -0.6129 -5.2534 -3.5265 -0.2432 -3.3171 -0.0587 -0.4576 -1.1610 -0.2538 -1.5452 -0.0705 -0.2101 -3.1448 -0.4225 -0.5539 -3.0377 -0.2075
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking ; functional capacity ; 6mwt ; physical ; activity ; symptoms ; hospital anxiety and depression scale
H-572	-0.9509944915771484	▁Nordic ▁walking ▁; ▁functional ▁capacity ▁; ▁w t ▁; ▁physical ▁activity ▁; ▁right ▁grip ▁strength ▁; ▁kg ▁; ▁ depressiv e ▁symptoms ▁; Hospital ▁an xie ty ▁and ▁de pression ▁Scal e
D-572	-0.9509944915771484	Nordic walking ; functional capacity ; wt ; physical activity ; right grip strength ; kg ; depressive symptoms ;Hospital anxiety and depression Scale
P-572	-1.7260 -1.4342 -0.3973 -0.1167 -0.3747 -0.5210 -4.7103 -0.0893 -0.4199 -2.0007 -0.6831 -0.5448 -3.9301 -0.3679 -1.4948 -0.5049 -4.2139 -0.5093 -0.3059 -0.1033 -0.1354 -0.8805 -0.4703 -0.9580 -1.1325 -0.0367 -0.0733 -1.4239 -0.1449 -0.1014 -0.9219 -0.0100 -1.4143 -0.1825
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients ; hyperkalemia ; patients ; diabetes ; egfr ; systolic blood pressure ; potassium ; hyperkalemia ; leading ; hospitalization ; hospitalization ; primary outcome ; hospitalization ; hf ; cardiovascular mortality
H-1225	-0.7018834352493286	▁hyper kal emia ▁; ▁w RF ▁; ▁diabetes ▁; ▁e g FR ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁h g ▁; po tas s ium ▁; ▁hyper kal emia ▁; ▁w RF ▁; ▁cardiovascular ▁mortal ity
D-1225	-0.7018834352493286	hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; wRF ; cardiovascular mortality
P-1225	-1.0525 -0.6410 -0.4046 -0.1289 -0.2174 -0.9113 -0.2825 -0.1185 -0.1336 -0.1151 -2.5957 -0.4980 -0.1429 -0.2942 -0.0896 -0.0786 -0.2904 -0.5194 -0.2666 -5.2482 -0.4188 -0.2729 -1.2722 -0.5084 -0.3455 -0.1482 -0.1787 -3.2245 -0.7427 -0.4937 -0.1832 -0.2885 -1.3689 -0.3657 -2.4140 -0.0335 -0.8369 -0.1633 -0.0848
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf ; biosynthetic enzymes ; lyso-paf acetyltransferase ; lyso-paf-at ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; paf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-ah ; lipoprotein-associated phospholipase a2 ; lp-pla2 ; leukocytes
H-1268	-0.6273720860481262	▁PA f ▁; ▁bio syn the tic ▁enzym es ▁; lys o - pa f ▁a ce tyl transfer ase ▁; lys o - pa f - at ▁; ▁di thi oth rei tol ▁; ▁d t ▁; ▁cd p ▁; ▁cho line ▁; ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁; ▁cho line phos pho transfer ase ▁; ▁p bf - c PT ▁; ▁cata bo lic ▁iso en zy mes ▁; ▁pa f - ace tyl hydro lase ▁; ▁pa f - AH ▁; ▁lipo prote in - as soci ated ▁ phos pho lipa se ▁; ▁l p - PLA 2]
D-1268	-0.6273720860481262	PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-at ; dithiothreitol ; dt ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pbf-cPT ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-AH ; lipoprotein-associated phospholipase ; lp-PLA2]
P-1268	-0.5794 -2.3383 -0.4741 -0.0270 -0.0609 -1.3800 -1.5407 -0.1194 -0.1517 -0.3434 -0.2492 -0.2353 -0.0976 -0.3636 -2.3746 -1.2525 -1.0908 -1.5534 -0.1025 -2.1641 -0.2225 -0.5957 -0.0741 -0.0655 -0.1988 -2.1929 -0.7930 -0.8319 -0.1827 -0.1291 -0.1363 -1.0169 -0.1116 -0.5838 -0.1981 -0.9328 -1.2013 -0.9812 -0.7482 -0.2664 -0.8117 -0.8399 -0.0462 -3.2216 -0.5227 -0.0640 -0.1531 -0.2390 -0.1585 -0.8677 -0.2097 -0.0762 -0.0668 -0.0088 -0.0526 -0.0766 -0.0201 -0.3263 -1.1083 -0.5460 -0.0668 -0.5047 -0.9588 -0.7669 -1.5405 -0.2052 -1.6795 -1.8131 -0.1711 -2.0125 -1.7826 -0.2723 -0.0940 -0.1438 -0.0104 -0.0103 -0.2055 -0.1469 -0.9707 -0.2321 -2.6406 -2.3006 -0.0802 -0.3971 -0.3887 -0.0258 -0.2182 -0.1759 -2.4095 -2.1696 -0.0978 -1.1893 -0.1333 -0.0740 -0.0964 -0.2775 -0.1054 -0.0547 -0.0015 -0.5849 -0.1180 -0.0732 -0.1888 -0.3710 -0.3151 -1.5218 -0.1098 -0.0158 -0.0628 -0.0122 -1.1803 -2.4574 -0.0806
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine ; baseline ; follow-up ; exercise capacity ; mets ; mets ; peak oxygen uptake ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1175	-0.7507832050323486	▁i va bra dine ▁group ▁; ▁follow - up ▁exercise ▁capacity ▁; ▁oxygen ▁up take ▁; ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1175	-0.7507832050323486	ivabradine group ; follow-up exercise capacity ; oxygen uptake ; early diastolic mitral flow velocity ; diastolic mitral annular velocity
P-1175	-0.0383 -0.0652 -0.3413 -0.2480 -2.1716 -0.5133 -0.1311 -0.1275 -0.0209 -1.8069 -0.8178 -0.4263 -3.9194 -2.6388 -0.2778 -0.6459 -3.2334 -0.0126 -0.1499 -0.0677 -0.3511 -0.1938 -1.9385 -2.2719 -0.0878 -0.5804 -1.4359 -0.1455 -0.1227 -0.3817 -0.2177 -1.3724 -0.0071 -0.5620 -0.0908 -0.2577 -0.1083
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate analysis ; chf ; odds ratio ; chest ; hypertension ; genes ; rac2 ; doxorubicin efflux transporter ; abcc2
H-1455	-0.8740776181221008	▁CHF ▁; Od ds ▁Ra tio ▁; ▁h bf ▁; ▁che st ▁radi ation ▁; ▁hyper tension ▁; ▁ NAD ( p h - oxid ase ▁sub un it ▁ RAC 2 ▁; ▁g bf ▁; ▁do xor ubi cin ▁ eff lux ▁transporter ▁ABC c 2
D-1455	-0.8740776181221008	CHF ;Odds Ratio ; hbf ; chest radiation ; hypertension ; NAD(ph-oxidase subunit RAC2 ; gbf ; doxorubicin efflux transporter ABCc2
P-1455	-1.1422 -0.6473 -1.8232 -0.0145 -1.4046 -0.5325 -0.2723 -3.9098 -3.9649 -0.3285 -0.6597 -0.0490 -0.0988 -0.6190 -0.1748 -0.2033 -0.0499 -0.3141 -2.7425 -0.5402 -3.8725 -1.6467 -2.4067 -0.2039 -0.0646 -2.0037 -0.0749 -0.1928 -0.1346 -0.6758 -0.3381 -0.1762 -0.2259 -4.5839 -0.6335 -0.1377 -1.4253 -0.0440 -0.0262 -0.1491 -0.2407 -0.0324 -0.0641 -0.1066 -0.6389 -1.4615 -0.8826 -0.7554 -0.1403
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline ; follow-up ; nyha classification ; patients ; patient ; change ; patient ; quality of life ; duke activity status index ; kansas city cardiomyopathy questionnaire ; 6 min walk test
H-1958	-0.7713043689727783	▁NY ha ▁classifica tion ▁; ▁class ▁II ▁; ▁class ▁III ▁; ▁class ▁I ▁; ▁patient ▁; ▁quality ▁of ▁life ▁; ▁Duke ▁Activ ity ▁status ▁index ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire
D-1958	-0.7713043689727783	NYha classification ; class II ; class III ; class I ; patient ; quality of life ; Duke Activity status index ; Kansas City Cardiomyopathy Questionnaire
P-1958	-1.1556 -0.4933 -1.0050 -0.3184 -0.3717 -0.8785 -2.4771 -0.5774 -1.7228 -1.1818 -0.8638 -0.8562 -0.6322 -0.5353 -0.7039 -0.3811 -1.8041 -0.6126 -0.9683 -0.2947 -0.1247 -0.9314 -0.5464 -0.3957 -0.4613 -0.2425 -1.4915 -1.0570 -1.0399 -0.0782 -0.1328 -0.8067 -0.1024 -0.5263 -0.0161 -2.5742 -0.1773
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo ; dopamine ; dopamine ; placebo ; change ; cystatin c ; dopamine ; placebo
H-80	-1.278898000717163	▁low - dos e ▁dop amine ▁; ▁cum ul ative ▁urin e ▁volume ▁; dop amine
D-80	-1.278898000717163	low-dose dopamine ; cumulative urine volume ;dopamine
P-80	-7.7187 -0.0922 -0.9251 -0.4962 -0.3584 -0.2884 -0.4229 -0.9044 -0.0768 -0.0550 -0.6763 -0.3312 -0.1636 -0.2325 -3.4464 -0.3477 -6.2657 -0.2187
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard ratio ; confidence interval ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; new york heart association class ; atrial fibrillation ; congestive hf ; mortality
H-66	-0.7346373796463013	▁ha ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; CI ▁; ▁base line ▁glo mer ular ▁filtr ation ▁rate ▁; HR ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; HR ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁h ▁; ▁i CD ▁shock s ▁; ▁New ▁York ▁Heart ▁association ▁class ▁; ▁at rial ▁fi bril lation ▁; ▁con ges tive ▁ HF
D-66	-0.7346373796463013	haard ratio ;HR ; confidence interval ;CI ; baseline glomerular filtration rate ;HR ; chronic obstructive pulmonary disease ; diabetes ;HR ; peripheral vascular disease ; left ventricular ejection fraction ; h ; iCD shocks ; New York Heart association class ; atrial fibrillation ; congestive HF
P-66	-4.2482 -0.2393 -0.0324 -0.2164 -2.5177 -0.3332 -5.2170 -0.0567 -0.1922 -3.7226 -0.3689 -0.2248 -0.0480 -0.3648 -0.2188 -0.0581 -0.1273 -0.5726 -0.5858 -0.3471 -1.6883 -0.5402 -1.1102 -0.5511 -0.1636 -0.3940 -0.0049 -0.2139 -0.3742 -0.2563 -0.4927 -0.2270 -2.2426 -0.6534 -0.7555 -0.1863 -0.3042 -0.1361 -0.2054 -0.4175 -0.3682 -0.3056 -3.4762 -0.0661 -2.0900 -0.4037 -0.1078 -0.1074 -0.0520 -0.7857 -0.0361 -0.4000 -5.1106 -1.7807 -0.9783 -0.8167 -0.1694 -0.1190 -0.1885 -2.2755 -0.3699 -0.9802 -0.3231 -1.5847 -0.0984 -0.1345 -0.0557 -0.2179 -0.0631 -0.2974 -0.2367 -0.1732 -0.1830 -1.0620 -0.1971 -0.3081 -0.6089 -0.1610
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable analysis ; end point ; peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
H-1761	-0.8471357822418213	▁oxygen ▁up take ▁; ▁hazard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; CI ▁; ▁ventilator y ▁efficiency ▁s lope ▁; ▁hem o glob in ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁renal ▁function ▁; ▁renal ▁disease ▁; ▁so dium
D-1761	-0.8471357822418213	oxygen uptake ; hazard ratio ;HR ; confidence interval ;CI ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
P-1761	-2.0592 -2.9397 -0.4278 -0.2755 -0.2853 -0.0374 -0.1506 -2.7519 -0.3076 -0.5564 -0.0394 -0.1603 -5.0993 -0.4970 -0.2269 -0.1854 -0.0948 -0.3191 -0.1479 -0.1553 -4.3404 -0.6659 -0.2499 -1.2034 -0.3191 -3.2319 -0.0520 -2.0953 -0.4199 -0.1300 -0.1495 -0.0595 -0.7457 -0.0431 -0.2388 -1.9179 -1.0048 -0.2171 -0.9340 -0.7274 -0.2501 -0.1402 -0.2942 -1.8286 -0.1454
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute walked distance ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; beck depression inventory ; flow-mediated dilatation ; fes ; placebo ; b-type natriuretic peptide ; mitral
H-1331	-0.5465891361236572	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁summary ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁z ung ▁; ▁flow - media ted ▁di la tation ▁diameter ▁; ▁f es ▁group ▁; ▁na tri ure tic ▁pe pti de ▁; ▁mit ral ▁e / e ▁wa ve ▁ratio
D-1331	-0.5465891361236572	Kansas City Cardiomyopathy Questionnaire summary ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes group ; natriuretic peptide ; mitral e/e wave ratio
P-1331	-0.4975 -0.9489 -1.8028 -0.0711 -0.1732 -0.7620 -0.0920 -1.3328 -0.0142 -1.8595 -0.1218 -0.0744 -0.2523 -0.2750 -0.4458 -0.2589 -0.5989 -0.3398 -0.0372 -0.3497 -0.6110 -0.2348 -0.0247 -0.2808 -0.1774 -0.0398 -0.3535 -0.5051 -1.0011 -0.3837 -0.6403 -0.0545 -0.1066 -0.2284 -0.1259 -0.3319 -0.0605 -0.0365 -0.2630 -2.3675 -1.5398 -2.6433 -0.3021 -0.5578 -0.2810 -0.8651 -0.9724 -1.0664 -0.0534 -0.6062 -0.6879 -1.3269 -0.0515 -2.2106 -0.4666 -0.0270 -0.9681 -0.0307 -0.0773 -0.3389 -0.1341
2021-01-18 15:10:21 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-18 15:10:21 | INFO | fairseq_cli.generate | Translated 2,024 sentences (36,386 tokens) in 183.7s (11.02 sentences/s, 198.07 tokens/s)
2021-01-18 15:10:21 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 46.51, 68.3/54.4/45.7/38.4 (BP=0.921, ratio=0.924, syslen=36386, reflen=39387)
